Clustering O 0 4.4957909267395735e-05
of O 0 5.426057214208413e-06
missense O 0 7.50242452340899e-06
mutations O 0 1.505955822267424e-07
in O 0 2.8297801435428482e-08
the O 0 1.186243025586009e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 9.579091511113802e-07
in O 0 3.847263840839332e-08
a O 0 9.09966999529388e-08
sporadic B-Disease 0 8.780812095210422e-06
T I-Disease 1 0.9996166229248047
- I-Disease 0 0.019753385335206985
cell I-Disease 0 9.516894351691008e-05
leukaemia I-Disease 0 0.0017713693669065833
. O 0 4.2481510718062054e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 1.9537283151294105e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.5984368434706084e-08
is O 0 8.528884265501802e-09
a O 0 9.973976311528077e-09
recessive B-Disease 0 2.900475521983026e-07
multi I-Disease 0 2.8718877729261294e-06
- I-Disease 1 0.9995556473731995
system I-Disease 1 0.9991728663444519
disorder I-Disease 1 0.9999839067459106
caused O 0 2.703983170704305e-08
by O 0 1.0455742938120238e-09
mutations O 0 2.4868944681344374e-09
in O 0 1.3749924532291402e-09
the O 0 4.574956591341106e-08
ATM O 0 4.50332481705118e-06
gene O 0 5.65479361114285e-08
at O 0 2.6919090601040807e-07
11q22 O 0 9.383283213537652e-06
- O 0 2.8700642360490747e-06
q23 O 0 1.4538291907228995e-05
( O 0 5.2605123812554666e-08
ref O 0 2.868988758564228e-06
. O 0 4.259256058958272e-08
3 O 0 4.6907612727409287e-07
) O 0 2.49045683631266e-07
. O 0 1.673752421993413e-06

The O 0 1.4543272754963255e-06
risk O 0 2.152115712306113e-06
of O 0 7.253415787999984e-07
cancer B-Disease 0 0.4794006645679474
, O 0 4.214848203787369e-08
especially O 0 1.0504806624567209e-07
lymphoid B-Disease 0 0.00042723622755147517
neoplasias I-Disease 1 0.9999740123748779
, O 0 8.250634664364043e-08
is O 0 2.2121819043263713e-08
substantially O 0 8.120087358065575e-08
elevated O 0 4.520481070358073e-06
in O 0 1.2475832811276177e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.3474389365674142e-07
and O 0 1.4116303681532827e-08
has O 0 1.3011892896486188e-08
long O 0 2.2226963380944653e-08
been O 0 1.0008889717028069e-08
associated O 0 1.92166549339845e-08
with O 0 1.939613980539434e-07
chromosomal O 1 1.0
instability O 1 1.0
. O 0 5.6729324569460005e-05

By O 0 1.1543826303750393e-06
analysing O 0 3.620264396886341e-05
tumour B-Disease 1 1.0
DNA O 0 1.6001748690541717e-06
from O 0 1.952228956270119e-08
patients O 0 1.3555155220501547e-08
with O 0 2.835002677059606e-09
sporadic B-Disease 0 2.760161805781536e-06
T I-Disease 1 0.997217059135437
- I-Disease 0 8.560504647903144e-05
cell I-Disease 0 1.0930686585197691e-05
prolymphocytic I-Disease 1 0.9834619760513306
leukaemia I-Disease 1 0.9944971203804016
( O 0 9.524011801431698e-08
T B-Disease 0 0.01676451414823532
- I-Disease 0 2.0307139493525028e-05
PLL I-Disease 0 0.3066393733024597
) O 0 1.6039097161524296e-08
, O 0 6.319020418033006e-09
a O 0 1.1926704956977119e-08
rare O 0 1.315989237582471e-07
clonal B-Disease 0 1.8042277361018932e-06
malignancy I-Disease 0 7.625396847288357e-06
with O 0 5.934845948019074e-09
similarities O 0 2.4107130514039454e-08
to O 0 6.732608248682936e-09
a O 0 1.5394640229260403e-08
mature B-Disease 0 1.1315287196111967e-07
T I-Disease 0 1.8245206092615263e-06
- I-Disease 0 5.777354772362742e-07
cell I-Disease 0 3.259139305100689e-07
leukaemia I-Disease 0 2.3353950382443145e-06
seen O 0 1.6372514011209205e-08
in O 0 7.262197065927012e-09
A B-Disease 1 0.9991441965103149
- I-Disease 1 0.9846001267433167
T I-Disease 1 1.0
, O 0 1.4063362918648181e-08
we O 0 2.9460813788517726e-09
demonstrate O 0 4.165662481625532e-09
a O 0 3.1985329940198426e-09
high O 0 2.1934098981546413e-08
frequency O 0 2.3458403219933643e-08
of O 0 3.716129981512495e-08
ATM O 0 8.68407641974045e-06
mutations O 0 2.5029376615748333e-07
in O 0 2.2961373247198935e-07
T B-Disease 1 0.9944135546684265
- I-Disease 0 0.04233952611684799
PLL I-Disease 0 0.3753927946090698
. O 0 1.1561383871594444e-05

In O 0 6.554759579557867e-07
marked O 0 7.336761882470455e-07
contrast O 0 6.862021706410815e-08
to O 0 2.9433925519128934e-08
the O 0 1.0254615290250513e-07
ATM O 0 1.0967861271637958e-05
mutation O 0 5.465103569690655e-08
pattern O 0 3.24147038099909e-08
in O 0 8.270609974658782e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 3.5631494199606095e-08
the O 0 1.9702330433801762e-08
most O 0 3.347650601170926e-09
frequent O 0 1.1165254498735067e-08
nucleotide O 0 1.76271637286618e-08
changes O 0 6.167815147506417e-09
in O 0 2.4507869067491583e-09
this O 0 1.416804007448036e-08
leukaemia B-Disease 0 5.672018232871778e-06
were O 0 2.918945369856374e-07
missense O 0 2.0845078324782662e-05
mutations O 0 4.106113465240924e-06
. O 0 2.8994959393457975e-06

These O 0 8.939849180933379e-07
clustered O 0 8.613815225544386e-07
in O 0 4.041314127789519e-08
the O 0 4.211071669146804e-08
region O 0 6.344444614114764e-08
corresponding O 0 2.009563715432705e-08
to O 0 1.671305227546327e-08
the O 0 9.27944654449675e-08
kinase O 0 2.99760728239562e-07
domain O 0 5.0636099757639386e-08
, O 0 2.561411749368858e-09
which O 0 1.4691846628167582e-09
is O 0 1.9841439602430455e-09
highly O 0 1.1102459396283848e-08
conserved O 0 4.772288164645033e-08
in O 0 5.627794230633754e-09
ATM O 0 2.458842800479033e-06
- O 0 2.1555715079557558e-07
related O 0 5.864296070967612e-08
proteins O 0 3.9529770567980904e-09
in O 0 3.157412331589171e-09
mouse O 0 3.5763420669354673e-07
, O 0 2.1661778148995836e-08
yeast O 0 1.3371351315072388e-07
and O 0 8.733692880014132e-08
Drosophila O 0 8.678811354911886e-06
. O 0 2.2707142761646537e-06

The O 0 3.4433460314176045e-06
resulting O 0 8.432834306404402e-07
amino O 0 2.1711751685415948e-07
- O 0 1.6537401847926958e-07
acid O 0 6.597493040771951e-08
substitutions O 0 4.9326406070804296e-08
are O 0 3.3809410826535213e-09
predicted O 0 1.6679264192021037e-08
to O 0 1.508093738777916e-08
interfere O 0 9.243304077699577e-08
with O 0 3.7071817615697e-08
ATP O 1 0.9945916533470154
binding O 0 2.4756798211456044e-07
or O 0 6.990266143702684e-08
substrate O 0 8.712743237992981e-07
recognition O 0 8.855005830810114e-07
. O 0 3.696954308907152e-06

Two O 0 6.072577320992423e-07
of O 0 8.321960081048019e-07
seventeen O 0 6.565947842318565e-06
mutated O 0 5.269809662422631e-06
T B-Disease 0 8.430048183072358e-05
- I-Disease 0 2.1445928723551333e-05
PLL I-Disease 0 0.0002602095191832632
samples O 0 9.411348145249576e-08
had O 0 1.87052027200707e-08
a O 0 1.2208350774756127e-08
previously O 0 1.1232543783989968e-07
reported O 0 1.6763533494668081e-07
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999967813491821
T I-Disease 1 1.0
allele O 0 2.3896056518424302e-05
. O 0 4.701160833064932e-06

In O 0 5.991855687170755e-07
contrast O 0 3.5171476042705763e-07
, O 0 5.9300848676002715e-08
no O 0 4.048527557642956e-08
mutations O 0 1.8518337085993153e-08
were O 0 6.109611927485048e-09
detected O 0 3.0597565370271695e-08
in O 0 3.2577200936856343e-09
the O 0 2.757598416280871e-08
p53 O 0 2.255349471624868e-07
gene O 0 2.614289940083836e-08
, O 0 8.281769936502315e-09
suggesting O 0 1.3400298648491571e-08
that O 0 1.610226396664416e-09
this O 0 9.85078418835883e-09
tumour B-Disease 1 1.0
suppressor O 1 0.9999409914016724
is O 0 6.743920266671921e-08
not O 0 6.0569695925494216e-09
frequently O 0 3.629229183843563e-08
altered O 0 1.1792189269499431e-07
in O 0 2.257126041627089e-08
this O 0 1.471833712685111e-07
leukaemia B-Disease 0 7.465163071174175e-05
. O 0 6.468124411185272e-06

Occasional O 0 0.0001292685337830335
missense O 0 1.8387027012067847e-05
mutations O 0 2.2192656956576684e-07
in O 0 2.8402054041976044e-08
ATM O 0 0.00045828628935851157
were O 0 5.2376655901298363e-08
also O 0 1.8100058341019576e-08
found O 0 4.219382621073464e-09
in O 0 5.150710080670251e-09
tumour B-Disease 1 1.0
DNA O 0 6.044853506637082e-08
from O 0 2.683558486538118e-09
patients O 0 1.2209880884128665e-09
with O 0 6.797792884150056e-10
B B-Disease 0 3.580287511795177e-06
- I-Disease 0 3.305645748241659e-07
cell I-Disease 0 6.456362484641431e-07
non I-Disease 0 3.0564606277039275e-05
- I-Disease 1 0.9995445609092712
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 0 0.2936815619468689
( O 0 1.9960864960921754e-08
B B-Disease 0 2.3749721549393144e-06
- I-Disease 0 2.1342876266317035e-07
NHL I-Disease 0 0.004212634637951851
) O 0 4.540217535264901e-09
and O 0 5.207251962957571e-09
a O 0 2.9603846485315444e-08
B B-Disease 0 5.27082511325716e-06
- I-Disease 0 3.5579419090936426e-06
NHL I-Disease 1 0.9998840093612671
cell O 0 4.768721737491433e-06
line O 0 7.638344868610147e-06
. O 0 3.5084347018710105e-06

The O 0 1.0014466624852503e-06
evidence O 0 1.0536793126902921e-07
of O 0 6.439660893420296e-08
a O 0 9.383454901978894e-09
significant O 0 1.6354473331148256e-08
proportion O 0 2.7505384636583585e-08
of O 0 3.5528749720015185e-08
loss O 0 1.9628818392902758e-07
- O 0 1.5030460076559393e-07
of O 0 1.5290410715351754e-07
- O 0 2.089974913133119e-07
function O 0 1.7262106410953493e-08
mutations O 0 3.3637286289689428e-09
and O 0 1.1937918431570438e-09
a O 0 1.7986618860987846e-09
complete O 0 1.2216596623204623e-08
absence O 0 2.476855343047646e-08
of O 0 2.9409571666860757e-08
the O 0 1.2344369082484263e-08
normal O 0 4.899146421877276e-09
copy O 0 1.3131767673257855e-08
of O 0 1.806429317241509e-08
ATM O 0 9.81846483227855e-07
in O 0 6.72421451852756e-09
the O 0 1.054853271398315e-08
majority O 0 4.361631500415797e-09
of O 0 5.796483293352139e-08
mutated O 0 3.253113618484349e-06
tumours B-Disease 1 1.0
establishes O 0 8.499038699483208e-07
somatic O 0 3.446637322213064e-07
inactivation O 0 7.905928782747651e-07
of O 0 3.2782597969571725e-08
this O 0 1.6042516204350932e-09
gene O 0 2.2798620769037825e-09
in O 0 1.4659852221043934e-09
the O 0 1.690290041267417e-08
pathogenesis O 0 1.2667662304011174e-05
of O 0 3.9499047943536425e-07
sporadic B-Disease 0 0.0015584803186357021
T I-Disease 1 0.9999998807907104
- I-Disease 0 0.13256055116653442
PLL I-Disease 0 0.007559466175734997
and O 0 5.03624484338161e-08
suggests O 0 3.664138503722825e-08
that O 0 2.8865598800109638e-09
ATM O 0 1.4863599062664434e-06
acts O 0 1.3447004221234238e-07
as O 0 8.220396807701036e-08
a O 0 7.821486747161543e-07
tumour B-Disease 1 1.0
suppressor O 1 0.9965991377830505
. O 0 1.8408012692816556e-05

As O 0 1.8075343177770264e-06
constitutional O 0 2.3554764538857853e-06
DNA O 0 4.483705708935304e-07
was O 0 7.512861799341408e-08
not O 0 1.7075116875986396e-09
available O 0 3.880085142071721e-09
, O 0 5.865210539468535e-09
a O 0 3.8061354956653304e-08
putative O 0 6.454278718592832e-06
hereditary O 1 0.9923257827758789
predisposition O 1 0.9818529486656189
to O 0 8.129809430101886e-06
T B-Disease 1 1.0
- I-Disease 1 0.999954104423523
PLL I-Disease 1 0.9845773577690125
will O 0 5.565733474099943e-08
require O 0 1.856905562647171e-08
further O 0 5.356506704856656e-08
investigation O 0 2.5192798602802213e-07
. O 0 2.194590393855833e-07
. O 0 2.394588136667153e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 1.1542369065864477e-05
kinase O 0 6.408747026398487e-07
is O 0 6.695393572897501e-09
involved O 0 1.8082106922889807e-09
in O 0 6.80709544287339e-10
the O 0 4.967931843680162e-09
modulation O 0 9.083889551675384e-08
of O 0 8.945888652078793e-08
the O 0 3.624988664796547e-07
Ca2 O 0 8.17773980088532e-06
+ O 0 2.9772986636089627e-06
homeostasis O 0 4.462165634322446e-06
in O 0 1.3078805238819768e-07
skeletal O 0 0.015986885875463486
muscle O 0 1.6589163351454772e-05
cells O 0 1.0271749033563538e-06
. O 0 1.8609212020237464e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.8241065144538879
DM B-Disease 1 1.0
) O 0 7.486169693038391e-07
, O 0 4.483782589659313e-08
the O 0 2.4185933256148928e-08
most O 0 1.721288889200423e-08
prevalent O 0 5.939836682955502e-06
muscular B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 2.3592342301981262e-08
adults O 0 2.3169764773456336e-08
, O 0 4.764436845050568e-09
is O 0 3.70138608651871e-09
caused O 0 1.0827557517245623e-08
by O 0 4.149453669555214e-09
( O 0 2.663488807286285e-08
CTG O 0 0.00022136002371553332
) O 0 2.3154390405011327e-08
n O 0 2.982454105904253e-08
- O 0 1.0453579335489849e-07
repeat O 0 4.727542446403277e-08
expansion O 0 8.121357808477114e-08
in O 0 3.547645732737692e-09
a O 0 8.390076189357387e-09
gene O 0 1.5682950049722422e-08
encoding O 0 4.7405901426600394e-08
a O 0 1.9071801915515607e-08
protein O 0 1.2495401335854694e-07
kinase O 0 9.062298431672389e-07
( O 0 7.64058114555155e-08
DM B-Disease 1 1.0
protein O 0 2.8523069772745657e-07
kinase O 0 2.1942848604794563e-07
; O 0 9.460838334973687e-09
DMPK O 0 0.00041256521944887936
) O 0 1.0953163709359615e-08
and O 0 9.582882931624681e-09
involves O 0 1.9713493060180554e-08
changes O 0 1.0891850976690876e-08
in O 0 1.5679301412774294e-08
cytoarchitecture O 0 1.3828083865519147e-05
and O 0 6.15568410466949e-07
ion O 0 0.00014010634913574904
homeostasis O 0 0.0008370532304979861
. O 0 1.7496900909463875e-05

To O 0 7.346269512709114e-07
obtain O 0 2.0349750684545143e-07
clues O 0 3.8757013953727437e-07
to O 0 1.2760560608171545e-08
the O 0 2.2888869466441975e-08
normal O 0 1.0609388034765743e-08
biological O 0 2.729727022199313e-08
role O 0 2.004866317406595e-08
of O 0 1.0757285906493053e-07
DMPK O 1 1.0
in O 0 6.256945539462322e-08
cellular O 0 4.481115354337817e-07
ion O 0 5.1386223276495e-06
homeostasis O 0 7.58048599891481e-06
, O 0 2.5798092551099217e-08
we O 0 8.656587446864705e-09
have O 0 1.1854328629823385e-09
compared O 0 5.431379790366009e-09
the O 0 2.6450004853018072e-08
resting O 0 6.978422675274487e-07
[ O 0 8.618567903795338e-08
Ca2 O 0 1.6969387672816083e-07
+ O 0 4.394501118554217e-08
] O 0 2.4458335801114117e-08
i O 0 1.1199892568924952e-08
, O 0 2.00742511502483e-09
the O 0 2.3118238434705063e-09
amplitude O 0 2.1441204367533828e-08
and O 0 5.121106649852436e-09
shape O 0 6.409443642496626e-08
of O 0 7.173213134592515e-08
depolarization O 0 3.0060525091357704e-07
- O 0 9.053081839738297e-07
induced O 0 6.06903370226064e-07
Ca2 O 0 1.9607882961736323e-07
+ O 0 4.533201902745532e-08
transients O 0 5.348880449673743e-08
, O 0 1.6941817948534776e-09
and O 0 1.7919161710011622e-09
the O 0 8.292344588767264e-09
content O 0 3.5437789591696855e-08
of O 0 1.0307109477025733e-07
ATP O 1 0.9997406601905823
- O 0 7.5054517765238415e-06
driven O 0 8.564937274968543e-07
ion O 0 7.160103336900647e-07
pumps O 0 3.447330811923166e-07
in O 0 2.340267357681114e-08
cultured O 0 1.5478411796721048e-07
skeletal O 0 1.2376571021377458e-06
muscle O 0 1.0565167940512765e-07
cells O 0 4.1696051056305805e-09
of O 0 2.930687514890451e-08
wild O 0 2.0949677548287582e-07
- O 0 9.803011380427051e-08
type O 0 4.709291090421175e-08
and O 0 2.389640840760876e-08
DMPK O 1 0.9999942779541016
[ O 0 3.0795291650065337e-07
- O 0 2.2448398340202402e-06
/ O 0 5.153836355020758e-06
- O 0 1.956618689291645e-05
] O 0 4.8752112888905685e-06
knockout O 0 0.000380223267711699
mice O 0 1.273386715183733e-05
. O 0 1.8955444147650269e-06

In O 0 2.2283518319454743e-06
vitro O 0 3.216869799871347e-06
- O 0 5.52609390069847e-06
differentiated O 0 1.5137388800212648e-05
DMPK O 1 0.9997649788856506
[ O 0 1.7586617104825564e-06
- O 0 6.172741450427566e-06
/ O 0 1.0898088476096746e-05
- O 0 1.4951993762224447e-05
] O 0 1.4785022131036385e-06
myotubes O 0 6.251736976992106e-06
exhibit O 0 3.690468872719066e-07
a O 0 2.0354674390432592e-08
higher O 0 5.754952425718329e-08
resting O 0 1.2135761835452286e-06
[ O 0 2.4304065959768195e-07
Ca2 O 0 3.171743685470574e-07
+ O 0 1.225896681944505e-07
] O 0 9.144437740360445e-08
i O 0 2.5830788175085218e-08
than O 0 4.045114021522522e-09
do O 0 1.2530994020210073e-08
wild O 0 3.2011411121857236e-07
- O 0 2.5066020725716953e-07
type O 0 1.6279662418128282e-07
myotubes O 0 1.4856159396003932e-06
because O 0 6.110520978097611e-09
of O 0 1.828542295356783e-08
an O 0 4.049390600613378e-09
altered O 0 2.298209089701686e-08
open O 0 1.570869656575269e-08
probability O 0 5.37003774780942e-09
of O 0 1.5490721594346724e-08
voltage O 0 1.7155178966277163e-07
- O 0 2.2574580782475095e-07
dependent O 0 2.0479484774682533e-08
l O 0 3.101013135164976e-08
- O 0 7.903051368884917e-08
type O 0 1.0026931107631754e-07
Ca2 O 0 1.155268734009951e-07
+ O 0 7.062838136562277e-08
and O 0 3.647911839266271e-08
Na O 0 3.131772609776817e-05
+ O 0 1.620872353669256e-06
channels O 0 1.6617475466773612e-06
. O 0 2.1850289613212226e-06

The O 0 1.3633607522933744e-05
mutant O 0 3.405211464269087e-05
myotubes O 0 4.766855272464454e-05
exhibit O 0 1.6037068917285069e-06
smaller O 0 2.814670949646825e-07
and O 0 5.302418770725126e-08
slower O 0 1.7148440178971214e-07
Ca2 O 0 2.747215148701798e-07
+ O 0 5.8163738714256397e-08
responses O 0 1.0813709927504078e-08
upon O 0 7.561304471437325e-09
triggering O 0 1.0696805219367889e-07
by O 0 6.320189704922541e-09
acetylcholine O 0 9.537142204862903e-07
or O 0 5.250988976968074e-08
high O 0 7.251050533341186e-07
external O 0 7.536226007687219e-07
K O 0 9.208949450112414e-06
+ O 0 5.128771135787247e-06
. O 0 1.7663702465142705e-06

In O 0 4.968455868947785e-07
addition O 0 3.940261876778095e-07
, O 0 5.165480132518496e-08
we O 0 1.2740618338114018e-08
observed O 0 1.6714549744278884e-08
that O 0 1.8694921166684253e-09
these O 0 8.394798634014933e-09
Ca2 O 0 6.281363198468171e-07
+ O 0 4.464803282644425e-07
transients O 0 5.018951014790218e-07
partially O 0 9.072375206642391e-08
result O 0 2.5706865525165767e-09
from O 0 9.679578250043619e-10
an O 0 1.3347183358547454e-09
influx O 0 1.4639964796003824e-08
of O 0 2.0938966116546e-08
extracellular O 0 1.2780795088929153e-07
Ca2 O 0 1.3719862579364417e-07
+ O 0 3.010998383956576e-08
through O 0 3.486673838537513e-09
the O 0 1.4730717090571943e-08
l O 0 6.587107037603346e-08
- O 0 4.209931319110183e-07
type O 0 6.672677841379482e-07
Ca2 O 0 2.1974124138068873e-06
+ O 0 1.3695760117116151e-06
channel O 0 2.1572116111201467e-06
. O 0 2.8872386792500038e-06

Neither O 0 4.981245638191467e-06
the O 0 2.940512331406353e-07
content O 0 1.8119165190455533e-07
nor O 0 3.284205263298645e-08
the O 0 1.659931747610699e-08
activity O 0 1.9419491792405097e-08
of O 0 1.4843341489267914e-07
Na O 0 0.0004357495636213571
+ O 0 2.1789755919598974e-06
/ O 0 2.440548087179195e-06
K O 0 2.8044619284628425e-06
+ O 0 4.818900265490811e-07
ATPase O 0 1.3243064813650562e-06
and O 0 1.1815558309535845e-07
sarcoplasmic O 0 2.1001435015932657e-05
reticulum O 0 6.033546924300026e-06
Ca2 O 0 3.6700880627904553e-06
+ O 0 8.540248472854728e-07
- O 0 6.630942834817688e-07
ATPase O 0 1.323408923781244e-06
are O 0 6.803633656460306e-09
affected O 0 2.296097179055323e-08
by O 0 2.9751587860005202e-08
DMPK O 1 0.9999988079071045
absence O 0 1.848904685175512e-05
. O 0 6.971305992919952e-06

In O 0 7.228810545711895e-07
conclusion O 0 5.434433205664391e-07
, O 0 5.767644495335844e-08
our O 0 2.8332149071275126e-08
data O 0 1.803527105437297e-08
suggest O 0 1.7772805449567386e-08
that O 0 5.09156627970242e-09
DMPK O 1 0.9265227317810059
is O 0 2.3095815038232104e-08
involved O 0 7.634167964454264e-09
in O 0 5.20251619562373e-09
modulating O 0 2.886617380681855e-07
the O 0 2.2690093359756247e-08
initial O 0 2.5379389256841023e-08
events O 0 1.722320064345695e-08
of O 0 3.894478339816487e-08
excitation O 0 9.676398349256488e-07
- O 0 3.457337015788653e-06
contraction O 0 2.8639186666623573e-07
coupling O 0 9.529881594971812e-08
in O 0 2.4320081948303596e-08
skeletal O 0 2.5490820917184465e-05
muscle O 0 1.3762323760602158e-06
. O 0 1.997317298219059e-07
. O 0 1.7588328091733274e-06

Constitutional O 0 0.0015914319083094597
RB1 O 1 1.0
- O 0 0.00024370569735765457
gene O 0 1.0473671636646031e-06
mutations O 0 1.443608113049777e-07
in O 0 1.3391050046607234e-08
patients O 0 4.284661869746742e-08
with O 0 3.8979489858093075e-08
isolated O 0 4.348552920419024e-06
unilateral B-Disease 0 5.9540398069657385e-05
retinoblastoma I-Disease 1 0.9999992847442627
. O 0 4.010937118437141e-05

In O 0 6.618124643864576e-07
most O 0 1.285137898321409e-07
patients O 0 4.0645904419989165e-08
with O 0 1.1843351188645102e-08
isolated O 0 1.45472972690186e-06
unilateral B-Disease 0 2.1701825971831568e-05
retinoblastoma I-Disease 1 1.0
, O 0 6.403156476153526e-07
tumor B-Disease 1 0.9698456525802612
development O 0 4.92917990868591e-08
is O 0 8.472137658088741e-09
initiated O 0 1.957687700837596e-08
by O 0 2.097304996340199e-09
somatic O 0 1.1130281762916638e-07
inactivation O 0 7.540323849752895e-07
of O 0 5.780717415859726e-08
both O 0 1.153603701453676e-08
alleles O 0 1.9052858846180243e-08
of O 0 1.0052341536948006e-07
the O 0 9.034383197104034e-07
RB1 O 1 0.9999963045120239
gene O 0 4.617963440978201e-06
. O 0 3.1526230941381073e-06

However O 0 1.2702215599347255e-06
, O 0 5.000980962677204e-08
some O 0 8.069304335833749e-09
of O 0 4.164806099993257e-08
these O 0 2.1432331465121024e-08
patients O 0 2.843067292701562e-08
can O 0 1.0570203379245413e-08
transmit O 0 2.130565007973928e-06
retinoblastoma B-Disease 0 0.006535755470395088
predisposition O 0 6.376209785230458e-05
to O 0 2.7848093964166765e-07
their O 0 4.106036897155718e-07
offspring O 0 4.539199380815262e-06
. O 0 1.6851063264766708e-06

To O 0 2.822687008574576e-07
determine O 0 5.1084171559523384e-08
the O 0 1.708890806639829e-08
frequency O 0 4.789897545265376e-08
and O 0 1.0126870897408935e-08
nature O 0 9.998056071935935e-08
of O 0 1.1593148485644633e-07
constitutional O 0 6.550636953761568e-06
RB1 O 1 1.0
- O 0 7.702430593781173e-06
gene O 0 1.0099406466679284e-07
mutations O 0 1.312085196047974e-08
in O 0 1.6679128078678218e-09
patients O 0 4.771411710180473e-09
with O 0 2.8285969122521237e-09
isolated O 0 4.157005832894356e-07
unilateral B-Disease 0 3.4792003589245724e-06
retinoblastoma I-Disease 1 0.9997208714485168
, O 0 8.124022343736215e-08
we O 0 1.045479169903274e-08
analyzed O 0 3.0260597583264826e-08
DNA O 0 1.2523872605640918e-08
from O 0 3.133253434484118e-09
peripheral O 0 0.3210821747779846
blood O 0 1.0157923213682807e-07
and O 0 2.4465474979251667e-08
from O 0 1.5999140146050195e-07
tumor B-Disease 1 0.9999963045120239
tissue O 0 1.509366757090902e-05
. O 0 2.7141654754814226e-06

The O 0 1.1252136573602911e-06
analysis O 0 2.020776150857273e-07
of O 0 1.381734819005942e-06
tumors B-Disease 1 1.0
from O 0 8.278962582153326e-08
54 O 0 2.973366974856617e-07
( O 0 4.625273053449064e-09
71 O 0 5.412292836126653e-08
% O 0 1.4770040746014956e-09
) O 0 1.7542902686074058e-09
of O 0 1.8946460400570686e-08
76 O 0 3.178429608396982e-07
informative O 0 2.880567251395405e-07
patients O 0 1.0242803938353973e-08
showed O 0 8.47391490310656e-09
loss O 0 6.611702474401682e-08
of O 0 2.7374653654987924e-07
constitutional O 0 5.350469109544065e-06
heterozygosity O 1 0.9998966455459595
( O 0 7.263092811626848e-07
LOH O 1 1.0
) O 0 4.354767781933333e-07
at O 0 3.33211710312753e-06
intragenic O 0 0.00015211278514470905
loci O 0 2.4479199055349454e-05
. O 0 6.160309112601681e-06

Three O 0 1.8506138985685539e-06
of O 0 1.7185650449391687e-06
13 O 0 2.1484675016836263e-06
uninformative O 0 0.00048223085468634963
patients O 0 1.121162540584919e-06
had O 0 4.868376777267258e-07
constitutional O 0 8.384763532376382e-06
deletions O 0 3.261599340476096e-05
. O 0 1.0771657798613887e-05

For O 0 2.1477853806572966e-06
39 O 0 1.9198228073946666e-06
randomly O 0 1.5558522648007056e-07
selected O 0 5.680402068719559e-07
tumors B-Disease 1 1.0
, O 0 2.591962982023688e-07
SSCP O 1 1.0
, O 0 4.634295578398451e-07
hetero O 0 6.438853233703412e-06
- O 0 7.44672888686182e-07
duplex O 0 5.586045404015749e-07
analysis O 0 2.0174173442910615e-08
, O 0 7.410291047449391e-09
sequencing O 0 3.011963300991738e-08
, O 0 8.001546092373246e-09
and O 0 1.0592767551997895e-08
Southern O 0 2.3274122895600158e-07
blot O 0 4.777260983246379e-06
analysis O 0 1.816636086005019e-08
were O 0 5.50091927564722e-09
used O 0 6.970279464724172e-09
to O 0 3.529047631900539e-08
identify O 0 6.097752134337497e-07
mutations O 0 1.760285954333085e-06
. O 0 2.68124040303519e-06

Mutations O 0 5.233958290773444e-06
were O 0 9.728411498599598e-08
detected O 0 7.043519900662432e-08
in O 0 6.852889367081616e-09
21 O 0 5.600384511694756e-08
( O 0 2.9501245890628525e-09
91 O 0 6.055874735011457e-08
% O 0 1.5497865213376372e-09
) O 0 2.178465630109372e-09
of O 0 6.668187069180931e-08
23 O 0 3.1527013106824597e-06
tumors B-Disease 1 1.0
with O 0 1.0314732207916677e-05
LOH O 1 1.0
. O 0 0.00010364467016188428

In O 0 5.510046889867226e-07
6 O 0 8.011771797100664e-07
( O 0 2.0692374036457295e-08
38 O 0 4.606276249319308e-08
% O 0 2.1522073012647525e-09
) O 0 1.2905406743257686e-09
of O 0 1.7098395588277526e-08
16 O 0 3.7726971413576393e-07
tumors B-Disease 1 1.0
without O 0 1.5315761459078203e-07
LOH O 1 1.0
, O 0 1.242584772853661e-07
one O 0 1.4508009904545816e-08
mutation O 0 1.684721695482949e-08
was O 0 1.3425473177619551e-08
detected O 0 2.9471452833718104e-08
, O 0 2.738847149075241e-09
and O 0 2.2418975564875154e-09
in O 0 2.609769955697061e-09
9 O 0 5.765147648162383e-08
( O 0 2.094778350780757e-09
56 O 0 2.4802307763138742e-08
% O 0 9.469174333531782e-10
) O 0 9.852433313639608e-10
of O 0 1.5483927029436018e-08
the O 0 1.4864646402656945e-07
tumors B-Disease 1 1.0
without O 0 6.870632205391303e-07
LOH O 1 1.0
, O 0 1.448387791924688e-07
both O 0 2.7654305512214705e-08
mutations O 0 4.254546936977022e-08
were O 0 3.186793762210982e-08
found O 0 1.6478728070978832e-07
. O 0 1.3041631063970271e-06

Thus O 0 3.856535840895958e-06
, O 0 8.024230879755123e-08
a O 0 1.4266611891855518e-08
total O 0 1.1644579522851473e-08
of O 0 1.9599369238676445e-08
45 O 0 5.1970939551893025e-08
mutations O 0 1.981089248204171e-08
were O 0 6.947860509143311e-09
identified O 0 2.6841844302794016e-08
in O 0 2.5016772653430053e-08
tumors B-Disease 1 1.0
of O 0 1.6034704458434135e-05
36 O 0 7.731360710749868e-06
patients O 0 4.7261721647373633e-07
. O 0 1.0043485190180945e-06

Thirty O 0 1.1394437933631707e-05
- O 0 7.460469078068854e-07
nine O 0 1.0028919916749146e-07
of O 0 3.5671749998300584e-08
the O 0 1.1954376155642876e-08
mutations O 0 6.82195544499109e-09
- O 0 2.7496046328678858e-08
including O 0 1.1261240828730479e-08
34 O 0 6.823988485393784e-08
small O 0 1.1371666275294956e-08
mutations O 0 5.353174348243783e-09
, O 0 1.238924962621013e-09
2 O 0 1.4788314572911077e-08
large O 0 1.7630965132298115e-08
structural O 0 3.3231981433345936e-07
alterations O 0 4.99405132359243e-07
, O 0 1.5271663045268724e-08
and O 0 1.59003530342261e-08
hypermethylation O 0 4.8314675950678065e-05
in O 0 5.4895181733627396e-08
3 O 0 2.2515385353472084e-05
tumors O 1 1.0
- O 0 6.094804234635376e-07
were O 0 1.8001555801561153e-08
not O 0 3.02284508535422e-09
detected O 0 2.8487342262906168e-08
in O 0 2.477024363400915e-09
the O 0 1.8024712389319575e-08
corresponding O 0 1.1441377267829012e-07
peripheral O 0 4.1389313992112875e-05
blood O 0 7.709065812377958e-07
DNA O 0 2.089824420181685e-06
. O 0 1.2054982789777569e-06

In O 0 5.7683752174853e-07
6 O 0 8.637474024908443e-07
( O 0 1.8113597732849485e-08
17 O 0 3.668313297566783e-08
% O 0 1.93286142646798e-09
) O 0 9.707366022126962e-10
of O 0 6.9550600834134e-09
the O 0 1.2945796434848944e-08
36 O 0 3.2736362953755815e-08
patients O 0 6.984879341587202e-09
, O 0 4.648763152204083e-09
a O 0 1.1452071291273569e-08
mutation O 0 3.0647857585108795e-08
was O 0 4.0742460072351605e-08
detected O 0 1.8592871242617548e-08
in O 0 3.321370956044234e-09
constitutional O 0 4.151569399368782e-08
DNA O 0 1.4482270493942906e-08
, O 0 1.5438976763704204e-09
and O 0 8.540487206332159e-10
1 O 0 1.1173137082209905e-08
of O 0 9.154381253040356e-09
these O 0 2.493011574955517e-09
mutations O 0 5.770876221333765e-09
is O 0 1.1928973364661033e-09
known O 0 3.0484774704575557e-09
to O 0 1.7215014969096387e-09
be O 0 3.5673910492306504e-09
associated O 0 1.3571685997249006e-08
with O 0 2.626830664098634e-08
reduced O 0 3.631969093476073e-06
expressivity O 0 0.00012716324999928474
. O 0 4.863443336944329e-06

The O 0 1.0838818980118958e-06
presence O 0 1.1940001343191398e-07
of O 0 1.3617871275073412e-07
a O 0 3.260462833054589e-08
constitutional O 0 3.352995179284335e-07
mutation O 0 3.584198182693399e-08
was O 0 1.55274015867235e-08
not O 0 5.116827517248623e-10
associated O 0 1.2666322435350708e-09
with O 0 1.1739933469812058e-09
an O 0 5.306817207895165e-09
early O 0 3.679805615774967e-08
age O 0 1.0919271176135226e-07
at O 0 2.1525538329569827e-07
treatment O 0 6.026722303431598e-07
. O 0 7.599259674861969e-07

In O 0 6.630075972680061e-07
1 O 0 1.5889779660938075e-06
patient O 0 5.42932070857205e-07
, O 0 9.805124534523202e-08
somatic O 0 7.442501100740628e-06
mosaicism O 1 0.8815454840660095
was O 0 7.089452651598549e-07
demonstrated O 0 3.869917009069468e-08
by O 0 2.7753739306746184e-09
molecular O 0 2.4426261902021906e-08
analysis O 0 2.629747086757561e-09
of O 0 9.029180070285747e-09
DNA O 0 2.256480335915967e-08
and O 0 7.087476383560443e-09
RNA O 0 1.135105549110449e-06
from O 0 1.259077464510483e-07
peripheral O 1 0.9996495246887207
blood O 0 1.0344295333197806e-05
. O 0 2.8945944450242678e-06

In O 0 1.288369389840227e-06
2 O 0 3.3777700991777238e-06
patients O 0 1.1156700452374935e-07
without O 0 9.50667633503599e-09
a O 0 1.6849305950472626e-08
detectable O 0 4.120584435440833e-06
mutation O 0 6.410299135950481e-08
in O 0 8.83197159851079e-09
peripheral O 1 0.9999597072601318
blood O 0 1.7711911368678557e-06
, O 0 5.783341805454256e-08
mosaicism O 0 0.25224053859710693
was O 0 1.1524517162797565e-07
suggested O 0 1.0845684350613283e-08
because O 0 2.1356949542195025e-09
1 O 0 1.1828181989415043e-08
of O 0 1.3935196108150194e-08
the O 0 3.1185106053044365e-08
patients O 0 3.082814004073953e-08
showed O 0 3.6946244108548854e-07
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 5.880262392565783e-07
the O 0 3.3164607771141164e-07
other O 0 2.411591459861029e-08
later O 0 7.609341423631122e-08
developed O 0 3.313817842354183e-07
bilateral B-Disease 0 9.259259968530387e-06
retinoblastoma I-Disease 1 0.9988564252853394
. O 0 1.913435335154645e-05

In O 0 7.380277793345158e-07
conclusion O 0 3.5166411294085265e-07
, O 0 4.036791878547774e-08
our O 0 1.9417935703813782e-08
results O 0 7.823365066883525e-09
emphasize O 0 1.1615458106462029e-07
that O 0 3.6967153782541118e-09
the O 0 2.5266801984002996e-08
manifestation O 0 4.2187011217720283e-07
and O 0 3.552983329768722e-08
transmissibility O 0 5.718336069548968e-06
of O 0 2.3455947939510224e-07
retinoblastoma B-Disease 0 9.868433608062332e-07
depend O 0 1.0982177833795959e-08
on O 0 1.671802429825675e-08
the O 0 9.068617856655692e-09
nature O 0 2.0883764051404796e-08
of O 0 1.429447671341677e-08
the O 0 6.133173524602853e-09
first O 0 3.890356037317133e-09
mutation O 0 1.3882951455101988e-09
, O 0 3.921554470043276e-10
its O 0 5.894073562551227e-10
time O 0 5.396340596597327e-10
in O 0 3.654475055903106e-10
development O 0 1.944587157964861e-09
, O 0 1.2522720638230567e-09
and O 0 9.346600160498042e-10
the O 0 2.5811270898401517e-09
number O 0 1.9793018335434454e-09
and O 0 2.2072201844025585e-09
types O 0 1.8311601124310073e-08
of O 0 2.572080859408743e-08
cells O 0 1.6869846630740426e-09
that O 0 5.427742144625824e-10
are O 0 4.99348451477033e-10
affected O 0 9.718096549704569e-09
. O 0 3.070959309070531e-08
. O 0 1.0155362133446033e-06

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9952372312545776
the I-Disease 0 2.717710958677344e-05
fifth I-Disease 0 8.612060810264666e-06
component I-Disease 0 2.5499443836451974e-06
of I-Disease 0 3.3614475114518427e-07
complement I-Disease 0 3.113468096671568e-07
in O 0 1.2341736521648272e-07
man O 0 3.125804823866929e-06
. O 0 2.533512088120915e-06

I O 0 0.19333675503730774
. O 0 0.0003087374789174646

Clinical O 0 0.003962763585150242
, O 0 6.923917794665613e-07
immunochemical O 0 0.00047146526048891246
, O 0 2.620336090330966e-07
and O 0 1.5679098908094602e-07
family O 0 4.0681430846234434e-07
studies O 0 1.4001343515701592e-06
. O 0 1.788093527466117e-06

The O 0 3.861802724713925e-06
first O 0 3.3982055924752785e-07
recognized O 0 8.50537162477849e-07
human O 0 2.6632710614649113e-07
kindred O 0 0.00014451374590862542
with O 0 1.8753577535335353e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999997615814209
the I-Disease 0 0.010748852975666523
fifth I-Disease 0 2.4476732960465597e-06
component I-Disease 0 1.265222408619593e-06
of I-Disease 0 2.707674013890937e-07
complement I-Disease 0 7.559792720712721e-07
( O 0 8.645700688703073e-08
C5 O 1 1.0
) O 0 5.7607838499507125e-08
is O 0 6.304360056219593e-08
described O 0 4.832918989450263e-07
. O 0 1.5493816363232327e-06

The O 0 1.2467869055399206e-05
proband O 0 0.00023526052245870233
, O 0 3.342752563639806e-07
a O 0 6.065283741918392e-08
20 O 0 6.524810203245579e-08
- O 0 7.24905291349387e-08
year O 0 1.102547653175634e-08
- O 0 1.2084755951491388e-07
old O 0 1.8384361055723275e-07
black O 0 5.866354513273109e-08
female O 0 9.05470365353267e-09
with O 0 5.4234632784755377e-08
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.09987762570381165
age O 0 1.3854861435902421e-06
11 O 0 1.089266632448016e-07
, O 0 2.3520499325968558e-08
lacked O 0 8.741507144804928e-07
serum O 0 1.6179427575480076e-06
hemolytic O 1 0.8173927068710327
complement O 0 3.502924528220319e-07
activity O 0 1.0893476343198927e-07
, O 0 3.847315355187675e-08
even O 0 6.315637079978842e-08
during O 0 6.332614361781452e-07
remission O 0 1.2458302080631256e-05
. O 0 2.0998274976591347e-06

C5 O 1 1.0
was O 0 2.6566793167148717e-05
undetectable O 0 4.1827490349533036e-05
in O 0 4.5547828619874053e-08
her O 0 2.899440154635613e-08
serum O 0 5.1742166107260346e-08
by O 0 3.935876513594394e-09
both O 0 4.5001900872421174e-08
immunodiffusion O 0 0.0005033662309870124
and O 0 1.8417140381643549e-06
hemolytic O 1 0.9999693632125854
assays O 0 2.5810310035012662e-05
. O 0 1.032411091728136e-05

Other O 0 4.085273133114242e-07
complement O 0 5.713761765946401e-07
components O 0 2.2809773270182632e-07
were O 0 1.3458623548956439e-08
normal O 0 1.2995399423232357e-08
during O 0 5.989258866634373e-09
remission O 0 1.9574886778173095e-07
of O 0 1.1797767740517884e-07
lupus O 1 1.0
, O 0 6.348052039584218e-08
but O 0 3.258088199231679e-08
C1 O 1 0.9998413324356079
, O 0 1.4774224155189586e-07
C4 O 1 1.0
, O 0 2.126968610127733e-07
C2 O 0 0.1523621827363968
, O 0 5.4998938736616765e-08
and O 0 8.3908801684629e-08
C3 O 1 1.0
levels O 0 5.17503440278233e-06
fell O 0 1.1322036698402371e-05
during O 0 2.2577735308004776e-06
exacerbations O 0 0.0006546567310579121
. O 0 1.0486531209608074e-05

A O 0 8.918516869016457e-06
younger O 0 2.2855327586057683e-07
half O 0 9.426438651871649e-08
- O 0 1.057859321917931e-06
sister O 0 3.6642649092755164e-07
, O 0 3.503594925291509e-08
who O 0 1.3860416814281962e-08
had O 0 2.8723698974886247e-08
no O 0 4.785824714303999e-08
underlying O 1 0.9999996423721313
disease O 1 0.9999971389770508
, O 0 3.833968165167789e-08
was O 0 2.799307878831314e-07
also O 0 3.376869628368695e-08
found O 0 2.034345669699178e-08
to O 0 4.770923212049638e-08
lack O 0 2.3961367787705967e-06
immunochemically O 1 0.9991094470024109
detectable O 1 0.9997054934501648
C5 O 1 1.0
. O 0 1.53203473018948e-05

By O 0 3.860506240016548e-06
hemolytic O 0 0.3872605264186859
assay O 0 3.6767969504580833e-06
, O 0 2.658049140791263e-07
she O 0 7.121097667095455e-08
exhibited O 0 1.2654936654143967e-07
1 O 0 5.264627844780989e-08
- O 0 5.825522464419919e-08
2 O 0 5.414739590037243e-08
% O 0 2.287964706582102e-09
of O 0 5.985194118096615e-09
the O 0 1.5339624681587338e-08
normal O 0 5.7673474884722964e-08
serum O 0 4.410165956869605e-07
C5 O 1 0.9989768266677856
level O 0 1.2160528228832845e-07
and O 0 9.270066492206297e-09
normal O 0 1.1320895332289638e-08
concentrations O 0 3.2336217259398836e-08
of O 0 1.352416489908137e-08
other O 0 1.162059515280589e-08
complement O 0 2.322255312492416e-07
components O 0 2.921016175605473e-06
. O 0 3.0528747174685122e-06

C5 O 1 0.9999305009841919
levels O 0 5.680618642145419e-07
of O 0 6.71447750733023e-08
other O 0 9.412242540918214e-09
family O 0 6.821903486553538e-09
members O 0 6.506001848372023e-10
were O 0 1.907910496257159e-09
either O 0 4.0149976676673305e-09
normal O 0 8.710265397837702e-09
or O 0 1.895870571644309e-09
approximately O 0 3.566411388433721e-09
half O 0 7.523627942873645e-09
- O 0 7.789539324676298e-08
normal O 0 2.1386922455235435e-08
, O 0 5.596163976662183e-09
consistent O 0 2.756173422824304e-08
with O 0 7.1855756900163215e-09
autosomal O 0 9.175604418487637e-07
codominant O 0 6.830265647295164e-06
inheritance O 0 4.047192874168104e-07
of O 0 9.656774579980265e-08
the O 0 1.266062241711552e-07
gene O 0 5.972720487079641e-07
determining O 0 0.0001519514189567417
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.6262849132763222e-05

Normal O 0 9.410057100467384e-05
hemolytic O 0 0.04867345467209816
titers O 0 5.7858298532664776e-05
were O 0 1.4455589791850798e-07
restored O 0 4.135376627800724e-07
to O 0 3.264489123466774e-08
both O 0 1.1614351080879715e-07
homozygous O 0 0.00010614174243528396
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 6.743367180206405e-07
C5D B-Disease 1 1.0
) O 0 1.1514234898868381e-07
sera O 0 5.690449597750558e-06
by O 0 5.1678221701934035e-09
addition O 0 4.9692044257199086e-08
of O 0 1.818581409906983e-07
highly O 0 1.5845395182623179e-06
purified O 0 3.963333256251644e-06
human O 0 1.8719071022132994e-06
C5 O 1 0.9999994039535522
. O 0 8.107626854325645e-06

In O 0 8.722254278836772e-07
specific O 0 2.428547077215626e-06
C5 O 1 0.9999996423721313
titrations O 0 1.1563060070329811e-05
, O 0 5.109440337491833e-08
however O 0 1.0635119451762876e-08
, O 0 6.651607264984705e-09
it O 0 4.116486707061995e-09
was O 0 5.831058302874226e-08
noted O 0 1.1378522124516621e-08
that O 0 1.123407589176395e-09
when O 0 3.211400700919853e-09
limited O 0 2.9155651226631107e-09
amounts O 0 1.3642798002422296e-08
of O 0 8.28978627964716e-08
C5 O 1 0.9998069405555725
were O 0 3.930544778540934e-08
assayed O 0 2.0757211416366772e-07
in O 0 3.2258089532888334e-09
the O 0 7.789981992800676e-09
presence O 0 1.6186801232720427e-08
of O 0 6.382531125836977e-08
low O 0 3.458770834185998e-07
dilutions O 0 3.942147486668546e-06
of O 0 4.7121886836976046e-07
either O 0 5.424776077234128e-07
C5D B-Disease 1 1.0
serum O 0 1.8709503137870342e-06
, O 0 5.479057918478247e-08
curving O 0 1.4363535001393757e-06
rather O 0 1.9303977083495738e-08
than O 0 3.4364635581596303e-09
linear O 0 2.657719022636229e-08
dose O 0 1.0581826614952661e-07
- O 0 4.179791446290437e-08
response O 0 8.384525074234261e-09
plots O 0 4.363414518593345e-08
were O 0 1.0350366785871756e-08
consistently O 0 3.1341695461151176e-08
obtained O 0 5.931496183109175e-09
, O 0 5.630628407971017e-09
suggesting O 0 2.1501282532199184e-08
some O 0 8.084633407179354e-09
inhibitory O 0 1.7153295175376115e-06
effect O 0 1.3933846503277891e-06
. O 0 1.8259497664985247e-06

Further O 0 3.940907390642678e-06
studies O 0 3.184983654591633e-07
suggested O 0 7.91410812439608e-08
that O 0 3.3056277715104443e-09
low O 0 2.0965187275123753e-07
dilutions O 0 5.043136297899764e-06
of O 0 1.5232353689498268e-06
C5D B-Disease 1 1.0
serum O 0 4.368860970771493e-07
contain O 0 7.304960547571682e-08
a O 0 6.480789682683508e-09
factor O 0 2.2173145097781344e-08
( O 0 7.644421762265097e-10
or O 0 1.177105524163835e-09
factors O 0 3.0831768249584e-09
) O 0 1.3942792476129284e-09
interfering O 0 2.18701003973365e-08
at O 0 1.6955759463144204e-08
some O 0 3.3107452335201515e-09
step O 0 2.605757210005777e-08
in O 0 3.3619840245080468e-09
the O 0 8.865747957997883e-08
hemolytic O 0 2.3676928321947344e-05
assay O 0 2.6882864290200814e-07
of O 0 9.690592150946031e-07
C5 O 1 1.0
, O 0 2.5659312896664233e-08
rather O 0 6.663340545998153e-09
than O 0 3.6937342073883883e-09
a O 0 2.4103774975969827e-08
true O 0 6.137786954241164e-07
C5 O 1 0.9569478631019592
inhibitor O 0 4.023635028715944e-06
or O 0 7.345085464294243e-07
inactivator O 0 0.00012071729724993929
. O 0 9.690485057944898e-06

Of O 0 1.5728952348581515e-05
clinical O 0 2.304533336427994e-05
interest O 0 1.651746401876153e-07
are O 0 3.9182670441562095e-09
( O 0 1.6582191175729122e-09
a O 0 1.4889717236954425e-09
) O 0 1.12507370086945e-09
the O 0 3.3672977739485077e-09
documentation O 0 1.4578166940282244e-07
of O 0 5.635739626086433e-07
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 0 0.10213223099708557
vasculitis B-Disease 1 1.0
, O 0 1.322176444773504e-06
and O 0 9.738037078932393e-06
arthritis B-Disease 1 1.0
in O 0 3.318542241004252e-08
an O 0 1.4701245554249454e-08
individual O 0 1.6086309173601876e-08
lacking O 0 7.680233693463379e-07
C5 O 1 1.0
( O 0 6.80486644810685e-09
and O 0 5.753412413156411e-09
its O 0 3.4240912327732076e-09
biologic O 0 2.59740176034029e-07
functions O 0 5.576792805328523e-09
) O 0 1.2906933299916545e-09
, O 0 1.4653758206861767e-09
and O 0 2.5323141361610624e-09
( O 0 2.6999567026564364e-09
b O 0 3.315511420964867e-08
) O 0 3.667359971259998e-09
a O 0 1.0053009091848253e-08
remarkable O 0 4.882776849512993e-08
propensity O 0 2.702338974813756e-07
to O 0 1.7491256443236125e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 0.9999992847442627
in O 0 4.951991261492594e-09
the O 0 2.9535602408259365e-08
proband O 0 3.9423859561793506e-05
, O 0 1.2083069655943746e-08
even O 0 4.0387306832201375e-09
during O 0 6.490388670954417e-09
periods O 0 1.864685472696692e-08
of O 0 1.5716519641273408e-08
low O 0 5.561403781939589e-08
- O 0 8.674441431821833e-08
dose O 0 1.0152171370236829e-07
or O 0 6.435066701726555e-09
alternate O 0 4.108174778139073e-08
- O 0 2.861919767838117e-07
day O 0 5.564830303228518e-07
corticosteroid O 0 0.00013294543896336108
therapy O 0 5.342300937627442e-06
. O 0 1.3687651971849846e-06

Other O 0 2.525910531403497e-06
observations O 0 1.4614375913879485e-06
indicate O 0 6.500575011614274e-08
that O 0 5.227084098891055e-09
the O 0 6.5798616333268e-08
C5D B-Disease 1 1.0
state O 0 5.6206740595143856e-08
is O 0 1.4174635687425052e-08
compatible O 0 4.895907323998472e-08
with O 0 3.5705769452221148e-09
normal O 0 1.7901884419302405e-08
coagulation O 0 2.0364154806884471e-07
function O 0 6.237104166473273e-09
and O 0 3.089770217457044e-09
the O 0 1.0811771034013873e-08
capacity O 0 5.694505134101746e-08
to O 0 7.481488495386657e-08
mount O 0 4.092052040505223e-05
a O 0 2.5444446691835765e-06
neutrophilic O 1 0.9985468983650208
leukocytosis O 0 0.0020597842521965504
during O 0 9.61181922320975e-06
pyogenic B-Disease 1 0.8630360960960388
infection I-Disease 0 2.7808608138002455e-05
. O 0 5.304441970110929e-07
. O 0 3.148044470435707e-06

Susceptibility O 0 0.0007739639841020107
to O 0 2.271502853545826e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 2.001024222408887e-05
twins O 0 8.347889206561376e-07
: O 0 4.32744151623865e-09
the O 0 5.566261229716929e-09
role O 0 1.505771507481768e-08
of O 0 3.957429939305257e-08
genes O 0 3.1933470978628975e-08
, O 0 2.0557797242304332e-08
HLA O 1 0.9939951300621033
, O 0 1.0878734713060112e-07
and O 0 9.998112915354795e-08
the O 0 8.326096008204331e-07
environment O 0 1.8659895886230515e-06
. O 0 3.516715196383302e-06

OBJECTIVE O 0 5.334705929271877e-05
To O 0 1.5497228389449447e-07
determine O 0 7.899373599684623e-08
the O 0 1.674320238009841e-08
relative O 0 2.092563100575262e-08
effects O 0 1.3293993106344715e-07
of O 0 5.454845819485854e-08
genetic O 0 4.3617834677434075e-08
and O 0 8.851298360923465e-09
environmental O 0 6.385209871950792e-07
factors O 0 2.1378722792064764e-08
in O 0 3.587123487136523e-09
susceptibility O 0 6.28115913059446e-07
to O 0 1.4836973605270032e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.3697080910205841
AS B-Disease 1 1.0
) O 0 2.080819740513107e-06
. O 0 4.272871137800394e-06

METHODS O 0 2.0620078430511057e-05
Twins O 0 6.505238729914709e-07
with O 0 1.6124461765798515e-08
AS B-Disease 1 0.7274518013000488
were O 0 9.813802215319356e-09
identified O 0 5.525683910434509e-09
from O 0 2.7982300920825764e-09
the O 0 1.4615300081288751e-08
Royal O 0 1.5235390264933812e-06
National O 0 0.00010299834684701636
Hospital O 0 0.42953386902809143
for O 0 1.0442693110235268e-06
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 2.823622889991384e-05
. O 0 3.999883574579144e-06

Clinical O 0 0.00015730209997855127
and O 0 5.638605102831207e-07
radiographic O 0 4.758770955959335e-05
examinations O 0 1.1040123126804247e-06
were O 0 2.022406597745885e-08
performed O 0 2.5908155620868456e-08
to O 0 5.491201271468071e-09
establish O 0 4.4028908519067045e-08
diagnoses O 0 7.548305347881978e-06
, O 0 3.490781352866179e-08
and O 0 1.82670945036989e-07
disease O 1 0.9999661445617676
severity O 1 0.6262355446815491
was O 0 1.3337245263755904e-07
assessed O 0 1.10270995890005e-07
using O 0 3.5877802950778914e-09
a O 0 3.3711340385877975e-09
combination O 0 9.869553174723933e-09
of O 0 7.454879380475177e-08
validated O 0 5.859108114236733e-07
scoring O 0 1.2479566748879733e-06
systems O 0 1.3513083104044199e-05
. O 0 3.1901895454211626e-06

HLA O 0 0.0015480053843930364
typing O 0 1.1464076123957057e-05
for O 0 6.711973696837958e-07
HLA O 1 0.9782190322875977
- O 0 4.6685789129696786e-05
B27 O 0 6.20680075371638e-05
, O 0 1.1125082011176346e-07
HLA O 0 1.5252052435243968e-05
- O 0 1.447384192942991e-06
B60 O 0 4.9814407248049974e-06
, O 0 2.612610217056499e-08
and O 0 2.39009683156155e-08
HLA O 1 0.5956295728683472
- O 0 0.07778284698724747
DR1 O 1 1.0
was O 0 2.5854008072201395e-06
performed O 0 1.604149133527244e-07
by O 0 7.839601856574063e-09
polymerase O 0 1.3194942027894285e-07
chain O 0 8.387168293211289e-08
reaction O 0 3.842436591128262e-09
with O 0 1.2449797859304113e-09
sequence O 0 5.802941238641779e-09
- O 0 1.0603076638915354e-08
specific O 0 4.023184896340126e-09
primers O 0 8.266875539675311e-08
, O 0 6.512486550036556e-09
and O 0 2.5421877936082637e-08
zygosity O 0 9.119406058744062e-06
was O 0 4.468240604182938e-07
assessed O 0 1.9054876929658349e-06
using O 0 4.15141954590581e-07
microsatellite O 0 3.5361510526854545e-05
markers O 0 2.260606925119646e-05
. O 0 6.133432179922238e-06

Genetic O 0 1.3737181689066347e-05
and O 0 1.792861183957939e-07
environmental O 0 7.823202849976951e-07
variance O 0 1.0485029378060062e-07
components O 0 4.8444551481452436e-08
were O 0 4.14546663662918e-09
assessed O 0 2.8212973290919763e-08
with O 0 1.0200492672751693e-09
the O 0 1.049142728248853e-08
program O 0 2.4507182061483945e-08
Mx O 0 2.804018004098907e-05
, O 0 4.69313921058756e-09
using O 0 2.0139907519478584e-09
data O 0 1.8970063297985007e-09
from O 0 9.686097479644218e-10
this O 0 3.328522735213113e-10
and O 0 1.8732113638009196e-09
previous O 0 7.698388593269101e-09
studies O 0 4.126825103867304e-09
of O 0 1.3017850797325536e-08
twins O 0 3.710024998326844e-08
with O 0 1.7112229855342775e-08
AS B-Disease 1 0.9999903440475464
. O 0 4.278877895558253e-06

RESULTS O 0 7.226698926388053e-06
Six O 0 4.909925337415189e-07
of O 0 4.652256109238806e-07
8 O 0 1.93340088117111e-06
monozygotic O 0 1.457377311453456e-05
( O 0 2.6853885515265574e-07
MZ O 1 0.9999998807907104
) O 0 1.766352113463654e-07
twin O 0 1.476419697610254e-06
pairs O 0 2.412769362081235e-08
were O 0 1.9783101379289292e-08
disease O 0 5.870126074114523e-07
concordant O 0 2.6720992991613457e-06
, O 0 7.830217363391512e-09
compared O 0 3.3772675767096416e-09
with O 0 1.9591586131184613e-09
4 O 0 3.294922024110747e-08
of O 0 3.0556101648926415e-08
15 O 0 5.454564799833861e-08
B27 O 0 1.8868638562707929e-06
- O 0 4.976242280463339e-07
positive O 0 6.81646952216397e-08
dizygotic O 0 3.942609964724397e-06
( O 0 1.0528415117505574e-07
DZ O 1 0.9975460171699524
) O 0 1.4001487613768404e-07
twin O 0 9.620124501452665e-07
pairs O 0 2.284451205980531e-08
( O 0 3.4954568128853225e-09
27 O 0 2.714343594334423e-08
% O 0 1.716825570596825e-09
) O 0 8.59095350413952e-10
and O 0 2.492987594138185e-09
4 O 0 4.356121507953503e-08
of O 0 4.597183078658418e-08
32 O 0 1.0195759614362032e-06
DZ O 1 0.9999948740005493
twin O 0 1.9859487565554446e-06
pairs O 0 1.892728107577568e-08
overall O 0 2.6122414453766396e-08
( O 0 3.1354174812037172e-09
12 O 0 1.9301472420352184e-08
. O 0 3.753119148797168e-09
5 O 0 6.884557990360918e-08
% O 0 2.4956436917022984e-08
) O 0 1.1325511195536819e-07
. O 0 1.7965185179491527e-06

Nonsignificant O 0 0.0006034665857441723
increases O 0 6.663380531790608e-07
in O 0 1.9816825513885306e-08
similarity O 0 5.427147087289086e-08
with O 0 3.3154721190697956e-09
regard O 0 4.369727690800573e-08
to O 0 1.161381568692832e-08
age O 0 1.4266343839608453e-07
at O 0 1.886011489204975e-07
disease O 0 3.189938433934003e-05
onset O 0 2.060817365645562e-07
and O 0 4.525252172982164e-09
all O 0 7.223694975522221e-09
of O 0 4.0755050889629274e-08
the O 0 7.754643860380384e-08
disease O 0 2.5610722786950646e-06
severity O 0 6.093444540056225e-07
scores O 0 3.4549330507616105e-08
assessed O 0 5.924014345737305e-08
were O 0 4.923764951314524e-09
noted O 0 1.7777754379721955e-08
in O 0 1.7650783945555304e-08
disease O 0 6.783875960536534e-06
- O 0 1.8865252059185877e-05
concordant O 0 0.004301762208342552
MZ O 1 0.999996542930603
twins O 0 6.45980549052183e-07
compared O 0 8.278599494815353e-08
with O 0 2.1135745953415608e-07
concordant O 0 0.0015697365161031485
DZ O 1 1.0
twins O 0 3.2749579986557364e-05
. O 0 6.388910605892306e-06

HLA O 1 0.9999921321868896
- O 0 0.0004575583734549582
B27 O 0 9.662941738497466e-05
and O 0 1.8444281124629924e-07
B60 O 0 2.5438623652007664e-06
were O 0 6.397581131523111e-09
associated O 0 2.469829674112134e-09
with O 0 2.377242624973519e-09
the O 0 5.3208573547181004e-08
disease O 0 2.760812822089065e-05
in O 0 7.765163623218996e-09
probands O 1 0.7820709347724915
, O 0 1.3134021870087054e-08
and O 0 4.885336135629359e-09
the O 0 1.6736912300530093e-08
rate O 0 1.2761704581976119e-08
of O 0 5.382971934864145e-08
disease O 0 2.353747504457715e-06
concordance O 0 4.1092724245572754e-07
was O 0 4.744697079672733e-08
significantly O 0 5.398958169422485e-09
increased O 0 9.247692389635631e-09
among O 0 5.596647056904658e-08
DZ O 1 0.9999938011169434
twin O 0 1.007614173431648e-06
pairs O 0 4.208275061756694e-09
in O 0 5.659751001196867e-10
which O 0 1.6670318458977817e-09
the O 0 1.550088946089545e-08
co O 0 1.46809640000356e-07
- O 0 8.12078269518679e-07
twin O 0 1.5535184729742468e-06
was O 0 5.8227900723295534e-08
positive O 0 4.011017296079444e-09
for O 0 6.465060486959828e-09
both O 0 6.613594649707011e-08
B27 O 0 1.9762752344831824e-05
and O 0 2.2710107714374317e-06
DR1 O 1 0.9999978542327881
. O 0 3.0533195968018845e-05

Additive O 0 1.391272871842375e-05
genetic O 0 9.466597248319886e-07
effects O 0 5.301048418004939e-07
were O 0 1.1882518080597038e-08
estimated O 0 1.5769487049510644e-08
to O 0 6.667879581812031e-09
contribute O 0 3.498126233125731e-08
97 O 0 1.7705482946439588e-07
% O 0 3.6348939413954895e-09
of O 0 1.3239432661293904e-08
the O 0 2.8978368149523703e-08
population O 0 1.1629198048979106e-08
variance O 0 6.150349349809403e-07
. O 0 9.498430131316127e-07

CONCLUSION O 0 2.0931451217620634e-05
Susceptibility O 0 6.579782166227233e-06
to O 0 1.7084516912291292e-07
AS B-Disease 1 0.9999998807907104
is O 0 5.346626252844544e-08
largely O 0 2.2830660029171668e-08
genetically O 0 1.2867808152350335e-08
determined O 0 4.195252145677841e-09
, O 0 1.7412293829011105e-09
and O 0 2.8208817504093986e-09
the O 0 1.7911856886598798e-08
environmental O 0 2.1496398403542116e-06
trigger O 0 1.1231151120227878e-07
for O 0 6.667332463905495e-09
the O 0 9.08810164901297e-08
disease O 0 1.0742563063104171e-05
is O 0 6.942948971300211e-08
probably O 0 3.8797472257101617e-07
ubiquitous O 0 1.2443554624042008e-05
. O 0 3.4119555039069382e-06

HLA O 1 0.988810658454895
- O 0 3.302588811493479e-05
B27 O 0 1.5697885828558356e-05
accounts O 0 4.580649459740016e-08
for O 0 7.4399761906818185e-09
a O 0 1.5027330491079738e-08
minority O 0 1.6389011037176715e-08
of O 0 5.371372324702861e-08
the O 0 7.585749983718415e-08
overall O 0 2.2288972445494437e-07
genetic O 0 2.3485046085625072e-07
susceptibility O 0 4.984473775948572e-07
to O 0 2.5658417257545807e-07
AS B-Disease 1 1.0
. O 0 9.195628081215546e-06

Cell O 0 2.7504460376803763e-05
cycle O 0 2.2682902454107534e-06
- O 0 9.611494533601217e-07
dependent O 0 1.9924735283893824e-07
colocalization O 0 3.985924649896333e-06
of O 0 5.077299647382461e-07
BARD1 O 1 0.9999974966049194
and O 0 3.123708154362248e-07
BRCA1 O 0 1.0037146012109588e-06
proteins O 0 1.4391346780939784e-08
in O 0 1.1386338094609982e-08
discrete O 0 9.144679893324792e-07
nuclear O 0 4.3323266254446935e-06
domains O 0 7.501837899326347e-06
. O 0 4.479090875975089e-06

Germ O 0 0.0002751282590907067
- O 0 4.7936632654455025e-06
line O 0 1.1450474630692042e-06
mutations O 0 5.7111257945052785e-08
of O 0 7.898033516084979e-08
the O 0 2.8564909371198155e-07
BRCA1 O 0 8.600635737820994e-06
gene O 0 1.1532344501574698e-07
predispose O 0 5.712213919650821e-07
women O 0 1.507230229513823e-09
to O 0 7.592516615417821e-10
early O 0 1.5044422596588447e-08
- O 0 7.723591261310503e-05
onset O 1 0.9978559613227844
breast B-Disease 1 1.0
and I-Disease 1 0.9999836683273315
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 7.416258274162146e-09
compromising O 0 9.780447953744442e-07
the O 0 9.015553814606392e-08
genes O 0 3.979258877961911e-08
presumptive O 0 1.258886754840205e-06
function O 0 3.6216572851799356e-08
as O 0 3.1893964802520713e-08
a O 0 2.5905791289915214e-07
tumor B-Disease 0 0.0170393418520689
suppressor O 0 0.4620510935783386
. O 0 1.848904685175512e-05

Although O 0 2.920620545410202e-06
the O 0 4.2326726656938263e-07
biochemical O 0 2.4783121261862107e-06
properties O 0 7.804959523127764e-07
of O 0 4.3894166878999386e-07
BRCA1 O 0 6.72301155191235e-07
polypeptides O 0 5.9319066991747604e-08
are O 0 7.725980410988598e-10
not O 0 4.3460837706454925e-10
understood O 0 1.6027996707634884e-08
, O 0 3.576656748549567e-09
their O 0 3.6562337601964146e-09
expression O 0 2.2305361113694744e-08
pattern O 0 4.050304269753724e-08
and O 0 1.3823823863390317e-08
subcellular O 0 6.758425570296822e-07
localization O 0 3.875309744216793e-07
suggest O 0 2.999351522703364e-08
a O 0 2.6088654792033594e-08
role O 0 6.872920010891903e-08
in O 0 2.692449996288815e-08
cell O 0 8.54182815146487e-07
- O 0 4.376389824756188e-06
cycle O 0 2.7474718535813736e-06
regulation O 0 3.67540496881702e-06
. O 0 1.8264913705934305e-06

When O 0 2.362085751883569e-06
resting O 0 1.1013098628609441e-05
cells O 0 4.0251059374440956e-08
are O 0 2.382476438356207e-09
induced O 0 3.508175794308954e-08
to O 0 6.034241994967715e-09
proliferate O 0 7.116793909744956e-08
, O 0 6.850563227800421e-09
the O 0 1.0097168434697323e-08
steady O 0 3.370614720665799e-08
- O 0 1.7883932557083426e-08
state O 0 2.9625522035559015e-09
levels O 0 9.12098840899489e-09
of O 0 1.8508167443087586e-08
BRCA1 O 0 4.5352258837283443e-08
increase O 0 1.1891263529406615e-09
in O 0 3.011077387427008e-09
late O 0 5.579966000368586e-08
G1 O 0 5.056008376413956e-06
and O 0 1.530300863805678e-08
reach O 0 2.3202137100497566e-08
a O 0 1.46900891451196e-08
maximum O 0 8.54632844493608e-08
during O 0 1.9963518127497082e-07
S O 0 1.9296105165267363e-05
phase O 0 9.524059350951575e-06
. O 0 3.312482476758305e-06

Moreover O 0 9.434995263291057e-06
, O 0 2.7120157142235257e-07
in O 0 9.6661736392889e-08
S O 0 5.707946002075914e-06
phase O 0 5.738017989642685e-07
cells O 0 3.490568190045451e-08
, O 0 4.266419040277469e-08
BRCA1 O 0 5.653865855492768e-07
polypeptides O 0 1.6378797340621531e-07
are O 0 6.8912942019494494e-09
hyperphosphorylated O 0 1.4976674265199108e-06
and O 0 5.10011304299951e-08
accumulate O 0 3.1855850579631806e-07
into O 0 5.532330860091861e-08
discrete O 0 5.18360138812568e-07
subnuclear O 0 9.660837349656504e-06
foci O 0 9.819365914154332e-06
termed O 0 2.8416902750905138e-06
" O 0 1.670596475378261e-06
BRCA1 O 0 1.5388322935905308e-05
nuclear O 0 1.60640302055981e-05
dots O 0 6.93140464136377e-05
. O 0 1.2667529517784715e-05

" O 0 0.00013456081796903163
BRCA1 O 0 0.00015382030687760562
associates O 0 3.3189458008564543e-06
in O 0 1.147832833225948e-07
vivo O 0 6.22905815816921e-07
with O 0 1.755586609419879e-08
a O 0 1.0974267183883057e-07
structurally O 0 2.0967556793038966e-06
related O 0 1.0478946705916314e-06
protein O 0 2.172965650970582e-06
termed O 0 1.4234955415304285e-05
BARD1 O 1 0.9999992847442627
. O 0 1.6326555851264857e-05

Here O 0 8.123291763695306e-07
we O 0 7.715075867054111e-08
show O 0 4.3491478862733857e-08
that O 0 3.220736788378531e-09
the O 0 1.4581136298374986e-08
steady O 0 2.2483520822902392e-08
- O 0 2.0051913907082053e-08
state O 0 3.740277421115934e-09
levels O 0 1.2580374075810141e-08
of O 0 2.3939747961776447e-08
BARD1 O 1 0.9696512222290039
, O 0 6.834353971640894e-09
unlike O 0 7.521576250724138e-09
those O 0 4.582018764409668e-09
of O 0 5.5687596756115454e-08
BRCA1 O 0 8.00178440840682e-07
, O 0 1.9907938408891823e-08
remain O 0 4.686281229737688e-08
relatively O 0 1.4875872089703535e-08
constant O 0 4.42213874407571e-08
during O 0 9.763470387724738e-08
cell O 0 1.2083781939509208e-06
cycle O 0 2.1665057374775643e-06
progression O 0 7.3897822403523605e-06
. O 0 2.0419242900970858e-06

However O 0 6.43275279799127e-06
, O 0 8.190314702005708e-07
immunostaining O 0 4.491788422456011e-05
revealed O 0 1.198360564558243e-06
that O 0 6.627194437669459e-08
BARD1 O 1 0.9999955892562866
resides O 0 8.353563316632062e-06
within O 0 3.0971239084465196e-07
BRCA1 O 0 1.5719957673354656e-06
nuclear O 0 5.786701535726024e-07
dots O 0 6.101160465732391e-07
during O 0 6.396095386662637e-08
S O 0 8.805506013231934e-07
phase O 0 1.1496327800841755e-07
of O 0 3.352316824134505e-08
the O 0 1.6360369059498225e-08
cell O 0 6.78630769357369e-08
cycle O 0 4.7130829017305587e-08
, O 0 3.843052542862324e-09
but O 0 2.858786096737731e-09
not O 0 2.0163664071759513e-09
during O 0 4.067707948252064e-08
the O 0 4.937837161378411e-07
G1 O 0 0.00024370523169636726
phase O 0 2.0120825865888037e-05
. O 0 6.914772711752448e-06

Nevertheless O 0 5.586296538240276e-05
, O 0 1.606848513802106e-06
BARD1 O 0 0.003997510764747858
polypeptides O 0 7.915147648418497e-07
are O 0 5.47213119261869e-09
found O 0 2.044009850266093e-09
exclusively O 0 4.678348375364294e-09
in O 0 9.407643553061007e-10
the O 0 8.626194869520987e-09
nuclear O 0 4.790938845644632e-08
fractions O 0 1.5671917097392907e-08
of O 0 1.7293976029009173e-08
both O 0 1.0073200940041716e-08
G1 O 0 2.6694511689129286e-05
- O 0 8.517879450664623e-07
and O 0 1.3781470897811232e-07
S O 0 9.994697393267415e-06
- O 0 2.035601255556685e-06
phase O 0 3.768712304008659e-06
cells O 0 5.749356546402851e-07
. O 0 7.970816682245641e-07

Therefore O 0 3.2033476600190625e-06
, O 0 1.9533281658823398e-07
progression O 0 6.935423471077229e-07
to O 0 4.77292552147901e-08
S O 0 4.1496919038763735e-06
phase O 0 2.3034715468384093e-07
is O 0 7.4279093986717726e-09
accompanied O 0 6.543289909899386e-09
by O 0 7.178024286069729e-10
the O 0 1.0824212637317032e-08
aggregation O 0 1.1677524724973409e-07
of O 0 2.4102402562675707e-07
nuclear O 0 2.9944694688310847e-06
BARD1 O 0 0.08677513897418976
polypeptides O 0 1.9260837689216714e-06
into O 0 5.173348540665756e-07
BRCA1 O 0 1.6276497262879275e-05
nuclear O 0 1.1547939720912836e-05
dots O 0 5.079688344267197e-05
. O 0 7.661691597604658e-06

This O 0 1.0036322919404483e-06
cell O 0 1.3340238638193114e-06
cycle O 0 4.587202511174837e-07
- O 0 2.9384068511717487e-07
dependent O 0 6.513396044738329e-08
colocalization O 0 1.6174844859051518e-06
of O 0 2.340497928798868e-07
BARD1 O 1 0.9999992847442627
and O 0 2.3198336407403986e-07
BRCA1 O 0 1.3536598544305889e-06
indicates O 0 3.29342668692334e-08
a O 0 4.5960408812106834e-09
role O 0 2.484283534442966e-08
for O 0 3.8696217785627596e-08
BARD1 O 1 0.9999998807907104
in O 0 4.501357580011245e-07
BRCA1 O 0 8.695632277522236e-05
- O 0 2.2039788746042177e-05
mediated O 0 1.6880378097994253e-05
tumor B-Disease 1 0.9335601329803467
suppression O 1 0.969977855682373
. O 0 1.4617841770814266e-05

Ethnic O 0 1.1012804861820769e-05
differences O 0 6.789260623918381e-06
in O 0 6.448929070757004e-07
the O 0 2.0997931642341428e-06
HFE O 0 0.0029546192381531
codon O 0 2.478149144735653e-05
282 O 0 1.0810298590513412e-05
( O 0 1.5205503132165177e-06
Cys O 1 1.0
/ O 0 0.003801795421168208
Tyr O 0 0.042337559163570404
) O 0 2.081979118884192e-06
polymorphism O 0 7.404632015095558e-06
. O 0 6.9657835410907865e-06

Recent O 0 1.3275373476062668e-06
studies O 0 5.0436085530236596e-08
have O 0 3.9123819739472765e-09
shown O 0 1.2015960670908044e-08
that O 0 6.56351701877611e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9999772310256958
HH B-Disease 1 1.0
) O 0 1.555706745648422e-07
is O 0 1.2482615829867427e-08
likely O 0 3.974280904373018e-09
to O 0 3.120520286614692e-09
be O 0 3.9330170231721695e-09
caused O 0 1.8243619948066225e-08
by O 0 2.8419380182498344e-09
homozygosity O 0 4.724401151179336e-06
for O 0 2.960412892605291e-08
a O 0 4.8009461295350775e-08
Cys282Tyr O 0 8.502520358888432e-06
mutation O 0 3.098021750247426e-08
in O 0 5.761780830226826e-09
the O 0 9.122348387791135e-08
HFE O 0 0.0007754541584290564
gene O 0 3.5622736049845116e-07
located O 0 1.0147346074518282e-06
4 O 0 2.8253145956114167e-06
. O 0 1.7571294392837444e-06

5 O 0 6.912499520694837e-05
Mb O 0 0.0006922687753103673
telomeric O 0 0.0002958577824756503
to O 0 5.3125081649341155e-06
HLA O 1 0.9999994039535522
- O 0 0.42161574959754944
A O 0 0.0001529099972685799
. O 0 1.2112592230550945e-05

Population O 0 4.378663334136945e-07
studies O 0 8.396323636361558e-08
of O 0 2.8453619904666994e-08
this O 0 1.6116215029171599e-09
polymorphism O 0 9.53271417358792e-09
are O 0 1.081937761604479e-09
facilitated O 0 9.721693672304355e-09
by O 0 1.5174907996851061e-09
the O 0 1.6677354608418682e-08
fact O 0 2.396414444660877e-08
that O 0 3.4851979080485762e-09
the O 0 1.0637639036303881e-07
Cys282Tyr O 0 5.174677062314004e-05
mutation O 0 3.723715167325281e-07
creates O 0 7.680922635699972e-07
a O 0 3.201715230716218e-07
Rsal O 0 8.850599260767922e-05
restriction O 0 4.131567038712092e-06
site O 0 1.1587058907025494e-05
. O 0 5.38458061782876e-06

We O 0 1.4658400004918803e-06
have O 0 6.082662196149613e-08
studied O 0 5.974708869871392e-07
the O 0 1.5052981439112045e-07
codon O 0 1.8002471051659086e-06
282 O 0 1.302460191254795e-06
( O 0 3.703698041590542e-07
Cys O 1 1.0
/ O 0 0.00016458012396469712
Tyr O 0 0.00019578312640078366
) O 0 3.6784445711646185e-08
polymorphism O 0 8.348795432766565e-09
in O 0 3.692008698763516e-09
different O 0 2.9119693323309548e-09
ethnic O 0 4.562991406942274e-08
groups O 0 3.6793565527659666e-08
. O 0 9.423919209439191e-07

In O 0 2.771982394733641e-07
agreement O 0 2.3184934150322078e-07
with O 0 2.0506140785414573e-08
previous O 0 1.2850287589571963e-07
observations O 0 2.1016955997765763e-07
the O 0 1.2237426005867746e-07
Tyr O 0 0.00017539234249852598
allele O 0 1.6695757665274868e-07
appeared O 0 2.8160179965652787e-08
to O 0 3.5252916141814694e-09
be O 0 6.392946172439906e-09
rare O 0 6.417052134111145e-08
or O 0 3.00640756734083e-08
absent O 0 8.045947197388159e-08
in O 0 8.914970095474928e-09
Asiatic O 0 2.6707234610512387e-06
( O 0 6.9451311368595725e-09
Indian O 0 1.7390229700708915e-08
, O 0 1.4713952722900103e-08
Chinese O 0 9.47156735264798e-08
) O 0 1.0020200846838634e-07
populations O 0 5.380820198297442e-07
. O 0 1.1624473472693353e-06

The O 0 2.8704366741294507e-06
highest O 0 9.894113190966891e-07
allele O 0 1.3300207513111673e-07
frequency O 0 5.375308020916236e-08
( O 0 3.106777723971277e-09
7 O 0 2.756920025603904e-08
. O 0 2.0862773730812023e-09
5 O 0 1.498493951146429e-08
% O 0 3.681615234896185e-09
) O 0 3.87283183300724e-09
was O 0 5.673505398817724e-08
found O 0 3.2212241762863414e-08
in O 0 6.95968083164189e-08
Swedes O 0 1.4646392628492322e-05
. O 0 4.999187240173342e-06

Saamis O 0 0.0009652490844018757
( O 0 3.606636767017335e-07
2 O 0 4.997267524231574e-07
% O 0 1.6431515703629884e-08
) O 0 6.967780574740345e-09
and O 0 1.8029355786097767e-08
Mordvinians O 0 7.004191957094008e-06
( O 0 6.232359517355235e-09
1 O 0 2.854793557105495e-08
. O 0 2.568319557028076e-09
8 O 0 2.0488158725129324e-08
% O 0 4.821251398112736e-09
) O 0 2.2993567050377806e-09
had O 0 4.834059819103231e-09
significantly O 0 4.17452294954046e-09
lower O 0 1.6048430140358505e-08
frequencies O 0 2.1899653646073602e-08
of O 0 9.013456292450428e-08
the O 0 5.190956926526269e-07
Tyr O 0 0.0003441664157435298
allele O 0 7.505809662688989e-06
. O 0 3.4480256090319017e-06

Comparisons O 0 4.358142632554518e-06
with O 0 1.771689994711778e-07
allele O 0 4.3498204149727826e-07
frequencies O 0 9.409768608747981e-08
based O 0 1.4578661833297701e-08
on O 0 4.689392696377581e-08
prevalence O 0 3.0244447657423734e-07
estimates O 0 5.597672014800992e-08
of O 0 1.5043883649923373e-07
HH B-Disease 1 1.0
showed O 0 2.2274481636941346e-07
some O 0 2.3929567660729845e-08
disagreements O 0 1.0464725619385717e-06
with O 0 2.9520622391032703e-08
the O 0 1.7151711517726653e-07
RFLP O 0 8.313413673022296e-06
data O 0 1.08984849589433e-07
, O 0 3.086873689994718e-08
particularly O 0 8.437019261009482e-08
in O 0 1.4532830050484336e-07
Finns O 0 5.208262155065313e-05
. O 0 5.797351150249597e-06

The O 0 1.6943133232416585e-05
newly O 0 3.5894281609216705e-05
described O 0 7.805869245203212e-06
HFE O 1 0.9990228414535522
marker O 0 2.3086948203854263e-05
provides O 0 9.350405605346168e-08
a O 0 8.977525389752827e-09
new O 0 3.74387409962651e-09
approach O 0 5.964805538383189e-09
to O 0 1.1440363101300477e-09
the O 0 5.0692019470943706e-09
screening O 0 4.172112966216446e-08
of O 0 1.3352313033010432e-07
HH B-Disease 1 1.0
as O 0 4.313006840561684e-08
well O 0 9.604878670188555e-09
as O 0 2.707599477957956e-09
studies O 0 4.086509353129486e-09
of O 0 8.45712300190371e-09
the O 0 9.22776433043282e-09
relationship O 0 7.199238982735778e-09
between O 0 9.65690016840881e-09
the O 0 1.6381314082991594e-07
HFE O 1 0.9844909310340881
Tyr O 0 0.00013730552745983005
allele O 0 2.5551679527779925e-07
and O 0 2.09186463706601e-08
different O 0 1.6676916914093454e-07
disorders O 1 0.9999997615814209
including O 0 0.00024766294518485665
cancer B-Disease 1 1.0

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999635219573975
associated O 0 4.517557670169481e-07
with O 0 6.780356187618963e-08
a O 0 1.9240664528297202e-07
missense O 0 1.9791912109212717e-06
mutation O 0 1.409856338341342e-07
encoding O 0 6.725704793097975e-07
Gly23 O 0 0.0002934995573014021
- O 0 2.52587105933344e-05
- O 0 2.641397986735683e-05
> O 0 5.395478638092754e-06
Val O 0 2.9973904020152986e-05
in O 0 3.4710996033027186e-07
neurophysin O 0 0.00044487009290605783
II O 1 1.0
. O 0 2.253972525068093e-05

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 2.6983263978763716e-06
ADNDI B-Disease 1 1.0
) O 0 1.8518413469337247e-07
is O 0 3.809134696552974e-08
an O 0 8.157467590308443e-08
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 3.886023023369489e-06
by O 0 3.4211684152296584e-08
progressive O 1 0.9595219492912292
degeneration O 1 1.0
of O 1 0.9999716281890869
the O 0 1.054064432537416e-05
magnocellular O 0 0.4301004111766815
neurons O 0 2.0046449833444058e-07
of O 0 1.0961146017507417e-06
the O 0 3.5545469927455997e-06
hypothalamus O 0 0.00015607906971126795
leading O 0 6.75733588195726e-07
to O 0 4.494202698879235e-08
decreased O 0 2.1147559436940355e-07
ability O 0 1.511191882741514e-08
to O 0 1.6510211864328994e-08
produce O 0 1.264111375576249e-07
the O 0 2.792218367630994e-07
hormone O 0 2.013075800277875e-06
arginine O 0 5.766010872321203e-06
vasopressin O 0 1.2897528904431965e-05
( O 0 5.988028419778857e-07
AVP O 1 0.9620627760887146
) O 0 1.3745625437877607e-06
. O 0 4.909517883788794e-06

Affected O 0 1.4690419902763097e-06
individuals O 0 1.7910421590272563e-08
are O 0 2.898222328795441e-09
not O 0 2.9096653975102527e-09
symptomatic O 0 4.3531568394428177e-07
at O 0 7.971221549496477e-08
birth O 0 3.6949831638821706e-08
, O 0 5.796347846143135e-09
but O 0 6.482668624130383e-09
usually O 0 5.0974190202168757e-08
develop O 0 1.160635065389215e-06
diabetes B-Disease 1 0.9999908208847046
insipidus I-Disease 0 0.00011803597590187564
at O 0 2.3024567497031967e-07
1 O 0 3.4530231118878874e-07
- O 0 1.3766905340162339e-06
6 O 0 2.2668175461149076e-06
yr O 0 7.333144458243623e-05
of O 0 1.2426244211383164e-06
age O 0 1.7504544302937575e-06
. O 0 1.2394123132253299e-06

The O 0 5.363077434594743e-06
genetic O 0 2.6621055440045893e-06
locus O 0 5.9296316976542585e-06
of O 0 5.089316914563824e-07
the O 0 2.3910823188089125e-07
disease O 0 0.000363453320460394
is O 0 2.4824505118203888e-08
the O 0 1.0793396398867117e-07
AVP O 1 0.9999984502792358
- O 0 3.619677227106877e-05
neurophysin O 1 0.9999382495880127
II O 1 1.0
( O 0 1.1828139889757949e-07
NPII O 1 0.9999998807907104
) O 0 1.861203280384416e-08
gene O 0 1.3881979121777022e-08
, O 0 4.816701704157822e-09
and O 0 8.521290340013365e-09
mutations O 0 2.9722604821813547e-08
that O 0 2.965865331105988e-09
cause O 0 6.00510986714653e-07
ADNDI B-Disease 1 1.0
have O 0 1.4836174067056618e-08
been O 0 4.980417855904307e-09
found O 0 1.2384193670555987e-09
in O 0 5.517540313526581e-10
both O 0 1.4972562079051954e-09
the O 0 5.096735922194284e-09
signal O 0 2.4505077078629256e-08
peptide O 0 1.9059509526186957e-08
of O 0 4.560729038871614e-08
the O 0 1.250483023795823e-07
prepro O 0 0.04034307971596718
- O 0 0.040084805339574814
AVP O 1 0.9999998807907104
- O 0 5.196365964366123e-05
NPII O 1 0.9999394416809082
precursor O 0 8.756416605137929e-07
and O 0 9.579633797329734e-08
within O 0 3.3830559686975903e-07
NPII O 1 0.8474181890487671
itself O 0 3.5797686450678157e-06
. O 0 3.0239882562455023e-06

An O 0 1.1365169712007628e-06
affected O 0 1.0395654044259572e-06
girl O 0 7.677568305552995e-07
who O 0 3.49455184789349e-08
presented O 0 4.594991409589966e-08
at O 0 3.7646277206704326e-08
9 O 0 3.622189126417652e-08
months O 0 4.012057797098123e-09
of O 0 7.228974308048919e-09
age O 0 1.0311844711452522e-08
and O 0 2.7526361190410853e-09
her O 0 8.95023788416438e-09
similarly O 0 1.1892971052418488e-08
affected O 0 1.3345255567287495e-08
younger O 0 2.7378769473784814e-08
brother O 0 4.7911218103990905e-08
and O 0 2.3459611142584436e-08
father O 0 7.049782624335421e-08
were O 0 1.4697964623167081e-08
all O 0 9.138505951966636e-09
found O 0 3.104953183452608e-09
to O 0 3.5965501687940105e-09
have O 0 5.196932661988285e-09
a O 0 2.817586697290153e-08
novel O 0 1.0549960052230745e-06
missense O 0 2.0131449218752095e-06
mutation O 0 1.484591791722778e-07
( O 0 1.3795403042138332e-08
G1758 O 0 4.74121407023631e-06
- O 0 1.7684535578155192e-06
- O 0 2.0940738068020437e-06
> O 0 4.931737862534646e-07
T O 0 4.1337997913615254e-07
) O 0 4.476491177740627e-09
encoding O 0 2.8559806963812662e-08
the O 0 1.4793449132355363e-08
amino O 0 1.580966113579052e-08
acid O 0 1.6640147038060604e-08
substitution O 0 5.0225178682694605e-08
Gly23 O 0 1.9189230442862026e-05
- O 0 7.947862286528107e-06
- O 0 3.487443973426707e-05
> O 0 1.3260834748507477e-05
Val O 0 0.00020397080515976995
within O 0 3.280685859863297e-06
NPII O 1 0.9444060921669006
. O 0 1.9064229491050355e-05

The O 0 5.981161848467309e-06
mutation O 0 1.392849299008958e-06
was O 0 2.9775185339531163e-07
confirmed O 0 1.1506605801514525e-07
by O 0 2.9768731479862254e-08
restriction O 0 1.4631654039476416e-06
endonuclease O 0 1.4303021089290269e-05
analysis O 0 1.0860775319088134e-06
. O 0 2.437145440126187e-06

A O 0 0.0001973266334971413
T1 O 0 0.0017878200160339475
- O 0 9.865444553724956e-06
weighted O 0 4.303793048165971e-06
magnetic O 0 4.0047402194431925e-07
resonance O 0 2.3448859565178282e-07
imaging O 0 6.551721867253946e-07
of O 0 2.704471171455225e-07
the O 0 6.216228030098137e-07
fathers O 0 2.5732911126397084e-06
pituitary O 1 0.9999879598617554
gland O 1 0.8050206303596497
demonstrates O 0 7.515591278206557e-07
an O 0 1.1085641204999774e-07
attenuated O 0 9.752559708431363e-05
posterior O 0 9.362717537442222e-05
pituitary O 1 0.9999997615814209
bright O 0 0.001105435541830957
spot O 0 0.00030759963556192815
. O 0 2.4337208742508665e-05

This O 0 4.1266898165304156e-07
mutation O 0 1.9985365895536233e-07
may O 0 8.006340479482787e-09
be O 0 2.69790279006088e-09
valuable O 0 2.785791508586044e-08
for O 0 2.959316125483724e-09
developing O 0 7.040400706870287e-09
models O 0 1.6373762790067303e-08
of O 0 9.630820585471156e-08
dominantly B-Disease 1 0.999847412109375
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 7.455476946915951e-08
as O 0 8.246368032871487e-09
the O 0 5.8150178006144415e-09
early O 0 3.4325329245632474e-09
age O 0 8.419139163606815e-09
of O 0 9.20557852168713e-09
onset O 0 2.023477236434701e-06
of O 0 1.1241806987527525e-06
symptoms O 1 0.511265754699707
suggests O 0 8.825066899476042e-09
that O 0 3.2540542482806245e-10
this O 0 1.0140086548204863e-09
mutation O 0 5.657477153420132e-09
may O 0 1.341927124975939e-09
be O 0 2.2906281316181776e-09
particularly O 0 1.8581172156473258e-08
deleterious O 0 4.4513939201351604e-07
to O 0 5.093026089753039e-08
the O 0 8.533522759535117e-07
magnocellular O 0 0.0001572673354530707
neuron O 0 2.951777560156188e-06
. O 0 4.2984791548406065e-07
. O 0 2.648509507707786e-06

Frequent O 0 2.5461640689172782e-05
inactivation O 0 0.00028508054674603045
of O 0 0.0001504425599705428
PTEN O 1 1.0
/ O 1 0.9999657869338989
MMAC1 O 1 1.0
in O 0 2.0190243503748206e-06
primary O 1 0.9999986886978149
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.6687028619344346e-05

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 0.00036841590190306306
the O 0 4.527809949195216e-07
most O 0 3.5268875819838286e-08
common O 0 1.3938350207354233e-07
male B-Disease 0 8.522838612634587e-08
cancer I-Disease 0 1.5056599522722536e-07
in O 0 2.1705524044790536e-09
the O 0 2.0421598634356997e-08
Western O 0 1.1904641183946296e-07
world O 0 1.0191123500646881e-08
, O 0 1.237519753338745e-09
yet O 0 5.960663074233707e-10
many O 0 3.8492492526742694e-10
of O 0 3.7940655062129736e-09
the O 0 7.824066727835088e-09
major O 0 7.840457527663602e-08
genetic O 0 3.54582105899226e-08
events O 0 9.248044996468252e-09
involved O 0 3.039849261199379e-09
in O 0 1.0924927629218928e-09
the O 0 9.881665263833384e-09
progression O 0 1.402530358518561e-07
of O 0 1.966587426238675e-08
this O 0 6.057154333660719e-09
often O 0 9.112557819435096e-08
fatal O 0 0.0553981214761734
cancer B-Disease 0 3.7793437513755634e-05
remain O 0 1.2203560117995949e-07
to O 0 3.870802700589593e-08
be O 0 1.9426924779963883e-07
elucidated O 0 4.750600055558607e-05
. O 0 4.83144867757801e-06

Numerous O 0 2.822034730343148e-05
cytogenetic O 0 0.05402359366416931
and O 0 1.4310046481114114e-06
allelotype O 0 0.3068787455558777
studies O 0 1.9638255821519124e-07
have O 0 3.380844493250379e-09
reported O 0 1.1464900140367718e-08
frequent O 0 8.959550257259252e-08
loss O 0 6.825757736805826e-07
of O 0 1.4914445500835427e-06
heterozygosity O 1 0.9707334041595459
on O 0 4.163474841334391e-06
chromosomal O 0 0.01035909540951252
arm O 0 1.5089996850292664e-05
10q O 0 5.652660547639243e-05
in O 0 3.536821111538302e-07
sporadic B-Disease 1 0.9999949932098389
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.397539901721757e-05

Deletion O 0 0.00010061647481052205
mapping O 0 3.2731359169702046e-06
studies O 0 7.445343612744182e-07
have O 0 4.546294363194647e-08
unambiguously O 0 1.564435706313816e-06
identified O 0 7.548987213112923e-08
a O 0 2.2423776613322843e-08
region O 0 2.0586388416177215e-07
of O 0 2.7403959279581613e-07
chromosome O 0 6.422592946364603e-07
10q23 O 0 1.5496076457566232e-06
to O 0 8.104795945484966e-09
be O 0 5.530428559552547e-09
the O 0 1.2480616540244682e-08
minimal O 0 1.799861024665006e-07
area O 0 3.840731892523763e-07
of O 0 5.608598598882963e-07
loss O 0 1.3538273378799204e-05
. O 0 3.651856331998715e-06

A O 0 1.3823865629092325e-05
new O 0 1.2065104328939924e-06
tumor B-Disease 0 4.2923205910483375e-05
suppressor O 0 0.00017149580526165664
gene O 0 5.871341386409767e-07
, O 0 3.6769299072147987e-07
PTEN O 1 1.0
/ O 1 0.9998592138290405
MMAC1 O 1 1.0
, O 0 4.3615924028017616e-07
was O 0 1.2613719491127995e-06
isolated O 0 3.0930328875911073e-07
recently O 0 5.524326951444891e-08
at O 0 3.336382192742349e-08
this O 0 3.5079263938087024e-09
region O 0 6.901754545651784e-08
of O 0 8.205923052173603e-08
chromosome O 0 4.826967483495537e-07
10q23 O 0 1.9289088868390536e-06
and O 0 9.438741344069967e-09
found O 0 3.5299208001049465e-09
to O 0 1.672930904916825e-09
be O 0 1.0601048927583179e-09
inactivated O 0 1.655103432085525e-07
by O 0 3.0218363367140455e-09
mutation O 0 1.4407001813765419e-08
in O 0 5.6847566654028014e-09
three O 0 5.341845508155529e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.00012785532453563064
lines O 0 8.688151865499094e-06
. O 0 5.7337792895850725e-06

We O 0 3.3889150472532492e-06
screened O 0 1.4983766050136182e-05
80 O 0 4.0952763811219484e-05
prostate B-Disease 1 1.0
tumors I-Disease 1 1.0
by O 0 4.277696419308086e-08
microsatellite O 0 3.93339814763749e-06
analysis O 0 4.8238383953957964e-08
and O 0 1.876888688912004e-08
found O 0 3.826932370998293e-08
chromosome O 0 1.4247989099658298e-07
10q23 O 0 8.923699397200835e-07
to O 0 2.082958161508941e-08
be O 0 2.4409681387282944e-08
deleted O 0 4.4950942879040667e-07
in O 0 2.7944180303052235e-08
23 O 0 7.013784397713607e-07
cases O 0 2.4721975933061913e-07
. O 0 1.1840662637041532e-06

We O 0 1.6947633412200958e-06
then O 0 1.7106297889313282e-07
proceeded O 0 8.542580332004945e-08
with O 0 2.7203388430763198e-09
sequence O 0 6.996345724985531e-09
analysis O 0 3.2273106409519414e-09
of O 0 2.444728330885937e-08
the O 0 7.790460188061843e-08
entire O 0 6.520557235489832e-06
PTEN O 1 1.0
/ O 0 0.0001130104428739287
MMAC1 O 1 1.0
coding O 0 5.478782895806944e-06
region O 0 1.6794817270238127e-07
and O 0 1.989044129402373e-08
tested O 0 2.8672790364225875e-08
for O 0 5.524967150449811e-09
homozygous O 0 6.905612792706961e-08
deletion O 0 3.2590083520744884e-08
with O 0 2.264939347185191e-09
new O 0 2.914388197439166e-08
intragenic O 0 1.6506377505720593e-05
markers O 0 3.0219104019124643e-07
in O 0 4.850758461572013e-09
these O 0 3.194953634988451e-09
23 O 0 1.467827015488865e-08
cases O 0 2.520378572512527e-09
with O 0 7.688981895626057e-09
10q23 O 0 1.938467175932601e-05
loss O 0 5.610216248896904e-06
of O 0 1.3950100765214302e-05
heterozygosity O 0 0.4091019928455353
. O 0 1.3777970707451459e-05

The O 0 4.1839433606583043e-07
identification O 0 1.216834704109715e-07
of O 0 2.0707760484128812e-07
the O 0 1.3391463937750814e-07
second O 0 4.0480225038663775e-07
mutational O 0 1.5389041436719708e-05
event O 0 1.7158959053631406e-07
in O 0 8.797304218433055e-09
10 O 0 1.8242994670458756e-08
( O 0 3.015031335706908e-09
43 O 0 4.4597729953466114e-08
% O 0 9.541736289975233e-09
) O 0 8.868319412158598e-08
tumors B-Disease 1 1.0
establishes O 0 0.00017447791469749063
PTEN O 1 1.0
/ O 0 0.00020814192248508334
MMAC1 O 1 0.9999991655349731
as O 0 6.83777301446753e-08
a O 0 2.1630851776421878e-08
main O 0 2.0808425915674889e-07
inactivation O 0 1.5083749076438835e-06
target O 0 6.893453274869898e-08
of O 0 1.0983396947494839e-07
10q O 0 1.0388011105533224e-05
loss O 0 1.0772012046800228e-06
in O 0 1.0481150525265548e-07
sporadic B-Disease 1 0.9999972581863403
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.93992605090898e-06
. O 0 4.120215180591913e-06

Risk O 0 7.209493196569383e-05
reversals O 0 4.498011549003422e-06
in O 0 1.0312044196325587e-07
predictive O 0 1.7021965277308482e-06
testing O 0 4.4178943880979205e-07
for O 0 6.534299927807297e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.0722379556682426e-05

The O 0 1.8117350464308402e-06
first O 0 9.694127101056438e-08
predictive O 0 4.019666732801852e-07
testing O 0 5.740393760333973e-08
for O 0 9.157353275668356e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 8.285297070642628e-08
HD B-Disease 1 1.0
) O 0 1.2286560213681241e-08
was O 0 1.2523514669737779e-08
based O 0 2.7225759424709395e-09
on O 0 4.71668704093986e-09
analysis O 0 4.687386923052372e-09
of O 0 2.9033250470433813e-08
linked O 0 1.8362950982009352e-07
polymorphic O 0 6.765150715182244e-07
DNA O 0 7.105061428092085e-08
markers O 0 7.007834312844352e-08
to O 0 3.768361622746852e-09
estimate O 0 1.6684035486491666e-08
the O 0 1.814880157269272e-08
likelihood O 0 5.5827658940188485e-08
of O 0 7.875920005062653e-08
inheriting O 0 6.744730853824876e-07
the O 0 1.4042996099306038e-07
mutation O 0 9.70685647416758e-08
for O 0 1.0778028780578097e-07
HD B-Disease 1 0.999966025352478
. O 0 6.7468927227309905e-06

Limits O 0 3.6523506423691288e-06
to O 0 9.166947734229325e-08
accuracy O 0 3.100132346389728e-07
included O 0 4.3688359596671944e-08
recombination O 0 1.1223073137500705e-08
between O 0 7.854239925109141e-09
the O 0 1.0127218175171038e-08
DNA O 0 2.0603096118065878e-08
markers O 0 5.146009129930462e-08
and O 0 4.415949828029397e-09
the O 0 2.2350077344412966e-08
mutation O 0 1.1429595048184638e-08
, O 0 3.5197891268268222e-09
pedigree O 0 7.480803532189384e-08
structure O 0 4.8895991255903937e-08
, O 0 6.291564158544816e-09
and O 0 3.240844481666727e-09
whether O 0 3.00012770182434e-09
DNA O 0 6.2967981939721085e-09
samples O 0 2.3407393801022636e-09
were O 0 1.0551706175476738e-09
available O 0 1.3244275676171924e-09
from O 0 6.560135101807418e-09
family O 0 5.992701090917762e-08
members O 0 7.670763579881168e-08
. O 0 9.605272452972713e-07

With O 0 1.741340582839257e-07
direct O 0 3.4667749559957883e-08
tests O 0 5.400080826944986e-09
for O 0 2.9030133852359086e-09
the O 0 3.1796780319837126e-08
HD B-Disease 1 0.9999990463256836
mutation O 0 6.275411124079255e-08
, O 0 5.7074203141382895e-09
we O 0 2.109517227566471e-09
have O 0 8.771146031705257e-10
assessed O 0 6.613392855570055e-08
the O 0 1.168759222736071e-08
accuracy O 0 7.291485815130727e-08
of O 0 3.3810977129178355e-08
results O 0 5.4325921539088995e-09
obtained O 0 2.9204019202921927e-09
by O 0 9.650450438769553e-10
linkage O 0 5.835264360598558e-08
approaches O 0 3.365982692571379e-08
when O 0 3.3899232310119487e-09
requested O 0 1.2459162590516826e-08
to O 0 7.906350241171367e-09
do O 0 8.644641447119739e-09
so O 0 3.5966121192387845e-09
by O 0 3.6104406131443056e-09
the O 0 6.459910650846723e-08
test O 0 7.350201514100263e-08
individuals O 0 4.288324717549585e-08
. O 0 7.809189241925196e-07

For O 0 4.1148177842842415e-07
six O 0 3.986277974377117e-08
such O 0 7.487880537837555e-09
individuals O 0 2.1095334368226304e-09
, O 0 3.389877933912544e-09
there O 0 5.882160980519302e-09
was O 0 6.37396695424286e-08
significant O 0 7.054504180814547e-08
disparity O 0 6.548998499056324e-07
between O 0 3.6696778948908104e-08
the O 0 5.181411779631162e-07
tests O 0 5.041445092501817e-07
. O 0 1.8941095731861424e-06

Three O 0 1.7914406953423168e-06
went O 0 4.5497424139284703e-07
from O 0 3.534949044592395e-08
a O 0 2.0960664315339272e-08
decreased O 0 7.850887584481825e-08
risk O 0 1.0030350772183283e-08
to O 0 7.981148519853321e-10
an O 0 8.095553671871869e-10
increased O 0 5.320245577422611e-09
risk O 0 1.9538678230901496e-08
, O 0 1.7802923579779417e-09
while O 0 1.6894866616823379e-09
in O 0 1.350907496977527e-09
another O 0 5.535494285169307e-09
three O 0 5.519058543512756e-09
the O 0 3.0093104896877776e-08
risk O 0 2.354299226681178e-07
was O 0 6.989752137087635e-07
decreased O 0 2.650811438797973e-06
. O 0 3.74515889234317e-06

Knowledge O 0 3.0546307243639603e-06
of O 0 4.474355250749795e-07
the O 0 1.0067691391668632e-07
potential O 0 5.551356707655941e-08
reasons O 0 1.4819741878113746e-08
for O 0 1.6630081756119353e-09
these O 0 1.21900090022109e-09
changes O 0 1.8651824529314354e-09
in O 0 6.810848551808135e-10
results O 0 1.523828063731969e-09
and O 0 1.6177068573597353e-09
impact O 0 1.965953622118377e-08
of O 0 1.072875832619502e-08
these O 0 1.606483723826102e-09
risk O 0 9.104649478786087e-09
reversals O 0 1.7269385921281355e-08
on O 0 1.3103096385691515e-08
both O 0 3.4857960962142442e-09
patients O 0 4.988517154913552e-09
and O 0 3.4078158073214126e-09
the O 0 2.497653284194712e-08
counseling O 0 1.4964433248110254e-08
team O 0 2.8008839692006404e-09
can O 0 5.825249727031689e-10
assist O 0 7.009181679507037e-09
in O 0 1.6502049726696555e-09
the O 0 4.521559127113051e-09
development O 0 2.17162887672373e-09
of O 0 4.477294091032036e-09
strategies O 0 3.1208058359766255e-09
for O 0 3.6304301231915304e-10
the O 0 1.6758403553751577e-09
prevention O 0 6.772498295504192e-08
and O 0 2.3496273815482027e-09
, O 0 1.57454638216592e-09
where O 0 1.575291452837746e-09
necessary O 0 6.353354731203353e-09
, O 0 2.5168764850036496e-09
management O 0 2.4375765406148275e-08
of O 0 3.637226342334543e-08
a O 0 3.514518098768349e-08
risk O 0 9.989039995161875e-08
reversal O 0 1.9830626030170606e-08
in O 0 2.9114641808547503e-09
any O 0 1.3322087433209617e-08
predictive O 0 5.587858353806041e-08
testing O 0 2.8505494853448e-08
program O 0 3.2547344375188914e-08
. O 0 3.651740243526547e-08
. O 0 5.15762451414048e-07

A O 0 4.7919867938617244e-05
novel O 0 2.481100455042906e-05
common O 0 2.702225401662872e-06
missense O 0 4.662583705794532e-06
mutation O 0 2.425472303002607e-07
G301C O 0 1.0856674634851515e-06
in O 0 9.274364387579226e-09
the O 0 4.3859433418447225e-08
N O 0 5.306688422024308e-07
- O 0 5.05921263993514e-07
acetylgalactosamine O 0 8.152961527230218e-06
- O 0 8.114063234643254e-07
6 O 0 1.1996470448139007e-06
- O 0 2.3928485006763367e-06
sulfate O 0 4.847056970902486e-06
sulfatase O 0 5.25436807947699e-05
gene O 0 4.625151461823407e-07
in O 0 3.381246642675251e-07
mucopolysaccharidosis B-Disease 1 0.6312541365623474
IVA I-Disease 1 1.0
. O 0 9.61757468758151e-05

Mucopolysaccharidosis B-Disease 1 1.0
IVA I-Disease 1 1.0
( O 1 0.8530149459838867
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.235111423942726e-06
is O 0 1.0506930436804396e-07
an O 0 7.822219316722112e-08
autosomal B-Disease 1 0.9994753003120422
recessive I-Disease 1 0.9999983310699463
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 8.161777032000828e-07
by O 0 7.994849227088707e-09
a O 0 1.8887978114889847e-07
genetic B-Disease 1 1.0
defect I-Disease 1 0.999998927116394
in O 0 4.777661644084219e-08
N O 0 1.4970191841712222e-06
- O 0 6.821176725679834e-07
acetylgalactosamine O 0 1.2522159522632137e-05
- O 0 1.1232601764277206e-06
6 O 0 1.2807531675207429e-06
- O 0 3.947753157262923e-06
sulfate O 0 7.66498033044627e-06
sulfatase O 0 0.0001123405309044756
( O 0 2.9708982651754923e-07
GALNS O 1 0.9978341460227966
) O 0 1.3260201967568719e-06
. O 0 5.103361218061764e-06

In O 0 5.013789063923468e-07
previous O 0 1.224933754429003e-07
studies O 0 4.580815726740184e-08
, O 0 7.470049467883655e-09
we O 0 2.575009983019072e-09
have O 0 5.720080520354998e-10
found O 0 1.0478483636333635e-09
two O 0 1.3969944090419517e-09
common O 0 1.30367352468852e-08
mutations O 0 8.184113831077866e-09
in O 0 4.784361351539701e-09
Caucasians O 0 7.858675985517038e-07
and O 0 5.528332636117739e-08
Japanese O 0 1.6280808949886705e-06
, O 0 2.6613363957039837e-07
respectively O 0 2.733802375587402e-06
. O 0 3.829156412393786e-06

To O 0 1.5668680362068699e-06
characterize O 0 4.753728262585355e-06
the O 0 8.879707138476078e-07
mutational O 0 1.8803712009685114e-05
spectrum O 0 5.930186830482853e-07
in O 0 7.046459415960271e-09
various O 0 7.290467340936857e-09
ethnic O 0 1.659187987002042e-08
groups O 0 1.3786610741917116e-09
, O 0 5.071097319842011e-09
mutations O 0 6.286454468096281e-09
in O 0 3.1513838205654565e-09
the O 0 6.635340099592213e-08
GALNS O 1 0.9999558925628662
gene O 0 3.5552883304035277e-08
in O 0 5.643164602275874e-09
Colombian O 0 1.2778647942468524e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 7.202783763204934e-06
were O 0 1.663595661227646e-08
investigated O 0 8.233860882000954e-08
, O 0 5.155693205693979e-09
and O 0 7.129588919241314e-09
genetic O 0 4.6080685933702625e-08
backgrounds O 0 9.857362925913549e-09
were O 0 5.20589127361859e-09
extensively O 0 1.5238319051036342e-08
analyzed O 0 1.4539783599332168e-08
to O 0 2.56045917801373e-09
identify O 0 1.29232970991211e-08
racial O 0 4.098188455259333e-08
origin O 0 4.882466875244518e-09
, O 0 1.0633917080227206e-09
based O 0 2.3768209622687664e-09
on O 0 1.5063056579833756e-08
mitochondrial O 0 4.004659359679863e-08
DNA O 0 5.46944143309247e-08
( O 0 1.9138232332238658e-08
mtDNA O 0 1.415170629570639e-07
) O 0 9.938677436593935e-08
lineages O 0 7.593471309519373e-07
. O 0 1.1662316410365747e-06

Three O 0 6.263456270971801e-06
novel O 0 2.024325294769369e-05
missense O 0 1.155461541202385e-05
mutations O 0 3.03290164538339e-07
never O 0 1.3867773418496654e-07
identified O 0 2.2571647662061878e-08
previously O 0 4.4971180557240586e-08
in O 0 2.5152016025487e-09
other O 0 2.731246340204052e-09
populations O 0 2.8069859769885852e-09
and O 0 1.2579792763034447e-09
found O 0 2.184773917335292e-09
in O 0 1.0386531634765106e-09
16 O 0 1.1853769521508184e-08
out O 0 5.0281037111687965e-09
of O 0 3.200774401079798e-08
19 O 0 2.3558106931886869e-07
Colombian O 0 3.996783561888151e-06
MPS B-Disease 1 0.999421238899231
IVA I-Disease 1 1.0
unrelated O 0 1.334362241323106e-05
alleles O 0 1.0791666937848277e-07
account O 0 1.3385329289405945e-08
for O 0 5.0138748264316746e-08
84 O 0 5.489311206474667e-06
. O 0 2.749482064245967e-06

2 O 0 2.013524863286875e-06
% O 0 4.557606914090684e-08
of O 0 5.7040821843656886e-08
the O 0 5.755831011811097e-08
alleles O 0 3.031466988545617e-08
in O 0 7.2473773649051054e-09
this O 0 2.6765821559138203e-08
study O 0 3.8268896673798736e-07
. O 0 1.1033723694708897e-06

The O 0 1.6256053640972823e-05
G301C O 0 0.00010974179167533293
and O 0 1.1954191450058715e-06
S162F O 0 3.5733453842112795e-05
mutations O 0 6.694897933812172e-07
account O 0 1.5256880203651235e-07
for O 0 1.8193829021129204e-07
68 O 0 1.2249632163729984e-05
. O 0 5.750569016527152e-06

4 O 0 1.046345460053999e-05
% O 0 5.390172646002611e-07
and O 0 2.228159843298272e-07
10 O 0 1.4275942703534383e-06
. O 0 6.252941147977253e-06

5 O 0 1.0380921366959228e-06
% O 0 4.735068515060448e-08
of O 0 3.476316834394311e-08
mutations O 0 2.7635167043627007e-08
, O 0 1.1469078131653987e-08
respectively O 0 3.104155155142507e-08
, O 0 9.497070685426934e-09
whereas O 0 2.0673438072549288e-08
the O 0 3.5695503441957044e-08
remaining O 0 7.119440397218568e-07
F69V O 1 0.9996473789215088
is O 0 4.4115154196333606e-08
limited O 0 2.3479575617102455e-08
to O 0 2.3271542914926613e-08
a O 0 8.051750199911112e-08
single O 0 2.4706514523131773e-07
allele O 0 1.6368991282433853e-06
. O 0 1.9422957393544493e-06

The O 0 4.577602339850273e-06
skewed O 0 3.5245718663645675e-06
prevalence O 0 3.0385579066205537e-06
of O 0 4.742724399875442e-07
G301C O 0 7.077434929669835e-06
in O 0 1.997770127104559e-08
only O 0 1.1055083959377043e-08
Colombian O 0 4.1934544015020947e-07
patients O 0 3.127707870476115e-08
and O 0 1.4038759488244068e-08
haplotype O 0 3.572364164483588e-07
analysis O 0 1.4766499134566402e-08
by O 0 3.1289415503010787e-09
restriction O 0 4.881705706338835e-08
fragment O 0 7.935769019695726e-08
length O 0 4.7838625505391974e-08
polymorphisms O 0 4.108174778139073e-08
in O 0 1.2919896263952069e-08
the O 0 2.2568791280264122e-07
GALNS O 1 0.9999816417694092
gene O 0 3.001749462328007e-07
suggest O 0 6.698616061839857e-08
that O 0 1.1939222943624372e-08
G301C O 0 2.4853272861946607e-06
originated O 0 4.9606246221856054e-08
from O 0 9.158030778166903e-09
a O 0 4.138358633554162e-08
common O 0 3.1825152291276027e-07
ancestor O 0 2.1210021259321366e-06
. O 0 2.3601380689797224e-06

Investigation O 0 5.1488746066752356e-06
of O 0 9.80377535597654e-07
the O 0 2.104587650819667e-07
genetic O 0 9.990926486125318e-08
background O 0 1.883674194402829e-08
by O 0 2.469862536713663e-09
means O 0 6.429744559000028e-08
of O 0 1.0920687998350331e-07
mtDNA O 0 7.784949218603288e-08
lineages O 0 1.9292198061293675e-08
indicate O 0 1.929137738443387e-09
that O 0 5.392502555601197e-10
all O 0 2.2082897732644824e-09
our O 0 5.12133091490341e-09
patients O 0 4.074298232126239e-09
are O 0 6.819987352635337e-10
probably O 0 1.073797051276415e-08
of O 0 7.143421498767566e-08
native O 0 1.4255045925892773e-06
American O 0 4.704538241639966e-06
descent O 0 2.3873071768321097e-05

Low O 0 6.187534836499253e-06
frequency O 0 1.1487487654449069e-06
of O 0 9.481161669100402e-07
BRCA1 O 0 6.840799869678449e-06
germline O 0 1.1999582056887448e-06
mutations O 0 3.391095404481348e-08
in O 0 6.437792077207405e-09
45 O 0 2.1315130993571074e-07
German O 1 0.9999995231628418
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.135860305927054e-07
. O 0 1.2854851547672297e-06

In O 0 5.393787887442159e-07
this O 0 2.2448940484309787e-08
study O 0 2.844054236561533e-08
we O 0 5.329447549939914e-09
investigated O 0 6.389365125869517e-08
45 O 0 7.092388187857068e-08
German O 1 0.9991629123687744
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.1918864501202506e-09
for O 0 2.9035673865251965e-09
germline O 0 1.3215519345521898e-07
mutations O 0 1.7241344352214583e-08
in O 0 1.4180908891603394e-08
the O 0 5.123972073306504e-07
BRCA1 O 0 9.671032785263378e-06
gene O 0 1.245600060428842e-06
. O 0 2.32695151680673e-06

We O 0 7.468855187653389e-07
identified O 0 3.4012725791399134e-07
four O 0 4.6094751127156997e-08
germline O 0 4.866385552304564e-07
mutations O 0 2.0817866541733565e-08
in O 0 3.938249282242623e-09
three O 0 3.88618239810512e-08
breast B-Disease 1 0.9996953010559082
cancer I-Disease 0 1.3932337424193975e-05
families O 0 7.22746806847141e-10
and O 0 1.073616306968006e-09
in O 0 2.839857460301687e-09
one O 0 2.4531109943382035e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 2.123206499504704e-08
. O 0 8.949533336632953e-10
among O 0 1.5019785415404385e-09
these O 0 5.674982150871699e-10
were O 0 2.4001092224779086e-09
one O 0 1.5311474754753363e-08
frameshift O 0 1.0110226185133797e-06
mutation O 0 3.569666162661633e-08
, O 0 7.086895514873959e-09
one O 0 1.217365763750422e-08
nonsense O 0 2.805265069127927e-07
mutation O 0 1.6142003289587592e-08
, O 0 5.078492293364434e-09
one O 0 1.3763181705428451e-08
novel O 0 2.5225398303518887e-07
splice O 0 1.718042199172487e-06
site O 0 2.1316310494512436e-07
mutation O 0 3.637649470533688e-08
, O 0 7.539587620897237e-09
and O 0 2.7556266601891366e-08
one O 0 2.18977987742619e-07
missense O 0 1.3243267858342733e-05
mutation O 0 3.6635556170949712e-06
. O 0 2.480231842127978e-06

The O 0 1.653498475207016e-05
missense O 0 4.3683518015313894e-05
mutation O 0 1.6504283166796085e-06
was O 0 8.826415864859882e-07
also O 0 1.330762842144395e-07
found O 0 4.8281002307248855e-08
in O 0 5.6510952362032185e-08
2 O 0 5.4817410273244604e-06
. O 0 4.711331257567508e-06

8 O 0 1.5528548829024658e-06
% O 0 4.3152205364549445e-08
of O 0 3.3057872883546224e-08
the O 0 1.3976774404511616e-08
general O 0 1.801577731441739e-08
population O 0 2.9025097880719386e-09
, O 0 3.5376721552182744e-09
suggesting O 0 6.052661927213876e-09
that O 0 1.291496132260761e-09
it O 0 3.829807582178546e-09
is O 0 8.941877460699743e-09
not O 0 9.257344224522512e-09
disease O 0 1.212976940223598e-06
associated O 0 4.3407862904132344e-07
. O 0 4.079248810739955e-06

The O 0 2.028193193837069e-06
average O 0 2.458469623434212e-07
age O 0 1.5195587366179097e-07
of O 0 2.5532776248837763e-07
disease O 0 0.0017367885448038578
onset O 0 4.076967172750301e-07
in O 0 5.146752357632067e-09
those O 0 6.755942916214508e-09
families O 0 3.3556608602935967e-09
harbouring O 0 2.5312613161077024e-06
causative O 0 8.139063538692426e-06
mutations O 0 4.240143312017608e-07
was O 0 4.066734788921167e-07
between O 0 2.1019199891725293e-07
32 O 0 6.683869742118986e-06
. O 0 4.5710153244726826e-06

3 O 0 1.9949804482166655e-05
and O 0 3.4551878798083635e-06
37 O 0 3.479106453596614e-05
. O 0 1.3710899111174513e-05

4 O 0 2.5996669137384742e-06
years O 0 1.3377805885284033e-07
, O 0 2.2667382637564515e-08
whereas O 0 2.8084119918503347e-08
the O 0 2.038548529981199e-08
family O 0 4.756403626515748e-08
harbouring O 0 4.580493168759858e-06
the O 0 1.6271870606487937e-07
missense O 0 1.3003131016375846e-06
mutation O 0 3.782030333354669e-08
had O 0 1.0056595556307002e-08
an O 0 2.4881137150600807e-09
average O 0 6.896304416414978e-09
age O 0 2.482251559854376e-08
of O 0 7.999383200285592e-08
onset O 0 1.0430231895952602e-06
of O 0 1.281217464565998e-06
51 O 0 9.699888323666528e-06
. O 0 2.825422370733577e-06

2 O 0 0.0001680729037616402
years O 0 2.4031596694840118e-05
. O 0 3.55522170139011e-05

These O 0 6.374976351253281e-07
findings O 0 1.768398334434096e-07
show O 0 5.837802419250693e-08
that O 0 3.855939922914331e-08
BRCA1 O 0 2.4361042960663326e-06
is O 0 2.1438095743064878e-08
implicated O 0 1.1722915616019236e-07
in O 0 3.735144193939277e-09
a O 0 4.442722634223628e-09
small O 0 5.699826832739063e-09
fraction O 0 1.687355499768728e-08
of O 0 1.3203593880461995e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.790398217518032e-09
suggesting O 0 5.63245450280192e-09
the O 0 5.306867389975878e-09
involvement O 0 3.4344076027537085e-08
of O 0 5.115905565844514e-08
another O 0 8.459933553695009e-08
susceptibility O 0 1.8372968497715192e-06
gene O 0 8.495959491483518e-07
( O 0 3.363884957252594e-07
s O 0 8.595618055551313e-06
) O 0 4.2690426198532805e-06

Paternal O 0 0.0012963362969458103
transmission O 1 0.9939642548561096
of O 1 0.9999996423721313
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9848949313163757

We O 0 1.321728859693394e-06
report O 0 1.3979325785840047e-07
a O 0 4.934475938966898e-08
rare O 0 9.079957408175687e-08
case O 0 8.648768101693349e-08
of O 0 8.012910370780446e-07
paternally O 1 0.9999997615814209
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9877408146858215
DM B-Disease 1 1.0
) O 0 6.025025413691765e-06
. O 0 9.093690096051432e-06

The O 0 9.370253792440053e-06
proband O 0 0.0001448119874112308
is O 0 1.1180261338950004e-07
a O 0 2.6857717827510896e-08
23 O 0 4.478628312654109e-08
year O 0 1.4805559445107974e-08
old O 0 1.0906403531407705e-06
, O 0 5.919993100178544e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 4.025776433991268e-06
who O 0 2.1565203951467993e-06
suffers O 1 1.0
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.07595410943031311

He O 0 4.688763056037715e-06
presented O 0 1.969550794456154e-06
with O 0 4.20262239231306e-07
respiratory O 1 1.0
and O 0 6.657193694081798e-07
feeding O 0 4.7529611038044095e-05
difficulties O 0 1.0350689990445971e-05
at O 0 4.532166258286452e-06
birth O 0 2.571237928350456e-06
. O 0 1.76117589489877e-06

His O 0 2.4709941499168053e-05
two O 0 4.362255367595935e-06
sibs O 1 0.9639458656311035
suffer O 0 1.1271994480921421e-05
from O 0 1.424623860657448e-06
childhood O 0 0.15489362180233002
onset O 1 0.9999921321868896
DM B-Disease 1 1.0
. O 0 6.001318615744822e-05

Their O 0 6.001840802127845e-07
late O 0 4.2975284486601595e-07
father O 0 2.8080916081307805e-07
had O 0 3.22132827079713e-08
the O 0 1.512985825513624e-08
adult O 0 2.529202092205196e-08
type O 0 1.862360932136653e-08
of O 0 4.6476529291794577e-07
DM B-Disease 1 1.0
, O 0 1.3978191759633773e-07
with O 0 2.8180918931752785e-08
onset O 0 2.706424083953607e-06
around O 0 1.7762579318514327e-07
30 O 0 4.5173638341111655e-07
years O 0 2.2921990705526696e-07
. O 0 2.0042523374286247e-06

Only O 0 3.0884703505762445e-07
six O 0 3.926617964111756e-08
other O 0 2.9203071072458897e-09
cases O 0 2.4664073006164244e-09
of O 0 1.9731889011609383e-08
paternal O 0 2.3952413812367013e-06
transmission O 1 0.9867755770683289
of O 1 1.0
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 3.4975659218616784e-05
been O 0 5.75183548789937e-07
reported O 0 6.991625696173287e-07
recently O 0 2.766064426396042e-06
. O 0 2.72229249276279e-06

We O 0 1.8233761238661828e-06
review O 0 1.000826046038128e-06
the O 0 1.0502121483568772e-07
sex O 0 3.1158769786543417e-08
related O 0 3.642613677357076e-08
effects O 0 1.916307468263767e-07
on O 0 9.172177328764519e-08
transmission O 0 4.5241249608807266e-06
of O 0 0.002168136416003108
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0005073504289612174

Decreased O 0 2.4310393200721592e-05
fertility O 0 9.632655064706341e-07
of O 0 9.030905090412489e-08
males O 0 8.252645677941928e-09
with O 0 2.4962232281211527e-09
adult O 0 3.6189439356348885e-07
onset O 0 8.860007073963061e-05
DM B-Disease 1 1.0
and O 0 1.430683767011942e-07
contraction O 0 1.026637690415555e-07
of O 0 2.6236961048198282e-08
the O 0 2.1986874543244994e-08
repeat O 0 5.251019175034344e-08
upon O 0 2.4904416306981147e-08
male O 0 2.169328361389944e-08
transmission O 0 1.9584421195872892e-08
contribute O 0 6.816817332833125e-09
to O 0 5.964373439582005e-09
the O 0 2.866590165240268e-08
almost O 0 2.1804622107879368e-08
absent O 0 8.40491196640869e-08
occurrence O 0 6.737954549862479e-08
of O 0 3.833171291489634e-08
paternal O 0 6.058185135771055e-07
transmission O 0 3.640950581029756e-06
of O 0 0.013944133184850216
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.00035306948120705783

Also O 0 1.148559249486425e-06
the O 0 1.621636442905583e-07
fathers O 0 8.836828868652447e-08
of O 0 6.307558919615985e-08
the O 0 6.334191482437745e-08
reported O 0 1.345975704225566e-07
congenitally O 0 3.1173772185866255e-06
affected O 0 3.013710525578972e-08
children O 0 6.789296236320297e-09
showed O 0 6.8428058774827605e-09
, O 0 2.5602591158246923e-09
on O 0 8.980435950434185e-09
average O 0 1.629904211597477e-08
, O 0 1.4962036942733903e-08
shorter O 0 5.163475407243823e-07
CTG O 0 0.3412187993526459
repeat O 0 7.701210620325583e-07
lengths O 0 9.480529001848481e-07
and O 0 2.4550363519892926e-08
hence O 0 6.099379845636577e-08
less O 0 1.792798975941423e-08
severe O 0 7.747339054731128e-07
clinical O 0 9.006974323710892e-06
symptoms O 0 3.4295970863240655e-07
than O 0 1.5830745603295782e-09
the O 0 5.157444249448417e-09
mothers O 0 5.602390107384281e-09
of O 0 1.4826640359899557e-08
children O 0 5.660890778358407e-08
with O 0 1.5181883554760134e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.009027455933392048

We O 0 1.6143053471751045e-06
conclude O 0 4.542645228866604e-07
that O 0 1.1495095542102263e-08
paternal O 0 6.02935529059323e-07
transmission O 0 2.4259348720079288e-05
of O 1 0.9999821186065674
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.0006153205176815391
rare O 0 3.0398399530895404e-07
and O 0 2.4718811886259573e-08
preferentially O 0 2.9413721236437596e-08
occurs O 0 2.263147225178841e-09
with O 0 8.016788344278325e-10
onset O 0 1.2838222573918756e-07
of O 0 4.6762539795963676e-07
DM B-Disease 1 1.0
past O 0 3.285465481894789e-07
30 O 0 2.666228482439692e-08
years O 0 3.749169419364762e-09
in O 0 1.6974875949316015e-09
the O 0 1.7378491534714158e-08
father O 0 1.0873382194631631e-07
. O 0 1.1912943165270917e-07
. O 0 1.2740420061163604e-06

The O 0 2.0181456420687027e-05
RB1 O 1 0.9999837875366211
gene O 0 5.238464950707566e-07
mutation O 0 6.15782624890926e-08
in O 0 1.0509933368041402e-08
a O 0 1.1868479532495257e-07
child O 0 1.081328605323506e-06
with O 0 2.0748673250636784e-06
ectopic B-Disease 1 0.9999079704284668
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 6.188881525304168e-05

The O 0 3.2061085221357644e-05
RB1 O 1 1.0
gene O 0 2.0737043087137863e-06
mutation O 0 5.114832788422063e-07
was O 0 1.526948523178362e-07
investigated O 0 1.221414294150236e-07
in O 0 9.92702187119221e-09
a O 0 6.742916980329028e-08
child O 0 4.331775187438325e-07
with O 0 4.7293551119764743e-07
ectopic B-Disease 1 0.8025041222572327
intracranial I-Disease 1 0.9999998807907104
retinoblastoma I-Disease 0 2.3927226720843464e-05
using O 0 2.4897483186236968e-08
DNA O 0 2.5514806267779022e-08
obtained O 0 2.4093833594918124e-09
from O 0 2.7609756703128596e-09
both O 0 7.176863991986693e-09
the O 0 7.437978410962387e-08
pineal B-Disease 1 0.9951398372650146
and I-Disease 0 7.838534656912088e-07
retinal I-Disease 1 1.0
tumours I-Disease 1 1.0
of O 1 0.9999957084655762
the O 0 0.00013263736036606133
patient O 0 7.69147118262481e-06
. O 0 2.3177603907242883e-06

A O 0 3.788462345255539e-05
nonsense O 0 3.398055923753418e-05
mutation O 0 4.848439516536018e-07
in O 0 6.615751857452778e-08
exon O 0 4.206233825243544e-06
17 O 0 3.8808278191027057e-07
( O 0 1.7515160877223934e-08
codon O 0 1.1195754012760517e-07
556 O 0 1.1685232692570935e-07
) O 0 7.013180258752527e-09
of O 0 7.731235029950767e-08
the O 0 2.799983462864475e-07
RB1 O 1 0.9999997615814209
gene O 0 9.843219572758244e-08
was O 0 5.97774629795822e-08
found O 0 2.8320032985362786e-09
to O 0 1.7582698630391747e-09
be O 0 2.729543480128882e-09
present O 0 1.213566047653103e-08
homozygously O 0 1.289704414375592e-06
in O 0 1.0306514752755902e-08
both O 0 1.6869565300225986e-08
the O 0 1.0268648509281775e-07
retinal B-Disease 0 0.00017337391909677535
and I-Disease 0 7.449690997418656e-07
the I-Disease 0 2.5296125386375934e-05
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 3.600721538532525e-05

The O 0 9.21494290651026e-07
same O 0 9.236202203055655e-08
mutation O 0 4.491417726626423e-08
was O 0 5.495499877383736e-08
present O 0 1.827538298471154e-08
heterozygously O 0 1.5118657756829634e-06
in O 0 4.8452197809467634e-09
the O 0 5.777771150405897e-09
DNA O 0 5.067462005570178e-09
from O 0 1.2555055883822774e-09
the O 0 3.5874929693591184e-09
constitutional O 0 2.977185431518592e-08
cells O 0 1.6003732783431701e-09
of O 0 1.208957023379753e-08
the O 0 2.4425283129403397e-08
patient O 0 2.945324517611425e-08
, O 0 4.7273505110467795e-09
proving O 0 2.9756355601762152e-08
it O 0 1.674638760995606e-09
to O 0 4.8948685105187906e-09
be O 0 1.3458880232519732e-08
of O 0 1.4945983650704875e-07
germline O 0 4.048446044180309e-06
origin O 0 6.58870305869641e-07
. O 0 2.003847157538985e-06

The O 0 1.616906160961662e-06
initial O 0 7.341024002016638e-07
mutation O 0 1.6040374362091825e-07
was O 0 9.432680059262566e-08
shown O 0 1.28597363868721e-08
to O 0 1.140559646728434e-08
have O 0 4.866670622050151e-09
occurred O 0 2.2304766034153545e-08
in O 0 8.85622863933122e-09
the O 0 1.4669963377400563e-07
paternally O 0 6.37366656519589e-06
derived O 0 1.6735114058974432e-06
RB1 O 0 0.0028572946321219206
allele O 0 7.483680747100152e-06
. O 0 3.3110675303760218e-06

The O 0 2.556045728852041e-06
mutation O 0 1.541636152069259e-07
is O 0 6.25026341793955e-09
in O 0 1.2197498566735021e-09
an O 0 2.3165862561569384e-09
area O 0 5.5823718980718695e-08
of O 0 3.412455029661032e-08
the O 0 3.211825116977707e-08
gene O 0 7.248012856564401e-09
that O 0 1.0503155012386856e-09
encodes O 0 9.321342808732425e-09
the O 0 5.3980215852789115e-09
protein O 0 4.854395996289895e-09
- O 0 1.3466120662997128e-08
binding O 0 7.220719577816226e-09
region O 0 2.7229305032960838e-08
known O 0 1.4095479450304538e-08
as O 0 3.1926330468223796e-09
the O 0 3.243641089056837e-08
pocket O 1 0.9999998807907104
region O 0 5.537437027669512e-05
and O 0 2.0559176050483075e-07
has O 0 5.019003523898391e-08
been O 0 1.6737136121491858e-08
detected O 0 1.9572471643414247e-08
in O 0 1.8635823995083456e-09
other O 0 4.225696681459112e-09
cases O 0 9.267415279623492e-09
of O 0 1.1833149926587794e-07
retinoblastoma B-Disease 0 0.21294529736042023
. O 0 1.1547966778380214e-06
. O 0 4.7284447646234185e-06

Low O 0 6.598867003049236e-06
levels O 0 5.371494466999138e-07
of O 0 1.9170167320226028e-07
beta O 0 1.1120431508970796e-06
hexosaminidase O 0 5.089162368676625e-05
A O 0 4.4585058844859304e-07
in O 0 1.0624008339732427e-08
healthy O 0 1.9161973341397243e-08
individuals O 0 5.992443763425115e-10
with O 0 2.4646862328836505e-09
apparent O 0 1.2452057944756234e-06
deficiency O 1 0.892944872379303
of O 0 2.0193818272673525e-05
this O 0 2.539889010222396e-07
enzyme O 0 1.5186431028268998e-06
. O 0 9.967892538043088e-07

Appreciable O 0 0.0001373614650219679
beta O 0 1.5088226973603014e-05
hexosaminidase O 0 0.00013365215272642672
A O 0 8.910466931411065e-06
( O 0 1.6573541472553188e-07
hex O 0 0.3074810206890106
A O 0 4.181508302281145e-06
) O 0 5.3286168366639686e-08
activity O 0 6.160304621971591e-08
has O 0 1.3129013431978365e-08
been O 0 9.824196567365107e-09
detected O 0 7.119847822423253e-08
in O 0 9.272047130082228e-09
cultured O 0 2.556537879172538e-07
skin O 0 1.838573007262312e-05
fibroblasts O 0 3.4264749615431356e-07
and O 0 4.713730561434204e-07
melanoma B-Disease 1 1.0
tissue O 0 0.0001092155507649295
from O 0 4.366194872318374e-08
healthy O 0 3.3927904041775037e-08
individuals O 0 2.64468502653159e-10
previously O 0 9.065400874419538e-09
reported O 0 2.159242562527197e-09
as O 0 8.434343889973661e-09
having O 0 7.581974159620586e-08
deficiency B-Disease 0 0.12783488631248474
of I-Disease 0 0.00012472399976104498
hex I-Disease 1 1.0
A I-Disease 0 1.464391175431956e-06
activity O 0 2.360620676711278e-08
indistinguishable O 0 1.0205732259294109e-08
from O 0 3.2614796974250737e-10
that O 0 1.3038810309229376e-10
of O 0 2.1420509810354815e-09
patients O 0 1.631352830600008e-09
with O 0 1.0308854214713392e-08
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 8.759415663917025e-07
TSD B-Disease 1 0.9999988079071045
) O 0 1.1364995771145914e-06
. O 0 5.319139290804742e-06

Identification O 0 1.4261912610891159e-06
and O 0 3.4588433095450455e-07
quantitation O 0 4.149179221712984e-05
of O 0 2.223498267994728e-05
hex O 1 0.9997770190238953
A O 0 9.863731975201517e-06
, O 0 1.1911249941931601e-07
amounting O 0 3.751833048681874e-07
to O 0 1.394174091728928e-07
3 O 0 5.133160811965354e-06
. O 0 4.1357575355505105e-06

5 O 0 1.0240938536298927e-05
% O 0 1.3297624263941543e-06
- O 0 7.297200681932736e-06
6 O 0 1.1851069757540245e-05
. O 0 9.051856068253983e-06

9 O 0 1.603939608685323e-06
% O 0 4.824648414114563e-08
of O 0 3.7888170822952816e-08
total O 0 3.681925875298475e-08
beta O 0 4.2311228298785863e-07
hexosaminidase O 0 7.0803034759592265e-06
activity O 0 3.86235861071782e-08
, O 0 7.94845966822777e-09
has O 0 4.3188990161979746e-09
been O 0 3.973795958955861e-09
obtained O 0 3.5538763043518884e-09
by O 0 6.192380830327693e-09
cellulose O 0 4.466014161152998e-06
acetate O 0 7.4901354309986345e-06
gel O 0 3.492264568194514e-06
electrophoresis O 0 3.8475945984828286e-07
, O 0 5.2243958492681486e-08
DEAE O 0 0.0002718128089327365
- O 0 1.0296179198121536e-06
cellulose O 0 5.899258667341201e-06
ion O 0 7.094158263498684e-06
- O 0 4.932593583362177e-06
exchange O 0 4.6974494694040914e-07
chromatography O 0 1.1228917173866648e-05
, O 0 1.5149818466397846e-07
radial O 0 7.0783326009404846e-06
immunodiffusion O 0 9.816602687351406e-05
, O 0 4.818128331862681e-07
and O 0 1.0020609124694602e-06
radioimmunoassay O 0 0.0007718656561337411
. O 0 1.8876860849559307e-05

Previous O 0 2.016581674979534e-05
family O 0 8.350341431651032e-07
studies O 0 1.2493839562921494e-07
suggested O 0 3.534598391752297e-08
that O 0 1.5704283429229804e-09
these O 0 2.103249796547857e-09
individuals O 0 9.198167782997757e-10
may O 0 1.55739021678869e-09
be O 0 2.0754540308587366e-09
compound O 0 4.40068284035533e-08
heterozygotes O 0 7.825890691037785e-08
for O 0 5.5905733375993805e-09
the O 0 3.540765547427327e-08
common O 0 1.6431083338375174e-07
mutant O 0 6.7731834860751405e-06
TSD B-Disease 1 0.746640682220459
gene O 0 5.668302804906489e-08
and O 0 2.2401078325628987e-08
a O 0 5.279701653648772e-08
rare O 0 1.9437580078829342e-07
( O 0 7.010294211795554e-08
allelic O 0 7.3947730925283395e-06
) O 0 2.1475813127835863e-07
mutant O 0 5.311434051691322e-06
gene O 0 1.1414168739065644e-06
. O 0 1.3112041870044777e-06

Thus O 0 2.872408231269219e-06
, O 0 2.293812997322675e-07
the O 0 1.5349407078701915e-07
postulated O 0 9.978373327612644e-07
rate O 0 8.510784965665152e-08
mutant O 0 4.0200308148996555e-07
gene O 0 1.7063145563156468e-08
appears O 0 5.052810614358805e-09
to O 0 1.0304269659755505e-09
code O 0 2.945514054886189e-09
for O 0 2.7477107256146382e-09
the O 0 1.3154178191143728e-08
expression O 0 7.148775793552886e-09
of O 0 2.032274792895805e-08
low O 0 6.400891550129018e-08
amounts O 0 4.976773837483961e-08
of O 0 1.85150227594022e-07
hex O 0 0.0001727684575598687
A O 0 1.2335139217611868e-05
. O 0 4.869152235187357e-06

Heterozygotes O 0 4.437724419403821e-05
for O 0 3.2565233709647146e-07
the O 0 5.960804969618039e-07
rare O 0 1.1791125871241093e-06
mutant O 0 3.733860694410396e-06
may O 0 1.4601007514158937e-08
be O 0 3.0701610143069047e-09
indistinguishable O 0 6.963757215316946e-08
from O 0 7.532860557546428e-09
heterozygotes O 0 1.702573513284733e-07
for O 0 9.587013849454706e-09
the O 0 2.00736920419331e-07
common O 0 1.048407398229756e-06
TSD B-Disease 1 0.9992434978485107
mutant O 0 9.195196616929024e-05
. O 0 5.673013674822869e-06

However O 0 1.6818920585137676e-06
, O 0 2.161390852961631e-07
direct O 0 1.3496081407993188e-07
visualization O 0 9.291637184105639e-07
and O 0 8.562073361417788e-08
quantitation O 0 1.843052996264305e-05
of O 0 3.5951434256276116e-06
hex O 1 0.9153327345848083
A O 0 7.562734936072957e-07
by O 0 6.922622031169112e-09
the O 0 1.65780242866731e-08
methods O 0 2.0120836552450783e-08
described O 0 1.776992419877388e-08
may O 0 8.15709011448007e-09
prevent O 0 6.896648585552612e-08
false O 0 9.175186477250463e-08
- O 0 1.5803698261152022e-07
positive O 0 1.3985841817998335e-08
prenatal O 0 7.928658618538975e-08
diagnosis O 0 8.369222115334196e-08
of O 0 1.5745929715649254e-07
TSD B-Disease 1 0.9999998807907104
in O 0 5.372806555214993e-08
fetuses O 0 1.2605504196017137e-07
having O 0 6.829376175687685e-09
the O 0 1.3036586032910691e-08
incomplete O 0 5.63251091989514e-07
hex B-Disease 1 0.8906202912330627
A I-Disease 0 2.1835519874002784e-05
deficiency I-Disease 0 0.014092755503952503
of O 0 1.6247848861894454e-06
the O 0 2.8239307425792504e-07
type O 0 4.5566338258140604e-07
described O 0 5.0734701773080815e-08
in O 0 1.0796871841023403e-08
the O 0 2.0419579982444702e-07
four O 0 3.7037546007923083e-07
healthy O 0 1.8574849036667729e-06
individuals O 0 5.398908911047329e-07

The O 0 2.6688274374464527e-05
tumor B-Disease 0 0.020030852407217026
suppressor O 0 0.4854196012020111
gene O 0 7.601972811244195e-06
Smad4 O 1 0.9999974966049194
/ O 0 0.0006569299148395658
Dpc4 O 0 0.38669252395629883
is O 0 2.222246919814097e-08
required O 0 2.49069209701247e-09
for O 0 3.46193651523663e-09
gastrulation O 0 3.051539465559472e-07
and O 0 8.148538732655197e-09
later O 0 1.4549409677044878e-08
for O 0 8.581918287120516e-09
anterior O 0 4.595193274781195e-07
development O 0 4.873091086210479e-08
of O 0 5.08553284817026e-07
the O 0 8.701931619725656e-07
mouse O 0 1.6100351786008105e-05
embryo O 0 2.8994461445108755e-06
. O 0 1.9263500234956155e-06

Mutations O 0 5.083484666101867e-06
in O 0 1.4631778810780816e-07
the O 0 8.90915885065624e-07
SMAD4 O 1 1.0
/ O 1 0.9999808073043823
DPC4 O 1 1.0
tumor B-Disease 1 0.633847713470459
suppressor O 0 5.110239362693392e-05
gene O 0 5.0412811702926774e-08
, O 0 1.026795981573514e-08
a O 0 2.2023222356892802e-08
key O 0 6.505573537651799e-07
signal O 0 2.7881577580046724e-07
transducer O 0 7.17323985099938e-07
in O 0 1.4966259342941157e-08
most O 0 2.716321922946463e-08
TGFbeta O 0 0.0001107764765038155
- O 0 1.0894874549194355e-06
related O 0 8.094647796497156e-07
pathways O 0 1.2419924644291314e-07
, O 0 2.7473701091906833e-09
are O 0 4.929287533705917e-10
involved O 0 1.1111774833594268e-09
in O 0 5.796024216131457e-10
50 O 0 1.16331246857726e-08
% O 0 9.684494095552054e-09
of O 0 3.8017824977032433e-07
pancreatic B-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.247821819561068e-05

Homozygous O 0 0.0006650706636719406
Smad4 O 0 0.07754866033792496
mutant O 0 0.0002560591383371502
mice O 0 7.994416591827758e-06
die O 0 1.4474145473286626e-06
before O 0 9.292889302514595e-08
day O 0 3.293684756044968e-07
7 O 0 4.304195044824155e-06
. O 0 3.7672032249247422e-06

5 O 0 3.0288021662272513e-05
of O 0 1.7920314348884858e-05
embryogenesis O 0 7.323130557779223e-05
. O 0 2.251489058835432e-05

Mutant O 0 2.3270462406799197e-05
embryos O 0 2.493030137884489e-07
have O 0 1.6931998025881967e-09
reduced O 0 7.77312081368109e-09
size O 0 2.5399971903539154e-08
, O 0 9.068254591682035e-09
fail O 0 3.1559689972482374e-08
to O 0 1.4785523028137959e-08
gastrulate O 0 1.4640777408203576e-05
or O 0 5.322460694401343e-08
express O 0 1.7716216049734612e-08
a O 0 2.1380968107109766e-08
mesodermal O 0 1.2314806099311681e-06
marker O 0 2.939980959126842e-06
, O 0 3.8214476916209605e-08
and O 0 4.970967637518697e-08
show O 0 9.678632295617717e-07
abnormal O 0 1.9688955035235267e-06
visceral O 0 7.919994823168963e-05
endoderm O 0 0.00016882170166354626
development O 0 2.9621101020893548e-06
. O 0 3.4941667763632722e-06

Growth B-Disease 1 0.9999997615814209
retardation I-Disease 1 1.0
of O 0 1.0567830031504855e-05
the O 0 2.04474781639874e-06
Smad4 O 1 0.9999855756759644
- O 0 2.2031719709048048e-05
deficient O 0 2.5446920517424587e-06
embryos O 0 1.4827036487474743e-08
results O 0 8.620729130548455e-10
from O 0 8.426236375314033e-10
reduced O 0 9.135386669356649e-09
cell O 0 3.409358129147222e-08
proliferation O 0 4.405839888477203e-07
rather O 0 1.6629073229523783e-08
than O 0 7.681550506788426e-09
increased O 0 1.6474531605581433e-07
apoptosis O 0 3.692873860927648e-06
. O 0 3.2055268093245104e-06

Aggregation O 0 1.712136327114422e-05
of O 0 6.3290135585702956e-06
mutant O 0 4.318918945500627e-05
Smad4 O 1 0.8949008584022522
ES O 0 0.04280740022659302
cells O 0 3.076939592006056e-08
with O 0 5.465048413810791e-09
wild O 0 9.084181442631234e-07
- O 0 1.2234153246026835e-06
type O 0 8.779620657151099e-07
tetraploid O 0 2.9761802124994574e-06
morulae O 0 2.9281585739227012e-05
rescues O 0 7.436619398504263e-06
the O 0 7.699197794863721e-07
gastrulation B-Disease 0 0.00012110584793845192
defect I-Disease 0 8.725752559257671e-05
. O 0 8.503379831381608e-06

These O 0 1.186924237117637e-06
results O 0 1.5291971067199484e-07
indicate O 0 4.18801100465771e-08
that O 0 9.250497257085044e-09
Smad4 O 0 2.9047294447082095e-05
is O 0 2.4141133536659254e-08
initially O 0 1.2593963205631553e-08
required O 0 1.8458168327128988e-09
for O 0 3.061605857723748e-09
the O 0 1.0773379521822335e-08
differentiation O 0 3.1403807554397645e-08
of O 0 6.610744662793877e-08
the O 0 6.095832816299662e-08
visceral O 0 4.493783762882231e-06
endoderm O 0 2.6284355953976046e-06
and O 0 2.4314608992881404e-08
that O 0 5.53412204951087e-09
the O 0 7.700418791500852e-08
gastrulation B-Disease 0 6.269988716667285e-06
defect I-Disease 0 7.236674264277099e-07
in O 0 1.1805371791240304e-08
the O 0 9.878446149969022e-08
epiblast O 0 2.3885029804660007e-05
is O 0 9.383204435664538e-09
secondary O 0 9.273342271853835e-08
and O 0 8.360156122932949e-09
non O 0 5.85685086207377e-07
- O 0 8.009297744138166e-06
cell O 0 4.595527116180165e-06
autonomous O 0 1.2427770343492739e-05
. O 0 3.9866317820269614e-06

Rescued O 0 2.786560435197316e-05
embryos O 0 1.8092935079039307e-06
show O 0 1.0528229950068635e-06
severe O 0 1.8805452782544307e-05
anterior O 0 8.353354496648535e-05
truncations O 1 0.9997896552085876
, O 0 6.099962206462806e-07
indicating O 0 2.803352856517449e-07
a O 0 2.668299181607381e-08
second O 0 5.121822610476556e-08
important O 0 4.201043779517022e-08
role O 0 1.6219163967434724e-07
for O 0 1.397968532046434e-07
Smad4 O 0 0.03962726891040802
in O 0 4.0997215933202824e-07
anterior O 0 4.128339787712321e-05
patterning O 0 3.195997851435095e-05
during O 0 2.80812855635304e-06
embryogenesis O 0 2.2794018150307238e-05
. O 0 6.411352842405904e-06

Prevalence O 0 7.970370643306524e-05
of O 0 4.3804025153804105e-06
p16 O 0 1.547097235743422e-05
and O 0 1.7263809013456921e-06
CDK4 O 1 1.0
germline O 0 1.8087439457303844e-05
mutations O 0 4.0332983530788624e-07
in O 0 3.162681849744331e-08
48 O 0 1.2406811720211408e-06
melanoma B-Disease 1 0.9999998807907104
- O 0 0.00365792540833354
prone O 0 2.988804226333741e-05
families O 0 2.34248265229553e-08
in O 0 8.461450562435857e-08
France O 0 9.077609320229385e-06
. O 0 5.326072823663708e-06

The O 0 2.4176921215257607e-05
French O 0 0.0021865207236260176
Familial B-Disease 1 1.0
Melanoma I-Disease 1 1.0
Study O 0 2.738965667958837e-05
Group O 0 4.8882925511861686e-06
. O 0 3.816855041804956e-06

Germline O 0 9.027401392813772e-05
mutations O 0 3.9388004324791837e-07
in O 0 4.64778153741463e-08
the O 0 1.1301461455559547e-07
p16 O 0 1.7971628949453589e-06
and O 0 1.3057693593054864e-07
CDK4 O 1 1.0
genes O 0 1.7041426758623857e-07
have O 0 6.580172851045063e-09
been O 0 8.073492097082635e-09
reported O 0 5.145849524268442e-09
in O 0 1.6497579968799414e-09
a O 0 1.1636875463238994e-08
subset O 0 1.374534832621066e-07
of O 0 2.164406538440744e-07
melanoma B-Disease 1 0.9999890327453613
pedigrees O 0 6.726519359290251e-07
, O 0 1.0743911538213524e-08
but O 0 3.0408060514020008e-09
their O 0 2.8238047455886317e-09
prevalence O 0 1.7714873479235393e-07
is O 0 4.86569584623453e-09
not O 0 3.1107623144066565e-09
well O 0 4.917948004390382e-08
known O 0 8.678824769958737e-07
. O 0 1.8504938452679198e-06

We O 0 7.809158546479011e-07
searched O 0 7.192495559138479e-07
for O 0 3.5206770832019174e-08
such O 0 9.165636782881847e-08
germline O 0 1.4762437103854609e-06
mutations O 0 2.7549223347023144e-08
in O 0 8.85241213666177e-09
48 O 0 2.486555104042054e-07
French O 0 0.0003911459061782807
melanoma B-Disease 1 1.0
- O 0 0.001138819265179336
prone O 0 2.525060153857339e-06
families O 0 1.8841221915977258e-09
selected O 0 1.86516824207672e-09
according O 0 3.110143809159638e-10
to O 0 1.2125636050797084e-09
two O 0 8.478308055615003e-10
major O 0 1.986159148259503e-08
criteria O 0 6.177648259608759e-08
families O 0 3.688226946074735e-10
with O 0 3.4259645120826576e-10
at O 0 1.8174020510741684e-08
least O 0 2.887385885941285e-09
three O 0 3.237606849282315e-09
affected O 0 6.066843472041228e-09
members O 0 1.0055228871763688e-09
( O 0 2.3767530166196593e-09
n O 0 9.651818011491287e-09
= O 0 3.7234502148209003e-09
20 O 0 4.1404488726470845e-09
) O 0 6.9541944425211e-10
or O 0 9.349648832923663e-10
families O 0 6.137262920091757e-11
with O 0 9.735192513238289e-11
two O 0 3.201338638625373e-10
affected O 0 1.219991774270568e-09
members O 0 2.7459856610789757e-10
, O 0 8.124076966709026e-10
one O 0 7.061673468200524e-10
of O 0 4.56906779078281e-09
them O 0 6.815891184785983e-10
affected O 0 2.1309829456583884e-09
before O 0 2.0427119995503062e-09
the O 0 2.9306803650541724e-09
age O 0 5.032612993005614e-09
of O 0 7.2705681475326855e-09
50 O 0 1.7509883321054076e-08
( O 0 2.5095039379863238e-09
n O 0 1.0842541087185964e-08
= O 0 6.324205603647215e-09
28 O 0 8.481644719893211e-09
) O 0 1.7112546935038608e-09
, O 0 2.568392831747701e-09
and O 0 4.1549972351617726e-09
one O 0 1.2189690146158227e-08
additional O 0 1.249932211067062e-07
minor O 0 7.597654075652827e-06
criterion O 0 0.20163944363594055
. O 0 1.0772540917969309e-05

Sixteen O 0 3.7821744626853615e-05
different O 0 3.5295965972181875e-07
p16 O 0 7.13417421138729e-06
germline O 0 2.054785682048532e-06
mutations O 0 4.6358117344880156e-08
were O 0 6.921407447180172e-09
found O 0 2.447811286998558e-09
in O 0 1.0228625724195695e-09
21 O 0 1.2655269721051354e-08
families O 0 2.974849533377011e-10
, O 0 1.0885490286938193e-09
while O 0 3.5101952455818264e-09
one O 0 1.5003529085788614e-08
germline O 0 2.2781685515838035e-07
mutation O 0 2.2629496498893786e-08
, O 0 1.027607066106384e-08
Arg24His O 0 0.009805570356547832
, O 0 4.102920314608127e-08
was O 0 1.4302062822935113e-07
detected O 0 5.0039769661225364e-08
in O 0 1.1370235419860819e-08
the O 0 2.05159281563283e-07
CDK4 O 1 0.9999662637710571
gene O 0 2.453502020216547e-06
. O 0 1.8449645722284913e-06

The O 0 1.008561184789869e-06
frequency O 0 4.246561502441182e-07
of O 0 3.3662661280686734e-07
p16 O 0 1.6030495544328005e-06
gene O 0 6.617847247980535e-08
mutation O 0 1.1499019514360498e-08
in O 0 1.8347531272056017e-09
our O 0 3.54012907877177e-09
sample O 0 6.017530473911847e-09
( O 0 6.427936516395505e-10
44 O 0 5.45966205578452e-09
% O 0 5.401592506615316e-10
) O 0 6.625116011349519e-10
is O 0 1.6923731305240608e-09
among O 0 1.2096899038027686e-09
the O 0 5.638796540807789e-09
highest O 0 6.519572792740291e-08
rates O 0 4.9669273138874814e-09
yet O 0 3.051112695828806e-09
reported O 0 3.440398410603507e-09
and O 0 6.443688693735794e-09
the O 0 5.5552654032453574e-08
CDK4 O 1 0.9998144507408142
mutation O 0 3.405575554893403e-08
is O 0 6.508301453322929e-09
the O 0 1.592384535342717e-08
second O 0 5.4002487814841516e-08
mutation O 0 2.241107921463481e-08
detected O 0 1.4315785890062216e-08
in O 0 2.8024174092422527e-09
this O 0 7.849806138437998e-09
gene O 0 2.73844449338867e-07
worldwide O 0 4.4793119968744577e-07
. O 0 2.5503748020128114e-06

In O 0 1.1818640359706478e-06
summary O 0 2.5235121938749216e-06
, O 0 5.742693787169628e-08
our O 0 1.546701255961125e-08
results O 0 6.965163112937489e-09
show O 0 1.6753105569478066e-08
frequent O 0 3.340444720834057e-08
involvement O 0 5.3591534765473625e-08
of O 0 8.069230261753546e-08
the O 0 9.843651582741586e-08
p16 O 0 1.0068745268654311e-06
gene O 0 6.279278608189998e-08
in O 0 2.5599089070738046e-08
familial B-Disease 0 0.0008482653647661209
melanoma I-Disease 1 0.9998075366020203
and O 0 3.857492103520599e-08
confirm O 0 1.24077015328794e-08
the O 0 1.527472193174617e-08
role O 0 2.4189992231526958e-08
of O 0 1.5382407525521558e-07
the O 0 2.458010044392722e-07
CDK4 O 1 1.0
gene O 0 1.0883881174095222e-07
as O 0 4.202790648832888e-08
a O 0 1.2384984415803046e-07
melanoma B-Disease 1 0.999901294708252
- O 0 7.753241516184062e-05
predisposing O 0 0.00012756283103954047
gene O 0 4.639274777673563e-07
. O 0 1.0683653783871705e-07
. O 0 1.8141640794056002e-06

Progression O 0 0.00013731351646129042
of O 0 9.36256219574716e-06
somatic O 0 0.00011146203178213909
CTG O 1 0.9773312211036682
repeat O 0 2.1242776711005718e-06
length O 0 2.8408834396032034e-07
heterogeneity O 0 8.926329542191525e-07
in O 0 9.188562799522515e-09
the O 0 2.8973614618621468e-08
blood O 0 1.4372068335433141e-07
cells O 0 9.65867243962748e-08
of O 0 4.211853138258448e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.00013052549911662936
. O 0 5.865403181815054e-06

The O 0 1.2346545190666802e-06
genetic O 0 3.294102555173595e-07
basis O 0 1.4032983131073706e-07
of O 0 3.2142877444130136e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0001827692613005638
DM B-Disease 1 1.0
) O 0 3.296154105214555e-08
is O 0 6.483757086783726e-09
the O 0 6.340365565904449e-09
expansion O 0 4.486528482061658e-08
of O 0 5.4767699708691e-08
an O 0 4.125780250774369e-08
unstable O 0 1.878301645774627e-06
CTG O 0 0.0007954020402394235
repeat O 0 4.0344141893911e-07
in O 0 6.882177938649647e-09
the O 0 3.33733716217921e-08
34 O 0 7.735468443570426e-08
UTR O 0 2.637388570292387e-05
of O 0 2.2136029542707547e-07
the O 0 2.572581934146001e-07
DM B-Disease 1 1.0
protein O 0 3.849730774163618e-07
kinase O 0 4.191135474229668e-07
gene O 0 3.358588784863059e-08
on O 0 1.4737622677785112e-07
chromosome O 0 1.9391861769690877e-06
19 O 0 2.095792069667368e-06
. O 0 2.239489731437061e-06

One O 0 5.788246539850661e-07
of O 0 3.321110284559836e-07
the O 0 5.3728783200313046e-08
principal O 0 2.582719957899826e-07
features O 0 7.290108783308824e-08
of O 0 3.1537729228148237e-07
the O 0 1.7416524542568368e-06
DM B-Disease 1 1.0
mutation O 0 2.96716649472728e-07
is O 0 1.0003469164132639e-08
an O 0 5.426792348828258e-09
extraordinarily O 0 1.1113629483361365e-07
high O 0 1.1336803140693519e-07
level O 0 1.0644418324545768e-07
of O 0 2.279796547099977e-07
somatic O 0 5.104125193611253e-06
mosaicism O 0 0.00014494611241389066
, O 0 1.654946402140922e-08
due O 0 2.23275815613988e-08
to O 0 4.3524566173402945e-09
an O 0 4.855340574039246e-09
extremely O 0 1.3546806343356366e-08
high O 0 2.9819762659144544e-08
degree O 0 2.6097264793634167e-08
of O 0 4.694583211062309e-08
somatic O 0 6.633137559219904e-07
instability O 0 2.770420337583346e-07
both O 0 1.0036187880757552e-08
within O 0 7.558983661226648e-09
and O 0 5.559576798930266e-09
between O 0 1.2687945805112122e-08
different O 0 5.39749898109676e-08
tissues O 0 1.689181885922153e-06
. O 0 8.036780627662665e-07

This O 0 1.989338215935277e-06
instability O 0 6.565478088305099e-06
appears O 0 2.2747774153231148e-07
to O 0 1.0633983471564079e-08
be O 0 7.113927225077532e-09
biased O 0 4.0257045696989735e-08
towards O 0 1.1534034172200336e-08
further O 0 6.665208829303992e-09
expansion O 0 2.5046947627060945e-08
and O 0 4.634279626714033e-09
continuous O 0 1.4355103772345501e-08
throughout O 0 4.029113043202415e-09
the O 0 6.119081685795891e-09
life O 0 2.8073019464613935e-09
of O 0 3.607900866953173e-09
an O 0 1.6115845324904399e-09
individual O 0 1.2659946424520285e-09
, O 0 1.272608796121233e-09
features O 0 9.345321849707489e-09
that O 0 6.677230435236936e-10
could O 0 6.052174317261461e-10
be O 0 3.1313940329624756e-10
associated O 0 9.753764462772097e-10
with O 0 1.5210491755013322e-09
the O 0 5.690314353046233e-08
progressive O 0 8.847670756040316e-07
nature O 0 3.330079323404789e-07
of O 0 5.508932758857554e-07
the O 0 2.260500878037419e-06
disease O 0 0.0006182403885759413
. O 0 3.2991029002005234e-06

Although O 0 1.1425844377299654e-06
increasing O 0 1.9783523441674333e-07
measured O 0 2.026633580953785e-07
allele O 0 9.75760627852651e-08
size O 0 7.352584674436002e-08
between O 0 3.268158366154239e-08
patients O 0 6.397242202638154e-08
clearly O 0 1.564261964404068e-08
correlates O 0 6.475453773191475e-08
with O 0 1.445508046593602e-09
an O 0 2.8958022646463633e-09
increased O 0 7.852952066400576e-09
severity O 0 5.327848953129433e-07
of O 0 1.1203999861209013e-07
symptoms O 0 1.2017331982860924e-06
and O 0 2.764975581825979e-09
an O 0 1.5053054358560303e-09
earlier O 0 4.064665937164591e-09
age O 0 1.2096813328810185e-08
of O 0 2.256678222067876e-08
onset O 0 3.6076309584132105e-07
, O 0 3.1175573234065723e-09
this O 0 5.095663890841706e-10
correlation O 0 4.270715781018453e-09
is O 0 1.544221639449006e-09
not O 0 3.886571342537337e-10
precise O 0 1.3658576492048269e-08
and O 0 6.230588933675563e-09
measured O 0 5.971000405224913e-08
allele O 0 2.5876943254843354e-08
length O 0 2.0295168212669523e-08
cannot O 0 2.8530720008745902e-09
be O 0 1.0087385371448931e-09
used O 0 2.060296599992739e-09
as O 0 1.800673277152498e-09
an O 0 1.0392834370875903e-09
accurate O 0 2.2614742078985728e-08
predictor O 0 4.74606366651642e-07
of O 0 7.505700949650418e-08
age O 0 1.3618156913253188e-07
of O 0 3.832638242329267e-07
onset O 0 9.858276825980283e-06
. O 0 1.9486856217554305e-06

In O 0 3.326565547467908e-07
order O 0 5.045408002501972e-08
to O 0 1.3624855021987514e-08
further O 0 5.3897935003988096e-08
characterize O 0 3.493506426366366e-07
the O 0 6.468109603474659e-08
dynamics O 0 4.6414476173595176e-07
of O 0 1.5979696854628855e-06
DM B-Disease 1 1.0
CTG O 1 1.0
repeat O 0 2.1157900391699513e-06
somatic O 0 7.273912956407003e-07
instability O 0 3.5216854143982346e-07
, O 0 1.2152638895202017e-08
we O 0 5.012897208445111e-09
have O 0 1.5435619449277738e-09
studied O 0 4.08071656465836e-08
repeat O 0 3.185833463703602e-08
length O 0 9.955654967086502e-09
changes O 0 2.57295762473575e-09
over O 0 6.247844019924287e-09
time O 0 5.0393555994787675e-09
in O 0 9.331232675435785e-09
111 O 0 1.2542620424937923e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.3343631621864915e-07
with O 0 5.239991107686137e-09
varying O 0 3.15275592299713e-08
clinical O 0 2.7793970502898446e-07
severity O 0 2.0655545540648745e-06
and O 0 3.677329019069475e-08
CTG O 0 0.0005557365948334336
repeat O 0 7.073447960692647e-08
size O 0 2.1652359905033336e-08
over O 0 1.4135379089452726e-08
time O 0 3.6014515814031256e-09
intervals O 0 1.211981537352358e-08
of O 0 1.1644579522851473e-08
1 O 0 1.1344764061504975e-07
- O 0 3.6183709539727715e-07
7 O 0 7.246529207804997e-07
years O 0 3.5537769349502923e-07
. O 0 1.4768634173378814e-06

We O 0 1.1715621894836659e-06
have O 0 2.5814239634769365e-08
found O 0 1.0517393178588463e-08
a O 0 4.163549505165065e-09
direct O 0 6.85376511100344e-09
progression O 0 1.127016275859205e-07
of O 0 3.892829525398156e-08
the O 0 3.4384978420121115e-08
size O 0 5.3918398634777986e-08
heterogeneity O 0 2.9782825095026055e-07
over O 0 3.293238393098363e-08
time O 0 1.1891360784943572e-08
related O 0 2.3780463820344266e-08
to O 0 1.0675481831867728e-08
initial O 0 1.2357648415672884e-07
CTG O 0 5.3086725529283285e-05
repeat O 0 1.2563882023641781e-07
size O 0 2.3036596630277018e-08
and O 0 5.085597720722035e-09
the O 0 9.74006830745111e-09
time O 0 9.440073611699518e-09
interval O 0 4.2629622498679964e-08
and O 0 1.874012767189015e-08
always O 0 4.444165568884273e-08
biased O 0 1.894903363108824e-07
towards O 0 8.364722248188627e-08
further O 0 2.2424767109896493e-07
expansion O 0 3.7466877529368503e-06
. O 0 2.432260089335614e-06

Attempts O 0 6.391427632479463e-06
to O 0 2.0463639316403714e-07
mathematically O 0 2.7649991807265906e-07
model O 0 3.709374141180888e-08
the O 0 3.146022109490332e-08
dynamics O 0 4.807681648344442e-07
have O 0 7.117184619431782e-09
proved O 0 9.372797649120912e-08
only O 0 9.402338463360138e-09
partially O 0 2.0878432849258388e-07
successful O 0 3.595701159042619e-08
suggesting O 0 1.546972860921869e-08
that O 0 4.509774498284713e-10
individual O 0 4.611704351731305e-10
specific O 0 1.3494139139424988e-09
genetic O 0 4.092593819393642e-09
and O 0 3.8268797020180045e-09
/ O 0 6.860738608338579e-07
or O 0 2.6631028049450833e-08
environmental O 0 1.5425024457726977e-06
factors O 0 2.949957078612897e-08
also O 0 6.062367496895149e-09
play O 0 3.207404830618543e-08
a O 0 2.0048052107313197e-08
role O 0 1.3226539863353537e-07
in O 0 9.359345654047502e-08
somatic O 0 5.158409294381272e-06
mosaicism O 0 0.00010004320938605815
. O 0 8.360908054783067e-07
. O 0 3.727257535501849e-06

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 1.5002754480519798e-05
Palestinian O 0 3.2301319151883945e-05
Arabs O 0 2.0216206394252367e-05
. O 0 1.4021497008798178e-05

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.8630812168121338
AGU B-Disease 1 1.0
) O 0 7.140165507735219e-07
is O 0 9.755856922311068e-08
a O 0 6.43607549477565e-08
rare O 0 8.232389518525451e-06
disorder B-Disease 1 1.0
of I-Disease 1 0.9200282692909241
glycoprotein I-Disease 1 0.9999936819076538
metabolism I-Disease 0 4.722838184534339e-06
caused O 0 4.282831511659424e-08
by O 0 3.3440961111352863e-09
the O 0 9.035471038032483e-08
deficiency B-Disease 0 6.938705337233841e-05
of I-Disease 0 2.100882966260542e-06
the I-Disease 0 1.6522612895641942e-06
lysosomal I-Disease 1 0.9546362161636353
enzyme I-Disease 0 2.1343050775612937e-06
aspartylglucosaminidase I-Disease 0 2.6425243049743585e-05
( O 0 2.2731900628514268e-07
AGA O 0 0.12016301602125168
) O 0 1.8869448012992507e-06
. O 0 5.65095069759991e-06

AGU B-Disease 1 1.0
is O 0 1.1601101505220868e-05
inherited O 0 0.00016409998352173716
as O 0 2.53288163776233e-07
an O 0 4.1737925471352355e-07
autosomal O 1 0.9996427297592163
recessive O 1 0.5836715698242188
trait O 0 3.978939639637247e-05
and O 0 3.916908752898962e-08
occurs O 0 4.901165251425255e-09
with O 0 1.4371617229613776e-09
a O 0 6.863289048197885e-09
high O 0 7.774266208571134e-08
frequency O 0 3.531909342768813e-08
in O 0 8.952081742563678e-09
Finland O 0 2.9376502652667114e-07
because O 0 1.2460208864695232e-08
of O 0 7.704899473992555e-08
a O 0 1.4402954207071161e-07
founder O 0 5.607210368907545e-06
effect O 0 2.531949576223269e-06
. O 0 2.971755975522683e-06

While O 0 1.1095598893007264e-06
very O 0 6.02594028009662e-08
few O 0 4.706418010869129e-08
patients O 0 3.3759938844468707e-08
with O 0 7.691831171996455e-08
AGU B-Disease 1 1.0
have O 0 7.882547237159088e-08
been O 0 1.3219397132502309e-08
reported O 0 4.8837618393804405e-09
from O 0 1.7031629440111828e-09
non O 0 1.0468244937555937e-07
- O 0 1.7627610304771224e-07
Finnish O 0 1.3133168977219611e-05
origin O 0 1.067947330568586e-08
, O 0 3.752882449248318e-09
we O 0 8.108987259447531e-09
diagnosed O 0 2.1216881123109488e-06
the O 0 9.090511099429932e-08
disorder O 1 0.5379703044891357
in O 0 6.0182880901038516e-09
8 O 0 1.1640664610013118e-07
patients O 0 5.174894734949476e-09
originating O 0 1.8877122087701537e-09
from O 0 7.815441072089868e-10
3 O 0 6.6413896604444744e-09
unrelated O 0 1.3154931366443634e-08
families O 0 9.331081046726197e-11
, O 0 2.017888772742893e-10
all O 0 5.241817535583948e-10
Palestinian O 0 5.3001003585961826e-09
Arabs O 0 2.8089246484341857e-09
from O 0 1.2457731513038084e-09
the O 0 1.5392174645967316e-08
region O 0 1.503625242094131e-07
of O 0 1.2573090089063044e-06
Jerusalem O 0 8.282475755549967e-05
. O 0 8.089785296760965e-06

The O 0 5.009524556953693e-06
clinical O 0 8.261020411737263e-05
diagnosis O 0 0.3625688850879669
of O 1 0.9995811581611633
AGU B-Disease 1 1.0
is O 0 2.698082539609459e-07
often O 0 1.2727381815125227e-08
difficult O 0 2.0502582742665254e-08
, O 0 2.888575600934473e-09
in O 0 1.4348253696283564e-09
particular O 0 4.984284984743681e-09
early O 0 3.823187988416521e-09
in O 0 9.725250604830649e-10
the O 0 6.6692660283251826e-09
course O 0 1.3375045071484237e-08
of O 0 1.4992087571386037e-08
the O 0 1.9031757503285007e-08
disease O 0 3.158768549837987e-06
, O 0 1.868272869742782e-09
and O 0 1.8202042095794013e-09
most O 0 1.3294285672316164e-09
of O 0 1.4724818697686715e-08
the O 0 1.6675796743470528e-08
patients O 0 9.622206142978484e-09
are O 0 1.08965003686734e-09
diagnosed O 0 1.3515402486063977e-07
after O 0 8.17954148857325e-09
the O 0 2.20292726282878e-08
age O 0 4.430691191714686e-08
of O 0 6.89195474024018e-08
5 O 0 3.6219893218003563e-07
years O 0 3.237701662328618e-07
. O 0 1.6268531908281147e-06

However O 0 1.4913932773197303e-06
, O 0 1.8377735955255048e-07
since O 0 3.086926625428532e-08
these O 0 1.9034986920019037e-08
patients O 0 1.932103010915398e-08
excrete O 0 4.242917839292204e-07
early O 0 1.981512554039e-08
large O 0 6.110523287361502e-08
amounts O 0 1.1768573671133709e-07
of O 0 1.6127299318213772e-07
aspartylglucosamine O 0 1.4684097550343722e-05
in O 0 3.448454677368318e-08
urine O 0 2.2123069243207283e-07
, O 0 8.75336780836733e-09
biochemical O 0 4.7888558896147515e-08
screening O 0 6.251660522593738e-08
is O 0 8.506789050954922e-09
easy O 0 2.2737834726171968e-08
by O 0 1.7616310188373063e-08
urine O 0 1.4660301985713886e-06
chromatography O 0 1.0778624528029468e-05
. O 0 3.6246294143893465e-07
. O 0 1.4472502698481549e-06

Detection O 0 2.228848279628437e-05
of O 0 1.7618009451325634e-06
heterozygous O 0 4.7154213689282187e-07
carriers O 0 2.242227914450723e-08
of O 0 4.692416766260976e-08
the O 0 5.766697768194717e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 6.595026320610486e-07
ATM O 0 0.00016291820793412626
) O 0 5.2972126241002115e-08
gene O 0 3.9621880887352745e-08
by O 0 8.884263102970635e-09
G2 O 0 0.00036733466549776495
phase O 0 1.7064371604647022e-06
chromosomal O 0 3.645926653916831e-06
radiosensitivity O 0 9.349646279588342e-05
of O 0 6.570884124812437e-06
peripheral O 1 1.0
blood O 0 8.89189905137755e-05
lymphocytes O 0 3.481901148916222e-05
. O 0 4.737959443446016e-06

In O 0 1.0320252840756439e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 1.00178767752368e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.996576308258227e-08
patients O 0 1.83386532626173e-08
, O 0 2.9479083618610957e-09
mutations O 0 2.7235733668362627e-09
in O 0 1.1748714223713819e-09
a O 0 6.469031976763517e-09
single O 0 4.952964260951376e-09
gene O 0 5.588931539790565e-09
, O 0 5.889772225486922e-09
ATM O 0 1.3413025953923352e-05
, O 0 5.075683873201342e-09
result O 0 3.4992457820237632e-09
in O 0 3.5831984046552634e-09
an O 0 2.0458917049381853e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 6.254308715369916e-08
embraces O 0 3.151430689740664e-07
a O 0 7.181465200289949e-09
variety O 0 2.573867163846444e-08
of O 0 3.655350155895576e-08
clinical O 0 3.8264991530923e-07
features O 0 1.2121044790092128e-07
and O 0 2.7920791012547852e-08
manifests O 0 1.7461765366988402e-07
extreme O 0 4.1720818444446195e-07
radiosensitivity O 0 6.361242412822321e-06
and O 0 3.7901322968991735e-08
a O 0 4.096375150197673e-08
strong O 0 5.703375194343607e-08
pre O 0 2.8924889647896634e-06
- O 0 4.179858024144778e-06
disposition O 0 1.1436044587753713e-05
to O 0 1.0689396958696307e-06
malignancy B-Disease 0 0.12729187309741974
. O 0 7.1123263296613e-06

Heterozygotes O 0 3.841344368993305e-05
for O 0 2.556842559897632e-07
the O 0 2.84811534356777e-07
ATM O 0 1.5088543477759231e-05
gene O 0 7.306201155188319e-08
have O 0 3.019485772526309e-09
no O 0 7.335800411567561e-09
clinical O 0 6.422733633826283e-08
expression O 0 7.10999348285668e-09
of O 0 1.1177574776866095e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.3920611330320298e-08
may O 0 4.219101068514419e-09
be O 0 1.3714781310625312e-08
cancer B-Disease 0 4.904520096715714e-07
prone O 0 1.8209938446034357e-07
with O 0 1.0235539527059245e-08
a O 0 6.548036424192105e-08
moderate O 0 1.3670832288426027e-07
increase O 0 1.7162763654710034e-08
in O 0 2.192824233304691e-08
in O 0 1.01089661086462e-07
vitro O 0 2.23782467401179e-06
radiosensitivity O 0 9.680529910838231e-05
. O 0 4.635450295609189e-06

We O 0 2.064317868644139e-06
performed O 0 2.166096692235442e-06
a O 0 4.0286545299750287e-07
blind O 0 2.456805759720737e-06
chromosomal O 0 7.172076834649488e-07
analysis O 0 5.133039948646001e-08
on O 0 1.4290434080521663e-07
G2 O 0 0.00013313331874087453
- O 0 2.7816085435006244e-07
phase O 0 1.56028448827783e-07
lymphocytes O 0 4.324101965380578e-08
from O 0 2.6388411455968708e-09
7 O 0 5.640402278572765e-08
unrelated O 0 5.379840786190471e-07
A B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 8.602620482633938e-08
, O 0 8.477875290680004e-09
13 O 0 2.3096784929066416e-08
obligate O 0 2.1131977234745136e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
heterozygotes O 0 1.166772221949941e-06
( O 0 4.814359577665073e-09
parents O 0 2.8049578215672e-09
of O 0 3.6889322707622796e-09
the O 0 4.3324792642351895e-09
patients O 0 2.3218991174189796e-09
) O 0 1.1641153596642084e-09
, O 0 3.1407565437291396e-09
and O 0 6.937399987805293e-09
14 O 0 4.09381328836389e-08
normal O 0 1.8672620782922422e-08
controls O 0 6.075635639035681e-08
following O 0 1.7350341607880182e-08
X O 0 4.184729220924055e-07
- O 0 8.29587634143536e-08
irradiation O 0 1.3725359337968257e-07
with O 0 7.122249900959332e-09
1 O 0 2.0873177675184706e-07
Gy O 0 9.487435818300582e-06
in O 0 3.088615363466829e-09
order O 0 2.6958091314810417e-09
to O 0 2.52978926695846e-09
evaluate O 0 4.057169888938006e-08
this O 0 4.414122400930864e-09
cytogenetic O 0 1.7330912669422105e-06
method O 0 1.6503317823435282e-08
as O 0 4.189231184170694e-09
a O 0 4.2164702840352675e-09
tool O 0 5.081983189825223e-08
for O 0 8.277853957849857e-09
detection O 0 5.122545303493098e-07
of O 0 9.337197752756765e-07
ATM O 0 0.00125311769079417
carriers O 0 2.419039901724318e-06
. O 0 2.2378160338121234e-06

Both O 0 6.465349088102812e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.11897990852594376
and O 0 5.796991899842396e-07
heterozygotes O 0 4.25601774622919e-06
showed O 0 3.6764244981668526e-08
significantly O 0 1.5133956310364738e-08
increased O 0 4.844203260745417e-09
levels O 0 2.042674118740706e-08
of O 0 2.668808107841869e-08
radiation O 0 4.828426972380839e-05
- O 0 3.269679154982441e-06
induced O 0 3.7447159684234066e-06
chromatid O 0 5.882320238015382e-06
damage O 0 3.598817102101748e-07
relative O 0 1.297986784720706e-08
to O 0 4.347918025615627e-09
that O 0 3.0207587542463443e-09
of O 0 1.323405882658335e-07
normal O 0 2.991535836827097e-07
controls O 0 7.95910364104202e-06
. O 0 4.487077603698708e-06

These O 0 4.38642871358752e-07
results O 0 3.806476556178495e-08
show O 0 3.134348958155897e-08
that O 0 6.919942396876877e-09
the O 0 1.0859702825882778e-07
G2 O 1 0.9953567385673523
- O 0 9.23834704735782e-06
phase O 0 4.06595472668414e-06
chromosomal O 0 3.446391474426491e-06
radiosensitivity O 0 1.86201828000776e-06
assay O 0 4.034867373547968e-08
can O 0 1.3859061676058104e-09
be O 0 5.272480230189558e-10
used O 0 5.727504581720666e-10
for O 0 1.1312817349562465e-09
the O 0 5.680833137233776e-09
detection O 0 1.2873569232851878e-07
of O 0 5.031790237808309e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.0001285778998862952
. O 0 6.586945801245747e-06

In O 0 5.760585395364615e-07
combination O 0 3.269056776389334e-07
with O 0 1.3084814121100408e-08
molecular O 0 3.393613212665514e-07
genetic O 0 3.850780672109977e-08
analyses O 0 3.4829930939395126e-08
, O 0 3.685767691052888e-09
this O 0 8.016421415568686e-10
test O 0 1.5904774164354762e-09
may O 0 7.184612904609367e-10
be O 0 2.6386789975241243e-10
of O 0 1.7683292607983958e-09
value O 0 1.4980588991519994e-09
in O 0 3.3509070518356054e-10
studies O 0 1.954284511995752e-09
of O 0 5.828665106122344e-09
familial B-Disease 0 3.3776015584408015e-07
and I-Disease 0 2.519336916861903e-08
sporadic I-Disease 0 1.8299610928806942e-06
cancers I-Disease 0 3.537857992341742e-05
aimed O 0 7.749955699409838e-08
at O 0 1.0102099601283498e-08
determination O 0 8.238365545309989e-09
of O 0 1.1863066085027185e-08
the O 0 7.262099810390055e-09
potential O 0 1.4264081471537793e-08
involvement O 0 2.483857031165826e-08
of O 0 1.2410546901264752e-07
ATM O 1 0.856726884841919
mutations O 0 1.5413215237458644e-07
in O 0 1.6043840034285495e-08
tumor B-Disease 1 0.9952449202537537
risk O 0 3.045051073513605e-07
or O 0 1.4362417921631732e-08
development O 0 5.6588934427281856e-08
. O 0 1.2471292620830354e-07
. O 0 1.23474035262916e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 2.0024323532652488e-07
identification O 0 1.1057428395133684e-07
and O 0 1.0623765867023849e-08
detection O 0 4.211955229038722e-07
of O 0 6.318697387541761e-07
founder O 0 1.6253598005278036e-06
- O 0 3.1510131748291315e-07
effect O 0 5.769569710878386e-08
mutations O 0 4.240083839590625e-09
in O 0 1.2538255989014147e-09
the O 0 1.233928426103148e-08
ATM O 0 1.8899488622992067e-06
gene O 0 2.58322661039756e-08
in O 0 1.982646580245273e-08
ethnic O 0 5.47886941149045e-07
populations O 0 6.414176709768071e-07
. O 0 1.1682275271596154e-06

To O 0 7.247904818541429e-07
facilitate O 0 4.1856552002172975e-07
the O 0 1.1415851730589566e-07
evaluation O 0 2.85142306211128e-07
of O 0 3.3942990285140695e-07
ATM O 1 0.6261909604072571
heterozygotes O 0 9.276823789150512e-07
for O 0 1.7681648145639883e-08
susceptibility O 0 8.231411641190789e-08
to O 0 4.906870465504198e-09
other O 0 1.4630278322158574e-08
diseases O 1 0.9997498393058777
, O 0 4.038831047381564e-09
such O 0 1.400898863579414e-08
as O 0 2.5599877062632004e-07
breast B-Disease 1 1.0
cancer I-Disease 1 0.9964489936828613
, O 0 1.0852203580213882e-08
we O 0 5.306462824705704e-09
have O 0 1.2574802310538757e-09
attempted O 0 2.8949861174965008e-08
to O 0 3.842715035062838e-09
define O 0 2.7189862805698795e-08
the O 0 5.475409459165803e-09
most O 0 3.5713603185882903e-09
common O 0 2.9274009882840346e-09
mutations O 0 1.6113417267149543e-09
and O 0 1.1799288213154568e-09
their O 0 8.298274289941787e-10
frequencies O 0 1.9319298161235565e-08
in O 0 1.4343035203978616e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 7.135087116694194e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 5.675778069758053e-08
homozygotes O 0 9.859093097475125e-07
from O 0 1.1228705076860024e-08
10 O 0 7.13160446252914e-08
ethnic O 0 2.0358602625947242e-07
populations O 0 3.528516288042738e-07
. O 0 1.3353896974876989e-06

Both O 0 2.129403128492413e-06
genomic O 0 3.3857813832582906e-06
mutations O 0 6.725051093781076e-08
and O 0 1.1209830397262976e-08
their O 0 6.442276045959261e-09
effects O 0 1.4698839834181854e-07
on O 0 1.2275192773358867e-07
cDNA O 0 7.891782161095762e-07
were O 0 1.1354678974839771e-07
characterized O 0 1.5805280781933106e-06
. O 0 2.2404810806619935e-06

Protein O 0 3.002373205163167e-06
- O 0 9.913343319567502e-07
truncation O 0 1.8567659481050214e-06
testing O 0 1.299996625903077e-07
of O 0 1.4840622952760896e-07
the O 0 1.3496595840933878e-07
entire O 0 9.192701213578403e-07
ATM O 0 5.025075552111957e-06
cDNA O 0 1.0370819154559285e-06
detected O 0 1.9789108307577408e-07
92 O 0 5.221636456553824e-07
( O 0 7.687706471415368e-09
66 O 0 2.129103648940145e-07
% O 0 9.477418849712649e-09
) O 0 9.883832419177452e-09
truncating O 0 1.0402259249531198e-06
mutations O 0 5.5886893335355126e-08
in O 0 1.082276757102818e-08
140 O 0 3.1612137263437035e-07
mutant O 0 2.1230787297099596e-06
alleles O 0 2.0114434562401584e-07
screened O 0 2.857321305782534e-06
. O 0 3.5573004879552172e-06

The O 0 1.075629006663803e-05
haplotyping O 0 0.0014141619903966784
of O 0 2.800880565700936e-06
patients O 0 1.262752249431287e-07
with O 0 1.096357227226008e-08
identical O 0 2.800522906909464e-07
mutations O 0 2.0510132259232705e-08
indicates O 0 3.1881846052073115e-09
that O 0 4.2209583051011634e-10
almost O 0 9.014857749178873e-10
all O 0 5.827516802447974e-10
of O 0 2.7344833064546492e-09
these O 0 1.0925719218235486e-09
represent O 0 1.3296187484357347e-09
common O 0 3.0174704956920095e-09
ancestry O 0 1.4234748935137986e-09
and O 0 1.5076154769033678e-09
that O 0 1.6483583387127965e-09
very O 0 5.794402735403992e-09
few O 0 6.721499090645011e-08
spontaneously O 0 3.091791427323187e-07
recurring O 0 4.8591162340017036e-05
ATM O 0 0.0012272974709048867
mutations O 0 2.292492808919633e-06
exist O 0 1.0370166592110763e-06
. O 0 2.5783933779166546e-06

Assays O 0 1.0848698366316967e-05
requiring O 0 7.828187449376856e-07
minimal O 0 5.908740376980859e-07
amounts O 0 1.0399327976529094e-07
of O 0 4.498713579437208e-08
genomic O 0 9.67901385706682e-08
DNA O 0 2.3554978412221317e-08
were O 0 3.156864325504216e-09
designed O 0 1.5115206863924868e-08
to O 0 4.71597605411489e-09
allow O 0 6.2824745405976046e-09
rapid O 0 2.179522518019894e-08
screening O 0 2.159169376625414e-08
for O 0 1.309597497112236e-08
common O 0 4.926200602994868e-08
ethnic O 0 4.109848816824524e-07
mutations O 0 9.634850357542746e-07
. O 0 1.417245243828802e-06

These O 0 3.031955429833033e-06
rapid O 0 1.652129071771924e-06
assays O 0 8.253371674982191e-07
detected O 0 2.6690045729083067e-07
mutations O 0 1.4856874841484569e-08
in O 0 3.140702586890143e-09
76 O 0 6.331860191721717e-08
% O 0 2.455864178685374e-09
of O 0 1.544947103582217e-08
Costa O 0 6.669820891147538e-07
Rican O 0 1.6862637721715146e-06
patients O 0 1.801237559106994e-08
( O 0 9.53281786841842e-10
3 O 0 1.0818247631050326e-08
) O 0 1.3558069111851978e-09
, O 0 1.4927309388568233e-09
50 O 0 2.898631334957713e-09
% O 0 1.1751202233512004e-09
of O 0 7.277893843138372e-09
Norwegian O 0 1.4004331205796916e-07
patients O 0 6.846121891612711e-09
( O 0 6.72705890991665e-10
1 O 0 1.3989096103728116e-08
) O 0 1.6587030637893463e-09
, O 0 1.245937020222243e-09
25 O 0 3.0708813270052815e-09
% O 0 7.138075686086154e-10
of O 0 4.866809621972834e-09
Polish O 0 2.3770453481120057e-06
patients O 0 1.2871661958513414e-08
( O 0 9.349935270464016e-10
4 O 0 1.5622672933091053e-08
) O 0 1.912475511289813e-09
, O 0 1.3309026103414112e-09
and O 0 2.1689052775997197e-09
14 O 0 7.698476522932651e-09
% O 0 7.862209217002203e-10
of O 0 3.0673747986043054e-09
Italian O 0 4.114652938369545e-07
patients O 0 5.085753151945482e-09
( O 0 7.734797247138658e-10
1 O 0 2.609841054379558e-08
) O 0 2.6131870001222524e-09
, O 0 1.991301790127409e-09
as O 0 1.8091765863204046e-09
well O 0 2.6863495872220255e-09
as O 0 2.3648645264273682e-09
in O 0 4.2288657020606024e-09
patients O 0 1.4017301097624113e-08
of O 0 4.838074829649486e-08
Amish O 0 1.2165578482381534e-06
/ O 0 1.9019510091311531e-06
Mennonite O 0 1.109619233830017e-06
and O 0 6.914640948707529e-08
Irish O 0 1.560524196975166e-06
English O 0 9.941405778590706e-07
backgrounds O 0 1.2038657359880744e-06
. O 0 1.8697232917475048e-06

Additional O 0 2.1761222797067603e-06
mutations O 0 2.5388595759068266e-07
were O 0 2.4804485576623847e-08
observed O 0 2.504083163046289e-08
in O 0 7.192226370023036e-09
Japanese O 0 2.2871593330364703e-07
, O 0 3.5882063542658216e-08
Utah O 0 9.132722311733232e-07
Mormon O 0 1.6976122196865617e-07
, O 0 6.081592118789558e-09
and O 0 1.2693853079781547e-08
African O 0 8.877474755308867e-08
American O 0 4.662511798869673e-07
patients O 0 4.973381919626263e-07
. O 0 1.0506926173547981e-06

These O 0 6.674523547189892e-07
assays O 0 2.594928503185656e-07
should O 0 1.2220325196210524e-08
facilitate O 0 7.728282902519368e-09
screening O 0 4.1535574979434386e-08
for O 0 2.3171665475274494e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 1.3694258313989849e-06
in O 0 1.3833609813218573e-08
the O 0 3.6215535459405146e-08
populations O 0 1.7627433734901388e-08
studied O 0 2.027319823127982e-07
. O 0 8.267616635748709e-08
. O 0 1.4822393268332235e-06

The O 0 3.810652196989395e-05
von B-Disease 1 0.9999028444290161
Hippel I-Disease 1 1.0
- I-Disease 1 0.999996542930603
Lindau I-Disease 1 1.0
tumor I-Disease 1 0.9711962938308716
suppressor O 0 0.00011857770005008206
gene O 0 1.0389791782472457e-07
is O 0 8.93338736318583e-09
required O 0 4.759096672302121e-09
for O 0 8.028206543997385e-09
cell O 0 1.031434635478945e-07
cycle O 0 1.3986192470838432e-07
exit O 0 2.1442804154503392e-07
upon O 0 1.1216272355341061e-07
serum O 0 9.455598615204508e-07
withdrawal O 0 1.3292792573338374e-06
. O 0 2.6557077035249677e-06

The O 0 2.8184711027279263e-06
inactivation O 0 8.984825399238616e-06
of O 0 6.789239819227078e-07
the O 0 3.779312294227566e-07
von B-Disease 1 0.999785840511322
Hippel I-Disease 1 1.0
- I-Disease 1 0.999994158744812
Lindau I-Disease 1 1.0
( I-Disease 0 2.3359320948657114e-06
VHL I-Disease 1 1.0
) I-Disease 0 8.90864839675487e-07
tumor I-Disease 0 0.2145838886499405
suppressor O 1 0.8074879050254822
gene O 0 1.125106336985482e-06
predisposes O 0 2.7153073460794985e-06
affected O 0 1.9554709851377083e-08
individuals O 0 4.676222742361347e-10
to O 0 1.3945186116970376e-09
the O 0 1.3395832354490267e-07
human O 1 1.0
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.2967124263241203e-08
is O 0 4.0516621169217615e-09
associated O 0 4.612779935797562e-09
with O 0 7.083097663951321e-09
sporadic B-Disease 1 0.5286336541175842
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 1 0.9992307424545288
RCC B-Disease 1 1.0
) O 0 1.363053002023662e-06
and O 0 1.9658507426356664e-06
brain B-Disease 1 0.9180923700332642
hemangioblastomas I-Disease 0 0.21394938230514526
. O 0 5.407965545600746e-06

VHL O 1 0.9999934434890747
- O 0 4.6300461690407246e-05
negative O 0 2.9487839583453024e-06
786 O 0 1.3872398994863033e-05
- O 0 4.563506081467494e-06
0 O 0 2.614300910863676e-06
RCC B-Disease 1 0.9999996423721313
cells O 0 9.943588707983508e-08
are O 0 9.917257237646027e-09
tumorigenic O 0 1.4598089364881162e-05
in O 0 6.260049190132122e-08
nude O 0 1.0832352927536704e-05
mice O 0 9.50269125610248e-08
which O 0 2.3012782790488018e-09
is O 0 3.392374603450321e-09
suppressed O 0 6.233764793250884e-08
by O 0 3.489887490104593e-09
the O 0 9.62958992545282e-08
reintroduction O 0 1.2857983165304177e-05
of O 0 3.563840436981991e-06
VHL B-Disease 1 0.9999953508377075
. O 0 2.2838970835437067e-05

Remarkably O 0 1.6919044355745427e-05
, O 0 1.2189032361220598e-07
this O 0 4.066519121437295e-09
occurs O 0 3.784625945968401e-09
without O 0 4.338101877721101e-09
affecting O 0 2.2566482016372902e-08
the O 0 8.033721243805303e-09
growth O 0 7.660013068289118e-09
rate O 0 3.753204858014669e-09
and O 0 3.286672933811019e-09
cell O 0 1.6655864243375618e-08
cycle O 0 2.9595717876418348e-08
profile O 0 1.45407543783449e-08
of O 0 1.792361281616195e-08
these O 0 6.043122002807877e-09
cells O 0 5.799377866821942e-09
in O 0 1.217570133604795e-08
culture O 0 4.383317389056174e-07
. O 0 1.3024142617723555e-06

The O 0 4.82564200865454e-06
786 O 0 1.4083653695706744e-05
- O 0 7.981572593962483e-07
0 O 0 2.129999217004297e-07
cell O 0 9.355276375799804e-08
line O 0 1.875037725085349e-07
, O 0 9.662612043825902e-09
like O 0 1.7381706740593472e-08
many O 0 1.5716848267288697e-08
cancer B-Disease 0 4.861088314100925e-07
cells O 0 4.028329225747029e-09
, O 0 4.77014738820003e-09
fails O 0 3.006281446005232e-08
to O 0 5.707496253393174e-09
exit O 0 2.189439527455761e-07
the O 0 7.223753328844396e-08
cell O 0 2.2000072874561738e-07
cycle O 0 1.8936965773264092e-07
upon O 0 7.42526324870596e-08
serum O 0 6.203601969900774e-07
withdrawal O 0 1.4292412515715114e-06
. O 0 2.796849912556354e-06

Here O 0 7.214870834104659e-07
, O 0 6.207638136856986e-08
it O 0 8.767621295646677e-09
is O 0 3.6595548813522782e-09
shown O 0 1.313692155058277e-09
that O 0 7.126295109571856e-10
reintroduction O 0 2.385019683970313e-07
of O 0 4.342259884992927e-08
the O 0 2.3765592160884808e-08
wild O 0 5.068624773230113e-07
- O 0 9.269235761166783e-07
type O 0 1.2346650919425883e-06
VHL B-Disease 1 0.964588463306427
gene O 0 6.995681900434647e-08
restores O 0 9.047077043078389e-08
the O 0 1.1259523091666779e-08
ability O 0 1.393636495095052e-08
of O 0 1.9656204131024424e-07
VHL O 1 1.0
- O 0 0.02402808703482151
negative O 0 6.121184469520813e-06
RCC B-Disease 1 1.0
cancer I-Disease 0 4.715898285212461e-06
cells O 0 5.22449283835158e-09
to O 0 3.751480015523612e-09
exit O 0 8.952136454354331e-08
the O 0 3.28866889276469e-08
cell O 0 9.861052774340351e-08
cycle O 0 1.2873680077518657e-07
and O 0 4.123813113210417e-08
enter O 0 6.312349114523386e-07
G0 O 0 0.003709335345774889
/ O 0 1.5095410162757616e-05
quiescence O 0 1.3646173101733439e-05
in O 0 2.641341154685506e-07
low O 0 4.392943992570508e-06
serum O 0 3.475824087217916e-06
. O 0 1.5350622106780065e-06

Both O 0 2.08284254767932e-05
VHL O 1 0.9999998807907104
- O 0 2.0840387151110917e-05
positive O 0 2.3578809305035975e-07
and O 0 1.1468929272950845e-07
VHL O 1 0.9999990463256836
- O 0 8.234038432419766e-06
negative O 0 6.993253123255272e-07
RCC B-Disease 1 0.9995688796043396
cells O 0 3.134372761337545e-08
exit O 0 8.944711282765638e-08
the O 0 2.7083446596520844e-08
cell O 0 1.1912977271322234e-07
cycle O 0 1.8643835630882677e-07
by O 0 1.8151501635088607e-08
contact O 0 2.9458590233844006e-07
inhibition O 0 6.013689016981516e-06
. O 0 4.438694304553792e-06

The O 0 1.1686246580211446e-05
cyclin O 0 4.3015810661017895e-05
- O 0 8.133749361149967e-06
dependent O 0 1.2600686432051589e-06
kinase O 0 1.1663361192404409e-06
inhibitor O 0 3.934467827093613e-07
, O 0 4.5505800017053843e-08
p27 O 0 1.8997683355337358e-06
, O 0 2.0317671101111046e-08
accumulates O 0 1.1102442698529558e-07
upon O 0 1.0062946920186278e-08
serum O 0 2.377316299373433e-08
withdrawal O 0 1.1306265257360337e-08
, O 0 2.3012607375250127e-09
only O 0 6.594216284128152e-10
in O 0 6.99946600679624e-10
the O 0 5.751064957593144e-09
presence O 0 1.531740601024012e-08
of O 0 2.3353631206646241e-07
VHL B-Disease 1 1.0
, O 0 3.6084806254166324e-08
as O 0 8.74320527088912e-09
a O 0 3.814447424588252e-09
result O 0 3.907445034201373e-09
of O 0 2.461314352331101e-08
the O 0 1.1308077141336526e-08
stabilization O 0 3.4412374816383817e-07
of O 0 2.319099223768717e-07
the O 0 3.939731811897218e-07
protein O 0 8.526478154635697e-07
. O 0 7.809829298821569e-07

We O 0 6.630569941989961e-07
propose O 0 1.7603687751943653e-07
that O 0 5.000749592198872e-09
the O 0 2.525509401607451e-08
loss O 0 2.015337372540671e-07
of O 0 2.590850840533676e-07
wild O 0 1.0025006304203998e-05
- O 0 2.5213055778294802e-05
type O 0 3.711889439728111e-05
VHL B-Disease 1 0.9999992847442627
gene O 0 2.425393219596117e-08
results O 0 2.8488358339018305e-09
in O 0 8.051727062863279e-10
a O 0 4.277376230987784e-09
specific O 0 2.2973193125608304e-08
cellular O 0 5.835280489918659e-07
defect O 0 5.710836035177635e-07
in O 0 1.5955523124944193e-08
serum O 0 1.713948023507328e-07
- O 0 5.946212695562281e-07
dependent O 0 2.7350063547260106e-08
growth O 0 8.58643733891995e-09
control O 0 6.179133293926498e-08
, O 0 1.1101930041945707e-08
which O 0 1.039232344623997e-08
may O 0 2.479218608186784e-08
initiate O 0 7.075417443047627e-07
tumor B-Disease 0 0.0005044724675826728
formation O 0 7.757076673442498e-06
. O 0 3.779423650485114e-06

This O 0 3.0154734531606664e-07
is O 0 1.0757614177236974e-07
corrected O 0 1.5480669901535293e-07
by O 0 5.771052968839285e-09
the O 0 2.821932376662062e-08
reintroduction O 0 8.768333259467909e-07
of O 0 9.3191054872932e-08
wild O 0 1.1732919347196002e-06
- O 0 2.4019068405323196e-06
type O 0 9.101212526729796e-06
VHL B-Disease 1 1.0
, O 0 1.5749894544114795e-07
implicating O 0 0.0005183292087167501
VHL B-Disease 1 1.0
as O 0 1.7637009364079859e-07
the O 0 1.0565753427727032e-07
first O 0 3.536864312536636e-08
tumor B-Disease 0 2.4971686798380688e-06
suppressor O 0 2.2343826913129305e-06
involved O 0 1.3120751596318314e-08
in O 0 3.5554288402295242e-09
the O 0 8.78425954198292e-09
regulation O 0 4.751407445269251e-08
of O 0 6.576085098686235e-08
cell O 0 1.1595271587339084e-07
cycle O 0 7.746601227154315e-08
exit O 0 7.951132374728331e-08
, O 0 4.300404032875349e-09
which O 0 1.946112160311486e-09
is O 0 2.637492668711161e-09
consistent O 0 5.754400511648328e-09
with O 0 7.074183461242001e-10
its O 0 7.585283512412389e-09
gatekeeper O 0 4.372328987756191e-07
function O 0 1.0375290848685381e-08
in O 0 5.1597068839726035e-09
the O 0 1.1164662083729127e-07
kidney O 1 0.6332751512527466
. O 0 1.6512927913936437e-07
. O 0 1.6800228195279487e-06

Piebaldism B-Disease 1 1.0
with O 0 0.003533110022544861
deafness B-Disease 1 1.0
: O 0 8.265896553893981e-07
molecular O 0 6.564060868186061e-07
evidence O 0 2.6475342806975277e-08
for O 0 1.6615567588473823e-08
an O 0 7.594523054876845e-08
expanded O 0 3.855414979625493e-05
syndrome O 1 0.9999967813491821
. O 0 5.577966476266738e-06

In O 0 5.956167683507374e-07
a O 0 1.9920631189052074e-07
South O 0 3.3201251881109783e-07
African O 0 1.037974968198796e-07
girl O 0 2.2913182817774214e-07
of O 0 1.1674852373744216e-07
Xhosa O 0 1.7408870917279273e-05
stock O 0 4.3811903083224024e-07
with O 0 1.431035290266891e-08
severe O 0 3.003920392075088e-05
piebaldism B-Disease 1 0.9999994039535522
and O 0 0.007952592335641384
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 2.4236089302576147e-05
identified O 0 2.594982788650668e-07
a O 0 3.517972047006879e-08
novel O 0 2.588805614323064e-07
missense O 0 4.105684467958781e-07
substitution O 0 9.064764583399665e-08
at O 0 9.559282432292093e-08
a O 0 2.12687893963448e-08
highly O 0 8.174912835556825e-08
conserved O 0 2.2887083162004274e-07
residue O 0 3.333781251058099e-07
in O 0 9.571520465101457e-09
the O 0 3.2093144142208985e-08
intracellular O 0 1.3435597168154345e-07
kinase O 0 2.465351087721501e-07
domain O 0 5.6727369468489997e-08
of O 0 7.808446156332138e-08
the O 0 1.1933467192193348e-07
KIT O 0 0.01221236027777195
proto O 0 0.0004643216379918158
- O 0 0.00019014861027244478
oncogene O 0 0.00026647126651369035
, O 0 9.025168310472509e-07
R796G O 0 0.00010155726340599358
. O 0 7.507427199016092e-06

Though O 0 7.269042725965846e-06
auditory B-Disease 0 0.030455388128757477
anomalies I-Disease 0 0.19755424559116364
have O 0 3.3624470319182365e-08
been O 0 2.479455041282108e-08
observed O 0 1.5261500507790515e-08
in O 0 6.216806625047866e-09
mice O 0 1.0905930025728594e-07
with O 0 9.617711071996382e-09
dominant O 0 3.862660832965048e-06
white O 0 6.010432684888656e-07
spotting O 0 0.16631582379341125
( O 0 6.773376526325592e-08
W O 0 5.443726695375517e-05
) O 0 5.505380151760164e-09
due O 0 9.98006566277354e-09
to O 0 1.2275245708792681e-08
KIT O 1 0.9999996423721313
mutations O 0 2.9474485927494243e-06
, O 0 2.3095977041975857e-07
deafness B-Disease 1 1.0
is O 0 9.652889332301129e-08
not O 0 6.098225924233702e-09
typical O 0 1.1462149274166222e-07
in O 0 4.59371207739423e-08
human O 0 6.437598472075479e-07
piebaldism B-Disease 0 0.0002535358362365514
. O 0 7.175161044870038e-06

Thus O 0 2.538828312026453e-06
, O 0 1.2828016338062298e-07
the O 0 9.346768337081812e-08
occurrence O 0 1.257437361346092e-06
of O 0 3.604606899898499e-05
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 2.600740572233917e-06
this O 0 9.649907184439144e-08
patient O 0 1.6905036659409234e-07
extends O 0 5.55845574012892e-08
considerably O 0 1.0652720483506073e-08
the O 0 1.1383905373918424e-08
phenotypic O 0 1.7820556763581408e-07
range O 0 1.4343314092002402e-07
of O 0 5.592656293629261e-08
piebaldism B-Disease 0 1.2787357945853728e-06
due O 0 2.07374952765349e-08
to O 0 8.899271541906728e-09
KIT O 0 0.016099482774734497
gene O 0 5.3109914688320714e-08
mutation O 0 7.3323875859898635e-09
in O 0 1.7133121588130962e-09
humans O 0 7.687897429775603e-09
and O 0 7.033595927907754e-09
tightens O 0 6.217105692485347e-07
the O 0 3.8636038368622394e-08
clinical O 0 2.2185271575381194e-07
similarity O 0 4.551152699150407e-08
between O 0 1.175894404070732e-08
piebaldism B-Disease 0 1.4598134612242575e-06
and O 0 8.659973183000602e-09
the O 0 5.4856532649694145e-09
various O 0 6.324483159403371e-09
forms O 0 2.0074415019166736e-08
of O 0 1.736826015985571e-05
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 5.087036356599128e-07
. O 0 3.481888825263013e-06

Cycloheximide O 0 0.0007987333228811622
facilitates O 0 4.100537353224354e-06
the O 0 2.127495974946214e-07
identification O 0 1.1034253333264132e-07
of O 0 4.553731685064122e-07
aberrant O 0 8.580053076912009e-07
transcripts O 0 4.0237475218418695e-07
resulting O 0 7.525468248559264e-08
from O 0 1.2081202704905536e-08
a O 0 1.959073614443696e-08
novel O 0 2.2116320508303033e-07
splice O 0 1.9471754058031365e-06
- O 0 4.066079668518796e-07
site O 0 3.933417360713065e-07
mutation O 0 5.522515067468703e-08
in O 0 1.165122309743083e-08
COL17A1 O 1 0.6789287328720093
in O 0 3.477284948871784e-08
a O 0 6.599632484949325e-08
patient O 0 1.7554232556449278e-07
with O 0 1.6763820553933328e-07
generalized O 0 0.0001883276563603431
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999998807907104
. O 0 0.00013251928612589836

Patients O 0 1.674387567618396e-05
with O 0 1.3089752428641077e-06
generalized O 0 0.07940874993801117
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
often O 0 1.1815213838417549e-06
show O 0 4.7135779368545627e-07
decreased O 0 3.5443440538074356e-07
expression O 0 4.598095060259766e-08
of O 0 1.219209053715531e-07
type O 0 1.4684797861264087e-05
XVII O 1 1.0
collagen O 1 0.9985597729682922
, O 0 2.209888378956748e-07
a O 0 1.3683353472515591e-07
transmembrane O 0 7.607366114825709e-07
hemidesmosomal O 0 3.9251017369679175e-06
protein O 0 9.002700807059227e-08
encoded O 0 6.663139373586091e-08
by O 0 6.019450182748187e-08
COL17A1 O 1 0.9999622106552124
. O 0 1.180729941552272e-05

This O 0 5.517471777238825e-07
report O 0 1.989908042787647e-07
documents O 0 3.2833418117661495e-07
a O 0 1.231828861136819e-07
novel O 0 1.332266720055486e-06
splice O 0 1.1919622011191677e-05
- O 0 2.047274847427616e-06
site O 0 9.167032430923427e-07
mutation O 0 5.4756835510261226e-08
in O 0 7.547501290616765e-09
COL17A1 O 1 0.9993917942047119
in O 0 1.656155745877186e-08
a O 0 2.4766190875880056e-08
patient O 0 6.961658982618246e-08
with O 0 5.068025288323952e-08
generalized O 0 0.005519909784197807
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 5.011049779568566e-07
and O 0 8.487603508910979e-08
applies O 0 6.167476129803617e-08
a O 0 5.617863063633877e-09
new O 0 4.3026684437563745e-09
methodology O 0 2.1339737088510446e-08
to O 0 7.237209942445588e-09
define O 0 7.820295166993674e-08
and O 0 3.12255217238544e-08
characterize O 0 6.245510917324282e-07
the O 0 1.0658090587867264e-07
resulting O 0 1.3134803111825022e-07
mRNA O 0 1.6708005432519712e-06
splice O 0 1.1917019037355203e-05
variants O 0 5.4868878578417934e-06
. O 0 2.9503337373171235e-06

Mutational O 0 0.00025161655503325164
analysis O 0 9.467220820624789e-07
of O 0 1.8070138594339369e-06
COL17A1 O 1 0.9999959468841553
identified O 0 4.088079208486306e-07
a O 0 1.3897377471039363e-07
maternally O 0 1.944644054674427e-06
inherited O 0 3.239911848140764e-06
G O 0 2.0911800220346777e-06
- O 0 1.1980949921053252e-07
to O 0 5.9429368093333323e-08
- O 0 1.4586482393497135e-05
T O 0 1.4543131328537129e-05
transversion O 0 5.267302185529843e-06
at O 0 1.2984402530946682e-07
the O 0 3.709968510179351e-08
- O 0 1.26492665231126e-07
1 O 0 1.765900634609352e-07
position O 0 1.5255280061410303e-07
of O 0 1.9094191827662144e-07
exon O 0 1.158646227850113e-05
32 O 0 7.129657660698285e-06
. O 0 2.93960533781501e-06

This O 0 5.150860147296044e-07
acceptor O 0 2.027677652449711e-07
splice O 0 4.702335900219623e-06
- O 0 1.1786538607339025e-06
site O 0 8.527584327566728e-07
mutation O 0 4.426391697620602e-08
led O 0 2.515169228445302e-08
to O 0 1.0409940465194722e-08
the O 0 2.885229299920411e-08
formation O 0 6.859574597228857e-08
of O 0 1.8293872017238755e-07
aberrant O 0 4.578614323236252e-07
transcripts O 0 4.92790150019573e-07
present O 0 7.816522185066788e-08
at O 0 3.1615783768756955e-07
extremely O 0 5.142094323673518e-07
low O 0 1.9607484773587203e-06
levels O 0 2.2356637146003777e-06
. O 0 1.8671039470063988e-06

Based O 0 1.648980855861737e-06
on O 0 4.601613454724429e-07
our O 0 8.989745481358113e-08
recent O 0 5.69059643851233e-08
finding O 0 6.107656957965446e-08
that O 0 1.1947970612879999e-08
cycloheximide O 0 7.150139481382212e-06
stabilized O 0 3.191352107023704e-06
mutant O 0 5.091961156722391e-06
COL17A1 O 0 0.19730617105960846
transcripts O 0 1.3362495110413874e-06
in O 0 7.240527111207484e-08
keratinocytes O 0 6.439710773520346e-07
homozygous O 0 1.6900618504678278e-07
for O 0 1.6641511280113264e-08
a O 0 5.7309637924163326e-08
frameshift O 0 9.05359115677129e-07
mutation O 0 3.1476727002655025e-08
, O 0 3.497057310397622e-09
the O 0 8.79113137841614e-09
effects O 0 1.2948864025474904e-07
of O 0 5.523558144204799e-08
the O 0 5.485551568540359e-08
splice O 0 1.145667852142651e-06
- O 0 2.0833206804127258e-07
site O 0 1.4961813121772138e-07
mutation O 0 8.953601415839785e-09
on O 0 4.6447037327368434e-09
splicing O 0 4.424813582204479e-08
of O 0 5.473427933111452e-08
COL17A1 O 0 0.0009202657965943217
transcripts O 0 4.4519288167066406e-07
were O 0 3.100315026927092e-08
determined O 0 2.062538939640035e-08
using O 0 8.704038378937184e-09
reverse O 0 4.103194228832763e-08
transcriptase O 0 3.848768415082304e-08
polymerase O 0 2.9785882205146663e-08
chain O 0 4.3003730354485015e-08
reaction O 0 3.7198157887274874e-09
of O 0 1.6465241614582737e-08
total O 0 1.563760676503989e-08
RNA O 0 1.967300846672515e-07
from O 0 4.628142846740957e-08
keratinocytes O 0 3.9408894281223183e-07
incubated O 0 2.2142742750475009e-07
for O 0 3.8993171358470136e-08
2 O 0 2.358083747822093e-06
. O 0 2.9270115646795603e-06

5 O 0 2.5937829377653543e-06
h O 0 3.856028740756301e-07
in O 0 1.4325372887924459e-08
the O 0 2.1021039131596808e-08
presence O 0 2.2553358292043413e-08
or O 0 9.571575532163479e-09
absence O 0 5.307639838747491e-08
of O 0 1.639939881670216e-07
10 O 0 3.479348720247799e-07
microg O 0 2.803595816658344e-05
cycloheximide O 0 3.074896085308865e-05
per O 0 9.302320336246339e-07
ml O 0 3.6745845136465505e-05
. O 0 3.0603721370425774e-06

Using O 0 3.690356606966816e-07
this O 0 2.2622074880018772e-08
approach O 0 1.2452444764221582e-07
, O 0 2.353912442742967e-08
an O 0 3.888132482643414e-08
abnormally O 0 9.87038220046088e-07
spliced O 0 2.6087966489285463e-06
transcript O 0 6.886999130983895e-07
was O 0 1.760503067771424e-07
identified O 0 4.591869995351772e-09
that O 0 8.497995085399168e-10
contains O 0 2.275015553721005e-08
an O 0 2.0453319038438167e-09
extra O 0 2.787960262651268e-08
264 O 0 4.958014088174423e-08
bases O 0 4.313451285042902e-08
upstream O 0 1.6660224844144977e-07
from O 0 1.7426787124463772e-08
exon O 0 6.990806014073314e-07
32 O 0 1.5795802710272255e-07
, O 0 1.2511887526045484e-08
resulting O 0 1.8145790647849935e-08
in O 0 1.130406523941474e-08
a O 0 3.7285762033434366e-08
premature O 0 2.223527957312399e-07
termination O 0 3.636956193986407e-07
codon O 0 1.12743816771399e-06
27 O 0 3.033289317500021e-07
bp O 0 3.739865519492014e-07
downstream O 0 4.5516131308431795e-07
from O 0 5.172558914523506e-08
the O 0 4.780587801178626e-07
cryptic O 0 3.18106212944258e-05
splice O 0 5.6697412219364196e-05
site O 0 3.5707358620129526e-05
. O 0 1.3443582247418817e-05

Three O 0 7.512123261221859e-07
other O 0 1.0228049518445914e-07
splice O 0 1.7040888451447245e-06
variants O 0 2.1342997058582114e-07
, O 0 1.3366322271224362e-08
including O 0 1.0687013052290695e-08
one O 0 6.530746610167171e-09
derived O 0 4.439486556151451e-09
from O 0 2.8980233768294283e-09
the O 0 1.0740879297088668e-08
skipping O 0 2.1742748401720746e-07
of O 0 8.319121036493016e-08
exon O 0 1.0528470966164605e-06
32 O 0 2.218461503389335e-07
, O 0 2.7252998080484758e-08
were O 0 2.984240765613322e-08
also O 0 1.9271055862191133e-07
identified O 0 6.563472538800852e-07
. O 0 1.9079425328527577e-06

These O 0 7.11470249825652e-07
results O 0 1.0374444059380039e-07
indicate O 0 3.593651243249951e-08
the O 0 4.468167702498249e-08
usefulness O 0 2.9912621357652824e-07
of O 0 1.749443470089318e-07
cycloheximide O 0 2.1029572963016108e-05
treatment O 0 9.305571069262442e-08
in O 0 4.104945716676411e-09
evaluating O 0 5.787192947082076e-08
the O 0 1.4427488537194222e-08
abnormal O 0 1.2431674356605527e-08
processing O 0 1.2618440514700069e-08
of O 0 1.0378734316418559e-08
mRNA O 0 3.8099265964319784e-08
due O 0 1.164571195033659e-08
to O 0 4.656554697390902e-09
splice O 0 1.121853529184591e-06
- O 0 2.3098333201687637e-07
site O 0 2.0801401490189164e-07
mutations O 0 1.86559248049889e-08
, O 0 3.27898375118707e-09
because O 0 6.234487592848836e-09
( O 0 1.029949903141869e-08
i O 0 8.672291329503423e-08
) O 0 1.976145469484436e-08
aberrant O 0 1.3736489279381203e-07
splicing O 0 6.300862054331446e-08
often O 0 6.946549113706624e-09
generates O 0 3.4447207752918985e-08
a O 0 1.0611938883187122e-08
premature O 0 6.265508289970967e-08
termination O 0 6.165500820998204e-08
codon O 0 1.1582318393266178e-07
, O 0 8.398994388869596e-09
( O 0 5.236224343008189e-09
ii O 0 3.2835966976563213e-06
) O 0 2.782350527752442e-08
transcripts O 0 3.0889472668604867e-07
with O 0 5.364809396724013e-08
premature O 0 9.54838242250844e-07
termination O 0 4.3165786678400764e-07
codons O 0 8.860006914801488e-07
can O 0 6.344962777404817e-09
occur O 0 2.2396409171676623e-09
at O 0 1.751322287191215e-08
low O 0 6.646423145184599e-08
or O 0 1.4187429009382413e-08
undetectable O 0 4.638597772554931e-07
levels O 0 9.192629768506322e-09
due O 0 5.425219384846969e-09
to O 0 4.109144580155544e-09
nonsense O 0 2.0060582528458326e-07
- O 0 8.249644167790393e-08
mediated O 0 3.4696594042316065e-08
mRNA O 0 2.0364266717365354e-08
decay O 0 4.0739351447882655e-08
, O 0 1.5108366779870153e-09
and O 0 1.5507948258886017e-09
( O 0 6.073848091148193e-09
iii O 0 2.3677945137023926e-05
) O 0 7.1729915340768e-09
the O 0 9.870023909286374e-09
levels O 0 1.4211994248114479e-08
of O 0 7.877073215922792e-09
these O 0 1.9449581944996908e-09
transcripts O 0 4.202702541533654e-08
can O 0 3.3340461502717744e-09
be O 0 3.553815242085534e-09
increased O 0 1.4373680912171949e-08
by O 0 5.384368506611281e-08
cycloheximide O 0 0.000146174177643843
. O 0 8.163356142176781e-06

A O 0 2.7071651857113466e-05
deletion O 0 9.292263712268323e-06
mutation O 0 3.4839541740439017e-07
in O 0 4.6095106398524877e-08
COL17A1 O 1 0.999983549118042
in O 0 6.611728053940169e-08
five O 0 5.376609735208149e-08
Austrian O 0 1.146984118349792e-06
families O 0 1.223950008011343e-08
with O 0 8.829280062627731e-08
generalized O 0 4.9129139370052144e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9988168478012085
represents O 0 1.140853100878303e-06
propagation O 0 5.773763405159116e-07
of O 0 2.397626417405263e-07
an O 0 9.853738447418436e-08
ancestral O 0 5.491326646733796e-06
allele O 0 5.23932203577715e-06
. O 0 4.7652574721723795e-06

Patients O 0 1.8689048374653794e-05
with O 0 1.036154685607471e-06
generalized O 0 0.4291270971298218
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 2.0336860870884266e-06
a O 0 1.599604217972228e-07
usually O 0 3.969313411289477e-08
nonlethal O 0 2.15464569919277e-06
form O 0 1.005842094059517e-07
of O 0 2.895130137403612e-06
junctional B-Disease 1 0.9999997615814209
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999998807907104
, O 0 2.994427177327452e-07
have O 0 1.8939559254249616e-08
generalized O 0 4.6119993157844874e-07
blistering B-Disease 0 8.904163223633077e-06
, O 0 4.496929477681988e-07
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 4.8481284466106445e-05
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 1.8468146663508378e-05
and O 0 2.9284352422109805e-05
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 2.8675402063527144e-05

Skin B-Disease 1 1.0
fragility I-Disease 1 0.9974837303161621
in O 0 1.0878319045559692e-07
most O 0 2.6613156123289627e-08
cases O 0 1.2609778998751153e-08
is O 0 2.9336444384853166e-09
due O 0 8.514921212565696e-09
to O 0 5.338268049825956e-09
mutations O 0 8.862075517868107e-09
in O 0 2.064958648517745e-09
the O 0 2.3486206757183936e-08
gene O 0 4.1609947487586396e-08
encoding O 0 4.5814883264938544e-07
type O 0 4.8158685785892885e-06
XVII O 1 1.0
collagen O 1 0.9999991655349731
( O 0 1.0674829127310659e-06
COL17A1 O 1 1.0
) O 0 1.661200826674758e-06
. O 0 4.7123016884143e-06

Recently O 0 2.821149246301502e-05
, O 0 4.321851463373605e-07
we O 0 6.071337566027069e-08
reported O 0 4.259264230199733e-08
five O 0 3.051015440291849e-08
Austrian O 0 8.305690357701678e-07
families O 0 1.4346263732534226e-08
with O 0 6.442154898422814e-08
generalized O 0 9.216643229592592e-05
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
who O 0 1.3325462759894435e-06
share O 0 1.4652542290605197e-07
the O 0 1.313541844183419e-07
same O 0 2.623601744744519e-07
COL17A1 O 1 0.999993085861206
mutation O 0 6.918209237483097e-06
. O 0 3.4335248528805096e-06

Affected O 0 2.377811824771925e-06
individuals O 0 2.4407167842355193e-08
in O 0 4.5780268465023255e-09
three O 0 4.0404102286117904e-09
families O 0 4.929504027195719e-10
are O 0 2.0167036096641056e-10
homozygous O 0 8.381423555192669e-09
for O 0 3.16391712829045e-09
4003delTC O 0 6.877836540297722e-07
, O 0 4.882318105359218e-09
whereas O 0 5.137856362580351e-09
those O 0 1.3780458996137668e-09
in O 0 1.145322281459471e-09
two O 0 3.1670022160312783e-09
others O 0 2.6123510465936306e-08
are O 0 1.2866286702717389e-08
compound O 0 1.5488114968320588e-06
heterozygotes O 0 2.0980534827685915e-05
. O 0 5.787187546957284e-06

To O 0 6.848383691249182e-07
determine O 0 2.4147587396328163e-07
if O 0 2.173163160534841e-08
the O 0 2.6113347928458097e-08
occurrence O 0 1.2328949594575533e-07
of O 0 7.114363853588657e-08
4003delTC O 0 4.675504783335782e-07
in O 0 4.898678795939304e-09
these O 0 4.086127436409015e-09
unrelated O 0 2.8690079645343758e-08
families O 0 5.459950824793225e-10
signifies O 0 8.083707925266026e-09
propagation O 0 1.981716657439847e-08
of O 0 1.7658798867614678e-08
an O 0 1.0843926645520696e-08
ancestral O 0 2.0311341586420895e-07
allele O 0 1.1905447649951384e-07
or O 0 2.455251824073912e-08
a O 0 4.8711861211359064e-08
mutational O 0 3.952040788135491e-05
hot O 0 2.5911231205100194e-05
spot O 0 3.1189977107715094e-06
, O 0 5.930255042585486e-08
haplotypes O 0 1.8293209791409026e-07
were O 0 8.197596379488914e-09
determined O 0 6.735395352563955e-09
for O 0 4.6421178012678865e-09
polymorphisms O 0 4.845934142849728e-08
both O 0 1.5974890743564174e-08
within O 0 5.284315918174798e-08
and O 0 1.7849998812380363e-07
flanking O 1 0.5158503651618958
COL17A1 O 1 1.0
. O 0 5.116100874147378e-05

Five O 0 1.2195861927466467e-05
intragenic O 0 5.1712537242565304e-05
polymorphisms O 0 1.3423036762105767e-06
were O 0 1.1014277134790973e-07
chosen O 0 1.322759999311529e-07
based O 0 3.441587992369932e-08
on O 0 1.8086225850311166e-07
their O 0 1.3891175854041649e-07
informativeness O 0 0.00013752789527643472
. O 0 8.939559847931378e-06

One O 0 4.608025108154834e-07
of O 0 1.3736436699218757e-07
these O 0 1.3506300078347522e-08
, O 0 6.6149166144668925e-09
not O 0 2.6794875207514224e-09
previously O 0 4.399885611405807e-08
reported O 0 1.4984253837724282e-08
, O 0 1.127166271430724e-08
was O 0 1.538308254112053e-07
2988 O 0 7.6134874689159915e-06
A O 0 3.385541162970185e-07
or O 0 2.6692561050367658e-08
C O 0 2.7097559041067143e-07
that O 0 3.5432363709730907e-09
introduces O 0 5.7619597981783954e-08
a O 0 7.511683719485518e-09
new O 0 8.299639198128261e-09
restriction O 0 3.371277301766895e-08
site O 0 2.165504895401682e-07
for O 0 7.42080388249633e-08
Eco0109 O 0 4.286384501028806e-05
I O 0 5.077039168099873e-05
. O 0 7.581071713502752e-06

All O 0 1.4830338841420598e-06
the O 0 5.506673801392026e-07
4003delTC O 0 9.606567800801713e-06
alleles O 0 2.1677074357739912e-07
showed O 0 5.290639037980327e-08
the O 0 1.1233610486272028e-08
same O 0 7.782185562632549e-09
haplotype O 0 2.0444990411760955e-07
for O 0 5.9076730174467684e-09
these O 0 7.763445886155296e-09
five O 0 3.115941993314664e-08
polymorphic O 0 2.528245659050299e-06
markers O 0 1.2011297258140985e-05
. O 0 3.7727256767539075e-06

Fourteen O 0 9.354854410048574e-05
microsatellite O 0 3.9251823181984946e-05
polymorphisms O 0 1.1629806522250874e-06
were O 0 7.17475927558553e-08
selected O 0 5.680836068222561e-08
based O 0 1.7647854733127133e-08
on O 0 2.4123275821352763e-08
their O 0 7.235981591691143e-09
high O 0 2.951142903384607e-07
heterozygosity O 0 1.9269637050456367e-06
and O 0 1.6744545305868996e-08
their O 0 7.868004026079234e-09
location O 0 7.334530494063074e-08
within O 0 4.642456730152844e-08
10q23 O 0 1.2861723917012569e-05
- O 0 6.311618108156836e-06
q25 O 0 9.379489347338676e-05
near O 0 5.076259549241513e-05
COL17A1 O 1 0.9914641976356506
. O 0 3.032151835213881e-05

Three O 0 1.0028362567027216e-06
families O 0 5.834818850303236e-08
shared O 0 1.0565208441448704e-07
microsatellite O 0 1.2305578138693818e-06
polymorphisms O 0 1.9752832258745912e-07
covering O 0 2.283524736412801e-06
at O 0 1.6748448672387894e-07
most O 0 1.6417731174556138e-08
19 O 0 4.33229985219441e-08
cM O 0 3.031126425412367e-07
, O 0 7.9845019484992e-09
whereas O 0 7.479944663657534e-09
the O 0 1.2139943272870823e-08
others O 0 9.636844211513562e-09
shared O 0 1.2446289332501692e-08
smaller O 0 2.315805680552785e-08
regions O 0 1.584582953739755e-08
consistent O 0 1.580122166444653e-08
with O 0 1.9489576619236004e-09
cross O 0 6.355077886155414e-08
- O 0 1.018885384951318e-07
over O 0 3.67502899223382e-08
events O 0 1.5134130393335e-08
during O 0 7.226230724910465e-09
passage O 0 1.237843783030712e-08
of O 0 8.164390941090005e-09
this O 0 1.2247713954138817e-09
mutation O 0 6.377344874408664e-09
through O 0 5.932899060923091e-09
several O 0 3.824429839482946e-08
generations O 0 2.9341222784751153e-07
. O 0 7.587731261082808e-07

These O 0 2.3262725790118566e-06
results O 0 4.321884432556544e-07
indicate O 0 8.944149243461652e-08
that O 0 1.3656076269796813e-08
4003delTC O 0 1.1790731377914199e-06
occurs O 0 1.1280717693296083e-08
on O 0 1.9350496316405952e-08
a O 0 2.1691420215574908e-08
single O 0 4.478449255884698e-08
ancestral O 0 5.315091016200313e-07
allele O 0 3.6371434930515534e-07
. O 0 1.7031223364938342e-07
. O 0 2.1006405859225197e-06

The O 0 2.3560120098409243e-05
haptoglobin O 0 0.00015885947505012155
- O 0 8.320743290823884e-06
gene O 0 7.019271492936241e-07
deletion O 0 1.9900894585589413e-06
responsible O 0 3.7101392535987543e-07
for O 0 3.1829702606955834e-07
anhaptoglobinemia B-Disease 0 0.06091969832777977
. O 0 1.6122827219078317e-05

We O 0 9.086729164664575e-07
have O 0 2.430839529665718e-08
found O 0 1.3659748887562273e-08
an O 0 9.158066305303691e-09
allelic O 0 1.6271449112537084e-06
deletion O 0 4.440094585334009e-07
of O 0 3.840401916477276e-07
the O 0 4.0503050513507333e-07
haptoglobin O 0 0.00018110216478817165
( O 0 2.1420683893325076e-08
Hp O 0 2.446370785946783e-07
) O 0 6.3307346032104306e-09
gene O 0 4.009013565564601e-09
from O 0 2.531222786927856e-09
an O 0 5.671782155047822e-09
individual O 0 6.142562458677503e-09
with O 0 2.6172985556627282e-08
anhaptoglobinemia B-Disease 0 0.0002703216450754553
. O 0 7.623441433679545e-06

The O 0 1.0186315194005147e-05
Hp O 0 1.3601607861346565e-05
gene O 0 2.2291631296411651e-07
cluster O 0 4.185056639016693e-07
consists O 0 5.7591691415836976e-08
of O 0 3.278685056784525e-08
coding O 0 1.9551583818611107e-07
regions O 0 5.4753282796582425e-08
of O 0 5.109313860884868e-07
the O 0 2.6380232043266005e-07
alpha O 0 3.101386027992703e-07
chain O 0 4.27091357835252e-08
and O 0 6.249726958174051e-09
beta O 0 1.1295384894083327e-07
chain O 0 4.402798481351056e-08
of O 0 2.7602451879715773e-08
the O 0 4.390630792272532e-08
haptoglobin O 0 2.1353760075726314e-06
gene O 0 2.4550034893877637e-08
( O 0 2.8882838343236017e-09
Hp O 0 1.1772480235094918e-07
) O 0 3.09844527812686e-09
and O 0 4.671901088215691e-09
of O 0 3.1754780138726346e-08
the O 0 3.7447833278747567e-08
alpha O 0 8.498813741653066e-08
chain O 0 1.648161074285781e-08
and O 0 4.880437387555503e-09
beta O 0 5.4782219649496255e-08
chain O 0 3.6484681942283714e-08
of O 0 2.6600874392102014e-08
the O 0 3.361094513820717e-08
haptoglobin O 0 1.6066217085608514e-06
- O 0 2.1465308464030386e-07
related O 0 1.0948237871843958e-07
gene O 0 2.542915389369682e-08
( O 0 7.987883243743e-09
Hpr O 0 2.1189480321481824e-06
) O 0 1.3496617157215951e-08
, O 0 1.0907817760141825e-08
in O 0 4.9993000850179214e-09
tandem O 0 1.2291042139622732e-07
from O 0 1.2599440601945844e-08
the O 0 7.183741956851009e-08
5 O 0 7.266078796419606e-07
side O 0 3.4138658975280123e-06
. O 0 2.782154751912458e-06

Southern O 0 5.178695937502198e-05
blot O 0 0.00022147910203784704
and O 0 5.436398282654409e-07
PCR O 0 7.051651209621923e-07
analyses O 0 1.9916453197765804e-07
have O 0 5.5716147251416714e-09
indicated O 0 7.062417761716233e-09
that O 0 6.544509933981146e-10
the O 0 2.938679077857387e-09
individual O 0 6.768321458849869e-10
with O 0 1.1501932739577114e-09
anhaptoglobinemia B-Disease 0 3.4516313007770805e-06
was O 0 7.286842418352535e-08
homozygous O 0 2.812249988437543e-08
for O 0 3.888679156460739e-09
the O 0 1.2970908791487545e-08
gene O 0 8.86555806545175e-09
deletion O 0 2.1338800948456083e-08
and O 0 1.9565966624668363e-09
that O 0 1.4197464315302e-09
the O 0 6.585295864169893e-09
gene O 0 7.342743746363567e-09
deletion O 0 5.564607974406499e-08
was O 0 2.9762825093371248e-08
included O 0 1.1510365105493747e-08
at O 0 2.1805080407943933e-08
least O 0 1.1368993524385473e-09
from O 0 1.3971809265100887e-09
the O 0 1.4081667387699781e-08
promoter O 0 4.214127329760231e-06
region O 0 7.291693577826663e-07
of O 0 9.5208855555029e-07
Hp O 0 3.615387868194375e-06
to O 0 3.117663709417684e-07
Hpr O 0 2.4681890863575973e-05
alpha O 0 3.592507482608198e-07
but O 0 5.82053250042236e-09
not O 0 3.826354344482752e-09
to O 0 3.3672865384914985e-08
Hpr O 0 2.8982436560909264e-05
beta O 0 4.530726982920896e-06
( O 0 3.1325294003181625e-07
Hpdel O 0 0.00022104533854871988
) O 0 1.0163752222069888e-06
. O 0 2.998790478159208e-06

In O 0 2.2058372906030854e-07
addition O 0 1.1216914685974189e-07
, O 0 1.7581701428071028e-08
we O 0 4.19241263927006e-09
found O 0 2.0430939162707773e-09
seven O 0 1.8706585169780965e-09
individuals O 0 1.2689409245592032e-10
with O 0 6.95514978943379e-10
hypohaptoglobinemia B-Disease 0 1.948562839970691e-06
in O 0 3.495096656536134e-09
three O 0 3.5902241179996963e-09
families O 0 4.639017781027377e-10
, O 0 1.0099976410771205e-09
and O 0 1.8336265839025145e-09
the O 0 9.70835145608362e-09
genotypes O 0 1.3739109760990686e-07
of O 0 4.713325552074821e-08
six O 0 6.826602394482961e-09
of O 0 3.4982797103566554e-08
the O 0 2.2141067645975454e-08
seven O 0 1.1203525218661525e-08
individuals O 0 8.932360961999564e-10
were O 0 1.8374671784116003e-09
found O 0 3.032032180882993e-09
to O 0 1.3721375147213166e-08
be O 0 1.5184042467808467e-07
Hp2 O 1 0.9999281167984009
/ O 0 0.22081780433654785
Hpdel O 1 0.9996007084846497
. O 0 3.185840614605695e-05

The O 0 2.8722329261654522e-06
phenotypes O 0 1.8500880969440914e-06
and O 0 5.374805667202054e-08
genotypes O 0 2.6458286583874724e-07
in O 0 4.85654449988715e-09
one O 0 3.3556670775425346e-09
of O 0 8.466677137164424e-09
these O 0 1.5074114179114417e-09
three O 0 1.2749266087297428e-09
families O 0 4.991827506906077e-10
showed O 0 2.7449345019192606e-09
the O 0 7.899521925480713e-09
father O 0 1.4291477334893443e-08
to O 0 6.129384555464412e-09
be O 0 1.713372022038584e-08
hypohaptoglobinemic B-Disease 0 2.5849230951280333e-05
( O 0 3.4092931144869e-08
Hp2 O 0 3.350822225911543e-05
) O 0 1.3920770314257425e-08
and O 0 1.8548949043406537e-08
Hp2 O 0 0.00014819949865341187
/ O 0 1.956301275640726e-06
Hpdel O 0 0.00018282659584656358
, O 0 3.180090502041821e-08
the O 0 1.885090128439515e-08
mother O 0 1.0337364741985766e-08
to O 0 2.7584754480614038e-09
be O 0 5.758616694606644e-09
Hp2 O 0 3.175658775944612e-06
- O 0 1.9045505439407862e-07
1 O 0 2.5746905407686427e-07
and O 0 4.7630852151314684e-08
Hp1 O 0 9.204452362610027e-05
/ O 0 1.6366070667572785e-06
Hp2 O 0 4.125344639760442e-05
, O 0 1.689635631407782e-08
one O 0 3.269254200688465e-09
of O 0 1.1579023073693406e-08
the O 0 4.937269260096855e-09
two O 0 1.164412899434808e-09
children O 0 1.2734586718465835e-09
to O 0 1.458185239222587e-09
be O 0 5.1277040391539686e-09
hypohaptoglobinemic B-Disease 0 6.640342235186836e-06
( O 0 1.7663749574126086e-08
Hp2 O 0 2.3082589905243367e-05
) O 0 1.6046350026499567e-08
and O 0 3.004194937261673e-08
Hp2 O 0 0.004973847884684801
/ O 0 3.3697651815600693e-06
Hpdel O 0 0.1791709065437317
, O 0 2.0664449706941923e-08
and O 0 5.73232705747273e-09
the O 0 8.140196072758954e-09
other O 0 1.8305166271659346e-09
child O 0 6.699047094826938e-09
to O 0 2.2571249314040642e-09
be O 0 9.537187928287949e-09
Hp1 O 0 7.908787665655836e-05
and O 0 1.7193291057537863e-07
Hp1 O 1 0.9999587535858154
/ O 0 3.263478720327839e-05
Hpdel O 0 0.40512529015541077
, O 0 4.837714939753823e-08
showing O 0 3.086084987558024e-08
an O 0 1.066676968974889e-08
anomalous O 0 7.540676278949832e-07
inheritance O 0 8.092116559055285e-07
of O 0 1.1220503211006871e-06
Hp O 0 4.839865141548216e-06
phenotypes O 0 4.4892124151374446e-07
in O 0 1.1357100149211874e-08
the O 0 6.849128908470448e-08
child O 0 2.626971706831682e-07
with O 0 1.7733094637151225e-07
Hp1 O 0 0.4451502859592438
. O 0 1.1607851774897426e-05

The O 0 2.4237058823928237e-05
Hp2 O 1 0.9992769360542297
/ O 0 0.0004936059121973813
Hpdel O 1 0.8893793225288391
individuals O 0 7.318418226986978e-08
had O 0 4.919571239270226e-08
an O 0 1.1570501889934803e-08
extremely O 0 4.992165614225996e-08
low O 0 1.113552698939202e-07
level O 0 1.5621098725659976e-07
of O 0 2.254936504186844e-07
Hp O 0 1.3051534324404201e-06
( O 0 2.9186159267169387e-08
mean O 0 1.4231571299205825e-07
+ O 0 1.8897185327659827e-07
/ O 0 4.848642447541351e-07
- O 0 1.3087081924822996e-06
SD O 0 0.00013252055214252323
= O 0 2.0329693484200106e-07
0 O 0 9.265757228149596e-08
. O 0 3.0774206294381656e-08
049 O 0 8.516454727214295e-06
+ O 0 2.3943999849507236e-07
/ O 0 1.9741250412153022e-07
- O 0 3.510854185151402e-07
0 O 0 9.050183535919132e-08
. O 0 1.769801194484444e-08
043 O 0 5.763075478171231e-06
mg O 0 1.7067822000171873e-06
/ O 0 4.135999915888533e-07
ml O 0 7.2563290132166e-07
; O 0 5.098300892569796e-09
n O 0 1.503469881924957e-08
= O 0 6.008630482057242e-09
6 O 0 1.0999514188370085e-08
) O 0 1.7744986591239353e-09
, O 0 1.2535793514345528e-09
compared O 0 1.6749838183116594e-09
with O 0 7.48419326512817e-10
the O 0 3.9332275214576384e-09
level O 0 1.5125818819683445e-08
( O 0 1.1894576434912096e-09
1 O 0 2.4421044741984588e-08
. O 0 4.0482324159540894e-09
64 O 0 9.961964053673e-08
+ O 0 4.215652182892882e-08
/ O 0 9.122121724658427e-08
- O 0 1.4353084054619103e-07
1 O 0 1.473555641950952e-07
. O 0 1.705013197295102e-08
07 O 0 3.820307028945535e-06
mg O 0 3.4469733236619504e-06
/ O 0 8.363045367332234e-07
ml O 0 1.047190380631946e-06
) O 0 1.0349359591543816e-08
obtained O 0 1.201431043540424e-08
from O 0 1.458864762327039e-08
52 O 0 1.604819317435613e-07
healthy O 0 5.928388802090012e-08
volunteers O 0 3.002659809681063e-08
having O 0 2.506606477936657e-08
phenotype O 0 2.1583711884431978e-07
Hp2 O 0 1.0901871974056121e-05
, O 0 4.151601018520523e-08
whereas O 0 5.2226422297962927e-08
the O 0 5.01104508998651e-08
serum O 0 1.0458704480242886e-07
Hp O 0 1.90815399037092e-07
level O 0 8.130129458550073e-08
of O 0 3.851449292824327e-08
an O 0 9.398285705231046e-09
individual O 0 4.7345509734952884e-09
with O 0 1.3896656270162566e-08
Hp1 O 0 0.017648158594965935
/ O 0 2.665414103830699e-05
Hpdel O 0 0.0018996212165802717
was O 0 2.328387836314505e-06
0 O 0 3.0808676001470303e-06
. O 0 1.857793222370674e-06

50 O 0 8.7896760305739e-06
mg O 0 7.566490239696577e-05
/ O 0 2.418847543594893e-05
ml O 0 6.291409226832911e-05
, O 0 3.617397581479054e-08
which O 0 3.971916573419776e-09
was O 0 9.505606080040252e-09
approximately O 0 1.586756503968445e-09
half O 0 1.7494318216293436e-09
the O 0 2.0834698410965302e-09
level O 0 2.0329261829488132e-08
of O 0 3.625880395929926e-08
Hp O 0 2.2948105993236823e-07
in O 0 1.2022746354034552e-08
control O 0 6.685111202386906e-07
sera O 0 8.107796747935936e-05
from O 0 4.329978153805314e-08
the O 0 1.4074262821850425e-07
Hp1 O 0 8.168946806108579e-06
phenotype O 0 3.846141538588199e-08
( O 0 1.5426613320101978e-09
1 O 0 2.103210761106311e-08
. O 0 3.181696683896007e-09
26 O 0 4.56002418047774e-08
+ O 0 3.015999183730855e-08
/ O 0 6.474886049545603e-08
- O 0 1.0772890846055816e-07
0 O 0 6.077327441289526e-08
. O 0 7.1952994673551984e-09
33 O 0 1.520625687589927e-07
mg O 0 1.3280576922625187e-06
/ O 0 5.099013833387289e-07
ml O 0 1.0098633538291324e-06
; O 0 1.0304569642016759e-08
n O 0 2.344959071365338e-08
= O 0 9.138087619930957e-09
9 O 0 1.6870078667352573e-08
) O 0 5.269527925122475e-09
, O 0 1.3119350938950447e-08
showing O 0 3.2535673710754054e-08
a O 0 3.634091783055737e-08
gene O 0 1.0871059430428431e-07
- O 0 1.3404667242866708e-06
dosage O 0 1.0544173164817039e-05
effect O 0 1.7029808532242896e-06
. O 0 1.8684096403376316e-06

The O 0 1.3174638979762676e-06
other O 0 1.443185624339094e-07
allele O 0 3.273917741353216e-07
( O 0 1.4010671733899471e-08
Hp2 O 0 1.1444119081716053e-05
) O 0 9.296909908584894e-09
of O 0 3.197704856461314e-08
individuals O 0 2.5668600578399037e-09
with O 0 9.475466633546148e-09
Hp2 O 1 0.9999997615814209
/ O 0 0.09361473470926285
Hpdel O 1 0.999976634979248
was O 0 2.431480083942006e-07
found O 0 4.2211940609604426e-09
to O 0 1.4371506207311313e-09
have O 0 5.911411360415286e-10
, O 0 1.2669222337891028e-09
in O 0 1.034357266505026e-09
all O 0 3.3449061298540528e-09
exons O 0 2.0399765787715296e-07
, O 0 9.025391989325726e-09
no O 0 1.2785874581311418e-08
mutation O 0 1.082815703767892e-08
, O 0 4.030619837891436e-09
by O 0 5.807391900702896e-09
DNA O 0 1.8323693495858606e-07
sequencing O 0 1.2011374792564311e-06
. O 0 1.395736148879223e-06

On O 0 9.149032393906964e-07
the O 0 4.7113214662886094e-08
basis O 0 1.9317603516810777e-08
of O 0 1.7907245464243715e-08
the O 0 1.103288127524138e-08
present O 0 6.704645727495517e-09
study O 0 4.5501264978042855e-09
, O 0 2.5641393452957573e-09
the O 0 4.529483454973615e-09
mechanism O 0 2.0664057132080416e-08
of O 0 4.3195683474550606e-08
anhaptoglobinemia B-Disease 0 3.3899689242389286e-06
and O 0 2.22699494401013e-08
the O 0 3.851757668371647e-08
mechanism O 0 6.31927576932867e-08
of O 0 1.0717697307427443e-07
anomalous O 0 1.3338457165446016e-06
inheritance O 0 7.80042796577618e-07
of O 0 1.1570632523216773e-06
Hp O 0 6.254438176256372e-06
phenotypes O 0 1.7029841501425835e-06
were O 0 7.359614784263613e-08
well O 0 1.390234842801874e-07
explained O 0 1.898743221318e-06
. O 0 2.020337888097856e-06

However O 0 2.3958375550137134e-06
, O 0 2.615520031667984e-07
the O 0 2.643200787133537e-07
mechanism O 0 1.3975568435853347e-06
of O 0 2.883666866182466e-06
hypohaptoglobinemia B-Disease 0 0.07360861450433731
remains O 0 0.00015402697317767888
unknown O 0 5.6530428992118686e-05

ATM O 0 0.008482309989631176
mutations O 0 3.399509296286851e-06
and O 0 3.214994421796291e-07
phenotypes O 0 8.687091394676827e-06
in O 0 2.631510085393529e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 3.212462118540316e-08
in O 0 5.663847169046221e-09
the O 0 2.1797054827743523e-08
British O 0 4.336565595508546e-08
Isles O 0 3.8420651549131435e-07
: O 0 5.181314488567068e-09
expression O 0 5.2657700422287235e-09
of O 0 7.83570008877632e-09
mutant O 0 1.503536424252161e-07
ATM O 0 6.140415393929288e-07
and O 0 4.148915433432876e-09
the O 0 1.1216738649011404e-08
risk O 0 5.7805188191650814e-08
of O 0 9.723552096829735e-08
leukemia B-Disease 1 1.0
, O 0 8.589947356085759e-06
lymphoma B-Disease 1 1.0
, O 0 8.901693036023062e-06
and O 0 5.5162709031719714e-05
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 5.860846613359172e-06

We O 0 6.472225209108728e-07
report O 0 7.60707763447499e-08
the O 0 5.2574829823015534e-08
spectrum O 0 5.853640345776512e-07
of O 0 1.4176156071243895e-07
59 O 0 8.065212000474276e-07
ATM O 0 1.4952363926568069e-05
mutations O 0 1.2747210575980716e-07
observed O 0 5.346901588154651e-08
in O 0 3.016867822225322e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 3.4568622595543275e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.48454393620068e-08
patients O 0 7.642763755200122e-09
in O 0 5.613963960371393e-09
the O 0 1.1193532856168531e-07
British O 0 8.946543630372616e-07
Isles O 0 2.4218783437390812e-05
. O 0 3.339051772854873e-06

Of O 0 1.977421561605297e-05
51 O 0 1.1681901014526375e-05
ATM O 0 0.0003013259847648442
mutations O 0 1.673558074344328e-07
identified O 0 1.7039079480696273e-08
in O 0 4.970547973215389e-09
families O 0 1.6295366167540237e-09
native O 0 6.6910534890496365e-09
to O 0 3.725631358975079e-09
the O 0 2.71007571939208e-08
British O 0 7.23864914675687e-08
Isles O 0 3.6971832173549046e-07
, O 0 1.1401289690127214e-08
11 O 0 1.9423641361981936e-08
were O 0 1.3809303922585059e-08
founder O 0 1.8694240111472027e-07
mutations O 0 1.214404221627774e-08
, O 0 3.1792761756577193e-09
and O 0 1.9688457530975256e-09
2 O 0 2.976634760898378e-08
of O 0 2.2117896847362317e-08
these O 0 3.947567162043697e-09
11 O 0 1.984636810448137e-08
conferred O 0 4.98775918345018e-08
a O 0 1.2919107561515375e-08
milder O 0 3.920235371879244e-07
clinical O 0 1.538956979629802e-07
phenotype O 0 9.336948103566556e-09
with O 0 8.046875943357179e-10
respect O 0 9.307768777944148e-09
to O 0 2.0060788585851697e-08
both O 0 4.918454692415253e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 0.09132866561412811
cellular O 0 9.069525549421087e-05
features O 0 3.9453418139601126e-05
. O 0 7.487228231184417e-06

We O 0 7.154602030823298e-07
report O 0 1.4587958219181019e-07
, O 0 2.1356145296635987e-08
in O 0 3.723223063190062e-09
two O 0 6.6008509769233115e-09
A B-Disease 0 0.05824283882975578
- I-Disease 0 0.0014558619586750865
T I-Disease 1 0.9999998807907104
families O 0 4.989221924489584e-09
, O 0 2.7958506620962e-09
an O 0 4.628740946088783e-09
ATM O 0 2.9039010769338347e-06
mutation O 0 6.624868831295316e-08
( O 0 1.0368861325105172e-08
7271T O 0 1.9643102859845385e-06
- O 0 6.691004728054395e-07
- O 0 9.530023703518964e-07
> O 0 2.6136723363379133e-07
G O 0 6.209449452398985e-07
) O 0 1.9027173170371725e-09
that O 0 5.070814323993034e-10
may O 0 6.614749303857081e-10
be O 0 2.453007241776106e-10
associated O 0 6.789888096214725e-10
with O 0 6.791857076748897e-10
an O 0 1.5434618028109526e-09
increased O 0 7.644979760357273e-09
risk O 0 1.0032440656004837e-07
of O 0 2.500702294128132e-07
breast B-Disease 1 0.9999786615371704
cancer I-Disease 0 2.3287852854991797e-06
in O 0 3.80485598583391e-09
both O 0 1.014767558871199e-08
homozygotes O 0 1.0642879715305753e-06
and O 0 1.8861223693988904e-08
heterozygotes O 0 2.3284469818918296e-07
( O 0 3.171517493072429e-09
relative O 0 1.3097973372566685e-08
risk O 0 8.20335266382699e-09
12 O 0 4.3076857636492605e-09
. O 0 1.0927303506491626e-09
7 O 0 1.59029003299338e-08
; O 0 3.965399564265226e-09
P O 0 1.6294544025186042e-07
= O 0 1.0031824260181565e-08
. O 0 2.5769064659897367e-09
0025 O 0 4.1145429463540495e-07
) O 0 2.463135251318249e-09
, O 0 1.4090929534305019e-09
although O 0 9.384345522889248e-10
there O 0 1.0775964565112872e-09
is O 0 2.026135259569628e-09
a O 0 2.6064419511584447e-09
less O 0 1.2985934105813612e-08
severe O 0 1.609423998161219e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 5.446227291372452e-08
in O 0 8.998486955569263e-10
terms O 0 2.2296036128466312e-09
of O 0 8.498096448761316e-09
the O 0 1.4154049488013243e-08
degree O 0 2.3465099729946814e-07
of O 0 1.4242870065572788e-06
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 0.00017124546866398305

This O 0 7.323737918341067e-07
mutation O 0 5.387501005316153e-07
( O 0 4.053920932278743e-08
7271T O 0 6.062125521566486e-06
- O 0 1.4662650755781215e-06
- O 0 2.1512373677978758e-06
> O 0 6.554534479619178e-07
G O 0 9.180313327306067e-07
) O 0 3.490286726304248e-09
also O 0 2.5406063919319877e-09
allows O 0 2.3405966054212968e-09
expression O 0 3.574242679604822e-09
of O 0 8.533180384517891e-09
full O 0 1.1474197592065138e-08
- O 0 4.610934922766319e-08
length O 0 5.568494287899739e-08
ATM O 0 9.094766255657305e-07
protein O 0 2.764555162571014e-08
at O 0 1.6672519365101834e-08
a O 0 3.687293359533328e-09
level O 0 1.295913776289126e-08
comparable O 0 1.0900435221117277e-08
with O 0 1.3297608569828867e-09
that O 0 1.6473212793854941e-09
in O 0 1.573499552876001e-08
unaffected O 0 1.3132915910318843e-06
individuals O 0 3.478584886806857e-08
. O 0 7.083748982950056e-07

In O 0 2.9718873406636703e-07
addition O 0 9.812476520210112e-08
, O 0 1.9348025404042346e-08
we O 0 3.9252983086157656e-09
have O 0 1.4135937975723323e-09
studied O 0 4.928033092710393e-08
18 O 0 6.900438620505156e-08
A B-Disease 1 0.9999183416366577
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 6.125436158299635e-08
, O 0 2.0575241510556452e-09
in O 0 5.914276290930331e-10
15 O 0 4.232860284503204e-09
families O 0 2.8622546000001137e-10
, O 0 1.859655207603339e-09
who O 0 1.0087986446194463e-08
developed O 0 9.443694466426678e-07
leukemia B-Disease 1 1.0
, O 0 8.74592806212604e-05
lymphoma B-Disease 1 1.0
, O 0 2.5232741336367326e-06
preleukemic O 1 0.9999986886978149
T O 1 0.8883495926856995
- O 0 2.7951141419180203e-06
cell O 0 2.9819645988027332e-06
proliferation O 1 0.9999818801879883
, O 0 6.703932342588814e-08
or O 0 5.718837655876996e-06
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 4.6454772473225603e-07
mostly O 0 1.0451964271851466e-07
in O 0 9.019010605015865e-08
childhood O 0 1.1544416338438168e-05
. O 0 2.8612641926883953e-06

A O 0 1.033362696034601e-05
wide O 0 2.3423183392878855e-06
variety O 0 4.853852146879944e-07
of O 0 4.089794742867525e-07
ATM O 0 2.4133663828251883e-05
mutation O 0 5.02639920796355e-08
types O 0 2.8596874201980427e-08
, O 0 3.898430023241417e-09
including O 0 1.1211305661618098e-08
missense O 0 2.1986208764701587e-07
mutations O 0 7.451152583826115e-09
and O 0 2.7028523863492637e-09
in O 0 3.881698962260316e-09
- O 0 2.3818442684842012e-07
frame O 0 1.419184627593495e-07
deletions O 0 1.5730906000044342e-07
, O 0 1.0869293021187332e-08
were O 0 7.264565837772352e-09
seen O 0 2.6254683760384978e-08
in O 0 7.587873440684234e-09
these O 0 4.84395634714474e-08
patients O 0 9.664089617444915e-08
. O 0 3.777859944875672e-07

We O 0 3.920930851109006e-07
also O 0 2.092543027742977e-08
show O 0 1.0883524304006187e-08
that O 0 5.901644728467659e-10
25 O 0 5.2468318578746675e-09
% O 0 6.160581489389472e-10
of O 0 1.5096470740161294e-09
all O 0 3.526690495192497e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.973729174016171e-08
carried O 0 1.1519634135481738e-08
in O 0 2.5104471834680453e-09
- O 0 1.402716236498236e-07
frame O 0 2.4073824533843435e-07
deletions O 0 2.17965208548776e-07
or O 0 4.142899712178405e-08
missense O 0 3.1834835567678965e-07
mutations O 0 1.3852699431993187e-08
, O 0 1.3611678451042053e-09
many O 0 7.430087656246087e-10
of O 0 4.1458778632375015e-09
which O 0 5.590762852669684e-10
were O 0 8.256546557561251e-10
also O 0 8.058702594126999e-10
associated O 0 1.3445480284701716e-09
with O 0 2.299637369418406e-09
expression O 0 1.8468602647203625e-08
of O 0 1.2688727224485774e-07
mutant O 0 4.976668151357444e-06
ATM O 0 4.783786425832659e-05
protein O 0 3.4016495646937983e-06
. O 0 1.7121685687015997e-06

The O 0 1.2244143363204785e-05
DMPK O 1 0.9999996423721313
gene O 0 3.8394682633224875e-06
of O 0 4.943203293805709e-06
severely O 1 0.9999998807907104
affected O 1 0.9998544454574585
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.014711766503751278
is O 0 2.9241695642667764e-07
hypermethylated O 0 5.2158171456540003e-05
proximal O 0 8.266516488220077e-06
to O 0 9.12979842837558e-08
the O 0 3.8750289377276204e-07
largely O 0 5.199801194066822e-07
expanded O 0 1.4134038792690262e-06
CTG O 0 0.007088684476912022
repeat O 0 1.4057874977879692e-05
. O 0 3.986399860878009e-06

Using O 0 1.0520292335058912e-06
methylation O 0 1.9231745227443753e-06
- O 0 2.817818312905729e-06
sensitive O 0 2.7317589683661936e-06
restriction O 0 1.3014653177378932e-07
enzymes O 0 4.2812633438416015e-08
, O 0 7.077493702212223e-09
we O 0 4.049823143503772e-09
characterized O 0 1.7146795983080665e-08
the O 0 6.447721911939652e-09
methylation O 0 3.270222492801622e-08
pattern O 0 3.005364135333366e-08
on O 0 9.543629886366034e-09
the O 0 4.743834658427204e-09
5 O 0 1.0934773087001304e-08
side O 0 1.4812195914259974e-08
of O 0 2.4760570482840194e-08
the O 0 5.216688592213359e-08
CTG O 0 0.0004130518063902855
repeat O 0 1.0564261287981935e-07
in O 0 4.497990868657098e-09
the O 0 5.123561308550961e-08
DMPK O 1 0.9583417773246765
gene O 0 2.962135781103825e-08
of O 0 1.2681559802274478e-08
normal O 0 1.1795738608100237e-08
individuals O 0 3.901128309280466e-10
and O 0 1.1430069113416153e-09
of O 0 3.164334927419077e-08
patients O 0 2.123271514165026e-08
affected O 0 2.2067792926350194e-08
with O 0 1.3551023414493102e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.6769097871692793e-07
showing O 0 2.2867665450121422e-07
expansions O 0 6.789181270505651e-07
of O 0 3.077887811286928e-07
the O 0 4.7294861360569485e-07
repetitive O 0 1.7298420061706565e-05
sequence O 0 1.6656998695907532e-06
. O 0 1.8372915064901463e-06

The O 0 1.4383861525857355e-05
gene O 0 1.182693836199178e-06
segment O 0 1.4817785540799377e-06
analyzed O 0 2.055225536423677e-07
corresponds O 0 8.02804223098974e-08
to O 0 3.494811906534778e-08
the O 0 1.9694445541063033e-07
genomic O 0 4.1228563532058615e-06
SacI O 0 4.31237458542455e-05
- O 0 1.758591224643169e-06
HindIII O 0 1.4411212760023773e-05
fragment O 0 4.782001497005695e-07
carrying O 0 1.3904164575251343e-07
exons O 0 1.9580727439461043e-06
11 O 0 2.5892600774568564e-07
- O 0 1.5078023807291174e-06
15 O 0 1.418772171746241e-06
. O 0 2.149395868400461e-06

There O 0 3.0756305022805464e-06
is O 0 5.059926593276032e-07
constitutive O 0 4.391402853798354e-06
methylation O 0 1.0050440550912754e-06
in O 0 1.1663989596399915e-07
intron O 0 1.0660205589374527e-05
12 O 0 2.8577687771758065e-07
at O 0 1.0020678331557065e-07
restriction O 0 4.4957801037526224e-08
sites O 0 2.7921323919599672e-08
of O 0 4.5779856350236514e-08
SacII O 0 9.035942639457062e-06
and O 0 4.1344453194369635e-08
HhaI O 0 2.4966802811832167e-05
, O 0 3.568985462720775e-08
localized O 0 3.865336566377664e-07
1 O 0 1.3674691956566676e-07
, O 0 1.006764982491859e-08
159 O 0 4.7678209824653095e-08
- O 0 5.851257256495046e-08
1 O 0 1.193822640743747e-07
, O 0 1.5845253997781583e-08
232 O 0 5.432397998106353e-08
bp O 0 5.613656739456019e-08
upstream O 0 1.0024311336565006e-07
of O 0 4.181537605063568e-08
the O 0 8.083109293011148e-08
CTG O 0 0.0592513270676136
repeat O 0 1.917715195531855e-07
, O 0 6.7246763713058044e-09
whereas O 0 3.123890701672849e-09
most O 0 1.3544163568468548e-09
, O 0 1.168689478525664e-09
if O 0 3.8592620765776076e-10
not O 0 2.0553775348375325e-10
all O 0 4.1293660157926126e-10
, O 0 8.444030474841213e-10
of O 0 3.2965987717403777e-09
the O 0 3.846983176458707e-09
other O 0 1.628542412035472e-09
sites O 0 1.1430642210541464e-08
of O 0 2.294744305686436e-08
SacII O 0 3.6357127100927755e-05
, O 0 3.021307293238351e-08
HhaI O 0 2.997433148266282e-05
, O 0 2.3783094604823418e-08
and O 0 1.949966232928091e-08
HpaII O 0 5.660843271471094e-06
in O 0 5.864864149884852e-09
this O 0 2.3595796427855475e-09
region O 0 2.7370051114417038e-08
are O 0 3.613561672111132e-09
unmethylated O 0 7.803158723618253e-07
, O 0 9.714483439893229e-09
in O 0 2.5495821009968722e-09
normal O 0 9.307893122922906e-09
individuals O 0 3.291325822996072e-10
and O 0 9.868174055682744e-10
most O 0 4.62063454165218e-09
of O 0 9.266181422162845e-08
the O 0 4.6079415483291086e-07
patients O 0 4.5944833004796237e-07
. O 0 7.575135896331631e-07

In O 0 1.7326173917808774e-07
a O 0 1.6428632676479538e-08
number O 0 9.18069709143765e-09
of O 0 1.0050155907492808e-07
young O 0 1.0145356554858154e-07
and O 0 2.382313724069718e-08
severely O 0 1.9252449419582263e-05
affected O 0 6.024630039291878e-08
patients O 0 1.0738278710675786e-08
, O 0 2.192045212012772e-09
however O 0 3.197544895527926e-09
, O 0 5.707659234133189e-09
complete O 0 1.0166215425044811e-08
methylation O 0 4.647471030239103e-08
of O 0 3.376199941840241e-08
these O 0 5.191048035868562e-09
restriction O 0 2.29866508050236e-08
sites O 0 4.5003442750157774e-08
was O 0 3.171368234688998e-08
found O 0 3.556927863357373e-09
in O 0 2.482861249930579e-09
the O 0 8.695612763176541e-08
mutated O 0 1.82523945113644e-06
allele O 0 1.1790451708293403e-06
. O 0 1.8774528598441975e-06

In O 0 2.5412626314391673e-07
most O 0 3.7098342176022925e-08
of O 0 2.9660592204550085e-08
these O 0 4.380773965806384e-09
patients O 0 2.795722542359158e-09
, O 0 1.4652025148720327e-09
the O 0 6.1614069402082805e-09
onset O 0 2.8679443175860797e-07
of O 0 2.2172855551616522e-07
the O 0 7.881756573624443e-06
disease O 1 1.0
was O 1 0.9999474287033081
congenital O 1 1.0
. O 0 3.4394077374599874e-05

Preliminary O 0 1.4559672308678273e-05
in O 0 1.3660384183822316e-06
vivo O 0 1.7988561012316495e-05
footprinting O 0 4.912482836516574e-05
data O 0 1.0696784613628552e-07
gave O 0 6.650455475210038e-08
evidence O 0 1.5977756007146127e-08
for O 0 4.6497032890613355e-09
protein O 0 1.4583028118408947e-08
- O 0 6.899846027863532e-08
DNA O 0 4.091908678560685e-08
contact O 0 4.69651517676084e-09
in O 0 1.88730897576761e-09
normal O 0 1.3060677872545057e-08
genes O 0 4.2700558644526154e-09
at O 0 2.4940447929111542e-08
an O 0 2.4321010982930602e-08
Sp1 O 0 2.438964475004468e-05
consensus O 0 2.292964182970536e-07
binding O 0 3.647021173946996e-08
site O 0 7.537319390849007e-08
upstream O 0 1.4684157179090107e-07
of O 0 5.5412858301906454e-08
the O 0 8.010957230908389e-08
CTG O 0 0.00025787335471250117
repeat O 0 1.117525130212016e-07
and O 0 3.477236720783594e-09
for O 0 2.0826989022282305e-09
a O 0 2.0145056733866795e-09
significant O 0 3.805618042918013e-09
reduction O 0 2.36127810637754e-08
of O 0 8.645234750304098e-09
this O 0 8.48409953402296e-10
interaction O 0 2.447456237675283e-09
in O 0 1.400075388957589e-09
cells O 0 1.87283988317688e-09
with O 0 3.3398253052041582e-09
a O 0 1.0439313058441257e-07
hypermethylated O 0 7.137230568332598e-05
DMPK O 1 0.9998786449432373
gene O 0 7.84754718097247e-07
. O 0 3.9330083723143616e-07
. O 0 1.9221788534196094e-06

The O 0 0.00011268375237705186
hemochromatosis B-Disease 1 1.0
gene O 0 6.643253982474562e-07
product O 0 1.647212712896362e-07
complexes O 0 5.954737147817468e-08
with O 0 8.646455107452766e-09
the O 0 1.0568574282387999e-07
transferrin O 0 1.3274880075186957e-06
receptor O 0 1.484413303387555e-07
and O 0 2.2915296327141732e-08
lowers O 0 1.372825522594212e-06
its O 0 2.5093617850302508e-08
affinity O 0 7.085005648832521e-08
for O 0 5.0005233731553744e-08
ligand O 0 2.5799183731578523e-06
binding O 0 3.1220629352901597e-06
. O 0 4.322760105424095e-06

We O 0 2.6273628463968635e-06
recently O 0 9.049145432982186e-07
reported O 0 1.7270085095333343e-07
the O 0 8.035058840505371e-08
positional O 0 8.233764674514532e-07
cloning O 0 9.941540923819048e-08
of O 0 7.098871179778143e-08
a O 0 1.5113476692363292e-08
candidate O 0 4.2469174843517976e-08
gene O 0 9.437809467272018e-08
for O 0 4.3323657905602886e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 1.0
. O 0 3.5336903238203377e-05

The O 0 2.205228611273924e-06
gene O 0 6.25695761868883e-08
product O 0 5.169994565790148e-08
, O 0 1.2234855795156818e-08
a O 0 9.772670672703043e-09
member O 0 1.386308756679e-08
of O 0 4.386027185887542e-08
the O 0 1.1530123344982712e-07
major O 0 1.7533629943500273e-06
histocompatibility O 1 0.9999885559082031
complex O 0 8.827401870803442e-06
class O 0 4.177185175535669e-08
I O 0 3.3699149071253487e-07
- O 0 1.1317218451267763e-07
like O 0 2.2272455879601694e-08
family O 0 1.6750167475265698e-08
, O 0 4.537282993766212e-09
was O 0 1.6528014512573463e-08
found O 0 9.459047989324176e-10
to O 0 1.3193470760342052e-09
have O 0 1.702990859442366e-09
a O 0 1.1412864431292746e-08
mutation O 0 2.333256610143053e-08
, O 0 2.7619675435630597e-08
Cys O 0 0.010977945290505886
- O 0 2.0150116597505985e-06
282 O 0 1.0786702659970615e-06
- O 0 4.485254521569004e-06
- O 0 7.122141141735483e-06
> O 0 2.6974516913469415e-06
Tyr O 0 6.266022683121264e-05
( O 0 3.38252306164577e-08
C282Y O 0 1.9776932731474517e-06
) O 0 8.49352677079196e-09
, O 0 5.337626340917723e-09
in O 0 2.5408195547527157e-09
85 O 0 8.44522958232119e-08
% O 0 1.190386456073611e-08
of O 0 7.574544724775478e-08
patient O 0 3.5461189895613643e-07
chromosomes O 0 4.565672782064212e-07
. O 0 1.0646057262420072e-06

This O 0 5.884413667445187e-07
mutation O 0 4.3625823309412226e-07
eliminates O 0 1.1655745311145438e-06
the O 0 5.999265084710714e-08
ability O 0 5.828101024007992e-08
of O 0 2.863639849692845e-07
HFE O 0 0.14416886866092682
to O 0 1.425667477406023e-07
associate O 0 3.7721179069194477e-07
with O 0 3.332960574198296e-08
beta2 O 0 0.016066867858171463
- O 0 8.106119639705867e-05
microglobulin O 0 0.08857197314500809
( O 0 5.2180222809283805e-08
beta2m O 0 1.0899335393332876e-05
) O 0 1.745732802760358e-08
and O 0 1.9558143549147644e-08
prevents O 0 1.3672774912265595e-07
cell O 0 2.454414413932682e-07
- O 0 1.3810062000629841e-06
surface O 0 1.8869554878619965e-06
expression O 0 1.199365556203702e-06
. O 0 1.2327673175605014e-06

A O 0 1.608116872375831e-05
second O 0 5.201383146413718e-07
mutation O 0 4.51809611945464e-08
that O 0 1.5223523552876372e-09
has O 0 4.21767687441843e-09
no O 0 5.243460332593486e-09
effect O 0 1.40098164180813e-08
on O 0 2.6250576823372285e-08
beta2m O 0 1.4542312783305533e-05
association O 0 3.952677118945758e-08
, O 0 4.475494819189407e-08
H63D O 1 1.0
, O 0 5.228173449722817e-08
was O 0 9.475000695147173e-08
found O 0 4.903820460810948e-09
in O 0 1.6679446712686286e-09
eight O 0 6.377248062960916e-09
out O 0 6.975985122892325e-09
of O 0 2.983910718512561e-08
nine O 0 5.0706741916428655e-08
patients O 0 1.3299238155184412e-08
heterozygous O 0 2.326142478636939e-08
for O 0 1.0881759493486243e-08
the O 0 3.881079635448259e-07
C282Y O 0 0.00012367492308840156
mutant O 0 3.774693686864339e-05
. O 0 3.0014973617653595e-06

In O 0 3.229572484997334e-07
this O 0 1.9179561050464145e-08
report O 0 2.46372859891153e-08
, O 0 1.7940509522418324e-08
we O 0 9.85999548674954e-09
demonstrate O 0 2.6906532113457615e-08
in O 0 1.704688123993492e-08
cultured O 0 1.4172694307035272e-07
293 O 0 3.329295168441604e-07
cells O 0 3.8791025502860066e-08
overexpressing O 0 2.0008567389595555e-06
wild O 0 5.343282509784331e-07
- O 0 2.3943772475831793e-07
type O 0 9.392429944909964e-08
or O 0 2.1654919635238912e-08
mutant O 0 6.085307973080489e-07
HFE O 0 9.429813871975057e-06
proteins O 0 2.4031185930084575e-09
that O 0 4.299909595051332e-10
both O 0 1.22219967479964e-09
the O 0 1.0457005039654632e-08
wild O 0 1.9287567454284726e-07
- O 0 2.8620127068279544e-07
type O 0 2.071366651534845e-07
and O 0 7.611286179098897e-08
H63D O 1 0.9999992847442627
HFE O 0 0.001686236821115017
proteins O 0 6.407634600691381e-08
form O 0 1.0057650712269606e-08
stable O 0 1.767247681527806e-08
complexes O 0 1.9727410816017255e-08
with O 0 4.181312185380648e-09
the O 0 8.537611506653775e-08
transferrin O 0 7.632811502844561e-06
receptor O 0 1.2715925095108105e-06
( O 0 1.4891008959239116e-07
TfR O 0 2.327891706954688e-05
) O 0 2.1642125602738815e-07
. O 0 1.921905777635402e-06

The O 0 1.1250225725234486e-05
C282Y O 0 8.27392577775754e-05
mutation O 0 3.243898447635729e-07
nearly O 0 4.8148486087029596e-08
completely O 0 9.603233053212534e-08
prevents O 0 2.6192761737320325e-08
the O 0 2.3002876048394683e-08
association O 0 1.0664796157300316e-08
of O 0 1.155431803567808e-07
the O 0 2.2497596319226432e-07
mutant O 0 2.737501517913188e-06
HFE O 0 0.00013137434143573046
protein O 0 2.038337214571584e-07
with O 0 3.0726525324098475e-08
the O 0 1.5151524621614954e-06
TfR O 0 0.00023286548093892634
. O 0 5.542328835872468e-06

Studies O 0 1.5307145986298565e-06
on O 0 5.677499075318337e-07
cell O 0 7.485155606445915e-07
- O 0 9.731509180710418e-07
associated O 0 1.13888077635238e-07
transferrin O 0 1.9730023268493824e-06
at O 0 1.9019060459868342e-07
37 O 0 1.8772365706354321e-07
degrees O 0 1.3033395873662812e-07
C O 0 3.1451949666916335e-07
suggest O 0 1.677548766565451e-08
that O 0 3.309085006009127e-09
the O 0 4.5305398543860065e-08
overexpressed O 0 8.912421435525175e-06
wild O 0 2.3424433948093792e-06
- O 0 2.0827058051509084e-06
type O 0 1.0188878150074743e-06
HFE O 0 4.340819577919319e-05
protein O 0 5.248015355618918e-08
decreases O 0 2.028108170293308e-08
the O 0 8.957854902291729e-09
affinity O 0 3.0928969607657564e-08
of O 0 1.145476247188526e-07
the O 0 3.283742557869118e-07
TfR O 0 1.620692273718305e-05
for O 0 3.6210050780027814e-07
transferrin O 0 3.2670286600477993e-05
. O 0 5.6611188483657315e-06

The O 0 4.640199404093437e-05
overexpressed O 0 0.0005718179163523018
H63D O 1 0.9999408721923828
protein O 0 4.572217449094751e-07
does O 0 1.2123259729435176e-08
not O 0 1.2800189796990935e-09
have O 0 2.953118027892998e-10
this O 0 2.644503505067064e-10
effect O 0 5.544348979924507e-09
, O 0 1.6008678827006406e-09
providing O 0 3.750993293749616e-09
the O 0 3.633050305040797e-09
first O 0 2.9097986242732077e-09
direct O 0 3.4919915847808625e-09
evidence O 0 3.851601260151938e-09
for O 0 2.394192621935076e-09
a O 0 9.390186406221801e-09
functional O 0 1.362259922643716e-07
consequence O 0 1.3576351420852006e-07
of O 0 1.738690400543419e-07
the O 0 6.988466338953003e-07
H63D O 1 0.9999970197677612
mutation O 0 5.053144832345424e-06
. O 0 1.7999759620579425e-06

Addition O 0 3.8723796933481935e-06
of O 0 2.763517386483727e-06
soluble O 0 2.4057670088950545e-05
wild O 0 1.2604806215676945e-05
- O 0 1.516762040409958e-05
type O 0 0.0007470092386938632
HFE O 1 1.0
/ O 1 0.9998372793197632
beta2m O 1 0.9693238139152527
heterodimers O 0 2.1614006982417777e-05
to O 0 1.0905887393164448e-07
cultured O 0 9.064591921514875e-08
cells O 0 1.094364066034359e-08
also O 0 4.2326182558838354e-09
decreased O 0 1.7446909694740498e-08
the O 0 9.01276564491127e-09
apparent O 0 3.1688408341778995e-08
affinity O 0 3.325499164930079e-08
of O 0 1.1251155740410468e-07
the O 0 5.6745442122974055e-08
TfR O 0 5.539980065805139e-07
for O 0 2.907723839484788e-09
its O 0 2.7158439941388224e-09
ligand O 0 2.2942410637938337e-08
under O 0 1.1044060777010145e-08
steady O 0 4.132127529032914e-08
- O 0 4.341614001646121e-08
state O 0 7.93018273270718e-09
conditions O 0 3.1837561920156077e-08
, O 0 4.1601833089544016e-09
both O 0 1.8133775592232837e-09
in O 0 3.955541227895765e-09
293 O 0 8.15350134075743e-08
cells O 0 8.283839392220216e-09
and O 0 1.0982576625906404e-08
in O 0 7.104641497335251e-08
HeLa O 0 9.001107537187636e-05
cells O 0 5.615776217382518e-07
. O 0 1.5581121033392265e-06

Furthermore O 0 8.002349204616621e-06
, O 0 2.2427356327625603e-07
at O 0 1.293844604788319e-07
4 O 0 1.304333068219421e-07
degrees O 0 1.2983164765500987e-07
C O 0 2.910245200382633e-07
, O 0 5.289637616812115e-09
the O 0 1.5515411178057548e-08
added O 0 9.690725022437618e-08
soluble O 0 4.452990083336772e-07
complex O 0 4.6744972337364743e-07
of O 0 1.229787130796467e-06
HFE O 1 0.9999998807907104
/ O 0 5.801276711281389e-05
beta2m O 0 4.6153709263307974e-05
inhibited O 0 3.8891343479008356e-07
binding O 0 1.0687872276093913e-07
of O 0 1.5068378900195967e-07
transferrin O 0 2.7451617370388703e-06
to O 0 3.206020267043641e-07
HeLa O 0 0.00018136498692911118
cell O 0 5.474594217957929e-06
TfR O 0 7.078008820826653e-06
in O 0 2.555684019966975e-08
a O 0 6.081304348981575e-08
concentration O 0 8.449964639112295e-07
- O 0 7.021072292445751e-07
dependent O 0 1.4268141512729926e-07
manner O 0 3.8306981764435477e-07
. O 0 1.2255253523107967e-06

Scatchard O 0 6.68271241011098e-05
plots O 0 2.390180043221335e-06
of O 0 7.976534561748849e-07
these O 0 2.2177882641472024e-08
data O 0 3.19201944876113e-08
indicate O 0 1.0825306873130103e-08
that O 0 2.7970454841153014e-09
the O 0 3.922628266650463e-08
added O 0 3.0758104685446597e-07
heterodimer O 0 1.14873114398506e-06
substantially O 0 5.367685318447002e-08
reduced O 0 2.563514733822103e-08
the O 0 1.5491577798343314e-08
affinity O 0 1.0420076534956024e-07
of O 0 4.6094933736640087e-07
TfR O 0 2.3553378923679702e-05
for O 0 5.37861978955334e-07
transferrin O 0 8.069346949923784e-05
. O 0 9.617705472919624e-06

These O 0 1.0803668146763812e-06
results O 0 1.681483325910449e-07
establish O 0 1.2637184454433736e-07
a O 0 3.245082780267694e-08
molecular O 0 2.533222129841306e-07
link O 0 2.2151000678150012e-07
between O 0 5.8923038892544355e-08
HFE O 1 0.9997249245643616
and O 0 6.37445296547412e-08
a O 0 3.180005592184898e-08
key O 0 2.4310722324116796e-07
protein O 0 1.3326382664047287e-08
involved O 0 4.595006597440943e-09
in O 0 3.7195464486217134e-09
iron O 0 1.4161428225634154e-06
transport O 0 7.922203337784595e-08
, O 0 1.7185628919946794e-08
the O 0 3.406212201184644e-08
TfR O 0 1.997085973926005e-06
, O 0 8.158444586570113e-09
and O 0 3.9517331629213e-09
raise O 0 3.1989859650138897e-08
the O 0 1.7329568891000235e-08
possibility O 0 3.210930543673385e-08
that O 0 7.576662075514662e-10
alterations O 0 3.6735784192387655e-08
in O 0 2.5834023809068185e-09
this O 0 1.4276431148374513e-09
regulatory O 0 4.739857573099471e-08
mechanism O 0 1.802333926548272e-08
may O 0 2.72802358480817e-09
play O 0 1.6620893106278345e-08
a O 0 8.16411027670938e-09
role O 0 1.750504097230987e-08
in O 0 4.785465801404598e-09
the O 0 7.021534997875278e-08
pathogenesis O 1 0.9523789286613464
of O 1 0.9988312125205994
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.010535217821598053
. O 0 1.6424752175225876e-05

Genomic O 0 1.1747759344871156e-05
organization O 0 8.614464377387776e-07
of O 0 8.278439622699807e-07
the O 0 1.9175045053998474e-06
UBE3A O 1 1.0
/ O 1 0.9629217982292175
E6 O 1 1.0
- O 0 1.7963069694815204e-05
AP O 0 6.914146069902927e-06
gene O 0 1.2068609578363976e-07
and O 0 3.710194818040691e-08
related O 0 1.0000551355915377e-06
pseudogenes O 0 2.2552090740646236e-05
. O 0 4.385196461953456e-06

The O 0 3.929777449229732e-05
UBE3A O 0 0.001746822614222765
gene O 0 1.288386556552723e-06
encodes O 0 7.789329288243607e-07
the O 0 6.243968755370588e-07
E6 O 1 0.7215005159378052
- O 0 5.180208972888067e-06
AP O 0 5.625244284601649e-06
ubiquitin O 0 1.1729484867828432e-06
- O 0 2.3680982508267334e-07
protein O 0 4.362241057265237e-08
ligase O 0 9.521033206283391e-08
and O 0 6.909852245939874e-09
has O 0 8.497885950475847e-09
recently O 0 1.75043073369352e-08
been O 0 2.9172118054532348e-09
shown O 0 4.485112281571446e-10
to O 0 8.496520709222466e-10
be O 0 6.270323815726897e-09
mutated O 0 7.51504671825387e-07
in O 0 1.1672685786834336e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.1800688071161858e-06
who O 0 7.330866225174759e-08
lack O 0 5.654862889059586e-07
15q11 O 0 0.00019674235954880714
- O 0 1.3121062693244312e-05
q13 O 0 2.5387402274645865e-05
deletions O 0 2.2868809992360184e-06
or O 0 2.7256282919552177e-07
chromosome O 0 1.7323708334515686e-06
15 O 0 7.275182838384353e-07
paternal O 0 1.3565763765654992e-05
uniparental B-Disease 1 0.9992300271987915
disomy I-Disease 1 0.9992408752441406
. O 0 4.9487447540741414e-05

Previous O 0 0.00010352938988944516
UBE3A O 0 0.003854620037600398
cDNA O 0 1.0675382327463012e-05
analysis O 0 2.8425148457245086e-07
has O 0 3.9304843824083946e-08
shown O 0 1.808408178760601e-08
a O 0 1.573244468033863e-08
coding O 0 5.816939392389031e-07
region O 0 3.4902163292827026e-07
of O 0 5.10013251187047e-07
approximately O 0 3.604597793582798e-07
2 O 0 3.374852894921787e-06
. O 0 3.292568180768285e-06

6 O 0 2.3666229026275687e-05
kb O 0 5.799943028250709e-05
and O 0 2.0885045159957372e-07
a O 0 6.862885726377499e-08
3 O 0 2.4943881271610735e-07
- O 0 8.440823648925289e-07
untranslated O 0 0.001405332237482071
region O 0 5.498750397237018e-07
( O 0 4.176261114707813e-08
UTR O 0 0.0021727660205215216
) O 0 3.666207959440726e-08
of O 0 1.6322303508786717e-07
< O 0 4.2595689819791005e-07
50 O 0 6.1012997321086e-08
bp O 0 1.0952226858762515e-07
, O 0 1.4242279355869414e-08
whereas O 0 1.9538976658850515e-08
Northern O 0 7.882878350073952e-08
analysis O 0 3.263312464696355e-08
has O 0 1.0636661329499475e-08
indicated O 0 6.216249293089504e-09
mRNA O 0 2.406881449701359e-08
sizes O 0 1.4835578987515419e-08
of O 0 2.1153766738279955e-08
5 O 0 1.3823276390212413e-07
- O 0 1.139380856329808e-06
8 O 0 2.8977322017453844e-06
kb O 0 0.00013760766887571663
. O 0 5.508410140464548e-06

We O 0 1.891355168481823e-06
have O 0 2.456315151277977e-08
analyzed O 0 9.194439343218619e-08
additional O 0 7.641309451855705e-08
cDNA O 0 4.3258015125502425e-07
clones O 0 1.1987900450094457e-07
and O 0 5.474208197853159e-09
provide O 0 3.725680652877372e-09
evidence O 0 4.899146421877276e-09
for O 0 2.81800449641878e-09
an O 0 6.776204042324707e-09
additional O 0 1.3669476572886197e-07
0 O 0 1.6290345001834794e-06
. O 0 2.044636630671448e-06

5 O 0 4.2866176954703405e-06
kb O 0 2.8993383239139803e-05
of O 0 1.080845095202676e-06
5 O 0 7.587108825646283e-07
- O 0 1.7023410237015923e-06
UTR O 0 0.00031093551660887897
and O 0 9.485632546102352e-08
> O 0 4.498310488543211e-07
2 O 0 3.536517567681585e-07
kb O 0 2.93065113510238e-06
of O 0 3.1246824505615223e-07
3 O 0 1.7630918591748923e-06
- O 0 1.7476839275332168e-05
UTR O 1 0.8932197690010071
. O 0 6.725847015331965e-06

We O 0 1.0527155609452166e-06
have O 0 2.464048343142622e-08
established O 0 2.8566018883680044e-08
the O 0 1.3095150741548878e-08
genomic O 0 7.444960914426701e-08
organization O 0 7.481542496634574e-09
of O 0 1.1580971204239177e-07
UBE3A O 1 0.6483974456787109
and O 0 7.661010670290125e-08
the O 0 7.297440163256397e-08
sequence O 0 3.6818981641317805e-08
of O 0 1.3809757604121842e-07
intron O 0 3.1603554816683754e-05
- O 0 7.088712300173938e-05
exon O 0 7.820122118573636e-05
borders O 0 8.300793524540495e-06
. O 0 3.5689286050910596e-06

We O 0 1.924211119330721e-06
have O 0 9.442634762990565e-08
also O 0 5.5752106931095113e-08
mapped O 0 4.7508910938631743e-07
two O 0 1.9328624034642417e-08
highly O 0 9.975273940199259e-08
homologous O 0 3.31310943124663e-08
processed O 0 6.251983108995773e-08
pseudogenes O 0 5.785173016192857e-07
, O 0 4.869096059678668e-08
UBE3AP1 O 1 0.996440589427948
and O 0 3.425050749683578e-07
UBE3AP2 O 1 0.9999901056289673
, O 0 4.95613257101013e-08
to O 0 1.3448717695041523e-08
chromosomes O 0 4.0842182968958696e-09
2 O 0 1.0214203705061209e-08
and O 0 2.177564351057981e-09
21 O 0 3.095865608315762e-08
, O 0 3.6140717085686447e-09
respectively O 0 1.9621811730985428e-08
, O 0 8.49210124442834e-09
and O 0 7.755246222984624e-09
determined O 0 3.522739433492461e-08
their O 0 2.4576365831308067e-08
genomic O 0 1.0266254548696452e-06
organization O 0 5.814050041408336e-07
. O 0 2.363976591368555e-06

These O 0 1.1203993608432938e-06
results O 0 6.623757542456588e-08
will O 0 1.1138963529333523e-08
form O 0 4.200480407945406e-09
the O 0 4.974569201010581e-09
basis O 0 2.274485044750918e-09
for O 0 1.3656407116258151e-09
studies O 0 4.808201836681292e-09
of O 0 1.1311463765650842e-08
mutation O 0 1.2219159906123878e-08
and O 0 1.3003954357770908e-08
imprinting O 0 4.990099114365876e-06
of O 0 5.6768558351905085e-06
UBE3A O 1 0.9999990463256836
. O 0 2.5472110792179592e-05

Mutation O 0 1.615371547813993e-05
spectrum O 0 5.796113327960484e-06
and O 0 2.0341271067536582e-07
genotype O 0 2.5494141482340638e-06
- O 0 1.0302779855919653e-06
phenotype O 0 3.0503642278745247e-07
analyses O 0 8.412754226583274e-08
in O 0 3.0964503849872926e-08
Cowden B-Disease 1 1.0
disease I-Disease 0 0.2000691443681717
and O 0 2.1263642224766954e-07
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.1386190834627996e-07
two O 0 2.2603578031521465e-07
hamartoma B-Disease 1 0.9999819993972778
syndromes I-Disease 0 0.20003321766853333
with O 0 3.2286257010127883e-06
germline O 1 0.5132553577423096
PTEN O 1 1.0
mutation O 0 3.851383371511474e-05
. O 0 1.06366451291251e-05

The O 0 0.0001052421357599087
tumour B-Disease 1 1.0
suppressor O 1 0.9999996423721313
gene O 0 0.00017746569938026369
PTEN O 1 0.9999997615814209
, O 0 5.923437811361509e-07
which O 0 1.444266359840185e-07
maps O 0 1.4562870092049707e-06
to O 0 1.0974953283948707e-06
10q23 O 0 0.0002781423390842974
. O 0 1.1679249837470707e-05

3 O 0 6.637759270233801e-06
and O 0 4.033244920265133e-07
encodes O 0 7.058393407533003e-07
a O 0 6.480767211769489e-08
403 O 0 2.5447039320170006e-07
amino O 0 2.967811383314256e-07
acid O 0 1.9989903421446797e-07
dual O 0 5.068953896625317e-07
specificity O 0 8.358125569429831e-07
phosphatase O 0 3.710844976012595e-05
( O 0 5.289166082889096e-08
protein O 0 1.580635142772735e-07
tyrosine O 0 5.438658945422503e-07
phosphatase O 0 1.4310675169326714e-06
; O 0 6.669494734268255e-09
PTPase O 0 5.767176844528876e-06
) O 0 9.852362481410637e-09
, O 0 8.903686676831057e-09
was O 0 5.867126517955512e-08
shown O 0 8.51022896597442e-09
recently O 0 2.1947574424530103e-08
to O 0 4.898912830952895e-09
play O 0 6.530213170208299e-08
a O 0 3.376135637722655e-08
broad O 0 3.346005996718304e-07
role O 0 1.517668835049335e-07
in O 0 1.227913912771328e-07
human O 0 2.6454627004568465e-06
malignancy B-Disease 0 0.18945161998271942
. O 0 9.247574780602008e-06

Somatic O 0 0.003346547018736601
PTEN O 0 0.33545973896980286
deletions O 0 6.762443263141904e-06
and O 0 2.7358942134014796e-07
mutations O 0 1.0920000192982116e-07
were O 0 1.1498801022469252e-08
observed O 0 2.3170029450625407e-08
in O 0 5.556438864573465e-09
sporadic B-Disease 0 2.8491816919995472e-05
breast I-Disease 1 1.0
, I-Disease 0 2.412996309431037e-06
brain I-Disease 1 1.0
, I-Disease 0 4.215596334233851e-07
prostate I-Disease 1 1.0
and I-Disease 1 0.8317590951919556
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 1.983828724405612e-06
lines O 0 7.238303822987291e-08
and O 0 6.960779952436269e-09
in O 0 3.673674697779461e-09
several O 0 2.860314651798035e-08
primary O 0 5.660162969434168e-06
tumours B-Disease 1 1.0
such O 0 5.62657305636094e-07
as O 0 1.3698459042643663e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 1.0
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.002499894704669714

In O 0 5.641827556246426e-07
addition O 0 9.224140171681938e-07
, O 0 8.35000719234813e-07
PTEN O 1 0.9999891519546509
was O 0 6.114767643339292e-07
identified O 0 6.898411442080032e-08
as O 0 1.176717745465794e-08
the O 0 2.38936284091551e-08
susceptibility O 0 2.166971597716838e-07
gene O 0 2.4432505796312398e-08
for O 0 1.5094922645175757e-08
two O 0 2.1048285248070897e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 8.165952181116154e-08
CD B-Disease 1 1.0
; O 0 2.895931459079293e-07
MIM O 0 0.19860409200191498
158350 O 0 8.568690645915922e-06
) O 0 3.5810955978377024e-08
and O 0 3.9246412342208714e-08
Bannayan B-Disease 0 0.00015710965089965612
- I-Disease 0 2.5132780137937516e-05
Zonana I-Disease 1 0.9457204937934875
( I-Disease 0 4.7518608425889397e-07
BZS I-Disease 0 0.00182925455737859
) I-Disease 0 8.740475720969698e-08
or I-Disease 0 7.591264505890649e-08
Ruvalcaba I-Disease 0 2.910733201133553e-05
- I-Disease 0 2.3284030703507597e-06
Riley I-Disease 0 3.2936062780208886e-05
- I-Disease 1 0.885760486125946
Smith I-Disease 1 0.9924449324607849
syndrome I-Disease 1 1.0
( O 0 3.9255888850675547e-07
MIM O 1 0.9999921321868896
153480 O 0 0.0003639560891315341
) O 0 1.5801980453034048e-06
. O 0 5.356667315936647e-06

Constitutive O 0 2.111812136718072e-05
DNA O 0 9.160486342807417e-07
from O 0 4.7562402016865235e-08
37 O 0 1.853685915875758e-07
CD B-Disease 0 2.9168266337364912e-05
families O 0 4.284471444293558e-09
and O 0 8.8516696195029e-09
seven O 0 5.6153162120153866e-08
BZS B-Disease 0 0.00037875742418691516
families O 0 1.982835939884353e-08
was O 0 1.2636135693355754e-07
screened O 0 1.2555202602015925e-06
for O 0 6.963477972021792e-07
germline O 0 0.00022612068278249353
PTEN O 1 0.9999743700027466
mutations O 0 1.733756289468147e-05
. O 0 7.555197498732014e-06

PTEN O 1 0.9954721927642822
mutations O 0 1.8558506553745246e-06
were O 0 1.068495834033456e-07
identified O 0 1.99247676135883e-08
in O 0 6.300715504892196e-09
30 O 0 3.4920866198717704e-08
of O 0 3.9112947547437216e-08
37 O 0 1.341618514061338e-07
( O 0 4.241920148473355e-09
81 O 0 1.2506141899848444e-07
% O 0 1.7299145449456432e-09
) O 0 1.7461249113281951e-09
CD B-Disease 0 5.6348603720834944e-06
families O 0 3.0148932239626447e-09
, O 0 2.4239350526755743e-09
including O 0 7.744367813700137e-09
missense O 0 2.4947593146862346e-07
and O 0 3.987882735145831e-08
nonsense O 0 3.979190751124406e-06
point O 0 1.5006270359663176e-06
mutations O 0 3.4961651351750334e-08
, O 0 5.758308940784218e-09
deletions O 0 1.4284452731772035e-07
, O 0 4.2133695643542524e-08
insertions O 0 1.1142042239953298e-06
, O 0 9.171949955089076e-08
a O 0 1.466022894192065e-07
deletion O 0 3.769539262066246e-06
/ O 0 2.1755970465164864e-06
insertion O 0 8.893555332178948e-07
and O 0 2.2503992624933744e-07
splice O 0 2.7996735298074782e-05
site O 0 6.135181592981098e-06
mutations O 0 2.6052960038214223e-06
. O 0 2.3787463305779966e-06

These O 0 5.031742489336466e-07
mutations O 0 9.026359037989096e-08
were O 0 1.498917256981258e-08
scattered O 0 6.939122698668143e-08
over O 0 1.992195564071153e-08
the O 0 2.1434866326330848e-08
entire O 0 3.910056278755292e-08
length O 0 1.8064879370172093e-08
of O 0 6.337006652756827e-08
PTEN O 0 0.00039084802847355604
, O 0 3.8273686442380495e-09
with O 0 7.163594717418675e-10
the O 0 3.998963382656484e-09
exception O 0 7.938187884803938e-09
of O 0 1.706802876810798e-08
the O 0 2.1016068885160166e-08
first O 0 3.5220537597524526e-08
, O 0 2.568937951252792e-08
fourth O 0 2.795949001210829e-07
and O 0 8.885453439688717e-08
last O 0 1.0299321502316161e-06
exons O 0 6.92323301336728e-05
. O 0 7.022042609605705e-06

A O 0 6.755119102308527e-05
hot O 0 6.615880556637421e-05
spot O 0 8.813757631287444e-06
for O 0 4.2146956502620014e-07
PTEN O 0 0.0028169627767056227
mutation O 0 6.376751571224304e-08
in O 0 1.3302434709316913e-08
CD B-Disease 1 0.9994590878486633
was O 0 4.701384455074731e-07
identified O 0 1.1291394486079298e-08
in O 0 2.801231246962743e-09
exon O 0 1.7496503801339713e-07
5 O 0 2.1264609628701692e-08
that O 0 1.2984168185070644e-09
contains O 0 3.584054653060775e-08
the O 0 1.715324060569401e-08
PTPase O 0 7.0486385084223e-06
core O 0 1.0123474112333497e-06
motif O 0 1.2318125186538964e-07
, O 0 2.084845185379436e-09
with O 0 8.719985844507505e-10
13 O 0 1.4455777019861671e-08
of O 0 2.0394120170408314e-08
30 O 0 4.056473557056961e-08
( O 0 4.5174042284656934e-09
43 O 0 6.501927174440425e-08
% O 0 3.2017799522776613e-09
) O 0 7.606725915820789e-09
CD B-Disease 0 0.0001245545136043802
mutations O 0 4.8639446248444074e-08
identified O 0 2.2630274543189444e-08
in O 0 1.4280087334839209e-08
this O 0 1.0162962382764817e-07
exon O 0 4.491573781706393e-05
. O 0 7.127577646315331e-06

Seven O 0 6.487853738690319e-07
of O 0 1.8562475645467202e-07
30 O 0 6.379184469551546e-08
( O 0 2.9826461300785923e-09
23 O 0 1.4156208649751534e-08
% O 0 9.912676235401818e-10
) O 0 7.552970471280673e-10
were O 0 1.6143040237892592e-09
within O 0 3.338570531141727e-09
the O 0 8.483570290707121e-09
core O 0 4.631140768651676e-07
motif O 0 7.444464955597141e-08
, O 0 3.6393894564668017e-09
the O 0 7.182643813052891e-09
majority O 0 1.6957756310276295e-09
( O 0 6.564725429925033e-10
five O 0 1.3091997486114337e-09
of O 0 4.597005442974478e-09
seven O 0 1.5576724354815497e-09
) O 0 5.161869820469178e-10
of O 0 5.0502673154539934e-09
which O 0 1.9269570383784185e-09
were O 0 7.078843289320957e-09
missense O 0 4.876699222222669e-07
mutations O 0 2.8985832400962863e-08
, O 0 7.563352610873153e-09
possibly O 0 2.6972404754133095e-08
pointing O 0 5.7525820551518336e-08
to O 0 6.42785380478017e-09
the O 0 1.4010939075603801e-08
functional O 0 6.938196861483448e-08
significance O 0 2.3093267031981668e-07
of O 0 1.3933565412571625e-07
this O 0 7.906232468712915e-08
region O 0 2.299271500305622e-06
. O 0 2.7195728762308136e-06

Germline O 0 0.0070158266462385654
PTEN O 1 0.9807135462760925
mutations O 0 5.426608140624012e-07
were O 0 2.925705366862985e-08
identified O 0 7.455303041581374e-09
in O 0 1.3577425850286318e-09
four O 0 4.761329996938457e-09
of O 0 2.6272115150050013e-08
seven O 0 1.6570783856195703e-08
( O 0 7.130880774752768e-09
57 O 0 2.2898611007349245e-07
% O 0 1.6393073565268423e-08
) O 0 5.6506426204805393e-08
BZS B-Disease 0 0.0004885467933490872
families O 0 1.0131917349553987e-07
studied O 0 2.9304414965736214e-06
. O 0 2.437958983136923e-06

Interestingly O 0 7.5757811828225385e-06
, O 0 1.553425050815349e-07
none O 0 4.220077087779828e-08
of O 0 2.58089212223922e-08
these O 0 9.584747218127632e-09
mutations O 0 2.8691392373048075e-08
was O 0 6.936595298157044e-08
observed O 0 3.401109793799151e-08
in O 0 1.5413208487302654e-08
the O 0 2.861690688860108e-07
PTPase O 0 0.00110085669439286
core O 0 0.0002057549572782591
motif O 0 3.646253753686324e-05
. O 0 5.3210874284559395e-06

It O 0 4.912623694508511e-07
is O 0 4.826360111565009e-08
also O 0 1.6507220479411444e-08
worthy O 0 3.838058830751834e-07
of O 0 7.641396848612203e-08
note O 0 2.8339227853280136e-08
that O 0 3.203942888774236e-09
a O 0 1.2462299636695207e-08
single O 0 2.9412825952590538e-08
nonsense O 0 4.6283460619633843e-07
point O 0 3.8466700402750575e-07
mutation O 0 2.4345236937506343e-08
, O 0 8.776890325634668e-09
R233X O 0 1.466088860979653e-06
, O 0 1.6757644161202734e-08
was O 0 5.857856777424786e-08
observed O 0 1.2507258340122007e-08
in O 0 3.310246299292885e-09
the O 0 2.1785917070360483e-08
germline O 0 1.0407423900460344e-07
DNA O 0 1.4335103770690694e-08
from O 0 1.9418926466840958e-09
two O 0 1.536641147659168e-09
unrelated O 0 7.634608323314751e-08
CD B-Disease 0 0.0004971407470293343
families O 0 7.680612590377223e-09
and O 0 2.6705546218863674e-08
one O 0 2.1494193447324506e-07
BZS B-Disease 1 0.9996157884597778
family O 0 3.674132813102915e-06
. O 0 6.199856215971522e-06

Genotype O 0 5.106167736812495e-05
- O 0 5.221056198934093e-06
phenotype O 0 5.213853455643402e-07
studies O 0 2.3551431027613035e-08
were O 0 3.3989937531231362e-09
not O 0 8.844137644459238e-10
performed O 0 1.7172586908031917e-08
on O 0 1.0379843651264764e-08
this O 0 2.2280943756669558e-09
small O 0 2.9505423881914794e-08
group O 0 5.217842868887601e-08
of O 0 4.269390672106965e-07
BZS B-Disease 1 0.9969428181648254
families O 0 5.25938901319023e-07
. O 0 2.014827259699814e-06

However O 0 2.102245844071149e-06
, O 0 3.603384470807214e-07
genotype O 0 8.828629916024511e-07
- O 0 6.312656637419423e-07
phenotype O 0 9.146688739747333e-08
analysis O 0 1.614372635572181e-08
inthe O 0 2.7407776315158117e-07
group O 0 7.07101710517577e-09
of O 0 3.4536416393393665e-08
CD B-Disease 1 0.9990988969802856
families O 0 4.685134502580013e-09
revealed O 0 1.1417393253054797e-08
two O 0 5.665670155252656e-10
possible O 0 2.806065380056566e-09
associations O 0 1.5090366733971905e-09
worthy O 0 1.1097340291144064e-07
of O 0 8.613127278067623e-08
follow O 0 2.6069553626939523e-08
- O 0 1.863565870507955e-07
up O 0 1.4536794878949877e-07
in O 0 4.089989147360029e-08
independent O 0 3.223609326141741e-07
analyses O 0 2.824417606461793e-06
. O 0 3.1740662507218076e-06

The O 0 2.7004116418538615e-06
first O 0 2.7024111659557093e-07
was O 0 3.5301658840580785e-07
an O 0 2.8267699292428006e-08
association O 0 1.0535221584007104e-08
noted O 0 1.4312482754519351e-08
in O 0 2.578617541715289e-09
the O 0 1.0191609334242457e-08
group O 0 4.168117850866793e-09
of O 0 2.308137148077094e-08
CD B-Disease 1 0.9999949932098389
families O 0 1.2690802186909877e-08
with O 0 1.1370001118393702e-07
breast B-Disease 1 1.0
disease I-Disease 1 0.9993808269500732
. O 0 5.4758888836659025e-06

A O 0 1.1355364222254138e-05
correlation O 0 6.98341580118722e-07
was O 0 2.4179252022804576e-07
observed O 0 4.39695746479174e-08
between O 0 5.284282789119743e-09
the O 0 2.038186863728697e-08
presence O 0 5.414078785292986e-08
/ O 0 4.6328241865012387e-07
absence O 0 9.782932153257207e-08
of O 0 1.8043776606191386e-07
a O 0 1.5574183009903209e-07
PTEN O 1 0.7238169312477112
mutation O 0 1.653740966389705e-08
and O 0 2.4841211310189237e-09
the O 0 8.174097843038908e-09
type O 0 4.788162044633282e-08
of O 0 2.8766936566171353e-07
breast O 1 0.9989222288131714
involvement O 0 1.5174733789535821e-06
( O 0 4.231861439052409e-08
unaffected O 0 1.2439570582500892e-06
versus O 0 3.6239246128388913e-06
benign O 0 0.0003114128776360303
versus O 0 5.927142046857625e-05
malignant O 1 0.9999172687530518
) O 0 4.876717980550893e-07
. O 0 2.4810647119011264e-06

Specifically O 0 1.4086335795582272e-06
and O 0 4.3695941087662504e-08
more O 0 2.4275856880251467e-09
directly O 0 1.0553462992390905e-08
, O 0 5.979739370332027e-09
an O 0 7.248317057673148e-09
association O 0 1.7630728876838475e-08
was O 0 1.2829080731080467e-07
also O 0 1.6853002549055418e-08
observed O 0 1.972244412229429e-08
between O 0 2.8124738093993074e-09
the O 0 1.1379476916317799e-08
presence O 0 1.755824285964991e-08
of O 0 6.420320630695642e-08
a O 0 2.0786448828857829e-07
PTEN O 1 1.0
mutation O 0 2.7273101750324713e-06
and O 0 2.2974588773649884e-06
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 9.826101631915662e-06

Secondly O 0 7.068887953209924e-06
, O 0 1.5376907924746774e-07
there O 0 1.740167654418201e-08
appeared O 0 2.1023003782261185e-08
to O 0 4.492691552115957e-09
be O 0 6.143921371659644e-09
an O 0 1.488308054575782e-08
interdependent O 0 1.3186229352868395e-06
association O 0 3.513318347359018e-08
between O 0 2.991598435642118e-08
mutations O 0 5.376742961971104e-08
upstream O 0 9.899986963546326e-08
and O 0 6.812957309421108e-09
within O 0 7.236768517770997e-09
the O 0 2.996949532985127e-08
PTPase O 0 0.0006600519409403205
core O 0 3.435088001424447e-05
motif O 0 9.952162827175925e-07
, O 0 1.7320648026952767e-08
the O 0 2.1831255025972496e-08
core O 0 3.294043153800885e-07
motif O 0 7.09121152908665e-08
containing O 0 1.851028486044015e-08
the O 0 6.3645617665031295e-09
majority O 0 2.7257560653026758e-09
of O 0 2.693358958083536e-08
missense O 0 2.4535953002668975e-07
mutations O 0 1.2621907075072158e-08
, O 0 2.0432653347057794e-09
and O 0 1.5686383303403773e-09
the O 0 8.68592753278108e-09
involvement O 0 1.4599613962218427e-08
of O 0 2.5302201223098564e-08
all O 0 4.963452315820405e-09
major O 0 2.7920214051846415e-07
organ O 1 1.0
systems O 1 1.0
( O 0 5.744764308701633e-08
central O 0 0.01070441585034132
nervous O 0 5.936138677498093e-06
system O 0 4.827722932532197e-06
, O 0 6.021402327860415e-07
thyroid O 1 1.0
, O 0 2.3372865598503267e-06
breast O 1 1.0
, O 0 6.77725267905771e-07
skin O 1 0.9999996423721313
and O 0 5.6058826885418966e-05
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 5.519605110748671e-06
. O 0 9.12318046175642e-06

However O 0 2.1741720956924837e-06
, O 0 1.698561220564443e-07
these O 0 1.2934541437914504e-08
observations O 0 7.184810613125592e-08
would O 0 3.1646594234047143e-09
need O 0 3.044990704026418e-09
to O 0 3.334154285994373e-09
be O 0 2.2836266211356815e-09
confirmed O 0 4.292323829702127e-09
by O 0 1.114388803458155e-09
studying O 0 1.9681822394090887e-08
a O 0 2.9919220434493354e-09
larger O 0 1.0575083031483246e-08
number O 0 1.0273601525057074e-08
of O 0 1.3000288845432806e-07
CD B-Disease 0 0.38149645924568176
families O 0 2.4620570115985174e-07
. O 0 1.4161659009914729e-06

Molecular O 1 0.9999996423721313
defects O 1 0.9997733235359192
leading O 0 1.4886524013490998e-06
to O 0 6.65282797740474e-08
human O 0 2.0684292678652128e-07
complement B-Disease 0 0.0002857365761883557
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.717275471297853e-08
an O 0 1.4773795520284239e-08
African O 0 2.139961274849611e-08
- O 0 3.6070633768758853e-07
American O 0 4.916068405691476e-07
family O 0 7.132093742256984e-07
. O 0 1.2338234682829352e-06

Complement B-Disease 0 0.0006515531567856669
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 6.580676767953264e-07
C6D B-Disease 1 1.0
) O 0 2.0278883994251373e-07
was O 0 1.8300098645340768e-06
diagnosed O 0 8.246228162533953e-07
in O 0 4.155742416855901e-09
a O 0 8.705133502928675e-09
16 O 0 2.506195251328336e-08
- O 0 2.8151802666798176e-08
year O 0 8.331948464501693e-09
- O 0 1.2292706230709882e-07
old O 0 3.216061656985403e-07
African O 0 2.140255084270848e-08
- O 0 1.1670132238350561e-07
American O 0 7.94526542335916e-08
male O 0 6.77559910400305e-08
with O 0 7.157127868140378e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999998807907104
. O 0 9.526511348667555e-06

The O 0 1.3008811947656795e-06
patients O 0 1.5282655851933669e-07
father O 0 4.4503575935550543e-08
and O 0 2.120798470173213e-08
two O 0 1.9557248265300586e-08
brothers O 0 6.12018766332767e-07
also O 0 5.8188263096781156e-08
had O 0 1.8230494447379897e-07
C6D B-Disease 1 1.0
, O 0 4.877610848552649e-08
but O 0 5.377448264454188e-09
gave O 0 4.462231828483709e-08
no O 0 1.8260053025187517e-08
history O 0 4.806865305795327e-08
of O 0 1.2169832075414888e-07
meningitis B-Disease 1 0.9999994039535522
or O 0 1.4521970115310978e-07
other O 0 1.8327767747905455e-07
neisserial B-Disease 1 0.9999666213989258
infection I-Disease 0 7.729610661044717e-05
. O 0 2.9964121495140716e-06

By O 0 6.513793096019072e-07
using O 0 3.862554649458616e-07
exon O 0 3.981479494541418e-06
- O 0 8.086361731329816e-07
specific O 0 1.0841139186368309e-07
polymerase O 0 1.2293268980556604e-07
chain O 0 8.776258653142577e-08
reaction O 0 1.271626803855952e-08
( O 0 3.754300426095369e-09
PCR O 0 7.994715645054384e-08
) O 0 1.2280656491725495e-08
/ O 0 1.4842802897874208e-07
single O 0 2.1592065024833573e-08
- O 0 1.2033878249440022e-07
strand O 0 4.561294275617911e-08
conformation O 0 1.403742100336558e-08
polymorphism O 0 3.4680034399769966e-09
as O 0 2.437803070520772e-09
a O 0 1.8120153155720686e-09
screening O 0 7.975187621411806e-09
step O 0 1.8505661003587193e-08
and O 0 2.0620578577990045e-09
nucleotide O 0 5.2529598448813886e-09
sequencing O 0 5.600008012862645e-09
of O 0 1.0724564347697196e-08
target O 0 2.7167883942524895e-08
exons O 0 1.4826420624558523e-07
, O 0 4.4069721205630685e-09
we O 0 1.7064243351683217e-09
determined O 0 2.621483918829881e-09
that O 0 8.888444980037491e-10
the O 0 1.7960504195002613e-08
proband O 0 5.309843800205272e-06
was O 0 2.2797334509050415e-07
a O 0 3.787993207993168e-08
compound O 0 1.8684133351598575e-07
heterozygote O 0 5.626014853987726e-07
for O 0 2.944729082798858e-08
two O 0 8.380739302538132e-08
C6 O 1 0.9999986886978149
gene O 0 1.8002712067755056e-06
mutations O 0 1.340406583949516e-06
. O 0 1.228707333211787e-06

The O 0 2.880877218558453e-06
first O 0 2.504413600945554e-07
, O 0 9.230232222989798e-08
1195delC O 0 2.2224223812372657e-06
located O 0 1.810852410244479e-07
in O 0 1.9029215536647826e-08
exon O 0 4.933544346386043e-07
7 O 0 8.07252433787653e-08
, O 0 7.289466363857855e-09
is O 0 2.5123010338745644e-09
a O 0 3.1908795605772866e-09
novel O 0 5.1945967527444736e-08
mutation O 0 6.398130469875696e-09
, O 0 1.8503427678950857e-09
while O 0 3.0646438720083324e-09
the O 0 1.222344891971261e-08
second O 0 3.430688977346108e-08
, O 0 1.5953849796801478e-08
1936delG O 0 5.475933448906289e-07
in O 0 9.986806936979065e-09
exon O 0 7.007412818893499e-07
12 O 0 1.02210670149816e-07
, O 0 1.1491872342617171e-08
has O 0 8.833252351791998e-09
been O 0 5.6537876602646975e-09
described O 0 9.080109997228192e-09
before O 0 5.489107390843628e-09
to O 0 1.6410623970841698e-08
cause O 0 4.6130287501000566e-07
C6D B-Disease 1 0.9999909400939941
in O 0 2.8905832394343633e-08
an O 0 1.6252229784186056e-08
unrelated O 0 3.7235659533507715e-07
African O 0 3.639467749394498e-08
- O 0 5.249006562735303e-07
American O 0 6.755377057743317e-07
individual O 0 2.0534564271201816e-07
. O 0 8.371566764253657e-07

Both O 0 2.8850367925770115e-06
mutations O 0 6.378990065059043e-07
result O 0 8.261327621994496e-08
in O 0 7.625599351968049e-08
premature O 0 9.249791332877066e-07
termination O 0 1.2204111499158898e-06
codons O 0 3.548301492628525e-06
and O 0 6.764299769201898e-07
C6 O 1 0.9999656677246094
null O 0 2.9525257559726015e-05
alleles O 0 2.062222392851254e-06
. O 0 1.7699957197692129e-06

Allele O 0 6.428692358895205e-06
- O 0 1.0452557717144373e-06
specific O 0 1.3642075202824344e-07
PCR O 0 1.9146926888424787e-07
indicated O 0 2.6001124808772147e-08
that O 0 2.118298869646651e-09
the O 0 1.5235993799933567e-08
probands O 0 8.083469765551854e-06
two O 0 3.652660041097988e-08
brothers O 0 3.49950198597071e-07
also O 0 5.982422379702257e-08
inherited O 0 1.703078282844217e-06
the O 0 1.753076048771618e-07
1195delC O 0 2.529986886656843e-06
mutation O 0 1.73822716220684e-08
from O 0 2.072665150620878e-09
their O 0 4.58989113383268e-09
heterozygous O 0 5.550128889808548e-08
mother O 0 1.1942365318873271e-08
and O 0 7.621713926653229e-09
the O 0 4.311345236374109e-08
1936delG O 0 1.151489755102375e-06
mutation O 0 1.693604190222686e-08
from O 0 4.240698903146267e-09
their O 0 6.335348246011563e-09
homozygous O 0 4.949213234795025e-07
father O 0 2.645112147092732e-07
. O 0 3.2116969350681757e-07
. O 0 3.381057467777282e-06

PAX6 O 1 0.9986795783042908
mutations O 0 0.0002336033503524959
reviewed O 0 0.00016625612624920905
. O 0 3.153786019538529e-05

Mutations O 0 7.235498742375057e-06
in O 0 2.1033838493167423e-07
PAX6 O 1 0.8226393461227417
are O 0 1.884651545935867e-08
responsible O 0 4.611876036619833e-08
for O 0 1.0274287198797083e-08
human O 0 3.7673183328479354e-07
aniridia B-Disease 1 1.0
and O 0 8.13530903087667e-07
have O 0 1.0381823400962276e-08
also O 0 7.650946542980819e-09
been O 0 3.775815216044975e-09
found O 0 1.7193356738332e-09
in O 0 6.572468125298769e-10
patients O 0 2.976116464381562e-09
with O 0 4.317968205214129e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 4.207635413422395e-07
with O 1 0.9707098007202148
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.010598812252283096
with O 0 0.00013045532978139818
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 3.530179242261511e-07
and O 0 1.9815226437458477e-07
with O 0 1.4259084082368645e-06
isolated B-Disease 1 0.9999570846557617
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.0003857398696709424

No O 0 6.3652901189925615e-06
locus O 0 1.1266050933045335e-05
other O 0 9.054672744923664e-08
than O 0 3.086761779513836e-08
chromosome O 0 7.600752951475442e-07
11p13 O 0 5.588855401583714e-06
has O 0 2.7636273713937953e-08
been O 0 1.5440809519873255e-08
implicated O 0 1.7119255346642603e-07
in O 0 2.0676120371376783e-08
aniridia B-Disease 1 1.0
, O 0 6.708294364443645e-08
and O 0 7.362746146100108e-08
PAX6 O 1 0.9999998807907104
is O 0 6.090184712093105e-08
clearly O 0 2.2031160895608082e-08
the O 0 1.3971177104110666e-08
major O 0 1.386010524129233e-07
, O 0 9.82533965299126e-09
if O 0 1.5671071107448142e-09
not O 0 1.6720568263295377e-09
only O 0 6.0273634971963475e-09
, O 0 2.70137974212048e-08
gene O 0 2.275562849263224e-07
responsible O 0 1.097578092412732e-06
. O 0 2.4008968466660008e-06

Twenty O 0 1.2156056982348673e-05
- O 0 1.3772552165391971e-06
eight O 0 1.8711381244429504e-07
percent O 0 3.568298012623927e-08
of O 0 4.0033992121379924e-08
identified O 0 6.810478225816041e-08
PAX6 O 0 0.19342634081840515
mutations O 0 3.156227634804054e-08
are O 0 2.148298872128862e-09
C O 0 1.1018119039363228e-06
- O 0 3.504609139781678e-06
T O 0 5.940238679613685e-06
changes O 0 4.696992661479271e-08
at O 0 1.2414973582508537e-07
CpG O 0 2.3978925582923694e-06
dinucleotides O 0 4.050473307870561e-06
, O 0 1.9014413155105103e-08
20 O 0 2.1338555811212245e-08
% O 0 1.3465035753057464e-09
are O 0 3.1203994943496127e-10
splicing O 0 1.6420111492720935e-08
errors O 0 8.183102551129195e-08
, O 0 5.169459083020911e-09
and O 0 2.689405143030399e-09
more O 0 5.953549875314934e-10
than O 0 8.253523420265196e-10
30 O 0 1.026600049414128e-08
% O 0 1.8384173072760746e-09
are O 0 1.1087746276672306e-09
deletion O 0 1.563203824161974e-07
or O 0 5.288621096610768e-08
insertion O 0 8.018751032068394e-07
events O 0 1.2743506658807746e-06
. O 0 2.1987477794027654e-06

There O 0 2.1949747406324605e-06
is O 0 3.086776985128381e-07
a O 0 1.2880042277174653e-07
noticeably O 0 2.1859189018869074e-06
elevated O 0 1.0646083865140099e-05
level O 0 2.4972513301690924e-07
of O 0 1.301676348930414e-07
mutation O 0 1.2264925963734186e-08
in O 0 3.0644744519747746e-09
the O 0 1.3236832074881022e-08
paired O 0 2.29714842703288e-08
domain O 0 1.1928820597972845e-08
compared O 0 3.017948335681808e-09
with O 0 1.1482861328460103e-09
the O 0 1.8610078811320818e-08
rest O 0 5.797003055363348e-08
of O 0 1.3837284029705188e-07
the O 0 4.063408880483621e-07
gene O 0 1.3361706123760086e-06
. O 0 2.4844550807756605e-06

Increased O 0 3.4019640224869363e-06
mutation O 0 1.5616421933373204e-07
in O 0 2.2157882639817217e-08
the O 0 1.0837272412800303e-07
homeodomain O 0 5.1961696954094805e-06
is O 0 2.0662282551597855e-08
accounted O 0 2.987783176422454e-08
for O 0 5.237103639643692e-09
by O 0 5.859127849561219e-09
the O 0 3.9367949966617743e-07
hypermutable O 0 0.00011550533963600174
CpG O 0 7.851197005948052e-05
dinucleotide O 0 3.222689338144846e-05
in O 0 9.498411941422091e-07
codon O 0 1.0138669495063368e-05
240 O 0 6.139488050393993e-06
. O 0 5.123042228660779e-06

Very O 0 5.822217303830257e-07
nearly O 0 1.023829625523831e-07
all O 0 1.4948771109857262e-08
mutations O 0 1.5182152424131345e-08
appear O 0 4.508039719297585e-09
to O 0 6.328464863258887e-09
cause O 0 4.498242134332031e-08
loss O 0 1.4104359991051751e-07
of O 0 8.107721782835142e-08
function O 0 4.177135526362008e-09
of O 0 1.3878033833236714e-08
the O 0 1.2213637212710182e-08
mutant O 0 1.1159829682583222e-07
allele O 0 5.204044750684034e-09
, O 0 1.1168017621798754e-09
and O 0 1.099621504963011e-09
more O 0 5.045903139766494e-10
than O 0 1.2449369313216607e-09
80 O 0 1.60301976137589e-08
% O 0 3.0733482425659986e-09
of O 0 2.4881861904191283e-08
exonic O 0 3.86049168810132e-06
substitutions O 0 3.804081813996163e-07
result O 0 5.905174660369994e-08
in O 0 7.148383218691379e-08
nonsense O 0 6.593733814952429e-06
codons O 0 2.9545368306571618e-05
. O 0 5.106398930365685e-06

In O 0 8.374553885914793e-07
a O 0 1.270887821647193e-07
gene O 0 1.2508261093557849e-08
with O 0 5.878650455315437e-09
such O 0 4.578072676508782e-08
extraordinarily O 0 6.696162699881825e-07
high O 0 4.566473990053055e-07
sequence O 0 2.331201365279867e-08
conservation O 0 5.1577220716580996e-08
throughout O 0 8.693453068531198e-09
evolution O 0 1.0322863452927322e-08
, O 0 1.2332102006240575e-09
there O 0 1.663686965969191e-09
are O 0 1.9087622593616516e-09
presumed O 0 1.8403693502477836e-07
undiscovered O 0 9.088659862754866e-05
missense O 0 9.420442097507475e-07
mutations O 0 2.9052969807707996e-08
, O 0 2.8775117844048737e-09
these O 0 1.2333795096353128e-09
are O 0 7.305051008543728e-10
hypothesized O 0 2.0231164299389093e-08
to O 0 3.750335597629828e-09
exist O 0 7.0921148953573265e-09
in O 0 2.3800872384072136e-09
as O 0 1.0106532499776222e-08
- O 0 2.2773343744120211e-07
yet O 0 4.2889546136848367e-08
unidentified O 0 2.4207398041653505e-07
phenotypes O 0 7.192667226263438e-07
. O 0 8.688765262832021e-08
. O 0 1.4294388392954716e-06

Genetic O 0 1.4500157703878358e-05
heterogeneity O 0 9.868285815173294e-06
and O 0 2.195733515009124e-07
penetrance O 0 4.172799890511669e-06
analysis O 0 3.7036407718460396e-08
of O 0 1.3821298239236057e-07
the O 0 4.0223588371191e-07
BRCA1 O 0 4.0689528759685345e-06
and O 0 2.226921225201295e-07
BRCA2 O 0 8.720194455236197e-05
genes O 0 8.721191591121169e-08
in O 0 4.4334299786896736e-08
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.5967128872871399
families O 0 1.2457053344405722e-07
. O 0 9.378391609971004e-07

The O 0 0.002909861272200942
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.001752794603817165
Consortium O 0 3.331088009872474e-05
. O 0 6.01122337684501e-06

The O 0 6.14649138697132e-07
contribution O 0 5.270923111311276e-07
of O 0 1.411387415828358e-06
BRCA1 O 0 7.237334557430586e-06
and O 0 2.2362108609286224e-07
BRCA2 O 1 0.7394668459892273
to O 0 1.1967673572144122e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 5.084818440082017e-06
assessed O 0 3.5653087593345845e-07
by O 0 4.498376782180458e-09
linkage O 0 8.773363191494354e-08
and O 0 1.1509552422239722e-08
mutation O 0 7.583258465615472e-09
analysis O 0 9.692954217044303e-10
in O 0 6.807121533114469e-10
237 O 0 1.1911404307340945e-08
families O 0 2.559750189590204e-10
, O 0 3.7614947268060916e-10
each O 0 2.0235543796154332e-10
with O 0 4.212063475783623e-10
at O 0 1.072875832619502e-08
least O 0 1.3229202178166588e-09
four O 0 7.561359316454741e-10
cases O 0 2.0401382805346202e-09
of O 0 1.3033408663432056e-07
breast B-Disease 1 1.0
cancer I-Disease 0 0.0046078963205218315
, O 0 3.19497206469066e-09
collected O 0 7.918288247310556e-09
by O 0 5.402965630452172e-09
the O 0 8.500895205543202e-07
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 6.532426050398499e-05
Consortium O 0 8.581750989833381e-06
. O 0 2.3254208372236462e-06

Families O 0 2.005702555152311e-07
were O 0 1.407103589201597e-08
included O 0 2.171315394150497e-08
without O 0 8.233810078195347e-09
regard O 0 3.004137738571444e-08
to O 0 8.841916532276173e-09
the O 0 3.587289398865323e-08
occurrence O 0 4.279814334040566e-07
of O 0 2.674736242624931e-05
ovarian B-Disease 1 1.0
or I-Disease 0 5.119820229992911e-07
other I-Disease 0 1.1550333738341578e-06
cancers I-Disease 1 0.9999972581863403
. O 0 2.713896265049698e-06

Overall O 0 0.0002709992986638099
, O 0 1.7106556242652005e-06
disease O 0 0.2207212895154953
was O 0 3.87010203439786e-07
linked O 0 2.065675488438501e-07
to O 0 3.3927644693676484e-08
BRCA1 O 0 2.6292826760254684e-07
in O 0 4.524354224599847e-09
an O 0 2.6531035146604154e-09
estimated O 0 4.257239449856343e-09
52 O 0 8.161837428133367e-09
% O 0 7.883412256326494e-10
of O 0 3.925702429796729e-09
families O 0 7.022439296733296e-10
, O 0 2.146824273907555e-09
to O 0 9.757342489535858e-09
BRCA2 O 0 4.1422447338845814e-07
in O 0 2.938993048928751e-09
32 O 0 1.5900656791245638e-08
% O 0 7.806308932600814e-10
of O 0 2.997479597866004e-09
families O 0 4.52006543305572e-10
, O 0 1.2001638571845774e-09
and O 0 2.021194767110046e-09
to O 0 9.949257417929402e-09
neither O 0 4.6218179505785884e-08
gene O 0 7.813761193631308e-09
in O 0 5.262245750259353e-09
16 O 0 3.475415155662631e-08
% O 0 2.881477056959625e-09
( O 0 1.7464946155953953e-09
95 O 0 8.448839139418851e-08
% O 0 1.244315583903699e-08
confidence O 0 2.4522845976093777e-08
interval O 0 1.8465260609445977e-07
[ O 0 4.2539630840110476e-07
CI O 1 0.9999978542327881
] O 0 1.6444785444491572e-07
6 O 0 7.182180183917808e-08
% O 0 3.475791210405532e-09
- O 0 1.5690789112454695e-08
28 O 0 2.098842699638226e-08
% O 0 2.439458857139698e-09
) O 0 1.929310711190624e-09
, O 0 6.6041505597524974e-09
suggesting O 0 3.3462541182416317e-08
other O 0 3.644809609681943e-08
predisposition O 0 3.9740671127219684e-06
genes O 0 7.93572894508543e-07
. O 0 1.0487605095477193e-06

The O 0 2.816141886796686e-06
majority O 0 8.342113488879477e-08
( O 0 1.4869858233623745e-08
81 O 0 1.8879406127325637e-07
% O 0 3.3465270554700055e-09
) O 0 1.3053472747159844e-09
of O 0 1.6510179889905885e-08
the O 0 2.321480252476249e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.461571443518778e-10
were O 0 5.720593443392374e-10
due O 0 3.970379136575275e-09
to O 0 9.470624284801943e-09
BRCA1 O 0 1.6606482233783026e-07
, O 0 3.269378989756433e-09
with O 0 2.379615171577143e-09
most O 0 9.504283582373318e-09
others O 0 6.812840513958918e-09
( O 0 2.9092328546198587e-09
14 O 0 3.067195208927842e-08
% O 0 4.426938815527137e-09
) O 0 8.70908589689634e-09
due O 0 2.5729647745720285e-07
to O 0 9.468944881518837e-07
BRCA2 O 0 0.0002622338361106813
. O 0 4.689527486334555e-06

Conversely O 0 5.922064246988157e-06
, O 0 1.455746598821861e-07
the O 0 4.38996075047271e-08
majority O 0 5.012265713588704e-09
of O 0 2.1131588923140043e-08
families O 0 1.164750629278899e-09
with O 0 2.816843647224232e-09
male B-Disease 0 7.975373250701523e-08
and I-Disease 0 4.8602629476590664e-08
female I-Disease 0 1.1131506880701636e-06
breast I-Disease 1 0.9999983310699463
cancer I-Disease 0 0.0010892142308875918
were O 0 9.465351169524183e-09
due O 0 5.0706358223351344e-08
to O 0 8.80366997080273e-08
BRCA2 O 0 3.1925559596857056e-05
( O 0 2.8517568750885403e-08
76 O 0 1.545294026072952e-06
% O 0 5.2759670410296167e-08
) O 0 1.2746153288389905e-07
. O 0 1.7102103129218449e-06

The O 0 2.6569896363071166e-06
largest O 0 6.685748985546525e-07
proportion O 0 9.758890939792764e-08
( O 0 6.338515046167004e-09
67 O 0 4.4474216309708936e-08
% O 0 2.039084012750436e-09
) O 0 7.872262841601696e-10
of O 0 1.0259854299476956e-08
families O 0 3.373776258364103e-10
due O 0 2.98414826183091e-09
to O 0 1.2223955181411839e-09
other O 0 3.689502481307727e-09
genes O 0 3.462478082028042e-09
was O 0 1.3946336530068493e-08
found O 0 1.1907991259718642e-09
in O 0 4.141844645033643e-10
families O 0 1.3949116861589062e-10
with O 0 2.7636667954134e-10
four O 0 1.5649803675188423e-09
or O 0 2.863812520459419e-09
five O 0 2.3082813438435323e-09
cases O 0 4.243838169770697e-09
of O 0 3.7089364468556596e-07
female O 0 6.064063200028613e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.8509393930435181
only O 0 1.292446114575796e-07
. O 0 1.0548611726335366e-06

These O 0 9.983037898564362e-07
estimates O 0 4.2227142671436013e-07
were O 0 3.564849038184548e-08
not O 0 5.308821826588428e-09
substantially O 0 2.5013719096023124e-08
affected O 0 9.757025409840026e-09
either O 0 2.4032333900692038e-09
by O 0 8.07596656215992e-10
changing O 0 1.0128860417069063e-08
the O 0 9.123737321203862e-09
assumed O 0 3.1567154223921534e-08
penetrance O 0 2.868893602681055e-07
model O 0 6.968644328253504e-09
for O 0 4.210169990415125e-09
BRCA1 O 0 7.663158640980328e-08
or O 0 1.4150612903662818e-09
by O 0 7.473095475774016e-10
including O 0 1.592718668064208e-08
or O 0 7.115001920965369e-08
excluding O 0 1.6735416465962771e-06
BRCA1 O 0 3.1483566544920905e-06
mutation O 0 2.2646558761607594e-07
data O 0 2.65946141553286e-07
. O 0 1.437216724298196e-06

Among O 0 8.101938533400244e-07
those O 0 5.037503569838009e-08
families O 0 2.847244218173728e-09
with O 0 5.269105596283907e-09
disease O 0 0.00013657378440257162
due O 0 2.3641312907329848e-07
to O 0 1.2567261364893056e-07
BRCA1 O 0 2.106235342580476e-06
that O 0 2.1200652344788296e-09
were O 0 2.9109865629095566e-09
tested O 0 2.519941144640825e-09
by O 0 1.8902730769543297e-10
one O 0 1.2202453492093923e-09
of O 0 5.223416366106903e-09
the O 0 4.676519171908922e-09
standard O 0 9.832725744729487e-09
screening O 0 1.090981527340773e-08
methods O 0 7.664310075483627e-09
, O 0 3.241005019916088e-09
mutations O 0 4.057121749667658e-09
were O 0 1.811531480377937e-09
detected O 0 7.925691214438757e-09
in O 0 1.0199830979829017e-09
the O 0 8.707325527268495e-09
coding O 0 1.065355803575585e-07
sequence O 0 2.2457120607555225e-08
or O 0 8.054127142997913e-09
splice O 0 2.580513864813838e-07
sites O 0 1.9028853159852588e-08
in O 0 2.982554869745968e-09
an O 0 5.231013844309018e-09
estimated O 0 2.242044239153529e-08
63 O 0 8.876763502030371e-08
% O 0 9.815917856315082e-09
( O 0 4.9995190209983775e-09
95 O 0 2.910400667133217e-07
% O 0 5.566083771668673e-08
CI O 1 0.9836558103561401
51 O 0 1.956598367769402e-07
% O 0 9.049559324125767e-09
- O 0 1.3996708503327682e-07
77 O 0 5.320938498698524e-07
% O 0 5.8990956119941984e-08
) O 0 1.1385061071678138e-07
. O 0 2.1335602014005417e-06

The O 0 2.348057478229748e-06
estimated O 0 3.2745640510256635e-07
sensitivity O 0 6.8926573248973e-07
was O 0 1.7311342048742517e-07
identical O 0 2.081441152768093e-08
for O 0 4.18980672378666e-09
direct O 0 7.856321815324918e-09
sequencing O 0 5.724518103988885e-08
and O 0 2.821932376662062e-08
other O 0 4.0311903148904094e-08
techniques O 0 1.8442643749949639e-06
. O 0 2.2783735857956344e-06

The O 0 4.0772456486593e-06
penetrance O 0 8.091476047411561e-05
of O 0 1.8960517991217785e-05
BRCA2 O 0 9.745660645421594e-05
was O 0 1.8328448447846313e-07
estimated O 0 1.7459557355437028e-08
by O 0 3.3538369859087425e-09
maximizing O 0 7.866204327910964e-07
the O 0 1.1213342077098787e-07
LOD O 1 0.999737560749054
score O 0 5.423255515779601e-07
in O 0 7.720905159658287e-08
BRCA2 O 0 3.3577130125195254e-06
- O 0 9.592578464889812e-08
mutation O 0 9.903571296376867e-09
families O 0 3.0144375884333385e-10
, O 0 6.584802147990843e-10
over O 0 5.873002084655354e-09
all O 0 2.6401163921718762e-08
possible O 0 8.333557133255454e-08
penetrance O 0 8.416624950768892e-06
functions O 0 1.4107563401921652e-06
. O 0 3.1102383672987344e-06

The O 0 7.556030254818324e-07
estimated O 0 1.2315528863382497e-07
cumulative O 0 4.4186572267790325e-07
risk O 0 3.076893051456864e-07
of O 0 5.397055247158278e-07
breast B-Disease 1 0.9999955892562866
cancer I-Disease 0 5.1516883104341105e-05
reached O 0 3.807202730854442e-08
28 O 0 3.6018928284420326e-08
% O 0 3.1216094154018492e-09
( O 0 1.8360553077911845e-09
95 O 0 1.0759030288909344e-07
% O 0 3.012371507793432e-08
CI O 0 0.21618077158927917
9 O 0 6.884176428911815e-08
% O 0 2.3665160941988006e-09
- O 0 1.0688052221041744e-08
44 O 0 1.2466460752591502e-08
% O 0 6.811836095188539e-10
) O 0 2.9705174431349235e-10
by O 0 2.8318558609186084e-10
age O 0 7.332890739064624e-09
50 O 0 5.899171817702609e-09
years O 0 3.017344152311807e-09
and O 0 4.580192669578764e-09
84 O 0 1.5462801172816398e-07
% O 0 5.564043004113728e-09
( O 0 3.5843330525864303e-09
95 O 0 2.4276778276544064e-07
% O 0 4.2084380424967094e-08
CI O 0 0.17940033972263336
43 O 0 1.6915114997573255e-07
% O 0 5.753379994644092e-09
- O 0 2.1435683450476972e-08
95 O 0 5.8022020965609045e-08
% O 0 2.0533998945637677e-09
) O 0 8.527529238300247e-10
by O 0 1.62760771527104e-09
age O 0 3.30077192245426e-08
70 O 0 1.374186098246355e-07
years O 0 1.5576321743537846e-07
. O 0 1.1848208032461116e-06

The O 0 1.3732125808019191e-05
corresponding O 1 0.9944287538528442
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 5.4367548727896065e-05
were O 0 2.5544761683704564e-07
0 O 0 1.3287115052662557e-06
. O 0 1.2972957392776152e-06

4 O 0 7.5429657044878695e-06
% O 0 2.4672749532328453e-07
( O 0 2.8567979981630742e-08
95 O 0 6.566559136444994e-07
% O 0 6.169547361878358e-08
CI O 0 0.00033564530895091593
0 O 0 4.49689494530503e-08
% O 0 1.5082310955705225e-09
- O 0 7.210837704718642e-09
1 O 0 1.633402213485624e-08
% O 0 8.419054897679246e-10
) O 0 2.8826629971945295e-10
by O 0 3.817691995866568e-10
age O 0 4.412548548771156e-09
50 O 0 4.092749694706299e-09
years O 0 2.3410833271952924e-09
and O 0 3.086071620472808e-09
27 O 0 4.5880554466748436e-08
% O 0 5.107167577733662e-09
( O 0 3.985492824654102e-09
95 O 0 1.656068064903593e-07
% O 0 3.4904218182418845e-08
CI O 0 0.0004454308655112982
0 O 0 4.631030492419086e-08
% O 0 4.014875099045412e-09
- O 0 2.6274920017499426e-08
47 O 0 4.230037475849713e-08
% O 0 2.2554422773879423e-09
) O 0 8.71843874872269e-10
by O 0 2.825722544841369e-09
age O 0 4.6073040493865847e-08
70 O 0 2.3507297441938135e-07
years O 0 3.466095108706213e-07
. O 0 2.1433411347970832e-06

The O 0 2.1960111098451307e-06
lifetime O 0 2.5577235192031367e-06
risk O 0 3.1756103453517426e-06
of O 0 3.121092504443368e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.9917165637016296
appears O 0 1.4536207793014455e-08
similar O 0 5.612815212607813e-10
to O 0 1.0650399451250792e-09
the O 0 1.2717505271098162e-08
risk O 0 2.4928748842967252e-08
in O 0 4.337589398772934e-09
BRCA1 O 0 1.1458477189307814e-07
carriers O 0 3.1771967279325963e-09
, O 0 1.0322228627401842e-09
but O 0 5.651930590211407e-10
there O 0 1.7015686637478211e-09
was O 0 1.3179443314470518e-08
some O 0 3.1776636877367537e-09
suggestion O 0 4.711429468784445e-08
of O 0 7.565578385992922e-08
a O 0 4.664557451405926e-08
lower O 0 1.8946502677863464e-07
risk O 0 1.217286182964017e-07
in O 0 3.303681950228565e-08
BRCA2 O 0 2.446305870762444e-06
carriers O 0 1.920306047509257e-08
< O 0 7.510183053227593e-08
50 O 0 2.3460058784507964e-08
years O 0 1.2015066275239406e-08
of O 0 1.8218068476016924e-07
age O 0 8.902380841391277e-07
. O 0 1.1574759355426067e-06

Eye B-Disease 1 1.0
movement I-Disease 0 2.7095362383988686e-05
abnormalities I-Disease 0 0.00010803090845001861
correlate O 0 5.078476306152879e-07
with O 0 5.3643692154992095e-08
genotype O 0 1.074893361874274e-06
in O 0 9.803890321791187e-08
autosomal O 1 0.9994862079620361
dominant O 1 0.9999998807907104
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 3.1892875995254144e-05

We O 0 1.921887360367691e-06
compared O 0 7.317349854929489e-07
horizontal O 0 3.804843800025992e-06
eye O 0 7.04917692928575e-05
movements O 0 3.696274006870226e-07
( O 0 3.984370167131601e-08
visually O 0 1.9655793437323155e-07
guided O 0 6.61724072870129e-07
saccades O 0 3.3460169106547255e-06
, O 0 3.077913746096783e-08
antisaccades O 0 2.5886502044158988e-06
, O 0 2.301656998326962e-08
and O 0 1.5402598307900917e-08
smooth O 0 1.1244740960592026e-07
pursuit O 0 1.7571635169133515e-07
) O 0 6.028616716946544e-09
in O 0 7.405557944650809e-09
control O 0 2.0836186820361036e-07
subjects O 0 9.58394366534776e-07
( O 0 1.2728279763507544e-08
n O 0 5.4203713517608776e-08
= O 0 1.77455703465057e-08
14 O 0 7.364399756681905e-09
) O 0 1.6306155314893545e-09
and O 0 2.2694928158983885e-09
patients O 0 2.913319585573504e-09
with O 0 3.2603728050695224e-10
three O 0 2.6127782160045854e-09
forms O 0 2.3402003890282685e-08
of O 0 4.144307297337946e-07
autosomal O 1 0.923885703086853
dominant O 1 0.9999454021453857
cerebellar B-Disease 1 1.0
ataxias I-Disease 1 0.9999998807907104
type I-Disease 1 0.7775023579597473
I I-Disease 0 0.463317334651947
spinocerebellar B-Disease 1 0.9999998807907104
ataxias I-Disease 0 8.738159522181377e-05
1 I-Disease 0 4.838983613808523e-07
and I-Disease 0 2.236129326149694e-08
2 I-Disease 0 1.281938182273734e-07
( O 0 1.6087906118400497e-08
SCA1 B-Disease 0 0.00041991478065028787
, O 0 2.7929312196306455e-08
n O 0 3.542407256418301e-08
= O 0 9.609825823986284e-09
11 O 0 1.36420181817698e-08
; O 0 4.4901047324685806e-09
SCA2 B-Disease 0 4.371868635644205e-05
, O 0 1.515643077709683e-08
n O 0 1.2385900305389441e-08
= O 0 5.556163085174148e-09
10 O 0 5.114000334316415e-09
) O 0 6.908850824771662e-09
and O 0 5.5756466110779e-08
SCA3 B-Disease 1 1.0
/ O 0 1.1561604878806975e-05
Machado B-Disease 0 2.1973934053676203e-05
- I-Disease 0 2.5899762476910837e-06
Joseph I-Disease 0 7.891370478319004e-05
disease I-Disease 1 0.8815626502037048
( O 0 7.979070204555683e-08
MJD B-Disease 1 1.0
) O 0 1.0050577259335114e-07
( O 0 3.091705380597887e-08
n O 0 1.7659647255641175e-07
= O 0 7.5222679640774e-08
16 O 0 2.1878949496567657e-07
) O 0 2.094935780405649e-07
. O 0 1.8927950122815673e-06

In O 0 4.706970685219858e-06
SCA1 B-Disease 1 0.9988455772399902
, O 0 9.215953582497605e-07
saccade O 0 1.637533205212094e-05
amplitude O 0 2.508211991880671e-06
was O 0 2.0202328698815109e-07
significantly O 0 2.7862167684133965e-08
increased O 0 2.683135136294368e-08
, O 0 3.70718851172569e-08
resulting O 0 2.4040235757638584e-07
in O 0 2.568213517406548e-07
hypermetria B-Disease 0 0.00028617720818147063
. O 0 1.0415647921035998e-05

The O 0 2.2403261027648114e-05
smooth O 0 2.0340901755844243e-05
pursuit O 0 1.2496045201260131e-05
gain O 0 2.631181814649608e-06
was O 0 5.9284498092893045e-06
decreased O 0 1.8371394617133774e-05
. O 0 7.728588570898864e-06

In O 0 1.0990183909598272e-05
SCA2 B-Disease 1 0.9999613761901855
, O 0 3.3574729059182573e-06
saccade O 0 5.686906661139801e-05
velocity O 0 4.984253791917581e-06
was O 0 2.897124204537249e-06
markedly O 0 4.488892500376096e-06
decreased O 0 1.044462260324508e-05
. O 0 8.392484232899733e-06

The O 0 1.940103629749501e-06
percentage O 0 5.91671948768635e-07
of O 0 3.587187222819921e-07
errors O 0 5.217064426688012e-06
in O 0 1.371168707464676e-07
antisaccades O 1 0.9999730587005615
was O 0 1.1391157386242412e-06
greatly O 0 1.204402764187762e-07
increased O 0 1.4193248354388288e-08
and O 0 1.0813049122759821e-08
was O 0 5.513117073974172e-08
significantly O 0 1.4800533243430891e-08
correlated O 0 3.0936522676938694e-08
with O 0 5.599292141056367e-09
age O 0 1.9900693359886645e-07
at O 0 8.876862693796284e-07
disease O 0 7.355801062658429e-05
onset O 0 3.6581863241735846e-05
. O 0 4.770113264385145e-06

In O 0 6.578430884474074e-07
addition O 0 2.6335138159083726e-07
, O 0 5.667286373522984e-08
a O 0 2.26248353385472e-08
correlation O 0 4.0979227122761586e-08
between O 0 1.808370164724238e-08
smooth O 0 2.528840923332609e-07
pursuit O 0 2.448100246965623e-07
gain O 0 1.4343035203978616e-08
and O 0 5.1445541160433095e-09
the O 0 1.1513175302013678e-08
number O 0 1.3534124931879887e-08
of O 0 2.3877143462414097e-07
trinucleotide O 0 0.00016122631495818496
repeats O 0 9.568071845933446e-07
was O 0 9.218292120749538e-07
found O 0 5.228093868936412e-07
. O 0 1.844092025748978e-06

In O 0 7.430515324813314e-06
SCA3 B-Disease 1 1.0
, O 0 2.6870611691265367e-06
gaze B-Disease 0 0.00011231707321712747
- I-Disease 0 0.00017057795776054263
evoked I-Disease 0 2.6187019102508202e-05
nystagmus I-Disease 0 3.173253935528919e-05
was O 0 2.0415023982423008e-07
often O 0 1.4126431580052667e-08
present O 0 1.771000057715355e-08
as O 0 2.2818079870035035e-08
was O 0 2.8696322829091514e-07
saccade O 0 4.538325356406858e-06
hypometria O 0 1.6197434888454154e-05
and O 0 2.917242341027304e-07
smooth O 0 2.2879630705574527e-06
pursuit O 0 4.469789473660057e-06
gain O 0 1.2359255379124079e-06
was O 0 2.077890712826047e-06
markedly O 0 2.80418112197367e-06
decreased O 0 6.1161954363342375e-06
. O 0 4.367604560684413e-06

Three O 0 1.2360600294414326e-06
major O 0 1.1452506214482128e-06
criteria O 0 1.604427666279662e-06
, O 0 7.145329306013082e-08
saccade O 0 3.9615342757315375e-06
amplitude O 0 6.413705477825715e-07
, O 0 3.891330280225702e-08
saccade O 0 7.043847745080711e-07
velocity O 0 4.970929623482334e-08
, O 0 4.675671849696528e-09
and O 0 3.3802769472401906e-09
presence O 0 1.7937841434445545e-08
of O 0 9.923770249997688e-08
gaze B-Disease 0 1.5324294508900493e-05
- I-Disease 0 2.940117883554194e-05
evoked I-Disease 0 5.4186211855267175e-06
nystagmus I-Disease 0 3.356454953973298e-06
, O 0 1.0833652197561605e-08
permitted O 0 1.3952642596848364e-08
the O 0 7.56646922894788e-09
correct O 0 7.14683956459794e-09
assignment O 0 1.7005572061634666e-08
of O 0 1.308596253579708e-08
90 O 0 1.4192165664894674e-08
% O 0 1.0621329371574006e-09
of O 0 6.066253721570547e-09
the O 0 1.4132440995240358e-08
SCA1 B-Disease 0 0.17145510017871857
, O 0 7.542737989751913e-09
90 O 0 1.241253055894731e-08
% O 0 7.922543177052432e-10
of O 0 5.3326298932177e-09
the O 0 1.6181706641305027e-08
SCA2 B-Disease 1 0.9999319314956665
, O 0 1.0481306489396047e-08
and O 0 4.595129610152071e-09
93 O 0 4.605520587119827e-08
% O 0 1.3087901873376495e-09
of O 0 3.872033804697139e-09
the O 0 7.014424596718527e-09
patients O 0 3.3515479280765703e-09
with O 0 4.6049737356668174e-09
SCA3 B-Disease 1 1.0
to O 0 5.259278523794819e-08
their O 0 7.665714285565173e-09
genetically O 0 4.244488138738234e-08
confirmed O 0 5.185506246618843e-09
patient O 0 6.9456880247287245e-09
group O 0 2.744583893488084e-09
and O 0 3.6043306117505836e-09
, O 0 8.821836594563592e-09
therefore O 0 1.2663359250097983e-08
, O 0 4.152834076620593e-09
may O 0 4.081710525127846e-09
help O 0 1.753164013962305e-08
orient O 0 1.4696501011712826e-06
diagnoses O 0 1.8081672692460415e-07
of O 0 3.594909685489256e-07
SCA1 B-Disease 1 1.0
, O 0 1.3972621104585414e-07
SCA2 B-Disease 1 1.0
, O 0 6.112376382816365e-08
and O 0 6.77885694244651e-08
SCA3 B-Disease 1 1.0
at O 0 3.22751589010295e-07
early O 0 3.923847913256395e-08
clinical O 0 1.3407935739451204e-07
stages O 0 8.420170871659138e-08
of O 0 9.459291305802253e-08
the O 0 1.9634808268165216e-07
diseases O 0 0.01405849028378725
. O 0 1.1394326548952449e-07
. O 0 1.4523591289616888e-06

Genetic O 0 5.977192813588772e-06
basis O 0 2.209214216009059e-07
and O 0 4.3316056519415724e-08
molecular O 0 1.1897801641680417e-06
mechanism O 0 1.807356852623343e-06
for O 0 8.196532689908054e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.0005548955523408949

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999977350234985
causes O 0 1.380060894007329e-06
more O 0 7.82352937989117e-09
than O 0 5.9981419830990035e-09
300 O 0 3.307868468027664e-08
, O 0 8.737671031155969e-09
000 O 0 1.374146876287341e-07
sudden O 0 8.97848764225273e-08
deaths O 0 8.965272968453064e-09
each O 0 1.2847446440034105e-09
year O 0 3.126787717633306e-09
in O 0 1.0069685529856542e-08
the O 0 3.46354397606774e-07
USA O 0 1.650000376685057e-05
alone O 0 1.8338290601604967e-06
. O 0 3.6328488022263627e-06

In O 0 4.884868189947156e-07
approximately O 0 6.186633783045181e-08
5 O 0 3.8463689122636424e-08
- O 0 3.1280418255619225e-08
12 O 0 1.405145777511052e-08
% O 0 6.646290739986682e-10
of O 0 1.6787323753320038e-09
these O 0 1.662214532682782e-10
cases O 0 4.910613582431722e-10
, O 0 4.140707221544915e-10
there O 0 4.6205617110217645e-10
are O 0 4.3804881943998453e-10
no O 0 7.877885010998398e-09
demonstrable O 0 0.13614869117736816
cardiac O 1 0.9999980926513672
or O 0 2.765225701750751e-07
non O 1 0.9981077909469604
- O 1 0.993060827255249
cardiac O 1 0.9997767806053162
causes O 0 2.127418419206606e-08
to O 0 1.5117331830794e-09
account O 0 1.3738782334016264e-09
for O 0 1.203956156992092e-09
the O 0 2.0836298020299182e-08
episode O 0 2.3323450193402095e-07
, O 0 3.827106187515028e-09
which O 0 1.2533808435577498e-09
is O 0 1.5004552045283504e-09
therefore O 0 1.6857398810188329e-09
classified O 0 2.1432458652270725e-07
as O 0 7.722752570771263e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 1.9065393644268624e-05
IVF B-Disease 1 1.0
) O 0 1.483785240452562e-06
. O 0 4.762576736538904e-06

A O 0 5.724228685721755e-06
distinct O 0 5.266948619464529e-07
group O 0 4.235438311184225e-08
of O 0 6.90956426296907e-07
IVF B-Disease 1 1.0
patients O 0 2.525623301607993e-07
has O 0 4.974227696408207e-09
been O 0 1.0846796794083957e-09
found O 0 6.297588006631827e-10
to O 0 8.202112322663879e-10
present O 0 4.580201551362961e-09
with O 0 7.02892899440144e-09
a O 0 1.9928231154153764e-07
characteristic O 0 1.4802764781052247e-05
electrocardiographic O 0 0.001012903987430036
pattern O 0 1.7090860637836158e-05
. O 0 4.129494755034102e-06

Because O 0 4.4379316932463553e-07
of O 0 3.0563569453079253e-07
the O 0 4.537415065897221e-08
small O 0 1.084676082285796e-08
size O 0 1.954136230608583e-08
of O 0 1.8996868078602347e-08
most O 0 3.6892915389330483e-09
pedigrees O 0 3.623370403715853e-08
and O 0 3.2304205976885214e-09
the O 0 1.2122936432490405e-08
high O 0 2.0809457623727212e-07
incidence O 0 4.7200370545397163e-07
of O 0 1.4892627575591177e-07
sudden B-Disease 0 3.264022723215021e-07
death I-Disease 0 1.0133695127478859e-07
, O 0 4.208869253119474e-09
however O 0 5.822031745594813e-09
, O 0 5.539349423600015e-09
molecular O 0 5.9350639958211104e-08
genetic O 0 1.320304399143879e-08
studies O 0 7.450953631860102e-09
of O 0 5.138672420912371e-08
IVF B-Disease 1 0.9995112419128418
have O 0 4.555666954786375e-09
not O 0 2.2026318546863877e-09
yet O 0 1.588871256785751e-08
been O 0 4.6072955228737555e-08
done O 0 2.5360503741467255e-07
. O 0 1.5088554619069328e-06

Because O 0 3.2307234505424276e-05
IVF B-Disease 1 1.0
causes O 1 0.9714682698249817
cardiac O 1 1.0
rhythm O 1 1.0
disturbance O 1 1.0
, O 0 7.130815760092446e-08
we O 0 1.0857378995865474e-08
investigated O 0 9.410091905692752e-08
whether O 0 1.4205544296430617e-08
malfunction O 0 9.413916268385947e-05
of O 0 1.0310943565627895e-07
ion O 0 1.1621768862823956e-06
channels O 0 1.5770666550452006e-07
could O 0 1.7314603084628288e-08
cause O 0 6.899280435845867e-08
the O 0 4.9314181183035544e-08
disorder O 0 6.37079494936188e-07
by O 0 1.6569986494019417e-09
studying O 0 5.0582521282649395e-08
mutations O 0 9.921911292565255e-09
in O 0 3.431982920076848e-09
the O 0 6.502460081492245e-08
cardiac O 0 5.848997716384474e-06
sodium O 0 7.746748451609164e-07
channel O 0 3.0898952445568284e-06
gene O 0 3.298807087048772e-06
SCN5A O 1 0.9999704360961914
. O 0 1.830724249884952e-05

We O 0 1.058275074683479e-06
have O 0 2.9239872745279172e-08
now O 0 6.871596269775182e-08
identified O 0 9.229615471895158e-08
a O 0 4.066482262032878e-08
missense O 0 1.3791951687380788e-06
mutation O 0 8.969347220499913e-08
, O 0 1.205500765877332e-08
a O 0 1.1587506953958382e-08
splice O 0 9.308586186307366e-07
- O 0 2.0783276966085396e-07
donor O 0 2.347769623156637e-08
mutation O 0 2.2340699956657772e-08
, O 0 4.147562293610463e-09
and O 0 7.54600382180115e-09
a O 0 2.264361498305334e-08
frameshift O 0 3.031447022294742e-07
mutation O 0 6.134600383234101e-09
in O 0 1.3479065641419652e-09
the O 0 4.72281724839263e-09
coding O 0 7.784682054534642e-08
region O 0 5.737875952149807e-08
of O 0 2.3803023907476017e-07
SCN5A O 1 1.0
in O 0 5.5944916255157295e-08
three O 0 1.0387176274662124e-07
IVF B-Disease 0 0.00020098424283787608
families O 0 7.807507529378199e-08
. O 0 8.650696372569655e-07

We O 0 9.598112455933006e-07
show O 0 1.619971641275697e-07
that O 0 4.0754097874184936e-09
sodium O 0 2.333839610457744e-08
channels O 0 9.25628551584623e-09
with O 0 4.000275222182381e-09
the O 0 1.1183738024556078e-07
missense O 0 1.4456294366027578e-06
mutation O 0 9.614467444407637e-08
recover O 0 9.052393323827346e-08
from O 0 9.27666388150783e-09
inactivation O 0 3.0676510505145416e-06
more O 0 3.369713397205487e-09
rapidly O 0 1.0251482329692863e-08
than O 0 1.3019680888959329e-09
normal O 0 5.103213851498367e-09
and O 0 3.8490819420644584e-09
that O 0 3.8787679734753056e-09
the O 0 9.077914597810377e-08
frameshift O 0 4.021275799459545e-06
mutation O 0 8.791772643235163e-08
causes O 0 2.0799291178263957e-08
the O 0 7.020969583493297e-09
sodium O 0 2.590924275125417e-08
channel O 0 1.0346576928554896e-08
to O 0 3.4801561632491484e-09
be O 0 9.512879373119176e-09
non O 0 3.267180659349833e-07
- O 0 2.6271472961525433e-06
functional O 0 4.0224031181423925e-06
. O 0 1.7078438077078317e-06

Our O 0 3.490193648758577e-06
results O 0 1.6274074710054265e-07
indicate O 0 5.251609991319128e-08
that O 0 6.718138489958392e-09
mutations O 0 2.7022403870091694e-08
in O 0 1.1139728250952885e-08
cardiac O 0 5.601854354608804e-06
ion O 0 1.1706353006957215e-06
- O 0 1.3886966598875006e-06
channel O 0 1.498201669392074e-07
genes O 0 6.46774944712547e-09
contribute O 0 2.2632162810509726e-09
to O 0 1.2839852514545669e-09
the O 0 7.484796782364356e-09
risk O 0 3.455236097238412e-08
of O 0 5.7122040431067944e-08
developing O 0 2.988980725149304e-07
IVF B-Disease 1 0.6153706312179565
. O 0 2.7400719204706547e-07
. O 0 1.447497311346524e-06

Molecular O 0 3.90477835026104e-05
heterogeneity O 0 2.6003512175520882e-05
in O 0 6.163537591419299e-07
mucopolysaccharidosis B-Disease 1 0.9997596144676208
IVA I-Disease 1 1.0
in O 0 2.6135379016523075e-07
Australia O 0 3.708610307739946e-08
and O 0 1.0832639674163147e-08
Northern O 0 1.242167826376317e-07
Ireland O 0 1.1461887083896727e-07
: O 0 9.488886121289397e-09
nine O 0 3.002499227022781e-08
novel O 0 8.720409994111833e-08
mutations O 0 1.0271641315284796e-08
including O 0 4.5973735929294435e-09
T312S O 0 3.2408543120254762e-06
, O 0 1.5759594518272024e-08
a O 0 1.2195735976661126e-08
common O 0 3.058298148062022e-08
allele O 0 9.523503763375629e-08
that O 0 1.0633759650602315e-08
confers O 0 1.8157271597374347e-06
a O 0 7.363103122770553e-07
mild O 0 5.668660014634952e-05
phenotype O 0 1.6488284018123522e-05
. O 0 3.4613287880347343e-06

Mucopolysaccharidosis B-Disease 1 1.0
IVA I-Disease 1 1.0
( O 1 0.6363686919212341
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.416321649434394e-06
is O 0 1.4577221918443684e-07
an O 0 1.3192639869430423e-07
autosomal B-Disease 1 0.9996322393417358
recessive I-Disease 1 0.9999898672103882
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 1.8621639128468814e-06
by O 0 1.0348827572670416e-08
a O 0 2.0608840145541762e-07
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999997615814209
in O 0 4.451504054259203e-08
N O 0 9.180960773846891e-07
- O 0 3.661044161162863e-07
acetylgalactosamine O 0 7.606527105963323e-06
- O 0 6.385563438016106e-07
6 O 0 7.73513590957009e-07
- O 0 2.361968654440716e-06
sulfate O 0 5.18395518156467e-06
sulfatase O 0 0.00013939422206021845
( O 0 2.837211923178984e-07
GALNS O 1 0.9997641444206238
) O 0 1.0263827334711095e-06
. O 0 4.6675399971718434e-06

Previous O 0 2.2122635527921375e-06
studies O 0 1.6584324669111083e-07
of O 0 6.984428324585679e-08
patients O 0 7.167835658350441e-09
from O 0 1.7602026503027446e-09
a O 0 4.946846487996481e-09
British O 0 2.0681879320250118e-08
- O 0 3.435587814237806e-07
Irish O 0 5.51775542589894e-07
population O 0 2.4177109203549207e-09
showed O 0 1.313181119400042e-09
that O 0 4.612707438234054e-10
the O 0 8.20939405343779e-09
I113F O 0 7.771580499138508e-07
mutation O 0 1.223707268849239e-08
is O 0 1.1503116237321365e-09
the O 0 1.754631662187478e-09
most O 0 1.8132807477755364e-09
common O 0 4.711453893690987e-09
single O 0 1.3089906936158968e-08
mutation O 0 2.599735715591578e-08
among O 0 6.852422274050696e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.0005937754758633673
and O 0 1.2755333500535926e-07
produces O 0 7.045198344712844e-07
a O 0 1.9003957163477025e-07
severe O 0 1.2489171240304131e-05
clinical O 0 5.5620148486923426e-05
phenotype O 0 6.461823431891389e-06
. O 0 2.510080776119139e-06

We O 0 6.366834668369847e-07
studied O 0 8.92305195066001e-07
mutations O 0 7.094580212196888e-08
in O 0 8.447577748427193e-09
the O 0 6.373748107080246e-08
GALNS O 1 0.6459303498268127
gene O 0 2.177698377181514e-08
from O 0 5.331287411536323e-09
23 O 0 4.9359254461478486e-08
additional O 0 1.5024197352886404e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.5198776281977189e-06
( O 0 3.874250253943501e-09
15 O 0 8.471070955806681e-09
from O 0 1.2092216117309817e-09
Australia O 0 6.010690833946342e-10
, O 0 5.828917903905051e-10
8 O 0 2.7360484988747658e-09
from O 0 8.380044436151479e-10
Northern O 0 2.091290163264148e-08
Ireland O 0 1.5397899844060703e-08
) O 0 2.719550140639626e-09
, O 0 1.1615736150716316e-09
with O 0 4.261478114830908e-10
various O 0 1.243219660551631e-08
clinical O 0 3.248339226047392e-06
phenotypes O 0 6.294595095823752e-06
( O 0 1.687976691755466e-08
severe O 0 2.282767127326224e-05
, O 0 1.5186989443805032e-08
16 O 0 2.3415132943682693e-08
cases O 0 3.1672560130147076e-09
; O 0 1.0614544798670522e-09
intermediate O 0 1.1727835413921639e-07
, O 0 3.0889688584778696e-09
4 O 0 3.0632662628704566e-08
cases O 0 6.7963314975827416e-09
; O 0 7.267074497718795e-09
mild O 0 2.8261752049729694e-07
, O 0 1.0730191846164416e-08
3 O 0 8.019258501690274e-08
cases O 0 2.5542853165916313e-08
) O 0 8.738975054711773e-08
. O 0 1.1120113185825176e-06

We O 0 7.11124357621884e-07
found O 0 6.233051408344181e-08
two O 0 6.37661523583688e-09
common O 0 1.5627291460873494e-08
mutations O 0 5.1639896803123975e-09
that O 0 4.512114848420623e-10
together O 0 1.4193349828772739e-09
accounted O 0 8.9632727906519e-09
for O 0 1.5019441246266751e-09
32 O 0 1.831320695089289e-08
% O 0 1.6088511634038127e-09
of O 0 5.13371301025245e-09
the O 0 1.819375405887058e-08
44 O 0 6.608172498090426e-08
unrelated O 0 1.698784757309113e-07
alleles O 0 1.553270401188911e-08
in O 0 1.0064423960898239e-08
these O 0 6.576499345101183e-08
patients O 0 2.8123309903094196e-07
. O 0 8.674091986904386e-07

One O 0 2.177359419874847e-06
is O 0 2.0731668826101668e-07
the O 0 1.866212357981567e-07
T312S O 0 1.2824586519855075e-05
mutation O 0 1.6100068478408502e-07
, O 0 2.6335431613233595e-08
a O 0 2.658246422981847e-08
novel O 0 8.234078450186644e-07
mutation O 0 5.5948326860288944e-08
found O 0 9.020332036868695e-09
exclusively O 0 6.454860823623676e-08
in O 0 2.9164013426452584e-08
milder O 0 1.1605936379055493e-05
patients O 0 8.123678867377748e-07
. O 0 1.1466800060588866e-06

The O 0 1.630248334549833e-06
other O 0 1.326223468822718e-07
is O 0 2.9447402738469464e-08
the O 0 4.661355745838591e-08
previously O 0 3.2132288652064744e-07
described O 0 1.0802725114444911e-07
I113F O 0 3.0346718631335534e-06
that O 0 1.923421955041249e-08
produces O 0 4.848337766816257e-07
a O 0 2.0803068423447257e-07
severe O 0 1.4938254025764763e-05
phenotype O 0 1.1420721421018243e-05
. O 0 2.559829454185092e-06

The O 0 1.4719696991960518e-05
I113F O 0 5.143201633472927e-05
and O 0 7.128401193767786e-07
T312S O 0 1.0905864655796904e-05
mutations O 0 6.147850939441923e-08
accounted O 0 3.810137627624499e-08
for O 0 3.6620892984728926e-09
8 O 0 3.671252812864623e-08
( O 0 1.8296927306593602e-09
18 O 0 8.578939336700842e-09
% O 0 8.328830403137033e-10
) O 0 5.985110740347466e-10
and O 0 2.1254462634345828e-09
6 O 0 4.7221352161841423e-08
( O 0 2.60494581461046e-09
14 O 0 1.2027425277949533e-08
% O 0 1.0703408159784544e-09
) O 0 8.359163361504329e-10
of O 0 1.4208741738741537e-08
44 O 0 7.532145929189937e-08
unrelated O 0 3.185894854595972e-07
alleles O 0 6.947254149736182e-08
, O 0 4.549260523845078e-08
respectively O 0 5.283318387228064e-07
. O 0 2.9225179787317757e-06

The O 0 4.484656074055238e-06
relatively O 0 4.444886485543975e-07
high O 0 1.1728210438377573e-06
residual O 0 0.00011073992936871946
GALNS O 1 0.9999469518661499
activity O 0 1.453014277785769e-07
seen O 0 3.816712990101223e-08
when O 0 7.532041657043465e-09
the O 0 3.121343183920544e-08
T312S O 0 2.3742654775560368e-06
mutant O 0 1.0510493666515686e-06
cDNA O 0 5.195776111577288e-07
is O 0 5.168949357425845e-08
overexpressed O 0 1.2810231737603317e-06
in O 0 1.3515834673683003e-08
mutant O 0 3.417614493628207e-07
cells O 0 4.050827673296453e-09
provides O 0 1.4999516073643804e-09
an O 0 4.951479226633637e-10
explanation O 0 3.991343255904667e-09
for O 0 2.7174451577849368e-09
the O 0 5.382283774224561e-08
mild O 0 3.656776925708982e-06
phenotype O 0 8.001611462304936e-08
in O 0 3.455023600551499e-09
patients O 0 4.9495265663779264e-09
with O 0 2.8201445623210475e-09
this O 0 2.9561867620486737e-08
mutation O 0 9.42163694617193e-07
. O 0 1.289296051254496e-06

The O 0 8.686749310982123e-07
distribution O 0 8.119173600107388e-08
and O 0 1.1615211015225668e-08
relative O 0 9.148289237259633e-09
frequencies O 0 1.0780203396620891e-08
of O 0 2.1949247752672818e-08
the O 0 3.673837767337318e-08
I113F O 0 3.0990495361038484e-06
and O 0 7.428082682281456e-08
T312S O 0 5.335778496373678e-06
mutations O 0 3.4049520536427735e-08
in O 0 5.250886392360599e-09
Australia O 0 4.10640188519551e-09
corresponded O 0 8.124251493768497e-09
to O 0 2.573428803387401e-09
those O 0 3.0588334087866542e-09
observed O 0 3.1004081524343974e-09
in O 0 1.0044877152282083e-09
Northern O 0 3.253319391660625e-08
Ireland O 0 2.1433189445474454e-08
and O 0 4.801695041578569e-09
are O 0 7.466712248493934e-10
unique O 0 1.4182794938477628e-09
to O 0 6.880363501160502e-10
these O 0 5.897256016851316e-10
two O 0 7.491633979839207e-10
populations O 0 2.481033822832046e-09
, O 0 1.5404061359802768e-09
suggesting O 0 3.884728094760703e-09
that O 0 7.764448528568835e-10
both O 0 2.4309867452387834e-09
mutations O 0 5.896190646836885e-09
were O 0 4.822529930947894e-09
probably O 0 6.933629670413666e-09
introduced O 0 2.145731148317509e-09
to O 0 2.5037476536482473e-09
Australia O 0 2.658326003768252e-09
by O 0 1.4443064522140503e-09
Irish O 0 1.0409151229850977e-07
migrants O 0 7.964819914718646e-09
during O 0 1.0803133498882289e-08
the O 0 6.48387086243929e-08
19th O 0 1.0192756008109427e-06
century O 0 2.5352935608680127e-06
. O 0 4.0621598600409925e-06

Haplotype O 0 9.734682680573314e-05
analysis O 0 4.0979821847031417e-07
using O 0 1.5886446647073171e-07
6 O 0 9.907879530146602e-07
RFLPs O 0 2.0194260287098587e-05
provides O 0 3.379144075665863e-08
additional O 0 1.1480896233706517e-08
data O 0 6.813970720997986e-09
that O 0 2.0943948797480516e-09
the O 0 3.510987056642989e-08
I113F O 0 2.5045187612704467e-06
mutation O 0 2.211030469823072e-08
originated O 0 1.2167157947828855e-08
from O 0 4.766600003591748e-09
a O 0 2.8417931119406603e-08
common O 0 1.3535525056340703e-07
ancestor O 0 7.857912009967549e-07
. O 0 1.33289972836792e-06

The O 0 1.4834159856036422e-06
other O 0 8.858750533136117e-08
9 O 0 3.0751036206311255e-07
novel O 0 7.641482966391777e-07
mutations O 0 2.3716641095461455e-08
identified O 0 4.448861723460595e-09
in O 0 9.958194269188425e-10
these O 0 3.3503717578042824e-09
23 O 0 3.742077225865614e-08
patients O 0 3.3754901096472167e-09
were O 0 1.4836137873786015e-09
each O 0 1.342984501384592e-09
limited O 0 4.6013037824366165e-09
to O 0 9.179104587531128e-09
a O 0 8.53093737873678e-08
single O 0 3.633128926594509e-07
family O 0 1.1096975640612072e-06
. O 0 2.5097983780142386e-06

These O 0 8.292947768495651e-07
data O 0 1.4160603711843578e-07
provide O 0 2.3883423239112744e-08
further O 0 2.2957337364459818e-08
evidence O 0 1.4098194611733561e-08
for O 0 1.632249890803905e-08
extensive O 0 3.823241456757387e-07
allelic O 0 9.06312016013544e-06
heterogeneity O 0 5.537151082535274e-06
in O 0 2.3923001890580053e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
in O 0 2.0767467390214733e-07
British O 0 2.1487900880856614e-07
- O 0 1.1167403499712236e-06
Irish O 0 4.274156992778444e-07
patients O 0 4.4798569298620805e-09
and O 0 4.708837209044248e-10
provide O 0 9.267357437003909e-10
evidence O 0 1.3629345430032913e-09
for O 0 8.880463586713461e-10
their O 0 8.091138314902935e-10
transmission O 0 5.5366977669280004e-09
to O 0 2.1844324127329173e-09
Australia O 0 1.614042344222355e-09
by O 0 8.109725113669697e-10
British O 0 2.7300343319325293e-08
- O 0 3.523990130815946e-07
Irish O 0 8.45730141918466e-07
migrants O 0 5.514420919894292e-08
. O 0 5.073189868198824e-08
. O 0 6.642468406425905e-07

Identification O 0 3.560022378223948e-06
of O 0 5.0443481995898765e-06
constitutional O 0 0.03439726307988167
WT1 O 1 1.0
mutations O 0 4.156357590545667e-06
, O 0 2.6013724507834013e-08
in O 0 7.772602117483984e-09
patients O 0 2.6603663272339872e-08
with O 0 1.1053143289529999e-08
isolated O 0 0.0013725216267630458
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 1.9349674573732045e-07
and O 0 2.3410443361626676e-08
analysis O 0 3.598212572342163e-08
of O 0 1.7560461174070952e-07
genotype O 0 1.201774580295023e-06
/ O 0 8.223868803725054e-07
phenotype O 0 8.171046772531554e-08
correlations O 0 2.8035843868678967e-08
by O 0 1.4012214721859095e-09
use O 0 1.3168236279170742e-08
of O 0 1.2001900984159874e-07
a O 0 1.4707561035720573e-07
computerized O 0 1.6515603419975378e-05
mutation O 0 1.5742100458737696e-06
database O 0 1.566897822158353e-06
. O 0 1.4290218359747087e-06

Constitutional O 0 1.23524432638078e-05
mutations O 0 4.70739621505345e-07
of O 0 5.072038788966893e-07
the O 0 3.4618466315805563e-07
WT1 O 1 0.8801724910736084
gene O 0 7.49471382732736e-08
, O 0 1.534492177768243e-08
encoding O 0 1.4991692864896322e-07
a O 0 7.415851399628082e-08
zinc O 0 6.642406333412509e-06
- O 0 2.8701574592560064e-06
finger O 0 1.1309217370580882e-05
transcription O 0 3.7996182982169557e-06
factor O 0 2.9650195187969075e-07
involved O 0 2.439734636539015e-08
in O 0 1.846852981657321e-08
renal O 1 1.0
and O 0 1.279911884921603e-06
gonadal O 1 1.0
development O 0 2.3853471020629513e-07
, O 0 1.2262773019244833e-08
are O 0 1.368088864417416e-09
found O 0 1.3082760430549456e-09
in O 0 6.623220860646484e-10
most O 0 2.095545736935378e-09
patients O 0 2.3179520525218322e-09
with O 0 3.6505825029564676e-09
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.7319154582983174e-07
DDS B-Disease 1 1.0
) O 0 6.67849704427681e-08
, O 0 2.3188951203678698e-08
or O 0 1.511328093783959e-07
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.397599589836318e-06
DMS B-Disease 1 1.0
) O 0 1.0248471404850079e-08
associated O 0 1.019077444652794e-08
with O 0 1.1913200204105578e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 5.461903924697253e-07
/ O 0 0.008827573619782925
or O 0 2.367782826695475e-06
Wilms B-Disease 1 1.0
tumor I-Disease 1 1.0
( O 0 1.004687646855018e-06
WT B-Disease 1 1.0
) O 0 8.223688041653077e-07
. O 0 2.6264158350386424e-06

Most O 0 6.022830802976387e-06
mutations O 0 3.169595174767892e-06
in O 0 6.631050268879335e-07
DDS B-Disease 1 1.0
patients O 0 4.226516011840431e-06
lie O 0 9.575611557011143e-07
in O 0 3.286160321636089e-08
exon O 0 1.4221370747691253e-06
8 O 0 8.778836502187914e-08
or O 0 1.2076180944120551e-08
exon O 0 4.977182470611297e-07
9 O 0 1.623711654019644e-07
, O 0 2.6288153875952958e-08
encoding O 0 4.808167659575702e-07
zinc O 0 5.016236627852777e-06
finger O 0 8.314460501424037e-06
2 O 0 3.1239690088114003e-06
or O 0 1.2784536806975666e-07
zinc O 0 1.908714239107212e-06
finger O 0 1.1547547273949021e-06
3 O 0 1.8233328091810108e-07
, O 0 1.0532046346156676e-08
respectively O 0 1.422229889413984e-08
, O 0 4.04639521889294e-09
with O 0 4.3801557936262725e-09
a O 0 6.034025545886834e-08
hot O 0 6.324259175016778e-06
spot O 0 2.5856229513010476e-06
( O 0 6.40951682839841e-08
R394W O 0 3.157070068482426e-06
) O 0 4.1250089566347015e-08
in O 0 6.865320756332949e-08
exon O 0 1.5669931599404663e-05
9 O 0 6.391494480340043e-06
. O 0 3.8229022720770445e-06

We O 0 6.105409511292237e-07
analyzed O 0 2.7585460316004173e-07
a O 0 2.5072566245398775e-08
series O 0 3.548127835983905e-08
of O 0 4.727830926753995e-08
24 O 0 9.61054382742077e-08
patients O 0 9.870494643848815e-09
, O 0 2.953271627248455e-09
10 O 0 7.919556566093888e-09
with O 0 1.3858592495807898e-08
isolated B-Disease 0 1.0285913049301598e-05
DMS I-Disease 1 1.0
( O 0 3.0085016078373883e-07
IDMS B-Disease 1 1.0
) O 0 2.343545979499595e-08
, O 0 7.167411553155034e-09
10 O 0 1.0942827088911145e-08
with O 0 5.389657165011386e-09
DDS B-Disease 1 1.0
, O 0 2.635206186596406e-08
and O 0 7.91620369255952e-09
4 O 0 6.831216126101936e-08
with O 0 2.3960213368923178e-08
urogenital B-Disease 1 1.0
abnormalities I-Disease 1 1.0
and O 0 1.62680203175114e-06
/ O 1 0.9998695850372314
or O 0 0.00010434339492348954
WT B-Disease 1 1.0
. O 0 1.6419959138147533e-05

We O 0 5.921533556829672e-06
report O 0 4.179148618277395e-06
WT1 O 1 0.9989111423492432
heterozygous O 0 1.5540904314548243e-06
mutations O 0 4.820141086270269e-08
in O 0 5.592941665355511e-09
16 O 0 4.827391464345965e-08
patients O 0 7.495883025399053e-09
, O 0 1.980982711202728e-09
4 O 0 2.8976820942716586e-08
of O 0 7.294588044715056e-08
whom O 0 8.829903208606993e-08
presented O 0 6.359467761285487e-07
with O 0 1.0290170848747948e-06
IDMS B-Disease 1 1.0
. O 0 5.388010686147027e-05

One O 0 2.3137010884966003e-06
male O 0 4.918192075820116e-07
and O 0 3.152262806338513e-08
two O 0 4.892528338018565e-08
female O 0 4.232632306866435e-07
IDMS B-Disease 1 1.0
patients O 0 9.270580108022841e-07
with O 0 5.42564521310851e-07
WT1 O 1 1.0
mutations O 0 0.24435341358184814
underwent O 0 0.0016467941459268332
normal O 0 3.3755159165593795e-06
puberty O 0 9.506780770607293e-06
. O 0 1.4809704680374125e-06

Two O 0 8.387405614485033e-07
mutations O 0 2.742265223787399e-07
associated O 0 2.8468980062257287e-08
with O 0 3.413184046507922e-08
IDMS B-Disease 1 1.0
are O 0 6.5051124487069956e-09
different O 0 1.3433585355215882e-09
from O 0 2.4574480228523043e-09
those O 0 3.2452238674096634e-09
described O 0 5.5043958724354525e-08
in O 0 1.783281362577327e-07
DDS B-Disease 1 1.0
patients O 0 2.6149689801968634e-05
. O 0 6.0767988543375395e-06

No O 0 6.077941361581907e-05
WT1 O 1 0.9999998807907104
mutations O 0 1.7906207858686685e-06
were O 0 4.116151330890716e-08
detected O 0 4.518664553643248e-08
in O 0 3.5597649272745002e-09
the O 0 1.819496908694873e-08
six O 0 3.060492304030049e-08
other O 0 6.154797205226714e-08
IDMS B-Disease 1 1.0
patients O 0 3.441175238094729e-07
, O 0 1.681363848149431e-08
suggesting O 0 9.268531897532739e-08
genetic O 0 1.405213225780244e-07
heterogeneity O 0 1.3853169775757124e-06
of O 0 1.7689122842057259e-06
this O 0 2.9150618274798035e-07
disease O 0 0.0005603774334304035
. O 0 3.3705046007526107e-06

We O 0 9.360071999253705e-06
analyzed O 0 1.821105252020061e-05
genotype O 0 1.1201451343367808e-05
/ O 0 4.487539627007209e-06
phenotype O 0 5.416907811195415e-07
correlations O 0 9.66056958873196e-08
, O 0 6.729937052085688e-09
on O 0 7.328682105622875e-09
the O 0 6.079736714070805e-09
basis O 0 5.8645279743529954e-09
of O 0 1.5126770946949364e-08
the O 0 2.318284941793536e-08
constitution O 0 2.9354312758300694e-08
of O 0 6.900293669787061e-08
a O 0 1.3374732077409135e-07
WT1 O 0 0.0007038630428723991
mutation O 0 6.0566485160507e-08
database O 0 2.618581795843511e-08
of O 0 8.061093126343621e-08
84 O 0 3.015424283603352e-07
germ O 0 4.974404873792082e-06
- O 0 2.436852355458541e-06
line O 0 1.1872128879986121e-06
mutations O 0 1.7241047700622403e-08
, O 0 1.6360612864474433e-09
to O 0 1.2441749852598605e-09
compare O 0 6.517631323532669e-09
the O 0 2.6046975687421536e-09
distribution O 0 2.937961873783479e-09
and O 0 1.237607127890783e-09
type O 0 2.2598872106982526e-08
of O 0 5.922071011355001e-08
mutations O 0 1.613756950291645e-08
, O 0 1.8756638464623165e-09
according O 0 1.2727642273446804e-09
to O 0 5.127332780574534e-09
the O 0 1.1472954497548926e-07
different O 0 1.6038768535509007e-07
symptoms O 0 5.049012088420568e-06
. O 0 1.4582326457457384e-06

This O 0 2.7762763465943863e-07
demonstrated O 0 1.8902520082519914e-07
( O 0 7.424594716809452e-09
1 O 0 6.38801225250063e-08
) O 0 7.037245897123512e-09
the O 0 1.340083599643549e-08
association O 0 6.365314497713825e-09
between O 0 2.5787110224939624e-09
mutations O 0 4.9278519043127744e-09
in O 0 2.1629769086928263e-09
exons O 0 1.4906781586887519e-07
8 O 0 2.3702034113171067e-08
and O 0 7.0844081712095885e-09
9 O 0 5.99363829678623e-08
and O 0 3.6756809151938796e-08
DMS B-Disease 1 0.7568104267120361
; O 0 9.391960098525942e-09
( O 0 2.904558593641582e-09
2 O 0 3.814165694393523e-08
) O 0 4.537213271760265e-09
among O 0 6.127631291263924e-09
patients O 0 6.633439131320529e-09
with O 0 6.11940853545434e-09
DMS B-Disease 1 0.9999949932098389
, O 0 4.6571788203664255e-08
a O 0 5.939273517441279e-09
higher O 0 3.805734394290994e-09
frequency O 0 7.175577909634967e-09
of O 0 2.1271912231668466e-08
exon O 0 4.082172893049574e-07
8 O 0 1.1342059025309936e-07
mutations O 0 1.9149549501662477e-08
among O 0 4.140678022679367e-09
46 O 0 6.420430764819685e-08
, O 0 3.067470188966581e-08
XY O 0 0.36953413486480713
patients O 0 2.352978967223862e-08
with O 0 3.5395348874089905e-09
female O 0 3.276434412669005e-08
phenotype O 0 1.3852673674819016e-08
than O 0 1.3680548915928625e-09
among O 0 4.4505079621615096e-09
46 O 0 8.383889849028492e-08
, O 0 3.126377734474772e-08
XY O 1 0.89500892162323
patients O 0 1.0370265535186718e-08
with O 0 2.4477924132071394e-09
sexual O 0 2.2635195051634582e-08
ambiguity O 0 3.366934038240288e-07
or O 0 1.6668067814862297e-08
male O 0 2.2268888955068178e-08
phenotype O 0 5.264243707614469e-09
; O 0 5.556584636856599e-10
and O 0 3.964061079386738e-09
( O 0 3.3895803941419445e-09
3 O 0 4.157805832960548e-08
) O 0 2.58899612859409e-09
statistically O 0 3.0727855815371186e-09
significant O 0 2.1284563000989465e-09
evidence O 0 2.812012400710273e-09
that O 0 8.058548828238088e-10
mutations O 0 3.4925713432443217e-09
in O 0 3.060759201645169e-09
exons O 0 2.5927516844603815e-07
8 O 0 5.217822973691e-08
and O 0 7.658115031006218e-09
9 O 0 8.183211974710503e-08
preferentially O 0 3.899979006405374e-08
affect O 0 9.058711114562357e-09
amino O 0 1.3066009607598517e-08
acids O 0 3.112709201502639e-09
with O 0 4.887961702060295e-10
different O 0 1.629617552012519e-09
functions O 0 2.7852655293258977e-08
. O 0 6.749865377742026e-08
. O 0 1.0875451152969617e-06

The O 0 2.077966018987354e-05
185delAG O 0 0.00013895257143303752
BRCA1 O 0 7.642658601980656e-06
mutation O 0 4.961949784387798e-08
originated O 0 9.162206993096333e-09
before O 0 1.7627862503033498e-09
the O 0 2.325147629989033e-09
dispersion O 0 3.723927832766094e-08
of O 0 2.534741305737498e-08
Jews O 0 1.089139445298315e-08
in O 0 1.3300702761398497e-09
the O 0 6.905517935251737e-09
diaspora O 0 5.789674073497508e-09
and O 0 3.6355043420144284e-09
is O 0 5.801668034877139e-09
not O 0 3.4021656603044903e-09
limited O 0 5.5953449873413774e-08
to O 0 3.2145712225428724e-07
Ashkenazim O 0 0.00024548976216465235
. O 0 1.0318323802493978e-05

The O 0 1.1013496987288818e-05
185delAG O 0 5.073419015388936e-05
mutation O 0 6.433474482037127e-07
in O 0 5.3222784401896206e-08
BRCA1 O 0 1.3379507208810537e-06
is O 0 1.1335199445738908e-08
detected O 0 1.4722823848956068e-08
in O 0 1.718784781168381e-09
Ashkenazi O 0 2.0915940979193692e-07
Jews O 0 2.81427823267677e-08
both O 0 3.6460803265470076e-09
in O 0 7.53694262556337e-09
familial B-Disease 1 0.9999964237213135
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.1033192843542565e-08
in O 0 1.0853920429099162e-08
the O 0 7.169260385353482e-08
general O 0 2.184302729801857e-07
population O 0 1.8430952763992536e-07
. O 0 1.6025787772377953e-06

All O 0 4.728462499770103e-06
tested O 0 2.0773616142832907e-06
Ashkenazi O 0 3.72268232240458e-06
mutation O 0 2.2835327229131508e-07
carriers O 0 3.9815670760390276e-08
share O 0 1.5145277032502236e-08
the O 0 1.6397514457366924e-08
same O 0 1.1150931733538982e-08
allelic O 0 3.0520914151566103e-06
pattern O 0 5.189754119783174e-07
at O 0 6.965815941839537e-07
the O 0 1.4671099961560685e-06
BRCA1 O 0 3.398425178602338e-05
locus O 0 0.00015209769480861723
. O 0 6.793048669351265e-06

Our O 0 5.35638127985294e-06
previous O 0 6.673988650618412e-07
study O 0 1.1402686084238667e-07
showed O 0 3.5589586389050964e-08
that O 0 2.3004356197731113e-09
this O 0 5.9785079109531125e-09
Ashkenazi O 0 4.601613454724429e-07
mutation O 0 2.8686466535532418e-08
also O 0 4.376080831036688e-09
occurs O 0 1.203985910969152e-09
in O 0 6.010117958865635e-10
Iraqi O 0 2.7914614619817257e-08
Jews O 0 3.220437605477855e-08
with O 0 1.313592612461889e-08
a O 0 7.4530319693622e-08
similar O 0 2.710738158384629e-07
allelic O 0 5.807044362882152e-05
pattern O 0 8.259393325715791e-06
. O 0 3.405411689527682e-06

We O 0 1.4759017403775943e-06
extended O 0 2.6877302161665284e-07
our O 0 1.0153407004054316e-08
analysis O 0 4.474903114726203e-09
to O 0 4.0415590873976726e-09
other O 0 9.914514542685993e-09
non O 0 2.1681913153770438e-07
- O 0 4.549391405817005e-07
Ashkenazi O 0 3.843934166525287e-07
subsets O 0 1.188905187632372e-07
354 O 0 4.556607535732837e-08
of O 0 1.1995076931725634e-08
Moroccan O 0 2.893979740292707e-07
origin O 0 6.158164644887165e-09
, O 0 7.549862068856328e-09
200 O 0 4.5433644402237405e-08
Yemenites O 0 2.4414071049250197e-06
and O 0 4.513875495604225e-08
150 O 0 2.629398068165756e-07
Iranian O 0 9.78498178483278e-07
Jews O 0 2.1815037598571507e-06
. O 0 3.1464298899663845e-06

Heteroduplex O 0 0.0004918081103824079
analysis O 0 1.0188324495175038e-06
complemented O 0 8.652858127788932e-07
by O 0 6.79029366068562e-09
direct O 0 1.9551352536950617e-08
DNA O 0 5.05706552189622e-08
sequencing O 0 1.4442912288359366e-07
of O 0 1.8597559403588093e-07
abnormally O 0 3.3765292073439923e-07
migrating O 0 4.978748435746638e-08
bands O 0 6.444047926379426e-07
were O 0 1.0478272116642984e-07
employed O 0 9.173119224215043e-07
. O 0 2.0025825051561696e-06

Four O 0 1.3480687357514398e-06
of O 0 5.207930371398106e-07
Moroccan O 0 1.5734626686025877e-06
origin O 0 2.931078491030803e-08
( O 0 2.6020061660858573e-09
1 O 0 1.834711937931388e-08
. O 0 1.2313039476907761e-09
1 O 0 9.243724008456411e-09
% O 0 9.54293311039578e-10
) O 0 4.982134704789587e-10
and O 0 1.4987905361252274e-09
none O 0 2.534537024700967e-09
of O 0 1.0767216451768036e-08
the O 0 2.8555177777889185e-08
Yemenites O 0 2.880281044781441e-06
or O 0 2.2841680547003307e-08
Iranians O 0 3.217754596107625e-08
was O 0 3.4506914659004906e-08
a O 0 8.611087842780307e-09
carrier O 0 3.947614146682099e-08
of O 0 1.2999022658277681e-07
the O 0 4.1836835862341104e-07
185delAG O 0 4.5227614464238286e-05
mutation O 0 2.302062284798012e-06
. O 0 1.8704901094679371e-06

BRCA1 O 0 0.00012511613022070378
allelic O 0 1.5449726561200805e-05
patterns O 0 2.850506746199244e-07
were O 0 1.4075437704264004e-08
determined O 0 6.128952012574018e-09
for O 0 1.875052335620353e-09
four O 0 2.231701046184753e-09
of O 0 6.0375344723695434e-09
these O 0 7.832991477663143e-10
individuals O 0 1.2643724955907487e-10
and O 0 5.236761024818293e-10
for O 0 9.817354706953552e-10
12 O 0 5.3473478978105504e-09
additional O 0 9.498846154087914e-09
non O 0 6.697606380612342e-08
- O 0 2.2960847445574473e-07
Ashkenazi O 0 4.496629344430403e-07
185delAG O 0 8.456447062599182e-07
mutation O 0 2.760145356717203e-08
carriers O 0 1.2481211619785881e-08
who O 0 2.3512829017136028e-08
had O 0 1.3252565622678958e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.012449112953618e-05

Six O 0 3.146717972413171e-06
non O 0 2.6137572604056913e-06
- O 0 9.87777411864954e-07
Ashkenazi O 0 5.81568599500315e-07
individuals O 0 2.8086408754290915e-09
shared O 0 5.665910851604394e-09
the O 0 1.0236281156039695e-08
common O 0 2.9634467324513025e-08
Ashkenazi O 0 4.7389175961143337e-07
haplotype O 0 9.795177220439655e-07
, O 0 1.6978347616714018e-08
four O 0 1.4640884948846633e-08
had O 0 1.578730390860983e-08
a O 0 5.122366530940781e-09
closely O 0 6.136239072418448e-09
related O 0 4.533573871867702e-08
pattern O 0 4.523856134142079e-08
, O 0 3.6386398338805748e-09
and O 0 6.566782229100454e-09
the O 0 3.8350069786474705e-08
rest O 0 1.0346640522129746e-07
( O 0 1.6596152008219178e-08
n O 0 6.939705343711466e-08
= O 0 2.647110264319963e-08
6 O 0 3.785349633744772e-08
) O 0 6.230683524677261e-09
displayed O 0 1.0653273818661546e-07
a O 0 9.895796182490812e-08
distinct O 0 7.705236271249305e-07
BRCA1 O 0 9.17206853046082e-06
allelic O 0 4.7625293518649414e-05
pattern O 0 1.1763229849748313e-05
. O 0 5.042987140768673e-06

We O 0 1.3799425460092607e-06
conclude O 0 5.171237376089266e-07
that O 0 1.444505581815747e-08
the O 0 1.7002240326746687e-07
185delAG O 0 5.0948634452652186e-05
BRCA1 O 0 4.619038463715697e-06
mutation O 0 5.0304464593864395e-08
occurs O 0 2.0638639686154647e-09
in O 0 6.924084083870241e-10
some O 0 2.226496986779125e-09
non O 0 8.234551529540113e-08
- O 0 5.065850814389705e-07
Ashkenazi O 0 4.0070818840831635e-07
populations O 0 6.906953675667182e-09
at O 0 8.232930781559844e-09
rates O 0 1.7259136342318016e-09
comparable O 0 3.922214553142567e-09
with O 0 1.1144654088468542e-09
that O 0 6.3619882695320484e-09
of O 0 5.234389846009435e-07
Ashkenazim O 0 6.037752245902084e-05
. O 0 3.6650374113378348e-06

The O 0 2.752512273218599e-06
majority O 0 2.0760694496857468e-07
of O 0 7.008455895629595e-07
Jewish O 0 1.8773973806673894e-06
185delAG O 0 9.988798410631716e-06
mutation O 0 1.484676772633975e-07
carriers O 0 2.0839397762983936e-08
have O 0 5.170356587314018e-09
a O 0 1.5160566135818954e-08
common O 0 2.9904970944016895e-08
allelic O 0 1.5544743519058102e-06
pattern O 0 1.210022020359247e-07
, O 0 7.079356656447544e-09
supporting O 0 3.561545725005999e-08
the O 0 1.1469344940451265e-07
founder O 0 8.03081206868228e-07
effect O 0 1.1220231499464717e-07
notion O 0 1.0868115651874177e-07
, O 0 4.096732730829444e-09
but O 0 1.912267899584208e-09
dating O 0 3.5405476328520535e-09
the O 0 4.077633342092213e-09
mutations O 0 1.6211293418777473e-09
origin O 0 5.658283286358312e-10
to O 0 6.741843749935583e-10
an O 0 1.9456669608786115e-09
earlier O 0 7.407196633835156e-09
date O 0 3.792938585434058e-08
than O 0 1.0248373705223912e-08
currently O 0 1.3366863527153328e-07
estimated O 0 3.5834159461956006e-07
. O 0 1.5026978417154169e-06

However O 0 1.5164636124609387e-06
, O 0 1.822526201067376e-07
the O 0 5.551526527369788e-08
different O 0 1.270625471505582e-08
allelic O 0 1.983166612262721e-06
pattern O 0 2.1465800159603532e-07
at O 0 1.4245163981740916e-07
the O 0 2.0661778421526833e-07
BRCA1 O 0 1.655703158576216e-06
locus O 0 1.0521977173993946e-06
even O 0 1.2021828865727002e-08
in O 0 3.3264808685373737e-09
some O 0 5.008920833660113e-09
Jewish O 0 3.005622417617815e-08
mutation O 0 1.1648578102096963e-08
carriers O 0 4.640665629551677e-09
, O 0 5.7024474031663885e-09
might O 0 7.615465591470638e-09
suggest O 0 7.972084326013373e-09
that O 0 1.9376045212737836e-09
the O 0 3.8067959451382194e-08
mutation O 0 7.522311307184282e-08
arose O 0 3.529922665279628e-08
independently O 0 2.450446956459018e-08
. O 0 7.384037559177159e-08
. O 0 1.7213042156072333e-06

Crystal O 0 0.00016032246639952064
structure O 0 5.800934559374582e-06
of O 0 5.660859642375726e-06
the O 0 3.5657137686939677e-06
hemochromatosis B-Disease 1 1.0
protein O 0 4.78393576486269e-06
HFE O 1 0.9808588624000549
and O 0 1.1136949495949011e-07
characterization O 0 3.7848667489015497e-07
of O 0 2.718307996474323e-07
its O 0 6.188533774320604e-08
interaction O 0 4.95692695778871e-08
with O 0 7.360429066238794e-08
transferrin O 0 1.5658742995583452e-05
receptor O 0 5.1722217904170975e-06
. O 0 2.3585268991155317e-06

HFE O 1 0.9999871253967285
is O 0 1.3090215134070604e-06
an O 0 2.494787736395665e-07
MHC O 0 3.331462721689604e-05
- O 0 9.896755273075541e-07
related O 0 2.0437971670617117e-07
protein O 0 1.3627765582668872e-08
that O 0 8.418910568686044e-10
is O 0 2.4342299287383184e-09
mutated O 0 2.8617336056413478e-08
in O 0 3.458319852711611e-09
the O 0 5.9090055515298445e-08
iron B-Disease 1 0.9999990463256836
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9994211196899414

HFE O 0 0.012201222591102123
binds O 0 1.7101750927395187e-05
to O 0 1.9349170088389656e-06
transferrin O 0 3.545816070982255e-05
receptor O 0 2.9200191420386545e-06
( O 0 9.909734899338218e-08
TfR O 0 4.647081823350163e-06
) O 0 1.1362408791626422e-08
and O 0 1.104599878232193e-08
reduces O 0 4.8131223451264304e-08
its O 0 5.037683603603682e-09
affinity O 0 1.503813962244749e-08
for O 0 1.2594827403233921e-08
iron O 0 1.8531924297349178e-06
- O 0 1.1035806437575957e-06
loaded O 0 8.006830398699094e-07
transferrin O 0 2.8730219128192402e-06
, O 0 2.6235068162350217e-07
implicating O 0 7.741391891613603e-05
HFE O 1 1.0
in O 0 9.06946570466971e-06
iron O 1 0.9999680519104004
metabolism O 0 0.0003697850333992392
. O 0 1.897915171866771e-05

The O 0 5.237354707787745e-05
2 O 0 0.00013305767788551748
. O 0 2.9067634386592545e-05

6 O 0 2.882084299926646e-05
A O 0 8.623172107036225e-06
crystal O 0 1.0279979505867232e-05
structure O 0 7.942974775687617e-07
of O 0 2.3554744075227063e-06
HFE O 1 0.9999994039535522
reveals O 0 5.50899585505249e-07
the O 0 3.543224735835793e-08
locations O 0 5.232273281308153e-08
of O 0 7.508978683290479e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 5.035985850554425e-07
and O 0 4.5615642818575e-08
a O 0 8.005061147287051e-08
patch O 1 0.9999995231628418
of O 1 0.9865410923957825
histidines O 1 0.9999065399169922
that O 0 1.0302446895593675e-08
could O 0 7.3399992750466936e-09
be O 0 3.953648075594174e-09
involved O 0 1.0170094100203642e-08
in O 0 1.7385156425575587e-08
pH O 0 1.5849063856876455e-05
- O 0 2.6977502329827985e-06
dependent O 0 7.728506830062543e-07
interactions O 0 5.633595492327004e-07
. O 0 1.022240780912398e-06

We O 0 2.124988895957358e-06
also O 0 4.409989173836948e-07
demonstrate O 0 2.8331618295851513e-07
that O 0 3.3072883098839156e-08
soluble O 0 4.236333552398719e-06
TfR O 0 2.5710964109748602e-05
and O 0 2.250309023565933e-07
HFE O 0 0.007989521138370037
bind O 0 1.7358291870550602e-07
tightly O 0 2.2714390013334196e-07
at O 0 6.879398739556564e-08
the O 0 1.7668668306214386e-08
basic O 0 7.922822931050177e-08
pH O 0 3.038274769551208e-07
of O 0 4.5206473231473865e-08
the O 0 1.5465568381500816e-08
cell O 0 1.9195811162830978e-08
surface O 0 5.95746350029458e-08
, O 0 4.639524320282362e-09
but O 0 2.0878059281415062e-09
not O 0 1.731650933756157e-09
at O 0 2.5987739959987266e-08
the O 0 9.227186126281595e-08
acidic O 0 5.455612154037226e-06
pH O 0 7.768730029056314e-06
of O 0 1.0449248293298297e-06
intracellular O 0 7.203484074125299e-06
vesicles O 0 4.014308797195554e-05
. O 0 6.04151546212961e-06

TfR O 0 0.018631132319569588
HFE O 0 0.01545765157788992
stoichiometry O 0 8.85764166014269e-05
( O 0 5.086376404506154e-07
2 O 0 8.331807634931465e-07
1 O 0 3.3927716458492796e-07
) O 0 2.4098902429159352e-08
differs O 0 6.463731239136905e-08
from O 0 3.155054173475946e-08
TfR O 0 3.0572127798222937e-06
transferrin O 0 5.845088821843092e-07
stoichiometry O 0 3.4984338981303154e-07
( O 0 3.831137629362047e-09
2 O 0 3.7338068636927346e-08
2 O 0 6.558460796668442e-08
) O 0 7.667395607313665e-09
, O 0 8.015553554230337e-09
implying O 0 2.0918449195050925e-08
a O 0 1.3378201879632456e-09
different O 0 3.3372254959473935e-10
mode O 0 1.2815147165667895e-08
of O 0 4.224165905952759e-09
binding O 0 1.5466866898350418e-08
for O 0 1.1076442874013992e-08
HFE O 1 0.5027642846107483
and O 0 8.876627788367841e-08
transferrin O 0 1.3111229009155068e-06
to O 0 3.312591090320893e-08
TfR O 0 5.455154223454883e-06
, O 0 1.1240982367155539e-08
consistent O 0 1.099760638112457e-08
with O 0 2.3763493395279056e-09
our O 0 1.328407783773855e-08
demonstration O 0 1.5493786520437425e-07
that O 0 2.7374591482498545e-08
HFE O 1 0.7241645455360413
, O 0 1.3613808391710336e-07
transferrin O 0 1.8353337054577423e-06
, O 0 6.704635779897217e-08
and O 0 6.949453990046095e-08
TfR O 0 7.541858394688461e-06
form O 0 6.413883113509655e-08
a O 0 1.8274063506851235e-07
ternary O 0 1.751914169290103e-05
complex O 0 3.56439413735643e-05
. O 0 9.606558705854695e-06

Identification O 0 1.0902004987656255e-06
of O 0 5.204037734074518e-07
three O 0 5.1503000975117175e-08
novel O 0 3.2713586506361025e-07
mutations O 0 1.3649930075132488e-08
and O 0 4.0074006335544254e-09
a O 0 4.645146933768274e-09
high O 0 6.323628554127936e-08
frequency O 0 3.0526393857144285e-08
of O 0 4.463227654127877e-08
the O 0 3.6063269703845435e-08
Arg778Leu O 0 0.00032871056464500725
mutation O 0 4.9211102748358826e-08
in O 0 4.875506220969328e-09
Korean O 0 3.400092225547269e-07
patients O 0 1.2346911937299865e-08
with O 0 2.744548410760217e-08
Wilson B-Disease 0 0.19428154826164246
disease I-Disease 0 0.2843077480792999
. O 0 6.596048024221091e-06

Four O 0 4.001569777756231e-06
mutations O 0 6.711865125907934e-07
- O 0 7.664268650842132e-07
- O 0 8.119295671349391e-07
R778L O 0 3.917958110832842e-06
, O 0 3.843706863904117e-08
A874V O 0 1.66138784152281e-06
, O 0 1.853063302803548e-08
L1083F O 0 9.84425810202083e-07
, O 0 9.627290964431268e-09
and O 0 1.306890151653306e-08
2304delC O 0 5.814499104417337e-07
- O 0 1.7613662350868253e-07
- O 0 2.2827138934644609e-07
in O 0 1.110603875531524e-08
the O 0 3.725427077938548e-08
copper O 0 1.7869041357698734e-07
- O 0 1.3555315092617093e-07
transporting O 0 2.0510529452621995e-07
enzyme O 0 3.257324010519369e-08
, O 0 7.3566361891153065e-09
P O 0 2.1680631334675127e-07
- O 0 1.656933648064296e-07
type O 0 2.8831672693740984e-07
ATPase O 0 1.2942040257257759e-06
( O 0 2.2948274391865198e-08
ATP7B O 1 0.9999958276748657
) O 0 1.237796620756626e-08
, O 0 7.954420233602377e-09
were O 0 4.7543062819954685e-09
identified O 0 7.2659656069617995e-09
in O 0 3.3848772673650274e-09
Korean O 0 4.6492269234477135e-07
Patients O 0 3.4254060921057317e-08
with O 0 2.6813495423994027e-08
Wilson B-Disease 1 0.9615140557289124
disease I-Disease 1 0.5743773579597473
. O 0 4.326801899878774e-06

Arg778Leu O 1 0.9714665412902832
, O 0 1.1439919944677968e-06
the O 0 3.1341519957095443e-07
most O 0 7.275051672195332e-08
frequently O 0 4.295634781215085e-08
reported O 0 1.4360608702190802e-08
mutation O 0 6.797394647151123e-09
of O 0 8.664664541413458e-09
this O 0 9.379603760351074e-10
enzyme O 0 6.138415997725133e-09
, O 0 2.975514723502215e-09
was O 0 1.790423986847145e-08
found O 0 1.5599885827555227e-09
in O 0 3.8450959083391467e-10
six O 0 1.4264999181889948e-09
of O 0 1.0316013820954595e-08
eight O 0 2.3377779712063784e-08
unrelated O 0 2.018349363197558e-07
patients O 0 5.540839342899062e-09
studied O 0 4.1109966986141444e-08
, O 0 2.775860874493219e-09
an O 0 5.911719114237712e-09
allele O 0 4.088733263074573e-08
frequency O 0 5.8191258034412385e-08
of O 0 2.5593382702027156e-07
37 O 0 3.2514014947082615e-06
. O 0 2.973357595692505e-06

5 O 0 3.91991670767311e-06
% O 0 2.1159301866191527e-07
, O 0 3.23726894180254e-08
which O 0 6.359744286754676e-09
is O 0 2.5170781015049215e-09
considerably O 0 4.296476507903435e-09
higher O 0 3.1833418123738966e-09
than O 0 5.648955747616924e-10
those O 0 9.687094459920331e-10
in O 0 2.3052806330525755e-09
other O 0 2.2492871565304995e-08
Asian O 0 6.48572552108817e-07
populations O 0 7.65716777095804e-07
. O 0 1.3183914688852383e-06

The O 0 5.224149390414823e-06
novel O 0 2.7656526526698144e-06
single O 0 7.253686362673761e-08
nucleotide O 0 7.586241679291561e-08
deletion O 0 1.6558469440042245e-07
, O 0 1.4784846236182148e-08
2304delC O 0 2.030728865065612e-06
, O 0 4.0314212412795314e-08
was O 0 9.98730627088662e-08
found O 0 1.5082546767075655e-08
in O 0 1.3578417501491913e-08
one O 0 1.182996811621706e-07
patient O 0 8.90864839675487e-07
. O 0 1.4672609722765628e-06

Since O 0 2.204000566052855e-06
a O 0 4.998654503651778e-07
mutation O 0 1.6659494406212616e-07
at O 0 2.1316269283033762e-07
cDNA O 0 1.3483645489031915e-06
nucleotide O 0 9.409281460648344e-07
2302 O 0 2.8923264835611917e-05
( O 0 3.074874399544569e-08
2302insC O 0 2.628380343594472e-06
) O 0 1.7689407272314384e-08
had O 0 9.693327918114392e-09
been O 0 4.452274104949083e-09
previously O 0 2.3019994799255983e-08
described O 0 6.000270058592605e-09
, O 0 2.164627810330444e-09
this O 0 9.251956978317821e-10
region O 0 1.5981047596369535e-08
of O 0 6.120426121469791e-08
the O 0 2.0348004170500644e-07
ATP7B O 1 1.0
gene O 0 1.7307958444234828e-07
may O 0 7.163762472117696e-09
be O 0 5.219801035849514e-09
susceptible O 0 3.4739844068099046e-07
to O 0 6.287643827818101e-08
gene O 0 1.3828275768901221e-06
rearrangements O 1 0.9997628331184387
causing O 1 0.9998258948326111
Wilson B-Disease 1 0.9999836683273315
disease I-Disease 1 0.9807394742965698
. O 0 9.231865988112986e-06

Disruption O 0 3.185640161973424e-05
of O 0 2.1539308363571763e-06
splicing O 0 1.1793599696829915e-06
regulated O 0 1.8312147176402505e-07
by O 0 9.537024503458724e-09
a O 0 6.698589771758634e-08
CUG O 0 0.20869180560112
- O 0 1.5860454141147784e-06
binding O 0 4.801972295354062e-07
protein O 0 4.91925220558187e-07
in O 0 2.912735794780019e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 5.402643364504911e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9650192260742188
DM B-Disease 1 1.0
) O 0 9.66736820373626e-07
is O 0 9.136958567523834e-08
caused O 0 6.682204656272006e-08
by O 0 5.430768279524045e-09
a O 0 9.215718677069162e-08
CTG O 0 0.002020954852923751
expansion O 0 2.981601312512794e-07
in O 0 9.435285441838914e-09
the O 0 1.9391917405187087e-08
3 O 0 4.5910141466265486e-08
untranslated O 0 7.106780230969889e-06
region O 0 1.3601233206372854e-07
of O 0 1.966749181292471e-07
the O 0 1.2512243756646058e-06
DM B-Disease 1 1.0
gene O 0 1.0317782653146423e-05
. O 0 3.849822860502172e-06

One O 0 1.0571574193818378e-06
model O 0 4.225550185310567e-07
of O 0 3.545655999914743e-06
DM B-Disease 1 1.0
pathogenesis O 1 1.0
suggests O 0 1.2786939862508007e-07
that O 0 4.1665364491905166e-09
RNAs O 0 2.405620023182564e-07
from O 0 8.370176551864006e-09
the O 0 1.909589819604207e-08
expanded O 0 4.6930793473620724e-08
allele O 0 1.5821818521999376e-08
create O 0 1.1141173317241737e-08
a O 0 6.149877940231363e-09
gain O 0 7.2303940612528095e-09
- O 0 5.6344884313830335e-08
of O 0 6.193823764988338e-08
- O 0 1.4184837482389412e-07
function O 0 1.7401312391029933e-08
mutation O 0 2.404755505835965e-09
by O 0 2.1178414577605054e-10
the O 0 5.126530755461545e-09
inappropriate O 0 2.6318256018953434e-08
binding O 0 8.5005122940629e-09
of O 0 1.9531151806972957e-08
proteins O 0 4.420475541166979e-09
to O 0 2.2768388063809653e-08
the O 0 8.491925314046966e-07
CUG O 1 0.9999828338623047
repeats O 0 1.6966903785942122e-05
. O 0 8.395805707550608e-06

Data O 0 2.4532166662538657e-06
presented O 0 9.621500112189096e-07
here O 0 4.051648616609782e-08
indicate O 0 3.261794034870036e-08
that O 0 3.380193236424134e-09
the O 0 3.1508683662195835e-08
conserved O 0 1.1314159564790316e-06
heterogeneous O 0 1.6636203099551494e-06
nuclear O 0 3.098263505307841e-06
ribonucleoprotein O 0 2.497947025403846e-05
, O 0 1.305794228301238e-07
CUG O 0 5.5653788876952603e-05
- O 0 2.1574409458935406e-07
binding O 0 6.358982318488415e-08
protein O 0 2.538466681301088e-08
( O 0 4.9312931515999026e-09
CUG O 1 0.9997532963752747
- O 0 2.6176062419835944e-06
BP O 0 3.643041509349132e-06
) O 0 1.117241232861943e-08
, O 0 7.918695921205199e-09
may O 0 7.985202721272344e-09
mediate O 0 5.493750165896927e-08
the O 0 3.695124206615219e-08
trans O 0 5.220301773078972e-07
- O 0 3.1782113296685566e-07
dominant O 0 3.6560481930791866e-07
effect O 0 6.424939158478082e-08
of O 0 8.311571519925565e-08
the O 0 1.882205822312244e-07
RNA O 0 1.2240208889124915e-05
. O 0 2.6115246782865142e-06

CUG O 1 1.0
- O 1 0.5662358403205872
BP O 0 0.00019732248620130122
was O 0 7.510482760153536e-07
found O 0 1.2497767265529092e-08
to O 0 3.6562548544338824e-09
bind O 0 6.1222453773268626e-09
to O 0 1.8292958259280567e-08
the O 0 2.960769620585779e-07
human O 0 2.5319470751128392e-06
cardiac O 1 0.9999997615814209
troponin O 1 0.9999996423721313
T O 1 0.8196126818656921
( O 0 4.3842959485118627e-08
cTNT O 0 2.756221192612429e-06
) O 0 1.5542662268330787e-08
pre O 0 4.1741429868125124e-07
- O 0 4.3913928493566345e-07
messenger O 0 1.615124745057983e-07
RNA O 0 1.9716507893008384e-07
and O 0 2.1137795513936908e-08
regulate O 0 1.1023819013189495e-07
its O 0 4.7269651304304716e-08
alternative O 0 5.257232942312839e-07
splicing O 0 4.3176428334845696e-06
. O 0 2.370290530961938e-06

Splicing O 0 1.8471318981028162e-05
of O 0 5.958308975095861e-06
cTNT O 0 0.0005460141110233963
was O 0 5.61200931770145e-06
disrupted O 0 9.704071089799982e-06
in O 0 1.5214030781862675e-06
DM B-Disease 1 1.0
striated O 1 1.0
muscle O 0 0.0001276470284210518
and O 0 1.526287576325558e-07
in O 0 2.0471398798349583e-08
normal O 0 9.662412736588522e-08
cells O 0 1.2682478178760448e-08
expressing O 0 2.594445192016792e-08
transcripts O 0 1.8325442852074048e-07
that O 0 3.0223219482650165e-08
contain O 0 2.3198854250949807e-06
CUG O 1 0.9999264478683472
repeats O 0 7.839985300961416e-06
. O 0 3.1491374556935625e-06

Altered O 0 8.610032637079712e-06
expression O 0 4.219296556584595e-07
of O 0 2.2627754958648438e-07
genes O 0 4.97342398375622e-08
regulated O 0 1.1096980045977034e-07
posttranscriptionally O 0 3.6366545828059316e-06
by O 0 4.289617194785933e-08
CUG O 1 1.0
- O 0 0.19033493101596832
BP O 0 6.811117054894567e-05
therefore O 0 1.0614959222721154e-07
may O 0 9.483729357384618e-09
contribute O 0 2.5191541297431286e-08
to O 0 2.301526080827898e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.9999997615814209
. O 0 1.3461853995977435e-06
. O 0 5.142872396390885e-06

Identification O 0 3.1022018447401933e-06
of O 0 1.2552567341117538e-06
a O 0 2.47891193794203e-07
novel O 0 2.5326739887532312e-06
nonsense O 0 2.2541373709827894e-06
mutation O 0 5.9407835095726114e-08
and O 0 1.2856105513492366e-08
a O 0 2.1227288371505892e-08
missense O 0 1.3160821765723085e-07
substitution O 0 3.8188535000927004e-08
in O 0 1.1600531202304865e-08
the O 0 6.78788794061802e-08
vasopressin O 0 1.7356913986077416e-06
- O 0 2.1072842173452955e-06
neurophysin O 0 0.00016507378313690424
II O 1 0.9999998807907104
gene O 0 1.0823845286722644e-07
in O 0 9.373151144131953e-09
two O 0 1.022504125813839e-08
Spanish O 0 5.83895996442152e-07
kindreds O 0 1.571155917190481e-05
with O 0 4.571581087020604e-07
familial B-Disease 1 0.9999961853027344
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 4.910206553176977e-05

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.00024946648045443
FNDI B-Disease 1 1.0
) O 0 2.682803312836768e-07
is O 0 3.134026016482494e-08
an O 0 5.5652556341101445e-08
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 9.221421919392014e-07
by O 0 2.733921533604189e-08
deficiency O 1 0.9996740818023682
in O 0 1.2866487963947293e-07
the O 0 6.2295257521327585e-06
antidiuretic O 1 0.5899762511253357
hormone O 0 2.650338956300402e-06
arginine O 0 2.1560331333603244e-06
vasopressin O 0 4.5871206566516776e-06
( O 0 1.0197797450928192e-07
AVP O 0 2.9432796509354375e-05
) O 0 5.460141228041948e-09
encoded O 0 3.1418769808055913e-09
by O 0 1.5994151558729186e-09
the O 0 5.2531529348698314e-08
AVP O 1 0.9342718124389648
- O 0 1.5160446309891995e-05
neurophysin O 1 0.9909662008285522
II O 1 1.0
( O 0 1.6277688246191246e-06
AVP O 1 0.9999997615814209
- O 0 2.8243499400559813e-05
NPII O 1 0.9997664093971252
) O 0 1.3367028373068024e-07
gene O 0 1.8791389777561562e-07
on O 0 8.028147817640274e-07
chromosome O 0 5.848423370480305e-06
20p13 O 0 7.207418093457818e-05
. O 0 4.504613571043592e-06

In O 0 2.891965493745374e-07
this O 0 1.2984671116100799e-08
study O 0 2.5784466117784177e-08
, O 0 8.303724818858882e-09
we O 0 3.418981320280068e-09
analyzed O 0 2.0675607004250196e-08
two O 0 3.1874731742931317e-09
families O 0 1.28041466318507e-09
with O 0 9.372580045408085e-09
FNDI B-Disease 1 1.0
using O 0 6.56562022527396e-08
direct O 0 3.33399050589378e-08
automated O 0 3.396390866328147e-07
fluorescent O 0 9.443135695619276e-07
, O 0 3.356450051228421e-08
solid O 0 9.00599843589589e-08
phase O 0 8.293803688275148e-08
, O 0 3.1917803955394675e-09
single O 0 4.61589566569387e-09
- O 0 3.3919619113476074e-08
stranded O 0 2.073385729772781e-08
DNA O 0 8.483876712261917e-09
sequencing O 0 1.5678523368478636e-08
of O 0 2.747492011678787e-08
PCR O 0 6.840655260020867e-07
- O 0 4.617122613126412e-06
amplified O 0 2.1075407858006656e-05
AVP O 1 0.9846957325935364
- O 0 3.403659866307862e-05
NPII O 0 0.10411378741264343
DNA O 0 5.958388101134915e-06
. O 0 2.8577735520229908e-06

In O 0 2.02077430344616e-07
one O 0 2.9654481537022548e-08
of O 0 2.9585276450916353e-08
the O 0 1.4339670784124792e-08
families O 0 5.828083571302045e-10
, O 0 1.8971584303528743e-09
affected O 0 3.3827085577087246e-09
individuals O 0 4.957895760604458e-10
presented O 0 3.123106040447965e-08
a O 0 2.6355580828862912e-08
novel O 0 3.9378915062115993e-07
nonsense O 0 4.258679666691023e-07
mutation O 0 8.50613979253012e-09
in O 0 1.952220385348369e-09
exon O 0 1.1140051014990604e-07
3 O 0 2.4524014818894102e-08
of O 0 2.700174484004947e-08
the O 0 1.0101985026267357e-08
gene O 0 4.0674810186658306e-09
, O 0 1.5433323508062813e-09
consisting O 0 4.9669655055595285e-09
in O 0 2.0903041519915178e-09
a O 0 1.2026094786676822e-08
G O 0 5.783496135336463e-07
to O 0 3.574462681399382e-08
T O 0 3.1111521821003407e-06
transition O 0 9.386215538143006e-08
at O 0 6.832844690052298e-08
nucleotide O 0 1.487352250251206e-07
2101 O 0 6.050037882232573e-06
, O 0 2.3554125760938405e-08
which O 0 5.1537267786727625e-09
produces O 0 1.5151373489175057e-08
a O 0 9.707130210756532e-09
stop O 0 8.461208267362963e-08
signal O 0 1.062804670937112e-07
in O 0 3.687823024733916e-08
codon O 0 1.0603298505884595e-06
82 O 0 1.2066760746165528e-06
( O 0 1.0636482272730063e-07
Glu O 1 0.773645281791687
) O 0 2.440186790408916e-07
of O 0 5.32012336407206e-06
NPII O 1 0.999954342842102
. O 0 1.8661192370927893e-05

The O 0 1.3405380741460249e-05
premature O 0 4.806906872545369e-06
termination O 0 6.004394208503072e-07
eliminates O 0 1.1593650697250268e-06
part O 0 1.0603405087294959e-07
of O 0 9.317790272689308e-08
the O 0 3.104605639236979e-08
C O 0 2.8346101998977247e-07
- O 0 7.44773132055343e-08
terminal O 0 8.185740796307073e-08
domain O 0 2.981873947760505e-08
of O 0 3.992030173094463e-08
NPII O 1 0.9999988079071045
, O 0 2.9576868953995472e-08
including O 0 1.290443041312983e-08
a O 0 8.182085231567271e-09
cysteine O 0 1.2159896201069387e-08
residue O 0 1.4935953629446885e-07
in O 0 3.3009213140644533e-09
position O 0 1.8893882014481278e-08
85 O 0 5.939016034517408e-08
, O 0 3.6684373316830943e-09
which O 0 1.1230648633286933e-09
could O 0 2.0781236731437502e-09
be O 0 1.0157856777937013e-09
involved O 0 3.6178098294925576e-09
in O 0 2.1588513199333192e-09
the O 0 2.3431482532032533e-08
correct O 0 7.809875768316488e-08
folding O 0 1.4507588730339194e-06
of O 0 8.249091365541972e-07
the O 0 5.182768745726207e-06
prohormone O 1 0.6215495467185974
. O 0 1.0936318176391069e-05

In O 0 7.239339083753293e-07
the O 0 4.3783123260254797e-07
second O 0 1.829718598855834e-07
family O 0 7.866506734899303e-08
, O 0 2.024876799566755e-08
a O 0 1.7488954284772262e-08
G279A O 0 5.360707859836111e-07
substitution O 0 2.0258193345057407e-08
at O 0 3.544509041830679e-08
position O 0 3.227835421171221e-08
- O 0 2.5628205335692655e-08
1 O 0 4.027263500461231e-08
of O 0 3.723196329019629e-08
the O 0 2.333990778424777e-08
signal O 0 6.572975053131813e-08
peptide O 0 6.43146194079236e-08
was O 0 4.475127468595019e-08
observed O 0 1.0187372723180488e-08
in O 0 2.4528774567045275e-09
all O 0 1.130770943547077e-08
affected O 0 6.115548956131533e-08
individuals O 0 2.155042722051803e-08
. O 0 1.1186324400114245e-06

This O 0 1.8428966086503351e-06
missense O 0 1.8673797967494465e-05
mutation O 0 2.5643859657975554e-07
, O 0 3.139757964731871e-08
which O 0 2.8754778114148394e-08
replaces O 0 5.808651621919125e-06
Ala O 0 6.385555752785876e-05
with O 0 1.3265257337025105e-07
Thr O 1 0.9999992847442627
, O 0 1.7957323450445983e-07
is O 0 1.9015139685052418e-08
frequent O 0 7.9045591405702e-08
among O 0 1.8342647933877743e-07
FNDI B-Disease 1 1.0
patients O 0 1.9233564785281487e-07
and O 0 1.0041032005858597e-08
is O 0 9.161229108656244e-09
thought O 0 1.3152622990730833e-08
to O 0 4.246842433275333e-09
reduce O 0 6.557022658171263e-08
the O 0 2.82281504837556e-08
efficiency O 0 1.236355302580705e-07
of O 0 9.292463687415875e-08
cleavage O 0 2.5523138447169913e-07
by O 0 2.3856969733060396e-08
signal O 0 1.9868125491484534e-06
peptidases O 0 2.4273766030091792e-05
. O 0 1.1648465942926123e-06
. O 0 6.546459189848974e-06

Genetic O 0 1.4531277884088922e-05
heterogeneity O 0 2.0969891920685768e-05
of O 0 7.54072925701621e-06
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.8189251821686412e-08
due O 0 8.105325122187423e-08
to O 0 6.802532936944772e-08
TWIST O 0 0.00010538102651480585
and O 0 1.1348382713549654e-06
FGFR O 1 1.0
mutations O 0 1.2867944860772695e-05
. O 0 6.141116045910167e-06

Thirty O 0 4.113359682378359e-05
- O 0 3.18821571454464e-06
two O 0 3.2237561953252225e-08
unrelated O 0 3.7015263387729647e-07
patients O 0 1.8513877098058629e-09
with O 0 2.8157090548042163e-10
features O 0 5.604701769357234e-08
of O 0 3.378872179382597e-06
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.5035960860009254e-08
a O 0 3.16907033948155e-08
common O 0 1.4921558886271669e-06
autosomal B-Disease 1 0.9987425208091736
dominant I-Disease 1 0.8891647458076477
condition I-Disease 0 1.2545755453174934e-05
of O 1 0.5851513743400574
craniosynostosis B-Disease 1 1.0
and O 1 0.8978436589241028
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9999995231628418
, O 0 5.6579544605028786e-08
were O 0 1.2666667714711366e-08
screened O 0 9.378448595498412e-08
for O 0 1.0698862240587914e-08
mutations O 0 1.854817099911088e-08
in O 0 7.700855064740608e-09
TWIST O 0 1.9573724785004742e-05
, O 0 1.6503796018696448e-07
FGFR2 O 1 0.9999990463256836
, O 0 4.820012691197917e-07
and O 0 1.4869284541418892e-06
FGFR3 O 1 0.9999983310699463
. O 0 2.442146433168091e-05

Nine O 0 7.129589903343003e-06
novel O 0 2.228364564871299e-06
and O 0 9.641443909913505e-08
three O 0 6.236452776420265e-08
recurrent O 0 0.05652778595685959
TWIST O 1 0.8245898485183716
mutations O 0 8.678826901586945e-08
were O 0 8.822963692978192e-09
found O 0 4.043602341852193e-09
in O 0 4.334446579434825e-09
12 O 0 9.476898554794388e-08
families O 0 2.5604165898585052e-08
. O 0 5.123723099131894e-07

Seven O 0 9.870175290416228e-07
families O 0 1.1059322346795852e-08
were O 0 6.040529854089982e-09
found O 0 2.127859666245513e-09
to O 0 3.6594363095332483e-09
have O 0 4.1511794002246916e-09
the O 0 9.041815474120085e-08
FGFR3 O 1 0.9999998807907104
P250R O 0 2.0527158994809724e-05
mutation O 0 3.1634176167472106e-08
, O 0 5.1932169675694695e-09
and O 0 3.4869001019899315e-09
one O 0 5.000654113018754e-09
individual O 0 2.259808562499188e-09
was O 0 1.8425147629841376e-08
found O 0 2.949978261668207e-09
to O 0 5.5055688896743504e-09
have O 0 7.52130357994929e-09
an O 0 5.2642061376673155e-08
FGFR2 O 1 0.9950976967811584
VV269 O 0 4.304453614167869e-05
- O 0 6.385590950230835e-06
270 O 0 9.405115633853711e-06
deletion O 0 1.0565905540715903e-05
. O 0 3.142183686577482e-06

To O 0 4.049659878546663e-07
date O 0 3.098264471645962e-07
, O 0 3.2114087389345514e-08
our O 0 9.362145725333448e-09
detection O 0 3.973009654600901e-08
rate O 0 7.694307413430579e-09
for O 0 3.7040344125216507e-09
TWIST O 0 3.2036380162026035e-06
or O 0 6.248335182590381e-08
FGFR O 1 0.9999784231185913
mutations O 0 8.699063158701392e-08
is O 0 5.6112021695753356e-09
68 O 0 4.250239982184212e-08
% O 0 1.6726467988448235e-09
in O 0 1.0668677052905196e-09
our O 0 1.3955543387567104e-08
Saethre B-Disease 1 0.9999986886978149
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 4.5309548113436904e-08
, O 0 5.2391015969988075e-09
including O 0 7.60556595480466e-09
our O 0 2.38229578286564e-08
five O 0 2.1179687337280484e-08
patients O 0 9.012954826914665e-09
elsewhere O 0 8.672651041763402e-09
reported O 0 1.5889742854824362e-08
with O 0 4.3056008536268564e-08
TWIST O 0 0.0005502118146978319
mutations O 0 4.948273272020742e-06
. O 0 3.444383992246003e-06

More O 0 1.9863321654156607e-07
than O 0 1.8037438209717038e-08
35 O 0 3.432272777104117e-08
different O 0 3.358177291801212e-09
TWIST O 0 5.364839239518915e-07
mutations O 0 1.1667834698414481e-08
are O 0 1.3599767978433874e-09
now O 0 3.927334901732138e-09
known O 0 1.127566306990957e-08
in O 0 5.705635075514692e-09
the O 0 1.0891939439261478e-07
literature O 0 5.872180963706342e-07
. O 0 9.586502756064874e-07

The O 0 2.25823646360368e-06
most O 0 2.0993216764964018e-07
common O 0 8.089818948064931e-08
phenotypic O 0 2.6825881604963797e-07
features O 0 1.361205477223848e-07
, O 0 6.616683645432886e-09
present O 0 3.6904879152643844e-09
in O 0 5.979770567599019e-10
more O 0 4.046454837869362e-10
than O 0 6.951104691843568e-10
a O 0 1.6011366676949024e-09
third O 0 5.900510746670307e-09
of O 0 1.867226728791138e-08
our O 0 6.230540972040899e-09
patients O 0 1.8457816386430181e-09
with O 0 1.617947553711474e-09
TWIST O 0 3.4755910746753216e-05
mutations O 0 5.468439923106416e-08
, O 0 8.407233131890735e-09
are O 0 6.855360279445222e-09
coronal B-Disease 0 6.525017670355737e-05
synostosis I-Disease 0 0.0011428091675043106
, O 0 1.1404959110450363e-07
brachycephaly B-Disease 0 7.703230949118733e-05
, O 0 1.7177607958274166e-07
low B-Disease 0 2.966739521070849e-05
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 3.7087772852828493e-06
facial B-Disease 1 0.9999998807907104
asymmetry I-Disease 1 0.5949065089225769
, O 0 5.69848054965405e-07
ptosis B-Disease 1 0.9999998807907104
, O 0 6.156042218208313e-07
hypertelorism B-Disease 1 0.9955447912216187
, O 0 4.3331883148312045e-07
broad B-Disease 0 2.4625016521895304e-05
great I-Disease 0 0.0005389272118918598
toes I-Disease 0 0.20431864261627197
, O 0 6.198799837875413e-07
and O 0 1.4204102853909717e-06
clinodactyly B-Disease 0 0.00434438232332468
. O 0 2.278780084452592e-05

Significant O 0 1.8114957129000686e-05
intra O 0 0.0001119353692047298
- O 0 6.807426871091593e-06
and O 0 3.055905040127982e-07
interfamilial O 0 3.350949918967672e-05
phenotypic O 0 5.168227744434262e-06
variability O 0 9.762015906744637e-07
is O 0 7.083732711521407e-09
present O 0 3.2648985737182556e-09
for O 0 4.809430631524947e-09
either O 0 3.04264098360818e-08
TWIST O 0 1.5879852071520872e-05
mutations O 0 3.279936890976387e-07
or O 0 2.517101620469475e-07
FGFR O 1 0.9999979734420776
mutations O 0 7.543210813309997e-06
. O 0 3.6189410366205266e-06

The O 0 1.5802387451913091e-06
overlap O 0 3.676789219753118e-07
in O 0 1.2425084072731352e-08
clinical O 0 9.354901209235322e-08
features O 0 2.824091538400353e-08
and O 0 8.328294498483046e-09
the O 0 1.858454012904076e-08
presence O 0 8.276464846801446e-09
, O 0 2.1619994683419463e-09
in O 0 7.605242546837587e-10
the O 0 2.4941766429975587e-09
same O 0 8.47140635418242e-10
genes O 0 8.147446051154361e-10
, O 0 9.966687475326808e-10
of O 0 6.922899142836059e-09
mutations O 0 1.5957919430320544e-09
for O 0 5.801875091471231e-10
more O 0 3.5974195844445944e-10
than O 0 8.30205793000971e-10
one O 0 3.494703415540812e-09
craniosynostotic B-Disease 0 1.327346126345219e-06
condition I-Disease 0 3.759016919957503e-08
- O 0 4.914572571124154e-08
such O 0 1.3754678285238242e-08
as O 0 2.780907237820429e-08
Saethre B-Disease 0 3.184777233400382e-05
- I-Disease 0 1.022919491333596e-06
Chotzen I-Disease 0 7.771324453642592e-05
, I-Disease 0 2.6291063548455895e-08
Crouzon I-Disease 0 1.2671021977439523e-05
, I-Disease 0 2.8767503934545857e-08
and I-Disease 0 4.6961954325297484e-08
Pfeiffer I-Disease 1 0.9376067519187927
syndromes I-Disease 0 2.182136449846439e-05
- O 0 2.0593556371295563e-07
support O 0 2.0361351715791898e-08
the O 0 2.8386564210336473e-08
hypothesis O 0 2.552322797555462e-08
that O 0 1.2762745305039402e-09
TWIST O 0 4.6241856921369617e-07
and O 0 1.5681992593385985e-08
FGFRs O 0 5.158045041753212e-06
are O 0 2.0304991021902197e-09
components O 0 1.741535804455907e-08
of O 0 2.4934076137128613e-08
the O 0 1.2392989745535488e-08
same O 0 3.4416256511349275e-09
molecular O 0 3.211438937000821e-08
pathway O 0 8.088858471921867e-09
involved O 0 7.327378703791965e-10
in O 0 5.218892540348463e-10
the O 0 9.966446334885859e-09
modulation O 0 1.6817925825307611e-06
of O 0 7.585989806102589e-06
craniofacial O 1 1.0
and O 0 2.6055937269120477e-05
limb O 1 0.999998927116394
development O 0 1.778797127371945e-07
in O 0 3.2895030699364725e-08
humans O 0 8.644332183393999e-08
. O 0 5.857722840119095e-08
. O 0 7.636791679033195e-07

Mutation O 0 4.256963620719034e-06
analysis O 0 2.2422030099278345e-07
of O 0 1.3228070656623458e-06
UBE3A O 1 1.0
in O 1 0.9995146989822388
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 9.578539174981415e-05
. O 0 5.662149760610191e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00012379007239360362
AS B-Disease 1 1.0
) O 0 3.0370523518286063e-07
is O 0 4.8956739107097746e-08
caused O 0 5.172351436044664e-08
by O 0 1.5712531720168954e-08
chromosome O 0 1.5688027588112163e-06
15q11 O 0 9.289074114349205e-06
- O 0 1.9014286181118223e-06
q13 O 0 5.191791387915146e-06
deletions O 0 3.553011254098237e-07
of O 0 1.4828088978902088e-07
maternal O 0 9.142153345464976e-08
origin O 0 7.498571541475485e-09
, O 0 3.5853040536437675e-09
by O 0 4.20384660415607e-09
paternal O 0 3.8038822367525427e-06
uniparental B-Disease 1 0.9999997615814209
disomy I-Disease 1 1.0
( O 0 2.9908676424383884e-06
UPD B-Disease 1 1.0
) O 0 5.4231737323107154e-08
15 O 0 4.597919556204033e-08
, O 0 3.6967999772485882e-09
by O 0 2.4534483333837898e-09
imprinting O 0 8.232812433561776e-06
defects O 0 0.00013650048640556633
, O 0 8.9741698516832e-09
and O 0 6.047238709783187e-09
by O 0 7.010251490413566e-09
mutations O 0 3.479135557427071e-08
in O 0 2.9250134758740387e-08
the O 0 9.676047056927928e-07
UBE3A O 1 0.9999988079071045
gene O 0 8.015479579626117e-06
. O 0 4.326157977629919e-06

UBE3A O 1 0.9487900733947754
encodes O 0 3.813538569374941e-05
a O 0 1.635430749047373e-06
ubiquitin O 0 6.486594429588877e-06
- O 0 2.142495077350759e-06
protein O 0 3.652562838851736e-07
ligase O 0 6.367344553837029e-07
and O 0 5.748172782205074e-08
shows O 0 2.4964083422673866e-07
brain O 0 4.448102572496282e-06
- O 0 2.414443997622584e-06
specific O 0 1.8112269799530623e-06
imprinting O 0 5.0932459998875856e-05
. O 0 5.268498171062674e-06

Here O 0 3.356454953973298e-06
we O 0 3.938469603781414e-07
describe O 0 1.6945629113251925e-06
UBE3A O 1 0.8973167538642883
coding O 0 0.00010861265764106065
- O 0 0.0001450078998459503
region O 0 2.198420816057478e-06
mutations O 0 9.3979842574754e-08
detected O 0 2.2641758690156166e-08
by O 0 2.9324862538260277e-09
SSCP O 0 0.0005149642238393426
analysis O 0 6.2544853740575945e-09
in O 0 3.419424743356103e-09
13 O 0 5.4027104567921924e-08
AS B-Disease 0 0.11562961339950562
individuals O 0 9.478232421145094e-09
or O 0 3.175653873199735e-08
families O 0 3.0953280827361596e-08
. O 0 5.445062924991362e-07

Two O 0 1.4631361864303472e-06
identical O 0 1.1975334928138182e-06
de O 0 1.0856781955226324e-05
novo O 0 6.652505362580996e-06
5 O 0 1.168520498140424e-06
- O 0 1.282513267142349e-06
bp O 0 1.1142042239953298e-06
duplications O 0 2.2627828002441674e-06
in O 0 6.390108353571122e-08
exon O 0 3.839589226117823e-06
16 O 0 3.811097428751964e-07
were O 0 9.902479547463372e-08
found O 0 2.7051856932303053e-07
. O 0 1.1314094763292815e-06

Among O 0 1.4513428823192953e-06
the O 0 1.4135439130313898e-07
other O 0 3.2722002885066104e-08
11 O 0 2.7134273494766603e-08
unique O 0 2.542299348817778e-08
mutations O 0 1.525393500401151e-08
, O 0 4.195083835867308e-09
8 O 0 2.676740429308211e-08
were O 0 9.751406793157003e-09
small O 0 2.5599625530503545e-08
deletions O 0 1.317517472898544e-07
or O 0 2.7494840182384905e-08
insertions O 0 3.446203322710062e-07
predicted O 0 7.965096671114225e-08
to O 0 3.111078328288386e-08
cause O 0 4.797586825588951e-07
frameshifts O 0 3.092620681854896e-05
, O 0 3.647897628411556e-08
1 O 0 1.3575056811987452e-07
was O 0 6.386038364780688e-08
a O 0 6.178895617381386e-09
mutation O 0 2.7103792543670124e-09
to O 0 2.4476525251060366e-09
a O 0 6.450944223246324e-09
stop O 0 2.8533563067867362e-08
codon O 0 5.360339372373346e-08
, O 0 3.16329540339666e-09
1 O 0 2.3571384843990018e-08
was O 0 3.6167350003779575e-08
a O 0 1.2009796712675325e-08
missense O 0 1.6448862538709363e-07
mutation O 0 7.968527171442474e-09
, O 0 2.5923563296004204e-09
and O 0 5.042971373825367e-09
1 O 0 1.755774974299129e-07
was O 0 1.9115600480290595e-07
predicted O 0 3.6234052203099054e-08
to O 0 8.439267951132479e-09
cause O 0 1.8932011514039004e-08
insertion O 0 4.6215269833282946e-08
of O 0 7.103963639565336e-08
an O 0 2.6901862071326832e-08
isoleucine O 0 5.686337772203842e-06
in O 0 1.637676128041221e-08
the O 0 8.438659904186352e-08
hect O 0 1.8625119082571473e-06
domain O 0 4.1686128327000915e-08
of O 0 5.648315237749557e-08
the O 0 1.0155928720223528e-07
UBE3A O 0 0.0049742599949240685
protein O 0 2.8186349254610832e-08
, O 0 3.313992413822575e-09
which O 0 1.1155372181548273e-09
functions O 0 1.1495621343726725e-08
in O 0 6.372068206417225e-09
E2 O 0 6.152054083941039e-06
binding O 0 1.167988585848434e-07
and O 0 6.115828909969423e-08
ubiquitin O 0 5.729351869376842e-06
transfer O 0 5.480371783050941e-06
. O 0 5.885300197405741e-06

Eight O 0 1.1072429515479598e-06
of O 0 1.8736433560206933e-07
the O 0 3.292472072757846e-08
cases O 0 6.176962941140118e-09
were O 0 4.408442944026092e-09
familial O 0 1.2219554719195003e-06
, O 0 2.5034529116396698e-08
and O 0 4.86213593831053e-08
five O 0 9.808528744770229e-08
were O 0 9.49653085058344e-08
sporadic O 0 9.236039659299422e-06
. O 0 7.572776212327881e-06

In O 0 7.279714964170125e-07
two O 0 1.3140930832378217e-07
familial O 0 4.159065611020196e-06
cases O 0 6.505660365974109e-08
and O 0 3.131689396695947e-08
one O 0 2.7659107004751604e-08
sporadic O 0 3.4379672797513194e-07
case O 0 1.4244294277432346e-07
, O 0 3.9805190255037814e-08
mosaicism O 0 1.9774952306761406e-05
for O 0 1.7479025871125486e-07
UBE3A O 1 1.0
mutations O 0 2.648863528520451e-07
was O 0 4.313796608812481e-08
detected O 0 8.039730658992994e-09
in O 0 6.158537013689624e-10
the O 0 3.3696234691404925e-09
mother O 0 2.739672710916352e-09
of O 0 8.02689026357939e-09
three O 0 5.7496500893705615e-09
AS B-Disease 1 1.0
sons O 0 1.870852628371722e-07
, O 0 4.420323662657211e-09
in O 0 1.5011880627469054e-09
the O 0 6.0584950389852565e-09
maternal O 0 1.7430709320365168e-08
grandfather O 0 2.382413732959776e-08
of O 0 2.9745233831590667e-08
two O 0 6.35851948871391e-09
AS B-Disease 1 1.0
first O 0 3.2473057132165195e-08
cousins O 0 1.349663563132708e-07
, O 0 6.9910632838343645e-09
and O 0 3.29405969168306e-09
in O 0 4.481992998961459e-09
the O 0 2.611822935705277e-08
mother O 0 3.517609670211641e-08
of O 0 6.766016724668589e-08
an O 0 8.611009150172322e-08
AS B-Disease 1 1.0
daughter O 0 4.9911814130609855e-05
. O 0 9.007438166008797e-06

The O 0 7.276271958289726e-07
frequencies O 0 1.335219934617271e-07
with O 0 4.941386411161375e-09
which O 0 4.659308938670392e-09
we O 0 5.290656357459511e-09
detected O 0 1.8052549677349816e-08
mutations O 0 4.16312051498835e-09
were O 0 2.4374589013831383e-09
5 O 0 1.6957150350549455e-08
( O 0 1.7701412557968865e-09
14 O 0 1.1924134568630507e-08
% O 0 1.0405131201096651e-09
) O 0 6.905184757322047e-10
of O 0 7.35256833195308e-09
35 O 0 2.4284206645575068e-08
in O 0 2.4743325166554087e-09
sporadic O 0 6.864404156203818e-08
cases O 0 6.0190226136569436e-09
and O 0 5.5930908793300205e-09
8 O 0 4.13483967065531e-08
( O 0 2.0919275200981247e-09
80 O 0 1.7481918135331398e-08
% O 0 1.1333010085934347e-09
) O 0 8.707105592087316e-10
of O 0 6.122140572273338e-09
10 O 0 9.536896605766287e-09
in O 0 5.5138293930667714e-09
familial O 0 5.071477744422737e-07
cases O 0 6.594888191102655e-08
. O 0 9.132672573741729e-08
. O 0 1.030911903399101e-06

The O 0 0.00012882211012765765
hemochromatosis B-Disease 1 1.0
845 O 0 0.0007522089290432632
G O 0 7.903584628365934e-05
- O 0 3.3801127301558154e-06
- O 0 1.6645533378323307e-06
> O 0 3.4934197401526035e-07
A O 0 1.3796962150536274e-07
and O 0 1.228709844980358e-08
187 O 0 1.5825688137738325e-07
C O 0 8.048247082115267e-07
- O 0 8.423028248216724e-07
- O 0 3.0016117307241075e-06
> O 0 1.3369430007514893e-06
G O 0 4.1493317439744715e-06
mutations O 0 2.662457987412381e-08
: O 0 2.9011535396250565e-09
prevalence O 0 4.964789823702631e-08
in O 0 5.2559365748550135e-09
non O 0 7.522123723902041e-07
- O 0 7.745810762571637e-06
Caucasian O 0 1.8700029613683e-05
populations O 0 6.777705152671842e-07
. O 0 1.0767554385893163e-06

Hemochromatosis B-Disease 1 1.0
, O 0 2.7366011181584327e-06
the O 0 9.975798457162455e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9997426867485046
, O 0 1.0725202059802541e-07
leads O 0 2.6604760705595254e-07
, O 0 2.0148526402863354e-08
if O 0 2.3277936023191614e-08
untreated O 0 0.06662995368242264
, O 0 1.234754787304837e-08
to O 0 7.218202568992638e-08
progressive O 1 0.9995641112327576
iron B-Disease 1 1.0
overload I-Disease 1 0.9999991655349731
and O 0 9.617357136448845e-06
premature B-Disease 0 3.651912629720755e-05
death I-Disease 0 1.2658170817303471e-05
. O 0 4.723964138975134e-06

The O 0 5.224563938099891e-05
hemochromatosis B-Disease 1 1.0
gene O 0 6.726514584443066e-06
, O 0 1.036373987517436e-06
HFE O 1 1.0
, O 0 6.388426072589937e-07
recently O 0 3.5206241477681033e-07
has O 0 1.9876068790836143e-08
been O 0 5.987911055882478e-09
identified O 0 3.3106439811803057e-09
, O 0 1.6476260356057537e-09
and O 0 3.799315528851821e-09
characterization O 0 5.945748426938735e-08
of O 0 1.7238919269857433e-07
this O 0 8.33725710691624e-09
gene O 0 2.8600256385402645e-08
has O 0 6.3675975603416646e-09
shown O 0 1.4945029658264275e-09
that O 0 5.852423545782415e-10
it O 0 9.724007155043068e-10
contains O 0 6.905083171915294e-09
two O 0 1.2493470702423792e-09
mutations O 0 2.8123987583228427e-09
that O 0 6.210013059337882e-10
result O 0 3.6763805333350774e-09
in O 0 5.291120874773014e-09
amino O 0 3.372904444631786e-08
acid O 0 2.8349392167115184e-08
substitutions O 0 7.950707470172347e-08
- O 0 1.7068914814899472e-07
cDNA O 0 3.4853729857786675e-07
nucleotides O 0 7.804737833794206e-08
845 O 0 8.536607651876693e-07
G O 0 5.188135787648207e-07
- O 0 1.9985252208698512e-07
- O 0 3.351361499426275e-07
> O 0 1.373811358007515e-07
A O 0 1.300133050108343e-07
( O 0 6.206676506081976e-09
C282Y O 0 3.501945684547536e-07
) O 0 2.655852648913992e-09
and O 0 3.9027825415871575e-09
187 O 0 8.105836002414435e-08
C O 0 3.664432597361156e-07
- O 0 3.378480926130578e-07
- O 0 2.0688803488155827e-06
> O 0 1.6371816400351236e-06
G O 0 1.097082258638693e-05
( O 0 2.0215203733187082e-07
H63D O 0 0.4796420931816101
) O 0 1.1135712156828959e-06
. O 0 2.740913487286889e-06

Although O 0 0.00011372260632924736
hemochromatosis B-Disease 1 1.0
is O 0 5.80268306293874e-07
common O 0 1.447606337023899e-07
in O 0 2.9027271253312392e-08
Caucasians O 0 6.320231932477327e-06
, O 0 5.719541107396253e-08
affecting O 0 2.3595634957018774e-07
> O 0 2.033372652476828e-07
= O 0 2.6478019776732253e-08
1 O 0 6.151756792860397e-08
/ O 0 6.711135114301214e-08
300 O 0 1.3729490433433966e-08
individuals O 0 5.054331397857936e-10
of O 0 5.4079558609032574e-09
northern O 0 1.73675243075877e-08
European O 0 1.6307998507159027e-08
origin O 0 2.364729301262969e-09
, O 0 1.2490850576085677e-09
it O 0 1.14450349197881e-09
has O 0 1.4975675144413003e-09
not O 0 7.275099966896903e-10
been O 0 4.048997137573451e-09
recognized O 0 1.3903839857221101e-08
in O 0 7.732131379611928e-09
other O 0 5.307112971308925e-08
populations O 0 4.581802954817249e-07
. O 0 1.5929714436424547e-06

The O 0 5.142961072124308e-06
present O 0 3.122266605259938e-07
study O 0 6.794208218252606e-08
used O 0 1.118870418537199e-08
PCR O 0 1.2305045515859092e-07
and O 0 1.4155021155204395e-08
restriction O 0 6.528457419108236e-08
- O 0 1.0219234525266074e-07
enzyme O 0 1.2858117237612987e-08
digestion O 0 1.2481711664236173e-08
to O 0 1.9243382443079327e-09
analyze O 0 1.4601341469244744e-08
the O 0 8.562249576016256e-09
frequency O 0 1.5666088870602835e-08
of O 0 3.006086402024266e-08
the O 0 3.6536217606908394e-08
845 O 0 1.3100592468617833e-06
G O 0 8.518318850292417e-07
- O 0 1.5905214922895539e-07
- O 0 2.9883651109230414e-07
> O 0 7.644982957799584e-08
A O 0 5.941984682067414e-08
and O 0 2.8886968372887623e-09
187 O 0 3.610297838463339e-08
C O 0 1.953518165009882e-07
- O 0 2.0574140080498182e-07
- O 0 1.0063926083603292e-06
> O 0 8.726963187655201e-07
G O 0 3.105280029558344e-06
mutations O 0 2.9923686639676816e-08
in O 0 7.321542483396115e-09
HLA O 0 1.5168920072028413e-05
- O 0 6.428267624869477e-07
typed O 0 1.3016564537338127e-07
samples O 0 4.595523961370418e-09
from O 0 1.720326325838073e-09
non O 0 7.762797338273231e-08
- O 0 2.544107076118962e-07
Caucasian O 0 7.417810365950572e-07
populations O 0 1.2008216643266678e-08
, O 0 2.8353921432966445e-09
comprising O 0 7.214496999807807e-09
Australian O 0 3.548445803858158e-08
Aboriginal O 0 1.4976345141803904e-07
, O 0 1.084827161434987e-08
Chinese O 0 6.486467896138493e-08
, O 0 2.2215012052129168e-08
and O 0 9.994928262813119e-08
Pacific O 0 3.949674010073068e-06
Islanders O 0 2.620805571496021e-05
. O 0 6.381334969773889e-06

Results O 0 1.222214109475317e-06
showed O 0 1.3945597743258986e-07
that O 0 9.181660765023025e-09
the O 0 9.779611076510264e-08
845 O 0 3.371655338924029e-06
G O 0 5.705006969947135e-06
- O 0 1.2083665978934732e-06
- O 0 1.4837879689366673e-06
> O 0 2.336321074380976e-07
A O 0 1.1385430553900733e-07
mutation O 0 7.621133057966745e-09
was O 0 8.592826006292853e-09
present O 0 1.2723953002335975e-09
in O 0 8.427280540068693e-10
these O 0 1.3146747024350702e-09
populations O 0 2.613685268215704e-09
( O 0 6.516608364037779e-10
allele O 0 2.0325374716634315e-09
frequency O 0 2.6216688819857836e-09
0 O 0 2.691729505954754e-09
. O 0 3.9367004101009684e-10
32 O 0 3.963607220214271e-09
% O 0 4.897900973688252e-10
) O 0 6.215629677619461e-10
, O 0 1.1487570894530563e-09
and O 0 2.0854060700514765e-09
, O 0 3.1220679375110194e-09
furthermore O 0 9.189439431622759e-09
, O 0 2.1362733804153322e-09
it O 0 2.8588789113825896e-09
was O 0 4.775958117875234e-08
always O 0 2.457730374771927e-08
seen O 0 1.9945337825788556e-08
in O 0 2.3211774724529732e-09
conjunction O 0 5.277345493936991e-08
with O 0 2.8235099591711332e-08
HLA O 1 0.999320387840271
haplotypes O 0 2.3223271909955656e-06
common O 0 8.239516802177604e-08
in O 0 1.4857158170400453e-08
Caucasians O 0 4.140538578667474e-07
, O 0 1.886277267715286e-08
suggesting O 0 2.620835282129974e-08
that O 0 3.679263560485424e-09
845 O 0 1.3038894621786312e-06
G O 0 7.416666903736768e-06
- O 0 3.073343350479263e-06
- O 0 9.502312423137482e-06
> O 0 7.981853968885844e-07
A O 0 5.14785995164857e-07
may O 0 5.582144968485636e-09
have O 0 1.2689586048608703e-09
been O 0 2.856425984631983e-09
introduced O 0 5.252809742728459e-09
into O 0 3.0736471146042277e-09
these O 0 1.8860100148287984e-09
populations O 0 6.666136975752579e-09
by O 0 7.591811623797184e-09
Caucasian O 0 6.1218906921567395e-06
admixture O 0 2.4737100829952396e-05
. O 0 5.81978611080558e-06

187 O 0 1.552825233375188e-05
C O 0 8.433803486695979e-06
- O 0 2.8495574042608496e-06
- O 0 3.111763362539932e-06
> O 0 8.388461765207467e-07
G O 0 1.1639781405392569e-06
was O 0 3.254064040447702e-08
present O 0 4.74360861701939e-09
at O 0 1.4817282512069596e-08
an O 0 5.0813220298095985e-09
allele O 0 2.291284850741704e-08
frequency O 0 7.405377289160242e-08
of O 0 2.5839074169198284e-07
2 O 0 4.768903636431787e-06
. O 0 3.3741898732841946e-06

68 O 0 1.0964494322251994e-05
% O 0 9.96042572865008e-08
in O 0 9.405171752518982e-09
the O 0 3.120599245676203e-08
two O 0 8.998679135174825e-09
populations O 0 1.5936878483557848e-08
analyzed O 0 5.122095814158456e-08
( O 0 8.513703519952287e-09
Australian O 0 8.582217247976587e-08
Aboriginal O 0 1.8614379371229006e-07
and O 0 2.1475747402632805e-08
Chinese O 0 3.7585800782835577e-07
) O 0 4.40434860138339e-07
. O 0 2.7510479867487447e-06

In O 0 1.2635753137146821e-06
the O 0 7.749215455987724e-07
Australian O 0 6.641290042352921e-07
Aboriginal O 0 3.1966351343726274e-07
samples O 0 3.4948381966160014e-08
, O 0 6.362850246688367e-09
187 O 0 4.045840995559047e-08
C O 0 4.0961967329167237e-07
- O 0 7.68002905715548e-07
- O 0 3.573035883164266e-06
> O 0 6.76079082495562e-07
G O 0 3.951090548071079e-06
was O 0 4.355680971457332e-08
found O 0 2.1649044779081805e-09
to O 0 1.2914123104224018e-09
be O 0 1.4077981003168816e-09
associated O 0 7.01160196570072e-09
with O 0 2.8091674764141317e-08
HLA O 1 0.9999998807907104
haplotypes O 0 4.8815195441420656e-06
common O 0 8.968252274144106e-08
in O 0 1.0863096200353084e-08
Caucasians O 0 8.33288765988982e-07
, O 0 1.6446346506882037e-08
suggesting O 0 1.404944693916832e-08
that O 0 1.6866469332299516e-09
it O 0 5.348632647894647e-09
was O 0 6.962788035025369e-08
introduced O 0 2.1909679404075177e-08
by O 0 1.0361546287640522e-08
recent O 0 3.080181159020867e-07
admixture O 0 1.4098072824708652e-05
. O 0 4.898765382677084e-06

In O 0 1.0553583251748933e-06
the O 0 4.0277328139382007e-07
Chinese O 0 1.1826312373841574e-07
samples O 0 2.0822511714868597e-08
analyzed O 0 1.4353818578172195e-08
, O 0 4.254203656017808e-09
187 O 0 4.974116407652218e-08
C O 0 1.6218544374169142e-07
- O 0 1.7374357241806138e-07
- O 0 5.407168259807804e-07
> O 0 2.0703394909560302e-07
G O 0 1.2818665027225506e-06
was O 0 3.2355529810956796e-08
present O 0 3.18318371661519e-09
in O 0 1.572145746919773e-09
association O 0 1.9679597951238748e-09
with O 0 7.840076365894788e-10
a O 0 6.61095622689345e-09
wide O 0 1.1227295715343644e-07
variety O 0 1.5344913606440969e-07
of O 0 6.943106996004644e-07
HLA O 1 0.9999992847442627
haplotypes O 0 7.406817417177081e-07
, O 0 1.550127315397276e-08
showing O 0 1.5124433261348713e-08
this O 0 1.5764757277381136e-09
mutation O 0 2.802454934780485e-09
to O 0 1.9708032983345447e-09
be O 0 2.3566695261934e-09
widespread O 0 2.713277424959415e-08
and O 0 9.90833282088488e-09
likely O 0 9.460369376768085e-09
to O 0 9.01018637478046e-09
predate O 0 5.313777933224628e-07
the O 0 5.216231002691529e-08
more O 0 8.073230084448824e-09
genetically O 0 5.9341694225167885e-08
restricted O 0 5.043550999062063e-08
845 O 0 1.365493858429545e-06
G O 0 3.1885683711152524e-06
- O 0 1.6817573396110674e-06
- O 0 3.73867464986688e-06
> O 0 1.6424111208834802e-06
A O 0 2.593382077975548e-06
mutation O 0 1.2480638815759448e-06
. O 0 9.683977850727388e-07

Genotype O 0 0.00020659319125115871
- O 0 2.636407589307055e-05
phenotype O 0 3.928052137780469e-06
correlations O 0 2.8558692974911537e-06
in O 0 7.79448612320266e-07
attenuated B-Disease 1 0.9255126714706421
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.00036586823989637196

Germ O 0 0.0028499378822743893
- O 0 1.416518625774188e-05
line O 0 2.3024399524729233e-06
mutations O 0 1.424385942527806e-07
of O 0 9.791276056603238e-08
the O 0 1.935792397489422e-07
tumor B-Disease 1 0.8913627862930298
suppressor O 1 0.999254047870636
APC O 0 4.9634338211035356e-05
are O 0 2.572281943002963e-08
implicated O 0 4.6375052420444263e-07
in O 0 9.082001639626469e-08
attenuated B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.07836265861988068
AAPC B-Disease 1 1.0
) O 0 7.061235152150402e-08
, O 0 1.2226550438754202e-08
a O 0 1.59126702925505e-08
variant O 0 1.2096511454728898e-06
of O 0 2.9829998311470263e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0002806521370075643
FAP B-Disease 1 1.0
) O 0 4.186480055068387e-06
. O 0 6.669676622550469e-06

AAPC B-Disease 1 1.0
is O 0 2.810153773680213e-06
recognized O 0 5.304765409164247e-07
by O 0 1.249261938340851e-08
the O 0 8.316233390814887e-08
occurrence O 0 2.48412078462934e-07
of O 0 3.256989202782279e-07
< O 0 2.7510268409969285e-06
100 O 0 6.049842795619043e-07
colonic B-Disease 1 0.980459451675415
adenomas I-Disease 0 0.0003098027955275029
and O 0 3.3392854703606645e-08
a O 0 1.8615617491946068e-08
later O 0 2.8896680603907043e-08
onset O 0 8.501608022015716e-07
of O 0 4.0933871787274256e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.466378555889605e-08
age O 0 7.00939821740576e-08
> O 0 6.835360721879624e-08
40 O 0 5.367173372405887e-08
years O 0 4.280210319507205e-08
) O 0 1.9918807936392113e-07
. O 0 1.933823114086408e-06

The O 0 3.052365173061844e-06
aim O 0 2.3752415927447146e-06
of O 0 2.990737186792103e-07
this O 0 1.127174975579237e-08
study O 0 2.6748010029109537e-08
was O 0 3.457220287828022e-08
to O 0 9.48239087250613e-09
assess O 0 4.956798989041999e-07
genotype O 0 9.345874332211679e-07
- O 0 1.4251946822696482e-06
phenotype O 0 4.851103767578024e-07
correlations O 0 9.065021231435821e-07
in O 0 3.9136833152042527e-07
AAPC B-Disease 1 1.0
families O 0 1.7163473557957332e-06
. O 0 3.412798150748131e-06

By O 0 2.078531906590797e-07
protein O 0 1.5745419545964978e-07
- O 0 4.0360149000662204e-07
truncation O 0 1.2806029872081126e-06
test O 0 1.0207721601318553e-07
( O 0 2.1811944250771376e-08
PTT O 0 2.4925337129388936e-05
) O 0 8.92793661222413e-09
assay O 0 2.2662238308157612e-08
, O 0 4.367541883709691e-09
the O 0 3.6974208139639586e-09
entire O 0 1.6392949220289665e-08
coding O 0 6.628749815718038e-08
region O 0 4.6447244272940225e-08
of O 0 7.407214042132182e-08
the O 0 1.0140713868622697e-07
APC B-Disease 0 3.953295617975527e-06
gene O 0 2.4943778598185418e-08
was O 0 2.6395223784447808e-08
screened O 0 4.160114031037665e-08
in O 0 3.2968692220691764e-09
affected O 0 9.81941905564554e-09
individuals O 0 5.580375606051291e-10
from O 0 6.912567851458107e-09
11 O 0 6.362245699165214e-07
AAPC B-Disease 1 1.0
kindreds O 0 2.2686930606141686e-05
, O 0 2.4851935620517907e-08
and O 0 9.611237139495188e-09
their O 0 2.133851495500494e-08
phenotypic O 0 1.5355819869000698e-06
differences O 0 6.588897463188914e-07
were O 0 1.816525809772429e-07
examined O 0 2.3869863525760593e-06
. O 0 2.1593398287222954e-06

Five O 0 3.757035074158921e-06
novel O 0 5.941332346992567e-06
germ O 0 3.7988163967384025e-05
- O 0 7.338290743064135e-06
line O 0 6.836991360614775e-06
APC B-Disease 0 8.492981578456238e-06
mutations O 0 7.435467352934211e-08
were O 0 1.6109737543956726e-08
identified O 0 3.364153755569532e-08
in O 0 2.3664993520355893e-08
seven O 0 8.062413030529569e-07
kindreds O 0 9.184522787109017e-05
. O 0 5.007404070056509e-06

Mutations O 0 2.0472689357120544e-06
were O 0 4.180748192084138e-08
located O 0 5.2563397190397154e-08
in O 0 1.7266116314473834e-09
three O 0 6.482503978055831e-10
different O 0 4.784678764302441e-10
regions O 0 4.515397389326381e-09
of O 0 2.396642884150424e-08
the O 0 5.979684658541373e-08
APC B-Disease 0 1.674098712101113e-06
gene O 0 9.65660529317347e-09
( O 0 1.654191450484177e-09
1 O 0 2.3553676342658036e-08
) O 0 1.2009905292487133e-09
at O 0 1.3842795354435111e-08
the O 0 5.0692792186168845e-09
5 O 0 1.591036458137296e-08
end O 0 1.2072472799218303e-08
spanning O 0 4.353687543812157e-08
exons O 0 1.1413435174745246e-07
4 O 0 3.107040313921061e-08
and O 0 3.977883356043321e-09
5 O 0 2.0705442693724763e-08
, O 0 5.8883911080442886e-09
( O 0 1.901679702598358e-09
2 O 0 3.0282247820423436e-08
) O 0 3.3591702752744368e-09
within O 0 6.942217911642956e-09
exon O 0 1.4591242347705702e-07
9 O 0 4.006638221198955e-08
, O 0 2.9476723284460604e-09
and O 0 1.7383025019412912e-09
( O 0 1.2106362579089591e-09
3 O 0 1.2032175256138089e-08
) O 0 1.3723723268910248e-09
at O 0 1.239138303077425e-08
the O 0 7.778564459215431e-09
3 O 0 5.3270920119530274e-08
distal O 0 6.411289632524131e-07
end O 0 9.224212504932439e-08
of O 0 2.908952296820644e-07
the O 0 5.411703227764519e-07
gene O 0 8.614357511760318e-07
. O 0 1.8929285943158902e-06

Variability O 0 2.3793296350049786e-05
in O 0 4.0883978869032944e-08
the O 0 4.023892685722785e-08
number O 0 2.6844094946909536e-08
of O 0 0.0005251982365734875
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.46738505363464355
most O 0 2.2805460631047936e-08
apparent O 0 4.2814349399122875e-08
in O 0 1.40498157552571e-09
individuals O 0 4.533612374402196e-10
with O 0 1.2034233609625744e-09
mutations O 0 6.712835620703572e-09
in O 0 2.206875127086505e-09
region O 0 4.988291735230632e-08
1 O 0 3.796427847646555e-07
, O 0 1.541203253907497e-08
and O 0 1.9152508912156918e-08
upper O 0 4.159473974141292e-06
- O 0 0.48626893758773804
gastrointestinal O 1 1.0
manifestations O 0 0.2636318802833557
were O 0 4.928578434260089e-08
more O 0 9.996717231786079e-09
severe O 0 3.890855566623941e-07
in O 0 2.3404727045317486e-08
them O 0 9.676300294358953e-08
. O 0 1.1655921525743906e-06

In O 0 3.102226173723466e-07
individuals O 0 1.0693537610961812e-08
with O 0 5.863174834530582e-09
mutations O 0 1.058131804398954e-08
in O 0 2.007451982422026e-09
either O 0 4.262862507431464e-09
region O 0 2.7516612988165434e-08
2 O 0 1.1523088971898687e-07
or O 0 7.715439842570504e-09
region O 0 2.5109894608021932e-08
3 O 0 5.7945602094378046e-08
, O 0 4.897856786811872e-09
the O 0 6.962240561847466e-09
average O 0 5.133458547135206e-09
number O 0 7.721623340728456e-09
of O 0 8.76301058383433e-08
adenomas B-Disease 0 0.0002606305934023112
tended O 0 1.6834344762628461e-07
to O 0 1.1901003738046256e-08
be O 0 3.751122523709682e-09
lower O 0 1.0852575726971736e-08
than O 0 1.1424750034905173e-09
those O 0 6.208283886977028e-10
in O 0 5.384127033103425e-10
individuals O 0 1.9435923703792213e-10
with O 0 9.279508828008431e-10
mutations O 0 4.931961061771517e-09
in O 0 1.896557799696552e-09
region O 0 1.8810890622944498e-08
1 O 0 6.00850640353201e-08
, O 0 7.221642839283504e-09
although O 0 7.220581910161172e-09
age O 0 3.168490181337802e-08
at O 0 1.0519323012658788e-07
diagnosis O 0 8.476665129819594e-07
was O 0 3.573631772724184e-07
similar O 0 2.8352971526146575e-07
. O 0 1.7583984117663931e-06

In O 0 2.2135341168905143e-06
all O 0 2.4534083422622643e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.00014516465307679027
, O 0 1.9975325926679943e-07
a O 0 5.9691323883726e-08
predominance O 0 1.8774223917716881e-06
of O 0 1.0274061423842795e-06
right O 0 5.999258974043187e-06
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999717473983765
rectal B-Disease 1 1.0
polyp I-Disease 1 1.0
sparing O 0 6.148139800643548e-05
was O 0 6.2150224948709365e-06
observed O 0 2.279699401697144e-06
. O 0 2.3832924398448085e-06

No O 0 0.00010917618783423677
desmoid B-Disease 1 1.0
tumors I-Disease 1 1.0
were O 0 3.4624608247213473e-07
found O 0 6.363932669728456e-08
in O 0 3.3746676564305744e-08
these O 0 1.363830364198293e-07
kindreds O 0 5.929561666562222e-05
. O 0 5.202248757996131e-06

Our O 0 3.302470986454864e-06
data O 0 4.3556897821872553e-07
suggest O 0 5.885295095708898e-08
that O 0 2.6885893511519043e-09
, O 0 1.0956632046088544e-08
in O 0 2.7488495035754568e-08
AAPC B-Disease 1 1.0
families O 0 8.00606514417268e-09
, O 0 4.382144869197191e-09
the O 0 7.456981698794607e-09
location O 0 3.410580973195465e-08
of O 0 8.718181732092489e-08
the O 0 4.4926812847734254e-07
APC B-Disease 0 0.01147250086069107
mutation O 0 3.4313180208300764e-07
may O 0 2.681257349479438e-08
partially O 0 4.624119753771083e-07
predict O 0 1.1080018680331705e-07
specific O 0 1.1334382321592784e-07
phenotypic O 0 6.888050847919658e-06
expression O 0 2.1500459297385532e-06
. O 0 2.9607347187265987e-06

This O 0 3.3434159263379115e-07
should O 0 4.500722283751202e-08
help O 0 2.761498585357458e-08
in O 0 4.516215401650925e-09
the O 0 1.2763969436946354e-08
design O 0 6.465038637770704e-08
of O 0 3.691137351324869e-08
tailored O 0 8.251705452266833e-08
clinical O 0 7.366249406004499e-07
- O 0 5.739917128266825e-07
management O 0 8.017805441795645e-08
protocols O 0 1.2058174547746603e-07
in O 0 3.281110938502252e-09
this O 0 1.3897603068357967e-09
subset O 0 6.627902138234276e-08
of O 0 1.290032543010966e-07
FAP B-Disease 1 0.9999995231628418
patients O 0 3.3433329349463747e-07
. O 0 1.5886476489868073e-07
. O 0 1.3333560673345346e-06

Wilms B-Disease 1 1.0
' I-Disease 0 0.00010915160964941606
tumor I-Disease 0 0.0003509476373437792
1 O 0 1.6656777006573975e-06
and O 0 1.71446785657281e-07
Dax O 1 0.999995231628418
- O 0 7.369573040705291e-07
1 O 0 5.140202006259642e-07
modulate O 0 3.717087508903205e-07
the O 0 7.476182162236e-08
orphan O 0 6.462165629272931e-07
nuclear O 0 3.9246606320375577e-07
receptor O 0 2.2803401122928335e-07
SF O 1 0.9999997615814209
- O 0 8.56906297030946e-07
1 O 0 2.2165031055010331e-07
in O 0 9.39004340949623e-09
sex O 0 1.0387151583302057e-08
- O 0 2.991290060094798e-08
specific O 0 3.937620363103633e-08
gene O 0 1.474311801530348e-07
expression O 0 3.966816564116016e-07
. O 0 9.830411045186338e-07

Products O 0 5.210074050410185e-06
of O 0 2.2152785277285147e-06
steroidogenic O 0 7.601666584378108e-05
factor O 0 1.2186166031824541e-06
1 O 0 7.335872851399472e-07
( O 0 5.109567169370166e-08
SF O 1 1.0
- O 0 1.45868614254141e-06
1 O 0 2.872395157282881e-07
) O 0 1.779628000520006e-08
and O 0 4.167173983660177e-08
Wilms B-Disease 1 1.0
tumor I-Disease 1 0.5742868781089783
1 O 0 1.5345367501140572e-06
( O 0 7.42614147952736e-08
WT1 O 0 0.01476916205137968
) O 0 1.1741373207030392e-08
genes O 0 3.3863170045833613e-09
are O 0 3.6837347061613457e-10
essential O 0 5.78475134460632e-09
for O 0 7.1218013708573835e-09
mammalian O 0 4.832955937672523e-07
gonadogenesis O 0 5.792410775029566e-06
prior O 0 9.108838838756128e-08
to O 0 8.120071726125389e-08
sexual O 0 4.971840326106758e-07
differentiation O 0 1.3390202866503387e-06
. O 0 2.1673117771570105e-06

In O 0 1.5290950159396743e-06
males O 0 6.740274329786189e-07
, O 0 2.6715946432886994e-07
SF O 1 1.0
- O 0 2.8425760319805704e-05
1 O 0 1.1386291589587927e-06
participates O 0 2.3130164095164218e-07
in O 0 4.5289820782556944e-09
sexual O 0 5.079364484572579e-09
development O 0 9.591143435017102e-10
by O 0 4.295531985665235e-10
regulating O 0 6.927393059186215e-08
expression O 0 9.76667013929955e-09
of O 0 3.151745886498247e-08
the O 0 7.379771460591655e-08
polypeptide O 0 2.042831965809455e-06
hormone O 0 4.617553770458471e-07
Mullerian O 0 2.20949477807153e-05
inhibiting O 0 1.2929727972732508e-06
substance O 0 7.455091690644622e-07
( O 0 1.127985100879414e-07
MIS O 1 0.9999463558197021
) O 0 6.751970431650989e-07
. O 0 2.876695816667052e-06

Here O 0 1.2241295053172507e-06
, O 0 1.9178102661498997e-07
we O 0 3.5231291661830255e-08
show O 0 8.983112564919793e-08
that O 0 5.8925056833913914e-08
WT1 O 1 0.6897385716438293
- O 0 6.756866059731692e-05
KTS O 1 0.9864713549613953
isoforms O 0 1.43955423936859e-06
associate O 0 7.966492603372899e-07
and O 0 9.906957387784132e-08
synergize O 0 3.971835394622758e-05
with O 0 4.2544499478935904e-07
SF O 1 1.0
- O 0 1.6532841982552782e-05
1 O 0 1.5602503253830946e-06
to O 0 1.3328840964277333e-07
promote O 0 5.4482602536154445e-06
MIS O 1 0.9999995231628418
expression O 0 3.611989768614876e-06
. O 0 2.008994442803669e-06

In O 0 2.1030762127338676e-06
contrast O 0 2.407066176601802e-06
, O 0 2.1697624106309377e-06
WT1 O 1 0.9999984502792358
missense O 0 3.554137219907716e-05
mutations O 0 4.788975047631538e-07
, O 0 1.905195112783531e-08
associated O 0 1.3798404197018499e-08
with O 0 2.3803835347280256e-08
male B-Disease 0 5.051484208706825e-07
pseudohermaphroditism I-Disease 1 1.0
in O 0 7.259706791273857e-08
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 8.870703993579809e-08
fail O 0 1.6601097740931436e-07
to O 0 9.31939041493024e-08
synergize O 0 0.00010050620039692149
with O 0 1.3096332622808404e-06
SF O 1 1.0
- O 1 0.8961696624755859
1 O 0 6.165566446725279e-05
. O 0 7.11080747350934e-06

Additionally O 0 7.590303084725747e-06
, O 0 3.304854772068211e-07
the O 0 1.2517597269834368e-07
X O 0 6.473456323874416e-06
- O 0 9.222715107171098e-07
linked O 0 5.288752618071157e-07
, O 0 1.530668569671434e-08
candidate O 0 1.5118837737304602e-08
dosage O 0 4.957485089107649e-07
- O 0 2.533739120735845e-07
sensitive O 0 7.995743089850293e-07
sex O 0 2.408557620015017e-08
- O 0 6.599242396987393e-08
reversal O 0 7.366889320792325e-08
gene O 0 2.113231367673052e-08
, O 0 2.0176059933874058e-08
Dax O 1 0.9998290538787842
- O 0 5.148866648596595e-07
1 O 0 2.933602161192539e-07
, O 0 3.9682838348653604e-08
antagonizes O 0 1.7043976185959764e-06
synergy O 0 8.826382327242754e-07
between O 0 6.456239987073786e-08
SF O 1 1.0
- O 0 1.459999907638121e-06
1 O 0 4.2735945271488163e-07
and O 0 4.823599297765213e-08
WT1 O 1 0.9742962718009949
, O 0 3.159642858463485e-08
most O 0 1.0899291247312703e-08
likely O 0 4.121216257146898e-09
through O 0 2.523225850481481e-09
a O 0 3.250526514619878e-09
direct O 0 9.33009403070173e-09
interaction O 0 3.227373923664345e-08
with O 0 6.620170012183735e-08
SF O 1 1.0
- O 0 0.0011482540285214782
1 O 0 3.5989913158118725e-05
. O 0 5.844035513291601e-06

We O 0 1.2866098586528096e-06
propose O 0 1.399942107127572e-06
that O 0 9.841830461709833e-08
WT1 O 1 0.9994122982025146
and O 0 1.5275937812475604e-06
Dax O 1 1.0
- O 0 4.063756477989955e-06
1 O 0 8.327048703904438e-07
functionally O 0 2.34967856727053e-07
oppose O 0 1.1195322002777175e-08
each O 0 1.0148851758984279e-09
other O 0 1.6253276502453673e-09
in O 0 3.892322908427559e-09
testis O 0 7.10615893240174e-07
development O 0 1.1896328366844955e-08
by O 0 5.899070121273553e-09
modulating O 0 6.295297680480871e-06
SF O 1 1.0
- O 0 5.990654244669713e-05
1 O 0 6.8934396040276624e-06
- O 0 3.853929229080677e-06
mediated O 0 3.3803996757342247e-06
transactivation O 0 2.710042826947756e-05
. O 0 5.425945914794283e-07
. O 0 3.1259091883839574e-06

A O 0 2.4030290660448372e-05
mouse O 0 7.883870239311364e-06
model O 0 3.4169855211985123e-07
for O 0 3.513687829581613e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9980521202087402
- O 1 0.57220858335495
centre O 0 0.00013857784506399184
mutations O 0 2.632725454532192e-06
. O 0 1.3161101151126786e-06

Imprinting O 0 0.00019138511561322957
in O 0 8.101752655420569e-07
the O 0 9.11516281121294e-07
15q11 O 0 2.5431601898162626e-05
- O 0 3.2460973216075217e-06
q13 O 0 1.0467587344464846e-05
region O 0 2.2731467197445454e-07
involves O 0 5.7626412086619894e-08
an O 0 9.423811064834808e-09
imprinting O 0 1.5442672065546503e-06
centre O 0 1.88633657671744e-06
( O 0 3.218816502226218e-08
IC O 0 2.6740297471405938e-05
) O 0 1.0988841836478969e-08
, O 0 4.895932548265591e-09
mapping O 0 7.2793513439251e-09
in O 0 1.7346757363867482e-09
part O 0 1.2805154270267849e-08
to O 0 1.0467241295941676e-08
the O 0 3.728071362729679e-08
promoter O 0 2.7195419534109533e-06
and O 0 6.668415863941846e-08
first O 0 3.4848213203986234e-07
exon O 0 1.094495746656321e-05
of O 0 1.021206935547525e-05
SNRPN O 1 1.0
. O 0 1.3302809747983702e-05

Deletion O 0 9.736948413774371e-05
of O 0 5.686809799954062e-06
this O 0 3.532974517383991e-07
IC O 0 0.0002308965049451217
abolishes O 0 2.318705628567841e-05
local O 0 3.7041007772131707e-07
paternally O 0 3.387848437341745e-06
derived O 0 7.407171409568036e-08
gene O 0 2.5466428965614796e-08
expression O 0 1.1349110096148252e-08
and O 0 3.3861946580060476e-09
results O 0 7.715910577132945e-09
in O 0 2.9956865432723134e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 6.269297591643408e-05
PWS B-Disease 1 1.0
) O 0 4.186400474281982e-06
. O 0 6.225486686162185e-06

We O 0 7.211582442323561e-07
have O 0 1.935038618228191e-08
created O 0 4.203383952017248e-08
two O 0 1.1059237969845981e-08
deletion O 0 3.175211986672366e-07
mutations O 0 3.046450558485958e-08
in O 0 5.031068006644546e-09
mice O 0 1.024460587473186e-07
to O 0 2.6362418026337764e-08
understand O 0 3.607259486670955e-07
PWS B-Disease 1 1.0
and O 0 2.865765509341145e-07
the O 0 2.1737814392963628e-07
mechanism O 0 2.4879520310605585e-07
of O 0 2.571811705820437e-07
this O 0 2.1305700670382066e-07
IC O 0 0.0015582273481413722
. O 0 9.038519237947185e-06

Mice O 0 0.000944213243201375
harbouring O 0 0.00022392391110770404
an O 0 7.181179739745858e-07
intragenic O 0 0.0002345836255699396
deletion O 0 5.951710136287147e-06
in O 0 1.4437843276482454e-07
Snrpn O 1 0.9921532273292542
are O 0 5.404957192922666e-08
phenotypically O 0 1.771113375070854e-06
normal O 0 4.8336566749185295e-08
, O 0 4.9554591541323134e-09
suggesting O 0 9.144608625888395e-09
that O 0 1.2481919942075592e-09
mutations O 0 1.1370169694657761e-08
of O 0 5.0075957602757626e-08
SNRPN O 1 0.9999860525131226
are O 0 5.6587072805314165e-09
not O 0 2.2241413155654755e-09
sufficient O 0 4.744651604937644e-08
to O 0 1.791404855566725e-07
induce O 0 3.597944669309072e-05
PWS B-Disease 1 1.0
. O 0 5.7426786952419207e-05

Mice O 0 1.130126020143507e-05
with O 0 5.7220727711637664e-08
a O 0 1.0307246611773735e-07
larger O 0 2.535063572395302e-07
deletion O 0 6.322579224615765e-07
involving O 0 9.90229054309566e-08
both O 0 4.8511495265302074e-08
Snrpn O 0 4.3028856453020126e-05
and O 0 9.724293192903133e-08
the O 0 4.018026231733529e-07
putative O 0 6.0169164498802274e-05
PWS O 1 1.0
- O 0 0.007532489486038685
IC O 1 0.8029323220252991
lack O 0 4.0113874888447754e-07
expression O 0 5.4390433490425494e-08
of O 0 7.050549299947306e-08
the O 0 9.682484858331009e-08
imprinted O 0 1.0820496072483365e-06
genes O 0 1.5619818327650137e-07
Zfp127 O 0 1.7944663341040723e-05
( O 0 3.1411477863230175e-08
mouse O 0 9.383884957969713e-07
homologue O 0 1.5072705537022557e-06
of O 0 2.1177066855671e-07
ZNF127 O 1 0.9999998807907104
) O 0 9.403775891314581e-08
, O 0 1.8159506964821048e-07
Ndn O 0 6.495150591945276e-05
and O 0 1.7440228816667513e-07
Ipw O 0 1.8152137272409163e-05
, O 0 8.39810141428643e-08
and O 0 3.850567864560617e-08
manifest O 0 2.2146438993786433e-07
several O 0 2.4779279073072757e-08
phenotypes O 0 1.4220421462596278e-06
common O 0 2.7552857773116557e-07
to O 0 1.1109851811852423e-06
PWS B-Disease 1 1.0
infants O 1 0.8080783486366272
. O 0 7.706618816882838e-06

These O 0 3.0500180514536623e-07
data O 0 4.626139826768849e-08
demonstrate O 0 1.4009041926499322e-08
that O 0 1.2812256811045586e-09
both O 0 2.050910552497953e-09
the O 0 1.116133674372577e-08
position O 0 2.69343622960605e-08
of O 0 3.631652845115241e-08
the O 0 2.7400711033465086e-08
IC O 0 1.6472471543238498e-05
and O 0 1.5259347563301162e-08
its O 0 9.793009958514176e-09
role O 0 2.822228317711506e-08
in O 0 5.046088435989304e-09
the O 0 1.2035364704843232e-08
coordinate O 0 3.603638276672427e-08
expression O 0 2.192213699458989e-08
of O 0 2.9759419817310118e-08
genes O 0 8.899475822943259e-09
is O 0 2.390692754872248e-09
conserved O 0 3.4253144320928186e-08
between O 0 4.278314591488197e-09
mouse O 0 1.9397378991925507e-07
and O 0 7.377080724069174e-09
human O 0 1.2211239130976992e-08
, O 0 2.104132423852434e-09
and O 0 2.5578088536093446e-09
indicate O 0 4.237739492651826e-09
that O 0 1.1103321595484772e-09
the O 0 1.8167435555938027e-08
mouse O 0 2.513266110781842e-07
is O 0 4.780539519799731e-09
a O 0 2.929624098868544e-09
suitable O 0 2.206493121548192e-08
model O 0 6.637780547436023e-09
system O 0 7.557383163714348e-09
in O 0 8.484422608923126e-10
which O 0 8.174406151972846e-10
to O 0 2.709821034230231e-09
investigate O 0 2.7714344597029594e-08
the O 0 1.3402752685465202e-08
molecular O 0 5.9201511248829775e-08
mechanisms O 0 2.891206385413625e-08
of O 0 5.322217333514345e-08
imprinting O 0 4.389140428884275e-07
in O 0 4.173909662341657e-09
this O 0 2.779272811892497e-09
region O 0 4.369027450934482e-08
of O 0 1.2152158035405591e-07
the O 0 1.1754126916230234e-07
genome O 0 3.249146516282053e-07
. O 0 1.4224055178146955e-07
. O 0 1.1192694273631787e-06

Mutations O 0 5.72059434489347e-06
of O 0 1.858179530245252e-06
the O 0 1.0655747928467463e-06
ATM O 0 0.0032959431409835815
gene O 0 4.6229598638092284e-07
detected O 0 2.380615740094072e-07
in O 0 3.361793332601337e-08
Japanese O 0 0.00014470500173047185
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 1.6760061498644063e-06
: O 0 8.230983894463861e-09
possible O 0 1.7212791192378063e-08
preponderance O 0 1.1660891914289095e-06
of O 0 3.3437029856031586e-07
the O 0 1.4286413829722733e-07
two O 0 5.3634689578530015e-08
founder O 0 6.395121999958064e-06
mutations O 0 8.37092841265985e-07
4612del165 O 0 1.615113069419749e-05
and O 0 1.0147946341021452e-06
7883del5 O 0 0.0003010669315699488
. O 0 1.4683929293823894e-05

The O 0 6.575309726031264e-06
ATM O 0 0.017748000100255013
( O 0 5.375245564209763e-07
A O 1 1.0
- O 1 0.9999997615814209
T O 1 1.0
, O 0 1.0425940644154252e-07
mutated O 0 1.5698309141498612e-07
) O 0 9.947093815299013e-09
gene O 0 2.18101554594341e-08
on O 0 8.392112249566708e-08
human O 0 2.2502896968035202e-07
chromosome O 0 2.3716131636319915e-06
11q22 O 0 3.9924558222992346e-05
. O 0 2.5783244836929953e-06

3 O 0 1.4121123058430385e-05
has O 0 3.4215409527860174e-07
recently O 0 1.1060592441936024e-07
been O 0 1.512633929223739e-08
identified O 0 9.468998918293892e-09
as O 0 4.049390600613378e-09
the O 0 1.0430809105343997e-08
gene O 0 4.664840069779075e-09
responsible O 0 5.008883086077276e-09
for O 0 2.0634507436056992e-09
the O 0 2.2228192619877518e-08
human O 0 1.309007757299696e-06
recessive B-Disease 1 0.9999979734420776
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 5.5448126659030095e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.0619237400533166e-06
. O 0 2.5531492156005697e-06

In O 0 3.1553403800899105e-07
order O 0 6.037974031869453e-08
to O 0 1.996265552861587e-08
define O 0 5.17779028541554e-08
the O 0 6.484746073454062e-09
types O 0 4.506769357703888e-08
of O 0 1.1104412322993085e-07
disease O 0 0.24941499531269073
- O 0 5.241595772531582e-06
causing O 0 2.313363438588567e-06
ATM O 0 4.4446951505960897e-05
mutations O 0 2.828376999275406e-08
in O 0 3.1107563192023235e-09
Japanese O 0 2.893805799430993e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.289477845669353e-08
as O 0 3.7714964484791835e-09
well O 0 3.043991947393465e-09
as O 0 2.47937803621312e-09
to O 0 3.6750413823227746e-09
look O 0 1.0023408769654907e-08
for O 0 1.0204389333523523e-08
possible O 0 8.031029352650876e-08
mutational O 0 1.0905875569733325e-05
hotspots O 0 2.505271368136164e-06
, O 0 2.9090678310694784e-08
reverse O 0 5.9243983940859835e-08
- O 0 1.5234067518576921e-07
transcribed O 0 9.694571190266288e-08
RNA O 0 7.369742149876402e-08
derived O 0 2.8269895313570714e-09
from O 0 1.1076163319856391e-09
ten O 0 2.3475010380025196e-08
patients O 0 3.027674999600549e-09
belonging O 0 3.495416844856436e-09
to O 0 3.664611725184841e-09
eight O 0 3.200682741066885e-08
unrelated O 0 2.247079322614809e-07
Japanese O 0 4.818271008844022e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999983310699463
T I-Disease 1 1.0
families O 0 9.886774066103499e-09
was O 0 1.733680932147763e-08
analyzed O 0 7.205421148626101e-09
for O 0 1.871175880907572e-09
mutations O 0 3.6661149671601834e-09
by O 0 1.1098452157298766e-09
the O 0 5.120103452327385e-08
restriction O 0 1.7129838170149014e-07
endonuclease O 0 4.655279099097243e-06
fingerprinting O 0 2.7035348466597497e-06
method O 0 8.445357480013627e-07
. O 0 1.2447711696950137e-06

As O 0 3.171028538417886e-06
has O 0 2.215381158521268e-07
been O 0 2.9213058638788425e-08
reported O 0 1.1680548972492488e-08
by O 0 1.9882011592642357e-09
others O 0 1.3418432587286588e-08
, O 0 1.231227209075314e-08
mutations O 0 1.2403158500262634e-08
that O 0 1.6933450197598177e-09
lead O 0 2.656750908158756e-08
to O 0 5.9437983424004415e-08
exon O 0 1.421205797669245e-05
skipping O 0 3.6802452996198554e-06
or O 0 7.141909463825868e-08
premature O 0 1.1351387030344995e-07
protein O 0 8.670301809843295e-09
truncation O 0 1.9551285390662088e-07
were O 0 1.2411015326563302e-08
also O 0 1.4552379745680355e-08
predominant O 0 4.13568471913095e-07
in O 0 2.999339798748224e-08
our O 0 2.94398887490388e-07
mutants O 0 4.258519311406417e-06
. O 0 1.830599899221852e-06

Six O 0 7.365835017481004e-07
different O 0 1.5701028033276998e-08
mutations O 0 1.9280941288002396e-08
were O 0 2.7677404812465056e-09
identified O 0 5.337656983073202e-09
on O 0 1.9805225903724022e-08
12 O 0 5.381955858752008e-08
of O 0 7.937101287325277e-08
the O 0 1.673912350952378e-07
16 O 0 1.3252565622678958e-06
alleles O 0 1.1613923334152787e-06
examined O 0 5.942998086538864e-06
. O 0 3.057346930290805e-06

Four O 0 1.4649344848294277e-06
were O 0 1.0243569903423122e-07
deletions O 0 9.227676400769269e-07
involving O 0 1.8960420788971533e-07
a O 0 5.310860018425956e-08
loss O 0 6.181998628562724e-07
of O 0 7.307419309654506e-07
a O 0 9.983097015719977e-08
single O 0 8.926612338200357e-08
exon O 0 1.9955098196078325e-06
exon O 0 2.4598982690804405e-06
7 O 0 4.829034878639504e-07
, O 0 4.4688327704989206e-08
exon O 0 1.5872770973146544e-06
16 O 0 3.8262547263911983e-07
, O 0 8.850846455743522e-08
exon O 0 5.418466116680065e-06
33 O 0 1.9545018403732684e-06
or O 0 2.4607612658655853e-07
exon O 0 2.0196341210976243e-05
35 O 0 8.650186828162987e-06
. O 0 5.003222213417757e-06

The O 0 2.837682359313476e-06
others O 0 2.8274476449041686e-07
were O 0 7.570442761561935e-08
minute O 0 1.0236739171887166e-06
deletions O 0 1.7126913007814437e-06
, O 0 2.282039162082583e-07
4649delA O 0 4.1503608372295275e-06
in O 0 8.819905161772112e-08
exon O 0 4.519175035966327e-06
33 O 0 1.0686217137845233e-06
and O 0 1.7162771825951495e-07
7883del5 O 0 9.643735211284366e-06
in O 0 7.036650799818744e-07
exon O 0 8.716603770153597e-05
55 O 0 2.055681761703454e-05
. O 0 7.04729427525308e-06

The O 0 6.327843038889114e-06
mutations O 0 7.237129580062174e-07
4612del165 O 0 6.312966888799565e-06
and O 0 8.1438500387776e-08
7883del5 O 0 2.8685892630164744e-06
were O 0 1.5124491881124413e-08
found O 0 2.2821287082308572e-09
in O 0 3.6381450629896506e-10
more O 0 2.0051357796369018e-10
than O 0 5.93325832909386e-10
two O 0 7.924719214180698e-10
unrelated O 0 2.341874960620771e-08
families O 0 3.204589094085719e-10
; O 0 3.5246983109971097e-10
44 O 0 5.045010631476998e-09
% O 0 7.809213276033233e-10
( O 0 3.243446067280331e-10
7 O 0 1.1079422712612086e-08
of O 0 7.161631287999626e-09
16 O 0 7.995931916582322e-09
) O 0 1.50141143961946e-09
of O 0 1.7391556639267947e-08
the O 0 1.7953174946683248e-08
mutant O 0 1.3610160465304944e-07
alleles O 0 5.15980547177719e-09
had O 0 2.2695274548567568e-09
one O 0 2.2015904654892893e-09
of O 0 1.8945485180665855e-08
the O 0 6.918110528886245e-08
two O 0 8.142389873455613e-08
mutations O 0 7.732074891464435e-07
. O 0 1.0400176506664138e-06

The O 0 1.1589999303396326e-05
4612del165 O 0 4.689090565079823e-05
mutations O 0 1.1590936566108212e-07
in O 0 3.134909221103044e-09
three O 0 1.2800482895869436e-09
different O 0 2.3101343060716317e-10
families O 0 1.7675931551774937e-10
were O 0 5.853819096124369e-10
all O 0 1.4681258431181732e-09
ascribed O 0 5.546869275008248e-08
to O 0 6.458158452460339e-09
the O 0 3.2957139239897515e-08
same O 0 1.4480033172503681e-08
T O 0 1.7527912632431253e-06
- O 0 6.91727848334267e-07
- O 0 8.126328907565039e-07
> O 0 1.969576004512419e-07
A O 0 4.985020041203825e-08
substitution O 0 2.1207902989317517e-08
at O 0 3.70549919637142e-08
the O 0 3.371309276190004e-08
splice O 0 1.995498223550385e-06
donor O 0 7.068201313131794e-08
site O 0 5.317042450769804e-07
in O 0 2.0354953278456378e-07
intron O 0 9.959952876670286e-05
33 O 0 3.586228922358714e-05
. O 0 9.320087883679662e-06

Microsatellite O 0 0.0004781018942594528
genotyping O 0 4.631229239748791e-05
around O 0 8.383231602238084e-07
the O 0 8.693893391864549e-07
ATM O 0 0.030377408489584923
locus O 0 5.095951200928539e-05
also O 0 9.176376636332861e-08
indicated O 0 2.9783723931586792e-08
that O 0 2.5651960555705955e-09
a O 0 9.278345203256322e-09
common O 0 3.7210309500324e-08
haplotype O 0 9.020221227729053e-07
was O 0 9.13361262178114e-08
shared O 0 1.547607375584903e-08
by O 0 4.103966944057902e-09
the O 0 7.687416569979177e-08
mutant O 0 8.627109195913363e-07
alleles O 0 3.7145142073313764e-08
in O 0 1.2004231386697484e-08
both O 0 1.3654310748734133e-07
mutations O 0 1.4352798416439327e-06
. O 0 1.596294282535382e-06

This O 0 2.2236721974877582e-07
suggests O 0 8.807196394400307e-08
that O 0 2.0849169057868266e-09
these O 0 2.334764603872941e-09
two O 0 6.660900719879237e-09
founder O 0 4.797522592525638e-07
mutations O 0 5.660815105557049e-08
may O 0 1.1230739893619557e-08
be O 0 6.525280760172336e-09
predominant O 0 2.804737846417993e-07
among O 0 2.627958295420285e-08
Japanese O 0 3.394007990209502e-07
ATM O 0 3.045734774786979e-05
mutant O 0 1.3283492080518045e-05
alleles O 0 1.6640630065012374e-06
. O 0 1.258752376998018e-06

W474C O 0 0.00035522435791790485
amino O 0 2.938506440841593e-06
acid O 0 1.5428452115884284e-07
substitution O 0 3.5985141977334933e-08
affects O 0 1.0230658986642993e-08
early O 0 9.158917513296672e-10
processing O 0 7.47498152264825e-09
of O 0 1.462291354670242e-08
the O 0 1.8377379618073064e-08
alpha O 0 4.708366319050583e-08
- O 0 2.2402273813781903e-08
subunit O 0 1.6234817934446255e-08
of O 0 8.86008155731588e-09
beta O 0 7.703415860760288e-08
- O 0 8.449129040855041e-08
hexosaminidase O 0 2.4880546334316023e-06
A O 0 9.48385974197663e-08
and O 0 9.007059986743116e-09
is O 0 4.303932321647608e-09
associated O 0 4.807449549559806e-09
with O 0 2.446398106314973e-08
subacute O 1 0.999983549118042
G B-Disease 1 0.9995369911193848
( I-Disease 0 2.755730008630053e-07
M2 I-Disease 1 0.9999998807907104
) I-Disease 0 1.5336369187934906e-06
gangliosidosis I-Disease 0 0.00016767829947639257
. O 0 6.575548013643129e-06

Mutations O 0 2.2195458768692333e-06
in O 0 1.6526318802334572e-07
the O 0 4.709120275947498e-07
HEXA O 0 0.0003745925787370652
gene O 0 6.042432687536348e-08
, O 0 1.520562697976402e-08
encoding O 0 5.168672956301634e-08
the O 0 1.9615301383169026e-08
alpha O 0 2.996538128741122e-08
- O 0 2.354990336073115e-08
subunit O 0 1.7793121642739607e-08
of O 0 1.1825474821591797e-08
beta O 0 4.571275624698501e-08
- O 0 1.3594463155186531e-07
hexosaminidase O 0 4.516675744525855e-06
A O 0 3.9546162611259206e-07
( O 0 2.276560806535599e-08
Hex O 0 1.6387986761401407e-05
A O 0 1.2858967579632008e-07
) O 0 4.132606701290342e-09
, O 0 4.538563747047419e-09
that O 0 2.8655171568914284e-09
abolish O 0 7.713206287007779e-07
Hex O 0 3.924893826479092e-05
A O 0 3.2450029152641946e-07
enzyme O 0 4.183891277875773e-08
activity O 0 1.972135521555174e-08
cause O 0 7.765594887132465e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.0458465027340935e-07
TSD B-Disease 1 0.9999995231628418
) O 0 4.048805379852638e-08
, O 0 3.024755557134995e-08
the O 0 1.0373454983891861e-07
fatal O 0 4.121952315472299e-06
infantile B-Disease 0 2.8696922527160496e-06
form I-Disease 0 2.4026295619705706e-08
of I-Disease 0 5.795604351988004e-07
G I-Disease 0 0.00544137554243207
( I-Disease 0 5.1946265955393756e-08
M2 I-Disease 1 0.9999809265136719
) I-Disease 0 9.743806117512577e-08
gangliosidosis I-Disease 0 5.687162229150999e-06
, I-Disease 0 7.884036534733241e-08
Type I-Disease 0 7.987679282450699e-07
1 I-Disease 0 2.4105077045533108e-06
. O 0 1.5879220427450491e-06

Less O 0 5.9375820455898065e-06
severe O 0 0.013577856123447418
, O 0 5.710738264497195e-07
subacute O 1 1.0
( O 0 2.6908693939731165e-07
juvenile O 1 1.0
- O 0 0.3250980079174042
onset O 0 0.0004033179138787091
) O 0 7.880289309980526e-09
and O 0 1.850220243682088e-08
chronic O 1 1.0
( O 0 1.2971898222247091e-08
adult O 0 1.0072030818264466e-06
- O 0 8.990531910058053e-07
onset O 0 1.9845239762616984e-07
) O 0 1.1560017387779453e-09
variants O 0 6.551232445417554e-09
are O 0 3.9242031846242753e-10
characterized O 0 2.9644626753366765e-09
by O 0 3.774423551483608e-10
a O 0 5.474845021780084e-09
broad O 0 1.1260924281941698e-07
spectrum O 0 2.7187900286662625e-07
of O 0 5.260632818249178e-08
clinical O 0 7.182426315921475e-07
manifestations O 0 4.3046489395237586e-07
and O 0 5.691081828018696e-09
are O 0 7.545684077570058e-10
associated O 0 1.9792454342137944e-09
with O 0 2.9315356808723436e-09
residual O 0 1.450111267331522e-05
levels O 0 1.8459856221397786e-07
of O 0 3.397265686544415e-07
Hex O 0 0.0002704755461309105
A O 0 2.0058969312231056e-06
enzyme O 0 4.312061321343208e-07
activity O 0 3.2017030093811627e-07
. O 0 8.411356589022034e-07

We O 0 3.6667572658188874e-06
identified O 0 1.0870080586755648e-06
a O 0 3.8197356388991466e-07
1422 O 0 0.00028311170171946287
G O 0 9.643712837714702e-05
- O 0 1.1155376341775991e-05
- O 0 8.326911483891308e-06
> O 0 1.1493634701764677e-06
C O 0 1.5940944422254688e-06
( O 0 1.4612206555852936e-08
amino O 0 3.706566431560532e-08
acid O 0 1.5207803016892285e-08
W474C O 0 6.806504870837671e-08
) O 0 3.2483679635042506e-10
substitution O 0 3.040405927023926e-09
in O 0 1.6259477098046204e-09
the O 0 9.477310491945445e-09
first O 0 8.067826406943368e-09
position O 0 1.5310190448758476e-08
of O 0 2.9394261247261966e-08
exon O 0 6.826226695011428e-07
13 O 0 9.619567009622187e-08
of O 0 1.4267828873926192e-07
HEXA O 0 0.198660746216774
of O 0 2.007480333077183e-07
a O 0 3.5355693484007134e-08
non O 0 1.884238969296348e-07
- O 0 2.881284331124334e-07
Jewish O 0 3.1813223699828086e-07
proband O 0 1.1258018275839277e-05
who O 0 1.0205522471551376e-07
manifested O 0 3.32127825686257e-07
a O 0 4.434360789673519e-08
subacute O 0 2.2556929252459668e-05
variant O 0 3.9531632864964195e-06
of O 0 6.947273504920304e-06
G B-Disease 1 0.6755711436271667
( I-Disease 0 3.6564733818522654e-07
M2 I-Disease 1 0.9999971389770508
) I-Disease 0 2.3494012566516176e-06
gangliosidosis I-Disease 0 0.0002448282903060317
. O 0 9.359126124763861e-06

On O 0 2.804692030622391e-06
the O 0 5.213773874856997e-07
second O 0 4.794467827196058e-07
maternally O 0 2.324886281712679e-06
inherited O 0 2.0723855413962156e-06
allele O 0 1.4456223595971096e-07
, O 0 9.962151104048189e-09
we O 0 4.357839422652887e-09
identified O 0 6.636097005241481e-09
the O 0 1.8933599577053428e-08
common O 0 1.0353999186918372e-06
infantile O 1 1.0
disease O 1 1.0
- O 0 2.870194111892488e-05
causing O 0 1.9866422462655464e-06
4 O 0 6.029331984791497e-07
- O 0 5.213634608480788e-07
bp O 0 2.7788564693764783e-07
insertion O 0 1.2083350497960055e-07
, O 0 5.334524999511814e-08
+ O 0 7.624827276231372e-07
TATC O 0 0.00311457016505301
1278 O 0 0.0001811862748581916
, O 0 2.0902022868085623e-07
in O 0 1.4012547921993246e-07
exon O 0 1.7148082406492904e-05
11 O 0 3.890713742293883e-06
. O 0 3.617146830947604e-06

Pulse O 0 0.0005273839342407882
- O 0 1.2434124073479325e-05
chase O 0 1.3879075595468748e-06
analysis O 0 3.7045943201974296e-08
using O 0 3.455743424751745e-08
proband O 0 4.05174478146364e-06
fibroblasts O 0 1.4542314374921261e-07
revealed O 0 1.1549118283937787e-07
that O 0 2.6384034956805635e-09
the O 0 3.1723242699399634e-08
W474C O 0 9.59661974775372e-07
- O 0 1.603014396778235e-07
containing O 0 1.247284018290884e-07
alpha O 0 1.3283589339607715e-07
- O 0 1.422262982941902e-07
subunit O 0 1.0130719374501496e-07
precursor O 0 1.348939093759327e-07
was O 0 3.6132604464000906e-08
normally O 0 4.5735841780469855e-09
synthesized O 0 2.5131456027338572e-08
, O 0 2.7144921865840388e-09
but O 0 1.5146135456944876e-09
not O 0 1.164715102142111e-09
phosphorylated O 0 6.818407172204388e-08
or O 0 7.390798195672232e-09
secreted O 0 1.8267158452545118e-08
, O 0 5.055886376226226e-09
and O 0 6.5071472654665286e-09
the O 0 5.7053114232985536e-08
mature O 0 5.171395400793699e-07
lysosomal O 0 6.96750385031919e-06
alpha O 0 8.006371672308887e-07
- O 0 7.791914526933397e-07
subunit O 0 9.774852287591784e-07
was O 0 3.7297394328561495e-07
not O 0 1.4713425855461537e-07
detected O 0 4.040584826725535e-06
. O 0 3.792457619056222e-06

When O 0 1.1942978517254232e-06
the O 0 4.253362249073689e-07
W474C O 0 4.983122380508576e-06
- O 0 2.3613507948994084e-07
containing O 0 1.4578334628367884e-07
alpha O 0 1.1529331800375076e-07
- O 0 7.307748006724069e-08
subunit O 0 9.615146012720288e-08
was O 0 1.2399569015997258e-07
transiently O 0 2.747173084571841e-07
co O 0 8.57527879816189e-08
- O 0 6.10134662792916e-08
expressed O 0 1.2043953390161732e-08
with O 0 3.6997911401215333e-09
the O 0 3.2231781688096817e-08
beta O 0 9.846505122368399e-08
- O 0 6.1354100466815e-08
subunit O 0 2.7096261234760277e-08
to O 0 4.99749841509356e-09
produce O 0 5.294152316537293e-08
Hex O 0 7.666720921406522e-05
A O 0 1.1952913610002724e-06
( O 0 3.127898651200667e-08
alphabeta O 0 3.609944542404264e-06
) O 0 1.5310277490243607e-08
in O 0 1.9602060419288136e-08
COS O 0 1.360899204883026e-05
- O 0 1.410551675462557e-07
7 O 0 6.142342101611575e-08
cells O 0 2.482955840932277e-09
, O 0 1.4192239605748114e-09
the O 0 5.946799941369818e-09
mature O 0 1.691054407615411e-08
alpha O 0 1.9152691876911376e-08
- O 0 1.6422147197658887e-08
subunit O 0 1.6296805682713966e-08
was O 0 1.1285925971549204e-08
present O 0 3.808936721583223e-09
, O 0 2.3830308837347047e-09
but O 0 7.899547682654884e-10
its O 0 1.7235910476642857e-09
level O 0 1.649183012375488e-08
was O 0 2.1136587591286116e-08
much O 0 7.639979315854362e-09
lower O 0 9.363073871782035e-09
than O 0 9.344408580247432e-10
that O 0 4.5773607126875504e-10
from O 0 2.119515452037035e-09
normal O 0 1.1694704760145669e-08
alpha O 0 5.4328435084016746e-08
- O 0 1.1630445584387417e-07
subunit O 0 1.2520797554316232e-07
transfections O 0 2.0085653886781074e-06
, O 0 1.0364847646826547e-08
although O 0 1.9552239827191897e-09
higher O 0 3.6064284891779153e-09
than O 0 6.908004168693083e-10
in O 0 1.236243440949636e-09
those O 0 2.497747342289358e-09
cells O 0 2.2635271434978677e-09
transfected O 0 5.091763455311593e-08
with O 0 2.6350541748598744e-09
an O 0 9.937650702340761e-09
alpha O 0 1.9844577536787256e-07
- O 0 1.947203571717182e-07
subunit O 0 3.040599665382615e-07
associated O 0 7.705678228830948e-08
with O 0 2.878246903037507e-07
infantile O 1 0.6446551084518433
TSD B-Disease 1 0.9999996423721313
. O 0 2.2994838218437508e-05

Furthermore O 0 6.015851340634981e-06
, O 0 2.499636480024492e-07
the O 0 8.10438223197707e-08
precursor O 0 1.1112314979300209e-07
level O 0 8.93453346861861e-08
of O 0 1.0090337809742778e-07
the O 0 9.7564715417775e-08
W474C O 0 1.8158656303057796e-06
alpha O 0 1.2622514589111233e-07
- O 0 7.596101880835704e-08
subunit O 0 4.266484410209159e-08
was O 0 4.7295536376168457e-08
found O 0 2.8409514740701525e-09
to O 0 3.446855023625517e-09
accumulate O 0 2.203649884791048e-08
in O 0 1.6547878622930057e-09
comparison O 0 9.109721865740994e-09
to O 0 4.37287672738762e-09
the O 0 2.3723563558064598e-08
normal O 0 3.5433195932910166e-08
alpha O 0 9.944688628138465e-08
- O 0 1.930784776504879e-07
subunit O 0 4.018831134544598e-07
precursor O 0 1.0277735782437958e-06
levels O 0 7.934101518003445e-07
. O 0 9.57321958594548e-07

We O 0 1.538154265290359e-06
conclude O 0 4.558828550216276e-07
that O 0 1.4886658128432373e-08
the O 0 1.0337941347415835e-07
1422 O 0 4.327048372942954e-05
G O 0 3.620219285949133e-05
- O 0 4.685084149969043e-06
- O 0 3.029209892702056e-06
> O 0 7.812361673131818e-07
C O 0 7.587166805933521e-07
mutation O 0 1.7191201351351992e-08
is O 0 1.920448022829646e-09
the O 0 4.776984585674882e-09
cause O 0 1.9947391294294903e-08
of O 0 1.522899850670001e-07
Hex B-Disease 1 1.0
A I-Disease 1 0.9293866753578186
enzyme I-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999998807907104
in O 0 1.1914011111002765e-07
the O 0 1.5038189076221897e-06
proband O 0 0.0004595746286213398
. O 0 8.24389007902937e-06

The O 0 6.984327683312586e-06
resulting O 0 2.3009210963209625e-06
W474C O 0 1.0643017958500423e-05
substitution O 0 5.325903771336016e-07
clearly O 0 2.4172194912353007e-07
interferes O 0 1.316306850185356e-07
with O 0 7.77125297446446e-09
alpha O 0 8.391200623236728e-08
- O 0 3.8576981609139693e-08
subunit O 0 1.68525193799951e-08
processing O 0 1.500673540988373e-08
, O 0 1.4131192882516075e-09
but O 0 6.683626985193314e-10
because O 0 9.800292799511112e-10
the O 0 2.8802515927850436e-09
base O 0 1.2640048119294534e-08
substitution O 0 3.1348928786201213e-08
falls O 0 3.819010601091577e-07
at O 0 2.995492209834083e-08
the O 0 2.0332750594320714e-08
first O 0 1.4757516986207975e-08
position O 0 2.3151786265884766e-08
of O 0 7.244366884151532e-08
exon O 0 1.703149791865144e-06
13 O 0 1.2860967046890437e-07
, O 0 2.0104033993106896e-08
aberrant O 0 1.675451954952223e-07
splicing O 0 1.458912777252408e-07
may O 0 7.015535263832362e-09
also O 0 7.715557970300324e-09
contribute O 0 1.7656372364172057e-08
to O 0 4.418842181053151e-08
Hex B-Disease 1 1.0
A I-Disease 0 0.02809053659439087
deficiency I-Disease 0 0.000297743798000738
in O 0 4.161772793054297e-08
this O 0 5.7114629470333966e-08
proband O 0 2.7233567379880697e-05
. O 0 5.364552748687856e-07
. O 0 3.184675506417989e-06

Two O 0 3.2785089842946036e-06
frequent O 0 5.3058752200740855e-06
missense O 0 2.287591814820189e-05
mutations O 0 1.6812987269076984e-06
in O 0 1.5746605868116603e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.032329889014363e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.3352168884448474e-06
an O 0 1.2543792763608508e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.10041674226522446
by O 0 4.377853102255358e-08
early O 0 1.1262894759056508e-06
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 1.0
goiter B-Disease 1 1.0
. O 0 0.031809382140636444

A O 0 4.552091922960244e-06
century O 0 1.6456959883726086e-07
after O 0 1.2825613460165641e-08
its O 0 2.3272861415790658e-09
recognition O 0 1.0385170057247706e-08
as O 0 1.3417049693487115e-08
a O 0 1.5238819628393685e-07
syndrome O 0 0.01587386056780815
by O 0 4.018736454725058e-09
Vaughan O 0 4.6071995711827185e-06
Pendred O 1 0.9997691512107849
, O 0 4.149028143274336e-08
the O 0 6.795167450945883e-08
disease O 0 6.163026409922168e-05
gene O 0 1.1391936283189352e-07
( O 0 4.655189655977665e-08
PDS O 1 1.0
) O 0 8.281821095579289e-08
was O 0 4.1994573507508903e-07
mapped O 0 6.216038173079141e-07
to O 0 1.3906445417433133e-07
chromosome O 0 5.3978255891706795e-06
7q22 O 0 5.947592944721691e-05
- O 0 3.925725104636513e-05
q31 O 0 0.00022034000721760094
. O 0 7.589173492306145e-06

1 O 0 3.7496190543606644e-06
and O 0 2.745062204212445e-07
, O 0 1.1378700293107613e-07
recently O 0 1.373046529806743e-07
, O 0 1.3184370928343014e-08
found O 0 5.098661048918984e-09
to O 0 6.618513737066678e-09
encode O 0 1.1885786932452902e-07
a O 0 2.8417397857083415e-07
putative O 0 1.2990330105822068e-05
sulfate O 0 2.0014822439407e-05
transporter O 0 0.00013035794836468995
. O 0 9.045953447639477e-06

We O 0 1.3420208233583253e-06
performed O 0 4.242752140726225e-07
mutation O 0 1.8104893584336423e-08
analysis O 0 3.6423548621655755e-09
of O 0 2.7482677467105532e-08
the O 0 1.8580787752853212e-07
PDS B-Disease 1 1.0
gene O 0 4.9270553859059874e-08
in O 0 5.669618996506642e-09
patients O 0 6.95760782321031e-09
from O 0 2.6810567099744276e-09
14 O 0 4.747421655793005e-08
Pendred B-Disease 0 1.825921913223283e-06
families O 0 9.881340190531773e-10
originating O 0 2.0391306421174704e-09
from O 0 1.1606966499044802e-09
seven O 0 3.5317861968309217e-09
countries O 0 3.9702938159358325e-10
and O 0 6.055987711306443e-09
identified O 0 4.056891356185588e-08
all O 0 9.401068723491335e-08
mutations O 0 7.086221671670501e-07
. O 0 1.395489903188718e-06

The O 0 3.3311159768345533e-06
mutations O 0 4.126551971239678e-07
include O 0 1.778095111149014e-07
three O 0 2.06039221239962e-08
single O 0 2.3732253495722944e-08
base O 0 9.696438496575865e-08
deletions O 0 6.231755378394155e-07
, O 0 6.60181029843443e-08
one O 0 7.967193482727453e-08
splice O 0 3.048292455787305e-06
site O 0 7.681640568080184e-07
mutation O 0 8.046883692713891e-08
and O 0 3.6757999311021194e-08
10 O 0 5.863602723366057e-07
missense O 0 1.5909379726508632e-05
mutations O 0 2.8614551865757676e-06
. O 0 2.769141701719491e-06

One O 0 1.3498850421456154e-05
missense O 0 3.991747507825494e-05
mutation O 0 9.876954436549568e-07
( O 0 6.66039454699785e-08
L236P O 0 5.722121841245098e-06
) O 0 3.954140126438688e-08
was O 0 7.578836402899469e-08
found O 0 6.22096996139021e-09
in O 0 2.705668578073528e-09
a O 0 9.521084365360366e-09
homozygous O 0 4.969507827468078e-08
state O 0 6.162852894675552e-09
in O 0 3.5218106209100597e-09
two O 0 3.84886922333294e-09
consanguineous O 0 2.810572254929866e-07
families O 0 1.2170773278086244e-09
and O 0 2.174546986921655e-09
in O 0 3.2731537480401585e-09
a O 0 1.5502928718547082e-08
heterozygous O 0 1.612473887746546e-08
state O 0 1.8648125266196303e-09
in O 0 2.4314366076083616e-09
five O 0 6.059904578137321e-09
additional O 0 4.053789837143995e-08
non O 0 7.620582209710847e-07
- O 0 2.787657649605535e-06
consanguineous O 0 2.4000610210350715e-05
families O 0 1.939534399753029e-07
. O 0 1.219205955749203e-06

Another O 0 1.2271989362488966e-05
missense O 0 1.3712599866266828e-05
mutation O 0 3.5960309219262854e-07
( O 0 2.4600003811769966e-08
T416P O 0 2.838066620824975e-06
) O 0 1.3819316357910338e-08
was O 0 4.153446298005292e-08
found O 0 3.1043136949904238e-09
in O 0 1.4598438013990744e-09
a O 0 4.3250980574782716e-09
homozygous O 0 1.6450643514076546e-08
state O 0 2.21949236767216e-09
in O 0 1.7183423572930678e-09
one O 0 4.479600246298787e-09
family O 0 3.4462961373549206e-09
and O 0 3.4333447196388533e-09
in O 0 3.658794156535805e-09
a O 0 1.137316285593215e-08
heterozygous O 0 1.5816810972069106e-08
state O 0 3.0849534038424054e-09
in O 0 4.390184216163107e-09
four O 0 4.078880166957788e-08
families O 0 2.4594140057843106e-08
. O 0 5.679524406332348e-07

Pendred B-Disease 1 0.9995629191398621
patients O 0 2.365058890063665e-06
in O 0 6.691770693123544e-08
three O 0 3.0737602685348975e-08
non O 0 4.903776584797015e-07
- O 0 4.0939275436358e-07
consanguineous O 0 1.2169175533927046e-06
families O 0 2.5386106550229215e-09
were O 0 1.8641725940682363e-09
shown O 0 1.5835215361192923e-09
to O 0 3.7991925161406925e-09
be O 0 8.548624030879637e-09
compound O 0 2.1370922809182957e-07
heterozygotes O 0 9.040312534125405e-07
for O 0 9.25325309708569e-08
L236P O 0 1.9690140106831677e-05
and O 0 9.907852245305548e-07
T416P O 0 0.00019894454453606158
. O 0 8.494876965414733e-06

In O 0 1.4665458536455844e-07
total O 0 6.567636745558048e-08
, O 0 1.1417306211569667e-08
one O 0 2.1349129131209565e-09
or O 0 1.297273177769398e-09
both O 0 7.567678150799395e-10
of O 0 7.725851070006229e-09
these O 0 1.5819185961163384e-09
mutations O 0 1.8172208182676286e-09
were O 0 1.2944604277365102e-09
found O 0 1.2523103665174062e-09
in O 0 7.454332706657851e-10
nine O 0 7.988020911398053e-09
of O 0 2.8531278672971894e-08
the O 0 5.9246470840434995e-08
14 O 0 1.9852393506880617e-07
families O 0 1.388642889565972e-08
analyzed O 0 8.930952617447474e-07
. O 0 1.0915788379861624e-06

The O 0 5.129712121743069e-07
identification O 0 1.9991124133866833e-07
of O 0 2.5418151494704944e-07
two O 0 3.418539407107346e-08
frequent O 0 1.6002846905394108e-06
PDS B-Disease 1 1.0
mutations O 0 1.3548904576055065e-07
will O 0 1.3662380560219844e-08
facilitate O 0 5.457561869093297e-08
the O 0 5.9434810850689246e-08
molecular O 0 2.216791472164914e-06
diagnosis O 0 4.1322009565192275e-06
of O 0 0.2629415988922119
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.5873056074487977e-05

Insertional O 0 0.0005118102999404073
mutation O 0 9.103920888264838e-07
by O 0 4.173195478074376e-08
transposable O 0 1.644853182369843e-05
element O 0 8.644676086078107e-07
, O 0 1.0028996655364608e-07
L1 O 0 0.010409438982605934
, O 0 4.896644867358191e-08
in O 0 2.2701261315205556e-08
the O 0 2.2087294837547233e-07
DMD B-Disease 1 1.0
gene O 0 1.645595517629772e-07
results O 0 1.8293341952357878e-08
in O 0 2.098066254063724e-08
X B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999914169311523
linked I-Disease 1 0.9999890327453613
dilated I-Disease 0 0.0007252893410623074
cardiomyopathy I-Disease 1 1.0
. O 0 2.822066926455591e-05

X B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
linked I-Disease 1 1.0
dilated I-Disease 1 0.9999918937683105
cardiomyopathy I-Disease 1 1.0
( O 0 2.3287052499654237e-06
XLDCM B-Disease 1 1.0
) O 0 1.293960565362795e-07
is O 0 3.8042191619069854e-08
a O 0 1.782882641521155e-08
clinical O 0 5.575220143327897e-07
phenotype O 0 6.333152668958064e-08
of O 0 5.715418893714741e-08
dystrophinopathy B-Disease 0 0.07031724601984024
which O 0 9.708092996163487e-09
is O 0 6.446848388463877e-09
characterized O 0 7.328500473136046e-09
by O 0 1.6386251244782102e-09
preferential O 0 2.555762819156371e-07
myocardial B-Disease 0 0.03826010972261429
involvement I-Disease 0 2.1466333066655352e-07
without O 0 1.981565489472814e-08
any O 0 2.1380191839170948e-08
overt O 0 4.288578452360525e-07
clinical O 0 3.4523095564509276e-06
signs O 0 1.1368301784386858e-05
of O 0 0.10965045541524887
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0013195958454161882

To O 0 6.117759880908125e-07
date O 0 4.3429562879282457e-07
, O 0 3.320207397905506e-08
several O 0 2.0456839777693858e-08
mutations O 0 5.206013042879931e-08
in O 0 1.2950983396819993e-08
the O 0 1.5362850263045402e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.005944613367319107
, O 0 1.4727984307683073e-06
DMD O 1 1.0
, O 0 2.145172146583718e-07
have O 0 4.562501487725967e-09
been O 0 6.285254983140476e-09
identified O 0 4.604534531438276e-09
in O 0 1.871379495810288e-09
patients O 0 4.229397720934003e-09
with O 0 8.240722770835873e-09
XLDCM B-Disease 1 1.0
, O 0 6.529304386049262e-08
but O 0 5.098310662532413e-09
a O 0 5.5917785957149135e-09
pathogenic O 0 6.26511393875262e-08
correlation O 0 1.4241953394389384e-08
of O 0 1.369778868109961e-08
these O 0 6.4299383595312065e-09
cardiospecific O 0 2.619471842990606e-06
mutations O 0 3.92284498218487e-08
in O 0 1.3702570633711275e-08
DMD O 1 1.0
with O 0 5.434688432615076e-08
the O 0 1.614174493624887e-06
XLDCM B-Disease 1 1.0
phenotype O 0 1.2779921689798357e-06
has O 0 4.9200497898027606e-08
remained O 0 3.09735440851e-07
to O 0 3.729770980953617e-08
be O 0 2.6682386078391573e-07
elucidated O 0 6.08885966357775e-05
. O 0 7.2085699684976134e-06

We O 0 8.924329222281813e-07
report O 0 8.080642999175325e-08
here O 0 7.632624310360825e-09
the O 0 1.005375693807764e-08
identification O 0 1.4604961684483442e-08
of O 0 4.7742094722025286e-08
a O 0 2.1656571647099554e-08
unique O 0 5.73542529025417e-08
de O 0 7.686971002840437e-06
novo O 0 1.1131020073662512e-05
L1 O 0 4.8118148697540164e-05
insertion O 0 1.2365251222945517e-07
in O 0 8.31667446021811e-09
the O 0 2.0189801830383658e-08
muscle O 0 8.755493041689988e-08
exon O 0 1.0256293307975284e-06
1 O 0 2.777515817342646e-07
in O 0 4.7718604179181057e-08
DMD O 1 1.0
in O 0 2.8594474343890397e-08
three O 0 4.1442191900387115e-08
XLDCM B-Disease 1 0.9999994039535522
patients O 0 3.171295759329951e-08
from O 0 7.052981310096129e-09
two O 0 1.273942817903162e-08
unrelated O 0 6.151640263851732e-07
Japanese O 0 1.0578855835774448e-06
families O 0 6.77230431733733e-08
. O 0 1.262587488781719e-06

The O 0 6.607834620808717e-06
insertion O 0 5.244761268841103e-06
was O 0 4.794165988641907e-07
a O 0 3.245064306156564e-08
5 O 0 7.426382353514782e-08
- O 0 7.800466761409552e-08
truncated O 0 1.309188348841417e-07
form O 0 1.6855478790489542e-08
of O 0 8.122518835307346e-08
human O 0 1.0249843995779884e-07
L1 O 0 1.801905636966694e-05
inversely O 0 1.9853833066463267e-07
integrated O 0 6.201614155543211e-08
in O 0 1.6325948370976562e-09
the O 0 5.9459721590826575e-09
5 O 0 1.4529775604898987e-08
- O 0 8.446889410151925e-08
untranslated O 0 1.8023147276835516e-05
region O 0 9.120365263015628e-08
in O 0 7.985675232191625e-09
the O 0 2.7445013373039728e-08
muscle O 0 8.582986055216679e-08
exon O 0 4.408143183809443e-07
1 O 0 1.0531970673355318e-07
, O 0 5.690550253234505e-09
which O 0 1.0873745237560684e-09
affected O 0 1.3219743077996782e-09
the O 0 1.924778780804104e-09
transcription O 0 1.3950886668112616e-08
or O 0 3.168863171865155e-09
the O 0 7.846034044689532e-09
stability O 0 6.656635775925679e-08
of O 0 1.0872054900801231e-07
the O 0 5.1797464095670875e-08
muscle O 0 1.1759284745949117e-07
form O 0 8.969138320935599e-09
of O 0 9.996777805554302e-08
dystrophin O 0 7.282422984644654e-07
transcripts O 0 1.1389405329964575e-07
but O 0 2.1336510336311676e-09
not O 0 5.954390314144575e-10
that O 0 6.182758749417872e-10
of O 0 2.1961895413369348e-08
the O 0 1.0012100659650969e-07
brain O 0 0.0001817633310565725
or O 0 7.258267231691207e-08
Purkinje O 0 0.2643541097640991
cell O 0 4.608200754319114e-07
form O 0 2.177295499450338e-08
, O 0 9.24345933128734e-09
probably O 0 1.2149417472073765e-08
due O 0 7.50071738053748e-09
to O 0 3.6791583113426896e-09
its O 0 8.348348679021456e-09
unique O 0 3.4038354357335265e-08
site O 0 2.453815284297889e-07
of O 0 5.056251097812492e-07
integration O 0 3.7643301311618416e-06
. O 0 4.002363766630879e-06

We O 0 1.4079795391808148e-06
speculate O 0 4.833730145037407e-07
that O 0 3.5784857299603345e-09
this O 0 1.7313538380747673e-09
insertion O 0 3.573855877903043e-08
of O 0 5.1452236249360794e-08
an O 0 3.2914044822973665e-08
L1 O 0 9.297847282141447e-05
sequence O 0 7.702283966182222e-08
in O 0 2.129289811136914e-08
DMD O 1 1.0
is O 0 1.2620607670044137e-08
responsible O 0 2.9537674528512525e-09
for O 0 5.748134190852738e-10
some O 0 5.474142805717008e-10
of O 0 5.301546313063454e-09
the O 0 3.6050116225538886e-09
population O 0 1.125427750992003e-09
of O 0 3.603911391536485e-09
Japanese O 0 8.073602231206678e-08
patients O 0 9.505008335963794e-09
with O 0 2.175651658831157e-08
XLDCM B-Disease 1 0.9999998807907104
. O 0 8.06182868018368e-07
. O 0 2.8684662538580596e-06

Severe O 0 0.4180472493171692
early O 0 1.8669293240236584e-06
- O 0 0.12553785741329193
onset O 1 0.9999450445175171
obesity B-Disease 1 1.0
, O 0 1.6405687347287312e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.0006670717848464847
red O 1 0.9999997615814209
hair O 0 0.28023505210876465
pigmentation O 1 0.9999375343322754
caused O 0 1.5865203977227793e-06
by O 0 8.7921250724321e-08
POMC O 1 0.9999998807907104
mutations O 0 7.57204475121398e-07
in O 0 1.0399070049516013e-07
humans O 0 5.286271402837883e-07
. O 0 8.802089155324211e-07

Sequential O 0 1.3504412891052198e-05
cleavage O 0 1.9621757019194774e-06
of O 0 1.160108240583213e-06
the O 0 2.3672357940540678e-07
precursor O 0 5.600062991106824e-07
protein O 0 5.820480097895597e-08
pre O 0 9.32924876906327e-07
- O 0 3.701085233842605e-06
pro O 0 4.8281552153639495e-05
- O 0 2.4858038159436546e-05
opiomelanocortin O 0 0.00014523111167363822
( O 0 1.9431018927207333e-07
POMC O 0 9.132097329711542e-05
) O 0 4.5058673237008406e-08
generates O 0 6.345933911688917e-08
the O 0 8.353816127737446e-08
melanocortin O 0 2.2220230675884522e-05
peptides O 0 3.398017440758849e-07
adrenocorticotrophin O 0 6.5940857894020155e-06
( O 0 6.865452206739064e-08
ACTH O 0 8.021069334063213e-06
) O 0 3.390836766925531e-08
, O 0 4.415387877543253e-08
melanocyte O 0 1.1581622857192997e-05
- O 0 3.6923879633832257e-06
stimulating O 0 5.169253199710511e-06
hormones O 0 4.553671146823035e-07
( O 0 2.0680142043261185e-08
MSH O 0 0.0004960931255482137
) O 0 2.197287329863684e-08
alpha O 0 1.495284038810496e-07
, O 0 6.6418457400629904e-09
beta O 0 4.954251764388573e-08
and O 0 3.933977588133075e-09
gamma O 0 1.7513465877527779e-07
as O 0 5.920893553224005e-09
well O 0 3.930692660247814e-09
as O 0 6.038801458885246e-09
the O 0 2.236700780144929e-08
opioid O 0 1.2553430224215845e-06
- O 0 7.007660087765544e-07
receptor O 0 2.260474190052264e-07
ligand O 0 5.74400701225386e-07
beta O 0 2.450924739605398e-06
- O 0 9.622329343983438e-06
endorphin O 0 0.000433922978118062
. O 0 7.339165676967241e-06

While O 0 1.4729122312928666e-06
a O 0 6.972568655783107e-08
few O 0 3.933469372441323e-08
cases O 0 2.2749157224666305e-08
of O 0 7.181577075243695e-07
isolated O 1 0.9999994039535522
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
have O 0 1.4731868169803874e-08
been O 0 2.443492874704134e-08
reported O 0 4.3694690532447567e-08
( O 0 4.432838451862153e-08
OMIM O 1 0.9999847412109375
201400 O 0 1.5910320144030266e-05
) O 0 1.2762751744332945e-08
, O 0 1.726279919012086e-08
an O 0 5.308480055532527e-08
inherited O 1 0.9999998807907104
POMC O 1 1.0
defect O 1 0.9999637603759766
has O 0 8.408808582771599e-08
not O 0 7.487694908547837e-09
been O 0 1.6482964326769434e-08
described O 0 4.556033772473711e-08
so O 0 2.2594345949755734e-08
far O 0 1.748362734588227e-07
. O 0 1.407680088050256e-06

Recent O 0 3.059648179259966e-06
studies O 0 1.7101372407068993e-07
in O 0 1.6236365141253373e-08
animal O 0 8.500953896373176e-08
models O 0 1.8164593384994987e-08
elucidated O 0 1.927789554656556e-07
a O 0 5.760923738051815e-09
central O 0 4.001872255798844e-08
role O 0 3.126801217945285e-08
of O 0 1.8590961303743825e-07
alpha O 0 1.5411569620482624e-06
- O 0 5.370590770326089e-06
MSH O 1 0.9999837875366211
in O 0 2.22211991030008e-08
the O 0 2.340169302783579e-08
regulation O 0 5.5989964664604486e-08
of O 0 2.0331354377844946e-08
food O 0 8.121601169364112e-09
intake O 0 4.889531002305603e-09
by O 0 1.443823671731792e-10
activation O 0 1.1970598734478699e-08
of O 0 3.438910667341588e-08
the O 0 1.4615000054618577e-07
brain O 0 1.5578001466565183e-06
melanocortin O 0 1.7072745322366245e-05
- O 0 3.0781313853367465e-07
4 O 0 1.8308219296159223e-07
- O 0 2.389677717928862e-07
receptor O 0 4.849465895517824e-08
( O 0 1.34838558096817e-08
MC4 O 0 0.00029823160730302334
- O 0 1.4245247257349547e-06
R O 0 1.8137436654797057e-06
; O 0 5.572964756339616e-09
refs O 0 1.1880369754635467e-07
3 O 0 9.24263066082176e-09
- O 0 7.779483723879821e-09
5 O 0 5.661082269625695e-09
) O 0 6.133895613658069e-10
and O 0 1.2348388978011826e-09
the O 0 8.080917268671328e-09
linkage O 0 1.3006140875404526e-07
of O 0 2.026577590186207e-07
human O 0 4.344120156929421e-07
obesity B-Disease 1 1.0
to O 0 2.4457868619265355e-08
chromosome O 0 1.0509796766200452e-07
2 O 0 4.02063236037975e-08
in O 0 3.3868468030107124e-09
close O 0 1.4764301781156064e-08
proximity O 0 3.9685563280045244e-08
to O 0 1.535809701636026e-08
the O 0 2.1560545349075255e-07
POMC O 1 0.6196737885475159
locus O 0 5.512094048754079e-06
, O 0 3.2899297508492964e-08
led O 0 2.776148377847676e-08
to O 0 6.099703409034873e-09
the O 0 1.673956262493448e-08
proposal O 0 1.486554790375294e-08
of O 0 2.014352951107412e-08
an O 0 5.194257024498938e-09
association O 0 1.1387185416822376e-08
of O 0 3.094667704317544e-07
POMC O 1 0.9999990463256836
with O 0 7.831309289940691e-07
human O 0 2.689548273338005e-05
obesity B-Disease 1 1.0
. O 0 6.0251745708228555e-06

The O 0 1.9246606370870722e-06
dual O 0 2.060358610833646e-06
role O 0 5.57466762529657e-07
of O 0 1.2551826102935593e-06
alpha O 0 9.73118676483864e-06
- O 0 0.0009801273699849844
MSH O 1 1.0
in O 0 7.233266074990752e-08
regulating O 0 3.881145858031232e-07
food O 0 4.021859467684408e-08
intake O 0 5.867428853889578e-08
and O 0 7.039380633955261e-09
influencing O 0 4.545973695257999e-07
hair O 0 1.6498773902640096e-06
pigmentation O 0 7.986515265656635e-05
predicts O 0 2.4513545326954045e-07
that O 0 3.862570263635234e-09
the O 0 1.5731933089568884e-08
phenotype O 0 2.6198307523372932e-08
associated O 0 4.1290371122215674e-09
with O 0 4.695055011438853e-09
a O 0 6.700673083059883e-08
defect O 0 1.436669890608755e-06
in O 0 6.160622234574475e-08
POMC O 1 0.9999998807907104
function O 0 9.212818952164525e-08
would O 0 1.6187076568030534e-08
include O 0 6.36335016679368e-07
obesity B-Disease 1 1.0
, O 0 5.0559179953779676e-08
alteration O 0 1.0539220056671184e-06
in O 0 5.168081429474114e-08
pigmentation O 1 0.9999927282333374
and O 0 4.244342562742531e-05
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999884366989136
. O 0 7.447286407114007e-06

The O 0 2.2101105514593655e-06
observation O 0 5.628533926937962e-06
of O 0 6.055412882233213e-07
these O 0 6.117846851338982e-08
symptoms O 0 2.023021806962788e-06
in O 0 6.205907343570516e-09
two O 0 2.451022140803616e-08
probands O 0 2.239514287794009e-05
prompted O 0 2.0450644910852134e-07
us O 0 1.350449618797711e-08
to O 0 1.8700994530718162e-08
search O 0 8.082893288019477e-08
for O 0 2.1574280140157498e-08
mutations O 0 8.957909614082382e-08
within O 0 5.392004354121127e-08
their O 0 1.1668385013763327e-07
POMC O 0 0.014313154853880405
genes O 0 3.3197309221577598e-06
. O 0 2.5747715426405193e-06

Patient O 0 2.6624698875821196e-05
1 O 0 1.5875344843152561e-06
was O 0 2.4123258413055737e-07
found O 0 7.617470210163901e-09
to O 0 4.439317358162498e-09
be O 0 2.9888647112841227e-09
a O 0 9.83719061764532e-09
compound O 0 7.283034619831597e-08
heterozygote O 0 1.4378690593730425e-07
for O 0 6.595024526490079e-09
two O 0 6.12006223477124e-09
mutations O 0 6.449283329601485e-09
in O 0 4.1416572393870865e-09
exon O 0 1.2610255453182617e-06
3 O 0 3.238201884414593e-07
( O 0 2.4838760381840075e-08
G7013T O 0 2.585386255304911e-06
, O 0 4.112816043289058e-08
C7133delta O 0 7.346609891101252e-06
) O 0 1.1093526985916924e-08
which O 0 3.4193727849185507e-09
interfere O 0 1.0203260458752084e-08
with O 0 1.1679474054560046e-09
appropriate O 0 9.121753130614252e-09
synthesis O 0 3.104599599623725e-08
of O 0 9.19005671562445e-08
ACTH O 0 1.7332404240733013e-05
and O 0 2.568826005244773e-07
alpha O 0 1.4853771062917076e-05
- O 0 0.0001768614602042362
MSH O 1 0.9999960660934448
. O 0 1.4963545254431665e-05

Patient O 0 1.788507324818056e-05
2 O 0 1.4763000990569708e-06
was O 0 3.575581786208204e-07
homozygous O 0 1.1606489636051265e-07
for O 0 1.3767592399460682e-08
a O 0 2.1944307704302446e-08
mutation O 0 1.7528495988017312e-08
in O 0 6.968883692337613e-09
exon O 0 1.7103635627790936e-06
2 O 0 4.0512475152354455e-07
( O 0 3.6209943488074714e-08
C3804A O 0 3.3617404824326513e-06
) O 0 4.483645810182679e-08
which O 0 8.972136100737771e-08
abolishes O 0 3.613169974414632e-05
POMC O 0 0.000959739089012146
translation O 0 9.77586296357913e-06
. O 0 4.815290139958961e-06

These O 0 9.987884368456434e-07
findings O 0 1.2666600923694205e-07
represent O 0 2.058176917785204e-08
the O 0 1.561864948484981e-08
first O 0 5.110168288524619e-09
examples O 0 3.386454139331363e-08
of O 0 6.787330875113184e-08
a O 0 1.240083378206691e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 5.556780990900734e-08
the O 0 1.2137401483869326e-07
POMC O 0 0.03376651182770729
gene O 0 1.2694239437394117e-08
and O 0 5.5700950518655645e-09
define O 0 2.3237566537659404e-08
a O 0 6.041785738375438e-09
new O 0 6.041510403065331e-08
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
resulting O 0 6.888183179398766e-08
in O 0 2.184782355030279e-09
early O 0 2.4370462980982666e-08
- O 0 5.4573083616560325e-06
onset O 1 0.9208365082740784
obesity B-Disease 1 1.0
, O 0 1.6288061033264967e-06
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.3494448467099573e-05
red O 1 0.9998464584350586
hair O 0 0.00020741979824379086
pigmentation O 0 0.09122251719236374
. O 0 6.158297196634521e-07
. O 0 3.7992488159943605e-06

A O 0 3.4997108741663396e-05
European O 0 1.2197304386063479e-05
multicenter O 0 0.00013060243509244174
study O 0 5.813700454382342e-07
of O 0 4.7384655772475526e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.3692359952274273e-08
classification O 0 1.1915862785372155e-07
of O 0 7.8043065343536e-08
105 O 0 3.067043508053757e-07
mutations O 0 7.332750850963521e-09
and O 0 3.6716294449234965e-09
a O 0 5.534765978865153e-09
general O 0 1.2954640027373898e-08
system O 0 2.0445334314445063e-08
for O 0 3.584982533055836e-09
genotype O 0 2.1157884333433685e-08
- O 0 2.7864718532555344e-08
based O 0 1.9559708519523156e-08
prediction O 0 3.6637928246818774e-07
of O 0 3.075901418014837e-07
metabolic O 0 0.0010617752559483051
phenotype O 0 2.3355955818260554e-06
. O 0 1.4922725313226692e-06

Phenylketonuria B-Disease 1 1.0
( O 0 9.509265510132536e-06
PKU B-Disease 1 1.0
) O 0 3.6292988170316676e-07
and O 0 3.035242457372078e-07
mild B-Disease 1 0.9984353184700012
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.0009276102646254003
MHP B-Disease 1 1.0
) O 0 1.052324137162941e-06
are O 0 1.1709306591001223e-07
allelic B-Disease 1 1.0
disorders I-Disease 1 1.0
caused O 0 1.1531641064266296e-07
by O 0 6.166639199278734e-09
mutations O 0 3.0076581225557675e-08
in O 0 5.176799877659732e-09
the O 0 5.071380471122211e-08
gene O 0 1.0333328503975281e-07
encoding O 0 1.419964632987103e-06
phenylalanine O 0 1.4345970157592092e-05
hydroxylase O 0 0.0001952881139004603
( O 0 1.2913092177768704e-06
PAH O 1 1.0
) O 0 3.742231228898163e-06
. O 0 6.972296432650182e-06

Previous O 0 6.0568322624021675e-06
studies O 0 3.948172206946765e-07
have O 0 7.398583079520904e-09
suggested O 0 1.0611008072203276e-08
that O 0 1.0159000307652377e-09
the O 0 9.876369944095131e-09
highly O 0 1.6318367102030606e-07
variable O 0 2.1308220254923071e-07
metabolic O 0 4.0584360249340534e-05
phenotypes O 0 2.74361491392483e-06
of O 0 1.5911200534901582e-05
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9999972581863403
correlate O 0 6.6289403548580594e-06
with O 0 2.7411067549110157e-06
PAH O 1 1.0
genotypes O 1 0.7775751352310181
. O 0 1.0358915460528806e-05

We O 0 1.0998255675076507e-06
identified O 0 2.680854152004031e-07
both O 0 5.781290823847485e-08
causative O 0 4.2249198486388195e-06
mutations O 0 1.5149096554978314e-07
in O 0 2.48942519931461e-08
686 O 0 9.804068213270511e-06
patients O 0 3.7065170488403965e-08
from O 0 2.0191881944242596e-08
seven O 0 7.174704563794876e-08
European O 0 4.255224723692663e-07
centers O 0 1.3374020682022092e-06
. O 0 1.7384679722454166e-06

On O 0 1.594812260918843e-06
the O 0 1.6016711867905542e-07
basis O 0 4.2846782122296645e-08
of O 0 3.3199537341488394e-08
the O 0 3.7508520733808837e-08
phenotypic O 0 5.48195259852946e-07
characteristics O 0 6.282836295667948e-08
of O 0 1.0662136418204682e-07
297 O 0 9.93735739029944e-07
functionally O 0 2.354778189328499e-06
hemizygous O 0 1.379995774186682e-05
patients O 0 1.879708300123184e-08
, O 0 2.3101311974471628e-09
105 O 0 4.706094713924358e-08
of O 0 2.7099465782498555e-08
the O 0 1.8588792727314285e-08
mutations O 0 3.0637847814318775e-09
were O 0 7.683157998705781e-10
assigned O 0 6.796124107921742e-09
to O 0 1.9955679331218334e-09
one O 0 6.778168692989084e-09
of O 0 4.2712965608870945e-08
four O 0 2.7143540748397754e-08
arbitrary O 0 1.6180139539301308e-07
phenotype O 0 5.730432803829899e-07
categories O 0 5.547756813939486e-07
. O 0 9.734275181472185e-07

We O 0 2.2122846985439537e-06
proposed O 0 9.454057590119191e-07
and O 0 9.30262515907998e-08
tested O 0 7.151710690322943e-08
a O 0 6.113773487470553e-09
simple O 0 5.87775339511154e-09
model O 0 3.089723366045405e-09
for O 0 1.3292689171606753e-09
correlation O 0 9.23640985917018e-09
between O 0 7.100588117481266e-09
genotype O 0 1.0461916133408522e-07
and O 0 4.335457504112128e-08
phenotypic O 0 3.0685580441058846e-06
outcome O 0 2.5109786747634644e-06
. O 0 5.2188956942700315e-06

The O 0 5.3994317568140104e-06
observed O 0 7.189656230366381e-07
phenotype O 0 2.059116042119058e-07
matched O 0 6.477468161847355e-08
the O 0 4.5930288905537964e-08
predicted O 0 1.826935829285503e-07
phenotype O 0 2.1133281791207992e-08
in O 0 2.1666641814022114e-09
79 O 0 2.773094820440747e-08
% O 0 1.0715235365665876e-09
of O 0 5.434830807615754e-09
the O 0 5.08649966590724e-09
cases O 0 3.3574214519660472e-09
, O 0 2.0450119375681197e-09
and O 0 2.641822760551804e-09
in O 0 2.259063158760455e-09
only O 0 1.2658980530488861e-09
5 O 0 5.824852600255781e-09
of O 0 5.192087648708821e-09
184 O 0 2.4068951276490225e-08
patients O 0 6.729064860877543e-09
was O 0 3.117570912536394e-08
the O 0 1.5000125586084323e-08
observed O 0 9.995077654423312e-09
phenotype O 0 2.556969747047333e-09
more O 0 1.4242562684785298e-10
than O 0 3.295572426065263e-10
one O 0 1.7982364486357483e-09
category O 0 1.0778888004381315e-08
away O 0 1.5751510318295914e-08
from O 0 5.042663175913731e-09
that O 0 8.774112103537846e-09
expected O 0 3.845980529604276e-07
. O 0 1.808767365218955e-06

Among O 0 1.1147952818646445e-06
the O 0 1.2444466790384467e-07
seven O 0 1.6377198264194703e-08
contributing O 0 2.843544422148625e-08
centers O 0 2.114570030187224e-08
, O 0 3.640715506847414e-09
the O 0 4.379721474379039e-09
proportion O 0 8.920481242569167e-09
of O 0 9.663809308335658e-09
patients O 0 1.9044019694547387e-09
for O 0 1.3407016608013578e-09
whom O 0 8.500268044997483e-09
the O 0 2.5200096231969837e-08
observed O 0 1.702546725823595e-08
phenotype O 0 7.54289608551062e-09
did O 0 1.464702359399439e-09
not O 0 9.428462455218778e-10
match O 0 2.639572471707652e-08
the O 0 3.0201952938568866e-08
predicted O 0 7.89581946492035e-08
phenotype O 0 2.6469990643818164e-08
was O 0 2.0963502933568634e-08
4 O 0 3.151174965410064e-08
% O 0 2.9628008935134176e-09
- O 0 2.9745178764528646e-08
23 O 0 4.88636366924311e-08
% O 0 8.061504352951943e-09
( O 0 8.500787629373008e-09
P O 0 5.377419256547e-07
< O 0 1.545439971550877e-07
. O 0 1.0462630761765013e-08
0001 O 0 8.970337148639373e-07
) O 0 1.4949826265819866e-08
, O 0 1.337728949835082e-08
suggesting O 0 1.5794862306961477e-08
that O 0 1.7247815398135913e-09
differences O 0 1.4724677477317982e-08
in O 0 6.127639506914306e-10
methods O 0 2.749068528373755e-09
used O 0 1.969052476624711e-09
for O 0 3.1972275937874883e-09
mutation O 0 1.0236671954544363e-08
detection O 0 5.82562222462002e-07
or O 0 2.8466917711966744e-08
phenotype O 0 5.49699912255619e-08
classification O 0 4.333704595183008e-08
may O 0 1.2281352601561935e-09
account O 0 1.3048868652276724e-09
for O 0 1.1749162753815767e-09
a O 0 3.5598939351899617e-09
considerable O 0 4.338534509429337e-08
proportion O 0 3.3163967572136244e-08
of O 0 1.0129657113111534e-07
genotype O 0 1.3904764273320325e-06
- O 0 7.709845704084728e-06
phenotype O 0 7.14008911018027e-06
inconsistencies O 0 3.803278741543181e-05
. O 0 1.2173621144029312e-05

Our O 0 3.1372910598292947e-06
data O 0 3.657753495645011e-07
indicate O 0 7.437608928739792e-08
that O 0 9.846971238403057e-09
the O 0 2.4616531391075114e-07
PAH O 1 1.0
- O 0 3.4877397411037236e-05
mutation O 0 1.299281393585261e-07
genotype O 0 2.6281236742420333e-08
is O 0 1.7737304958131972e-09
the O 0 2.061090631499951e-09
main O 0 1.422233140147e-07
determinant O 0 2.191680096075288e-06
of O 0 9.069085535884369e-07
metabolic O 1 0.9999858140945435
phenotype O 0 1.0194082733505638e-07
in O 0 2.9658993039305415e-09
most O 0 1.2496623291724518e-08
patients O 0 7.184057437825686e-08
with O 0 1.7947307924259803e-06
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 8.831529703456908e-05

In O 0 4.236125334955432e-07
the O 0 1.2295707563225733e-07
present O 0 1.830133378177834e-08
study O 0 1.2523180714651971e-08
, O 0 3.7178582434904683e-09
the O 0 7.277796587601415e-09
classification O 0 8.454642141941804e-08
of O 0 6.24205753751994e-08
105 O 0 1.3396754184213933e-05
PAH O 1 1.0
mutations O 0 1.0529178950946516e-07
may O 0 1.8033542437123629e-09
allow O 0 1.7213175329544583e-09
the O 0 8.959290198617964e-09
prediction O 0 1.838700995904219e-07
of O 0 8.230155401633965e-08
the O 0 8.935947448662773e-08
biochemical O 0 8.87259659521078e-07
phenotype O 0 7.447120253800676e-08
in O 0 3.224418732017398e-09
> O 0 5.673472713851879e-08
10 O 0 1.3989922997836857e-08
, O 0 5.827453186668663e-09
000 O 0 1.0607026013076393e-07
genotypes O 0 4.414348211412289e-07
, O 0 7.0166858989750835e-09
which O 0 2.9725368833055654e-09
may O 0 1.2218034362021513e-09
be O 0 3.542450777160866e-10
useful O 0 2.582008384877099e-09
for O 0 1.3430895284827216e-09
the O 0 1.0233470071341344e-08
management O 0 1.0962656205038002e-07
of O 0 5.049836886428238e-07
hyperphenylalaninemia B-Disease 1 1.0
in O 0 1.5302591691579437e-06
newborns O 0 6.613231562369037e-06
. O 0 1.5090193983269273e-06

Somatic O 0 8.791533036855981e-05
instability O 0 7.694986379647162e-06
of O 0 4.465111487661488e-06
the O 0 5.327135113475379e-06
CTG O 1 0.9999998807907104
repeat O 0 2.2154770249471767e-06
in O 0 3.8601857710318654e-08
mice O 0 1.280138661741148e-07
transgenic O 0 1.4982974505528546e-07
for O 0 1.3048278013627623e-08
the O 0 7.465579301424441e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.0002740261552389711
is O 0 6.50708784633025e-08
age O 0 3.42564767663589e-08
dependent O 0 5.687891047045923e-09
but O 0 9.501559539160098e-10
not O 0 9.620018115441553e-10
correlated O 0 4.121501362419622e-08
to O 0 8.811510632256159e-09
the O 0 4.4566860424311017e-08
relative O 0 1.3572338275480433e-07
intertissue O 0 7.2240941335621756e-06
transcription O 0 1.05404467376502e-06
levels O 0 4.693491177931719e-07
and O 0 3.178690235472459e-07
proliferative O 1 0.9303499460220337
capacities O 0 0.00011495430953800678
. O 0 1.3821030734106898e-05

A O 0 0.0001094209001166746
( O 0 3.6160224681225372e-06
CTG O 1 0.8357229828834534
) O 0 4.917653200209315e-07
nexpansion O 0 8.330835044034757e-06
in O 0 2.036943236305433e-08
the O 0 2.890489625428927e-08
3 O 0 1.0540813377701852e-07
- O 0 4.95095491714892e-07
untranslated O 0 5.643913027597591e-05
region O 0 2.8716308975162974e-07
( O 0 1.9946707396911734e-08
UTR O 0 0.00011402991367504
) O 0 1.2010874073098421e-08
of O 0 7.05755880403558e-08
the O 0 2.0966906788544293e-07
DM O 1 1.0
protein O 0 1.0561778935880284e-06
kinase O 0 6.456886012529139e-07
gene O 0 4.252753882383331e-08
( O 0 1.0399263672411507e-08
DMPK O 1 0.9995521903038025
) O 0 1.7586396339197563e-08
is O 0 6.207623748366586e-09
responsible O 0 1.562854379244527e-08
for O 0 2.1469194422252258e-08
causing O 0 0.02136053703725338
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.000440501666162163
DM B-Disease 1 1.0
) O 0 4.07661991630448e-06
. O 0 5.638838501909049e-06

Major O 0 0.0018769903108477592
instability O 0 6.263125396799296e-05
, O 0 7.446069361094487e-08
with O 0 6.396886131909696e-09
very O 0 4.117452601093419e-09
large O 0 1.1849406789110617e-08
expansions O 0 9.286847557632427e-08
between O 0 7.612502628262519e-09
generations O 0 1.04829860347877e-08
and O 0 3.3841929258926484e-09
high O 0 5.217932752543675e-08
levels O 0 2.3275449123616454e-08
of O 0 8.131758022500435e-08
somatic O 0 2.2564431674254593e-06
mosaicism O 0 5.416887506726198e-05
, O 0 5.081450282773403e-08
is O 0 2.777075103210791e-08
observed O 0 6.575897515403994e-08
in O 0 5.7477343773371103e-08
patients O 0 3.9153593434093636e-07
. O 0 1.004363866741187e-06

There O 0 8.330885634677543e-07
is O 0 5.930616708837988e-08
a O 0 1.6842525596416635e-08
good O 0 1.5778843120983765e-08
correlation O 0 1.9010860441426303e-08
between O 0 5.625207855075587e-09
repeat O 0 5.847765294220153e-08
size O 0 5.582063167253182e-08
( O 0 3.642743662268799e-09
at O 0 2.6584642043303575e-08
least O 0 2.122545472715842e-09
in O 0 2.7037392325013343e-09
leucocytes O 0 1.8158656303057796e-06
) O 0 1.2535584126283084e-08
, O 0 1.0926308746661562e-08
clinical O 0 8.835581155608452e-08
severity O 0 1.8061921025491756e-07
and O 0 1.514588277018447e-08
age O 0 1.0555319107652394e-07
of O 0 2.7376793809708033e-07
onset O 0 1.2511118256952614e-05
. O 0 2.3572069949295837e-06

The O 0 3.827536420430988e-05
trinucleotide O 1 0.964593768119812
repeat O 0 2.0196473997202702e-05
instability O 0 5.04759191244375e-06
mechanisms O 0 1.0274736723658862e-06
involved O 0 7.119617606576867e-08
in O 0 4.633796280018032e-08
DM B-Disease 1 1.0
and O 0 3.0678859275212744e-07
other O 0 6.72838709192547e-08
human O 0 9.24811558888905e-07
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.8050770595200447e-08
unknown O 0 4.076010782227968e-07
. O 0 6.087792598918895e-07

We O 0 1.69455006471253e-06
studied O 0 4.999120392312761e-06
somatic O 0 3.3688270377751905e-06
instability O 0 8.063843210948107e-07
by O 0 2.5489319099847307e-08
measuring O 0 7.116546839824878e-06
the O 0 6.156793688205653e-07
CTG O 1 0.8802889585494995
repeat O 0 2.4823944499985373e-07
length O 0 3.122117320231155e-08
at O 0 3.2465564459016605e-08
several O 0 7.0136354501926235e-09
ages O 0 5.478752562737554e-09
in O 0 4.561455102525258e-10
various O 0 3.324501784973677e-09
tissues O 0 2.0995756244701624e-08
of O 0 2.383077379874976e-08
transgenic O 0 1.1107309774160967e-06
mice O 0 6.3039031772405e-08
carrying O 0 1.881663180824944e-08
a O 0 1.3699695600166706e-08
( O 0 3.4036663265624156e-08
CTG O 0 0.02283059060573578
) O 0 1.0935298888625766e-07
55expansion O 0 6.166669209051179e-06
surrounded O 0 6.369434117914352e-07
by O 0 4.317062263226035e-09
45 O 0 4.729039559947523e-08
kb O 0 1.1177291980857262e-06
of O 0 1.2302909624395397e-07
the O 0 9.107796472562768e-08
human O 0 4.1802539385571436e-07
DM B-Disease 1 1.0
region O 0 7.265258318511769e-06
, O 0 4.0262115419409383e-08
using O 0 3.7594684698660785e-08
small O 0 1.7943440866474702e-07
- O 0 2.609627927085967e-06
pool O 0 8.801242984191049e-06
PCR O 0 7.434059170918772e-06
. O 0 1.557348582537088e-06

These O 0 3.0568162401323207e-06
mice O 0 1.607007789061754e-06
have O 0 1.1248061149160549e-08
been O 0 6.021709797465746e-09
shown O 0 2.0685182455792983e-09
to O 0 3.54781470868204e-09
reproduce O 0 3.673550352800703e-08
the O 0 1.8630856857271283e-08
intergenerational O 0 1.6480881015468185e-07
and O 0 9.462986838570941e-09
somatic O 0 1.8437212645494583e-07
instability O 0 1.458651155417101e-07
of O 0 1.5683166054714093e-07
the O 0 1.3711596125176584e-07
55 O 0 6.645167331953417e-07
CTG O 0 0.008542634546756744
repeat O 0 3.130388108729676e-07
suggesting O 0 3.7349323633861786e-08
that O 0 9.401723843893706e-10
surrounding O 0 4.955140298079641e-08
sequences O 0 1.029034990551736e-08
and O 0 3.6775447131986994e-09
the O 0 1.3454516611943745e-08
chromatin O 0 1.3551954225476948e-07
environment O 0 2.807919408098769e-08
are O 0 1.3363105066943604e-09
involved O 0 1.154065820685446e-08
in O 0 3.176526064407881e-08
instability O 0 3.851680958177894e-06
mechanisms O 0 6.9550892476399895e-06
. O 0 5.400574991654139e-06

As O 0 1.0607183185129543e-06
observed O 0 9.818299417929666e-08
in O 0 4.811008924576754e-09
some O 0 3.58165408442801e-09
of O 0 1.9620316038526653e-08
the O 0 3.3938455601401074e-08
tissues O 0 3.868338183110609e-07
of O 0 6.6998563852394e-06
DM B-Disease 1 1.0
patients O 0 6.917700829944806e-07
, O 0 3.439473372779389e-09
there O 0 2.301686619077259e-09
is O 0 3.7779472883414655e-09
a O 0 2.7973763305766397e-09
tendency O 0 1.8277683366818565e-08
for O 0 2.8422848519227273e-09
repeat O 0 3.162392303579509e-08
length O 0 1.967713103567803e-08
and O 0 1.5274080666927148e-08
somatic O 0 2.1065635280592687e-07
mosaicism O 0 5.857241944795533e-07
to O 0 3.18146597955149e-09
increase O 0 1.333708143924639e-09
with O 0 1.311203923215487e-09
the O 0 1.4723609886857503e-08
age O 0 2.47774369910303e-08
of O 0 7.522368150603143e-08
the O 0 4.172376009137224e-07
mouse O 0 2.4593289708718657e-05
. O 0 5.029476596973836e-06

Furthermore O 0 9.828585461946204e-06
, O 0 4.686777401730069e-07
we O 0 5.829657467870675e-08
observed O 0 4.031429057249625e-08
no O 0 9.16304543352453e-09
correlation O 0 6.382602002474869e-09
between O 0 4.236147432834514e-09
the O 0 1.5125010577321518e-08
somatic O 0 1.6619664222616848e-07
mutation O 0 1.509215863393365e-08
rate O 0 4.303120082482792e-09
and O 0 5.287085436123107e-09
tissue O 0 2.477170255588135e-07
proliferation O 0 4.4233125663595274e-05
capacity O 0 2.6062800770887407e-06
. O 0 2.776501105472562e-06

The O 0 3.267814918217482e-06
somatic O 0 4.85333794131293e-06
mutation O 0 4.572043010853122e-08
rates O 0 6.28047347461802e-09
in O 0 8.322938449545347e-10
different O 0 1.8794170664193643e-09
tissues O 0 1.8703705251255087e-08
were O 0 3.374221790863885e-09
also O 0 2.9183080396677497e-09
not O 0 9.159074609854656e-10
correlated O 0 1.0404501260552479e-08
to O 0 3.757115507596609e-09
the O 0 2.1053459420272702e-08
relative O 0 3.263430770061859e-08
inter O 0 1.9455660549283493e-06
- O 0 9.685510349299875e-07
tissue O 0 7.911557986517437e-08
difference O 0 1.1855624038048518e-08
in O 0 9.294335301390788e-10
transcriptional O 0 6.4409979572133125e-09
levels O 0 4.548460275088928e-09
of O 0 4.5169477047579676e-09
the O 0 3.8746716946036486e-09
three O 0 2.4919086794028544e-09
genes O 0 4.202500125671804e-09
( O 0 7.652595002127782e-09
DMAHP O 1 0.9999864101409912
, O 0 9.150300428473201e-08
DMPK O 0 0.10653751343488693
and O 0 6.35838830476132e-08
59 O 0 3.397106809188699e-07
) O 0 1.5019422150430728e-08
surrounding O 0 4.7083841536732507e-07
the O 0 1.9178726518020994e-07
repeat O 0 7.877239909248601e-07
. O 0 1.9085052826994797e-07
. O 0 1.0718468956838478e-06

A O 0 7.151340105338022e-05
novel O 0 5.474577847053297e-05
missense O 0 2.551740726630669e-05
mutation O 0 3.995527322331327e-07
in O 0 1.3718208791146935e-08
patients O 0 2.751928995792241e-08
from O 0 8.49331627250649e-09
a O 0 8.371345217028647e-08
retinoblastoma B-Disease 0 0.0009716941276565194
pedigree O 0 6.167562787595671e-06
showing O 0 3.5239969520262093e-07
only O 0 3.098222478570278e-08
mild O 0 4.411608358623198e-07
expression O 0 4.166220435308787e-08
of O 0 1.5056944846492115e-07
the O 0 6.956435640859127e-07
tumor B-Disease 0 0.010375131852924824
phenotype O 0 6.307393960014451e-06
. O 0 2.081558022837271e-06

We O 0 1.470394408897846e-06
have O 0 3.4138611937351016e-08
used O 0 2.9891342734345017e-08
single O 0 2.6468475411434156e-08
strand O 0 3.116471347652805e-08
conformation O 0 1.7038102484434603e-08
polymorphism O 0 3.738764853267185e-09
analysis O 0 2.336996818286252e-09
to O 0 1.5956885812684618e-09
study O 0 4.798014874296541e-09
the O 0 8.186314737201883e-09
27 O 0 4.692846644616111e-08
exons O 0 1.8451864036705956e-07
of O 0 8.548089169835293e-08
the O 0 2.0391266275510134e-07
RB1 O 1 0.9999738931655884
gene O 0 1.3747125215957112e-08
in O 0 1.6638838085114571e-09
individuals O 0 7.720293848656468e-10
from O 0 1.8120636102736398e-09
a O 0 1.3273896648513528e-08
family O 0 3.611854637597389e-08
showing O 0 1.4953113236515492e-07
mild O 0 8.549782251066063e-07
expression O 0 8.616479618694939e-08
of O 0 2.0861398297711276e-07
the O 0 9.750255003382335e-07
retinoblastoma B-Disease 0 0.001580435666255653
phenotype O 0 1.3057587239018176e-05
. O 0 3.1068500447872793e-06

In O 0 3.53546198539334e-07
this O 0 3.3182384839847145e-08
family O 0 3.0634883074753816e-08
affected O 0 1.8294425530029912e-08
individuals O 0 1.893149637055558e-09
developed O 0 3.388657887626323e-08
unilateral B-Disease 0 0.0018860490527004004
tumors I-Disease 1 1.0
and O 0 1.5921908413929486e-07
, O 0 1.1024803292514207e-08
as O 0 4.082575166819424e-09
a O 0 2.7267699209687635e-09
result O 0 4.1986547572037125e-09
of O 0 1.1985151537885486e-08
linkage O 0 1.1202396876797138e-07
analysis O 0 9.160494585103152e-09
, O 0 6.2179927873273755e-09
unaffected O 0 1.1823064482996415e-07
mutation O 0 6.756741388613818e-09
carriers O 0 3.459276420869628e-09
were O 0 3.778149348931947e-09
also O 0 1.1486635642654619e-08
identified O 0 2.1392185800550578e-08
within O 0 3.267809489670981e-08
the O 0 2.646520158577914e-07
pedigree O 0 1.5254918253049254e-05
. O 0 4.210451606923016e-06

A O 0 2.2317919501801953e-05
single O 0 8.486711635669053e-07
band O 0 1.918108182508149e-06
shift O 0 1.9926312688767212e-07
using O 0 6.155700305043865e-08
SSCP O 1 0.9990906715393066
was O 0 6.230092139958288e-07
identified O 0 4.024583688533312e-08
in O 0 1.2925861270218775e-08
exon O 0 1.7520243318358553e-06
21 O 0 1.1858794835006847e-07
which O 0 4.572624945353709e-09
resulted O 0 2.0999518568487474e-08
in O 0 8.595153921930887e-09
a O 0 4.1679609097400316e-08
missense O 0 9.09781078917149e-07
mutation O 0 5.325415841639369e-08
converting O 0 1.6140484149218537e-07
a O 0 8.269777396208156e-08
cys O 0 0.006925556808710098
- O 0 7.7267604865483e-06
- O 0 4.631084721040679e-06
> O 0 1.3749008758168202e-06
arg O 0 4.0304134927282576e-06
at O 0 2.660118525454891e-07
nucleotide O 0 9.796674760309543e-08
position O 0 8.688102326459557e-08
28 O 0 1.0627093871562465e-07
in O 0 2.7589505791070223e-08
the O 0 4.075047002061183e-07
exon O 0 3.664146424853243e-05
. O 0 5.189202056499198e-06

The O 0 9.650966603658162e-06
mutation O 0 1.600167365722882e-06
destroyed O 0 4.264794370101299e-06
an O 0 3.1118386800699227e-07
NdeI O 0 7.540990191046149e-05
restriction O 0 2.569414164099726e-06
enzyme O 0 8.018284347599547e-07
site O 0 1.7097928548537311e-06
. O 0 2.3728100586595247e-06

Analysis O 0 7.20967136658146e-07
of O 0 2.9988282790327503e-07
all O 0 3.333049392040266e-08
family O 0 1.2749102218378994e-08
members O 0 1.3388158359717295e-09
demonstrated O 0 7.2887154090039985e-09
that O 0 1.4747042476059846e-09
the O 0 3.7865341084852844e-08
missense O 0 1.2639079614018556e-06
mutation O 0 1.537008955665442e-07
co O 0 1.4475868681529391e-07
- O 0 3.152191538902116e-07
segregated O 0 1.0308190212526824e-07
with O 0 3.0662634653566556e-09
patients O 0 7.956058922786724e-09
with O 0 1.3507819751623629e-08
tumors B-Disease 1 1.0
or O 0 1.9497972516546724e-06
who O 0 5.5559645772973454e-08
, O 0 5.358905763586108e-09
as O 0 6.142597541725081e-09
a O 0 5.651889622981798e-09
result O 0 6.8848695633505486e-09
of O 0 5.605621211657308e-08
linkage O 0 1.4124013603122876e-07
analysis O 0 2.3479845623342044e-08
had O 0 2.6077014325665004e-08
been O 0 1.2633154966579241e-08
predicted O 0 3.428530348514869e-08
to O 0 1.5172050282785676e-08
carry O 0 9.46039122595721e-08
the O 0 5.319436695572222e-07
predisposing O 0 5.474932913784869e-05
mutation O 0 4.98556119055138e-06
. O 0 4.186511887382949e-06

These O 0 5.956440531917906e-07
observations O 0 5.644275802296761e-07
point O 0 1.9322916955388791e-07
to O 0 8.322593281206991e-09
another O 0 1.8063122553257926e-08
region O 0 6.992360113144969e-08
of O 0 1.8443260785261373e-07
the O 0 6.119913109614572e-07
RB1 O 1 0.9999996423721313
gene O 0 4.431020883544079e-08
where O 0 1.5232652472718655e-08
mutations O 0 3.80162790136751e-09
only O 0 6.650817119258079e-10
modify O 0 9.753286178693088e-09
the O 0 3.5211924487299484e-09
function O 0 3.3051736902933726e-09
of O 0 9.139691670156935e-09
the O 0 8.129227069275657e-09
gene O 0 3.491498645757929e-09
and O 0 3.3205667104851955e-09
raise O 0 1.706135677181919e-08
important O 0 1.3093451656231991e-08
questions O 0 1.5981839851519908e-08
for O 0 3.6287772786636197e-09
genetic O 0 2.5054495367271556e-08
counseling O 0 4.660340113815664e-09
in O 0 7.001041413268183e-10
families O 0 5.033282124422556e-10
with O 0 1.4293078942628767e-09
these O 0 1.1207051286987735e-08
distinctive O 0 1.3863055983165395e-06
phenotypes O 0 1.84910368261626e-06
. O 0 4.063280982791184e-07
. O 0 2.8894617116748122e-06

Maternal B-Disease 0 0.00026824179803952575
disomy I-Disease 0 0.003579754615202546
and O 0 3.417215702938847e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 4.859864020545501e-06
with O 0 9.228701003394235e-08
gamete O 0 3.4390075143164722e-06
complementation O 0 6.312774075922789e-06
in O 0 1.585613773613659e-08
a O 0 2.1818767237391512e-08
case O 0 3.086031696852842e-08
of O 0 1.678031225083032e-07
familial O 0 4.4964162952965125e-06
translocation O 0 1.8725461359281326e-06
( O 0 5.0367612303148235e-09
3 O 0 3.762553291153381e-08
; O 0 2.187434233746899e-09
15 O 0 1.4732037811882037e-08
) O 0 5.481658238437603e-09
( O 0 1.1945669342594556e-08
p25 O 0 2.501838025636971e-06
; O 0 1.2324865572566068e-08
q11 O 0 1.2261297115401248e-06
. O 0 2.2841986080379684e-08
2 O 0 4.120668961604679e-07
) O 0 3.7504807437471754e-07
. O 0 2.207300667578238e-06

Maternal B-Disease 0 0.017598140984773636
uniparental I-Disease 1 1.0
disomy I-Disease 1 1.0
( I-Disease 0 3.4077973396051675e-05
UPD I-Disease 1 1.0
) I-Disease 0 1.6806144742531615e-07
for I-Disease 0 3.1656270493840566e-08
chromosome I-Disease 0 1.0268864514273446e-07
15 I-Disease 0 1.511526370734373e-08
is O 0 2.176015589938629e-09
responsible O 0 2.8065791912723626e-09
for O 0 1.0707084108219078e-09
an O 0 1.2507921365312313e-09
estimated O 0 2.368286011744658e-09
30 O 0 3.241474866300109e-09
% O 0 3.329646836025546e-10
of O 0 1.1099087204868852e-09
cases O 0 2.3369743917811547e-09
of O 0 1.137492517955252e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 5.04796662426088e-05
PWS B-Disease 1 1.0
) O 0 6.190196927491343e-06
. O 0 5.914173925702926e-06

We O 0 7.503180654566677e-07
report O 0 6.385916861972873e-08
on O 0 3.1381414800080165e-08
an O 0 4.054708124812123e-09
unusual O 0 1.9410677509767993e-08
case O 0 1.1767537166917919e-08
of O 0 5.840988137606473e-08
maternal B-Disease 0 4.772033435074263e-07
disomy I-Disease 0 5.0558151997393e-05
15 I-Disease 0 1.823517123966667e-07
in O 0 2.993870040768343e-08
PWS B-Disease 1 1.0
that O 0 9.019076152583239e-09
is O 0 6.1288001340642495e-09
most O 0 1.7898120763248926e-09
consistent O 0 3.6966802952065336e-09
with O 0 9.610736650955687e-10
adjacent O 0 6.589331746909011e-08
- O 0 6.320035339513197e-08
1 O 0 1.2373037350243976e-07
segregation O 0 1.3432138246116665e-07
of O 0 2.5361485356256708e-08
a O 0 1.1908269925697823e-08
paternal O 0 1.008908725452784e-07
t O 0 4.123907615394273e-08
( O 0 3.848186658217401e-09
3 O 0 2.351175254489135e-08
; O 0 2.007294774841739e-09
15 O 0 1.0513661941047303e-08
) O 0 4.716813162275457e-09
( O 0 7.952948521960934e-09
p25 O 0 1.3962819593871245e-06
; O 0 7.471018470539548e-09
q11 O 0 5.661948421220586e-07
. O 0 2.9869897666401357e-09
2 O 0 2.061496751082359e-08
) O 0 5.89203086320822e-09
with O 0 8.088365532898933e-09
simultaneous O 0 1.765951225252138e-07
maternal O 0 1.1178059367011883e-06
meiotic O 0 2.0849651264143176e-05
nondisjunction O 0 7.05339916748926e-05
for O 0 3.826670536000165e-07
chromosome O 0 3.3815799724834505e-06
15 O 0 1.7503008393759956e-06
. O 0 2.5174356323987013e-06

The O 0 7.399302376143169e-06
patient O 0 1.9718399926205166e-06
( O 0 2.7529265977932482e-08
J O 0 1.681656272012333e-06
. O 0 5.599356089902585e-09
B O 0 1.1105196051630628e-07
. O 0 7.173356908474204e-10
) O 0 1.4078948007423264e-09
, O 0 2.9899254183618496e-09
a O 0 4.444417278648416e-09
17 O 0 1.4138129778018538e-08
- O 0 2.3550981609332666e-08
year O 0 6.655820783407762e-09
- O 0 5.925494761527261e-08
old O 0 1.9618599367277056e-07
white O 0 2.1484106937919023e-08
male O 0 1.1167873736894762e-08
with O 0 5.925187007704835e-09
PWS B-Disease 1 1.0
, O 0 1.624247403242407e-07
was O 0 1.5831696487111913e-07
found O 0 9.16517794991023e-09
to O 0 5.648247203282608e-09
have O 0 2.6706552525013194e-09
47 O 0 4.3467760946214185e-08
chromosomes O 0 2.048861524883705e-09
with O 0 1.1584252446183996e-09
a O 0 1.9580051358047967e-08
supernumerary O 0 7.657279638806358e-06
, O 0 8.104706950007312e-08
paternal O 0 7.8081461651891e-07
der O 0 0.08769045025110245
( O 0 1.1920109344032426e-08
15 O 0 2.2895767060049366e-08
) O 0 1.4607461906734898e-09
consisting O 0 4.601935721382233e-09
of O 0 8.445837806903e-09
the O 0 1.1391008136740766e-08
short O 0 3.572131745954721e-08
arm O 0 1.453410618523776e-07
and O 0 2.391551312541651e-08
the O 0 1.3219654704244022e-07
proximal O 0 0.00024168008530978113
long O 0 4.824767643185623e-07
arm O 0 1.296111122428556e-06
of O 0 6.504543534902041e-07
chromosome O 0 5.355904590942373e-07
15 O 0 9.481472318384476e-08
, O 0 3.513157409429368e-08
and O 0 1.3693144751414366e-07
distal O 0 0.17592212557792664
chromosome O 0 0.00023591911303810775
arm O 0 0.0001840721961343661
3p O 0 0.3573470115661621
. O 0 3.592836219468154e-05

The O 0 4.942774467053823e-06
t O 0 6.93211120506021e-07
( O 0 1.0635849534423869e-08
3 O 0 2.2077772499073944e-08
; O 0 1.9411297014215734e-09
15 O 0 8.773911375214993e-09
) O 0 1.4346994703373639e-09
was O 0 1.1517128584159764e-08
present O 0 2.2882613581742817e-09
in O 0 1.2484800970824494e-09
the O 0 5.216457044099343e-09
balanced O 0 1.5561143484887907e-08
state O 0 2.8181978972696697e-09
in O 0 2.0074863993357894e-09
the O 0 1.4467112841032304e-08
patients O 0 9.832576530754977e-09
father O 0 3.546497140405336e-08
and O 0 3.9640099203097634e-08
a O 0 4.867174538958352e-07
sister O 0 9.451458026887849e-06
. O 0 4.1840935409709346e-06

Fluorescent O 0 8.703066123416647e-05
in O 0 5.384757741921931e-07
situ O 0 1.0447281965753064e-05
hybridization O 0 2.747309508777107e-07
analysis O 0 3.067399845235741e-08
demonstrated O 0 3.501524048488136e-08
that O 0 4.144027787589266e-09
the O 0 1.1024492607702996e-07
PWS B-Disease 1 1.0
critical O 0 1.6229378161369823e-05
region O 0 7.525539444941387e-07
resided O 0 4.201740750886529e-07
on O 0 7.490798026310586e-08
the O 0 3.431552997312792e-08
derivative O 0 5.86162336446705e-08
chromosome O 0 9.646517362682516e-09
3 O 0 5.8494133980957486e-09
and O 0 1.1255780751895372e-09
that O 0 3.27899457586156e-10
there O 0 1.8141939062132906e-09
was O 0 1.5489156623971212e-08
no O 0 8.652774496908933e-09
deletion O 0 5.7379420326242325e-08
of O 0 7.248969779993786e-08
the O 0 4.4088494632887887e-07
PWS B-Disease 1 1.0
region O 0 1.3817598301102407e-06
on O 0 2.237772491753276e-07
the O 0 7.50982493968877e-08
normal O 0 4.265540454184702e-08
pair O 0 1.3311368896040676e-08
of O 0 6.219382697736364e-08
15s O 0 3.534619509082404e-06
present O 0 1.4692506056235288e-07
in O 0 2.297907286674672e-07
J O 0 0.0007255939417518675
. O 0 5.190652700548526e-06

B O 0 0.03148720785975456
. O 0 6.322407716652378e-05

Methylation O 0 7.380555871350225e-06
analysis O 0 2.5295935301983263e-07
at O 0 2.610396734326059e-07
exon O 0 1.074903593689669e-06
alpha O 0 2.0741853745676053e-07
of O 0 4.779092321882672e-08
the O 0 4.118876617553724e-08
small O 0 8.639749893291082e-08
nuclear O 0 1.0870433015952585e-06
ribonucleoprotein O 0 6.114958523539826e-06
- O 0 2.735985447088751e-07
associated O 0 7.681627067768204e-08
polypeptide O 0 1.4191726904755342e-06
N O 0 1.7229875766133773e-06
( O 0 3.465419950998694e-08
SNRPN O 1 0.9996715784072876
) O 0 4.096203554126987e-08
gene O 0 3.167716755569927e-08
showed O 0 2.0224373287192066e-08
a O 0 4.338101877721101e-09
pattern O 0 1.530295001828108e-08
characteristic O 0 5.39706661584205e-08
of O 0 3.897755362913813e-08
only O 0 4.6632830930093405e-09
the O 0 2.61511292620753e-08
maternal O 0 1.3492451955698925e-07
chromosome O 0 3.2548405215493403e-07
15 O 0 1.6383296497224364e-07
in O 0 1.9737203160730132e-07
J O 0 0.0005696417647413909
. O 0 8.091891686490271e-06

B O 0 0.03548795357346535
. O 0 8.998146222438663e-05

Maternal B-Disease 0 0.0007327123894356191
disomy I-Disease 0 0.03358537331223488
was O 0 3.7581855849566637e-06
confirmed O 0 1.5416068777085457e-07
by O 0 1.9450297372713976e-08
polymerase O 0 2.432124972528982e-07
chain O 0 1.3611612814656837e-07
reaction O 0 1.1586468673385752e-08
analysis O 0 8.221475944480972e-09
of O 0 8.79423822652825e-08
microsatellite O 0 2.735982661761227e-06
repeats O 0 1.4149870253277186e-07
at O 0 1.0999477240147826e-07
the O 0 1.316146267527074e-07
gamma O 0 3.3619555779296206e-06
- O 0 2.306558599229902e-06
aminobutyric O 0 1.977413921849802e-05
acid O 0 1.1475628980406327e-06
receptor O 0 3.489357425223716e-07
beta3 O 0 6.1142004597058985e-06
subunit O 0 9.411991754859628e-07
( O 0 8.478671986722475e-08
GABRB3 O 0 0.4870675206184387
) O 0 1.147594616668357e-06
locus O 0 5.8072440879186615e-05
. O 0 4.081891347595956e-06

A O 0 5.4892050684429705e-05
niece O 0 3.0105591577012092e-05
( O 0 1.0089010515912378e-07
B O 0 1.4455274595093215e-06
. O 0 6.9871446406466475e-09
B O 0 1.3537562892906863e-07
. O 0 1.3016377975461069e-09
) O 0 8.403893692054965e-10
with O 0 1.1009311240428588e-09
45 O 0 1.0660098581638522e-08
chromosomes O 0 1.7147212538759504e-09
and O 0 1.6309048556095718e-09
the O 0 4.5508730117660434e-09
derivative O 0 8.64401528133385e-09
3 O 0 5.0753063973729695e-09
but O 0 5.102588351846293e-10
without O 0 1.8482546604303707e-09
the O 0 8.2241733423416e-09
der O 0 6.594503065571189e-05
( O 0 7.073984509275988e-09
15 O 0 3.2638475033763825e-08
) O 0 4.428340805162634e-09
demonstrated O 0 1.742625599376879e-08
a O 0 9.20765064194029e-09
phenotype O 0 2.5768390088387605e-08
consistent O 0 6.7391474622979786e-09
with O 0 8.009238272599362e-10
that O 0 1.3809402510389646e-09
reported O 0 1.0819052320698574e-08
for O 0 1.5539963982291738e-08
haploinsufficiency O 0 1.40478241519304e-05
of O 0 2.457637719999184e-06
distal O 0 0.004660929087549448
3 O 0 3.652706800494343e-05
p O 0 5.868184416613076e-06
. O 0 2.1820885649503907e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 2.3199672796181403e-06
with O 0 1.8817750913058262e-07
unbalanced O 0 6.9268116931198165e-06
segregation O 0 2.425949787721038e-06
of O 0 9.445251976103464e-07
non O 0 2.703117388591636e-05
- O 0 6.445241160690784e-05
Robertsonian O 1 0.985808253288269
translocations O 0 5.201832209422719e-06
has O 0 3.121974501141267e-08
been O 0 4.90372720207688e-09
reported O 0 4.930249097867545e-09
previously O 0 1.3986000801935461e-08
but O 0 1.2685229533460074e-09
has O 0 1.3335402782033157e-09
not O 0 6.185589818130666e-10
, O 0 1.0072043199471636e-09
to O 0 2.0178205772936053e-09
our O 0 7.4073098765836676e-09
knowledge O 0 2.6366642202901858e-08
, O 0 7.782927191612998e-09
been O 0 6.038571420674543e-09
observed O 0 6.14781336949477e-09
in O 0 2.272091625954431e-09
a O 0 2.2178094027935913e-08
case O 0 9.111879961665181e-08
of O 0 2.8733124963764567e-06
PWS B-Disease 1 1.0
. O 0 4.4989217713009566e-05

Furthermore O 0 2.8859787562396377e-05
, O 0 3.1220523055708327e-07
our O 0 7.561250470189407e-08
findings O 0 3.1544882261869134e-08
are O 0 2.5762971755938224e-09
best O 0 3.350807986635118e-08
interpreted O 0 6.769541016637959e-08
as O 0 2.7712971473192738e-08
true O 0 2.314883289500358e-07
gamete O 0 1.9845554106723284e-06
complementation O 0 8.405186235904694e-06
resulting O 0 3.409176940749603e-07
in O 0 9.926988298047945e-08
maternal B-Disease 0 1.812829759728629e-05
UPD I-Disease 1 1.0
15 I-Disease 0 8.355903264600784e-05
and O 0 3.845093306154013e-05
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9996114373207092
- I-Disease 1 1.0
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
type I-Disease 0 8.684190220265009e-07
2 I-Disease 0 5.812541985505959e-07
and O 0 8.762692971231445e-08
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 2.165975310219892e-08
a O 0 1.7387211670438774e-08
case O 0 1.6000566205320865e-08
for O 0 1.462815824027075e-08
" O 0 2.3823623962471174e-07
lumping O 0 4.516356966632884e-06
" O 0 2.1683663362637162e-06
. O 0 2.008253204621724e-06

Recent O 0 2.8363699584588176e-06
studies O 0 4.863156277679082e-07
demonstrated O 0 8.805702123027004e-08
the O 0 3.100882750572964e-08
existence O 0 1.9531151806972957e-08
of O 0 3.508416668296377e-08
a O 0 2.0891373964104787e-08
genetically O 0 1.1136418720525398e-07
distinct O 0 1.1237681896147933e-08
, O 0 1.1992692394713345e-09
usually O 0 8.474039803196831e-10
lethal O 0 3.0149793772693556e-09
form O 0 4.645826778837403e-10
of O 0 4.3931582816014725e-09
the O 0 2.1541550765391548e-08
Schwartz B-Disease 0 0.019118642434477806
- I-Disease 1 0.9999996423721313
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 7.727106776656001e-08
SJS B-Disease 1 1.0
) O 0 9.425414759789419e-08
of O 0 1.8153599512515939e-06
myotonia B-Disease 1 1.0
and O 0 1.8382169173492002e-06
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 1.2657423553719127e-07
which O 0 1.4148650251399886e-08
we O 0 3.615507537801932e-08
called O 0 5.31996420249925e-07
SJS B-Disease 1 1.0
type I-Disease 0 4.112912210985087e-05
2 I-Disease 0 3.1415209377883e-05
. O 0 6.257773748075124e-06

This O 0 1.2592325902005541e-06
disorder O 1 0.9997584223747253
is O 0 5.5561660161629334e-08
reminiscent O 0 6.55733515486645e-07
of O 0 1.902432131828391e-07
another O 0 4.703707290332204e-08
rare O 0 1.2122340820042155e-07
condition O 0 1.0974748931857903e-07
, O 0 1.0551429951988212e-08
the O 0 8.629308467789087e-08
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 8.056940714595839e-07
SWS B-Disease 1 1.0
) O 0 4.708698497779551e-08
, O 0 1.0944058992379269e-08
which O 0 5.078182763185168e-09
comprises O 0 9.501422937319148e-08
campomelia B-Disease 0 2.387664835623582e-06
at O 0 7.665352086405619e-08
birth O 0 6.34273931154894e-08
with O 0 4.202101422379201e-08
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 3.977020696765976e-06
contractures B-Disease 1 1.0
, O 0 2.7245260980635067e-07
and O 0 1.9435022124980605e-07
early B-Disease 0 8.060906111495569e-07
death I-Disease 0 4.3897866817133036e-06
. O 0 2.8160693545942195e-06

To O 0 4.268926829809061e-07
test O 0 4.8476533009989e-08
for O 0 1.3283571576039321e-08
possible O 0 3.3625628503841654e-08
nosologic O 0 6.096482138673309e-06
identity O 0 2.03711802981843e-08
between O 0 5.581208384342062e-09
these O 0 2.4975294721230057e-08
disorders O 1 0.9694936871528625
, O 0 8.870362222523909e-09
we O 0 4.659504337922726e-09
reviewed O 0 3.4974590334968525e-08
the O 0 1.1533264121510456e-08
literature O 0 6.1066991463576414e-09
and O 0 1.3140781796039391e-09
obtained O 0 1.891579559654133e-09
a O 0 1.8080209551740722e-09
follow O 0 3.08710190743966e-09
- O 0 1.136498806175723e-08
up O 0 9.566885061929042e-09
of O 0 1.0570788688823995e-08
the O 0 4.656288243864992e-09
only O 0 9.459859562355177e-10
two O 0 1.604272936717166e-09
surviving O 0 6.401208452189167e-08
patients O 0 3.4917251312549524e-09
, O 0 1.5808778730530548e-09
one O 0 2.706959101317352e-09
with O 0 8.916874350006765e-09
SJS B-Disease 1 1.0
type I-Disease 0 1.0133149999091984e-06
2 I-Disease 0 2.7079320830125653e-07
at O 0 6.121675966141993e-08
age O 0 8.796985362380383e-09
10 O 0 2.2462034454662216e-09
years O 0 1.960661411004594e-09
and O 0 1.9176442656032577e-09
another O 0 8.155970121492828e-09
with O 0 1.3584375402331261e-08
SWS B-Disease 1 0.9990516304969788
at O 0 7.727666115897591e-07
age O 0 2.3008544758340577e-07
7 O 0 3.545469837717974e-07
years O 0 1.352306071567e-07
. O 0 9.738992048369255e-07

Patients O 0 1.9094653907814063e-05
reported O 0 2.5185974550367973e-07
as O 0 1.1116829767843228e-07
having O 0 2.1161643815048592e-07
either O 0 7.349037218773447e-07
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 0.3076956868171692
SWS B-Disease 1 1.0
presented O 0 4.750818902721221e-07
a O 0 2.0766746544609305e-08
combination O 0 3.251222935318765e-08
of O 0 3.8580292738288335e-08
a O 0 3.4190090758556835e-08
severe O 0 4.14696614825516e-06
, O 0 3.9180594768595256e-08
prenatal O 0 5.7625697991170455e-06
- O 1 0.996300458908081
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 7.909059604571667e-06
with O 1 0.9917660355567932
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9992985725402832
respiratory O 1 1.0
and O 0 1.1659691381282755e-06
feeding O 0 0.29161012172698975
difficulties O 0 6.680699152639136e-05
, O 0 2.0585929405569914e-08
tendency O 0 7.319312089748564e-08
to O 0 3.185529706684065e-08
hyperthermia B-Disease 1 0.9989284873008728
, O 0 3.044167939947329e-08
and O 0 1.814551353618299e-08
frequent O 0 9.18530744797863e-08
death O 0 2.337941253927056e-07
in O 0 1.2385972247841437e-08
infancy O 0 9.924186628040843e-08
) O 0 2.942061039235e-09
with O 0 4.150419119497428e-09
a O 0 3.0490255653603526e-08
distinct O 0 2.774476399736159e-07
campomelic B-Disease 0 0.05728825554251671
- I-Disease 1 0.8517046570777893
metaphyseal I-Disease 1 0.9999986886978149
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 6.0189940995769575e-05

The O 0 2.980179260703153e-06
similarity O 0 1.535483875159116e-06
of O 0 6.352800028253114e-07
the O 0 2.4502841711182555e-07
clinical O 0 2.0791774204553803e-06
and O 0 4.4706570889729846e-08
radiographic O 1 0.9854286313056946
findings O 0 3.300363289326924e-07
is O 0 1.1020072854250884e-08
so O 0 2.3465327458893626e-09
extensive O 0 4.440699896690603e-08
that O 0 6.2141154444361746e-09
these O 0 5.5917816155215405e-08
disorders O 1 0.6648988127708435
appear O 0 2.5068453979315564e-08
to O 0 1.3259471742799178e-08
be O 0 1.8901271658933183e-08
a O 0 9.31594144049086e-08
single O 0 2.965421117551159e-07
entity O 0 4.115459432796342e-06
. O 0 3.08825701722526e-06

The O 0 2.649808038768242e-06
follow O 0 2.1564207486335363e-07
- O 0 3.559020740340202e-07
up O 0 9.164290304397582e-08
observation O 0 2.3628354028915055e-07
of O 0 3.343466303817877e-08
an O 0 2.1433219643540724e-09
identical O 0 5.0734967338428305e-09
and O 0 1.7342324243330154e-09
unique O 0 1.6802898628043295e-08
pattern O 0 1.282700026195016e-07
of O 0 1.5942738400553935e-06
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 4.706426892653326e-08
the O 0 7.845977734177723e-08
two O 0 5.756135124102002e-09
patients O 0 3.156900518774819e-09
( O 0 7.043177152610269e-10
one O 0 3.6167402406306337e-09
with O 0 7.314536087932311e-09
SJS B-Disease 1 1.0
type I-Disease 0 1.582407321620849e-06
2 I-Disease 0 3.5153033195456374e-07
, O 0 6.7400600656242204e-09
one O 0 8.903686676831057e-09
with O 0 1.95841600714175e-08
SWS B-Disease 1 0.9999490976333618
) O 0 1.23784900551982e-07
surviving O 0 1.1131846804346424e-06
beyond O 0 2.2957782164212404e-07
infancy O 0 6.581279876627377e-08
adds O 0 7.549488145741634e-09
to O 0 2.5130915126680975e-09
the O 0 8.780573601541164e-09
evidence O 0 6.64113652959486e-09
in O 0 3.842099527417986e-09
favor O 0 3.0962318930960464e-08
of O 0 2.6110464546036383e-07
identity O 0 4.37014449516937e-07
. O 0 1.4551097820003633e-06

The O 0 4.494208042160608e-06
hypothesis O 0 2.5452845875406638e-06
that O 0 8.62004725377119e-08
SWS B-Disease 1 0.9999992847442627
and O 0 1.8343712326895911e-06
SJS B-Disease 1 1.0
type I-Disease 0 5.997119842504617e-06
2 I-Disease 0 4.39597272361425e-07
are O 0 2.5551172289084434e-09
the O 0 8.85214213042218e-09
same O 0 2.4231644246697215e-08
disorder O 0 1.0870726327993907e-05
should O 0 5.935536506740391e-09
be O 0 4.5880881316406885e-09
testable O 0 6.806167363038185e-08
by O 0 3.682865346021913e-09
molecular O 0 1.4957834082451882e-07
methods O 0 6.114254347266979e-08
. O 0 9.214294749426699e-08
. O 0 1.592237822478637e-06

A O 0 3.357987952767871e-05
mouse O 0 4.910992629447719e-06
model O 0 1.6929396906562033e-07
of O 0 2.2774648300583067e-07
severe O 1 0.9574506282806396
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.0014854329638183117
defects O 1 0.9999755620956421
in O 0 2.5317558538517915e-07
hemostasis O 1 1.0
and O 0 6.966161436139373e-06
thrombosis B-Disease 1 0.9995601773262024
. O 0 9.620475793781225e-06

von B-Disease 1 0.9999797344207764
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.8041592240333557
( I-Disease 0 5.856019015482161e-06
vWf I-Disease 1 1.0
) I-Disease 0 0.00037815922405570745
deficiency I-Disease 1 1.0
causes O 0 0.012954683043062687
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 4.967374479747377e-06
humans O 0 3.4543577385193203e-06
. O 0 1.2065954706486082e-06

We O 0 1.7313682292297017e-06
generated O 0 3.3121935416602355e-07
a O 0 7.658848488745207e-08
mouse O 0 3.5939604003942804e-07
model O 0 1.4237118151072536e-08
for O 0 2.6903388405941087e-09
this O 0 2.5617099552732725e-09
disease O 0 5.217604126528386e-08
by O 0 3.0768849690332445e-09
using O 0 4.27466240182639e-08
gene O 0 2.264306004917671e-07
targeting O 0 1.952450702447095e-06
. O 0 2.9447821816575015e-06

vWf B-Disease 1 0.9998264908790588
- I-Disease 1 0.999991774559021
deficient I-Disease 1 0.9999971389770508
mice O 0 1.352942217636155e-05
appeared O 0 2.5347443965983985e-07
normal O 0 2.7935227464581658e-08
at O 0 2.7528844981361544e-08
birth O 0 5.419841020426475e-09
; O 0 9.117139820880027e-10
they O 0 1.2455616538176173e-09
were O 0 1.1534143418145959e-08
viable O 0 1.426850957386705e-07
and O 0 8.589307753936737e-08
fertile O 0 1.1026791071344633e-05
. O 0 4.231779257679591e-06

Neither O 0 0.0002093681978294626
vWf O 0 0.0019101431826129556
nor O 0 2.472958294674754e-05
vWf O 0 0.000624104926828295
propolypeptide O 0 0.00019237234664615244
( O 0 8.183194495359203e-07
von B-Disease 0 0.0059387097135186195
Willebrand I-Disease 1 1.0
antigen O 0 0.00024946648045443
II O 1 1.0
) O 0 5.5495991801990385e-08
were O 0 2.655180431077042e-08
detectable O 0 6.385051847246359e-07
in O 0 5.872464292622226e-09
plasma O 0 5.5930286180228e-07
, O 0 1.3558386413592416e-08
platelets O 0 2.1355988621962751e-07
, O 0 1.3998331382936158e-08
or O 0 6.86928691706612e-09
endothelial O 0 7.208241470380017e-08
cells O 0 7.836328030919049e-09
of O 0 5.888079357418974e-08
the O 0 2.622246029204689e-07
homozygous O 0 6.077622401789995e-06
mutant O 0 3.902020398527384e-05
mice O 0 8.75140176503919e-06
. O 0 2.715457412705291e-06

The O 0 2.5335206373711117e-05
mutant O 1 0.7587860822677612
mice O 0 0.00046403740998357534
exhibited O 0 2.0576666429406032e-05
defects O 0 0.006309764925390482
in O 0 1.9274434492899672e-08
hemostasis O 0 0.010472317226231098
with O 0 2.454170378030085e-08
a O 0 1.574849761709629e-07
highly O 0 1.4086123883316759e-05
prolonged O 0 0.02288719452917576
bleeding O 1 0.9999908208847046
time O 0 6.175080358161722e-08
and O 0 1.541746428301849e-07
spontaneous O 0 8.660651928948937e-07
bleeding O 0 4.9624544772086665e-05
events O 0 5.4853213526939726e-08
in O 0 8.790192573826516e-09
approximately O 0 1.2623110556830852e-08
10 O 0 2.4046558522172745e-08
% O 0 1.703212504367002e-08
of O 0 1.5073236170337623e-07
neonates O 0 8.223397344409022e-06
. O 0 2.449013436489622e-06

As O 0 5.573264161284897e-07
in O 0 2.8346093472464418e-08
the O 0 6.048117029422428e-08
human O 0 7.493455456142328e-08
disease O 0 2.2898095721757272e-06
, O 0 5.961836802015341e-09
the O 0 2.834641676940919e-08
factor O 0 1.9704177134372003e-07
VIII O 1 0.9999946355819702
level O 0 3.852400993764604e-07
in O 0 5.2351860624355595e-09
these O 0 7.773610199990344e-09
mice O 0 6.237083027826884e-08
was O 0 1.684307271432317e-08
reduced O 0 8.80499229083398e-09
strongly O 0 1.9742421031310187e-09
as O 0 1.3539618315405733e-09
a O 0 1.0117946480647788e-09
result O 0 2.1817341266938683e-09
of O 0 8.45170422536512e-09
the O 0 1.0338844447232987e-08
lack O 0 3.79649947035432e-08
of O 0 6.222609982842187e-08
protection O 0 4.546567424768e-07
provided O 0 9.58987058652383e-08
by O 0 1.0114983695075352e-07
vWf O 0 0.00025456506409682333
. O 0 7.225431090773782e-06

Defective O 1 1.0
thrombosis B-Disease 1 0.9615691304206848
in O 0 5.563790068663366e-07
mutant O 0 0.06338971108198166
mice O 0 2.9079474188620225e-06
was O 0 1.526248354366544e-07
also O 0 1.366118151935325e-08
evident O 0 4.601867686915284e-08
in O 0 3.569937012670721e-09
an O 0 6.623110504477836e-09
in O 0 1.0217905632714519e-08
vivo O 0 6.317564498203865e-07
model O 0 9.161284708625317e-08
of O 0 1.532160467832e-06
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 2.464038334437646e-05

In O 0 3.025379271548445e-07
this O 0 1.3156938649672156e-08
model O 0 2.9106383081511922e-08
, O 0 1.348797074030017e-08
the O 0 5.662769808623125e-08
exteriorized O 0 1.672194957791362e-05
mesentery O 0 0.0005453681224025786
was O 0 1.2080993201379897e-06
superfused O 0 3.697552529047243e-05
with O 0 2.6172043021688296e-07
ferric O 1 0.5662384033203125
chloride O 0 2.2968474695517216e-06
and O 0 1.1021317192216884e-07
the O 0 1.4931522684946685e-07
accumulation O 0 2.3388229237752967e-06
of O 0 1.9964556940976763e-06
fluorescently O 0 0.012244747020304203
labeled O 0 4.48147657152731e-05
platelets O 0 9.012868758873083e-06
was O 0 6.086805797167472e-07
observed O 0 1.2320909092977672e-07
by O 0 3.899093670156617e-08
intravital O 0 4.1253329982282594e-05
microscopy O 0 3.2672041925252415e-06
. O 0 6.459069481934421e-06

We O 0 1.632237967896799e-06
conclude O 0 5.356537826628482e-07
that O 0 1.163481133659161e-08
these O 0 2.4374601892418468e-08
mice O 0 2.6540800490693073e-07
very O 0 1.0140594142171722e-08
closely O 0 9.736430683915387e-08
mimic O 0 0.00027632195269688964
severe O 0 0.4601980447769165
human O 0 0.000737144029699266
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.6351346232568176e-07
will O 0 7.392024770069838e-09
be O 0 1.8312429350686443e-09
very O 0 6.476214009509818e-10
useful O 0 2.160985168586649e-09
for O 0 7.143224345362853e-10
investigating O 0 1.197050725210147e-08
the O 0 1.87149815644716e-08
role O 0 6.54310525760593e-08
of O 0 2.218188512870256e-07
vWf O 0 2.4156432118616067e-05
in O 0 2.2956898604320486e-08
normal O 0 1.1007263367446285e-07
physiology O 0 2.0523012267403828e-07
and O 0 7.241462984808322e-09
in O 0 1.558740159168792e-08
disease O 0 5.153827942194766e-07
models O 0 7.039221827653819e-08
. O 0 7.093213838516021e-08
. O 0 1.0099597602675203e-06

Oral O 0 0.0003551029658410698
contraceptives O 0 3.967739030485973e-05
and O 0 6.882627445747858e-08
the O 0 7.476837993181107e-08
risk O 0 8.832267894831602e-07
of O 0 0.04388776794075966
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.9077282306388952e-05

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 0.999868631362915
Study O 0 6.625761670875363e-06
Group O 0 2.2947831439523725e-06
. O 0 2.047575435426552e-06

BACKGROUND O 0 5.98045444348827e-05
Women O 0 3.916498059197693e-08
with O 0 3.9666931961335195e-09
mutations O 0 7.99916577420845e-09
in O 0 1.6940558955624851e-09
either O 0 6.1077711777102195e-09
the O 0 4.5687478689160343e-08
BRCA1 O 0 6.761223403373151e-07
or O 0 1.3616256566706397e-08
the O 0 1.6191036422696925e-07
BRCA2 O 0 2.8213512450747658e-06
gene O 0 8.17015433085544e-09
have O 0 9.494511843399778e-10
a O 0 2.8327056256216565e-09
high O 0 7.414493552460044e-08
lifetime O 0 1.5417332122069638e-07
risk O 0 9.535369827062823e-07
of O 0 0.002264468465000391
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.41136079543503e-06

Oral O 0 0.44766613841056824
contraceptives O 1 0.9998213648796082
protect O 1 0.9957976341247559
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.302406005265766e-08
general O 0 1.7409711006166617e-08
, O 0 3.7226477456187013e-09
but O 0 9.312292603702588e-10
it O 0 7.869005447247446e-10
is O 0 9.729610450648352e-10
not O 0 5.650765966258575e-10
known O 0 5.434405370152717e-09
whether O 0 3.338895382398732e-09
they O 0 2.4081336924552943e-09
also O 0 8.702875753385797e-09
protect O 0 7.800957746439963e-08
against O 0 1.661969548649722e-07
hereditary B-Disease 1 0.9993329644203186
forms I-Disease 0 0.003408077172935009
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3982160453451797e-05

METHODS O 0 1.0833386113517918e-05
We O 0 2.710521300741675e-07
enrolled O 0 4.423931727615127e-07
207 O 0 1.5637614581009984e-07
women O 0 6.6129737241737985e-09
with O 0 8.088723291166389e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.305331995941742e-08
161 O 0 4.946924292426047e-08
of O 0 6.186149903442129e-08
their O 0 7.853880212849162e-09
sisters O 0 1.0070419165231215e-07
as O 0 6.040011157892877e-09
controls O 0 1.272287164510999e-07
in O 0 1.2443345909218806e-08
a O 0 4.1070780554264275e-08
case O 0 1.2757840295307687e-07
- O 0 2.2814044768892927e-06
control O 0 3.9416440813511144e-06
study O 0 1.23563802389981e-06
. O 0 1.943511279023369e-06

All O 0 1.0728819006544654e-06
the O 0 3.0333413292282785e-07
patients O 0 4.090433947112615e-08
carried O 0 1.5650618578888498e-08
a O 0 1.2041151187247578e-08
pathogenic O 0 2.43364695506898e-07
mutation O 0 2.00239362868615e-08
in O 0 2.247561914359153e-09
either O 0 1.9088833624891777e-08
BRCA1 O 0 1.771997517607815e-07
( O 0 3.3078921823914698e-09
179 O 0 4.273863396520028e-08
women O 0 1.6701124927465116e-09
) O 0 5.409255265931279e-09
or O 0 5.472592690125566e-08
BRCA2 O 0 8.374638127861544e-06
( O 0 1.8169757254327124e-08
28 O 0 3.5696874078894325e-07
women O 0 1.7453197997951975e-08
) O 0 5.844933070875413e-08
. O 0 1.9072949726250954e-06

The O 0 4.1074608816416e-06
control O 0 4.10182792620617e-06
women O 0 1.2421103257054256e-08
were O 0 5.059851204691768e-09
enrolled O 0 2.2254834419754843e-08
regardless O 0 3.3347775652003975e-09
of O 0 7.1056684980419504e-09
whether O 0 3.575081342077624e-09
or O 0 3.45028206005793e-09
not O 0 1.85640192107428e-09
they O 0 4.577205725553313e-09
had O 0 3.822045258061735e-08
either O 0 1.0924082971541793e-07
mutation O 0 9.775664011613117e-07
. O 0 1.0373657914897194e-06

Lifetime O 0 2.5208393708453514e-05
histories O 0 3.420187795200036e-06
of O 0 9.800784255276085e-07
oral O 0 6.270114681683481e-06
- O 0 1.161826730822213e-06
contraceptive O 0 1.7018365383592027e-07
use O 0 3.4890954569988253e-09
were O 0 1.201943877759959e-09
obtained O 0 8.254845695887525e-10
by O 0 4.930566510630285e-10
interview O 0 2.6428319088722674e-08
or O 0 1.8803707479975174e-09
by O 0 3.7782627027027615e-10
written O 0 3.079767996183591e-09
questionnaire O 0 3.0553288787871224e-09
and O 0 1.0657328353147477e-09
were O 0 1.1506232633351487e-09
compared O 0 2.5790158897365245e-09
between O 0 1.884435052446065e-09
patients O 0 3.877347776182205e-09
and O 0 3.026508599290878e-09
control O 0 1.3244883803054108e-06
women O 0 4.692592980859445e-09
, O 0 2.1998105559362102e-09
after O 0 1.9142858409537666e-09
adjustment O 0 2.9461784123441248e-08
for O 0 2.4677577759035785e-09
year O 0 5.210003539701802e-09
of O 0 5.927631008262324e-08
birth O 0 6.957066034374293e-08
and O 0 1.0191127586267612e-07
parity O 0 7.2043844738800544e-06
. O 0 3.614739853219362e-06

RESULTS O 0 1.1046388863178436e-05
The O 0 8.665418818054604e-07
adjusted O 0 8.674737159708457e-07
odds O 0 1.599784354766598e-06
ratio O 0 4.3872236688002886e-07
for O 0 1.2701428886430222e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 2.3445609897976283e-08
with O 0 4.018828381191497e-09
any O 0 1.0293764951541107e-08
past O 0 1.5517692020239338e-08
use O 0 8.494239089884559e-09
of O 0 1.3575470347859664e-07
oral O 0 2.9681077649001963e-06
contraceptives O 0 8.30094450066099e-06
was O 0 8.172657999239163e-07
0 O 0 1.011648578241875e-06
. O 0 1.2240220712556038e-06

5 O 0 4.917216756439302e-06
( O 0 1.658239483504076e-07
95 O 0 1.1183166179762338e-06
percent O 0 2.3563073625609832e-07
confidence O 0 8.617827518264676e-08
interval O 0 8.840166287882312e-08
, O 0 1.0584386700429604e-08
0 O 0 1.6657738299841185e-08
. O 0 2.3106863089594754e-09
3 O 0 1.5144872023142852e-08
to O 0 8.148941965657741e-09
0 O 0 3.160619499453787e-08
. O 0 7.480615238364408e-09
8 O 0 2.1197109845161322e-07
) O 0 1.9990170585515443e-07
. O 0 1.487436179559154e-06

The O 0 7.008969532762421e-06
risk O 0 1.803766735974932e-06
decreased O 0 6.988026512999568e-08
with O 0 3.0122722094461096e-09
increasing O 0 1.943420180339217e-08
duration O 0 5.143791170780787e-08
of O 0 1.927266879420131e-08
use O 0 1.5188728497150805e-08
( O 0 1.0961167973277952e-08
P O 0 2.1268813554797816e-07
for O 0 1.1088787665869404e-08
trend O 0 6.097565119489445e-08
, O 0 3.669717862919697e-09
< O 0 1.8319354921914055e-08
0 O 0 5.191889584921228e-09
. O 0 8.719686084290856e-10
001 O 0 2.212810734647519e-08
) O 0 4.924504692915832e-10
; O 0 2.407576915608445e-10
use O 0 6.574499278322321e-10
for O 0 8.765660419740584e-10
six O 0 1.5772937400626574e-09
or O 0 9.659363309211244e-10
more O 0 2.894999795444164e-10
years O 0 2.042334079632724e-09
was O 0 8.740220991398928e-09
associated O 0 3.1308697856502476e-09
with O 0 2.5153310545533714e-09
a O 0 2.0623264873620428e-08
60 O 0 5.22169578687226e-08
percent O 0 1.9365561598760905e-08
reduction O 0 1.8506653987060417e-07
in O 0 7.752188224685597e-08
risk O 0 2.149025021935813e-06
. O 0 2.1333933091227664e-06

Oral O 0 0.0001278230338357389
- O 0 8.269987120002043e-06
contraceptive O 0 2.8711895083688432e-06
use O 0 8.138911766764068e-08
protected O 1 0.938599169254303
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 5.0294750586488135e-09
for O 0 2.357937400887522e-09
carriers O 0 3.394860170757852e-09
of O 0 1.0481686629759679e-08
the O 0 7.004453550507606e-08
BRCA1 O 0 8.661709216539748e-07
mutation O 0 2.4817024879553173e-08
( O 0 2.683205435616287e-09
odds O 0 9.679475709845065e-08
ratio O 0 1.0096301572559696e-08
, O 0 1.3222239969579164e-09
0 O 0 3.542053983451865e-09
. O 0 1.0264116223623887e-09
5 O 0 8.480576241254312e-09
; O 0 2.1177577469444486e-09
95 O 0 7.41289554184732e-08
percent O 0 2.0629087771339982e-08
confidence O 0 1.4997807440408906e-08
interval O 0 1.7826446097046755e-08
, O 0 3.594794684147473e-09
0 O 0 5.184665585744597e-09
. O 0 4.947268705812746e-10
3 O 0 3.0508975346066336e-09
to O 0 7.357797149332157e-10
0 O 0 2.478007132822313e-09
. O 0 5.52174084234025e-10
9 O 0 4.652258134285603e-09
) O 0 3.661829173218223e-10
and O 0 8.633004311420223e-10
for O 0 2.076495420055835e-09
carriers O 0 8.386108696356587e-09
of O 0 4.682966192603999e-08
the O 0 2.729730397277308e-07
BRCA2 O 0 7.137209195207106e-06
mutation O 0 5.7394085928308414e-08
( O 0 6.2764620167854446e-09
odds O 0 2.0095490071980748e-07
ratio O 0 1.5241544915056693e-08
, O 0 1.5461194546873003e-09
0 O 0 3.2999141197365134e-09
. O 0 5.906768407726304e-10
4 O 0 5.895189669757883e-09
; O 0 9.639816722639694e-10
95 O 0 5.128146796096189e-08
percent O 0 2.5880103393660647e-08
confidence O 0 1.4155722816155958e-08
interval O 0 1.5801914443613896e-08
, O 0 3.2635723012930384e-09
0 O 0 5.023885307764431e-09
. O 0 6.994754775391243e-10
2 O 0 6.700887400512556e-09
to O 0 1.5140013687187093e-09
1 O 0 2.1672770245118045e-08
. O 0 6.887838299718396e-09
1 O 0 2.2345523120748112e-07
) O 0 2.6651258622223395e-07
. O 0 1.6372628124372568e-06

CONCLUSIONS O 0 4.979105870006606e-05
Oral O 0 4.492233711061999e-05
- O 0 3.647769744929974e-06
contraceptive O 0 6.684894060526858e-07
use O 0 1.4203268783319345e-08
may O 0 2.4151438626773825e-09
reduce O 0 7.094198561929943e-09
the O 0 8.886805069607817e-09
risk O 0 4.117486867016851e-07
of O 1 0.9917618036270142
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.1910155528482846e-08
women O 0 6.313691791604015e-10
with O 0 4.2791853394064105e-10
pathogenic O 0 6.037122091129277e-08
mutations O 0 1.3479329652454908e-08
in O 0 8.225412351237082e-09
the O 0 3.080751014294947e-07
BRCA1 O 0 2.007783405133523e-05
or O 0 2.506306145733106e-06
BRCA2 O 0 0.000536538427695632
gene O 0 2.814259823935572e-05

A O 0 2.264942304464057e-05
Japanese O 0 4.768203325511422e-06
family O 0 3.105109271928086e-07
with O 0 1.709488230972056e-07
adrenoleukodystrophy B-Disease 1 1.0
with O 0 3.6757376165041933e-07
a O 0 2.93694427000446e-07
codon O 0 6.742428126926825e-07
291 O 0 1.5307890066651453e-07
deletion O 0 9.94370239482123e-08
: O 0 5.511579193040461e-09
a O 0 9.224649488714931e-09
clinical O 0 2.721368446145789e-07
, O 0 1.7638129179431417e-08
biochemical O 0 6.259344900172437e-07
, O 0 2.1837294639226457e-08
pathological O 0 3.571243360056542e-05
, O 0 2.976430302226163e-08
and O 0 7.988694505911553e-08
genetic O 0 1.2175722758911434e-06
report O 0 3.319720178751595e-07
. O 0 2.4087448764475994e-06

We O 0 1.3571965382652706e-06
report O 0 1.6949947223565687e-07
a O 0 2.521836783841991e-08
Japanese O 0 2.0727932792397041e-07
family O 0 4.373446316208174e-08
with O 0 9.156008928812298e-08
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.16270163655281067
ALD B-Disease 1 1.0
) O 0 3.537862980351747e-08
with O 0 5.47577494458551e-09
a O 0 8.273828733251776e-09
three O 0 9.222555164001278e-09
base O 0 9.293864167148058e-08
pair O 0 1.0411891082640068e-07
deletion O 0 6.221838475539698e-07
( O 0 3.090502431746245e-08
delGAG O 0 3.951422058889875e-06
291 O 0 1.3738834070409212e-07
) O 0 1.4838778206183179e-08
in O 0 3.6526319746599256e-08
the O 0 1.4753344430573634e-06
ALD B-Disease 1 1.0
gene O 0 2.1345336790545844e-05
. O 0 6.841895810794085e-06

A O 0 4.440354587131878e-06
variety O 0 8.123090537992539e-07
of O 0 7.469203637811006e-07
phenotypes O 0 1.67025871178339e-06
were O 0 3.980200347086793e-08
observed O 0 8.16352283550259e-08
within O 0 2.048761160722279e-08
this O 0 1.6222932330833828e-08
family O 0 3.7386388385129976e-07
. O 0 1.6387405139539624e-06

While O 0 1.8854660766010056e-06
the O 0 6.20464902567619e-07
proband O 0 0.0002063337160507217
( O 0 3.893089228768076e-08
patient O 0 7.159899695352578e-08
1 O 0 7.793343570483557e-08
) O 0 8.385324434811992e-09
was O 0 4.732251568384527e-08
classified O 0 1.8808958657245967e-07
as O 0 1.1107988306946481e-08
having O 0 1.5728783608892627e-08
a O 0 7.036265792237373e-09
rare O 0 3.5323875380299796e-08
intermediate O 0 3.1952180279404274e-07
type O 0 4.8506041849805115e-08
of O 0 1.4221328115127108e-07
adult O 0 1.4622852404500009e-06
cerebral O 0 1.6668853959345142e-06
and O 0 5.283761339569537e-08
cerebello O 1 0.9999988079071045
- O 0 0.02680833823978901
brain O 0 2.47046818913077e-06
stem O 0 2.4786606545035283e-08
forms O 0 4.613114334972579e-09
, O 0 1.3791607855750954e-09
his O 0 1.7995205325860297e-08
younger O 0 6.473107561077995e-08
brother O 0 1.201926522753638e-07
( O 0 9.089519359406495e-09
patient O 0 2.811488464260492e-08
2 O 0 6.800028984343953e-08
) O 0 7.307939586809198e-09
and O 0 4.6356525729152054e-08
nephew O 0 9.298629265686031e-06
( O 0 2.4024277678336148e-08
patient O 0 4.9560096471168436e-08
3 O 0 8.63688285335229e-08
) O 0 1.3029550771648246e-08
had O 0 3.884515109575659e-08
a O 0 2.0171333403595781e-07
childhood O 0 0.0001980229135369882
ALD B-Disease 1 1.0
type O 0 0.007970277220010757
. O 0 7.053170520521235e-06

Another O 0 2.2185020498000085e-05
nephew O 0 0.00044851095299236476
( O 0 2.66517673708222e-07
patient O 0 2.2735542870577774e-07
4 O 0 1.0967800534444905e-07
) O 0 5.977949246727121e-09
of O 0 3.1351682139302284e-08
patient O 0 2.621555239556983e-08
1 O 0 9.362594965978133e-08
was O 0 9.684978152790791e-08
classified O 0 1.7701093213418062e-07
as O 0 1.599608090430138e-08
having O 0 3.5450025137606644e-08
an O 0 4.106756890109864e-08
adolescent O 0 6.708807632094249e-06
form O 0 5.995090646138124e-07
. O 0 2.392570195297594e-06

The O 0 6.0777961152780335e-06
tau O 0 1.2162156053818762e-05
level O 0 7.17729108146159e-07
in O 0 3.3268694465959925e-08
the O 0 2.608836098261236e-07
cerebrospinal O 0 0.0001223359431605786
fluid O 0 2.482833224348724e-05
( O 0 2.849335487553617e-07
CSF O 1 1.0
) O 0 2.3152006534132852e-08
in O 0 4.9703867688322134e-09
patient O 0 1.665307003406724e-08
1 O 0 3.910816914753923e-08
was O 0 3.650403357369214e-08
as O 0 3.913165791402662e-09
high O 0 4.1801818895237375e-08
as O 0 3.508301205101816e-09
that O 0 1.2143318572910289e-09
of O 0 2.109232788427562e-08
patients O 0 1.4351326349526516e-08
with O 0 2.4721451552522922e-08
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999994039535522
( O 0 9.652263344150924e-08
AD B-Disease 0 7.772576282150112e-06
) O 0 4.494999927828758e-07
. O 0 1.8548331581769162e-06

His O 0 9.990363469114527e-05
brain O 0 0.004230412654578686
magnetic O 0 3.596824171836488e-06
resonance O 0 2.709657564992085e-06
image O 0 4.297165105526801e-06
( O 0 9.198631545359603e-08
MRI O 1 0.9993650317192078
) O 0 5.5942781074236336e-08
showed O 0 1.6798117030702997e-07
abnormalities B-Disease 0 4.512800842348952e-06
in I-Disease 0 6.445163958090916e-09
the I-Disease 0 8.225902803360441e-08
bilateral I-Disease 0 0.00011117776011815295
cerebellar I-Disease 1 1.0
hemispheres I-Disease 0 0.0009420184651389718
and O 0 4.903332637695712e-07
brain O 0 0.020409168675541878
stem O 0 2.0490196561695484e-07
, O 0 5.207619224734117e-09
but O 0 1.1495462359789599e-09
not O 0 6.565226140509139e-10
in O 0 2.1198469646321882e-09
the O 0 4.3765840729292904e-08
cerebral O 0 1.762217607392813e-06
white O 0 9.531662925610362e-08
matter O 0 5.912973932709065e-08
, O 0 4.128422936844345e-09
where O 0 3.2667981653133893e-09
marked O 0 9.342184803529108e-09
reductions O 0 5.530094071559688e-08
of O 0 3.7893300941505004e-08
the O 0 5.8121599977312144e-08
cerebral O 0 1.815436235119705e-06
blood O 0 5.9098056226503104e-08
flow O 0 5.070065256518319e-08
and O 0 1.396174731382871e-08
oxygen O 0 6.114942152635194e-08
metabolism O 0 3.5169655632216745e-08
were O 0 8.243819848985368e-09
clearly O 0 3.325873620951825e-08
demonstrated O 0 2.0518269749913998e-08
by O 0 8.90027340716415e-09
positron O 0 2.9411164632620057e-06
emission O 0 4.840358997171279e-06
tomography O 0 2.3677873741689837e-06
( O 0 2.889399013383809e-07
PET O 0 0.0005795424222014844
) O 0 8.084741693892283e-07
. O 0 3.587225592127652e-06

In O 0 7.235735779431707e-07
patients O 0 2.3720855324427248e-07
2 O 0 1.0189165067231443e-07
and O 0 1.3758903349980756e-08
3 O 0 1.0657256410695481e-07
, O 0 1.1776809749619588e-08
the O 0 2.3160311002357048e-08
autopsy O 0 3.972366471316491e-07
findings O 0 2.1479353407016788e-08
showed O 0 4.011417331639677e-08
massive O 0 1.3747036973654758e-05
demyelination B-Disease 1 1.0
of I-Disease 1 0.9881684184074402
the I-Disease 0 1.8990594981005415e-05
cerebral I-Disease 0 9.895812581817154e-06
white I-Disease 0 3.4860970998806806e-08
matter I-Disease 0 7.553837555462906e-09
with O 0 1.252604131529722e-09
sparing O 0 6.06480980991364e-08
of O 0 1.2824273198930314e-07
the O 0 2.4040741664066445e-07
U O 0 0.02963046357035637
- O 0 1.0536795343796257e-05
fibers O 0 8.410763143729127e-07
, O 0 1.9286973795829e-08
compatible O 0 6.97416524531036e-08
with O 0 5.783305834228258e-09
the O 0 4.391451469132335e-08
findings O 0 8.27174915229989e-08
of O 0 6.942484560568118e-07
childhood O 1 0.5997270941734314
ALD B-Disease 1 1.0
. O 0 6.629472045460716e-05

Oleic O 0 0.49880459904670715
and O 0 7.219659437396331e-06
erucic O 1 0.9284026622772217
acids O 0 2.4250477963505546e-06
( O 0 7.945901359107665e-08
Lorenzos O 0 2.3388911358779296e-05
Oil O 0 2.904184270846599e-07
) O 0 1.5650527984689688e-08
were O 0 8.44421155221653e-09
administered O 0 2.8962841014390506e-08
to O 0 5.562037497242045e-09
patients O 0 5.857518914353932e-09
1 O 0 1.658871440213261e-08
and O 0 4.139438125605466e-09
4 O 0 5.0204299384404294e-08
, O 0 3.97682109465336e-09
but O 0 2.1270440964116233e-09
sufficient O 0 1.810931316015285e-08
effectiveness O 0 1.0293690877460904e-07
was O 0 1.8104240950833628e-07
not O 0 2.3670816418075447e-08
obtained O 0 3.5115706964461424e-07
. O 0 1.401852500748646e-06

The O 0 5.7728061619855e-06
findings O 0 4.1017707985702145e-07
in O 0 1.4493240385604622e-08
this O 0 6.611511338405762e-09
family O 0 1.938263594070122e-08
suggest O 0 7.039178573364779e-09
that O 0 1.2193102083557505e-09
delGAG291 O 0 3.2432950547445216e-07
is O 0 6.233845883940603e-09
part O 0 1.8182097605290437e-08
of O 0 4.223225502641981e-08
the O 0 5.310880268893925e-08
cause O 0 1.2494102463733725e-07
of O 0 5.85527061502944e-07
Japanese O 0 1.8694343452807516e-05
ALD B-Disease 1 1.0
with O 0 1.0138755897060037e-06
phenotypic O 0 3.898523937095888e-05
variations O 0 2.6637066184775904e-05
. O 0 4.307467861508485e-06

Moreover O 0 5.611811047856463e-06
, O 0 1.1618870843221885e-07
although O 0 2.435015922230832e-08
the O 0 1.3400068610280869e-08
scale O 0 9.651379428987639e-08
of O 0 4.5795136571769035e-08
the O 0 1.8243412114316016e-08
study O 0 6.313635392274364e-09
is O 0 1.1562421020627767e-09
limited O 0 1.4902276079808985e-09
, O 0 1.2973870866517245e-09
there O 0 1.6083263609800724e-09
is O 0 2.1738959521400147e-09
a O 0 4.235000350405471e-09
possibility O 0 2.50641996046852e-08
that O 0 2.9521620703576446e-09
PET O 0 4.4870233978144825e-05
can O 0 1.0519780602180617e-08
detect O 0 5.173141062186914e-07
an O 0 8.307529952844561e-08
insidious B-Disease 0 0.0023376389872282743
lesion I-Disease 0 0.04311526566743851
which O 0 2.1121595139561578e-08
is O 0 1.6487176068835652e-08
undetectable O 0 3.367319436620164e-07
by O 0 1.901222734801422e-09
computed O 0 1.0633176117380572e-07
tomogram O 0 2.0033114196849056e-05
( O 0 4.386545882084647e-08
CT O 0 0.00313048018142581
) O 0 1.3684704924799007e-08
or O 0 8.737154111315704e-09
MRI O 0 4.079580833149521e-07
analysis O 0 5.956608539747776e-09
, O 0 2.523418363153951e-09
and O 0 2.4463082670678205e-09
that O 0 1.1573054736757626e-09
the O 0 7.114184796819245e-09
higher O 0 1.1435133728809888e-08
level O 0 2.2675470390254304e-08
of O 0 4.5131006487508785e-08
tau O 0 8.00057136984833e-07
reflects O 0 2.813677113522317e-08
the O 0 5.6661590974727005e-09
process O 0 2.9477282836865015e-09
of O 0 6.307499234026182e-08
neuronal B-Disease 0 1.9919270926038735e-05
degeneration I-Disease 1 1.0
in O 0 4.809383972315118e-05
ALD B-Disease 1 1.0
. O 0 8.723721839487553e-05

Lorenzos O 0 0.0011630223598331213
Oil O 0 2.4812823085085256e-06
should O 0 2.705845680850416e-08
be O 0 2.1434609642767555e-09
given O 0 1.6818217929426282e-09
in O 0 1.6980219452733536e-09
the O 0 1.9063181255773998e-08
early O 0 6.000890806490133e-08
stage O 0 9.108992458095599e-07
. O 0 2.2791681431044708e-07
. O 0 1.9660308225866174e-06

Nonsense O 0 0.00012256199261173606
mutation O 0 8.259812602773309e-07
in O 0 4.5786840985329036e-08
exon O 0 1.701026576483855e-06
4 O 0 2.3185640429801424e-07
of O 0 1.1739138017219375e-07
human O 0 3.966860973037001e-08
complement O 0 2.4152103605956654e-07
C9 O 1 0.9999998807907104
gene O 0 9.26794854194668e-08
is O 0 8.469439372049692e-09
the O 0 7.11257008845223e-09
major O 0 8.298867015810174e-08
cause O 0 1.0205638290017305e-07
of O 0 2.979430178129405e-07
Japanese O 0 3.818289314949652e-06
complement B-Disease 0 4.400857142172754e-05
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999980926513672
. O 0 1.97690496861469e-05

Deficiency B-Disease 1 0.9999972581863403
of I-Disease 0 1.4406349691853393e-05
the I-Disease 0 1.0315422969142674e-06
ninth I-Disease 0 3.2158513931790367e-06
component I-Disease 0 9.803663942875573e-07
of I-Disease 0 7.536701218668895e-08
human I-Disease 0 2.3836866702708903e-08
complement I-Disease 0 1.124870863122851e-07
( O 0 1.9493489489263993e-08
C9 O 1 1.0
) O 0 9.591678562514971e-09
is O 0 3.5032792222722264e-09
the O 0 3.018644889607458e-09
most O 0 3.848494856129037e-09
common O 0 9.884062990295206e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.0811442286449164e-08
Japan O 0 8.316947486264326e-08
but O 0 3.7813503439565466e-09
is O 0 7.314605365849047e-09
rare O 0 1.3813202137669123e-08
in O 0 4.901828720704771e-09
other O 0 1.3852488045529299e-08
countries O 0 1.5151401910884488e-08
. O 0 1.2321572739892872e-06

We O 0 2.0041968582518166e-06
studied O 0 9.349137144454289e-07
the O 0 8.63543334617134e-08
molecular O 0 2.0921525845096767e-07
basis O 0 5.680857739776002e-08
of O 0 8.076003155110811e-07
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999936819076538
in O 0 3.539577164701768e-08
four O 0 3.9613944124994305e-08
Japanese O 0 1.402443444931123e-06
C9 B-Disease 1 1.0
- I-Disease 1 0.9999943971633911
deficient I-Disease 1 0.9999959468841553
patients O 0 4.0320833250007126e-07
who O 0 7.143407998455586e-08
had O 0 1.9613474933066755e-07
suffered O 0 1.029845680022845e-05
from O 0 1.4372686791830347e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.2893212442577351e-05

Direct O 0 2.870343450922519e-06
sequencing O 0 2.4620480871817563e-06
of O 0 2.7114567728858674e-06
amplified O 0 2.216034226876218e-05
C9 O 0 0.0006209609564393759
cDNA O 0 1.2792859251931077e-06
and O 0 5.475223829876086e-08
DNA O 0 1.4513771873225778e-07
revealed O 0 3.627318889698472e-08
a O 0 1.7971196086818964e-08
nonsense O 0 4.2807573663594667e-07
substitution O 0 2.1040057163190795e-07
( O 0 4.814205567527097e-08
CGA O 0 4.7691377403680235e-05
- O 0 5.945367774984334e-06
- O 0 6.533916348416824e-06
> O 0 1.7857059901871253e-06
TGA O 0 1.2858253285230603e-05
) O 0 2.396112641633863e-08
at O 0 7.909354593493845e-08
codon O 0 1.1482719486366477e-07
95 O 0 3.470062992505518e-08
in O 0 4.995963642784318e-09
exon O 0 2.827784442160919e-07
4 O 0 5.2332520539266625e-08
in O 0 6.1892158065290914e-09
the O 0 3.858124841826793e-08
four O 0 1.0441642928071815e-07
C9 B-Disease 1 0.9999997615814209
- I-Disease 0 0.00010961869702441618
deficient I-Disease 0 5.3726285841548815e-05
individuals O 0 1.7146608399798424e-07
. O 0 1.3857979865861125e-06

An O 0 1.5141224594117375e-06
allele O 0 2.2608780909649795e-06
- O 0 8.863868856678891e-07
specific O 0 1.0646468240338436e-07
polymerase O 0 1.248033640877111e-07
chain O 0 9.425989588862649e-08
reaction O 0 8.596760636692125e-09
system O 0 1.5565417399443504e-08
designed O 0 3.133643389219287e-08
to O 0 1.0618761869807258e-08
detect O 0 1.659638115825146e-07
exclusively O 0 2.138675903040621e-08
only O 0 1.0365910352305718e-09
one O 0 1.2037011387633356e-09
of O 0 6.984879341587202e-09
the O 0 8.946398288856017e-09
normal O 0 1.0452517962278307e-08
and O 0 4.840924550109094e-09
mutant O 0 3.014371827703144e-07
alleles O 0 9.904667308546777e-09
indicated O 0 2.7482662812161607e-09
that O 0 4.456333357882869e-10
all O 0 1.3330926362797868e-09
the O 0 2.5817030735453272e-09
four O 0 2.4857893521357255e-09
patients O 0 1.514012804015863e-09
were O 0 1.4553899196911857e-09
homozygous O 0 8.816773089392882e-09
for O 0 2.0422992186297506e-09
the O 0 1.3958418421111674e-08
mutation O 0 2.7696627213913416e-09
in O 0 1.011333572442652e-09
exon O 0 1.1499705010464822e-07
4 O 0 2.1697255547792338e-08
and O 0 1.8499651810444107e-09
that O 0 3.30163757444879e-10
the O 0 4.165336520145502e-09
parents O 0 1.3283488753401684e-09
of O 0 1.0445742049114415e-08
patient O 0 3.753886446133947e-08
2 O 0 2.0409709122759523e-07
were O 0 1.604591375325981e-07
heterozygous O 0 1.768871811691497e-06
. O 0 1.7015263438224792e-06

The O 0 4.5043389036436565e-06
common O 0 8.202837875614932e-07
mutation O 0 9.524611499500679e-08
at O 0 1.0926333260385945e-07
codon O 0 3.30041387996971e-07
95 O 0 9.970461434249955e-08
in O 0 8.198019152416691e-09
exon O 0 6.027228209859459e-07
4 O 0 7.14536980694902e-08
might O 0 1.0681714179838764e-08
be O 0 1.8712686955524305e-09
responsible O 0 4.5601700193742545e-09
for O 0 2.686416200603503e-09
most O 0 2.5243053869417054e-08
Japanese O 0 2.8081230993848294e-06
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999781847000122
. O 0 1.0110852599609643e-06
. O 0 3.4007478006969905e-06

BRCA1 O 0 1.647850513109006e-05
required O 0 2.2157128398703207e-07
for O 0 5.490177912292893e-08
transcription O 0 3.496086719678715e-06
- O 0 3.3192307000717847e-06
coupled O 0 6.95622986768285e-07
repair O 0 8.968420388555387e-07
of O 0 7.051449983919156e-07
oxidative O 0 2.804381665555411e-06
DNA O 0 4.3616937546175905e-06
damage O 0 5.7138044212479144e-05
. O 0 3.994074177171569e-06

The O 0 4.4117317884229124e-05
breast B-Disease 1 1.0
and I-Disease 1 0.999970555305481
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.6925430297851562
gene O 0 7.160047516663326e-06
BRCA1 O 0 2.8684593416983262e-05
encodes O 0 1.0673790029613883e-06
a O 0 1.726679101921036e-07
zinc O 0 8.456418072455563e-06
finger O 0 5.222381332714576e-06
protein O 0 1.5288735255580832e-07
of O 0 1.9395103834085603e-07
unknown O 0 4.566012137274811e-07
function O 0 2.81444016536625e-07
. O 0 7.039744787107338e-07

Association O 0 2.822804617608199e-06
of O 0 1.120258389164519e-06
the O 0 4.223886094223417e-07
BRCA1 O 0 3.2459686849506397e-07
protein O 0 9.084874186271463e-09
with O 0 2.2816630806943294e-09
the O 0 2.0652237253671046e-08
DNA O 0 5.271309433396709e-08
repair O 0 2.731855488491419e-07
protein O 0 6.572938104909554e-08
Rad51 O 0 2.1827399905305356e-06
and O 0 1.6790663082133506e-08
changes O 0 8.180820465497618e-09
in O 0 2.501141738164847e-09
the O 0 9.989626903461613e-09
phosphorylation O 0 4.042206569465634e-09
and O 0 4.489137062080317e-09
cellular O 0 1.73619607579667e-08
localization O 0 3.494878342280572e-08
of O 0 2.8238709148808994e-08
the O 0 8.565826270512389e-09
protein O 0 4.402771036637887e-09
after O 0 1.9526151806559255e-09
exposure O 0 2.8787704664523517e-08
to O 0 2.2123411991259445e-09
DNA O 0 2.027547907346161e-07
- O 0 4.00932947286492e-07
damaging O 0 4.6309861545523745e-07
agents O 0 4.751233184663306e-09
are O 0 4.712449319654866e-10
consistent O 0 3.0320554955665102e-09
with O 0 3.379946322823457e-10
a O 0 3.0520381777421335e-09
role O 0 4.2520561294168147e-08
for O 0 3.8810046731896364e-08
BRCA1 O 0 5.438669745672087e-07
in O 0 2.9935332435115924e-08
DNA O 0 1.1010849902959308e-06
repair O 0 1.3254816622065846e-05
. O 0 4.064167114847805e-06

Here O 0 1.0423112826174474e-06
, O 0 1.3478923222010053e-07
it O 0 1.4759233835093255e-08
is O 0 1.0184187715367443e-08
shown O 0 8.265815587549241e-09
that O 0 5.975566264027066e-09
mouse O 0 1.9194806100131245e-06
embryonic O 0 1.013659016280144e-06
stem O 0 3.533675396738545e-07
cells O 0 1.2875025490188818e-08
deficient B-Disease 0 2.4756445782259107e-07
in I-Disease 0 1.1787371967386662e-08
BRCA1 I-Disease 0 3.279467648553691e-07
are O 0 1.9667816264501425e-09
defective O 0 1.0851358922536747e-07
in O 0 2.8556197406715e-09
the O 0 7.583460970295164e-09
ability O 0 1.3746463967123645e-09
to O 0 2.337527060802813e-09
carry O 0 1.017261652691559e-08
out O 0 1.2302459495572293e-08
transcription O 0 3.238467343180673e-07
- O 0 4.10980561582619e-07
coupled O 0 9.567198588911197e-08
repair O 0 1.9796544847849873e-07
of O 0 7.611896535308915e-08
oxidative O 0 1.633627277897176e-07
DNA O 0 7.875559759895623e-08
damage O 0 7.579905627608241e-07
, O 0 7.400404289370499e-09
and O 0 1.1490162599159248e-08
are O 0 7.670321267028157e-09
hypersensitive O 0 6.689928341074847e-06
to O 0 1.6432431948487647e-07
ionizing O 0 0.006118128076195717
radiation O 0 0.00015162200725171715
and O 0 2.1801800187404297e-07
hydrogen O 0 6.328116910481185e-07
peroxide O 0 1.972287464013789e-06
. O 0 1.0425508207845269e-06

These O 0 1.2216081586302607e-06
results O 0 1.7669114527052443e-07
suggest O 0 5.4330921983591907e-08
that O 0 2.308000546236144e-08
BRCA1 O 0 1.0624778497003717e-06
participates O 0 2.1411007367078128e-07
, O 0 1.1847305358969606e-08
directly O 0 1.292300133570734e-08
or O 0 8.089090286489409e-09
indirectly O 0 5.156335092237896e-08
, O 0 7.065543261575158e-09
in O 0 7.726780104633235e-09
transcription O 0 8.5114487546889e-07
- O 0 8.851941402099328e-07
coupled O 0 2.1551831252963893e-07
repair O 0 2.7518248657543154e-07
of O 0 1.7860180889783805e-07
oxidative O 0 3.712376042130927e-07
DNA O 0 3.521053884014691e-07
damage O 0 3.514100853863056e-06
. O 0 2.226422282092244e-07
. O 0 1.5193833178273053e-06

Truncation O 0 0.00013232963101472706
mutations O 0 1.573054532855167e-06
in O 0 4.029568501096037e-08
the O 0 9.401193779012829e-08
transactivation O 0 7.6118171818961855e-06
region O 0 5.354290237846726e-07
of O 0 2.0861129996774253e-06
PAX6 O 1 0.9999992847442627
result O 0 2.3508710000896826e-07
in O 0 5.276117676089598e-08
dominant O 0 4.580689619615441e-06
- O 0 5.428852091426961e-06
negative O 0 1.2204623089928646e-06
mutants O 0 5.061764113634126e-06
. O 0 1.294890466851939e-06

PAX6 O 1 0.9999299049377441
is O 0 1.13479063656996e-06
a O 0 1.0243081760563655e-07
transcription O 0 3.09132275333468e-07
factor O 0 4.530928521262467e-08
with O 0 3.2641638281205587e-09
two O 0 4.0538421508529154e-09
DNA O 0 3.095103906503027e-08
- O 0 8.696292042031928e-08
binding O 0 3.424850802957735e-08
domains O 0 4.97130905330323e-08
( O 0 4.564434163967235e-09
paired O 0 9.745126305915619e-08
box O 0 6.910921683811466e-07
and O 0 7.85418308169028e-08
homeobox O 0 4.155945134698413e-06
) O 0 1.9058855826870058e-08
and O 0 2.360733297734896e-08
a O 0 7.806599455761898e-08
proline O 0 2.013171751968912e-06
- O 0 3.3064529247894825e-07
serine O 0 3.2664453897268686e-07
- O 0 5.092715582577512e-07
threonine O 0 1.296791083404969e-06
( O 0 3.612412413644961e-08
PST O 1 0.9999287128448486
) O 0 2.792114628391573e-07
- O 0 2.4383357413171325e-06
rich O 0 1.0427128245282802e-06
transactivation O 0 7.108485442586243e-05
domain O 0 1.0662655768101104e-05
. O 0 4.456368969840696e-06

PAX6 O 1 1.0
regulates O 0 0.014019021764397621
eye O 1 0.645476222038269
development O 0 3.896745113252109e-07
in O 0 3.780053958735152e-08
animals O 0 6.14310380342431e-08
ranging O 0 8.708624932296516e-08
from O 0 8.479088542401314e-09
jellyfish O 0 1.346271005786548e-07
to O 0 1.7579756317331885e-08
Drosophila O 0 6.136575620985241e-07
to O 0 9.278561208247993e-08
humans O 0 7.351069939431909e-07
. O 0 1.0739649951574393e-06

Heterozygous O 0 1.1417650057410356e-05
mutations O 0 2.410998547475174e-07
in O 0 2.2681785338818372e-08
the O 0 7.878279006945377e-08
human O 0 2.354070289811716e-07
PAX6 O 1 0.9999998807907104
gene O 0 8.017193664500155e-08
result O 0 6.522729911750957e-09
in O 0 2.105722485268302e-09
various O 0 1.516033520942983e-08
phenotypes O 0 1.8025390602360858e-07
, O 0 6.700529908698627e-09
including O 0 5.294576155279174e-08
aniridia B-Disease 1 1.0
, O 0 2.0280540411476977e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 1.467889433115488e-06
autosomal B-Disease 1 0.9263071417808533
dominant I-Disease 1 0.8649474382400513
keratitis I-Disease 1 0.9999992847442627
, O 0 1.232462864209083e-06
and O 0 5.953492745902622e-06
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.0002758568443823606

It O 0 4.934226467412373e-07
is O 0 6.175692845999947e-08
believed O 0 2.6461812296929565e-08
that O 0 1.386538106551427e-09
the O 0 1.271706828731567e-08
mutated O 0 1.2441689989373117e-07
allele O 0 6.938567054248779e-08
of O 0 1.4543701354341465e-07
PAX6 O 1 0.9999986886978149
produces O 0 2.0409066792126396e-07
an O 0 1.1910359809519377e-08
inactive O 0 2.4431395218016405e-07
protein O 0 2.3324110642874984e-08
and O 0 2.501686680034254e-08
aniridia B-Disease 1 1.0
is O 0 1.327278766893869e-07
caused O 0 1.4449442176101002e-07
due O 0 1.4613370069582743e-07
to O 0 3.211657144674973e-07
genetic O 0 1.2002251423837151e-05
haploinsufficiency O 0 0.025584742426872253
. O 0 1.2298643014219124e-05

However O 0 1.5188371662588906e-06
, O 0 1.2024906936858315e-07
several O 0 1.0723054799655074e-07
truncation O 0 2.7047572075389326e-06
mutations O 0 6.31487822033705e-08
have O 0 3.4123750491943383e-09
been O 0 4.036928569206566e-09
found O 0 1.9265933293155513e-09
to O 0 7.710434513086284e-10
occur O 0 5.421575410835544e-10
in O 0 5.715478645917926e-10
the O 0 5.042144035627416e-09
C O 0 1.5197051084214763e-07
- O 0 5.757773990922033e-08
terminal O 0 9.810587187075726e-08
half O 0 1.0992321719527354e-08
of O 0 5.3237094732594414e-08
PAX6 O 1 0.8359292149543762
in O 0 1.2630696488713511e-08
patients O 0 8.562314413040895e-09
with O 0 4.849611379142971e-09
Aniridia B-Disease 1 1.0
resulting O 0 1.1325111159976586e-07
in O 0 6.430392218703673e-09
mutant O 0 9.55160928128862e-08
proteins O 0 1.0550700313416428e-09
that O 0 6.103761940323693e-10
retain O 0 1.594694509776673e-08
the O 0 7.71858932324676e-09
DNA O 0 1.9920170402087933e-08
- O 0 3.3394893961258276e-08
binding O 0 1.011000261286199e-08
domains O 0 1.3137654519823627e-08
but O 0 2.787948316651523e-09
have O 0 1.877528799099082e-09
lost O 0 6.281818087927604e-08
most O 0 7.025658277370894e-09
of O 0 5.966924021549858e-08
the O 0 2.516192125767702e-07
transactivation O 0 3.906387428287417e-05
domain O 0 6.874964583403198e-06
. O 0 3.435500047999085e-06

It O 0 4.063389269504114e-07
is O 0 2.6971271438469557e-08
not O 0 2.3504389545792037e-09
clear O 0 1.6288041138068365e-08
whether O 0 4.957633414903739e-09
such O 0 1.9665948869374006e-08
mutants O 0 7.931303116492927e-07
really O 0 9.734036154895875e-08
behave O 0 9.535622957912437e-09
as O 0 7.3459234251060934e-09
loss O 0 1.3042932778262184e-07
- O 0 1.3552289601648226e-07
of O 0 2.2954168343858328e-07
- O 0 3.7028115684734075e-07
function O 0 4.7143778658664814e-08
mutants O 0 1.0172717423984068e-07
as O 0 2.3337461740879917e-08
predicted O 0 1.9538796891538368e-07
by O 0 1.1702150715109383e-07
haploinsufficiency O 0 0.0002660607860889286
. O 0 1.343677649856545e-05

Contrary O 0 7.37175560061587e-06
to O 0 1.2305420682423573e-07
this O 0 1.1531285259991364e-08
theory O 0 5.557713578241419e-08
, O 0 7.381288469332503e-09
our O 0 3.3517781883318776e-09
data O 0 4.729848956941396e-09
showed O 0 5.976455774714395e-09
that O 0 6.481601366736811e-10
these O 0 2.416530753279744e-09
mutants O 0 4.4340051630342714e-08
are O 0 1.6543838521343446e-09
dominant O 0 1.2922045300456375e-07
- O 0 1.592427736341051e-07
negative O 0 2.989584402257606e-08
in O 0 8.223655534322916e-09
transient O 0 7.545575897438539e-08
transfection O 0 7.544899460754095e-08
assays O 0 1.7268199314912636e-08
when O 0 4.399816067035545e-09
they O 0 1.4614122134659624e-09
are O 0 1.4470472597949424e-09
coexpressed O 0 1.010406663226604e-06
with O 0 5.130348057491574e-08
wild O 0 1.0630681572365575e-05
- O 0 3.344867945997976e-05
type O 0 4.491034269449301e-05
PAX6 O 1 0.9997099041938782
. O 0 2.3002119633019902e-05

We O 0 5.667485538651817e-07
found O 0 6.075797642779435e-08
that O 0 4.444739687414767e-09
the O 0 4.3853745523847465e-08
dominant O 0 7.285146352842276e-07
- O 0 5.764553634435288e-07
negative O 0 6.923865925045902e-08
effects O 0 9.302820558332314e-08
result O 0 2.10423278801386e-09
from O 0 1.6899862620434192e-09
the O 0 4.66192284775957e-09
enhanced O 0 2.3020257700068214e-08
DNA O 0 1.3917611951796971e-08
binding O 0 6.111616990267521e-09
ability O 0 4.6722399282828064e-09
of O 0 4.0266108669584355e-08
these O 0 4.0701760184447267e-08
mutants O 0 1.6858456319823745e-06
. O 0 9.782967254068353e-07

Kinetic O 0 2.153503919544164e-05
studies O 0 3.8235336319303315e-07
of O 0 1.1904754870784018e-07
binding O 0 6.269070240705332e-08
and O 0 4.210975390606109e-08
dissociation O 0 1.085419398805243e-07
revealed O 0 6.253187478932887e-08
that O 0 2.8109508054541266e-09
various O 0 1.8386566935646442e-08
truncation O 0 1.60951685757027e-06
mutants O 0 1.8747640240235341e-07
have O 0 3.902574263747738e-09
3 O 0 2.423095146752985e-08
- O 0 7.406168833767879e-08
5 O 0 5.6890986144253475e-08
- O 0 5.848144724041049e-08
fold O 0 3.101225942714336e-08
higher O 0 3.531456238548003e-09
affinity O 0 2.1458990140388323e-09
to O 0 1.2748900823922327e-09
various O 0 3.2375020442287905e-09
DNA O 0 9.55998924467849e-09
- O 0 1.2157460815842569e-08
binding O 0 6.440199484814002e-09
sites O 0 8.001745044339259e-09
when O 0 1.508323133059264e-09
compared O 0 1.3144040300616666e-09
with O 0 1.2425362960755137e-09
the O 0 4.00875563855152e-08
wild O 0 1.9428848645475227e-06
- O 0 1.1540101695572957e-05
type O 0 1.5034724128781818e-05
PAX6 O 1 0.9997462630271912
. O 0 1.0855373147933278e-05

These O 0 3.391490395188157e-07
results O 0 2.179131719515226e-08
provide O 0 7.750366570746792e-09
a O 0 8.919426086606563e-09
new O 0 1.3321833414181583e-08
insight O 0 2.260430598255425e-08
into O 0 3.875018972365751e-09
the O 0 7.766081999704966e-09
role O 0 5.754502296895225e-08
of O 0 2.755685386546247e-07
mutant O 0 1.9856453945976682e-05
PAX6 O 1 0.9999604225158691
in O 0 2.57657433166969e-07
causing O 0 2.1475441826623864e-05
aniridia B-Disease 1 1.0
. O 0 1.360337705591519e-06
. O 0 4.765503035741858e-06

Reversal O 0 3.0479141059913673e-05
of O 0 4.5293825678527355e-05
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 1.2263974895176943e-05
excellent O 0 3.338682290632278e-05
neuropsychologic O 0 0.010164407081902027
outcome O 0 4.0564589198766043e-07
in O 0 1.1386207532382286e-08
very B-Disease 0 1.073358912861977e-08
- I-Disease 0 2.82450457689265e-07
long I-Disease 0 1.5375485418189783e-07
- I-Disease 0 9.89122668215714e-07
chain I-Disease 0 1.1311742582620354e-06
acyl I-Disease 0 1.5846212590986397e-06
- I-Disease 0 1.430838210580987e-06
coenzyme I-Disease 0 9.925896620188723e-07
A I-Disease 0 7.59539352657157e-06
dehydrogenase I-Disease 0 0.00028161273803561926
deficiency I-Disease 0 0.002180050127208233
. O 0 6.470123025792418e-06

Very B-Disease 0 2.169270146623603e-06
- I-Disease 0 6.671375558653381e-06
long I-Disease 0 9.713317012938205e-07
- I-Disease 0 1.720979298625025e-06
chain I-Disease 0 4.79921652640769e-07
acyl I-Disease 0 6.265281058404071e-07
- I-Disease 0 3.0697648867317184e-07
coenzyme I-Disease 0 9.917904009171252e-08
A I-Disease 0 3.9662262452111463e-07
dehydrogenase I-Disease 0 1.779266767698573e-06
( I-Disease 0 3.818066929284214e-08
VLCAD I-Disease 1 1.0
) I-Disease 0 5.021454967391037e-07
deficiency I-Disease 1 0.9818427562713623
is O 0 1.7249568884381006e-08
a O 0 4.797540853473947e-08
disorder O 1 0.9997071623802185
of O 0 1.361515842290828e-05
fatty O 0 0.00013882834173273295
acid O 0 4.817292165171239e-07
beta O 0 5.95970242045496e-08
oxidation O 0 1.4150810301316596e-08
that O 0 1.8404696655593966e-09
reportedly O 0 1.181860085353037e-07
has O 0 6.879055103325982e-09
high O 0 8.489433156455561e-08
rates O 0 1.2756228962018668e-08
of O 0 5.1143253188001836e-08
morbidity O 0 7.891504537838046e-06
and O 0 5.453955509437947e-07
mortality O 0 2.3286400391953066e-05
. O 0 2.704246526263887e-06

We O 0 4.983461394658661e-07
describe O 0 1.2147452821409388e-07
the O 0 3.8151334535996284e-08
outcome O 0 2.9032806381223963e-08
of O 0 1.790666459555723e-08
a O 0 2.773405505251958e-09
5 O 0 1.2405666716119867e-08
- O 0 2.5895902311390273e-08
year O 0 7.834564108577524e-09
- O 0 8.832751063891919e-08
old O 0 2.454615639635449e-07
girl O 0 5.0688758079786567e-08
with O 0 1.6419390291844138e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.03841687809836e-07
was O 0 3.526097884787305e-07
first O 0 2.236952489909072e-08
seen O 0 2.1573374198169404e-08
at O 0 1.939483773583106e-08
5 O 0 1.7931068185816912e-08
months O 0 3.6811660386604217e-09
of O 0 9.558932312359048e-09
age O 0 2.1737186273185216e-08
with O 0 2.0438276848722126e-08
severe O 1 0.999914288520813
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999990463256836
hepatomegaly B-Disease 1 1.0
, O 1 1.0
encephalopathy B-Disease 1 1.0
, O 0 2.1488672246050555e-06
and O 0 4.3029594962717965e-06
hypotonia B-Disease 1 0.9984824061393738
. O 0 3.6192319385008886e-05

Biochemical O 0 0.00022509825066663325
studies O 0 7.029989319562446e-06
indicated O 1 0.5280922651290894
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 2.476838017173577e-05
by O 0 4.688131838292975e-08
a O 0 2.4613009941276687e-07
stable O 0 5.62841876217135e-07
yet O 0 1.9434781961535919e-07
inactive O 0 3.1109889278013725e-06
enzyme O 0 9.363163826492382e-07
. O 0 6.77835146234429e-07

Molecular O 0 1.7615251636016183e-05
genetic O 0 5.777586125077505e-07
analysis O 0 5.383536461067706e-08
of O 0 2.7743388386625156e-07
her O 0 3.113266586751706e-07
VLCAD O 1 1.0
gene O 0 9.276708965444413e-07
revealed O 0 5.090948320685129e-07
a O 0 1.1117403175830987e-07
T1372C O 0 1.1150462341902312e-05
( O 0 8.314029287248559e-08
F458L O 0 8.027497642615344e-06
) O 0 1.198463053242449e-07
missense O 0 1.7587556158105144e-06
mutation O 0 7.039155036636657e-08
and O 0 3.1825418744801937e-08
a O 0 3.8828488868603017e-07
1668 O 0 0.0002584749599918723
ACAG O 1 0.999970555305481
1669 O 0 0.0004640017868950963
splice O 0 0.00018311743042431772
site O 0 3.096707587246783e-05
mutation O 0 1.0964880857500248e-05
. O 0 5.692935701517854e-06

After O 0 1.2173725281172665e-06
initial O 0 3.0269117701209325e-07
treatment O 0 1.583075999178618e-07
with O 0 1.1429377444471811e-08
intravenous O 0 1.2067612260580063e-06
glucose O 0 9.817689715418965e-06
and O 0 1.2962505024916027e-07
carnitine O 0 0.0007621137192472816
, O 0 4.371469941588657e-08
the O 0 7.537492052733796e-08
patient O 0 1.2947555205755634e-07
has O 0 1.791335968448493e-08
thrived O 0 1.0115292070622672e-07
on O 0 3.094985601137523e-08
a O 0 1.8201355089786375e-08
low O 0 1.3679178323400265e-07
- O 0 2.8562376996887906e-07
fat O 0 5.25635073245212e-07
diet O 0 1.3144904187356587e-07
supplemented O 0 3.006086402024266e-08
with O 0 4.018882115985889e-09
medium O 0 4.910594952889369e-07
- O 0 4.984563588550373e-07
chain O 0 1.9171685039509612e-07
triglyceride O 0 5.413861003944476e-07
oil O 0 8.099823389784433e-08
and O 0 2.5480034082647762e-08
carnitine O 0 5.165729817235842e-06
and O 0 1.217166527567315e-07
avoidance O 0 8.381713269045576e-05
of O 0 8.267566045105923e-06
fasting O 0 1.0806226782733575e-05
. O 0 3.3069650271499995e-06

Her O 0 0.00039881293196231127
ventricular O 1 1.0
hypertrophy O 1 0.9893679022789001
resolved O 0 1.3065955499769188e-06
significantly O 0 5.893360466302511e-08
over O 0 1.9327924150047693e-08
1 O 0 5.8900674559936306e-08
year O 0 1.144277028686247e-08
, O 0 5.5275601873461255e-09
and O 0 7.895846643179993e-09
cognitively O 0 5.535866307582182e-07
, O 0 5.972660588327017e-09
she O 0 7.5641031216378e-09
is O 0 2.5313386942116267e-09
in O 0 1.3297861700678482e-09
the O 0 1.4295730821345387e-08
superior O 0 4.247185074746085e-07
range O 0 4.494957295264612e-07
for O 0 1.264777012011109e-07
age O 0 1.2473118431444163e-06
. O 0 1.5562543467240175e-06

Clinical O 0 0.00010380598541814834
recognition O 0 2.880481588363182e-06
of O 1 0.9999985694885254
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.9085333608236397e-07
important O 0 3.13133696749901e-08
because O 0 2.8668620810634593e-09
it O 0 1.0941172412515243e-09
is O 0 1.2659921999613744e-09
one O 0 8.777287785477483e-10
of O 0 5.1299346992550454e-09
the O 0 3.841711393448577e-09
few O 0 1.2754452605179267e-08
directly O 0 3.903290490825384e-08
treatable O 1 0.9999293088912964
causes O 0 5.636455284729891e-07
of O 0 9.733252227306366e-05
cardiomyopathy B-Disease 1 1.0
in O 0 2.4323847469531756e-07
children O 0 2.0791146937426674e-07
. O 0 1.0625998925206659e-07
. O 0 1.1537222235347144e-06

Cloning O 0 3.96653194911778e-06
of O 0 5.660350552716409e-07
a O 0 6.269058161478824e-08
novel O 0 4.432880871263478e-07
member O 0 2.7392559331929078e-08
of O 0 4.443979051416136e-08
the O 0 2.343009875005464e-08
low O 0 1.1351365003520186e-07
- O 0 2.8234353521838784e-07
density O 0 2.339384508331932e-07
lipoprotein O 0 7.353389082709327e-05
receptor O 0 1.975005261556362e-06
family O 0 3.805547805768583e-07
. O 0 1.0182942560277297e-06

A O 0 1.0239805305900518e-05
gene O 0 4.277773939520557e-07
encoding O 0 5.125467623656732e-07
a O 0 1.28933876908377e-07
novel O 0 1.0993967407557648e-06
transmembrane O 0 5.669880920322612e-07
protein O 0 7.992596806616348e-08
was O 0 5.273169989550297e-08
identified O 0 5.656484169946907e-09
by O 0 6.225501225642915e-10
DNA O 0 8.480900426377502e-09
sequence O 0 2.837431622992881e-09
analysis O 0 1.3309229274227619e-09
within O 0 2.0136028400230543e-09
the O 0 4.287987298567941e-09
insulin B-Disease 0 1.8773203009914141e-06
- I-Disease 0 0.003965478390455246
dependent I-Disease 0 2.5778581402846612e-05
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 2.599123831714678e-07
IDDM B-Disease 1 0.9999996423721313
) O 0 4.578059815685265e-07
locus O 0 2.9843044103472494e-05
IDDM4 O 0 0.032834190875291824
on O 0 3.914794888260076e-06
chromosome O 0 1.9304719899082556e-05
11q13 O 0 0.00012411785428412259
. O 0 8.894811799109448e-06

Based O 0 1.262915020561195e-06
on O 0 1.9645597149064997e-07
its O 0 6.128603757815654e-08
chromosomal O 0 1.126708411902655e-06
position O 0 2.402279619673209e-07
, O 0 1.8063364137788085e-08
this O 0 2.3088140288507475e-09
gene O 0 8.674984286471954e-09
is O 0 4.032257638897363e-09
a O 0 7.528436540837902e-09
candidate O 0 1.794126269771823e-08
for O 0 1.1124949850227495e-08
conferring O 0 9.767510391611722e-07
susceptibility O 0 1.1453793376858812e-05
to O 0 2.754902197921183e-06
diabetes B-Disease 1 1.0
. O 0 1.6972178855212405e-05

The O 0 5.588045496551786e-06
gene O 0 3.884960051436792e-07
, O 0 9.250041443920054e-08
termed O 0 7.289399377441441e-07
low O 0 4.428220563568175e-07
- O 0 4.4176923097438703e-07
density O 0 1.9127217854020273e-07
lipoprotein O 0 5.2677046369353775e-06
receptor O 0 4.9448019012743316e-08
related O 0 2.0046751814106756e-08
protein O 0 7.460709383622088e-09
5 O 0 2.049409886240028e-08
( O 0 8.655728578332855e-09
LRP5 O 1 0.9996716976165771
) O 0 3.071896514938999e-08
, O 0 2.1095747371191464e-08
encodes O 0 2.955916045266349e-08
a O 0 7.915569533167854e-09
protein O 0 2.1181547182891336e-08
of O 0 3.577170204493996e-08
1615 O 0 1.1946452787015005e-06
amino O 0 4.346460968918109e-08
acids O 0 7.49488293649847e-09
that O 0 5.152741011649198e-10
contains O 0 2.3649199931696785e-08
conserved O 0 4.633805161802229e-08
modules O 0 2.462652837209589e-08
which O 0 8.145488727961947e-10
are O 0 4.2917405740361403e-10
characteristic O 0 3.02057010515e-08
of O 0 1.4457237185183658e-08
the O 0 1.3881238380974992e-08
low O 0 6.895162840692137e-08
- O 0 1.1639099994908975e-07
density O 0 7.331844642521901e-08
lipoprotein O 0 4.302262095734477e-05
( O 0 4.94409491125225e-08
LDL O 1 1.0
) O 0 1.6718031758955476e-07
receptor O 0 5.465175831886881e-07
family O 0 2.657377535797423e-07
. O 0 9.521901915832132e-07

These O 0 1.8777535615299712e-06
modules O 0 3.232110202588956e-06
include O 0 4.0126346334545815e-07
a O 0 1.6191160057132947e-07
putative O 0 8.365518056052679e-07
signal O 0 7.778226063237526e-08
peptide O 0 2.00655723148202e-08
for O 0 1.757813894442961e-09
protein O 0 3.4848588459368557e-09
export O 0 1.5776798534261616e-08
, O 0 1.0304589181941992e-08
four O 0 1.5780710072021975e-08
epidermal O 0 3.613681656133849e-06
growth O 0 4.3190325982322975e-08
factor O 0 1.1722703163741244e-07
( O 0 1.948597905254701e-08
EGF O 0 7.541824743384495e-05
) O 0 1.8475683205565474e-08
repeats O 0 1.9051586974683232e-08
with O 0 3.0395073125077943e-09
associated O 0 1.9842810061732052e-08
spacer O 0 5.439043206934002e-07
domains O 0 4.7175621631367903e-08
, O 0 1.0012212392496167e-08
three O 0 2.2197983895466677e-08
LDL O 1 1.0
- O 0 1.8782171537168324e-05
receptor O 0 5.715952511309297e-07
( O 0 2.131037035724148e-08
LDLR O 1 0.8499513864517212
) O 0 3.116607771858071e-08
repeats O 0 6.682638797883556e-08
, O 0 8.417164742979821e-09
a O 0 9.493919428393838e-09
single O 0 3.168659645780281e-08
transmembrane O 0 2.6914236173070094e-07
spanning O 0 3.255343301589164e-07
domain O 0 2.794386944060534e-07
, O 0 4.411970166984247e-08
and O 0 4.173267242890688e-08
a O 0 2.517053587780538e-07
cytoplasmic O 0 8.366528163605835e-06
domain O 0 5.94814628129825e-06
. O 0 5.559485543926712e-06

The O 0 3.2111747714225203e-06
encoded O 0 3.843791489543946e-07
protein O 0 1.0466886379845164e-07
has O 0 9.95172388940091e-09
a O 0 4.509699280674795e-09
unique O 0 8.809897700245983e-09
organization O 0 1.0693048224652557e-08
of O 0 1.8340023189011845e-07
EGF O 1 0.9996253252029419
and O 0 3.656051319467224e-07
LDLR O 1 0.9999994039535522
repeats O 0 2.5999543140642345e-07
; O 0 5.97833693660732e-09
therefore O 0 1.0748442136332415e-08
, O 0 1.0617202228502265e-08
LRP5 O 0 0.00036138357245363295
likely O 0 3.083831146000193e-08
represents O 0 3.594054165390048e-09
a O 0 1.2217942213510469e-09
new O 0 2.850395697251429e-09
category O 0 1.992507137060784e-08
of O 0 1.0631492841639556e-07
the O 0 3.9961139464139706e-07
LDLR O 1 0.9999991655349731
family O 0 2.7746136765927076e-06
. O 0 3.060532435483765e-06

Both O 0 1.4785488247071044e-06
human O 0 3.6767474398402555e-07
and O 0 1.6775943834090867e-07
mouse O 0 0.22534462809562683
LRP5 O 1 1.0
cDNAs O 1 0.9258378744125366
have O 0 2.2380151065704013e-08
been O 0 1.9655374217109056e-08
isolated O 0 3.801020653781961e-08
and O 0 3.3985789738011363e-09
the O 0 1.0725075938466944e-08
encoded O 0 2.150517808274799e-08
mature O 0 1.1227291096815861e-08
proteins O 0 4.2367997998837836e-10
are O 0 1.5166942701760888e-10
95 O 0 9.001529299723643e-09
% O 0 1.4705303641449063e-09
identical O 0 5.244880529886586e-09
, O 0 2.848298041868702e-09
indicating O 0 1.7747670000289872e-08
a O 0 8.388620464927499e-09
high O 0 1.0815178086431843e-07
degree O 0 6.114207451446418e-08
of O 0 6.10360402220067e-08
evolutionary O 0 2.072358569193966e-07
conservation O 0 4.932306865157443e-07
. O 0 9.319852267708484e-08
. O 0 8.612328770141175e-07

The O 0 1.1868147339555435e-05
APC B-Disease 0 4.6171007852535695e-05
variants O 0 3.945337084587663e-06
I1307K O 0 1.132724264607532e-05
and O 0 9.058386751803482e-08
E1317Q O 0 1.4619379271607613e-06
are O 0 2.9751971997171722e-09
associated O 0 3.549298810412438e-08
with O 0 0.0002616489655338228
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.454202328612155e-07
but O 0 3.1803619737758027e-09
not O 0 1.532765470102504e-09
always O 0 3.755560751272924e-09
with O 0 2.215330807686655e-09
a O 0 2.837801105215476e-08
family O 0 1.473010513564077e-07
history O 0 1.477263367632986e-06
. O 0 2.743800678217667e-06

Classical O 1 0.8735302686691284
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.005419911351054907
FAP B-Disease 1 1.0
) O 0 2.161139320833172e-07
is O 0 3.047060559424608e-08
a O 0 2.1606895828085726e-08
high O 0 1.3422085430647712e-05
- O 1 0.9999377727508545
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9909119606018066
that O 0 1.0768243186021209e-08
predisposes O 0 3.0149527674439014e-07
to O 0 5.104830336222221e-09
hundreds O 0 1.7918077688250378e-08
or O 0 4.021980082313803e-09
thousands O 0 3.7383532713874956e-08
of O 0 0.00015435248496942222
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 6.718212262057932e-06
that O 0 1.05035402597764e-08
results O 0 7.105586785627338e-09
from O 0 5.747599729488684e-09
truncating O 0 5.121861477164202e-07
mutations O 0 2.88349077948169e-08
in O 0 7.122371581402831e-09
the O 0 1.891815628596305e-07
APC B-Disease 0 3.22568703268189e-05
gene O 0 2.6718751087173587e-06
. O 0 4.631376214092597e-06

A O 0 7.8733210102655e-06
variant O 0 9.725470590637997e-06
of O 0 2.560732809797628e-06
FAP B-Disease 1 1.0
is O 0 3.2801412999106105e-06
attenuated B-Disease 1 0.9999867677688599
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
, O 0 2.1681211137547507e-07
which O 0 7.404711066527625e-09
results O 0 4.906206108046263e-09
from O 0 3.1913178766274086e-09
germ O 0 8.399356374866329e-07
- O 0 2.6302055289306736e-07
line O 0 1.2263971882475744e-07
mutations O 0 5.129230373768223e-09
in O 0 5.899483679350226e-10
the O 0 2.362439133207772e-09
5 O 0 5.986209750119542e-09
and O 0 1.6205790043244406e-09
3 O 0 2.278880728567856e-08
regions O 0 2.09121857608352e-08
of O 0 6.65181261183534e-08
the O 0 5.010567178942438e-07
APC B-Disease 0 3.522211409290321e-05
gene O 0 2.0238710476405686e-06
. O 0 2.5268307126680156e-06

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 0.00013250955089461058
have O 0 1.3027985801272735e-08
" O 0 1.0487669044323411e-07
multiple O 0 1.8554046619101427e-06
" O 1 0.9999992847442627
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.0967266323168587e-07
typically O 0 1.1522314657952393e-08
fewer O 0 2.4014004118555476e-09
than O 0 6.636675653481916e-10
100 O 0 8.601729994950347e-09
) O 0 2.02590721976037e-09
without O 0 4.38164349247927e-09
the O 0 1.880339439708223e-08
florid O 0 3.174804760419647e-06
phenotype O 0 2.5572816753083316e-07
of O 0 3.440866862547409e-07
classical O 0 7.736965926596895e-06
FAP B-Disease 1 0.5880914926528931
. O 0 1.1126731806143653e-05

Another O 0 2.862825567717664e-06
group O 0 1.287748716549686e-07
of O 0 1.6300977279115614e-07
patients O 0 5.6431247230648296e-08
with O 0 7.801891577230435e-09
multiple O 0 2.5347701011924073e-05
adenomas B-Disease 1 1.0
has O 0 1.4139888548925228e-07
no O 0 2.415891486862165e-08
mutations O 0 7.664660905959408e-09
in O 0 2.8784503669498918e-09
the O 0 4.0600266260071294e-08
APC B-Disease 0 4.762240678246599e-06
gene O 0 1.5264820518723354e-08
, O 0 4.345008353112689e-09
and O 0 5.7902926897668294e-09
their O 0 6.113388906214823e-09
phenotype O 0 5.26830454816718e-08
probably O 0 2.7219426712576933e-09
results O 0 8.297197928719413e-10
from O 0 1.1131927601937264e-09
variation O 0 3.6890892118890406e-08
at O 0 2.5321417851387196e-08
a O 0 1.613356914731412e-08
locus O 0 4.5501502654587966e-07
, O 0 7.03491087605812e-09
or O 0 7.550308822601437e-09
loci O 0 1.1310086733828939e-07
, O 0 1.3181503888404222e-08
elsewhere O 0 1.105139357804319e-08
in O 0 1.12533609097909e-08
the O 0 1.5861678548390046e-07
genome O 0 1.6559558844164712e-06
. O 0 1.6474341464345343e-06

Recently O 0 1.6523825252079405e-05
, O 0 3.612096293181821e-07
however O 0 6.587735157381758e-08
, O 0 2.709894886265829e-08
a O 0 2.9293126146967552e-08
missense O 0 5.685105861630291e-07
variant O 0 1.1171515552632627e-06
of O 0 2.5055271635210374e-06
APC B-Disease 1 0.9690449237823486
( O 0 4.114024321211218e-08
I1307K O 0 1.2531083484645933e-05
) O 0 1.4627375755082994e-08
was O 0 5.593445351337323e-08
described O 0 7.849986438657197e-09
that O 0 6.397322116491466e-10
confers O 0 2.758992678764116e-08
an O 0 1.0871257227762499e-09
increased O 0 4.8262105423191315e-09
risk O 0 7.51402282617164e-08
of O 0 0.0030602000188082457
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 8.569177794015559e-07
including O 0 4.2234350416947564e-07
multiple O 0 3.150627435388742e-06
adenomas B-Disease 1 0.9999809265136719
, O 0 3.310346130547259e-07
in O 0 6.065417892386904e-07
Ashkenazim O 0 0.0003554917930159718
. O 0 8.15406565379817e-06

We O 0 9.222363246408349e-07
have O 0 3.4117260128141425e-08
studied O 0 1.4552442451076786e-07
a O 0 1.0762042812473283e-08
set O 0 1.6223271614990153e-08
of O 0 1.8594361606005805e-08
164 O 0 7.762915998910103e-08
patients O 0 7.3896844199339284e-09
with O 0 6.618273928893359e-09
multiple O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
or I-Disease 1 0.5716699361801147
carcinoma I-Disease 1 1.0
and O 0 1.684328708506655e-06
analyzed O 0 1.5848871726120706e-06
codons O 0 2.3424033770425012e-06
1263 O 0 1.2098855222575366e-05
- O 0 1.133807245423668e-06
1377 O 0 9.473007594351657e-06
( O 0 8.801403339475655e-08
exon O 0 3.4339998364885105e-06
15G O 0 3.7297324979590485e-06
) O 0 1.0626745705621943e-08
of O 0 6.229225135712113e-08
the O 0 9.190424066218839e-08
APC B-Disease 0 1.2827591717723408e-06
gene O 0 4.372962436605121e-08
for O 0 2.4854493574366643e-08
germ O 0 2.8757178370142356e-05
- O 0 8.778049050306436e-06
line O 0 8.44494115881389e-06
variants O 0 1.0679109436750878e-05
. O 0 4.340014129411429e-06

Three O 0 1.5278297951226705e-06
patients O 0 1.5479268711260374e-07
with O 0 6.033332944355152e-09
the O 0 8.778383886465235e-08
I1307K O 0 7.273120445461245e-06
allele O 0 8.122442096691884e-08
were O 0 1.2871440802086909e-08
detected O 0 3.290908523467806e-08
, O 0 4.463600156157099e-09
each O 0 3.8231005028421805e-09
of O 0 1.380030454356529e-07
Ashkenazi O 0 9.420770766155329e-06
descent O 0 2.1967337033856893e-06
. O 0 1.9647525277832756e-06

Four O 0 1.0086101610795595e-05
patients O 0 7.40395080356393e-07
had O 0 2.0221487773142144e-07
a O 0 1.6240059608207957e-07
germ O 0 6.558104360010475e-05
- O 0 1.8201712009613402e-05
line O 0 7.628328603459522e-06
E1317Q O 0 1.6441130355815403e-05
missense O 0 1.013587507259217e-06
variant O 0 7.238785997287778e-07
of O 0 4.103304434011079e-07
APC O 0 3.837656095129205e-06
that O 0 4.8959143406079875e-09
was O 0 2.2430878487966766e-08
not O 0 1.276340255706998e-09
present O 0 1.994772347302387e-09
in O 0 1.6946697378728004e-09
controls O 0 6.758948245533247e-08
; O 0 2.313054414671001e-09
one O 0 2.8956532727164586e-09
of O 0 6.0857234807087934e-09
these O 0 1.0989128496063927e-09
individuals O 0 5.297095539980035e-10
had O 0 3.592244945949119e-09
an O 0 1.8647234867330553e-09
unusually O 0 2.3456300013435794e-08
large O 0 1.9370068216062464e-08
number O 0 1.3119050734644588e-08
of O 0 1.3039250745805475e-07
metaplastic B-Disease 0 0.00023520040849689394
polyps I-Disease 0 2.07670200325083e-05
of I-Disease 0 1.9954868548666127e-06
the I-Disease 0 2.068213689199183e-06
colorectum I-Disease 0 0.0005004398408345878
. O 0 8.219295523304027e-06

There O 0 5.520713557416457e-07
is O 0 4.376884632506517e-08
increasing O 0 1.7471418090053703e-08
evidence O 0 1.1860169735200543e-08
that O 0 2.607670079868285e-09
there O 0 7.652916522715714e-09
exist O 0 1.7010114206073013e-08
germ O 0 4.853560540141189e-07
- O 0 9.981573612094508e-08
line O 0 8.012179364413896e-08
variants O 0 3.646457713557538e-08
of O 0 5.9351204839686034e-08
the O 0 5.599166996717031e-08
APC B-Disease 0 2.500218442946789e-06
gene O 0 2.0371569320332128e-08
that O 0 1.480848887958075e-09
predispose O 0 3.140788251698723e-08
to O 0 1.6822453430265227e-09
the O 0 5.409204195672146e-09
development O 0 6.058182844270732e-09
of O 0 1.5611300341333845e-07
multiple O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 5.648751084663672e-07
but O 0 8.934682327321752e-09
without O 0 6.763472004678306e-09
the O 0 1.3787617270111241e-08
florid O 0 1.5916153870421113e-06
phenotype O 0 3.284531402414359e-08
of O 0 1.4356637656476323e-08
classical O 0 2.0005504097753146e-07
FAP B-Disease 1 0.9742675423622131
, O 0 9.094756059369047e-09
and O 0 2.314413327653142e-09
possibly O 0 1.5272442199787406e-09
with O 0 4.405641962357265e-10
importance O 0 1.6569464378335397e-07
for O 0 8.025055649341084e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.736618628456199e-06
in O 0 2.783920427518183e-09
the O 0 1.0401029371109871e-08
general O 0 2.3496690815250076e-08
population O 0 1.0357298130259096e-08
. O 0 5.993981488927602e-08
. O 0 1.0558273970673326e-06

Genomic O 0 3.714270633281558e-06
structure O 0 4.0784061638987623e-07
of O 0 4.4546976596393506e-07
the O 0 2.2283816178969573e-06
human O 1 0.9999998807907104
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 6.525851495098323e-05
CLD B-Disease 1 1.0
) O 0 1.7177063682538574e-06
gene O 0 2.6523161977820564e-06
. O 0 2.484540573277627e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9959825277328491
CLD B-Disease 1 1.0
) O 0 1.0023773029388394e-06
is O 0 5.031655803122703e-08
caused O 0 3.480489496610062e-08
by O 0 3.875965326471942e-09
mutations O 0 2.6350504001015906e-08
in O 0 4.018805732641795e-09
a O 0 1.0725956123280866e-08
gene O 0 9.992523253288255e-09
which O 0 8.104565019095844e-09
encodes O 0 2.845620485913969e-07
an O 0 1.4974318673921516e-07
intestinal O 1 0.7127935886383057
anion O 0 0.00019844193593598902
transporter O 0 0.0014147403417155147
. O 0 1.2664183486776892e-05

We O 0 9.56856410994078e-07
report O 0 1.403702469815471e-07
here O 0 1.6615407716358277e-08
the O 0 1.8768744780572888e-08
complete O 0 2.0303453140968486e-08
genomic O 0 6.708000199751041e-08
organization O 0 1.3252696717813706e-08
of O 0 5.51166614570775e-08
the O 0 1.0264145089422527e-07
human O 0 2.8601300527952844e-07
CLD B-Disease 1 0.9999905824661255
gene O 0 9.969187431124737e-08
which O 0 9.714891113787871e-09
spans O 0 2.663372811184672e-07
approximately O 0 3.217085620121907e-08
39kb O 0 1.722979504847899e-06
, O 0 1.476179622983409e-08
and O 0 3.721762098507497e-08
comprises O 0 7.158274115681706e-07
21 O 0 2.1474677396327024e-06
exons O 0 3.744641799130477e-05
. O 0 5.906554179091472e-06

All O 0 1.53072669490939e-05
exon O 0 0.00013320823200047016
/ O 0 1.854122274380643e-05
intron O 0 3.072334220632911e-05
boundaries O 0 6.854532443867356e-07
conform O 0 1.3089935180232715e-07
to O 0 5.551039450324424e-08
the O 0 5.471924282574037e-07
GT O 1 0.9999887943267822
/ O 1 0.9762274026870728
AG O 1 1.0
rule O 0 1.0139539881492965e-05
. O 0 9.221411346516106e-06

An O 0 3.503662640014227e-07
analysis O 0 1.1605914096435299e-07
of O 0 2.523032947010506e-07
the O 0 2.0615051710137777e-07
putative O 0 2.578236035333248e-06
promoter O 0 2.167836828448344e-05
region O 0 4.632541390492406e-07
sequence O 0 1.0990103049834943e-07
shows O 0 3.823000582769964e-08
a O 0 3.022909922378858e-08
putative O 0 1.433725856259116e-06
TATA O 0 0.000302581989672035
box O 0 8.946416528488044e-06
and O 0 1.394652713315736e-07
predicts O 0 5.136409413353249e-07
multiple O 0 1.3840821111443802e-07
transcription O 0 1.0800372365338262e-06
factor O 0 3.839215594325651e-07
binding O 0 3.160345727337699e-07
sites O 0 1.5523485217272537e-06
. O 0 1.911771050799871e-06

The O 0 6.22599736743723e-06
genomic O 0 5.807654815725982e-06
structure O 0 8.033837843868241e-07
was O 0 1.9785032634445088e-07
determined O 0 2.0880776219200925e-08
using O 0 4.674584275221605e-09
DNA O 0 8.948599194980034e-09
from O 0 7.881547636756636e-10
several O 0 1.3975913759622927e-09
sources O 0 4.520507079774916e-09
including O 0 9.842914927560287e-09
multiple O 0 2.901957429912727e-08
large O 0 2.6452735824022966e-07
- O 0 6.660523467871826e-06
insert O 0 3.826520696748048e-06
libaries O 0 7.840165380912367e-06
and O 0 5.628977817195846e-08
genomic O 0 3.3980043667725113e-07
DNA O 0 1.5811144749022787e-07
from O 0 5.259549240577144e-08
Finnish O 1 0.9997517466545105
CLD B-Disease 1 1.0
patients O 0 1.788190729712369e-06
and O 0 4.5636224399459024e-07
controls O 0 0.00011589479981921613
. O 0 6.883992227812996e-06

Exon O 0 0.00020756341109517962
- O 0 7.240965260280063e-06
specific O 0 7.866549935897638e-07
primers O 0 1.3091587334201904e-06
developed O 0 4.957068711064494e-08
in O 0 3.4785234692691347e-09
this O 0 2.612110527877576e-09
study O 0 7.600910123528593e-09
will O 0 1.946713679146228e-09
facilitate O 0 1.68374203468602e-08
mutation O 0 1.152092998779608e-08
screening O 0 1.2545558369936316e-08
studies O 0 7.338347263186051e-09
of O 0 1.2576512276041285e-08
patients O 0 3.559303296540861e-09
with O 0 4.066185610440698e-09
the O 0 8.482390398967254e-07
disease O 0 0.012784367427229881
. O 0 3.0516314382111887e-06

Genomic O 0 7.035629550955491e-06
sequencing O 0 1.160103806796542e-06
of O 0 7.838728492970404e-07
a O 0 6.943292305550131e-07
BAC O 1 1.0
clone O 0 0.005434265360236168
H O 1 1.0
_ O 0 1.0020067264804311e-07
RG364P16 O 0 1.4048544016986853e-06
revealed O 0 3.719632957199792e-08
the O 0 5.529922297853318e-09
presence O 0 5.98384675143393e-09
of O 0 2.106723862027593e-08
another O 0 2.3118644776332076e-08
, O 0 1.0878563827532162e-08
highly O 0 2.569065316038177e-08
homologous O 0 8.215518931820043e-09
gene O 0 4.3320409481850675e-09
3 O 0 1.3481797900283254e-08
of O 0 3.2901994018175174e-08
the O 0 6.523664808355534e-08
CLD B-Disease 1 0.9990221261978149
gene O 0 2.6358646820767717e-08
, O 0 4.174204537576998e-09
with O 0 1.396235238537713e-09
a O 0 2.9579112492683635e-09
similar O 0 3.5653642260768947e-09
genomic O 0 5.2598704058937074e-08
structure O 0 5.007203895956991e-08
, O 0 7.032133986228928e-09
recently O 0 1.639157254373913e-08
identified O 0 4.730101199612591e-09
as O 0 3.6533966962792874e-09
the O 0 1.8850045080398559e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.3142713441993692e-06
( O 0 1.2237683222338092e-07
PDS B-Disease 1 0.9999996423721313
) O 0 2.512168748580734e-07
. O 0 4.2457190829736646e-07
. O 0 3.0358728508872446e-06

The O 0 8.037094630708452e-06
APCI1307K O 1 1.0
allele O 0 3.187346237609745e-06
and O 0 5.025584641771275e-07
cancer B-Disease 1 0.7466717958450317
risk O 0 3.745540766431077e-07
in O 0 6.712733036096097e-09
a O 0 1.607128119474055e-08
community O 0 8.74083827540062e-09
- O 0 5.8857438034465304e-08
based O 0 1.548507810866795e-08
study O 0 1.8831388004514338e-08
of O 0 5.7307449452537185e-08
Ashkenazi O 0 2.1580924567388138e-06
Jews O 0 1.526321057099267e-06
. O 0 2.0000820768473204e-06

Mutations O 0 3.419999484322034e-05
in O 0 4.0223588371191e-07
APC O 0 2.3858528948039748e-05
are O 0 4.409597309518176e-08
classically O 0 1.7918541743711103e-06
associated O 0 7.03428284509755e-08
with O 0 3.133357040496776e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.03218518942594528
FAP B-Disease 1 1.0
) O 0 1.0206028377979237e-07
, O 0 1.997251786178822e-08
a O 0 2.980901570026617e-08
highly O 0 0.0017630776856094599
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 8.06116295279935e-05
by O 0 3.937620363103633e-08
multiple O 0 0.04232843592762947
intestinal O 1 1.0
polyps B-Disease 1 0.9999997615814209
and O 0 2.5897909949890163e-07
, O 0 3.1284596246905494e-08
without O 0 1.5991536983506194e-08
surgical O 0 2.6394165615784004e-05
intervention O 0 8.667991835409339e-08
, O 0 6.892871606822837e-09
the O 0 1.0229292968233494e-08
development O 0 3.5210732107771037e-08
of O 0 0.002564114984124899
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.4604009948016028e-06
CRC B-Disease 1 0.9999998807907104
) O 0 1.3307734434420126e-06
. O 0 2.694731620067614e-06

APC B-Disease 0 0.0009016134426929057
is O 0 1.7890914705276373e-06
a O 0 1.2447652579794521e-06
tumour O 1 1.0
- O 0 7.526169792981818e-05
suppressor O 0 0.004871761426329613
gene O 0 1.2248331415776192e-07
, O 0 1.8036612203786717e-08
and O 0 3.710718488036946e-08
somatic O 0 3.655563659776817e-06
loss O 0 4.028065632155631e-06
occurs O 0 1.6630096411063278e-07
in O 0 3.824583814093785e-07
tumours B-Disease 1 1.0
. O 0 2.024765490205027e-05

The O 0 1.8744523913483135e-05
germline O 0 2.1852560166735202e-05
T O 0 7.524874945374904e-06
- O 0 3.2308881259268674e-07
to O 0 3.654485780657524e-08
- O 0 4.103296760149533e-07
A O 0 2.7189508955416386e-07
transversion O 0 9.274983767681988e-07
responsible O 0 1.006175676110388e-08
for O 0 3.615368004972197e-09
the O 0 4.5500936352027566e-08
APC O 0 3.080644319197745e-06
I1307K O 0 5.060711828264175e-06
allele O 0 9.971164871558358e-08
converts O 0 3.461423503381411e-08
the O 0 1.8557724246193175e-08
wild O 0 2.300275241395866e-07
- O 0 8.103965143391179e-08
type O 0 4.389407948224289e-08
sequence O 0 1.0426234986482541e-08
to O 0 5.358690824408541e-09
a O 0 6.557284848440759e-08
homopolymer O 1 0.9999978542327881
tract O 1 1.0
( O 0 1.8431093451454217e-07
A8 O 1 1.0
) O 0 1.1563397350755622e-08
that O 0 2.5596047503739783e-09
is O 0 1.9706050125023467e-08
genetically O 0 2.5870932063298824e-07
unstable O 0 2.2161755452998477e-07
and O 0 2.7417335957125033e-08
prone O 0 1.8075551224683295e-06
to O 0 3.7539805930464354e-07
somatic O 0 2.575572580099106e-05
mutation O 0 3.5556929560698336e-06
. O 0 1.8350956452195533e-06

The O 0 1.4406610716832802e-05
I1307K O 0 0.00010239324910799041
allele O 0 2.334900727873901e-06
was O 0 5.020411322220752e-07
found O 0 3.97340365054788e-08
in O 0 4.771696637817513e-08
6 O 0 4.464940957404906e-06
. O 0 2.8568963443831308e-06

1 O 0 3.862428911816096e-06
% O 0 1.2777540803199372e-07
of O 0 3.5768638895206095e-07
unselected O 0 0.00019345429609529674
Ashkenazi O 0 2.317020062037045e-06
Jews O 0 1.6109345324366586e-07
and O 0 8.918711102978705e-09
higher O 0 1.1166830127251615e-08
proportions O 0 5.0367255255423515e-08
of O 0 3.108865698209229e-08
Ashkenazim O 0 8.910076303436654e-07
with O 0 3.123884928513121e-09
family O 0 1.1158867607719003e-08
or O 0 1.0450086129765168e-08
personal O 0 8.250918881458347e-08
histories O 0 1.3435403900530218e-07
of O 0 1.3900168596592266e-05
CRC B-Disease 1 1.0
( O 0 1.368176185678749e-07
ref O 0 5.071311079518637e-06
. O 0 5.395244784267561e-08
2 O 0 1.186899339700176e-06
) O 0 3.0241849913181795e-07
. O 0 2.2181152417033445e-06

To O 0 4.334647201176267e-07
evaluate O 0 6.217046006895544e-07
the O 0 7.170081062213285e-08
role O 0 7.910621491191705e-08
of O 0 2.247387982379223e-07
I1307K O 0 2.1426221792353317e-05
in O 0 1.0075317646851545e-07
cancer B-Disease 0 1.3520005268219393e-05
, O 0 3.220425526251347e-08
we O 0 2.7422460746606703e-08
genotyped O 0 4.4999851525062695e-06
5 O 0 4.784920974998386e-07
, O 0 1.507461604433047e-07
081 O 0 4.664142761612311e-05
Ashkenazi O 0 3.4235783914482454e-06
volunteers O 0 2.5888328991641174e-07
in O 0 5.562698035532776e-08
a O 0 1.6673909897235717e-07
community O 0 2.246038093289826e-07
survey O 0 4.874895012108027e-07
. O 0 1.689657210590667e-06

Risk O 0 7.903540790721308e-06
of O 0 1.0010169262386626e-06
developing O 0 0.061643265187740326
colorectal B-Disease 1 1.0
, I-Disease 0 0.0033984705805778503
breast I-Disease 1 0.9999995231628418
and I-Disease 0 1.2665852011650713e-07
other I-Disease 0 1.144803576380582e-07
cancers I-Disease 0 0.3717423379421234
were O 0 6.086895432133588e-09
compared O 0 4.423764909944339e-09
between O 0 7.844897176312315e-09
genotyped O 0 6.318363375612535e-06
I1307K O 0 1.0089680699820747e-06
carriers O 0 8.312075472360902e-09
and O 0 3.974402140727307e-09
non O 0 4.455581148476995e-08
- O 0 5.09975279783248e-08
carriers O 0 4.78445283391693e-09
and O 0 2.2149040379559892e-09
their O 0 1.9848629406737928e-09
first O 0 8.063226530907741e-09
- O 0 2.7550547088139865e-07
degree O 0 5.439022174869024e-07
relatives O 0 4.2893637441920873e-07
. O 0 9.758924761626986e-07

Sperm O 0 2.8952570119145093e-06
DNA O 0 5.167199788047583e-07
analysis O 0 4.0963911374092277e-08
in O 0 3.7582424283755245e-08
a O 0 6.262592933126143e-07
Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
premutation O 1 1.0
carrier O 0 1.5458066627616063e-05
suggests O 0 7.492640179407317e-07
both O 0 1.0537034000890344e-07
meiotic O 0 1.1675329915306065e-05
and O 0 3.9052719102983247e-07
mitotic O 0 1.1428404604885145e-06
expansion O 0 1.5874799146331497e-06
in O 0 9.739068218550528e-08
the O 0 7.716899403931166e-07
FRDA B-Disease 1 0.9998871088027954
gene O 0 5.629988208966097e-06
. O 0 4.37401558883721e-06

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 3.5988676245324314e-05
usually O 0 2.640187517499726e-07
caused O 0 8.943875684508384e-08
by O 0 2.660015097077917e-09
an O 0 7.76938513524783e-09
expansion O 0 2.0071090034434746e-07
of O 0 2.966818328786758e-07
a O 0 3.5000158504772116e-07
GAA O 0 0.0003917698049917817
trinucleotide O 0 9.67585074249655e-05
repeat O 0 5.463049888021487e-07
in O 0 2.386998687597952e-08
intron O 0 1.8017998399955104e-06
1 O 0 3.7354706705627905e-07
of O 0 3.409924715924717e-07
the O 0 7.174717779889761e-07
FRDA B-Disease 1 0.9995824694633484
gene O 0 3.116131892966223e-06
. O 0 3.3088451800722396e-06

Occasionally O 0 1.3914505871071015e-05
, O 0 4.049478548040497e-07
a O 0 1.123344333109344e-07
fully O 0 2.565393515396863e-07
expanded O 0 2.0167063041753863e-07
allele O 0 1.785745524784943e-07
has O 0 1.4114983848401152e-08
been O 0 6.715332734330559e-09
found O 0 2.971720425293256e-09
to O 0 3.737467224596003e-09
arise O 0 1.4195089548252326e-08
from O 0 6.144905917437882e-09
a O 0 2.7308935557357472e-08
premutation O 0 5.221872925176285e-06
of O 0 2.635422902130813e-07
100 O 0 2.5492047939223994e-07
or O 0 4.2345018158584935e-08
less O 0 9.802525369195791e-08
triplet O 0 1.2312608305364847e-05
repeats O 0 1.965981937246397e-06
. O 0 1.9456549580354476e-06

We O 0 1.6632521919746068e-06
have O 0 4.593098523741901e-08
examined O 0 1.6746372466514003e-07
the O 0 4.1002838457870894e-08
sperm O 0 9.389613531141094e-09
DNA O 0 2.2370549856987054e-08
of O 0 7.555253489499592e-08
a O 0 1.8851986283152655e-07
premutation O 0 0.00017839389329310507
carrier O 0 7.038106105028419e-06
. O 0 5.335229161573807e-06

This O 0 1.4533221701640286e-06
mans O 0 7.820188329787925e-05
leucocyte O 0 2.5122333681792952e-05
DNA O 0 8.350325515493751e-07
showed O 0 6.739394109445129e-08
one O 0 9.302125292265373e-09
normal O 0 1.19595755521118e-08
allele O 0 7.891344466770533e-09
and O 0 2.5212871790358804e-09
one O 0 4.788470064909234e-09
allele O 0 2.4482327276587057e-08
of O 0 5.0693497399834087e-08
approximately O 0 9.260597977345242e-08
100 O 0 5.04179126892268e-07
repeats O 0 1.7997218719756347e-06
. O 0 1.609612013453443e-06

His O 0 1.4259641829994507e-05
sperm O 0 3.672128912057815e-07
showed O 0 6.071939395724257e-08
an O 0 9.225969321846605e-09
expanded O 0 3.864001385522897e-08
allele O 0 3.564454686966201e-08
in O 0 6.60284094067265e-09
a O 0 4.74864414456988e-08
tight O 0 5.39340760496998e-07
range O 0 5.286049713504326e-07
centering O 0 8.855892588144343e-07
on O 0 7.60327694138141e-08
a O 0 2.808674537391198e-08
size O 0 7.610270813529496e-08
of O 0 1.4520612978685676e-07
approximately O 0 1.9641026938188588e-07
320 O 0 2.7045664410252357e-06
trinucleotide O 0 0.00019173983309883624
repeats O 0 1.3271082025312353e-05
. O 0 7.539384114352288e-06

His O 0 2.4751261662459e-05
affected O 0 6.371010840666713e-06
son O 0 7.3321416493854485e-06
has O 0 1.8323345329918084e-07
repeat O 0 2.8053639766767446e-07
sizes O 0 9.102586773224175e-08
of O 0 1.733582593033134e-07
1040 O 0 1.7607108020456508e-06
and O 0 4.4856301428808365e-07
540 O 0 1.3734980711888056e-05
. O 0 3.4624845284270123e-06

These O 0 6.533814485010225e-07
data O 0 1.279244088436826e-07
suggest O 0 3.337298792871479e-08
that O 0 2.126508524824544e-09
expansion O 0 5.9177580169489374e-08
occurs O 0 1.2445191543974943e-09
in O 0 3.690492911267995e-10
two O 0 3.4864391929012584e-10
stages O 0 1.6848213491016395e-08
, O 0 1.6391628054890361e-09
the O 0 4.088590799256053e-09
first O 0 7.346442121303198e-09
during O 0 1.038998576063932e-08
meiosis O 0 3.935345560535097e-08
followed O 0 2.4066380888143613e-08
by O 0 6.4757106343904525e-09
a O 0 4.416339649537804e-08
second O 0 3.2453002063448366e-07
mitotic O 0 3.0209962460503448e-06
expansion O 0 8.945785339165013e-06
. O 0 3.8776706787757576e-06

We O 0 9.399487339578627e-07
also O 0 9.510905130127867e-08
show O 0 2.072084903659288e-08
that O 0 8.046108224135651e-10
in O 0 8.77209971328341e-10
all O 0 2.9633941966977773e-09
informative O 0 1.1136057764815632e-07
carrier O 0 3.52041524820379e-08
father O 0 1.6121386892109513e-08
to O 0 5.849591921958108e-09
affected O 0 2.186467717990581e-08
child O 0 2.4554859479053448e-08
transmissions O 0 2.620305394884781e-08
, O 0 1.6155669024797703e-09
with O 0 7.863228956850321e-10
the O 0 7.320970052404618e-09
notable O 0 1.661338089320452e-08
exception O 0 1.7648359218469523e-08
of O 0 4.34075282385038e-08
the O 0 7.812929680994785e-08
premutation O 0 1.4236788047128357e-05
carrier O 0 1.2005885707822017e-07
, O 0 2.242805585694896e-08
the O 0 3.8731588603013734e-08
expansion O 0 2.481125704889564e-07
size O 0 2.6163459665440314e-07
decreases O 0 2.817507152030885e-07
. O 0 1.1713975567317902e-07
. O 0 1.1351467037457041e-06

The O 0 1.0137161552847829e-05
R496H O 0 7.485679088858888e-05
mutation O 0 8.220897029787011e-07
of O 0 6.218932071533345e-07
arylsulfatase O 0 0.0004994969931431115
A O 0 5.643981239700224e-06
does O 0 2.3757122846745915e-07
not O 0 1.8467231654994976e-07
cause O 0 1.9351928131072782e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 9.711761958897114e-05

Deficiency B-Disease 1 0.9999984502792358
of I-Disease 0 0.00010570458834990859
arylsulfatase I-Disease 1 0.9999986886978149
A I-Disease 0 0.008247061632573605
( O 0 1.8095022369379876e-06
ARSA O 1 0.9999985694885254
) O 0 2.706827046949911e-07
enzyme O 0 5.71824216422101e-07
activity O 0 1.7363623783239746e-07
causes O 0 1.062386672856519e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.1469642231531907e-05
MLD B-Disease 1 1.0
) O 0 8.696291843079962e-06
. O 0 1.1866291060869116e-05

A O 0 2.7592300284595694e-06
number O 0 1.9983956178748485e-07
of O 0 9.248812489204283e-07
ARSA O 1 0.9999998807907104
gene O 0 1.1763786460505798e-06
mutations O 0 1.2172895935691486e-07
responsible O 0 6.726782686428123e-08
for O 0 7.77634170390229e-08
MLD B-Disease 1 1.0
have O 0 1.5470030234610022e-07
been O 0 1.908323241650578e-07
identified O 0 3.840838189717033e-07
. O 0 9.146772868007247e-07

Recently O 0 1.0089689567394089e-05
, O 0 2.6604863023749203e-07
the O 0 1.689704163254646e-07
R496H O 0 3.971778824052308e-06
mutation O 0 1.303504859606619e-07
of O 0 1.9898151037978096e-07
ARSA O 1 0.9999998807907104
was O 0 3.1783264375917497e-07
proposed O 0 2.9181872918115914e-08
to O 0 5.231751920575789e-09
be O 0 2.8705606780476955e-09
a O 0 6.6866134851295556e-09
cause O 0 3.279798477251461e-08
of O 0 5.291234970172809e-07
MLD B-Disease 1 1.0
( O 0 2.127435152488033e-07
Draghia O 0 5.004440754419193e-05
et O 0 4.6759240035498806e-07
al O 0 1.4262631964356842e-07
. O 0 1.3057090519907888e-08
, O 0 2.9782587063209576e-08
1997 O 0 3.7333336422307184e-07
) O 0 2.894286126320367e-07
. O 0 2.0718105133710196e-06

We O 0 1.629255166335497e-06
have O 0 6.65702941660129e-08
investigated O 0 4.803566184818919e-07
the O 0 7.068821616940113e-08
R496H O 0 2.53017765317054e-06
mutation O 0 1.545424410664964e-08
and O 0 2.5700297445752085e-09
found O 0 2.0347832307976432e-09
this O 0 7.924840783601894e-10
mutation O 0 2.181193226036271e-09
at O 0 9.018543245531419e-09
a O 0 4.883202731065239e-09
relatively O 0 3.0596853939357516e-09
high O 0 1.339357869056812e-08
frequency O 0 5.367058353300536e-09
in O 0 8.178243082745951e-10
an O 0 2.4497119888167163e-09
African O 0 5.198736996447906e-09
American O 0 9.336003969906415e-09
population O 0 1.4051209085153005e-09
( O 0 1.5598665692451164e-09
f O 0 5.623376608809849e-08
= O 0 1.2269160798439316e-08
0 O 0 2.1579054987341806e-08
. O 0 8.228503212137639e-09
09 O 0 1.2195862382213818e-06
, O 0 4.304049383563324e-08
n O 0 9.008712709146494e-08
= O 0 7.432192461465092e-08
61 O 0 6.365298759192228e-07
subjects O 0 1.2890329799120082e-06
) O 0 3.7253914797474863e-07
. O 0 3.3464509670011466e-06

The O 0 3.757845479412936e-05
ARSA O 1 0.9995488524436951
enzyme O 0 5.564224920817651e-07
activity O 0 2.6851264323113355e-08
in O 0 2.0619634888419114e-09
subjects O 0 3.330914211119307e-08
with O 0 1.4343684018314207e-09
and O 0 4.593219138371296e-09
without O 0 6.9621082232629306e-09
the O 0 4.212758497601499e-08
R496H O 0 3.3783080652938224e-06
mutation O 0 3.3977961777509336e-08
was O 0 2.949405875085631e-08
determined O 0 1.0014885809539464e-08
and O 0 5.179170425861912e-09
found O 0 6.488940496041096e-09
to O 0 2.2170480562522243e-08
be O 0 4.872570968927903e-08
normal O 0 6.162726435832155e-07
. O 0 1.2775484492522082e-06

It O 0 1.2747980235872092e-06
is O 0 1.411387415828358e-07
therefore O 0 3.267491521796728e-08
concluded O 0 2.9017527936048282e-08
that O 0 2.6901489924568978e-09
the O 0 1.6629517318733633e-08
R496H O 0 2.584804406069452e-06
mutation O 0 7.50239408375819e-08
of O 0 2.1633334768011991e-07
ARSA O 1 0.9997522234916687
does O 0 9.151452218247869e-08
not O 0 6.981682343365492e-09
negatively O 0 2.5767555200673087e-08
influence O 0 1.5315681167749062e-08
the O 0 7.29404181498694e-09
activity O 0 5.72353231476086e-09
of O 0 3.295538064662651e-08
ARSA O 1 0.9999338388442993
and O 0 6.320240686363832e-08
is O 0 2.1261609361999945e-08
not O 0 1.0898689062344147e-08
a O 0 1.1909046548908009e-07
cause O 0 2.121064881066559e-06
of O 0 2.8695645596599206e-05
MLD B-Disease 1 1.0

Down O 0 3.2409745472250506e-05
- O 0 2.94809797196649e-06
regulation O 0 9.863522336672759e-07
of O 0 9.083593113246025e-07
transmembrane O 0 8.492220331390854e-06
carbonic O 0 0.00010150575690204278
anhydrases O 0 0.0007474828162230551
in O 0 3.0684302032568667e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999581575393677
lines O 0 9.866184882412199e-07
by O 0 2.581940883317202e-08
wild O 0 6.124448191258125e-06
- O 0 6.504520570160821e-06
type O 0 6.096953256928828e-06
von B-Disease 1 0.9364998936653137
Hippel I-Disease 1 0.9999983310699463
- I-Disease 0 0.024449706077575684
Lindau I-Disease 1 0.6232061982154846
transgenes O 0 0.0006310422322712839
. O 0 1.4819558600720484e-05

To O 0 3.056419927816023e-06
discover O 0 1.2311095360928448e-06
genes O 0 5.779041600817436e-08
involved O 0 1.9723497501900056e-08
in O 0 2.8612804570116168e-08
von B-Disease 1 0.9882116913795471
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999977350234985
Lindau I-Disease 1 1.0
( O 0 1.8011348856816767e-06
VHL B-Disease 1 1.0
) O 0 2.3648124169994844e-07
- O 0 2.953123612314812e-06
mediated O 0 1.2669515854213387e-06
carcinogenesis O 1 0.7516610026359558
, O 0 2.918126007500632e-08
we O 0 9.767489927980932e-09
used O 0 1.3237847440450423e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 0.0002527825126890093
stably O 0 2.4218945327447727e-05
transfected O 0 2.2208037080417853e-06
with O 0 2.054827064057463e-08
wild O 0 2.171296500819153e-06
- O 0 6.743765879946295e-06
type O 0 2.0596140529960394e-05
VHL O 1 1.0
- O 0 8.374857134185731e-05
expressing O 0 8.644917215860914e-06
transgenes O 0 0.00015537283616140485
. O 0 7.25603513274109e-06

Large O 0 5.188366230868269e-06
- O 0 2.3765603600622853e-06
scale O 0 1.917318058985984e-06
RNA O 0 1.7015132698361413e-06
differential O 0 1.868726968723422e-07
display O 0 1.7916816830165772e-07
technology O 0 3.9425955833394255e-08
applied O 0 8.713505472712768e-09
to O 0 2.430852408252804e-09
these O 0 2.0570221082039097e-09
cell O 0 1.7381376338221344e-08
lines O 0 1.6448698403337403e-08
identified O 0 5.276839409873446e-09
several O 0 4.857276358904983e-09
differentially O 0 1.886992038180324e-07
expressed O 0 8.361879189067167e-09
genes O 0 7.697272152995538e-09
, O 0 4.062254976844315e-09
including O 0 1.4710389351080266e-08
an O 0 3.392842273797214e-08
alpha O 0 2.033874125118018e-06
carbonic O 0 1.6304151358781382e-05
anhydrase O 0 3.4189430152764544e-05
gene O 0 5.339421136341116e-07
, O 0 2.1948039830022026e-07
termed O 0 1.3594320080301259e-05
CA12 O 1 0.9999984502792358
. O 0 2.329826202185359e-05

The O 0 6.049068360880483e-06
deduced O 0 1.8724210804066388e-06
protein O 0 8.000084505965788e-08
sequence O 0 1.49196885956826e-08
was O 0 2.7235330435360083e-08
classified O 0 8.466325596145907e-08
as O 0 7.620449160583576e-09
a O 0 7.563410342470434e-09
one O 0 1.1022805779248301e-08
- O 0 2.9055445338599384e-07
pass O 0 8.988251920527546e-07
transmembrane O 0 2.5018737233040156e-06
CA O 0 4.630862895282917e-05
possessing O 0 1.0352360959586804e-06
an O 0 5.0515613025936545e-08
apparently O 0 2.745983920249273e-07
intact O 0 1.6954538750724168e-07
catalytic O 0 3.428295656249247e-07
domain O 0 1.0014335316554934e-07
in O 0 1.7193825030403787e-08
the O 0 1.7408589769729588e-07
extracellular O 0 6.907179795234697e-06
CA O 0 0.2115313559770584
module O 0 6.246763950912282e-05
. O 0 4.459459887584671e-06

Reintroduced O 0 0.00015701769734732807
wild O 0 6.038201172486879e-05
- O 0 4.7834353608777747e-05
type O 0 3.924770135199651e-05
VHL B-Disease 1 0.9999650716781616
strongly O 0 2.788354436233931e-07
inhibited O 0 8.062476553050146e-08
the O 0 2.1422644991275774e-08
overexpression O 0 1.7004509800244705e-07
of O 0 7.025098369695115e-08
the O 0 9.78993170974718e-08
CA12 O 1 0.9999896287918091
gene O 0 2.297222856384451e-08
in O 0 2.610486715681759e-09
the O 0 4.559685251592782e-08
parental O 0 1.579644413141068e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 0.020804939791560173
. O 0 1.5890696886344813e-05

Similar O 0 1.4846076510366402e-06
results O 0 6.061710422500255e-08
were O 0 9.519813382041775e-09
obtained O 0 9.974661985268085e-09
with O 0 1.3922814900979574e-08
CA9 O 0 0.32559868693351746
, O 0 8.255923944489041e-08
encoding O 0 2.4795809849820216e-07
another O 0 8.438338738869788e-08
transmembrane O 0 6.646802717114042e-07
CA O 0 4.705404535343405e-06
with O 0 3.406153581408944e-08
an O 0 1.1384887699250612e-07
intact O 0 1.7046512539309333e-06
catalytic O 0 1.0949780516966712e-05
domain O 0 9.340295946458355e-06
. O 0 3.77583569388662e-06

Although O 0 5.930492079642136e-07
both O 0 8.91128451030454e-08
domains O 0 2.845666529083246e-07
of O 0 5.239199367679248e-07
the O 0 8.438771601504413e-07
VHL B-Disease 1 0.9992110729217529
protein O 0 7.316520367339763e-08
contribute O 0 1.5695908572865847e-08
to O 0 7.619374464695738e-09
regulation O 0 1.1032064861637991e-07
of O 0 5.537407901101687e-07
CA12 O 1 1.0
expression O 0 1.192839249597455e-07
, O 0 1.4658656510846413e-08
the O 0 3.431003037235314e-08
elongin O 0 1.727355765979155e-06
binding O 0 8.88706352952795e-08
domain O 0 1.0950513740226597e-07
alone O 0 4.0570615311708025e-08
could O 0 3.5261003006326064e-08
effectively O 0 7.115801849977288e-07
regulate O 0 7.111133072612574e-06
CA9 O 1 0.9999357461929321
expression O 0 1.4003899195813574e-05
. O 0 6.630217285419349e-06

We O 0 8.587735464971047e-06
mapped O 0 4.2619489249773324e-05
CA12 O 1 0.9998700618743896
and O 0 3.7885822621319676e-06
CA9 O 1 0.6001387238502502
loci O 0 8.017565960471984e-06
to O 0 3.863401616399642e-07
chromosome O 0 3.946548531530425e-06
bands O 0 5.52218489247025e-06
15q22 O 0 4.183650526101701e-05
and O 0 1.2760289109792211e-06
17q21 O 0 0.0003061017778236419
. O 0 9.306960237154271e-06

2 O 0 8.523993528797291e-06
respectively O 0 1.0553239917499013e-06
, O 0 1.2796931514458265e-07
regions O 0 3.5696228906090255e-07
prone O 0 1.6689754147591884e-06
to O 0 3.8775862520878945e-08
amplification O 0 5.078500180388801e-07
in O 0 2.3215859457081933e-08
some O 0 8.167634746314434e-08
human O 0 1.023397658173053e-06
cancers B-Disease 1 0.9992068409919739
. O 0 4.025131602247711e-06

Additional O 0 1.6904114090721123e-06
experiments O 0 2.1983106535117258e-07
are O 0 1.675485417074185e-09
needed O 0 2.866249682043076e-09
to O 0 2.748072436276061e-09
define O 0 2.5150015403596626e-08
the O 0 1.7622728165633816e-08
role O 0 3.8821596604066144e-08
of O 0 1.98173609078367e-07
CA O 0 0.00037405514740385115
IX O 1 1.0
and O 0 7.389447205241595e-07
CA O 0 0.01949779875576496
XII O 1 1.0
enzymes O 0 8.744878243760468e-08
in O 0 4.00042798887057e-09
the O 0 1.3712609714389146e-08
regulation O 0 8.499413439722048e-08
of O 0 6.08565571269537e-08
pH O 0 8.131631830110564e-07
in O 0 9.337731476932731e-09
the O 0 3.610339049942013e-08
extracellular O 0 2.552264959376771e-07
microenvironment O 0 7.661345762244309e-07
and O 0 1.5185657176175482e-08
its O 0 1.2413784666875927e-08
potential O 0 9.731845551641527e-08
impact O 0 2.561516510013462e-07
on O 0 4.5754450184176676e-07
cancer B-Disease 0 0.00013584797852672637
cell O 0 2.584459252830129e-06
growth O 0 1.3093123243379523e-06
. O 0 2.6042450826935237e-06

A O 0 1.741438427416142e-05
gene O 0 7.266231136782153e-07
encoding O 0 1.1106822057627141e-06
a O 0 1.2716370179077785e-07
transmembrane O 0 8.497450494360237e-07
protein O 0 1.444536366079774e-07
is O 0 1.0441558728757627e-08
mutated O 0 6.510799721581861e-08
in O 0 3.0933613448524966e-09
patients O 0 1.8311601124310073e-08
with O 0 1.8737596008122637e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9999988079071045
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 9.457195346840308e-07
. O 0 2.4175453745556297e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0007706177420914173
WFS B-Disease 1 1.0
; O 0 3.2969956009765156e-06
OMIM O 1 1.0
222300 O 0 0.00023391490685753524
) O 0 5.643254041842738e-08
is O 0 2.9377615007319946e-08
an O 0 8.326392020308049e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 8.990911481987496e-08
by O 0 4.286826005284183e-09
young O 0 1.0694622432083634e-07
- O 0 2.79719938589551e-06
onset O 0 0.00012959462765138596
non O 0 2.426814171485603e-05
- O 0 0.0005639430019073188
immune O 0 0.0003808149485848844
insulin B-Disease 0 0.00015381663979496807
- I-Disease 0 0.05359061434864998
dependent I-Disease 0 5.2991730626672506e-05
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.0002911851042881608
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 0.00015519250882789493

Linkage O 0 5.315328235155903e-05
to O 0 1.2046615438521258e-06
markers O 0 1.0341197594243567e-05
on O 0 2.0293405214033555e-06
chromosome O 0 1.3340593795874156e-05
4p O 0 0.000347293505910784
was O 0 7.21887658983178e-07
confirmed O 0 3.995595321271139e-08
in O 0 1.4152672811462708e-08
five O 0 5.118931767356116e-08
families O 0 2.0480579010495603e-08
. O 0 7.803158723618253e-07

On O 0 1.20691322536004e-06
the O 0 1.36442878329035e-07
basis O 0 8.324454370267631e-08
of O 0 1.544547103549121e-07
meiotic O 0 0.0002492886269465089
recombinants O 1 0.9999966621398926
and O 0 8.955053658610268e-07
disease O 0 0.42469990253448486
- O 0 8.408028406847734e-07
associated O 0 1.1036484437454419e-07
haplotypes O 0 7.589750339320744e-07
, O 0 3.481990518139355e-08
the O 0 2.0737938655202015e-07
WFS B-Disease 1 0.9999994039535522
gene O 0 3.8328431628542603e-07
was O 0 2.5799971581363934e-07
localized O 0 1.372150109091308e-06
to O 0 8.547143437453997e-08
a O 0 5.736080765927909e-07
BAC O 1 1.0
/ O 0 0.00011674109555315226
P1 O 1 0.5680398941040039
contig O 0 1.7942369595402852e-05
of O 0 3.733618427759211e-07
less O 0 6.439403676949951e-08
than O 0 4.687085564114568e-08
250 O 0 9.578589015291072e-07
kb O 0 9.456914995098487e-05
. O 0 6.300516815826995e-06

Mutations O 0 1.711802951831487e-06
in O 0 7.103571419975196e-08
a O 0 8.105804738534061e-08
novel O 0 8.745676041144179e-07
gene O 0 1.0752444268291583e-07
( O 0 2.9015424729550432e-08
WFS1 O 1 0.5066695213317871
) O 0 3.438917417497578e-08
encoding O 0 1.3406543075689115e-07
a O 0 3.83245470914062e-08
putative O 0 4.895828169537708e-07
transmembrane O 0 1.47664493965749e-07
protein O 0 1.615771161311841e-08
were O 0 2.5904927092312846e-09
found O 0 1.6604186914292995e-09
in O 0 3.5095776285132274e-10
all O 0 1.239064406632906e-09
affected O 0 1.7486578851588774e-09
individuals O 0 2.2912387265261458e-10
in O 0 1.2790624115410765e-09
six O 0 3.5763857653137165e-08
WFS B-Disease 1 0.9999948740005493
families O 0 2.5440685114119788e-09
, O 0 2.022752854102805e-09
and O 0 2.3276014449180593e-09
these O 0 2.8187732148410305e-09
mutations O 0 4.545008813749973e-09
were O 0 7.367683685366444e-10
associated O 0 3.044729357526421e-09
with O 0 7.998784745666399e-09
the O 0 1.312590484303655e-06
disease O 1 0.9662907719612122
phenotype O 0 4.148093466938008e-06
. O 0 1.5785426512593403e-06

WFS1 O 1 0.9999995231628418
appears O 0 3.1696072255726904e-06
to O 0 6.00466876221617e-08
function O 0 4.591925062413793e-08
in O 0 1.0934440020093916e-08
survival O 0 4.805527282769617e-07
of O 0 4.401531157327554e-07
islet O 0 0.00025793854729272425
beta O 0 8.619600748716039e-07
- O 0 7.442617402375618e-07
cells O 0 2.0183758664416018e-08
and O 0 1.8674830570830636e-08
neurons O 0 2.3428449935636309e-07
. O 0 1.555767568106603e-07
. O 0 1.922213641591952e-06

Stable O 0 1.2965243513463065e-05
interaction O 0 1.9684418361975986e-07
between O 0 2.300726542614484e-08
the O 0 4.863471403382391e-08
products O 0 6.036834321321294e-08
of O 0 1.1239958297437624e-07
the O 0 3.420105656459782e-07
BRCA1 O 0 1.0387377187726088e-05
and O 0 6.433897397073451e-07
BRCA2 O 0 0.0001553707552375272
tumor B-Disease 0 9.898099233396351e-05
suppressor O 0 4.116200580028817e-05
genes O 0 1.5070376946368924e-07
in O 0 3.5477420112783875e-08
mitotic O 0 6.985547429394501e-07
and O 0 4.4794745690523996e-07
meiotic O 0 0.00029530152096413076
cells O 0 4.299260126572335e-06
. O 0 4.663214895117562e-06

BRCA1 O 0 0.0012153033167123795
and O 0 2.72314923677186e-06
BRCA2 O 0 1.1144892596348654e-05
account O 0 1.050694642401595e-08
for O 0 2.94549695745161e-09
most O 0 1.6167938099442836e-09
cases O 0 1.86318405148711e-09
of O 0 2.549573707710806e-08
familial O 0 0.0013081420911476016
, O 0 1.748822242575443e-08
early O 0 3.306291773697012e-08
onset O 0 0.00037681334652006626
breast B-Disease 1 0.999683141708374
and I-Disease 0 3.862473022309132e-06
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.5688245369460674e-08
encode O 0 1.4514430546341828e-08
products O 0 1.6903126009992775e-08
that O 0 1.3854251079692403e-09
each O 0 5.355410781504588e-09
interact O 0 2.609701610367665e-08
with O 0 7.868112561482121e-08
hRAD51 O 0 5.904947829549201e-05
. O 0 5.629499810311245e-06

Results O 0 9.182073199553997e-07
presented O 0 3.910265888862341e-07
here O 0 2.497496076614425e-08
show O 0 4.652650886782794e-08
that O 0 1.360999934973961e-08
BRCA1 O 0 1.41459725000459e-06
and O 0 1.5694148203238e-07
BRCA2 O 0 1.845886799856089e-05
coexist O 0 9.650625543144997e-08
in O 0 6.253888518159556e-09
a O 0 1.4804993675454625e-08
biochemical O 0 1.4743147858098382e-07
complex O 0 2.1094908220220532e-07
and O 0 2.5792436630922566e-08
colocalize O 0 4.892742254014593e-06
in O 0 4.745357529145622e-08
subnuclear O 0 1.9825234630843624e-05
foci O 0 2.6040613647637656e-06
in O 0 1.0689622520487774e-08
somatic O 0 1.8615020280776662e-07
cells O 0 2.1723416399055395e-09
and O 0 1.263179782995394e-09
on O 0 1.4279952331719414e-08
the O 0 1.653592818229299e-08
axial O 0 2.700860193272092e-07
elements O 0 4.5423245609299556e-08
of O 0 1.3537358256598964e-07
developing O 0 2.5527029379190935e-07
synaptonemal O 0 7.511035073548555e-05
complexes O 0 5.972725375613663e-06
. O 0 2.2346853256749455e-06

Like O 0 1.9222143237129785e-05
BRCA1 O 0 5.8301331591792405e-05
and O 0 1.5681222294006147e-06
RAD51 O 1 1.0
, O 0 5.6896087698987685e-06
BRCA2 O 0 2.6924686608253978e-05
relocates O 0 3.859232947434066e-06
to O 0 3.177617315941461e-07
PCNA O 0 0.0010843550553545356
+ O 0 4.6640417394883116e-07
replication O 0 3.340100818149949e-08
sites O 0 2.9009559199266732e-08
following O 0 1.2153821060678638e-08
exposure O 0 3.215429842384765e-07
of O 0 2.0215124152400676e-07
S O 0 4.079023256053915e-06
phase O 0 6.401709811143519e-07
cells O 0 2.2148080702777406e-08
to O 0 5.383824230875689e-08
hydroxyurea O 0 2.40331773966318e-05
or O 0 7.905521783868608e-07
UV O 1 0.9999871253967285
irradiation O 0 2.381729063927196e-05
. O 0 3.320433734188555e-06

Thus O 0 4.7908752094372176e-06
, O 0 4.848633352594334e-07
BRCA1 O 0 1.7140246200142428e-06
and O 0 1.452723381589749e-07
BRCA2 O 0 2.641069158926257e-06
participate O 0 2.0041742487819647e-08
, O 0 5.3117079623632435e-09
together O 0 3.7189928914216352e-09
, O 0 3.6477427745040814e-09
in O 0 2.7905442401277014e-09
a O 0 1.069647570517418e-08
pathway O 0 5.433631145024265e-08
( O 0 2.702202905879858e-09
s O 0 1.4763373634707477e-08
) O 0 8.833028197763326e-10
associated O 0 1.2000700433389966e-09
with O 0 1.0054154175875851e-09
the O 0 6.423098497521096e-09
activation O 0 1.1680303835248651e-08
of O 0 2.348127914331144e-08
double O 0 2.626344652867374e-08
- O 0 2.0046259407990874e-07
strand O 0 9.834736403036004e-08
break O 0 1.0305222275519554e-07
repair O 0 4.1349196067130833e-07
and O 0 1.157453368705319e-07
/ O 0 2.2849101242172765e-06
or O 0 2.1891472101742693e-07
homologous O 0 5.861365934833884e-07
recombination O 0 7.828874686310883e-07
. O 0 2.2225813154364005e-06

Dysfunction O 1 0.9996131062507629
of O 0 4.354727934696712e-06
this O 0 4.4107750341026986e-08
pathway O 0 1.993484630702369e-07
may O 0 4.467433090127315e-09
be O 0 2.012961575204031e-09
a O 0 3.6318310581151536e-09
general O 0 1.257341786242705e-08
phenomenon O 0 3.046159946507032e-08
in O 0 1.1029803737017119e-09
the O 0 5.169370265178941e-09
majority O 0 1.0344559653319152e-09
of O 0 4.302323386440321e-09
cases O 0 5.591597407317295e-09
of O 0 3.653510418644146e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9999994039535522
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.973964564669586e-07
. O 0 1.8374755654804176e-06

A O 0 4.588770752889104e-05
novel O 0 2.2779437131248415e-05
Arg362Ser O 0 7.239338447107002e-05
mutation O 0 4.3345315248188854e-07
in O 0 2.274976473870538e-08
the O 0 9.912457699101651e-08
sterol O 0 3.6252138215786545e-06
27 O 0 6.570750201717601e-07
- O 0 1.3350165772862965e-06
hydroxylase O 0 3.050999657716602e-05
gene O 0 2.5405017822777154e-07
( O 0 3.938551884630215e-08
CYP27 O 1 0.9446802139282227
) O 0 1.738588473187974e-08
: O 0 3.0298930031591453e-09
its O 0 3.795976422082958e-09
effects O 0 5.950082382355504e-08
on O 0 2.518548924967945e-08
pre O 0 2.864366308585886e-07
- O 0 1.2400182924920955e-07
mRNA O 0 1.0971714203833471e-07
splicing O 0 1.044182127429849e-07
and O 0 2.065113235971694e-08
enzyme O 0 1.4262862180203228e-07
activity O 0 3.666411032554606e-07
. O 0 9.838111054705223e-07

A O 0 2.0466091882553883e-05
novel O 0 5.793399395770393e-06
C O 0 1.2708917438430944e-06
to O 0 3.491613753681122e-08
A O 0 3.438446185555222e-07
mutation O 0 1.8776191268443654e-08
in O 0 4.557909161206908e-09
the O 0 2.9049534333580596e-08
sterol O 0 1.0795356502057984e-06
27 O 0 2.204916143000446e-07
- O 0 7.869070373089926e-07
hydroxylase O 0 9.073100045497995e-06
gene O 0 1.4402638726096484e-07
( O 0 2.1504602543132023e-08
CYP27 O 1 0.9998213648796082
) O 0 1.6060987206856225e-08
was O 0 4.240296291868617e-08
identified O 0 8.467081258345388e-09
by O 0 2.9601179285521084e-09
sequencing O 0 2.9052148420305457e-07
amplified O 0 2.526630851207301e-06
CYP27 O 1 0.9694091081619263
gene O 0 8.309035592901637e-08
products O 0 2.8527905371333873e-08
from O 0 4.875877923637972e-09
a O 0 1.3312638103002428e-08
patient O 0 4.729093561195441e-08
with O 0 3.75321391743455e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 7.869934961490799e-06
CTX B-Disease 1 1.0
) O 0 2.019274916165159e-06
. O 0 4.740314125228906e-06

The O 0 8.223255463235546e-06
mutation O 0 1.0277519777446287e-06
changed O 0 1.9731179179416358e-07
the O 0 2.1184196441481618e-07
adrenodoxin O 0 1.2090642485418357e-05
cofactor O 0 5.403534260040033e-07
binding O 0 1.9878615376001108e-07
residue O 0 1.2425153954609414e-06
362Arg O 0 2.1588705294561805e-06
to O 0 1.2930821924328484e-07
362Ser O 0 1.5595836885040626e-05
( O 0 1.982904507258354e-07
CGT O 0 0.15742717683315277
362Arg O 0 1.3213395504863001e-05
to O 0 4.4720641767526104e-07
AGT O 1 1.0
362Ser O 0 2.4225782908615656e-05
) O 0 2.137823429393393e-08
, O 0 7.283059932916558e-09
and O 0 4.783156981602588e-09
was O 0 4.952872245667095e-08
responsible O 0 2.4783249230608817e-08
for O 0 1.8561477688194827e-08
deficiency O 0 2.5972733055823483e-05
in O 0 1.6790599133287287e-08
the O 0 9.63060031722307e-08
sterol O 0 2.8832353109464748e-06
27 O 0 1.898202270922411e-07
- O 0 2.641449441398436e-07
hydroxylase O 0 2.789492555166362e-06
activity O 0 2.0488158725129324e-08
, O 0 2.8370419347112374e-09
as O 0 2.0889212581920447e-09
confirmed O 0 2.0271790912573806e-09
by O 0 8.030960341187665e-10
expression O 0 1.4221593680474598e-08
of O 0 7.26244948623389e-08
mutant O 0 5.84084261845419e-07
cDNA O 0 8.838781582198862e-07
into O 0 1.4881227627938642e-07
COS O 0 0.0001191440605907701
- O 0 2.863584768419969e-06
1 O 0 3.411991201573983e-06
cells O 0 4.617157287611917e-07
. O 0 1.1382752518329653e-06

Quantitative O 0 1.0313818165741395e-05
analysis O 0 2.069360647283247e-07
showed O 0 4.5865331088634775e-08
that O 0 5.571423766781436e-09
the O 0 2.716301317207126e-08
expression O 0 4.311822365821172e-08
of O 0 1.2950222583185678e-07
CYP27 O 0 0.00040285641443915665
gene O 0 2.354339123655791e-08
mRNA O 0 4.0861138472791936e-08
in O 0 7.811466140594803e-09
the O 0 5.6462468478457595e-08
patient O 0 1.2866021847912634e-07
represented O 0 7.822293923709367e-08
52 O 0 2.494693035259843e-06
. O 0 3.6605661080102436e-06

5 O 0 4.052378244523425e-06
% O 0 1.5130903818771912e-07
of O 0 1.460290803834141e-07
the O 0 2.8622858394555806e-07
normal O 0 7.886740718276997e-07
level O 0 3.0837013582640793e-06
. O 0 6.027243671269389e-06

As O 0 1.879642013591365e-06
the O 0 3.220088160560408e-07
mutation O 0 1.3589382774625847e-07
occurred O 0 4.83260578221234e-08
at O 0 5.7894009586334505e-08
the O 0 4.0214988672460095e-08
penultimate O 0 5.276289130051737e-07
nucleotide O 0 4.679948162333858e-08
of O 0 1.0674650496866889e-07
exon O 0 9.139884014075506e-07
6 O 0 1.8202123897026468e-07
( O 0 5.0768553805369265e-09
- O 0 4.687568377903517e-08
2 O 0 7.51806510379538e-08
position O 0 4.7210004794351335e-08
of O 0 8.172714416332383e-08
exon O 0 6.774125154151989e-07
6 O 0 2.1342916056710237e-07
- O 0 2.7489187459650566e-07
intron O 0 1.7292278471359168e-06
6 O 0 1.4102477052801987e-07
splice O 0 3.0061528377700597e-07
site O 0 3.5600926651113696e-08
) O 0 2.2227291118781523e-09
of O 0 1.1662717902538589e-08
the O 0 1.1645822972639053e-08
gene O 0 1.140903371776858e-08
, O 0 7.0685359787603375e-09
we O 0 6.831069487844843e-09
hypothesized O 0 6.497438675978628e-08
that O 0 1.9110752980111556e-09
the O 0 2.3699321616277302e-08
mutation O 0 3.6897858990414534e-08
may O 0 6.364197169261843e-09
partially O 0 7.730748308176771e-08
affect O 0 6.968844168397936e-09
the O 0 4.714771240088567e-09
normal O 0 3.587150798622929e-09
splicing O 0 6.466466029309004e-09
efficiency O 0 1.264402627043637e-08
in O 0 3.970053619184455e-09
exon O 0 5.195092285248393e-07
6 O 0 8.398534134812508e-08
and O 0 7.90160115116123e-09
cause O 0 1.2580135155815242e-08
alternative O 0 1.3198460102614717e-08
splicing O 0 2.4500311113229145e-08
elsewhere O 0 8.743339385830495e-09
, O 0 4.965563515924032e-09
which O 0 2.766125550834886e-09
resulted O 0 2.4373393969767676e-08
in O 0 7.605710727887072e-09
decreased O 0 1.6452565887448145e-07
transcript O 0 4.705367757651402e-07
in O 0 5.051435891800793e-08
the O 0 7.99652866589895e-07
patient O 0 2.3477662125515053e-06
. O 0 2.492229668860091e-06

Transfection O 0 2.2167867427924648e-05
of O 0 2.194495436924626e-06
constructed O 0 2.16158150578849e-06
minigenes O 0 1.8392745914752595e-05
, O 0 2.2311319014534092e-08
with O 0 2.0582229254273443e-09
or O 0 5.774421829585208e-09
without O 0 3.967041362074042e-09
the O 0 1.5427238153620237e-08
mutation O 0 2.4148365085352452e-08
, O 0 7.830381676399156e-09
into O 0 2.339598026424028e-08
COS O 0 6.92185276420787e-05
- O 0 2.590685426184791e-07
1 O 0 7.709633109698188e-08
cells O 0 1.6866789076530608e-09
confirmed O 0 3.5057459157883386e-09
that O 0 7.491276488025278e-10
the O 0 1.490535339598864e-08
mutant O 0 7.788474931658129e-07
minigene O 0 7.124315743567422e-06
was O 0 1.1727679094519772e-07
responsible O 0 1.3072291693561056e-08
for O 0 4.350797055963085e-09
a O 0 9.657636468318742e-09
mRNA O 0 9.131069589329854e-08
species O 0 1.1440893565861643e-08
alternatively O 0 2.8805388296859746e-08
spliced O 0 1.605884989430706e-07
at O 0 4.576763146246776e-08
an O 0 4.1885222401560895e-08
activated O 0 2.774862650767318e-06
cryptic O 0 4.908632490696618e-06
5 O 0 3.912757904345199e-07
splice O 0 3.087120376221719e-06
site O 0 7.325714932449046e-07
88 O 0 4.4353927819429373e-07
bp O 0 1.10820472798423e-07
upstream O 0 1.2882867395092035e-07
from O 0 4.053965607653254e-09
the O 0 8.223420167041695e-09
3 O 0 6.885765202468974e-08
end O 0 7.953149605555154e-08
of O 0 4.619782316694909e-07
exon O 0 1.613907443243079e-05
6 O 0 9.344937097921502e-06
. O 0 4.587951934809098e-06

Our O 0 2.529024413888692e-06
data O 0 1.9953866114974517e-07
suggest O 0 3.399475190235535e-08
that O 0 2.8109721217361994e-09
the O 0 9.507111542461644e-09
C O 0 1.327617979995921e-07
to O 0 1.4762838063120398e-08
A O 0 3.2780479841676424e-07
mutation O 0 2.435875323669734e-08
at O 0 4.263327824105545e-08
the O 0 2.6852188028669843e-08
penultimate O 0 2.0580479542786634e-07
nucleotide O 0 1.6215414788689486e-08
of O 0 2.172781776721422e-08
exon O 0 1.7763916559943027e-07
6 O 0 7.169643367888057e-08
of O 0 3.757468292064914e-08
the O 0 3.752083088670588e-08
CYP27 O 1 0.9999788999557495
gene O 0 1.5620377880054548e-08
not O 0 1.4177332641196472e-09
only O 0 3.1652749310495665e-09
causes O 0 4.842607737032267e-08
the O 0 5.4368449298181076e-08
deficiency B-Disease 0 1.6688991308910772e-06
in I-Disease 0 9.98673144181339e-09
the I-Disease 0 7.843329541401545e-08
sterol I-Disease 0 1.9549027001630748e-06
27 I-Disease 0 4.15815577525791e-07
- I-Disease 0 5.782172252111195e-07
hydroxylase I-Disease 0 4.678440291172592e-06
activity I-Disease 0 5.551060411335129e-08
, O 0 5.409585668303407e-09
but O 0 4.470467107609011e-09
also O 0 2.0650581689096725e-08
partially O 0 3.8385056200240797e-07
leads O 0 2.2972930224796073e-08
to O 0 6.532192120545233e-09
alternative O 0 3.793148195541107e-08
pre O 0 1.2261374138233805e-07
- O 0 4.836478595393601e-08
mRNA O 0 4.864826053108118e-08
splicing O 0 1.394158175571647e-07
of O 0 7.216812036858755e-08
the O 0 1.3548904576055065e-07
gene O 0 6.859691552563163e-07
. O 0 1.3104165645927424e-06

To O 0 8.940803013501863e-07
our O 0 1.321498928064102e-07
knowledge O 0 1.1882318773359657e-07
, O 0 7.150930070309869e-09
this O 0 1.9330901324110528e-09
is O 0 5.0760231573576675e-09
the O 0 4.950621690369417e-09
first O 0 8.661377393082148e-09
report O 0 6.829246057549199e-09
regarding O 0 3.396882419792746e-08
effects O 0 6.099310212448472e-08
on O 0 2.8953726527447543e-08
pre O 0 1.7556911302563094e-07
- O 0 6.282046172145783e-08
mRNA O 0 3.584922581012506e-08
splicing O 0 1.9455898225828605e-08
of O 0 1.657932102716586e-08
a O 0 4.345406257044715e-09
mutation O 0 2.6987363455077684e-09
at O 0 6.008355590836345e-09
the O 0 7.714056948771031e-09
- O 0 4.375382189891752e-08
2 O 0 5.463810737182939e-08
position O 0 4.315796431342278e-08
of O 0 5.147756709789064e-08
a O 0 4.5333923281987154e-08
5 O 0 4.2748419559757167e-07
splice O 0 6.882245997985592e-06
site O 0 5.135364062880399e-06
. O 0 2.6851450911635766e-06

ATM O 0 0.021640891209244728
germline O 0 8.65481561049819e-05
mutations O 0 1.4489959312413703e-06
in O 0 1.1607463079599256e-07
classical O 1 0.8941194415092468
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 3.4640897865756415e-06
in O 0 2.586021707884356e-08
the O 0 1.2507167923558882e-07
Dutch O 0 1.4619067769672256e-05
population O 0 1.0696335550619551e-07
. O 0 6.520461965919822e-07

Germline O 0 0.0001715916587272659
mutations O 0 8.538146971659444e-07
in O 0 5.297121674630034e-08
the O 0 1.7601202273453964e-07
ATM O 0 9.35539628699189e-06
gene O 0 2.349247729682702e-08
are O 0 7.592951822843474e-10
responsible O 0 4.411538689907957e-09
for O 0 2.540504473458327e-09
the O 0 1.1432775863795541e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 3.86759675166104e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4264429637478315e-06
. O 0 2.9159480163798435e-06

In O 0 4.403269144859223e-07
our O 0 1.2013879313599318e-07
study O 0 3.207337684330014e-08
, O 0 6.801895047203743e-09
we O 0 2.643254060075151e-09
have O 0 6.085917325648893e-10
determined O 0 6.956440312677614e-09
the O 0 1.2161403439847618e-08
ATM O 0 1.6855564126672107e-06
mutation O 0 3.094802991654433e-08
spectrum O 0 5.424239191142988e-08
in O 0 3.573676909951473e-09
19 O 0 2.4791431130211095e-08
classical O 0 1.7235072391486028e-07
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 1.211036426695955e-08
, O 0 9.046723925543176e-10
including O 0 1.3747905036609609e-09
some O 0 2.4565716127966652e-09
immigrant O 0 2.996182191239427e-09
populations O 0 2.029562296002041e-09
, O 0 9.519554033943223e-10
as O 0 1.3159743295076964e-09
well O 0 2.608476101784163e-09
as O 0 3.0154452268504883e-09
12 O 0 1.9648888738288406e-08
of O 0 5.6407788662227176e-08
Dutch O 0 2.6540367343841353e-06
ethnic O 0 4.894796461485384e-07
origin O 0 4.08884744729221e-07
. O 0 1.394202286064683e-06

Both O 0 4.696190671893419e-07
the O 0 2.075986316185663e-07
protein O 0 6.042167655095909e-08
truncation O 0 5.607903403870296e-07
test O 0 7.294588044715056e-08
( O 0 2.7796453139217192e-08
PTT O 0 0.00014487301814369857
) O 0 2.044030367187588e-08
and O 0 1.5073776893359536e-08
the O 0 6.288195208981051e-08
restriction O 0 1.5194731872725242e-07
endonuclease O 0 1.5743933090561768e-06
fingerprinting O 0 9.697619134385604e-07
( O 0 6.625273130111964e-08
REF O 0 4.926350447931327e-05
) O 0 8.142136742605999e-09
method O 0 5.404367175998459e-09
were O 0 7.420117298373441e-10
used O 0 9.656785371348064e-10
and O 0 8.133906881369057e-10
compared O 0 1.378390179773703e-09
for O 0 9.21706433398839e-10
their O 0 6.072872205109547e-10
detection O 0 2.1501691094272246e-08
efficiency O 0 1.287664730398319e-08
, O 0 2.0573516223976185e-09
identifying O 0 8.61220428305387e-09
76 O 0 2.1123609528217457e-08
% O 0 3.7568698152412594e-10
and O 0 4.874666781340409e-10
60 O 0 4.588656565829297e-09
% O 0 1.2043557262586546e-09
of O 0 7.690243108982031e-09
the O 0 3.1387639154445424e-08
mutations O 0 7.98724713035881e-08
, O 0 4.677868403746288e-08
respectively O 0 8.004554388207907e-07
. O 0 3.833153641608078e-06

Most O 0 4.782722044183174e-06
patients O 0 5.687432462764264e-07
were O 0 2.8107699279189546e-08
found O 0 1.3641860974189512e-08
to O 0 2.7387857315375186e-08
be O 0 1.4369614120823826e-07
compound O 0 5.590550699707819e-06
heterozygote O 0 7.630267646163702e-05
. O 0 1.0050488526758272e-05

Seventeen O 0 3.5610850318335e-05
mutations O 0 5.387233841247507e-07
were O 0 3.457424568864553e-08
distinct O 0 5.298677763221349e-08
, O 0 1.0377409154216366e-08
of O 0 3.2168582464464635e-08
which O 0 4.781515183793772e-09
10 O 0 1.227658064095749e-08
were O 0 5.6812554660723436e-09
not O 0 5.8030518168550316e-09
reported O 0 9.1500560017721e-08
previously O 0 1.9034516753890784e-06
. O 0 3.62482683158305e-06

Mutations O 0 9.783109817362856e-06
are O 0 8.899514369886674e-08
small O 0 1.0601078770378081e-07
deletions O 0 9.935055231835577e-07
or O 0 2.748184613210469e-07
point O 0 3.2765776722953888e-06
mutations O 0 2.589546568287915e-07
frequently O 0 3.826378645044315e-07
affecting O 0 1.1825179626612226e-06
splice O 0 1.538239484943915e-05
sites O 0 6.071041298127966e-06
. O 0 4.460790933080716e-06

Moreover O 0 2.8891125111840665e-05
, O 0 1.3993546872370644e-06
a O 0 9.379804737363884e-07
16 O 0 5.086093551653903e-06
. O 0 3.821589871222386e-06

7 O 0 1.0054352060251404e-05
- O 0 4.994088612875203e-06
kb O 0 1.5055356016091537e-05
genomic O 0 4.419356685048115e-07
deletion O 0 1.7165129406748747e-07
of O 0 3.3499389928692835e-08
the O 0 8.538064477647822e-09
3 O 0 2.295904444338248e-08
end O 0 6.735690671888506e-09
of O 0 2.4078870453081436e-08
the O 0 1.3645192531441808e-08
gene O 0 7.380514865928944e-09
, O 0 3.55216855929541e-09
most O 0 5.793297397360675e-09
likely O 0 5.506829214851905e-09
a O 0 2.6338831116134998e-09
result O 0 2.617426941853296e-09
of O 0 8.940308049432133e-09
recombination O 0 3.652079971772082e-09
between O 0 2.2579302871861273e-09
two O 0 2.162086065737867e-09
LINE O 0 7.849807843740564e-07
elements O 0 8.596846612363152e-08
, O 0 2.0397735056576494e-08
was O 0 2.373173799696815e-07
identified O 0 3.471967318091629e-07
. O 0 9.930375881594955e-07

The O 0 2.7892424441233743e-06
most O 0 1.4647372381659807e-07
frequently O 0 4.359105432172328e-08
found O 0 7.681022928807124e-09
mutation O 0 3.828814598705321e-09
, O 0 1.5279434384396495e-09
identified O 0 9.809268952665207e-10
in O 0 5.70202052241342e-10
three O 0 2.6560351695792406e-09
unrelated O 0 4.498645367334575e-08
Turkish O 0 1.2637472934784455e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999866485595703
T I-Disease 1 1.0
individuals O 0 6.555794573870344e-09
, O 0 6.445779021646558e-09
was O 0 3.8942701507949096e-08
previously O 0 5.408453773725341e-08
described O 0 9.160005198793897e-09
to O 0 3.121157110541617e-09
be O 0 2.5866071506897015e-09
a O 0 1.2510026792256213e-08
Turkish O 0 8.704280389792984e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
founder O 0 0.00029966773581691086
mutation O 0 8.760687705944292e-06
. O 0 3.2043499231804162e-06

The O 0 2.08831625059247e-06
presence O 0 4.4536102450365433e-07
of O 0 5.878333126929647e-07
a O 0 2.3641470647817187e-07
founder O 0 2.7134794891026104e-06
mutation O 0 7.397670032105452e-08
among O 0 9.33343979880874e-09
relatively O 0 4.836143929765058e-09
small O 0 7.160839032849253e-09
ethnic O 0 1.3323967706924122e-08
population O 0 8.232267090235723e-10
groups O 0 6.070440261574106e-10
in O 0 1.7156471798784878e-09
Western O 0 1.1842633540481984e-07
Europe O 0 1.0831197272409554e-07
could O 0 2.7202625929589885e-08
indicate O 0 2.3577543473152218e-08
a O 0 9.794410615882043e-09
high O 0 1.0550287043997741e-07
carrier O 0 2.8034454757630556e-08
frequency O 0 2.3206077059967356e-08
in O 0 8.22476931006122e-09
such O 0 7.68949917073769e-08
communities O 0 4.46767415951399e-07
. O 0 1.6362200767616741e-06

In O 0 4.477962534110702e-07
patients O 0 1.1838071145575668e-07
of O 0 9.851915194758476e-08
Dutch O 0 1.8702938859860296e-06
ethnic O 0 4.496706296208686e-08
origin O 0 1.0122100491116726e-08
, O 0 2.5970825490162497e-09
however O 0 3.1194609118045946e-09
, O 0 3.0294482478154805e-09
no O 0 7.615145847239546e-09
significant O 0 4.092033378810811e-08
founder O 0 7.127076173674141e-07
effect O 0 9.593181715672472e-08
could O 0 2.998607939730391e-08
be O 0 3.102089607409653e-08
identified O 0 2.455247738453181e-07
. O 0 8.813647696115368e-07

The O 0 2.7364887955627637e-06
observed O 0 3.536379153956659e-07
genetic O 0 1.4261475200783025e-07
heterogeneity O 0 5.437341883407498e-07
including O 0 5.617566145588171e-08
the O 0 8.971092313458939e-08
relative O 0 7.358154618941626e-08
high O 0 2.223725346084393e-07
percentage O 0 6.81528646850893e-08
of O 0 5.558879578870801e-08
splice O 0 2.791397946566576e-06
- O 0 5.757740382250631e-07
site O 0 3.994128974227351e-07
mutations O 0 3.9493311732030634e-08
had O 0 1.1929139454025517e-08
no O 0 1.5174654421912237e-08
reflection O 0 9.440852011266543e-08
on O 0 1.429857263701706e-07
the O 0 4.361205583336414e-07
phenotype O 0 1.8824709968612297e-06
. O 0 1.8316616205993341e-06

All O 0 1.7392140989613836e-06
patients O 0 2.108589569616015e-07
manifested O 0 2.378478001219264e-07
classical O 0 1.0022558853961527e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
and O 0 1.8974205318045279e-07
increased O 0 1.7558015485974465e-07
cellular O 0 4.928916723656585e-07
radioresistant O 0 1.3186178875912447e-05
DNA O 0 1.2866380529885646e-06
synthesis O 0 3.0443011382885743e-06
. O 0 1.8349521724303486e-06

Determination O 0 1.684876042418182e-05
of O 0 1.3230795730123646e-06
the O 0 1.331180499164475e-07
genomic O 0 3.9110864236135967e-07
structure O 0 1.7925157180798124e-07
of O 0 1.6364590749162744e-07
the O 0 1.7405369590051123e-07
COL4A4 O 1 0.9999897480010986
gene O 0 3.580078100640094e-08
and O 0 1.5035157119314135e-08
of O 0 1.787002901210144e-07
novel O 0 1.2745700587402098e-05
mutations O 0 6.8877880039508455e-06
causing O 0 8.181283919839188e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.490070467814803e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 7.245344932016451e-06
a O 0 2.087816483253846e-06
progressive O 1 0.9999608993530273
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.007064045872539282
by O 0 4.95475262596301e-07
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9765142798423767
abnormalities I-Disease 1 0.9949814677238464
and O 0 1.0341663525537115e-08
associated O 0 1.352896283890459e-08
with O 0 9.394951483443492e-09
mutations O 0 2.3002000304472858e-08
in O 0 2.9832489811809637e-09
either O 0 7.693559567201191e-09
the O 0 6.154797205226714e-08
COL4A3 O 1 1.0
or O 0 4.961940192060865e-08
the O 0 1.353761547306931e-07
COL4A4 O 1 0.9999613761901855
gene O 0 3.598088937906141e-08
, O 0 5.728337804100647e-09
which O 0 2.0248991372540104e-09
encode O 0 1.2650925640400601e-08
the O 0 3.7337567704298635e-08
alpha3 O 0 7.210288458736613e-06
and O 0 7.822353609299171e-08
alpha4 O 0 0.00013848960225004703
type O 0 0.0004161231918260455
IV O 1 1.0
collagen O 1 0.9999997615814209
chains O 0 4.598644591169432e-05
, O 0 4.1713343534866e-07
respectively O 0 2.4598839445388876e-06
. O 0 3.833668870356632e-06

To O 0 4.7185116613945866e-07
date O 0 4.975526053385693e-07
, O 0 3.199266984665883e-08
mutation O 0 1.4488265698275882e-08
screening O 0 2.030504120398291e-08
in O 0 1.8270807089493246e-09
the O 0 9.50709377889325e-09
two O 0 4.449532298167469e-09
genes O 0 9.971066639025139e-09
has O 0 6.397129936885904e-09
been O 0 5.257520641066549e-09
hampered O 0 2.0667710032284958e-07
by O 0 5.8677058767386825e-09
the O 0 2.9151163261076363e-08
lack O 0 8.198022527494686e-08
of O 0 9.129572475785608e-08
genomic O 0 4.3458146592456615e-07
structure O 0 4.819516448151262e-07
information O 0 2.7873389285559824e-07
. O 0 1.391086357216409e-06

We O 0 1.0473771681063226e-06
report O 0 8.597486100825336e-08
here O 0 1.0001351746780074e-08
the O 0 1.5772764427879338e-08
complete O 0 2.0592880289882487e-08
characterization O 0 5.93099009904563e-08
of O 0 4.106004780624062e-08
the O 0 3.025090222763538e-08
48 O 0 5.29397006232557e-08
exons O 0 1.741845494507288e-07
of O 0 1.0920624760046849e-07
the O 0 1.1405600730540755e-07
COL4A4 O 1 0.9999990463256836
gene O 0 5.718166562473925e-08
, O 0 1.0774262371171517e-08
a O 0 8.35256930287187e-09
comprehensive O 0 5.6665946601697215e-08
gene O 0 1.5916981510599726e-08
screen O 0 1.692623357030243e-07
, O 0 1.2115701331083528e-08
and O 0 1.0269270767082617e-08
the O 0 1.217913858653219e-08
subsequent O 0 2.8286899933505083e-08
detection O 0 1.0173629760856784e-07
of O 0 5.067696662308663e-08
10 O 0 6.123578799588358e-08
novel O 0 4.225264262913697e-07
mutations O 0 4.836598677115944e-08
in O 0 3.6292688854189237e-09
eight O 0 8.811867502345194e-08
patients O 0 7.117458977745628e-08
diagnosed O 0 2.0784336811630055e-06
with O 0 3.2465939625581086e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 5.2755051001440734e-05

Furthermore O 0 1.0965414730890188e-05
, O 0 3.8166768945302465e-07
we O 0 7.172939575639248e-08
identified O 0 7.75014825649123e-08
a O 0 4.355398885991235e-08
glycine O 0 1.3419628430710873e-07
to O 0 1.8837676307725815e-08
alanine O 0 3.017328822352283e-07
substitution O 0 5.547313364218098e-08
in O 0 7.945731184122451e-09
the O 0 4.912154594194362e-08
collagenous O 0 5.855779363628244e-06
domain O 0 4.682903309571884e-08
that O 0 1.7537148400137426e-09
is O 0 5.1061155303955275e-09
apparently O 0 1.5584042500904616e-08
silent O 0 8.619455371672302e-08
in O 0 2.3147754824037747e-09
the O 0 3.429445882829896e-08
heterozygous O 0 5.939197222915027e-08
carriers O 0 1.2448094111050523e-08
, O 0 1.0393988780776908e-08
in O 0 2.743564486706873e-08
11 O 0 1.1407714737288188e-06
. O 0 2.8344472866592696e-06

5 O 0 6.572561233042507e-07
% O 0 2.6749031434292192e-08
of O 0 1.6494126953148225e-08
all O 0 3.0596152278405953e-09
control O 0 3.040361207240494e-08
individuals O 0 1.30931454567218e-09
, O 0 2.5771325073975504e-09
and O 0 3.825573191562626e-09
in O 0 3.549594618235119e-09
one O 0 9.675705570089121e-09
control O 0 8.883030488959776e-08
individual O 0 1.0241279824185767e-08
homozygous O 0 4.851316148801743e-08
for O 0 1.0912771131188492e-08
this O 0 1.7269714547296644e-08
glycine O 0 1.2987900390726281e-06
substitution O 0 2.226365950264153e-06
. O 0 1.8846499187930021e-06

There O 0 1.895428795251064e-06
has O 0 1.1647605191456023e-07
been O 0 1.7910865679482413e-08
no O 0 9.699189895684412e-09
previous O 0 1.2477974209446074e-08
finding O 0 7.872326790447914e-09
of O 0 1.3477838400888231e-08
a O 0 7.35203498081205e-09
glycine O 0 2.009042709971709e-08
substitution O 0 9.468998918293892e-09
that O 0 1.1217631268323203e-09
is O 0 1.3293627310062561e-09
not O 0 2.8714572386512316e-10
associated O 0 9.784565380144272e-10
with O 0 2.0515129595111148e-09
any O 0 3.5573233247987446e-08
obvious O 0 3.970995123836474e-07
phenotype O 0 1.3588967817668163e-07
in O 0 3.471737741733705e-08
homozygous O 0 1.6411835304097622e-06
individuals O 0 9.703487080514606e-08
. O 0 1.347386273664597e-06

Founder O 0 0.006875746417790651
BRCA1 O 0 0.00014116091188043356
and O 0 1.8404656429993338e-06
BRCA2 O 0 6.278212094912305e-05
mutations O 0 1.460588805457519e-07
in O 0 1.5037910472415206e-08
French O 0 1.5163974239840172e-05
Canadian O 0 0.0007600615499541163
breast B-Disease 1 1.0
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.1040638387148647e-07
. O 0 8.012490297915065e-07

We O 0 7.043720415822463e-07
have O 0 2.889976791209392e-08
identified O 0 1.4733611664041746e-08
four O 0 4.2648222731145324e-09
mutations O 0 2.0571317982387427e-09
in O 0 5.333959940401201e-10
each O 0 1.0522243076849236e-09
of O 0 3.797614667178095e-08
the O 0 4.2636008856788976e-07
breast B-Disease 1 0.9999998807907104
cancer I-Disease 0 0.005172587465494871
- O 0 3.9118174299801467e-07
susceptibility O 0 3.623968893862184e-07
genes O 0 1.3230773809880247e-08
, O 0 6.953031039813595e-09
BRCA1 O 0 2.4171157519958797e-07
and O 0 2.4997216740985095e-08
BRCA2 O 0 7.052289674902568e-06
, O 0 5.705275807343924e-09
in O 0 3.583410235208362e-09
French O 0 3.889811978297075e-06
Canadian O 0 6.673895313724643e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999938011169434
and O 0 8.74887246027356e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.709651880650199e-08
from O 0 8.313917732039044e-08
Quebec O 0 4.2575054976623505e-05
. O 0 3.250021791245672e-06

To O 0 9.073947353499534e-07
identify O 0 1.8400112367089605e-06
founder O 0 8.432596587226726e-06
effects O 0 0.0001135589845944196
, O 0 5.2866244715232824e-08
we O 0 1.2283724259987139e-08
examined O 0 9.711541082424446e-08
independently O 0 2.3073623012237476e-08
ascertained O 0 3.663869847514434e-07
French O 0 6.701854431412357e-07
Canadian O 0 3.537654151841707e-07
cancer B-Disease 0 1.1341983707779946e-07
families O 0 5.803823532879449e-10
for O 0 1.2084261369338378e-09
the O 0 3.5169238632448696e-09
distribution O 0 8.560828490544736e-09
of O 0 2.7486555254085943e-08
these O 0 2.322223657813538e-08
eight O 0 2.1101607217133278e-07
mutations O 0 7.70708027175715e-07
. O 0 1.0487755162102985e-06

Mutations O 0 3.824156465270789e-06
were O 0 1.510031495399744e-07
found O 0 1.8972462711985827e-08
in O 0 1.0452199106225635e-08
41 O 0 1.7080085967791092e-07
of O 0 2.704321673263621e-07
97 O 0 4.540355348581215e-06
families O 0 1.4177102514167927e-07
. O 0 1.4770577081435476e-06

Six O 0 9.194085919261852e-07
of O 0 3.3235150453947426e-07
eight O 0 1.6303589234212268e-07
mutations O 0 4.130519926093257e-08
were O 0 1.3540865317906992e-08
observed O 0 3.876794707480258e-08
at O 0 1.9852980415180355e-07
least O 0 6.546900266357625e-08
twice O 0 8.764654353399237e-07
. O 0 2.487613301127567e-06

The O 0 3.382355862413533e-05
BRCA1 O 0 8.903030538931489e-05
C4446T O 0 4.369105590740219e-05
mutation O 0 3.7310022094061424e-07
was O 0 1.147906232290552e-07
the O 0 2.0290213953444436e-08
most O 0 1.2904750157360922e-08
common O 0 1.6636054311902626e-08
mutation O 0 9.244888410364638e-09
found O 0 3.5823919386501757e-09
, O 0 3.752281596547391e-09
followed O 0 6.412791631049686e-09
by O 0 1.5029019806434007e-08
the O 0 8.078452538029524e-07
BRCA2 O 0 9.228709677699953e-05
8765delAG O 0 6.847862096037716e-05
mutation O 0 6.383545041899197e-06
. O 0 2.471618245181162e-06

Together O 0 9.660234354669228e-07
, O 0 7.204434382401814e-08
these O 0 1.0544248141286516e-08
mutations O 0 1.7077928404773957e-08
were O 0 2.9802460499439576e-09
found O 0 2.0790198451692277e-09
in O 0 1.6160076610205465e-09
28 O 0 2.8540640073515533e-08
of O 0 3.5334863923708326e-08
41 O 0 5.808912817428791e-08
families O 0 1.079744293974727e-09
identified O 0 3.609222032352477e-09
to O 0 6.3309038011993835e-09
have O 0 1.59129136534375e-08
a O 0 2.1765818303265405e-07
mutation O 0 1.2201224990349147e-06
. O 0 1.7846061837190064e-06

The O 0 2.4621324428153457e-06
odds O 0 2.156397158614709e-06
of O 0 1.1672302946408308e-07
detection O 0 3.1779811138221703e-07
of O 0 5.706225536528109e-08
any O 0 7.400742685348405e-09
of O 0 4.2256669274820524e-08
the O 0 5.2067381517417743e-08
four O 0 6.556634701837538e-08
BRCA1 O 0 1.5113238305275445e-06
mutations O 0 1.21963921628776e-07
was O 0 3.412162641325267e-07
18 O 0 1.029038685373962e-06
. O 0 1.5170955975918332e-06

7x O 0 0.030283784493803978
greater O 0 3.042704520339612e-06
if O 0 3.273273918580344e-08
one O 0 5.851801265777112e-09
or O 0 1.6817512937805645e-09
more O 0 2.5065369224641643e-10
cases O 0 6.269773589195893e-09
of O 0 0.32237598299980164
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 4.543451126437503e-08
also O 0 6.827448384427726e-09
present O 0 6.584629730355118e-09
in O 0 7.447657157655385e-09
the O 0 1.4873835141315794e-07
family O 0 4.060306082465104e-07
. O 0 1.5173603742368869e-06

The O 0 2.2631713818555e-06
odds O 0 2.23591109715926e-06
of O 0 1.2653030978526658e-07
detection O 0 1.6704740346540348e-07
of O 0 6.230887805713792e-08
any O 0 9.710611870161756e-09
of O 0 3.651531699233601e-08
the O 0 6.737299429460109e-08
four O 0 1.0001392780623064e-07
BRCA2 O 0 6.6058814809366595e-06
mutations O 0 1.9308953369545634e-07
was O 0 3.092248448410828e-07
5 O 0 1.3226884902906022e-06
. O 0 2.3358741145784734e-06

3x O 0 0.000155686357175
greater O 0 1.2756565865856828e-06
if O 0 3.501764567204191e-08
there O 0 5.7636713179931576e-09
were O 0 3.6083891430394033e-09
at O 0 8.519356775593678e-09
least O 0 7.82492792783529e-10
five O 0 1.588988607359454e-09
cases O 0 2.7434949867455316e-09
of O 0 2.2158394585858332e-07
breast B-Disease 1 1.0
cancer I-Disease 0 0.0048898677341639996
in O 0 2.5113054746839225e-08
the O 0 2.9486193398042815e-07
family O 0 4.1545524709363235e-07
. O 0 1.307864749833243e-06

Interestingly O 0 9.293256880482659e-06
, O 0 1.6312625916725665e-07
the O 0 3.950461646695658e-08
presence O 0 5.3687294609972014e-08
of O 0 3.0140444096105057e-07
a O 0 5.994827461108798e-07
breast B-Disease 1 0.9999983310699463
cancer I-Disease 0 0.000454497872851789
case O 0 5.273683001405516e-08
< O 0 7.147919234284927e-08
36 O 0 1.118763748308993e-08
years O 0 2.0048231963443186e-09
of O 0 9.68805924372873e-09
age O 0 2.140965449370924e-08
was O 0 1.3859016156914095e-08
strongly O 0 2.9096653975102527e-09
predictive O 0 2.818511291025061e-08
of O 0 1.5685014176369805e-08
the O 0 9.246686083486111e-09
presence O 0 5.94842264334261e-09
of O 0 1.3173259816312566e-08
any O 0 5.697989635677914e-09
of O 0 3.1328905691907494e-08
the O 0 4.2597839922109415e-08
eight O 0 1.0919604420678297e-07
mutations O 0 1.716404796070492e-07
screened O 0 2.7881389996764483e-06
. O 0 2.3389545731333783e-06

Carriers O 0 1.1866707154695177e-06
of O 0 2.9520799671445275e-07
the O 0 5.814688108785049e-08
same O 0 1.0842065911731424e-08
mutation O 0 6.894357529318995e-09
, O 0 8.798977657598073e-10
from O 0 4.025977051735907e-10
different O 0 3.3613795080711384e-10
families O 0 2.3673818461134033e-10
, O 0 9.764803410305944e-10
shared O 0 3.294524653085773e-09
similar O 0 6.547160147363229e-09
haplotypes O 0 7.406902824413919e-08
, O 0 4.122702179643056e-09
indicating O 0 5.846669370868085e-09
that O 0 1.114169867477699e-09
the O 0 1.475048172494553e-08
mutant O 0 1.791295574093965e-07
alleles O 0 7.428107462459366e-09
were O 0 1.9659414096651062e-09
likely O 0 1.3238289353623145e-09
to O 0 1.2547777261673332e-09
be O 0 1.376635250238678e-09
identical O 0 4.187306057445994e-09
by O 0 9.221408081572235e-10
descent O 0 6.803412944123011e-09
for O 0 2.380023733650205e-09
a O 0 9.344573115299681e-09
mutation O 0 1.2708047947285195e-08
in O 0 8.695939968106359e-09
the O 0 1.8096748988227773e-07
founder O 0 5.5001005421218e-06
population O 0 1.8743672569598857e-07
. O 0 1.054277845469187e-06

The O 0 5.336071922101837e-07
identification O 0 1.6371771494050336e-07
of O 0 3.3242375252484635e-07
common O 0 1.5525291701123933e-06
BRCA1 O 0 1.9248485841671936e-05
and O 0 5.630480472973431e-07
BRCA2 O 0 6.770256004529074e-05
mutations O 0 3.4538455651045297e-08
will O 0 3.5784857299603345e-09
facilitate O 0 2.2990070291939446e-08
carrier O 0 2.1813315598251393e-08
detection O 0 1.2000047888705012e-07
in O 0 8.902803827481875e-09
French O 0 7.763685971440282e-06
Canadian O 0 9.349420906801242e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999884366989136
and O 0 2.3531716578872874e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.5747671966437338e-07
. O 0 6.033278054928815e-07

Are O 0 4.49420394943445e-06
Dp71 O 0 0.005681056994944811
and O 0 3.313183697173372e-06
Dp140 O 0 0.02790026180446148
brain O 0 0.0002463892742525786
dystrophin O 0 2.5805366021813825e-05
isoforms O 0 6.654483399870514e-07
related O 0 2.695770149330201e-07
to O 0 7.493412823578183e-08
cognitive B-Disease 1 0.7299283742904663
impairment I-Disease 1 0.9999995231628418
in O 0 6.004273473081412e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 0.004934287164360285

Molecular O 0 1.9708211766555905e-05
study O 0 2.962243854653934e-07
and O 0 3.7381251871693166e-08
neuropsychological O 0 2.658536004673806e-06
analysis O 0 1.8470045048957218e-08
were O 0 5.0212798363702404e-09
performed O 0 1.8985421235129252e-08
concurrently O 0 1.639548230514265e-08
on O 0 1.872694355142812e-08
49 O 0 2.123059346104128e-07
patients O 0 2.7112596612255402e-08
with O 0 1.069425437094651e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.24413183331489563
DMD B-Disease 1 1.0
) O 0 1.8217262365283204e-08
in O 0 4.994058500074061e-09
order O 0 4.32427293972637e-09
to O 0 4.935254427351765e-09
find O 0 6.504095040327229e-09
a O 0 4.528705854767168e-09
molecular O 0 4.202870940162029e-08
explanation O 0 7.690845293950588e-09
for O 0 2.514266350672756e-09
the O 0 3.308348084374302e-08
cognitive B-Disease 0 4.391818220028654e-05
impairment I-Disease 0 0.00020209878857713193
observed O 0 5.231734689914447e-08
in O 0 2.6930047525297596e-08
most O 0 5.427042992778297e-07
DMD B-Disease 1 1.0
patients O 0 2.9463046757882694e-06
. O 0 2.7849207526742248e-06

Complete O 0 1.5150873196034809e-06
analysis O 0 1.5326851610097947e-07
of O 0 3.046317544885824e-07
the O 0 2.9128054279681237e-07
dystrophin O 0 5.952175342827104e-06
gene O 0 7.535422241744527e-08
was O 0 1.1427201229707862e-07
performed O 0 2.531441545272628e-08
to O 0 8.401141116110011e-09
define O 0 4.80062567476125e-08
the O 0 2.0325693128597777e-08
localization O 0 1.5333985459164978e-07
of O 0 7.740560192814883e-08
deletions O 0 3.237784937937249e-07
and O 0 6.642038385962223e-08
duplications O 0 1.289262968384719e-06
in O 0 1.7980557487362603e-08
relation O 0 2.8806542928805356e-08
to O 0 1.2097459922699727e-08
the O 0 1.053924520988403e-07
different O 0 2.7039735073230986e-07
DMD B-Disease 1 1.0
promoters O 0 0.00035628199111670256
. O 0 2.1367108274716884e-05

Qualitative O 0 8.387602065340616e-06
analysis O 0 2.851251679203415e-07
of O 0 3.045213645691547e-07
the O 0 2.9319406280592375e-07
Dp71 O 0 0.000164623765158467
transcript O 0 3.9398932472067827e-07
and O 0 7.862302808803179e-09
testing O 0 7.832875681401674e-09
for O 0 7.922694167383781e-10
the O 0 2.0233741349073853e-09
specific O 0 1.7549662834071e-09
first O 0 6.647764561051872e-09
exon O 0 5.704636123482487e-07
of O 0 1.8554511882484803e-07
Dp140 O 0 4.277976131561445e-06
were O 0 2.101238116836157e-08
also O 0 1.630087709258987e-08
carried O 0 9.992850635853756e-08
out O 0 1.99797639766075e-07
. O 0 1.1284041647741105e-06

Neuropsychological O 0 0.0003082898329012096
analysis O 0 6.399280323421408e-07
assessed O 0 2.932132701971568e-06
verbal O 0 1.5140184359552222e-06
and O 0 2.1399087302143016e-07
visuospatial O 0 3.175697202095762e-05
intelligence O 0 5.349079401639756e-07
, O 0 1.5316359736061713e-07
verbal O 0 5.9841681832040194e-06
memory O 1 0.9999451637268066
, O 0 2.263243885636257e-07
and O 0 2.4695324896129023e-07
reading O 0 2.081376987916883e-05
skills O 0 6.444849532272201e-06
. O 0 4.056252691952977e-06

Comparison O 0 1.1993532098131254e-05
of O 0 3.3715396057232283e-06
molecular O 0 2.7845753720612265e-06
and O 0 1.8990533590113046e-07
psychometric O 0 8.423690815106966e-06
findings O 0 1.3581919233729423e-07
demonstrated O 0 6.470096280963844e-08
that O 0 5.274756631479249e-09
deletions O 0 1.5981633794126537e-07
and O 0 3.743105025932891e-08
duplications O 0 1.1338981948938454e-06
that O 0 6.432808952183677e-09
were O 0 8.839959875217573e-09
localized O 0 2.026059604531838e-07
in O 0 5.703165051329506e-09
the O 0 3.219442490376423e-08
distal O 0 2.4477737952111056e-06
part O 0 2.1042906439561193e-07
of O 0 6.444920472858939e-07
the O 0 3.985727801136818e-07
gene O 0 6.041096156650383e-08
seemed O 0 3.104564072486937e-08
to O 0 6.279144315612939e-09
be O 0 4.666904640515668e-09
preferentially O 0 6.126441576270736e-08
associated O 0 2.6540767805727228e-08
with O 0 1.1777421349279393e-07
cognitive B-Disease 0 0.0038317027501761913
impairment I-Disease 1 0.9996132254600525
. O 0 4.8736210374045186e-06

Two O 0 2.469704895702307e-06
altered O 0 4.514384727372089e-06
Dp71 O 0 5.7409375585848466e-05
transcripts O 0 2.2597314455197193e-06
and O 0 1.6453428486329358e-07
two O 0 7.287634673502907e-08
deleted O 0 9.904016451400821e-07
Dp140 O 0 1.5041429151096963e-06
DNA O 0 6.045003431154328e-08
sequences O 0 1.412977290726758e-08
were O 0 2.3547463978701444e-09
found O 0 2.905085061399859e-09
in O 0 2.189166403709919e-09
four O 0 8.7860350106439e-09
patients O 0 2.1718786769042708e-08
with O 0 6.008610142771431e-08
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 3.3735614124452695e-05

These O 0 1.7136029555331334e-06
findings O 0 2.4924332819864503e-07
suggest O 0 2.3196339071773764e-08
that O 0 9.266226119741816e-10
some O 0 1.4175061124888089e-09
sequences O 0 3.393461733836034e-09
located O 0 1.7927749951240912e-08
in O 0 1.8054605588346817e-09
the O 0 1.2756156131388252e-08
distal O 0 6.755448112016893e-07
part O 0 8.770385306888784e-08
of O 0 1.5729915503470693e-07
the O 0 3.7319058066032085e-08
gene O 0 4.8009254349778985e-09
and O 0 3.1221096818967453e-09
, O 0 2.2747019823299297e-09
in O 0 8.672696449885109e-10
particular O 0 2.1658377313826804e-09
, O 0 2.429735301845426e-09
some O 0 9.118831023613438e-09
DMD B-Disease 1 1.0
isoforms O 0 1.8090331366238388e-07
expressed O 0 2.3903201196162627e-08
in O 0 8.219374514339961e-09
the O 0 2.218084773630835e-07
brain O 0 0.0013551065931096673
may O 0 3.879300880527126e-09
be O 0 1.274479188850819e-09
related O 0 7.460509543477656e-09
to O 0 4.2584984427662675e-09
the O 0 5.408907455262124e-08
cognitive B-Disease 0 1.780841739673633e-05
impairment I-Disease 0 0.00010935561294900253
associated O 0 1.1790726972549237e-07
with O 0 4.359322076652461e-07
DMD B-Disease 1 1.0
. O 0 2.0941615730407648e-06
. O 0 3.660748006950598e-06

I1307K O 0 0.0010918695479631424
APC O 0 0.00011899838864337653
and O 0 1.4775155250390526e-06
hMLH1 O 0 3.4768672776408494e-05
mutations O 0 2.0027894720442418e-07
in O 0 9.970533731973319e-09
a O 0 1.5439749034840133e-08
non O 0 1.7827814247084461e-07
- O 0 2.577321538410615e-07
Jewish O 0 9.370277354037171e-08
family O 0 8.849137422828335e-09
with O 0 5.321219909149022e-09
hereditary B-Disease 1 0.9999951124191284
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00011028721928596497

We O 0 1.2341718047537142e-06
describe O 0 4.2492226270951505e-07
a O 0 6.926058659928458e-08
French O 0 1.0669505172700156e-06
Canadian O 0 1.0991566341544967e-06
hereditary B-Disease 1 0.9999995231628418
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.00030884818988852203
HNPCC B-Disease 1 1.0
) O 0 1.4752907873116783e-07
kindred O 0 2.5766480575839523e-06
which O 0 1.310814479182909e-08
carries O 0 1.7848978473011812e-07
a O 0 3.764455414057011e-08
novel O 0 1.0607668627926614e-06
truncating O 0 4.2078786464117e-06
mutation O 0 2.220639601091534e-07
in O 0 1.5247454143718642e-07
hMLH1 O 0 4.664845619117841e-05
. O 0 5.493610387929948e-06

Interestingly O 0 2.367819433857221e-05
, O 0 4.042987882257876e-07
the O 0 4.3024820683967846e-07
I1307K O 0 1.2705821063718759e-05
APC O 0 2.501954895706149e-06
polymorphism O 0 7.80043691861465e-08
, O 0 1.1339913008612257e-08
associated O 0 4.079157900349628e-09
with O 0 1.4274689208448876e-09
an O 0 2.0160277891534406e-09
increased O 0 8.797019113160331e-09
risk O 0 1.8073673402341228e-07
of O 0 0.1123618632555008
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 7.451055950014052e-08
is O 0 5.45812106622634e-09
also O 0 5.1845665538508e-09
present O 0 3.418981320280068e-09
in O 0 5.064157093670474e-09
this O 0 1.7260626705706272e-08
family O 0 3.1227429531099915e-07
. O 0 1.043089810082165e-06

The O 0 7.155869298003381e-06
I1307K O 0 1.649256046221126e-05
polymorphism O 0 5.099305440126045e-07
has O 0 4.440386547344133e-08
previously O 0 7.637171250962638e-08
only O 0 2.9423021796759485e-09
been O 0 1.9311772181396236e-09
identified O 0 1.1751404294102485e-09
in O 0 4.0274975021681314e-10
individuals O 0 4.808364262309794e-10
of O 0 1.8466698392671788e-08
self O 0 4.7100189703996875e-07
- O 0 1.48990932302695e-06
reported O 0 2.897243973620789e-07
Ashkenazi O 0 3.3982869354076684e-06
Jewish O 0 1.0595393860057811e-06
origins O 0 2.134484248017543e-06
. O 0 1.0597030950521003e-06

In O 0 3.357397986292199e-07
addition O 0 1.1755584239381278e-07
, O 0 1.5259900010278216e-08
in O 0 1.9714234689161003e-09
this O 0 1.9387247363056304e-09
family O 0 8.482549773702885e-09
, O 0 2.8426156983840656e-09
there O 0 2.590053060913533e-09
appears O 0 7.73307551327207e-09
to O 0 1.6142918113359883e-09
be O 0 2.3153450268154074e-09
no O 0 3.801809533854339e-09
relationship O 0 1.927622284014774e-09
between O 0 2.071898430600072e-09
the O 0 2.106486718389533e-08
I1307K O 0 3.3198057280969806e-07
polymorphism O 0 3.618092492274627e-09
and O 0 4.156836208579762e-09
the O 0 9.840380954528882e-09
presence O 0 2.0556463198317942e-08
or O 0 1.1397963461945437e-08
absence O 0 1.3201839976773044e-07
of O 0 9.250929906556848e-07
cancer B-Disease 0 0.00012806692393496633
. O 0 2.6070307512782165e-07
. O 0 1.666866296545777e-06

Identification O 0 1.7750753613654524e-06
of O 0 5.172450983081944e-07
a O 0 6.147932651856536e-08
novel O 0 2.760920096989139e-07
mutation O 0 1.8694787939921298e-08
of O 0 3.046270435902443e-08
the O 0 8.872328294273757e-08
CPO O 1 0.9806644916534424
gene O 0 8.776124360565518e-08
in O 0 1.481016198567886e-08
a O 0 8.898105363641662e-08
Japanese O 0 4.929785973217804e-06
hereditary B-Disease 1 0.9998452663421631
coproporphyria I-Disease 1 0.9999871253967285
family O 0 1.1274208191025537e-05
. O 0 7.468338026228594e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 3.8860780477989465e-05
HCP B-Disease 1 1.0
) O 0 5.647204943670658e-07
is O 0 9.990125704462116e-08
an O 0 1.2388339598601306e-07
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
characterized O 0 1.3780602614588133e-07
by O 0 5.335193176136954e-09
a O 0 7.895232556620613e-08
deficiency B-Disease 1 0.8685839176177979
of I-Disease 0 0.005539720878005028
coproporphyrinogen I-Disease 1 0.9999998807907104
oxidase I-Disease 0 1.4937689911675989e-06
( O 0 2.7731529073093952e-08
CPO O 1 0.9937840700149536
) O 0 4.059693381464058e-08
caused O 0 5.669545899422701e-08
by O 0 2.735547566246055e-09
a O 0 2.1566135544048848e-08
mutation O 0 2.4118261165995136e-08
in O 0 9.223329655583257e-09
the O 0 3.3027876611413376e-07
CPO O 1 0.9402032494544983
gene O 0 5.863714704901213e-06
. O 0 5.035831236455124e-06

Only O 0 5.459757517201069e-07
11 O 0 1.708648795784029e-07
mutations O 0 4.3524920556592406e-08
of O 0 3.738681542131417e-08
the O 0 3.458565700498184e-08
gene O 0 5.278211290260515e-08
have O 0 6.276222652701335e-09
been O 0 2.1307036135453927e-08
reported O 0 8.891030489621699e-08
in O 0 2.0525008892491314e-07
HCP B-Disease 1 1.0
patients O 0 9.6821249826462e-06
. O 0 4.741028533317149e-06

We O 0 1.4679818605145556e-06
report O 0 2.100084657286061e-07
another O 0 1.471555890475429e-07
mutation O 0 8.336832024724572e-08
in O 0 3.221260769237233e-08
a O 0 1.9403059070555173e-07
Japanese O 0 4.366338544059545e-06
family O 0 9.767668416316155e-07
. O 0 2.598858827695949e-06

Polymerase O 0 2.6030756998807192e-05
chain O 0 3.7977272313582944e-06
reaction O 0 2.2824440293334192e-07
- O 0 5.589951683759864e-07
single O 0 1.239703806277248e-07
strand O 0 1.3376376273299684e-07
conformational O 0 1.4215979504683673e-08
polymorphism O 0 8.713356258738258e-09
and O 0 5.131187030826823e-09
direct O 0 8.495017134180216e-09
sequence O 0 1.3480769389673242e-08
analyses O 0 5.652464452055028e-08
demonstrated O 0 4.239932849259276e-08
a O 0 1.766856883023138e-08
C O 0 1.8033728110822267e-07
to O 0 1.6122616131042378e-08
T O 0 1.7858374690149503e-07
substitution O 0 2.0947275913840713e-08
in O 0 5.153844906402583e-09
exon O 0 1.55705009774465e-07
1 O 0 7.153115433311541e-08
of O 0 7.02041020872457e-08
the O 0 5.317408025007353e-08
CPO O 0 2.4556144126108848e-05
gene O 0 1.798477455849934e-08
at O 0 2.7669344149217068e-08
nucleotide O 0 2.7737824481732787e-08
position O 0 1.991728204586707e-08
85 O 0 5.814255743530339e-08
, O 0 5.3436157720909705e-09
which O 0 3.250669289300845e-09
lies O 0 7.956457181990118e-08
in O 0 5.439652728256306e-09
the O 0 7.072260643781192e-08
putative O 0 1.1239739023949369e-06
presequence O 0 3.28228793478047e-06
for O 0 5.020037363578922e-08
targeting O 0 3.266934527346166e-07
to O 0 1.75510180611127e-07
mitochondria O 0 3.0005098778929096e-06
. O 0 3.281386625531013e-06

This O 0 5.855912377228378e-07
mutation O 0 2.2535476773555274e-07
changes O 0 2.459540482391276e-08
the O 0 6.322965617755472e-08
codon O 0 2.085149333197478e-07
for O 0 1.5877473558134625e-08
glutamine O 0 2.5456310481786204e-07
to O 0 1.5143658771421542e-08
a O 0 4.839154499336473e-08
termination O 0 2.7040817940360284e-07
codon O 0 3.755419868411991e-07
at O 0 1.975505483642337e-07
amino O 0 3.9209194824252336e-07
acid O 0 4.628752208191145e-07
position O 0 4.1336932099511614e-07
29 O 0 2.328012442376348e-06
. O 0 3.5297857721161563e-06

MaeI O 0 0.00045117881381884217
restriction O 0 1.9534600141923875e-06
analysis O 0 1.535417908371528e-07
showed O 0 3.605191878364167e-08
two O 0 2.4869228898438678e-09
other O 0 3.2148019801780947e-09
carriers O 0 1.208394539986557e-08
in O 0 1.2265650717324661e-08
the O 0 2.0632752750771033e-07
family O 0 5.76520221784449e-07
. O 0 1.6230009123319178e-06

The O 0 1.0931354154308792e-05
C O 0 0.0013075984315946698
- O 0 0.025432400405406952
T O 0 0.0006061450112611055
mutation O 0 1.6525467572137131e-07
is O 0 1.0235129188629344e-08
located O 0 5.1359290154096016e-08
within O 0 7.924135125847442e-09
a O 0 9.84180736907092e-09
recently O 0 4.7421274018688564e-08
proposed O 0 8.640722626296338e-08
putative O 0 3.765256622045854e-07
alternative O 0 3.4727843711834794e-08
translation O 0 2.6645864181773504e-08
initiation O 0 1.0642448700082241e-07
codon O 0 1.3407283461219777e-07
( O 0 3.94699517514141e-09
TIC O 0 7.490168627555249e-07
- O 0 6.463336887918558e-08
1 O 0 5.8937875024867026e-08
) O 0 3.5075315985011457e-09
, O 0 4.6103521000873116e-09
supporting O 0 1.5315798407300463e-08
that O 0 3.3169711421976444e-09
TIC O 0 3.1273734748538118e-06
- O 0 1.9066568768266734e-07
1 O 0 1.8712006522036972e-07
is O 0 8.09376654586913e-09
the O 0 2.023348066870767e-08
real O 0 1.986489479577358e-07
TIC O 0 9.276875061914325e-06
rather O 0 2.5363275923950823e-08
than O 0 1.8358180753352826e-08
TIC O 0 1.0147753528144676e-05
- O 0 1.4261014484873158e-06
2 O 0 1.5248602949213819e-06
. O 0 2.0364602448808e-07
. O 0 1.4906723890817375e-06

Human B-Disease 0 3.5317721085448284e-06
complement I-Disease 0 7.1613790169067215e-06
factor I-Disease 0 0.002336536068469286
H I-Disease 1 1.0
deficiency I-Disease 1 0.999930739402771
associated O 0 1.6356085552615696e-06
with O 1 0.8769068121910095
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0010079194325953722

This O 0 2.95065575528497e-07
study O 0 1.1231065144556851e-07
reports O 0 2.234897067410202e-08
on O 0 2.217318595398865e-08
six O 0 7.747631869392535e-09
cases O 0 5.291746596469693e-09
of O 0 1.2205352106775536e-07
deficiency B-Disease 0 0.237628772854805
in I-Disease 0 1.2305557461900207e-08
the I-Disease 0 3.94507004841671e-08
human I-Disease 0 8.438769683039027e-09
complement I-Disease 0 2.0268243972054734e-08
regulatory I-Disease 0 7.67529968470626e-08
protein I-Disease 0 9.062136996362824e-08
Factor I-Disease 0 1.3732498018725892e-06
H I-Disease 1 0.9999998807907104
( O 0 4.496997974001715e-08
FH O 0 0.029348652809858322
) O 0 3.140169457793718e-09
in O 0 1.423287487867242e-09
the O 0 4.391591090779912e-09
context O 0 5.664538615945958e-09
of O 0 1.300916352420245e-08
an O 0 7.777409649634137e-08
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.184288162738085e-05

Five O 0 1.033644821291091e-06
of O 0 2.3798484960479982e-07
the O 0 4.542038567478812e-08
cases O 0 9.698580605288498e-09
were O 0 3.0820950236432054e-09
observed O 0 3.7478611325525435e-09
in O 0 1.2640450908207868e-09
children O 0 5.086732812742412e-09
presenting O 0 8.918596705598247e-08
with O 0 2.8619774639082607e-07
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9897887110710144
HUS B-Disease 1 1.0
) O 0 2.463464807078708e-05
. O 0 1.6310852515744045e-05

Two O 0 2.1058886545688438e-07
of O 0 2.824307898663392e-07
the O 0 9.420939051096866e-08
children O 0 4.8722551326818575e-08
exhibited O 0 3.6247294588065415e-07
a O 0 1.6520772305739229e-07
homozygous O 0 3.267277861596085e-05
deficiency O 0 0.4031417667865753
characterized O 0 7.297899884406434e-08
by O 0 2.69431854604818e-09
the O 0 4.4549096855917014e-08
absence O 0 7.427430404050028e-08
of O 0 8.613243096533552e-08
the O 0 2.2788720244193428e-08
150 O 0 1.0959579022085109e-08
- O 0 3.425308037208197e-08
kD O 0 1.952862248799647e-06
form O 0 3.667108172678013e-09
of O 0 1.8655462952210655e-08
Factor O 0 1.2718940922695765e-07
H O 0 0.00011625186743913218
and O 0 5.253450563458273e-09
the O 0 1.3419250599611132e-08
presence O 0 1.5754904936216008e-08
, O 0 6.643721128796187e-09
upon O 0 8.284218644405428e-09
immunoblotting O 0 6.345582050926168e-07
, O 0 8.880146395995325e-09
of O 0 2.901570006486054e-08
the O 0 3.104593560010471e-08
42 O 0 1.1926469767331582e-07
- O 0 2.2550740652604873e-07
kD O 0 6.092995317885652e-05
Factor O 0 1.2684251942118863e-06
H O 0 1.5475561667699367e-05
- O 0 9.330773309557117e-08
like O 0 1.7145127984008468e-08
protein O 0 1.2721581121866166e-08
1 O 0 5.277254899738182e-08
( O 0 8.335842238693658e-09
FHL O 0 4.845143121201545e-05
- O 0 1.0800417982181898e-07
1 O 0 5.894360555203093e-08
) O 0 3.106564561150549e-09
and O 0 4.440214862455605e-09
other O 0 1.1441744440787716e-08
FH O 0 3.292544715804979e-05
- O 0 1.561844840125559e-07
related O 0 1.0949784012836972e-07
protein O 0 5.043829887085849e-08
( O 0 1.5208208026251668e-08
FHR O 1 0.830395519733429
) O 0 2.2571438762497564e-07
bands O 0 9.865575520962011e-06
. O 0 3.899387138517341e-06

Southern O 0 3.4187276469310746e-05
blot O 0 0.00010201422992395237
and O 0 2.600673667529918e-07
PCR O 0 1.9097707593118685e-07
analysis O 0 6.995358514672034e-09
of O 0 6.147027775682545e-09
DNA O 0 1.1548761946755803e-08
of O 0 1.1310319791846268e-08
one O 0 6.947728170558776e-09
patient O 0 1.5261820252021607e-08
with O 0 8.825404407275528e-09
homozygous O 0 1.3074283742753323e-05
deficiency O 0 0.3603024482727051
ruled O 0 6.556059872764308e-08
out O 0 1.3132543941196673e-08
the O 0 1.0335334366118332e-08
presence O 0 4.939774811418829e-09
of O 0 1.324486209597353e-08
a O 0 5.807790692813342e-09
large O 0 2.4154216404781437e-08
deletion O 0 1.2321625320055318e-07
of O 0 6.687802311944324e-08
the O 0 1.4064319486806198e-07
FH O 1 0.9999899864196777
gene O 0 3.145926186221004e-08
as O 0 6.884436576370945e-09
the O 0 3.118594094075888e-08
underlying O 0 1.2149080248491373e-05
defect O 0 1.0099557812282e-06
for O 0 1.5113367624053353e-07
the O 0 1.0812184882524889e-05
deficiency O 1 0.999998927116394
. O 0 1.2499298463808373e-05

The O 0 8.587797992731794e-07
other O 0 3.0327623079529076e-08
four O 0 5.359764632117958e-09
children O 0 3.8854470751914505e-09
presented O 0 2.985715497061392e-08
with O 0 2.9728274952844913e-08
heterozygous O 0 1.6349365978385322e-05
deficiency O 1 0.9999881982803345
and O 0 1.4086427313486638e-07
exhibited O 0 3.4237482395838015e-06
a O 0 7.213358088620225e-08
normal O 0 4.0959768909942795e-08
immunoblotting O 0 6.150737021926034e-07
pattern O 0 4.443233336814956e-08
of O 0 2.281081101784821e-08
proteins O 0 4.843851986180425e-09
of O 0 6.722345347043301e-08
the O 0 6.860620942461537e-07
FH O 1 0.9999991655349731
family O 0 1.6725859950383892e-06
. O 0 2.6854652332986007e-06

Factor B-Disease 1 1.0
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.5749654380670108e-07
the O 0 6.148507480929766e-08
only O 0 6.900346249949507e-08
complement B-Disease 1 0.9999995231628418
deficiency I-Disease 1 1.0
associated O 0 1.6111108607219649e-06
with O 0 3.962221853726078e-06
HUS B-Disease 1 1.0
. O 0 9.982915798900649e-05

These O 0 6.873155484754534e-07
observations O 0 4.748092123918468e-07
suggest O 0 5.633532396132068e-08
a O 0 1.4136753989646422e-08
role O 0 3.3222278261746396e-08
for O 0 2.5960192218121847e-08
FH O 1 1.0
and O 0 1.7250332007279212e-07
/ O 0 0.0005040729884058237
or O 0 5.902370503463317e-07
FH O 1 0.9996320009231567
receptors O 0 8.08585411959939e-08
in O 0 6.940284791312479e-09
the O 0 5.897115684661003e-08
pathogenesis O 0 0.002549069933593273
of O 0 2.4549377485527657e-05
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 2.0843945094384253e-05
. O 0 1.720402178762015e-05

Further O 0 3.320180439914111e-06
evidence O 0 2.1849298548204388e-07
for O 0 2.5805672265732937e-08
a O 0 2.242514618444602e-08
major O 0 3.921671236639668e-07
ancient O 0 6.51190703138127e-06
mutation O 0 1.682141919445712e-05
underlying O 1 0.9999773502349854
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.1105158819191274e-06
linkage O 0 4.642245585273486e-06
disequilibrium O 0 4.2992187445634045e-06
studies O 0 9.294927849623491e-08
in O 0 1.1115807829753521e-08
the O 0 3.844417761911245e-08
Japanese O 0 5.828434268551064e-07
population O 0 7.384150535472145e-08
. O 0 7.763995313325722e-07

The O 0 0.005073721520602703
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.07296501845121384
DM B-Disease 1 1.0
) O 0 3.868851194965828e-07
mutation O 0 8.752503788400645e-08
is O 0 6.941688113215605e-09
an O 0 6.857583390029731e-09
unstable O 0 3.401759158805362e-07
( O 0 3.95043109335802e-08
CTG O 0 0.0017484488198533654
) O 0 4.355897331720371e-08
n O 0 3.8870645369115664e-08
repeat O 0 4.1059578848035017e-08
, O 0 3.0957871821613026e-09
present O 0 5.0025814601895036e-09
at O 0 2.0732116468025197e-08
a O 0 5.393832491762396e-09
copy O 0 1.3895940398356288e-08
number O 0 3.0084423841003627e-09
of O 0 1.1390378418241198e-08
5 O 0 2.5565030981056225e-08
- O 0 5.9566907850694406e-08
37 O 0 4.534957653845595e-08
repeats O 0 1.2181020636603535e-08
on O 0 1.2181647690567843e-08
normal O 0 1.104022739895072e-08
chromosomes O 0 2.6451303369867674e-09
but O 0 1.3036902668517314e-09
amplified O 0 4.217220705982072e-08
to O 0 9.482735485732974e-09
50 O 0 8.06632201033608e-08
- O 0 3.1282095847018354e-07
3000 O 0 4.1219897184419096e-07
copies O 0 1.2985319131075812e-07
on O 0 1.3297864143169136e-06
DM B-Disease 1 1.0
chromosomes O 0 5.6244020925078075e-06
. O 0 2.2207316305866698e-06

Previous O 0 4.425583483680384e-06
findings O 0 2.933092844159546e-07
in O 0 1.6685085313383752e-08
Caucasian O 0 5.2876328027196e-07
populations O 0 1.9960712194233565e-08
of O 0 7.479861352521766e-08
a O 0 7.925510772111011e-07
DM B-Disease 1 1.0
founder O 0 0.13196644186973572
chromosome O 0 3.94545452309103e-07
raise O 0 5.1795780109387124e-08
a O 0 1.3259724873648793e-08
question O 0 1.8669915391456016e-08
about O 0 4.386242036247268e-09
the O 0 1.1245916198276973e-08
molecular O 0 5.459456886569569e-08
events O 0 2.182001601624961e-08
involved O 0 6.246128059217426e-09
in O 0 3.984603758055982e-09
the O 0 4.347621995748341e-08
expansion O 0 1.0977779538734467e-06
mutation O 0 1.2994379403608036e-06
. O 0 1.2017677590847597e-06

To O 0 1.036848516378086e-06
investigate O 0 1.1324458455419517e-06
whether O 0 1.9837480635942484e-07
a O 0 1.0112437820453124e-07
founder O 0 8.89901059508702e-07
chromosome O 0 1.5916775453206355e-07
for O 0 1.5986595158778982e-08
the O 0 4.379986933145119e-07
DM B-Disease 1 1.0
mutation O 0 1.2307768315622525e-07
exists O 0 6.375946881576056e-09
in O 0 8.305636733929589e-10
the O 0 5.433648642139133e-09
Japanese O 0 1.939143423612677e-08
population O 0 9.09704200857675e-10
, O 0 1.883023070803347e-09
we O 0 4.772941153419197e-09
genotyped O 0 5.825767175338115e-07
families O 0 1.927743742413668e-09
using O 0 4.9102881760632044e-09
polymorphic O 0 4.347373305790825e-07
markers O 0 3.430362482959026e-07
near O 0 2.9548405677815026e-07
the O 0 9.710615245239751e-08
( O 0 5.798053592798169e-08
CTG O 0 0.0023370874114334583
) O 0 5.873385688914823e-08
n O 0 1.3688926969734894e-07
repeat O 0 2.6706112521424075e-07
region O 0 1.2719063136046316e-07
and O 0 8.107072346774657e-08
constructed O 0 6.719461907778168e-06
haplotypes O 0 2.4863158614607528e-05
. O 0 5.659256203216501e-06

Six O 0 1.546140197206114e-06
different O 0 4.2852910553392576e-08
haplotypes O 0 5.078607046016259e-07
were O 0 1.4173418882990063e-08
found O 0 2.037327995196847e-08
and O 0 6.837786514779509e-08
DM B-Disease 1 1.0
alleles O 0 3.8424940385084483e-07
were O 0 8.39001543795348e-08
always O 0 5.045350235377555e-07
haplotype O 0 1.2098185834474862e-05
A O 0 1.3926174688094761e-05
. O 0 7.37575692255632e-06

To O 0 3.970987734192022e-07
find O 0 4.506872386400573e-08
an O 0 3.0525155736427223e-09
origin O 0 3.3520592968017127e-09
of O 0 1.3631302309136117e-08
the O 0 3.4771321821835954e-08
( O 0 2.5825958260838888e-08
CTG O 0 0.034153614193201065
) O 0 2.698017453894863e-08
n O 0 3.320828056985192e-08
repeat O 0 2.6511221662417483e-08
mutation O 0 2.192605652595603e-09
and O 0 8.335250267776928e-10
to O 0 2.1567234664843227e-09
investigate O 0 2.129947951345912e-08
the O 0 8.461285005978425e-09
mechanism O 0 1.7687181497194615e-08
of O 0 1.6267922120505318e-08
the O 0 1.6031666660865085e-08
expansion O 0 7.612709396198625e-08
mutation O 0 4.979030521212735e-09
in O 0 1.1957790313488204e-09
the O 0 8.45679970495894e-09
Japanese O 0 4.486451388174828e-08
population O 0 1.213871003713507e-09
we O 0 1.3567019729876506e-09
have O 0 8.142040375247461e-10
studied O 0 5.912815836950358e-08
90 O 0 9.250711485719876e-08
Japanese O 0 3.408318605124805e-07
DM B-Disease 1 1.0
families O 0 1.5612453552193983e-08
comprising O 0 2.0969341818499743e-08
190 O 0 4.3279388961536824e-08
affected O 0 1.2666281357098796e-08
and O 0 2.0636722553035725e-08
130 O 0 5.644943712468375e-07
unaffected O 0 4.002325567853404e-06
members O 0 2.5560260041856964e-07
. O 0 3.3163071293529356e-06

The O 0 5.645919372909702e-06
results O 0 3.449192149673763e-07
suggest O 0 5.249967927056787e-08
that O 0 2.333558013489778e-09
a O 0 7.196191642577787e-09
few O 0 1.7807789021162534e-08
common O 0 3.962822958669676e-08
ancestral O 0 2.7887907094736875e-07
mutations O 0 2.2577934188916515e-08
in O 0 4.230479078159988e-09
both O 0 1.6094718446879597e-08
Caucasian O 0 8.233599828599836e-07
and O 0 1.499643431657205e-08
Japanese O 0 1.1442861591604014e-07
populations O 0 7.990717421080262e-09
have O 0 5.3168952574012e-10
originated O 0 1.8579356941827996e-09
by O 0 3.627087241664384e-10
expansion O 0 5.34147872599533e-08
of O 0 5.2054968335824015e-08
an O 0 3.652269953136056e-08
ancestral O 0 9.313008604294737e-07
n O 0 1.6902392019346735e-07
= O 0 5.307133577048262e-08
5 O 0 7.573721205744732e-08
repeat O 0 8.07252433787653e-08
to O 0 2.781819929964513e-08
n O 0 1.6330058372204803e-07
= O 0 7.45802282153818e-08
19 O 0 2.7652046696857724e-07
- O 0 5.297222855915606e-07
37 O 0 9.665155857874197e-07
copies O 0 1.2375626283755992e-06
. O 0 2.759161588983261e-06

These O 0 6.151276465971023e-07
data O 0 2.0190657323837513e-07
support O 0 6.651394102163977e-08
multistep O 0 1.6534971791770658e-06
models O 0 2.668997183263855e-07
of O 0 6.288663030318276e-07
triplet O 0 1.4094026482780464e-05
repeat O 0 3.8177873307176924e-07
expansion O 0 1.7543756314353232e-07
that O 0 2.4039072954451512e-09
have O 0 7.927349887637547e-10
been O 0 2.5437338901923567e-09
proposed O 0 1.0120884574860156e-08
for O 0 6.102204963553959e-09
both O 0 1.0399882910405722e-07
DM B-Disease 1 1.0
and O 0 4.435085429577157e-06
Friedreichs B-Disease 1 0.9999998807907104
ataxia I-Disease 1 0.9999997615814209
. O 0 4.7831053961999714e-06
. O 0 9.857036275207065e-06

The O 0 2.3736608909530332e-06
molecular O 0 1.1575741609703982e-06
basis O 0 2.3752592426262709e-07
of O 0 0.036135077476501465
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 5.021723126219513e-08
the O 0 6.444896172297376e-08
western O 0 1.6288888105009391e-07
Cape O 0 2.2612382508668816e-06
, O 0 4.846654988455157e-08
South O 0 3.2638857305755664e-07
Africa O 0 3.3112399933088454e-07
. O 0 1.6530052562302444e-06

Deficiency B-Disease 1 0.9999924898147583
of I-Disease 0 2.150954787794035e-05
the I-Disease 0 2.2209032977116294e-06
sixth I-Disease 0 2.8088622912036953e-06
component I-Disease 0 1.2812602108169813e-06
of I-Disease 0 1.5257985808148078e-07
human I-Disease 0 5.24994732131745e-08
complement I-Disease 0 5.430107421489083e-07
( O 0 5.6761138012006995e-08
C6 O 1 1.0
) O 0 1.779885927533087e-08
has O 0 5.301849181904572e-09
been O 0 2.337794624551748e-09
reported O 0 1.4227012901102398e-09
in O 0 3.563424555430572e-10
a O 0 6.705512256566237e-10
number O 0 5.45956557740368e-10
of O 0 2.4881090521233773e-09
families O 0 1.375566188732691e-10
from O 0 3.263533332464874e-10
the O 0 4.419682841927397e-09
western O 0 1.799403825941681e-08
Cape O 0 8.627561669527495e-07
, O 0 2.0231011532700904e-08
South O 0 2.2556417889063596e-07
Africa O 0 2.0243524545549008e-07
. O 0 1.2918931133754086e-06

Meningococcal B-Disease 1 1.0
disease I-Disease 1 0.9999805688858032
is O 0 6.257983642399267e-08
endemic O 0 3.0764880420974805e-07
in O 0 6.387607331959089e-09
the O 0 2.782764596531706e-08
Cape O 0 7.77315221967001e-07
and O 0 7.468482721151304e-09
almost O 0 4.177979739949933e-09
all O 0 2.092877426917994e-09
pedigrees O 0 4.231102579410617e-08
of O 0 3.408786142244935e-08
total O 0 6.858213600935414e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.773629717012227e-07
C6Q0 O 1 1.0
) O 0 2.5427212335671356e-08
have O 0 4.304441247882096e-09
been O 0 6.586212464299024e-09
ascertained O 0 1.4301818396234012e-07
because O 0 1.2168411167579052e-08
of O 0 2.806683312428504e-07
recurrent O 1 0.9999998807907104
disease O 1 0.999993085861206
. O 0 9.877626325760502e-06

We O 0 7.606437861795712e-07
have O 0 3.008174331853297e-08
sequenced O 0 1.4727801556091435e-07
the O 0 3.059272657424117e-08
expressed O 0 2.0540904088761636e-08
exons O 0 7.748144525976386e-07
of O 0 3.957921137498488e-07
the O 0 6.142857955637737e-07
C6 O 1 1.0
gene O 0 2.3076969668522906e-08
from O 0 5.8512883427397355e-09
selected O 0 2.240616225890335e-08
cases O 0 3.561945183250259e-09
and O 0 2.799318998825129e-09
have O 0 1.826460538367769e-09
found O 0 6.689012010951956e-09
three O 0 8.252237115868866e-09
molecular O 0 0.39177730679512024
defects O 1 0.9410746097564697
leading O 0 4.75390066867476e-07
to O 0 2.211667293749997e-08
total O 0 2.272468918818049e-06
deficiency O 1 1.0
879delG O 0 0.16934551298618317
, O 0 2.5678016157826278e-08
which O 0 3.8944838465226894e-09
is O 0 3.382837565624186e-09
the O 0 9.031109193813336e-09
common O 0 3.8747248964909886e-08
defect O 0 1.1066943983450983e-07
in O 0 5.5600750670237176e-09
the O 0 7.058609696741769e-08
Cape O 0 2.3415097984980093e-06
and O 0 3.766552580941607e-08
hitherto O 0 6.933717031643027e-07
unreported O 0 5.080157166048593e-07
, O 0 1.18107772451026e-08
and O 0 1.4139855508688015e-08
1195delC O 0 5.502757858266705e-07
and O 0 2.4739422954667134e-08
1936delG O 0 2.2662254650640534e-06
, O 0 1.0671287853369904e-08
which O 0 1.955984929580268e-09
have O 0 1.159413343110316e-09
been O 0 4.130683350922482e-09
previously O 0 1.7263786844523565e-08
reported O 0 6.8153616084032365e-09
in O 0 4.747065851518073e-09
African O 0 5.0414737273740684e-08
- O 0 1.0666158232197631e-06
Americans O 0 3.942735133932729e-07
. O 0 1.442651864635991e-06

We O 0 7.722744612692622e-07
also O 0 8.181619648439664e-08
show O 0 4.581033863360062e-08
that O 0 4.521300667192918e-09
the O 0 3.3736249349658465e-08
879delG O 0 1.9576209524529986e-06
and O 0 9.113478682820642e-08
1195delC O 0 6.630255666095763e-05
defects O 0 3.880586064042291e-06
are O 0 3.03988989536208e-09
associated O 0 8.806638085445684e-09
with O 0 4.169288914113167e-08
characteristic O 1 1.0
C6 O 1 1.0
/ O 1 1.0
C7 O 1 1.0
region O 0 3.3054075174732134e-06
DNA O 0 1.621951696506585e-06
marker O 0 4.245052878104616e-06
haplotypes O 0 4.343962416442082e-07
, O 0 8.90572504630427e-09
although O 0 8.684171604045332e-09
small O 0 2.595345982570052e-08
variations O 0 4.0263884670821426e-07
were O 0 1.0478571965677475e-07
observed O 0 9.434854746359633e-07
. O 0 1.3722757330469904e-06

The O 0 1.8081540474668145e-05
1936delG O 0 0.005100858863443136
defect O 0 0.0007407822413370013
was O 0 1.4418486671274877e-06
observed O 0 4.506073381094211e-08
only O 0 4.347105786450811e-09
once O 0 1.0071895317764756e-08
in O 0 1.255143988743157e-09
the O 0 1.372865199300577e-08
Cape O 0 8.537381290807389e-07
, O 0 9.064812900305697e-09
but O 0 2.8700462006980842e-09
its O 0 9.089727193156705e-09
associated O 0 7.095256648881332e-08
haplotype O 0 1.8005819129029987e-06
could O 0 1.7358722459448472e-07
be O 0 1.696988931598753e-07
deduced O 0 4.151425400777953e-06
. O 0 2.146440010619699e-06

The O 0 2.5941144485841505e-06
data O 0 1.7969419729979563e-07
from O 0 4.6961591948502246e-08
the O 0 1.0749635492857124e-07
haplotypes O 0 3.745755066120182e-07
indicate O 0 1.1876695182877484e-08
that O 0 1.1820010525909197e-09
these O 0 1.988250453166529e-09
three O 0 2.8487108227892577e-09
molecular O 0 6.293391265899118e-07
defects O 0 3.793322491674189e-07
account O 0 3.49272455402172e-09
for O 0 7.841381766127142e-09
the O 0 1.949118910715697e-07
defects O 0 4.685209205490537e-06
in O 0 3.4621476796559136e-09
all O 0 7.125904755156398e-09
the O 0 1.9645966631287592e-08
38 O 0 1.148037611642394e-07
unrelated O 0 5.163037144484406e-07
C6Q0 O 1 0.999996542930603
individuals O 0 4.215577664723469e-09
we O 0 3.376597446091978e-09
have O 0 1.6546395364969158e-09
studied O 0 5.5853217162393776e-08
from O 0 1.1383016307320304e-08
the O 0 9.965328473526824e-08
Cape O 0 8.993602932605427e-06
. O 0 2.2253618681133958e-06

We O 0 1.2948064522788627e-06
have O 0 5.2346294410199334e-08
also O 0 6.679783837171271e-08
observed O 0 4.963842670235863e-08
the O 0 8.347652169504727e-08
879delG O 0 4.886092938249931e-06
defect O 0 6.848723046459781e-07
in O 0 1.4333380704556475e-08
two O 0 8.141923757420955e-08
Dutch O 1 1.0
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 4.698499105870724e-05
, O 0 2.986073965871583e-08
but O 0 8.297913467458784e-09
the O 0 7.096664234040873e-08
879delG O 0 5.49535025129444e-06
defect O 0 4.3401237803664117e-07
in O 0 8.038135490551213e-09
the O 0 8.043922150591243e-08
Cape O 0 3.2090013064589584e-06
probably O 0 2.585799663279431e-08
did O 0 3.844569995692382e-09
not O 0 1.1608383143624224e-09
come O 0 2.7689339709979777e-09
from O 0 4.828226707331851e-09
The O 0 6.675465868966057e-08
Netherlands O 0 1.1362362783984281e-06
. O 0 2.2459953186171333e-07
. O 0 1.4786588735660189e-06

Complement B-Disease 1 1.0
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.374976932311256e-06
seven O 0 2.7924261303269304e-07
further O 0 1.4583645224774955e-07
molecular O 0 2.1138310330570675e-05
defects O 0 4.567424639390083e-06
and O 0 3.1973815595165433e-08
their O 0 2.996938164301355e-08
associated O 0 2.687835376491421e-07
marker O 0 0.00015247915871441364
haplotypes O 0 3.485060733510181e-05
. O 0 6.046080670785159e-06

Seven O 0 3.164859208482085e-06
further O 0 1.9135828210892214e-07
molecular O 0 6.138852768344805e-07
bases O 0 5.655774657498114e-07
of O 0 0.4073498845100403
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 4.7504741473858303e-07
described O 0 2.0880911506537814e-06
. O 0 3.365195198057336e-06

All O 0 6.486888537438062e-07
these O 0 4.880197934653552e-08
new O 0 6.705646171667468e-08
molecular O 0 2.54912743002933e-06
defects O 0 2.6698066903918516e-06
involve O 0 4.499966976823089e-08
single O 0 2.0717173754292162e-08
- O 0 8.959943187392128e-08
nucleotide O 0 3.9729339817995424e-08
events O 0 1.8196287143723566e-08
, O 0 4.217918014859379e-09
deletions O 0 3.9686621988721527e-08
and O 0 4.1116066107349525e-09
substitutions O 0 5.327732210957947e-08
, O 0 4.75984096581783e-09
some O 0 2.09272577045283e-09
of O 0 1.541955896300351e-08
which O 0 6.860409129672007e-09
alter O 0 1.227492418820475e-07
splice O 0 7.163941972976318e-07
sites O 0 1.3513160013189918e-07
, O 0 2.469308135744086e-08
and O 0 4.283485210976323e-08
others O 0 3.292058181614266e-07
codons O 0 2.4238584956037812e-05
. O 0 3.8104465147625888e-06

They O 0 3.732988318461139e-07
are O 0 1.0540528450064812e-08
distributed O 0 2.4657783370685138e-08
along O 0 9.589413707544736e-08
the O 0 3.5091065342385264e-07
C7 O 1 0.9999971389770508
gene O 0 8.98844234598073e-08
, O 0 1.3672339704839942e-08
but O 0 2.5047508511732985e-09
predominantly O 0 6.935031660049162e-09
towards O 0 8.731939615813644e-09
the O 0 2.2352208972620247e-08
3 O 0 2.6205060521533596e-07
end O 0 6.945716108930355e-07
. O 0 1.761968974278716e-06

All O 0 1.1499446372909006e-06
were O 0 1.1377333208884011e-07
found O 0 3.319611963092939e-08
in O 0 2.411490385156867e-08
compound O 0 9.549949027132243e-07
heterozygous O 0 9.852016091826954e-07
individuals O 0 9.543870049810721e-08
. O 0 1.7140964700956829e-06

The O 0 0.0016332997474819422
C6 O 1 1.0
/ O 1 1.0
C7 O 1 1.0
marker O 0 0.0005728948162868619
haplotypes O 0 3.1120009680307703e-06
associated O 0 7.870693963241138e-08
with O 0 3.7824342768999486e-08
most O 0 5.4226743486651685e-06
C7 B-Disease 1 1.0
defects I-Disease 1 0.9999964237213135
are O 0 1.3578292623606103e-07
tabulated O 0 1.4466804714174941e-06
. O 0 2.576294093614706e-07
. O 0 1.4019996115166578e-06

A O 0 1.614001303096302e-05
genome O 0 1.7316671119260718e-06
- O 0 7.074216341607098e-07
wide O 0 3.2746171996222984e-07
search O 0 4.810644327335467e-08
for O 0 1.8700422543815876e-08
chromosomal O 0 4.646018624043791e-06
loci O 0 6.3798934206715785e-06
linked O 0 2.150823092961218e-06
to O 0 1.0832746966116247e-07
mental O 1 0.9999996423721313
health O 0 2.5213728804374114e-05
wellness O 0 1.6876194422366098e-05
in O 0 1.1682709910587619e-08
relatives O 0 1.314715536437916e-08
at O 0 1.807315008761634e-08
high O 0 2.0498248431977117e-07
risk O 0 9.874264605969074e-08
for O 0 7.946857039087263e-08
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 6.417933491320582e-07
the O 0 7.013597382865555e-07
Old O 0 1.4686898794025183e-05
Order O 0 1.852552827585896e-06
Amish O 0 7.580269539175788e-06
. O 0 2.1141058823559433e-06

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.2945772409439087
BPAD B-Disease 1 1.0
; O 0 0.0015007727779448032
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 3.9132494578097976e-08
is O 0 7.900847975861325e-09
characterized O 0 6.172817368366168e-09
by O 0 6.057416790383741e-10
episodes O 0 1.0214110801598508e-07
of O 0 9.696462939245976e-07
mania B-Disease 1 0.9999750852584839
and O 0 3.5032687151215214e-07
/ O 0 0.4578445851802826
or O 0 7.547201335000864e-07
hypomania B-Disease 0 0.0002947190369013697
interspersed O 0 9.151205517810013e-07
with O 0 2.595227144297496e-08
periods O 0 3.0544043738700566e-07
of O 0 1.1615308039836236e-06
depression B-Disease 0 4.827625889447518e-05
. O 0 2.256404513900634e-06

Compelling O 0 3.213338277419098e-05
evidence O 0 1.010208166007942e-06
supports O 0 2.751719989646517e-07
a O 0 3.410086790722744e-08
significant O 0 4.851704815678204e-08
genetic O 0 1.5347592352554784e-07
component O 0 2.004859283033511e-07
in O 0 8.555653963071563e-09
the O 0 6.738417113183459e-08
susceptibility O 0 4.445217030024651e-07
to O 0 2.6843386535801983e-07
develop O 0 0.00011679787712637335
BPAD B-Disease 1 1.0
. O 0 4.594822530634701e-05

To O 0 3.8104576560726855e-07
date O 0 3.003404742685234e-07
, O 0 5.158627303103458e-08
however O 0 2.6216003590207038e-08
, O 0 2.493065132114225e-08
linkage O 0 1.9182090227332083e-07
studies O 0 3.105096979538757e-08
have O 0 2.574764401686025e-09
attempted O 0 4.3510976155403114e-08
only O 0 2.018170741635572e-09
to O 0 5.224602084297203e-09
identify O 0 5.35335047402441e-08
chromosomal O 0 2.117071744578425e-06
loci O 0 7.734803375569754e-07
that O 0 1.2565458895608117e-08
cause O 0 3.5927673280866657e-08
or O 0 4.5583958829809035e-09
increase O 0 7.186233386136109e-09
the O 0 3.279510707443478e-08
risk O 0 1.8266761969698564e-07
of O 0 5.144635792930785e-07
developing O 0 9.563251296640374e-06
BPAD B-Disease 1 1.0
. O 0 3.700014713103883e-05

To O 0 4.020847370611591e-07
determine O 0 7.221466091777984e-08
whether O 0 9.638940312584054e-09
there O 0 5.410586645382409e-09
could O 0 3.3063907167729667e-09
be O 0 2.6367181771291825e-09
protective O 0 1.5397849040255096e-07
alleles O 0 8.798646256025222e-09
that O 0 8.565331222065709e-10
prevent O 0 1.334589239121442e-08
or O 0 2.5631468059117424e-09
reduce O 0 1.1227227147969643e-08
the O 0 7.834519699656539e-09
risk O 0 1.1543365374677705e-08
of O 0 1.039232344623997e-08
developing O 0 7.294740811403244e-08
BPAD B-Disease 1 1.0
, O 0 1.0295925001457817e-08
similar O 0 1.553856376901308e-09
to O 0 1.0229405100758981e-09
what O 0 2.768500761973769e-09
is O 0 1.4859984354131939e-09
observed O 0 2.641520335799896e-09
in O 0 8.902765191720619e-10
other O 0 3.1621269158677023e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 4.2070574579611275e-08
we O 0 1.0208593970162383e-08
used O 0 5.670670688573409e-08
mental O 1 0.9043841361999512
health O 0 1.3106390497341636e-06
wellness O 0 2.06153799808817e-05
( O 0 3.475373544503668e-09
absence O 0 1.336443578026092e-08
of O 0 2.515965746852089e-08
any O 0 5.3333646832243176e-08
psychiatric B-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9996823072433472
) O 0 5.4128990178980985e-09
as O 0 1.1891451379142381e-08
the O 0 2.4461975556278048e-08
phenotype O 0 2.124802733760589e-08
in O 0 2.679610089373341e-09
our O 0 1.0962088126120761e-08
genome O 0 9.664403677334121e-08
- O 0 4.156482589223742e-07
wide O 0 1.3468775250657927e-06
linkage O 0 7.243233426379447e-07
scan O 0 3.9808841734156886e-07
of O 0 1.260623747612044e-07
several O 0 6.594737556042674e-08
large O 0 2.806924328524474e-07
multigeneration O 0 2.045165456365794e-05
Old O 0 2.4073556232906412e-06
Order O 0 1.9186738597909425e-07
Amish O 0 5.225562063060352e-07
pedigrees O 0 7.526888907705143e-07
exhibiting O 0 2.379099584004507e-07
an O 0 1.622977130466552e-08
extremely O 0 1.1277302292000968e-07
high O 0 7.699315460740763e-07
incidence O 0 6.53370398140396e-06
of O 0 1.8418984836898744e-05
BPAD B-Disease 1 1.0
. O 0 4.234110747347586e-05

We O 0 2.3583065740240272e-06
have O 0 4.487059257485271e-08
found O 0 2.0333526862259532e-08
strong O 0 1.548575845333744e-08
evidence O 0 1.8651228117505525e-08
for O 0 8.700552278639861e-09
a O 0 4.220632376927824e-08
locus O 0 1.911758317874046e-06
on O 0 4.3870477384189144e-07
chromosome O 0 1.9404665181355085e-06
4p O 0 2.1459842173499055e-05
at O 0 5.998007281959872e-07
D4S2949 O 0 5.6872054301493336e-06
( O 0 3.146346472249206e-08
maximum O 0 3.0863444067108503e-07
GENEHUNTER O 0 9.858846169663593e-05
- O 0 1.3313015188032296e-06
PLUS O 0 2.474571147104143e-06
nonparametric O 0 1.3088291552776354e-06
linkage O 0 1.6074538677912642e-07
score O 0 7.3670577194207e-08
= O 0 1.818528971853084e-08
4 O 0 2.646186203492107e-08
. O 0 5.9694151843814325e-09
05 O 0 2.5682873001642292e-06
, O 0 7.107203003897666e-08
P O 0 2.8971194865334837e-07
= O 0 8.781779747835117e-09
5 O 0 1.2609009836239693e-08
. O 0 1.6378315370602081e-09
22 O 0 9.32532540076636e-09
x O 0 1.4153832772478836e-08
10 O 0 9.198628525552976e-09
( O 0 2.4446291657653774e-09
- O 0 5.1476192197696946e-08
4 O 0 6.648514272455941e-08
) O 0 5.4849840225301705e-09
; O 0 1.0208204059836135e-08
SIBPAL O 0 4.21767654188443e-05
Pempirical O 0 3.37427991325967e-06
value O 0 4.906976158736143e-08
< O 0 7.130326196147507e-08
3 O 0 2.1391491245026373e-08
x O 0 2.4007604793041537e-08
10 O 0 1.4358883859699745e-08
( O 0 1.7398350538044838e-09
- O 0 3.201623144377663e-08
5 O 0 1.99982874704574e-08
) O 0 1.806245819579999e-09
) O 0 2.2465804772053843e-09
and O 0 5.939647440555973e-09
suggestive O 0 1.3638198481658037e-07
evidence O 0 1.2424894890727955e-08
for O 0 6.230160831677267e-09
a O 0 3.8855599626685944e-08
locus O 0 3.452691316851997e-06
on O 0 9.151248150374158e-07
chromosome O 0 4.5360488911683206e-06
4q O 0 1.8490705770091154e-05
at O 0 4.553844803467655e-07
D4S397 O 0 4.690887180913705e-06
( O 0 4.277704590549547e-08
maximum O 0 4.693320931892231e-07
GENEHUNTER O 0 0.0001043423981172964
- O 0 1.6912467799556907e-06
PLUS O 0 2.5801102765399264e-06
nonparametric O 0 1.149088461716019e-06
linkage O 0 1.492429078098212e-07
score O 0 8.298106735082911e-08
= O 0 1.3571012758006873e-08
3 O 0 1.310109620789035e-08
. O 0 4.172866940876929e-09
29 O 0 6.573664990128236e-08
, O 0 1.965177709450927e-08
P O 0 2.99168988249221e-07
= O 0 1.3139885624013914e-08
2 O 0 2.2937598487260402e-08
. O 0 3.963985140131854e-09
57 O 0 3.0039199572229336e-08
x O 0 1.3618983274454877e-08
10 O 0 8.181241462068556e-09
( O 0 1.8293158099425e-09
- O 0 4.630518191106603e-08
3 O 0 5.586238316368508e-08
) O 0 7.2871308987032535e-09
; O 0 1.0922016180359151e-08
SIBPAL O 0 2.2517551769851707e-05
Pempirical O 0 3.431001232456765e-06
value O 0 4.250183138765351e-08
< O 0 3.614735177848161e-08
1 O 0 2.1354313872734565e-08
x O 0 1.1429333923729246e-08
10 O 0 6.056865675674317e-09
( O 0 1.5030016120576306e-09
- O 0 2.6230457805809237e-08
3 O 0 1.8462825934761895e-08
) O 0 1.3330621051466096e-09
) O 0 1.4241293699868152e-09
that O 0 7.63163088279839e-10
are O 0 1.9817838481372974e-09
linked O 0 9.596494265906585e-08
to O 0 8.751084834557332e-08
mental O 1 0.9957090616226196
health O 0 0.00011824528337456286
wellness O 0 0.0013636486837640405
. O 0 7.883794751251116e-06

These O 0 6.595806780751445e-07
findings O 0 1.1004513567058893e-07
are O 0 2.9898625797386558e-09
consistent O 0 1.2587551445619738e-08
with O 0 1.8853660854745158e-09
the O 0 1.7167673505014136e-08
hypothesis O 0 1.3655659714117974e-08
that O 0 3.2983205056069664e-10
certain O 0 3.648209068174424e-09
alleles O 0 5.938061597987598e-09
could O 0 4.076093684801663e-09
prevent O 0 3.293878947374651e-08
or O 0 8.464674294828e-09
modify O 0 6.485552717094833e-08
the O 0 2.6188164525819957e-08
clinical O 0 1.4718534657731652e-07
manifestations O 0 6.840355126769282e-07
of O 0 2.169723074985086e-06
BPAD B-Disease 1 1.0
and O 0 1.1396456045531522e-07
perhaps O 0 5.2746788270496836e-08
other O 0 2.2024481793891937e-08
related O 0 0.00012811772467102855
affective B-Disease 1 1.0
disorders I-Disease 1 1.0
. O 0 1.3380806194618344e-05

Segregation O 0 0.002715850481763482
distortion O 1 0.9996685981750488
in O 0 6.286090501816943e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0004744809994008392

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9993911981582642
DM B-Disease 1 1.0
) O 0 6.805738053117238e-07
is O 0 7.830639248140869e-08
an O 0 5.0387718886213406e-08
autosomal B-Disease 1 0.9999520778656006
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999957084655762
which O 0 9.402517875400918e-09
, O 0 5.761934929182644e-09
in O 0 2.8542965768707518e-09
the O 0 1.8699031656410625e-08
typical O 0 6.990599388245755e-08
pedigree O 0 1.1052642179265604e-07
, O 0 6.018046949662903e-09
shows O 0 1.6943376479616745e-08
a O 0 1.4451861929387633e-08
three O 0 4.2358344387594116e-08
generation O 0 7.884169122007734e-07
anticipation O 0 9.623724508855958e-06
cascade O 0 0.00023045044508762658
. O 0 6.864927399874432e-06

This O 0 5.574901251748088e-07
results O 0 1.4143637372399098e-07
in O 0 6.38652579709742e-08
infertility B-Disease 1 0.9644919633865356
and O 1 0.9972122311592102
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.849569111480378e-06
CDM B-Disease 1 0.9999939203262329
) O 0 7.588727868323986e-09
with O 0 2.8484066216805104e-09
the O 0 2.685305844352115e-08
disappearance O 0 3.1554003498968086e-07
of O 0 5.283298492031463e-07
DM B-Disease 1 1.0
in O 0 5.036374659539433e-07
that O 0 3.140351338970504e-07
pedigree O 0 3.3368425647495314e-05
. O 0 5.089558271720307e-06

The O 0 9.363217259306111e-07
concept O 0 3.1803398314877995e-07
of O 0 2.3653333869333437e-07
segregation O 0 1.867641685748822e-06
distortion O 0 0.001502597238868475
, O 0 1.4197255815417975e-08
where O 0 7.434231008573988e-09
there O 0 1.6953940473740658e-09
is O 0 1.1040812708529302e-09
preferential O 0 5.7601323710798624e-09
transmission O 0 1.0045074105846652e-08
of O 0 1.2792509274106578e-08
the O 0 1.6075054176667436e-08
larger O 0 2.5339099707366586e-08
allele O 0 1.5195045222071712e-08
at O 0 2.5009423865185454e-08
the O 0 1.2206446342588606e-07
DM B-Disease 1 1.0
locus O 0 0.006369865965098143
, O 0 4.0976804172032644e-08
has O 0 1.410077654639963e-08
been O 0 7.702103843598707e-09
put O 0 4.590751601085685e-08
forward O 0 3.989624985933915e-08
to O 0 2.2834404589389123e-08
explain O 0 1.3239058205272158e-07
partially O 0 2.2544590194684133e-07
the O 0 1.6537567759655758e-08
maintenance O 0 4.773116302203562e-07
of O 0 1.3623370023196912e-06
DM B-Disease 1 1.0
in O 0 1.833238201243148e-07
the O 0 3.3106081787082076e-07
population O 0 1.1145385769850691e-07
. O 0 6.028976144989429e-07

In O 0 9.451686082684319e-07
a O 0 1.1520825182742556e-07
survey O 0 7.130815760092446e-08
of O 0 2.3457424447315134e-07
DM B-Disease 1 1.0
in O 0 1.201525492433575e-07
Northern O 0 2.6925481506623328e-06
Ireland O 0 7.252551199599111e-07
, O 0 1.1138330791027329e-07
59 O 0 6.339907940855483e-07
pedigrees O 0 1.554686377858161e-06
were O 0 3.5231229844612244e-07
ascertained O 0 1.2825882549805101e-05
. O 0 2.3763880108162994e-06

Sibships O 0 0.00010198193922406062
where O 0 1.6067120611751307e-07
the O 0 2.4838854528752563e-08
status O 0 1.0775927705708455e-08
of O 0 1.0707538855569965e-08
all O 0 3.0143125773207657e-09
the O 0 9.343200879641245e-09
members O 0 2.104200813590751e-09
had O 0 1.407731797797851e-08
been O 0 1.0408927941796264e-08
identified O 0 8.954780028602727e-09
were O 0 3.3385323394696798e-09
examined O 0 1.746671962621349e-08
to O 0 1.8603079077195162e-09
determine O 0 3.206430676527816e-09
the O 0 6.285327369681681e-09
transmission O 0 2.878852711774016e-08
of O 0 7.260177881107666e-08
the O 0 5.677580361407308e-07
DM B-Disease 1 1.0
expansion O 0 4.685843578045024e-06
from O 0 3.021307293238351e-08
affected O 0 3.938874826303618e-08
parents O 0 3.6281821991224206e-09
to O 0 9.895792629777134e-09
their O 0 7.132964441325385e-08
offspring O 0 2.1129851575096836e-06
. O 0 1.690930616859987e-06

Where O 0 1.2777203437508433e-06
the O 0 3.591315191897593e-07
transmitting O 0 1.545532541058492e-05
parent O 0 4.528777424184227e-07
was O 0 4.919449452245317e-07
male O 0 1.9880322099652403e-07
, O 0 9.161616532082917e-08
58 O 0 2.753967009994085e-06
. O 0 2.2513445401273202e-06

3 O 0 7.980666509865841e-07
% O 0 2.33349677358774e-08
of O 0 3.636976586562923e-08
the O 0 3.045706975512985e-08
offspring O 0 1.4501702061409105e-08
were O 0 3.132124115623469e-09
affected O 0 5.872027752928943e-09
, O 0 2.781733732248881e-09
and O 0 3.526488878691225e-09
in O 0 2.7760040932633956e-09
the O 0 1.620592193773973e-08
case O 0 1.4775204171257883e-08
of O 0 3.191879471842185e-08
a O 0 2.633814233377052e-08
female O 0 6.149633691165945e-08
transmitting O 0 1.1712741070368793e-06
parent O 0 1.8640031385075417e-07
, O 0 1.1073638006564579e-07
68 O 0 5.495622644957621e-06
. O 0 3.5779905829258496e-06

7 O 0 1.2096305908926297e-05
% O 0 4.6016222654543526e-07
were O 0 2.2731380511231691e-07
affected O 0 1.3519181720766937e-06
. O 0 2.8490439945016988e-06

Studies O 0 4.333322522143135e-06
on O 0 9.047817002283409e-07
meiotic O 0 1.77917809196515e-05
drive O 0 2.247337533844984e-06
in O 0 2.302779620322326e-07
DM B-Disease 1 1.0
have O 0 2.121915265718144e-08
shown O 0 3.580151508586482e-09
increased O 0 1.706398244927243e-09
transmission O 0 5.715655948534959e-09
of O 0 9.736316641806297e-09
the O 0 8.456718880722747e-09
larger O 0 2.5628891009432664e-08
allele O 0 1.3951578559101563e-08
at O 0 2.3804153315154508e-08
the O 0 9.945485146545252e-08
DM B-Disease 1 1.0
locus O 0 8.007723408809397e-06
in O 0 9.951330071089615e-08
non O 0 5.318946477927966e-06
- O 0 0.00012855313252657652
DM O 1 1.0
heterozygotes O 0 1.2803812751371879e-05
for O 0 5.178195578992018e-07
CTGn O 0 0.0005071079940535128
. O 0 7.11320853952202e-06

This O 0 4.392310302137048e-07
study O 0 1.7601102797470958e-07
provides O 0 1.1319923665098486e-08
further O 0 6.7067689180078105e-09
evidence O 0 7.968177229145113e-09
that O 0 3.83077214394234e-09
the O 0 1.8354353414906655e-07
DM B-Disease 1 1.0
expansion O 0 1.697449442872312e-05
tends O 0 4.3555778006520995e-07
to O 0 5.225880528314519e-08
be O 0 1.023487925522204e-07
transmitted O 0 4.694194046805933e-07
preferentially O 0 1.6293001863232348e-06
. O 0 1.651432739890879e-06

Diagnosis O 1 0.9994683861732483
of O 0 0.4818074703216553
hemochromatosis B-Disease 1 1.0
. O 0 0.0015377517556771636

If O 0 3.161410495522432e-05
untreated O 1 1.0
, O 0 1.0079466846946161e-05
hemochromatosis B-Disease 1 1.0
can O 0 5.008655534766149e-06
cause O 1 0.980866551399231
serious O 1 1.0
illness O 1 0.9996088147163391
and O 0 1.2406943916687396e-08
early B-Disease 0 1.2176188946000366e-08
death I-Disease 0 7.302926974261936e-08
, O 0 3.50557871620083e-09
but O 0 2.8093105619575454e-09
the O 0 4.430150468692773e-08
disease O 0 1.772620453266427e-05
is O 0 9.211726492708294e-09
still O 0 1.1307192515630504e-08
substantially O 0 3.456547759128625e-08
under O 0 1.9507554327446996e-07
- O 0 0.054732415825128555
diagnosed O 0 0.00016448882524855435
. O 0 3.447177277848823e-06

The O 0 3.359478114361991e-06
cornerstone O 0 4.008020187029615e-05
of O 0 6.490898840638692e-07
screening O 0 2.84171790099208e-07
and O 0 2.8450852340711208e-08
case O 0 2.3390267500644768e-08
detection O 0 3.19211125088259e-07
is O 0 8.177809540654835e-09
the O 0 1.3657925457266629e-08
measurement O 0 1.1916715436655068e-07
of O 0 8.502980364255563e-08
serum O 0 3.932730976430321e-07
transferrin O 0 6.7231587763672e-07
saturation O 0 6.806945407333842e-07
and O 0 1.0315428511376012e-07
the O 0 3.1109306064536213e-07
serum O 0 2.6458335469214944e-06
ferritin O 0 2.698216303542722e-05
level O 0 4.523745701590087e-06
. O 0 5.234846867097076e-06

Once O 0 8.70369331096299e-06
the O 0 5.116266947879922e-07
diagnosis O 0 9.174989827442914e-06
is O 0 6.526951068508424e-08
suspected O 0 6.130837277851242e-07
, O 0 4.87139999449937e-08
physicians O 0 5.664033508878674e-08
must O 0 1.7880385172475144e-08
use O 0 3.599338072035607e-08
serum O 0 1.0605907618810306e-06
ferritin O 0 1.4556688256561756e-05
levels O 0 1.922838919199421e-06
and O 0 4.066475014496973e-07
hepatic O 1 1.0
iron O 1 0.9989033937454224
stores O 0 1.2415488299666322e-06
on O 0 1.2892985523649259e-06
liver O 1 0.9186689853668213
biopsy O 0 2.0448667328309966e-06
specimens O 0 1.2650448866224906e-07
to O 0 7.835176951687117e-09
assess O 0 5.501835076415773e-08
patients O 0 4.6029891009879975e-09
for O 0 1.8420641678673633e-09
the O 0 3.084890209947844e-08
presence O 0 1.659046233726258e-07
of O 0 5.427672022051411e-06
iron B-Disease 1 0.9999996423721313
overload I-Disease 1 0.9983603358268738
. O 0 2.6119578251382336e-05

Liver O 1 1.0
biopsy O 1 0.8491249084472656
is O 0 2.740631259712245e-07
also O 0 2.551543865081385e-08
used O 0 5.567216909696526e-09
to O 0 5.137160474788516e-09
establish O 0 1.7735757751324854e-08
the O 0 2.7775360678106154e-08
presence O 0 2.3779014313163316e-08
or O 0 1.2798073711906e-08
absence O 0 1.2292214535136736e-07
of O 0 1.2932713389091077e-06
cirrhosis B-Disease 1 1.0
, O 0 3.7516961981509667e-08
which O 0 9.25305521093378e-09
can O 0 7.86659359874875e-09
affect O 0 1.2234066559813073e-07
prognosis O 0 1.1765597264457028e-05
and O 0 1.9770924097883835e-07
management O 0 8.82017320691375e-06
. O 0 5.701389909518184e-06

A O 0 2.6662953587219818e-06
DNA O 0 1.8477732055544038e-07
- O 0 8.35835862744716e-08
based O 0 1.7181235989482957e-08
test O 0 3.896059030950028e-09
for O 0 3.322239150449491e-09
the O 0 7.585821748534727e-08
HFE O 1 0.9960391521453857
gene O 0 3.1769499031497617e-08
is O 0 2.2209365457825925e-09
commercially O 0 9.584089077918634e-09
available O 0 1.6585607331975893e-09
, O 0 8.53079940021928e-10
but O 0 1.834318252846856e-10
its O 0 5.552706627831583e-10
place O 0 3.1139797407320202e-09
in O 0 9.351807106483534e-10
the O 0 5.636172861755995e-09
diagnosis O 0 2.1195008059748943e-07
of O 0 8.84596602190868e-07
hemochromatosis B-Disease 1 1.0
is O 0 8.44284443246579e-07
still O 0 2.1753616863406933e-07
being O 0 2.1650176051934977e-07
evaluated O 0 1.237982928614656e-06
. O 0 9.94637389339914e-07

Currently O 0 4.0609861571283545e-06
, O 0 1.5259411156876013e-07
the O 0 3.883825883121972e-08
most O 0 9.143039214620785e-09
useful O 0 7.820738723296472e-09
role O 0 9.360967112570506e-09
for O 0 1.440556451903774e-09
this O 0 4.580636148165951e-10
test O 0 1.1665604038313404e-09
is O 0 6.756041837086002e-10
in O 0 4.638947004309557e-10
the O 0 2.8121038830875023e-09
detection O 0 1.9698879327734176e-07
of O 0 6.418025009224948e-07
hemochromatosis B-Disease 1 1.0
in O 0 4.36720277718905e-08
the O 0 7.785276068261737e-08
family O 0 8.274239071681677e-09
members O 0 7.311379834895604e-10
of O 0 1.1031155544571902e-08
patients O 0 2.8216402547798225e-09
with O 0 1.0958779439462774e-09
a O 0 1.3067430693070037e-08
proven O 0 1.85522466722432e-07
case O 0 2.3195587672830698e-08
of O 0 1.8641756582837843e-07
the O 0 1.6247445273620542e-06
disease O 0 0.010239033959805965
. O 0 3.695769692058093e-06

It O 0 7.405341762023454e-07
is O 0 1.1184931736352155e-07
crucial O 0 3.2357107215830183e-07
to O 0 2.691649569896981e-07
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 0.9999992847442627
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.3603023588657379
because O 0 3.091865039550612e-07
phlebotomy O 1 0.996819257736206
therapy O 0 1.8178927803091938e-06
can O 0 1.5290462229700097e-08
avert O 0 0.0004995633498765528
serious O 1 1.0
chronic O 1 1.0
disease O 1 1.0
and O 0 1.0558500918023128e-07
can O 0 6.708381405928776e-09
even O 0 1.9093784331403185e-08
lead O 0 2.7047310169336924e-08
to O 0 1.6490698584448182e-08
normal O 0 1.3122884467975382e-07
life O 0 1.0782038373235991e-07
expectancy O 0 1.6950981773788953e-07
. O 0 3.887383215328555e-08
. O 0 9.13307019345666e-07

Prevalence O 0 8.12224461697042e-05
of O 0 3.4608503938216018e-06
the O 0 1.1198503671039362e-06
I1307K O 0 0.00012477680866140872
APC B-Disease 0 1.7322885469184257e-05
gene O 0 6.696022580854333e-08
variant O 0 8.883979063512015e-08
in O 0 2.9664650735838904e-09
Israeli O 0 6.03517591457603e-08
Jews O 0 1.399352633768558e-08
of O 0 3.779223156641365e-09
differing O 0 3.002772697158207e-09
ethnic O 0 3.2883782363768432e-09
origin O 0 1.0359941793325333e-09
and O 0 2.1727186716447022e-09
risk O 0 1.7684084241409437e-07
for O 0 1.2734734582409146e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.3382249714341015e-05

BACKGROUND O 0 0.0001128000658354722
& O 0 1.4269178791437298e-05
AIMS O 0 1.0381593710917514e-05
Israeli O 0 5.096534323456581e-07
Jews O 0 9.74326752611887e-08
of O 0 5.3091078200395714e-08
European O 0 8.775656112902652e-08
birth O 0 2.235323215415974e-08
, O 0 4.715904111662894e-09
i O 0 7.825409653605675e-09
. O 0 1.727003540175076e-09
e O 0 7.389078238162483e-09
. O 0 3.0271436468609636e-09
, O 0 1.044199660071854e-08
Ashkenazim O 0 1.4357207192006172e-06
, O 0 7.931271639449733e-09
have O 0 1.1359997387216936e-09
the O 0 2.1579712239372384e-08
highest O 0 0.2168033868074417
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 1.2940477063239086e-05
of O 0 2.2603363447615266e-07
any O 0 3.182851315841617e-08
Israeli O 0 1.942505321039789e-07
ethnic O 0 3.5307181178723113e-07
group O 0 3.943299020647828e-07
. O 0 1.1145613143526134e-06

The O 0 2.8068756364518777e-05
I1307K O 0 0.00032944121630862355
APC B-Disease 0 7.92600039858371e-05
gene O 0 8.139172678056639e-07
variant O 0 3.863202437059954e-06
was O 0 6.02303373398172e-07
found O 0 8.564408915390231e-08
in O 0 7.692388948044027e-08
6 O 0 5.547764885704964e-06
. O 0 4.409599569044076e-06

1 O 0 1.1973164646406076e-06
% O 0 4.496672190157369e-08
of O 0 3.3974203006437165e-08
American O 0 3.604689879921352e-08
Jews O 0 4.4536356824664836e-08
, O 0 3.0756117652686044e-09
28 O 0 7.363739840116068e-09
% O 0 1.19963061706585e-09
of O 0 4.971097755657183e-09
their O 0 2.0834390213053666e-08
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 3.010642899425875e-07
, O 0 1.614815281492099e-09
but O 0 5.29095656176537e-10
not O 0 2.989382075213598e-10
in O 0 2.563562251367557e-09
non O 0 2.7785117140410875e-07
- O 0 2.3083896394382464e-06
Jews O 0 1.7335210031887982e-06
. O 0 1.3491439858626109e-06

We O 0 2.0127149582549464e-06
assessed O 0 5.022536242904607e-06
the O 0 2.5591137386982155e-07
I1307K O 0 2.9398686365311733e-06
prevalence O 0 1.6747458175814245e-07
in O 0 2.2596620130599376e-09
Israeli O 0 1.503839897054604e-08
Jews O 0 9.850672277877948e-09
of O 0 6.856497591911648e-09
differing O 0 3.9809573415539035e-09
ethnic O 0 5.540332193021413e-09
origin O 0 1.9485004720820598e-09
and O 0 4.2293333279985745e-09
risk O 0 2.0526067601167597e-07
for O 0 9.362055948258785e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.470417868811637e-05

METHODS O 0 8.082050953817088e-06
DNA O 0 2.605079600925819e-07
samples O 0 3.92542744975799e-08
from O 0 5.890210985626254e-09
500 O 0 3.216950617002112e-08
unrelated O 0 5.3387083198686014e-08
Jews O 0 1.4140529636108568e-08
of O 0 1.8573626192619486e-08
European O 0 1.4734482078893052e-08
or O 0 3.863704911566401e-09
non O 0 2.1504767744318087e-08
- O 0 2.1538181016467206e-08
European O 0 9.509033560561875e-09
origin O 0 8.729887368552625e-10
, O 0 1.7631721083155583e-10
with O 0 1.6801153523982038e-10
or O 0 9.91975057651473e-10
without O 0 1.2101099011729843e-09
a O 0 2.5996398367311713e-09
personal O 0 4.16199519293059e-08
and O 0 2.0475500406291758e-08
/ O 0 1.6557884237045073e-06
or O 0 4.288103738758764e-08
family O 0 1.1388228138287104e-08
history O 0 2.4884284854920224e-08
of O 0 7.594972117885845e-08
neoplasia B-Disease 0 0.1372552365064621
, O 0 7.120986467157309e-09
were O 0 4.2169530090063745e-09
examined O 0 2.3658538239601512e-08
for O 0 4.972567690941787e-09
the O 0 2.185241854135711e-08
I1307K O 0 8.957787258623284e-07
variant O 0 5.067077779585816e-08
by O 0 1.5904653150045078e-09
the O 0 1.6284934289956254e-08
allele O 0 3.738837861533284e-08
- O 0 5.189377816350316e-08
specific O 0 3.0618117818903556e-08
oligonucleotide O 0 9.07803269001306e-07
( O 0 7.933619627920052e-08
ASO O 0 0.0014853884931653738
) O 0 3.948458413560729e-07
method O 0 8.021351618481276e-07
. O 0 1.725860670376278e-06

RESULTS O 0 6.42171335130115e-06
In O 0 7.611896535308915e-08
persons O 0 1.5033091216309913e-08
at O 0 1.057903808998617e-08
average O 0 9.582663551555015e-09
risk O 0 2.7647397260466278e-08
for O 0 1.265217264290186e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 5.795609467895702e-07
I1307K O 0 2.0213834432070144e-05
was O 0 2.584863523225067e-07
found O 0 3.5667870434963334e-08
in O 0 3.066218212666172e-08
5 O 0 1.5947940710248076e-06
. O 0 2.0935226530127693e-06

0 O 0 1.8440427993482444e-06
% O 0 7.119780320863356e-08
of O 0 1.0379412174188474e-07
120 O 0 3.0218470215004345e-07
European O 0 5.51077221189189e-07
and O 0 2.745680092175462e-07
1 O 0 9.267077984986827e-06
. O 0 6.321292858046945e-06

6 O 0 3.2155753615370486e-06
% O 0 7.961421033542138e-08
of O 0 5.719639517565156e-08
188 O 0 1.261190050172445e-07
non O 0 1.948215810898546e-07
- O 0 3.9408669749718683e-07
European O 0 3.3769219953683205e-07
Jews O 0 8.380467875213071e-08
( O 0 1.7634226523455254e-08
P O 0 5.47948616258509e-07
= O 0 3.0403032980075295e-08
0 O 0 3.282608318500024e-08
. O 0 3.3759679496370154e-08
08 O 0 4.758481736644171e-06
) O 0 4.406049924909894e-07
. O 0 3.7759580209240085e-06

It O 0 2.5501803975203075e-06
occurred O 0 1.0986242386934464e-06
in O 0 1.8483160602045245e-07
15 O 0 3.7191407500358764e-06
. O 0 4.0063659980660304e-06

4 O 0 1.8388620901532704e-06
% O 0 4.3140680361375416e-08
of O 0 5.696786331554904e-08
52 O 0 1.3838787538134056e-07
Ashkenazi O 0 4.467665633001161e-07
Israelis O 0 1.7347336722650653e-07
with O 0 7.596913320639942e-08
familial O 1 0.9999992847442627
cancer B-Disease 1 1.0
( O 0 6.967384535983001e-08
P O 0 5.141750989423599e-07
= O 0 6.807307162404186e-09
0 O 0 4.506672812709667e-09
. O 0 9.939711276274465e-10
02 O 0 2.193121702021017e-07
) O 0 1.6971540839350041e-09
and O 0 5.244340517407409e-09
was O 0 3.065726872364394e-08
not O 0 1.4726411201593237e-09
detected O 0 9.0112521888841e-09
in O 0 2.0332546757373393e-09
51 O 0 4.30866542444619e-08
non O 0 5.109031420147403e-08
- O 0 1.1366791596856274e-07
European O 0 5.674435854530202e-08
Jews O 0 4.497495709188115e-08
at O 0 5.108202927317507e-08
increased O 0 2.0703080849671096e-07
cancer B-Disease 0 1.2326779142313171e-05
risk O 0 1.3701678653887939e-06
. O 0 1.0062543651656597e-06

Colorectal B-Disease 1 1.0
neoplasia I-Disease 1 1.0
occurred O 0 6.624427896895213e-06
personally O 0 1.8828499150913558e-06
or O 0 3.444471019520279e-08
in O 0 3.764683231821664e-09
the O 0 7.850135652631707e-09
families O 0 3.282586702457735e-10
of O 0 4.363553518516028e-09
13 O 0 8.78653860780787e-09
of O 0 1.800784232841579e-08
20 O 0 4.862980063080613e-08
Ashkenazi O 0 1.4556911764884717e-07
I1307K O 0 4.676325318087038e-07
carriers O 0 8.815797869488051e-09
, O 0 2.7052662332494037e-09
8 O 0 1.6403207681037202e-08
of O 0 4.012787258034223e-08
whom O 0 2.392723885691339e-08
also O 0 1.9377385029883953e-08
had O 0 3.2730056886975945e-08
a O 0 1.796345117099918e-08
personal O 0 1.2739019439322874e-07
or O 0 3.4570685869539375e-08
family O 0 5.3103335062587576e-08
history O 0 2.872754123472987e-07
of O 0 1.82068276899372e-06
noncolonic O 1 0.8604471683502197
neoplasia B-Disease 1 0.999566376209259
. O 0 1.8927819837699644e-05

CONCLUSIONS O 0 6.427055632229894e-05
The O 0 9.324747225036845e-06
I1307K O 0 0.0003101204929407686
APC O 0 9.057408897206187e-05
variant O 0 1.5578087186440825e-05
may O 0 4.1483477986048456e-08
represent O 0 6.764478754917036e-09
a O 0 6.347927961058986e-09
susceptibility O 0 1.9593133515627414e-07
gene O 0 1.877952193751753e-08
for O 0 3.965862660493258e-08
colorectal B-Disease 1 1.0
, I-Disease 0 1.8493510367534327e-07
or I-Disease 0 1.6384539947011945e-08
other I-Disease 0 9.133661826865591e-09
, I-Disease 0 7.83241294044501e-09
cancers I-Disease 0 1.0501856877453974e-06
in O 0 3.176984675334893e-09
Ashkenazi O 0 3.627534113093134e-07
Jews O 0 4.486357596533708e-08
, O 0 4.291906385844868e-09
and O 0 5.8547713344125896e-09
partially O 0 3.512287491957977e-07
explains O 0 2.82507741644622e-08
the O 0 4.056804225882615e-09
higher O 0 1.1710463709846408e-08
incidence O 0 6.259726887947181e-07
of O 0 6.919332372490317e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 4.0658005673321895e-07
European O 0 1.4490996136373724e-06
Israelis O 0 1.3322211316335597e-06
. O 0 1.595429807821347e-06

Systematic O 0 6.312545338005293e-06
analysis O 0 3.7322905654946226e-07
of O 0 4.970711984242371e-07
coproporphyrinogen O 1 0.9150996804237366
oxidase O 0 3.6249213735572994e-05
gene O 0 3.8637363104498945e-06
defects O 0 0.00041546442662365735
in O 0 1.9053773314681166e-07
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
and O 0 1.0154442861676216e-05
mutation O 0 4.877480478171492e-06
update O 0 9.010067515191622e-06
. O 0 6.422515525628114e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 2.1658614059560932e-05
HC B-Disease 1 1.0
) O 0 1.7262244682569872e-06
is O 0 8.319025823766424e-08
an O 0 5.748205822442287e-08
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.06277074664831161
autosomal O 1 1.0
dominant O 1 0.9999996423721313
inheritance O 0 0.0010150253074243665
caused O 0 5.834384637637413e-07
by O 0 1.5335997360921283e-08
deficient B-Disease 0 1.4735247759745107e-06
activity I-Disease 0 5.078882736597734e-08
of I-Disease 0 3.1426702662429307e-07
coproporphyrinogen I-Disease 1 0.5932018756866455
III I-Disease 1 1.0
oxidase I-Disease 0 8.821805749903433e-06
( O 0 3.7157548149480135e-07
CPO O 0 0.002422054996713996
) O 0 1.7489123820269015e-06
. O 0 4.361968422017526e-06

Clinical O 0 0.012297084555029869
manifestations O 0 0.24448207020759583
of O 0 2.976465293613728e-05
the O 0 6.8034546529816e-06
disease O 1 0.9999016523361206
are O 0 5.453084650497431e-09
characterized O 0 3.077784782590243e-08
by O 0 3.5311193968823318e-09
acute O 0 0.0020249623339623213
attacks O 0 6.375730094987375e-07
of O 1 0.9999998807907104
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 1.8906251852968126e-07
precipitated O 0 1.5052953017402615e-07
by O 0 1.8259623812966197e-09
drugs O 0 5.480688614056817e-08
, O 0 1.3546935129227222e-08
fasting O 0 1.275389820420969e-07
, O 0 4.96020824414245e-08
cyclical O 0 0.0058704642578959465
hormonal O 0 9.676513400336262e-06
changes O 0 5.5350746208659984e-08
, O 0 3.376496238161053e-08
or O 0 2.5767636202544963e-07
infectious B-Disease 1 0.999998927116394
diseases I-Disease 1 0.9999866485595703
. O 0 6.501345524156932e-06

Skin O 1 1.0
photosensitivity O 1 1.0
may O 0 3.8109665183583274e-06
also O 0 5.35091146502964e-07
be O 0 9.98528690843159e-08
present O 0 9.421493132322212e-07
. O 0 3.964557890867582e-06

The O 0 4.523987172433408e-06
seven O 0 9.679896493253182e-07
exons O 0 4.007757070212392e-06
, O 0 1.6268286628928763e-07
the O 0 4.175416847829183e-07
exon O 0 1.1526407433848362e-05
/ O 0 2.7898756798094837e-06
intron O 0 2.391691850789357e-06
boundaries O 0 5.788760404357163e-08
and O 0 6.375593830654225e-09
part O 0 3.1527079613624664e-08
of O 0 5.8505655431417836e-08
3 O 0 8.159413056318954e-08
noncoding O 0 4.979175969310745e-07
sequence O 0 1.8513745203563303e-08
of O 0 3.2839675867535334e-08
the O 0 4.662582853143249e-08
CPO O 0 0.00010973854659823701
gene O 0 4.57737421299953e-08
were O 0 1.4472578691027138e-08
systematically O 0 3.88716117072363e-08
analyzed O 0 1.4279244453518913e-08
by O 0 1.4517940183367273e-09
an O 0 1.0020006158129036e-08
exon O 0 1.1538719490999938e-06
- O 0 3.5773311424236454e-07
by O 0 4.856852697798786e-08
- O 0 5.084687018097611e-06
exon O 0 2.2336615074891597e-05
denaturing O 0 2.9784301659674384e-05
gradient O 0 2.5093627300520893e-06
gel O 0 2.4383680283790454e-06
electrophoresis O 0 6.234407123884012e-07
( O 0 4.488702742833084e-08
DGGE O 0 0.0056786383502185345
) O 0 2.5754239629804943e-08
strategy O 0 5.15298275161058e-08
followed O 0 5.672398550871094e-09
by O 0 1.1207366146237518e-09
direct O 0 8.259417150213721e-09
sequencing O 0 3.8866346585564315e-08
in O 0 1.0515066151128849e-08
seven O 0 4.551187515744459e-08
unrelated O 0 8.757018008509476e-07
heterozygous O 0 3.776592052417982e-07
HC B-Disease 1 1.0
patients O 0 4.644245876761488e-08
from O 0 5.136298497632197e-09
France O 0 2.2733851778866665e-07
, O 0 2.006220256589586e-08
Holland O 0 1.006060642794182e-06
, O 0 2.7429052806837717e-08
and O 0 7.230053000739645e-08
Czech O 0 9.628706175135449e-05
Republic O 0 5.426477946457453e-05
. O 0 1.5054006325954106e-05

Seven O 0 5.151969162398018e-06
novel O 0 2.9176558200560976e-06
mutations O 0 7.910772836794422e-08
and O 0 1.1597921734107786e-08
two O 0 6.152505616086046e-09
new O 0 4.431621292155796e-08
polymorphisms O 0 6.351236834234442e-07
were O 0 1.7453773182296572e-07
detected O 0 1.8741916392173152e-06
. O 0 2.488035534042865e-06

Among O 0 1.2260269386388245e-06
these O 0 6.916857131500365e-08
mutations O 0 2.123040587775904e-08
two O 0 4.095021655103892e-09
are O 0 3.585358676616579e-09
missense O 0 4.3626656065498537e-07
( O 0 2.6043213807724896e-08
G197W O 0 6.752229182893643e-06
, O 0 3.694180250590762e-08
W427R O 0 1.6310195860569365e-06
) O 0 1.0347623202733303e-08
, O 0 5.959756244067194e-09
two O 0 2.896244133410164e-09
are O 0 3.1910012410207855e-09
nonsense O 0 4.0995536210175487e-07
( O 0 1.7903454718748435e-08
Q306X O 0 3.9374813241011e-06
, O 0 2.455378300680877e-08
Q385X O 0 1.1551534271347919e-06
) O 0 1.2900541968008383e-08
, O 0 7.605087226636442e-09
two O 0 2.0576891301971045e-09
are O 0 1.449185216273463e-09
small O 0 2.040162705441162e-08
deletions O 0 3.517449442824727e-07
( O 0 2.832183021439505e-08
662de14bp O 0 1.8542248199082678e-06
; O 0 2.3207977761785514e-08
1168del3bp O 0 2.3748839339532424e-06
removing O 0 5.509279503712605e-07
a O 0 3.426418970775558e-08
glycine O 0 1.4555357097378874e-07
at O 0 6.692613396808156e-08
position O 0 3.212443999700554e-08
390 O 0 6.936303975635383e-08
) O 0 2.8312687749831866e-09
, O 0 3.47523432253638e-09
and O 0 2.4022066558160304e-09
one O 0 2.8010229691233235e-09
is O 0 1.1189168480640888e-09
a O 0 3.5963718669762557e-09
splicing O 0 1.1070511618527235e-07
mutation O 0 2.9109106236546722e-08
( O 0 1.4639042866804175e-08
IVS1 O 0 0.094223253428936
- O 0 1.8655588291949243e-06
15c O 0 4.465090114535997e-06
- O 0 7.39649806291709e-07
- O 0 7.204695293694385e-07
> O 0 2.903835536471888e-07
g O 0 7.848941407928578e-08
) O 0 3.791496894223201e-09
which O 0 3.1948927947667016e-09
creates O 0 4.078148663211323e-08
a O 0 7.89656873223521e-09
new O 0 2.322214953665025e-08
acceptor O 0 1.093302586241407e-07
splice O 0 8.399369107792154e-06
site O 0 5.982724815112306e-06
. O 0 2.8247111458767904e-06

The O 0 2.8997944809816545e-06
pathological O 0 1.1873944458784536e-05
significance O 0 1.6755554952396778e-06
of O 0 5.397910172177944e-07
the O 0 2.8298563847783953e-07
point O 0 1.0750860610642121e-06
mutations O 0 4.662885189077315e-08
G197W O 0 9.161884690911393e-07
, O 0 1.6418921333638536e-08
W427R O 0 8.633116976852762e-07
, O 0 9.104198284148879e-09
and O 0 6.425475707061423e-09
the O 0 1.2619596034824099e-08
in O 0 7.516814726216126e-09
- O 0 5.165302923160198e-07
frame O 0 7.828024308764725e-07
deletion O 0 4.3956498529951205e-07
390delGly O 0 7.115747280295182e-07
were O 0 6.251933193368586e-09
assessed O 0 2.8275788821474634e-08
by O 0 1.206362787442572e-09
their O 0 2.770333740187425e-09
respective O 0 2.04924948121743e-08
expression O 0 9.753527763223246e-09
in O 0 4.722799484824236e-09
a O 0 1.3481078475763297e-08
prokaryotic O 0 8.921284688767628e-08
system O 0 4.0317289062841155e-08
using O 0 2.8193337442417032e-08
site O 0 3.8294339788080833e-07
- O 0 5.166317578186863e-07
directed O 0 1.7419995401724009e-06
mutagenesis O 0 0.00016028042591642588
. O 0 6.678715180896688e-06

These O 0 6.801961944802315e-07
mutations O 0 2.6782478812492627e-07
resulted O 0 7.802371726484125e-08
in O 0 7.036199178855895e-09
the O 0 3.7340203817848305e-08
absence O 0 9.405874834556016e-08
or O 0 1.782447434095502e-08
a O 0 3.408818471939412e-08
dramatic O 0 3.1781326015334344e-07
decrease O 0 4.3701280105779006e-07
of O 0 1.2891043752460973e-06
CPO O 1 0.9997147917747498
activity O 0 4.821382844966138e-06
. O 0 3.6646736134571256e-06

The O 0 2.541849653425743e-06
two O 0 1.2572296270718653e-07
polymorphisms O 0 2.681278772342921e-07
were O 0 2.3979140451046987e-08
localized O 0 5.828900953019911e-07
in O 0 2.1751578316298037e-08
noncoding O 0 1.1613525430220761e-06
part O 0 1.3094405915126117e-07
of O 0 1.4736990294750285e-07
the O 0 3.7350602610786154e-08
gene O 0 1.0023083696353297e-08
1 O 0 3.446206164881005e-08
) O 0 5.651372259052323e-09
a O 0 2.2191295911966336e-08
C O 0 9.150865025731036e-07
/ O 0 2.918436052823381e-07
G O 0 3.17607202759973e-07
polymorphism O 0 3.652671942688812e-09
in O 0 3.02820613029553e-09
the O 0 3.529963166215566e-08
promotor O 0 4.106852793483995e-05
region O 0 4.199469287868851e-07
, O 0 5.466020880362521e-08
142 O 0 3.2369914038099523e-07
bp O 0 2.9918726340838475e-07
upstream O 0 2.7018029413738986e-07
from O 0 7.25236937171303e-09
the O 0 1.683703487742605e-08
transcriptional O 0 4.8318316459017296e-08
initiation O 0 1.0437839392807291e-07
site O 0 1.4472377074525866e-07
( O 0 1.2445007691042065e-08
- O 0 4.463806817511795e-07
142C O 0 3.835318238998298e-06
/ O 0 5.737350079471071e-07
G O 0 9.860372074399493e-07
) O 0 6.56679466359833e-09
, O 0 6.209755376573867e-09
and O 0 5.039528794270609e-09
2 O 0 6.787382034190159e-08
) O 0 8.78858319453002e-09
a O 0 2.170847324123315e-08
6 O 0 1.7668071450316347e-07
bp O 0 1.551515254050173e-07
deletion O 0 3.493485678518482e-08
polymorphism O 0 4.824848520712521e-09
in O 0 2.6009245868152675e-09
the O 0 1.2505398494511155e-08
3 O 0 5.196053365352782e-08
noncoding O 0 6.424498337764817e-07
part O 0 6.77862388442918e-08
of O 0 1.130844751173754e-07
the O 0 1.1031560376295602e-07
CPO O 0 0.006836592219769955
gene O 0 1.5865022362504533e-07
, O 0 4.2084138840436935e-08
574 O 0 8.630672709841747e-07
bp O 0 1.6864875362898601e-07
downstream O 0 1.2157245521393634e-07
of O 0 3.074223542398613e-08
the O 0 1.4740582088279552e-08
last O 0 6.971847987813362e-09
base O 0 3.812732884966863e-08
of O 0 5.8884950249193935e-08
the O 0 7.43943928682711e-08
normal O 0 1.1114413922541644e-07
termination O 0 4.515619025369233e-07
codon O 0 1.1861570783366915e-06
( O 0 8.600750334153417e-08
+ O 0 9.913645726555842e-07
574 O 0 3.96504947275389e-06
delATTCTT O 0 3.2233318052021787e-05
) O 0 7.12889800524863e-07
. O 0 5.018897354602814e-06

Five O 0 1.2008158591925167e-05
intragenic O 0 0.000234608247410506
dimorphisms O 0 7.009828550508246e-05
are O 0 3.450257324288941e-08
now O 0 2.203549165358254e-08
well O 0 8.581524824080589e-09
characterized O 0 3.4386552272280824e-08
and O 0 9.406355694352442e-09
the O 0 2.0217624907559184e-08
high O 0 1.1688153023214909e-07
degree O 0 3.340948140362343e-08
of O 0 5.774435862804239e-08
allelic O 0 4.07483958042576e-06
heterogeneity O 0 2.810577143463888e-06
in O 0 9.746464257887055e-08
HC B-Disease 1 1.0
is O 0 1.0946630624175668e-07
demonstrated O 0 1.8681742375292743e-08
with O 0 1.5042864731640293e-09
seven O 0 3.4162108697444182e-09
new O 0 1.0102769731901162e-09
different O 0 3.299452933092084e-10
mutations O 0 9.483345220218098e-10
making O 0 1.2620022804554765e-09
a O 0 1.1775367347865995e-09
total O 0 4.041520451636416e-09
of O 0 5.34893125347935e-08
nineteen O 0 3.5589939670899184e-06
CPO O 1 1.0
gene B-Disease 0 3.101188121945597e-05
defects I-Disease 0 0.005070487502962351
reported O 0 3.133631309992779e-08
so O 0 1.2156163187171387e-08
far O 0 5.239144584834321e-08
. O 0 1.1175528413787106e-07
. O 0 1.719873353067669e-06

Coincidence O 0 1.0954940989904571e-05
of O 0 1.0459976920174086e-06
two O 0 8.384097327507334e-08
novel O 0 2.045147539320169e-06
arylsulfatase O 0 1.3718773516302463e-05
A O 0 9.934486797646969e-07
alleles O 0 8.506760451609807e-08
and O 0 4.158440347623582e-08
mutation O 0 2.706785551254143e-07
459 O 0 1.7336996052108589e-06
+ O 0 1.0314046221537865e-06
1G O 0 0.0007871984271332622
> O 0 1.0295844958818634e-06
A O 0 4.268495104042813e-07
within O 0 2.5969205452724964e-08
a O 0 1.9415269392197843e-08
family O 0 2.333434601098361e-08
with O 0 6.860032897293422e-08
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 2.4229225914496055e-07
molecular O 0 2.9064730711070297e-07
basis O 0 9.319674632024544e-08
of O 0 3.2709903052818845e-07
phenotypic O 0 2.9462507882271893e-05
heterogeneity O 0 8.409589645452797e-05
. O 0 8.734558832657058e-06

In O 0 5.117067303217482e-07
a O 0 8.575180743264355e-08
family O 0 1.8509437538227758e-08
with O 0 5.9072786662284216e-09
three O 0 4.3754823764174944e-08
siblings O 0 1.8684846736505278e-07
, O 0 8.17041989620293e-09
one O 0 6.399790475342115e-09
developed O 0 1.7208851232908273e-08
classical O 0 3.6871762176815537e-07
late O 0 3.6207666198606603e-07
infantile O 1 0.9999879598617554
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 7.31716170321306e-07
MLD B-Disease 1 1.0
) O 0 1.4160778505356575e-07
, O 0 3.9783330407772155e-08
fatal O 0 4.738492691558349e-07
at O 0 4.9647514543949e-08
age O 0 2.3983622199352794e-08
5 O 0 1.519585701714732e-08
years O 0 3.743402920974859e-09
, O 0 2.11991557641511e-09
with O 0 7.289160386392268e-09
deficient O 0 8.146588697854895e-06
arylsulfatase O 0 0.0347217433154583
A O 0 2.1729660147684626e-05
( O 0 1.2617289257832454e-07
ARSA O 1 0.9939171671867371
) O 0 1.601583399235551e-08
activity O 0 6.026650289925328e-09
and O 0 2.4283266508717816e-09
increased O 0 4.8943945785140386e-08
galactosylsulfatide O 0 3.637584813986905e-05
( O 0 5.648475962516386e-07
GS O 1 0.9999998807907104
) O 0 8.775653554948804e-07
excretion O 0 1.4918906344973948e-05
. O 0 2.4746984763623914e-06

The O 0 8.34097363622277e-07
two O 0 2.7737030450225575e-08
other O 0 4.000414577376432e-08
siblings O 0 2.1635150915244594e-07
, O 0 2.5177708806722876e-08
apparently O 0 7.899163279034838e-08
healthy O 0 2.060969883643793e-08
at O 0 2.2422321777071375e-08
12 O 0 3.475468091096445e-08
( O 0 2.432276158259583e-09
1 O 0 5.341091124932973e-08
/ O 0 6.08171077942643e-08
2 O 0 3.0014859930815874e-08
) O 0 1.4312365737012556e-09
and O 0 1.3565001344417738e-09
15 O 0 5.005549752468141e-09
years O 0 2.4016797439685433e-09
, O 0 9.408056556026168e-10
respectively O 0 3.283314509161528e-09
, O 0 1.2871679277992598e-09
and O 0 2.2454451631404027e-09
their O 0 1.8333328188901987e-09
father O 0 4.2250061227377955e-08
, O 0 1.953472761329067e-08
apparently O 0 5.507294531525986e-08
healthy O 0 7.743244267999216e-09
as O 0 2.603654403188216e-09
well O 0 4.8884118974967805e-09
, O 0 7.3873591688311535e-09
presented O 0 2.5929247726708127e-07
ARSA O 1 0.9999948740005493
and O 0 3.6183951124257874e-07
GS O 1 0.9999991655349731
values O 0 2.9791680233870466e-08
within O 0 7.832233528404231e-09
the O 0 7.0120833584041975e-09
range O 0 1.88781456245124e-07
of O 0 5.112141252539004e-07
MLD B-Disease 1 1.0
patients O 0 7.178836767707253e-06
. O 0 3.98754400521284e-06

Mutation O 0 1.3306504342835979e-06
screening O 0 2.8590281431206677e-07
and O 0 2.6504899608426058e-08
sequence O 0 1.6099292565741052e-08
analysis O 0 4.0161998171583946e-09
disclosed O 0 3.3765605422786393e-08
the O 0 1.4111726898136112e-08
involvement O 0 2.974540436184725e-08
of O 0 4.9941942137365913e-08
three O 0 1.3634473994272867e-08
different O 0 2.201952398195317e-08
ARSA O 1 0.9995961785316467
mutations O 0 5.3887863060708696e-08
being O 0 1.3781255248090929e-08
the O 0 1.3906546136865927e-08
molecular O 0 4.6469928349779366e-08
basis O 0 2.1057235954913267e-08
of O 0 1.5248559748215484e-07
intrafamilial O 0 5.491874253493734e-05
phenotypic O 0 3.215055039618164e-05
heterogeneity O 0 0.00011672484833979979
. O 0 1.4232104149414226e-05

The O 0 6.7880955612054095e-06
late O 0 2.625922206789255e-06
infantile O 0 0.0008361316868104041
patient O 0 1.287620079892804e-06
inherited O 0 2.783624950097874e-06
from O 0 5.405225778076783e-08
his O 0 4.5734995524071564e-07
mother O 0 1.1442370606573604e-07
the O 0 5.8641283828819724e-08
frequent O 0 1.0382065340763802e-07
0 O 0 1.616823084304997e-07
- O 0 4.4429285139813146e-07
type O 0 5.995433980388043e-07
mutation O 0 1.594819849515261e-07
459 O 0 6.105316288085305e-07
+ O 0 1.763214925176726e-07
1G O 0 1.551489913254045e-05
> O 0 1.549654911059406e-07
A O 0 1.0908030390055501e-07
, O 0 4.36864189268249e-09
and O 0 1.5636913985872525e-09
from O 0 3.495550293663996e-09
his O 0 3.6166522221492414e-08
father O 0 5.927246604642278e-08
a O 0 1.675048544313995e-08
novel O 0 1.642550699898493e-07
, O 0 1.918460945660172e-08
single O 0 4.34131592896847e-08
basepair O 0 2.177413307435927e-06
microdeletion O 0 8.259503374574706e-06
of O 0 5.120381842971256e-07
guanine O 0 5.01470708513807e-07
at O 0 1.8976700744133268e-07
nucleotide O 0 7.888564113045504e-08
7 O 0 9.185131943922897e-08
in O 0 2.135337595632336e-08
exon O 0 1.7495714246251737e-06
1 O 0 6.546587769662437e-07
( O 0 8.610762591843013e-08
7delG O 0 9.525694622425362e-06
) O 0 5.314437316883414e-07
. O 0 3.1295662665797863e-06

The O 0 4.107213953830069e-06
two O 0 3.5898668215850194e-07
clinically O 0 1.7056925571523607e-05
unaffected O 0 1.782704543984437e-06
siblings O 0 2.492286057531601e-07
carried O 0 4.7595161589697454e-08
the O 0 6.92283563807905e-08
maternal O 0 4.4976928847972886e-07
mutation O 0 1.780484382152281e-07
459 O 0 8.702363061274809e-07
+ O 0 4.3702942775780684e-07
1G O 0 7.727216143393889e-05
> O 0 2.489587416221184e-07
A O 0 1.3341595206384227e-07
and O 0 5.876632513945879e-09
, O 0 1.91141813488116e-09
on O 0 1.0520803783720112e-08
their O 0 2.18667506324266e-09
paternal O 0 8.649378457903367e-08
allele O 0 2.557473521846987e-08
, O 0 7.863263817853294e-09
a O 0 2.8341986535451724e-08
novel O 0 2.753512831077387e-07
cytosine O 0 2.759893504844513e-07
to O 0 4.039780421294381e-08
thymidine O 0 1.4773029306525132e-06
transition O 0 1.9055698885495076e-07
at O 0 2.6527817453825264e-07
nucleotide O 0 4.769112820213195e-07
2435 O 0 1.3832252079737373e-05
in O 0 4.4409116384258596e-08
exon O 0 7.945845936774276e-07
8 O 0 1.1226032370359462e-07
, O 0 1.1978135816548274e-08
resulting O 0 1.1910132435843934e-08
in O 0 2.356296491257126e-09
substitution O 0 4.6990443536287785e-08
of O 0 1.29860382003244e-07
alanine O 0 1.4382696917891735e-06
464 O 0 1.09094924027886e-06
by O 0 7.429130732816702e-08
valine O 0 5.957560279057361e-05
( O 0 5.58094427560718e-07
A464V O 0 5.858104123035446e-05
) O 0 8.22709239400865e-07
. O 0 4.638474820239935e-06

The O 0 1.721342596283648e-05
fathers O 0 4.089645699423272e-06
genotype O 0 3.7213867472019047e-06
thus O 0 5.151120490154426e-07
was O 0 3.641287548816763e-06
7delG O 0 0.0001511213049525395
/ O 0 0.0002451931650284678
A464V O 0 0.0008769353153184056
. O 0 2.9350867407629266e-05

Mutation O 0 4.147794243181124e-05
A464V O 0 7.488534902222455e-05
was O 0 1.2932046047353651e-06
not O 0 1.7700275023457834e-08
found O 0 1.1264162935731292e-08
in O 0 8.00011257240385e-09
18 O 0 4.333841445713915e-07
unrelated O 0 4.2067826143465936e-05
MLD B-Disease 1 1.0
patients O 0 7.279575697793916e-07
and O 0 1.1906639230119254e-07
50 O 0 1.0337581670682994e-06
controls O 0 2.8200331144034863e-05
. O 0 8.933098797569983e-06

A464V O 0 0.0003880272852256894
, O 0 1.0555132803347078e-06
although O 0 2.4297000322803797e-07
clearly O 0 4.458914020233351e-07
modifying O 0 4.714288479590323e-06
ARSA O 1 1.0
and O 0 2.290814336447511e-06
GS O 1 1.0
levels O 0 1.7347812217849423e-06
, O 0 3.739972243010925e-08
apparently O 0 1.552951118810597e-07
bears O 0 5.946678243162751e-07
little O 0 6.422219200885593e-08
significance O 0 1.5145023724016937e-07
for O 0 1.3901162887464125e-08
clinical O 0 2.670794856385328e-07
manifestation O 0 3.0083406272751745e-06
of O 0 3.73261104869016e-06
MLD B-Disease 1 1.0
, O 0 1.088252702174941e-06
mimicking O 0 4.796754637936829e-06
the O 0 7.719446557530318e-07
frequent O 0 9.422595212527085e-06
ARSA O 1 0.99974125623703
pseudodeficiency O 0 0.002065767999738455
allele O 0 6.0952854255447164e-05
. O 0 1.1043639460694976e-05

Our O 0 7.144509254430886e-06
results O 0 2.7167035909769766e-07
demonstrate O 0 5.361954791283097e-08
that O 0 2.2296036128466312e-09
in O 0 1.8443879756802062e-09
certain O 0 1.0295375219016023e-08
genetic O 0 5.610884201701083e-08
conditions O 0 1.2044095853980252e-07
MLD B-Disease 1 1.0
- O 0 0.2050550878047943
like O 0 2.220229589511291e-06
ARSA O 1 1.0
and O 0 7.719261816419021e-07
GS O 1 0.9999998807907104
values O 0 3.2891328771711414e-08
need O 0 4.644013174015527e-09
not O 0 8.561901743142641e-10
be O 0 1.8934025458605674e-09
paralleled O 0 4.6041417789410843e-08
by O 0 3.964960804125894e-09
clinical O 0 0.00014080802793614566
disease O 0 0.010143157094717026
, O 0 1.216024436700991e-08
a O 0 1.1147550438295184e-08
finding O 0 1.8555530445496515e-08
with O 0 6.347371073189834e-09
serious O 0 1.2757442391375662e-06
diagnostic O 0 1.2839369446737692e-05
and O 0 4.436670337781834e-07
prognostic O 1 1.0
implications O 0 0.00038371936534531415
. O 0 5.137548669154057e-06

Moreover O 0 1.616151348571293e-05
, O 0 8.142006890921039e-07
further O 0 2.424686954327626e-06
ARSA O 0 0.42499130964279175
alleles O 0 6.784994184272364e-07
functionally O 0 3.345039374380576e-07
similar O 0 1.2148026584668514e-08
to O 0 2.0257035160398118e-08
A464V O 0 5.272564521874301e-06
might O 0 2.2558563017582856e-08
exist O 0 7.728430340137038e-09
which O 0 2.299681112205576e-09
, O 0 3.201602982727536e-09
together O 0 1.3003103038755626e-09
with O 0 1.1904016661290484e-09
0 O 0 5.405400926861148e-08
- O 0 3.100084882134979e-07
type O 0 4.46850947355415e-07
mutations O 0 2.9725610417585813e-08
, O 0 4.525545715949875e-09
may O 0 6.260321150364234e-09
cause O 0 1.512412381998729e-07
pathological O 1 0.9999427795410156
ARSA O 1 1.0
and O 0 4.042674390802858e-06
GS O 1 1.0
levels O 0 2.998170600676531e-07
, O 0 3.604131437739966e-09
but O 0 1.7739404389871538e-09
not O 0 1.090623147348424e-09
clinical O 0 9.948976043006041e-08
outbreak O 0 6.362476057120148e-08
of O 0 1.3560072886775743e-07
the O 0 4.382732186059002e-07
disease O 0 3.6400422686710954e-05
. O 0 1.8099477472333092e-07
. O 0 1.357649694000429e-06

Human O 1 0.999880313873291
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.08336979895830154
to O 0 5.6524272622482385e-06
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
and O 0 1.1575660209928174e-05
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 0.039998434484004974
1 I-Disease 0 0.0001635233056731522
. O 0 5.313379460858414e-06

Heterozygous O 0 9.454399696551263e-05
germ O 0 0.000146371268783696
- O 0 1.05788822111208e-05
line O 0 1.6224529417740996e-06
mutations O 0 6.379184469551546e-08
in O 0 5.497499788731375e-09
the O 0 2.3519557856843676e-08
DNA O 0 1.1269023758586627e-07
mismatch O 0 9.600367775419727e-06
repair O 0 1.7597656096768333e-06
genes O 0 8.379156923865594e-08
lead O 0 7.129238355219059e-08
to O 0 1.5424332389102346e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0001465139794163406

The O 0 6.770806521672057e-06
disease O 0 3.279577140347101e-05
susceptibility O 0 1.1196185596418218e-06
of O 0 1.2715511275018798e-06
individuals O 0 2.377026220301559e-08
who O 0 6.78608813586834e-08
constitutionally O 0 6.883322498651978e-07
lack O 0 1.2052643683091446e-07
both O 0 2.0526803368170476e-08
wild O 0 9.82564074547554e-07
- O 0 6.467665230047714e-07
type O 0 3.4976935125996533e-07
alleles O 0 8.799506190371176e-08
is O 0 3.8734096818870967e-08
unknown O 0 7.102350991772255e-07
. O 0 8.521747076883912e-07

We O 0 7.338336445172899e-07
have O 0 1.933459792269332e-08
identified O 0 2.8699986387437093e-08
three O 0 7.173484029010524e-09
offspring O 0 3.237861534444164e-08
in O 0 2.7902515853384102e-09
a O 0 9.065006878472559e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0013590201269835234
who O 0 4.0603018192086893e-07
developed O 0 2.752496357061318e-06
hematological B-Disease 1 1.0
malignancy I-Disease 1 0.9999994039535522
at O 0 2.0215162521708407e-07
a O 0 8.216458624588086e-09
very O 0 1.0917449166925053e-09
early O 0 6.2642033782367434e-09
age O 0 1.341789523934267e-08
, O 0 2.1302068997641754e-09
and O 0 2.2759518714110527e-09
at O 0 1.4811066151310115e-08
least O 0 9.277491552772688e-10
two O 0 3.9013067776316745e-10
of O 0 3.4113860625240022e-09
them O 0 2.0655377408473896e-09
displayed O 0 7.868607809768946e-08
signs O 0 3.5404150366957765e-07
of O 0 3.8193240925465943e-07
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 4.062036168761551e-06
1 I-Disease 0 4.91990886075655e-06
( O 0 2.2377618336122396e-07
NF1 B-Disease 1 0.8343151211738586
) O 0 6.267492835831945e-07
. O 0 2.5794163320824737e-06

DNA O 0 1.5477629631277523e-06
sequence O 0 6.163301691231027e-08
analysis O 0 7.155787073997999e-09
and O 0 4.6541219766993436e-09
allele O 0 2.3088857048492173e-08
- O 0 3.140242910149027e-08
specific O 0 1.4824773408861347e-08
amplification O 0 6.362051863106899e-08
in O 0 5.958665116878592e-09
two O 0 1.1733851223993952e-08
siblings O 0 1.1649738240748775e-07
revealed O 0 1.1170925517944852e-07
a O 0 1.415991448538989e-07
homozygous O 0 4.410381734487601e-06
MLH1 O 1 0.8212487697601318
mutation O 0 5.51443122276396e-07
( O 0 5.403432012940357e-08
C676T O 0 1.5677731425967067e-05
- O 0 8.525529665348586e-06
- O 0 1.2584217984112911e-05
> O 0 6.4161854425037745e-06
Arg226Stop O 0 7.606684812344611e-05
) O 0 1.1473123322502943e-06
. O 0 3.8618100006715395e-06

Thus O 0 5.194792720430996e-06
, O 0 3.275885376297083e-07
a O 0 1.3621715311273874e-07
homozygous O 0 1.8877331058320124e-06
germ O 0 0.00015864391752984375
- O 0 6.92500252625905e-05
line O 0 3.68689106835518e-05
MLH1 O 1 0.9999953508377075
mutation O 0 4.2189424220850924e-07
and O 0 6.459381296508582e-08
consequent O 0 0.00012224986858200282
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 2.421656404294481e-07
in O 0 4.180245838369956e-08
a O 0 2.1519379345136258e-07
mutator O 1 0.9717475771903992
phenotype O 0 5.803519229630183e-07
characterized O 0 4.385023189001913e-08
by O 0 4.742432668791707e-09
leukemia B-Disease 1 0.9999998807907104
and O 0 8.934666766435839e-07
/ O 1 1.0
or O 1 0.9999985694885254
lymphoma B-Disease 1 1.0
associated O 0 1.8595089841255685e-06
with O 0 2.956052469471615e-07
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 1.62236210599076e-05
1 I-Disease 0 3.2294387892761733e-06
. O 0 2.152902851548788e-07
. O 0 1.4013418194736005e-06

Missense O 0 0.00019878032617270947
mutations O 0 8.058553930823109e-07
in O 0 3.9219248293420605e-08
the O 0 4.5541572291085686e-08
most O 0 1.127598547867592e-08
ancient O 0 1.0630722613313992e-07
residues O 0 2.0169909475953318e-07
of O 0 1.4510672485812393e-07
the O 0 2.2776428920678882e-07
PAX6 O 1 0.9999538660049438
paired O 0 9.408509527020215e-07
domain O 0 7.279965075213113e-07
underlie O 0 1.92991001313203e-06
a O 0 2.64887791701085e-08
spectrum O 0 1.6388358972108108e-06
of O 0 1.0350709089834709e-05
human O 1 1.0
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.0004533803730737418

Mutations O 0 3.499773129078676e-06
of O 0 6.286564939728123e-07
the O 0 2.9983908689246164e-07
human O 0 5.016199793317355e-07
PAX6 O 1 1.0
gene O 0 1.8698765416047536e-05
underlie O 1 1.0
aniridia B-Disease 1 1.0
( O 1 0.9991356730461121
congenital B-Disease 1 1.0
absence I-Disease 0 1.8907203411799856e-06
of I-Disease 0 7.552424449386308e-06
the I-Disease 0 6.835803105786908e-07
iris I-Disease 0 0.0028046132065355778
) O 0 2.2727384418885777e-08
, O 0 1.7619770531496215e-08
a O 0 3.529727266027294e-08
rare O 0 1.908344756884617e-06
dominant O 1 0.9926161766052246
malformation B-Disease 1 0.9999998807907104
of I-Disease 0 0.01128383819013834
the I-Disease 0 0.00011263690248597413
eye I-Disease 1 0.9999986886978149
. O 0 9.91106662695529e-06

The O 0 3.0647443054476753e-06
spectrum O 0 7.414566425723024e-06
of O 0 4.616140813595848e-06
PAX6 O 1 1.0
mutations O 0 9.841545534072793e-07
in O 0 6.793443674268929e-08
aniridia B-Disease 1 1.0
patients O 0 1.3980165647353715e-07
is O 0 4.7084984799994345e-09
highly O 0 1.9472160772693314e-08
biased O 0 2.306904889337602e-08
, O 0 2.187209080517505e-09
with O 0 1.5208316828108082e-09
92 O 0 5.831025262637013e-08
% O 0 1.0630489821750189e-09
of O 0 6.5296013040949674e-09
all O 0 3.711672524886467e-09
reported O 0 1.813585903676085e-08
mutations O 0 3.0998304367813034e-08
leading O 0 8.345885049720891e-08
to O 0 3.0638798165227854e-08
premature O 0 1.6178472606043215e-07
truncation O 0 4.4345003402668226e-07
of O 0 1.6342568187610595e-07
the O 0 2.1372446923351163e-08
protein O 0 8.766233072776686e-09
( O 0 2.3225679157690138e-09
nonsense O 0 8.772442328108809e-08
, O 0 2.514232821937412e-09
splicing O 0 2.0858685445546143e-08
, O 0 3.639202050820245e-09
insertions O 0 6.909433380997143e-08
and O 0 6.157154341934756e-09
deletions O 0 6.101695504412419e-08
) O 0 4.117107543777365e-09
and O 0 5.172684058862842e-09
just O 0 1.0533674377199986e-08
2 O 0 3.4116283131879754e-08
% O 0 1.8574999316456342e-09
leading O 0 4.8296908694567264e-09
to O 0 1.1251445330984211e-09
substitution O 0 1.0629725544220037e-08
of O 0 2.576819468913527e-08
one O 0 5.87692383646754e-09
amino O 0 1.0211983259011959e-08
acid O 0 6.116584572168904e-09
by O 0 1.0396442595705935e-09
another O 0 3.856271035829195e-08
( O 0 5.8548632608790285e-08
missense O 0 2.14307533497049e-06
) O 0 3.6139877579444146e-07
. O 0 2.465090574332862e-06

The O 0 2.167489583371207e-06
extraordinary O 0 5.656087296301848e-07
conservation O 0 8.637276209810807e-07
of O 0 2.81346615338407e-07
the O 0 1.8190567629972065e-07
PAX6 O 0 0.03635011613368988
protein O 0 1.0538822436956252e-07
at O 0 4.037885403818109e-08
the O 0 2.988558378547168e-08
amino O 0 1.0925500504299634e-07
acid O 0 7.992779416099438e-08
level O 0 6.873457181200138e-08
amongst O 0 2.0007259138310474e-07
vertebrates O 0 1.9072913346462883e-06
predicts O 0 2.0030263669923443e-07
that O 0 1.3453901104298893e-08
pathological O 0 1.9063028958044015e-05
missense O 0 1.6345528592864866e-06
mutations O 0 5.8587730222825485e-08
should O 0 5.716746187545141e-09
in O 0 1.8140174917746776e-09
fact O 0 5.314150453017419e-09
be O 0 2.9886937369383304e-09
common O 0 4.773023309923019e-09
even O 0 2.5106339229807872e-09
though O 0 2.148343947183662e-09
they O 0 1.1297809354715582e-09
are O 0 1.2939765925423785e-09
hardly O 0 6.452091838582419e-08
ever O 0 7.193477102873658e-08
seen O 0 8.617120528242594e-08
in O 0 1.0971190533837216e-07
aniridia B-Disease 1 1.0
patients O 0 4.259055003785761e-06
. O 0 2.581023181846831e-06

This O 0 6.011521804794029e-07
indicates O 0 1.8707402205109247e-07
that O 0 5.062342101069817e-09
there O 0 8.26267854137086e-09
is O 0 5.318895990313877e-09
a O 0 1.2009727434758588e-08
heavy O 0 2.643203288243967e-06
ascertainment O 0 9.945233614416793e-05
bias O 0 4.51349251306965e-07
in O 0 1.0406724371136988e-08
the O 0 1.7095461046778837e-08
selection O 0 3.216527133531599e-08
of O 0 5.1843517923089166e-08
patients O 0 2.2943810407127785e-08
for O 0 2.6310075895707996e-08
PAX6 O 1 0.9998626708984375
mutation O 0 1.9476578572152903e-08
analysis O 0 2.9161046910530786e-09
and O 0 2.7528934687381934e-09
that O 0 2.7799937907246886e-09
the O 0 6.087257986564509e-08
missing O 0 1.154580786533188e-06
PAX6 O 1 0.999998927116394
missense O 0 7.006913801888004e-05
mutations O 0 1.0936524859062047e-06
frequently O 0 1.6640788658150996e-07
may O 0 6.405458918834483e-08
underlie O 0 6.180717264214763e-06
phenotypes O 0 1.5844776726225973e-06
distinct O 0 1.1149786871555989e-07
from O 0 1.5393267460694915e-07
textbook O 0 0.0003295080969110131
aniridia B-Disease 1 1.0
. O 0 3.6688314139610156e-05

Here O 0 5.679914352185733e-07
we O 0 4.9980439342789396e-08
present O 0 3.0311777976521626e-08
four O 0 3.0130955508411716e-08
novel O 0 1.561619910717127e-06
PAX6 O 1 0.9968319535255432
missense O 0 5.1360939323785715e-06
mutations O 0 1.956154278559552e-07
, O 0 1.9544867058129967e-08
two O 0 2.6547284370792568e-09
in O 0 4.748922144415246e-09
association O 0 1.0049386212074296e-08
with O 0 1.6188559825991433e-08
atypical O 0 2.387182212260086e-05
phenotypes O 0 0.001214260351844132
ectopia B-Disease 1 0.9999148845672607
pupillae I-Disease 1 0.9659974575042725
( O 0 4.238194506456239e-08
displaced B-Disease 0 4.6821444499300924e-08
pupils I-Disease 0 3.844021989607427e-08
) O 0 2.1129896055072095e-08
and O 0 1.6156375295395264e-06
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.8782039880752563
( O 0 2.190295234072437e-08
searching B-Disease 0 7.467289009355227e-08
gaze I-Disease 0 6.011223945279198e-07
) O 0 7.76337216734646e-09
, O 0 7.408199831360207e-09
and O 0 6.655072048999955e-09
two O 0 2.727851944328563e-09
in O 0 2.6933371088944114e-09
association O 0 6.614210512623231e-09
with O 0 4.431534250670666e-09
more O 0 3.2750225642530495e-08
recognizable O 0 0.00022106958203949034
aniridia B-Disease 1 1.0
phenotypes O 0 7.415397703880444e-05
. O 0 7.287359949259553e-06

Strikingly O 0 1.4728836504218634e-05
, O 0 1.8714878535774915e-07
all O 0 2.1989013276879632e-08
four O 0 1.0457104515637639e-08
mutations O 0 1.594688292527735e-08
are O 0 1.0106181447255835e-09
located O 0 7.366482179804734e-08
within O 0 3.4686671313011175e-08
the O 0 1.8374090871020599e-07
PAX6 O 1 0.9999903440475464
paired O 0 8.14279871974577e-07
domain O 0 1.3934138110016647e-07
and O 0 1.5282182630471652e-08
affect O 0 2.8024619069810797e-08
amino O 0 2.2359756712830858e-08
acids O 0 5.995511198619852e-09
which O 0 5.592735718984443e-10
are O 0 4.667952691050914e-10
highly O 0 6.378732209100235e-09
conserved O 0 4.0446220594958504e-08
in O 0 4.750018600674366e-09
all O 0 1.8099402865345837e-08
known O 0 8.341046964233101e-08
paired O 0 5.803950671179336e-07
domain O 0 5.500291990756523e-07
proteins O 0 2.2388184106603148e-07
. O 0 8.812168630356609e-07

Our O 0 2.4737310013733804e-06
results O 0 8.288094477393315e-08
support O 0 2.1273130812460295e-08
the O 0 2.1248718340416417e-08
hypothesis O 0 2.1330091470872503e-08
that O 0 6.246470563020523e-10
the O 0 3.7340472935909474e-09
under O 0 9.911168774578982e-09
- O 0 7.790757905468126e-08
representation O 0 3.288630878728327e-08
of O 0 1.760157175567656e-07
missense O 0 3.495663577268715e-06
mutations O 0 1.0409269890487849e-07
is O 0 6.762491899792167e-09
caused O 0 1.637060798032053e-08
by O 0 4.9375517008343195e-09
ascertainment O 0 0.007295970804989338
bias O 0 4.4742697014044097e-07
and O 0 1.6756684928509458e-08
suggest O 0 7.194489448636432e-09
that O 0 6.827497456285414e-10
a O 0 1.4368986001045414e-09
substantial O 0 1.7475384694876084e-08
burden O 0 2.1509900705041218e-07
of O 0 3.076241910093813e-07
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9537750482559204
related I-Disease 1 0.9916103482246399
disease I-Disease 1 0.9942157864570618
remains O 0 2.2938893096124957e-07
to O 0 1.1128302723761863e-08
be O 0 2.213583272236974e-08
uncovered O 0 1.0825935987668345e-06
. O 0 1.5737673209059722e-07
. O 0 1.1779616215790156e-06

The O 0 3.083230694755912e-06
chromosomal O 0 1.6651313217153074e-06
order O 0 1.0909986514207048e-07
of O 0 1.6820607129375276e-07
genes O 0 4.802640773959865e-08
controlling O 0 3.5602261050371453e-06
the O 0 1.4140023552045022e-07
major O 0 4.776495643454837e-06
histocompatibility O 1 1.0
complex O 0 2.870030039048288e-05
, O 0 2.8923425432481054e-08
properdin O 0 2.4180596938094823e-06
factor O 0 1.0942914485667643e-07
B O 0 2.263197075080825e-06
, O 0 6.206759550764218e-09
and O 0 1.537486227221052e-08
deficiency B-Disease 0 5.232431249169167e-06
of I-Disease 0 7.926055332063697e-07
the I-Disease 0 3.9958285924512893e-07
second I-Disease 0 3.3628521123318933e-07
component I-Disease 0 1.4520476270263316e-06
of I-Disease 0 1.0935127647826448e-06
complement I-Disease 0 4.102086222701473e-06
. O 0 3.853885573334992e-06

The O 0 2.769099637589534e-06
relationship O 0 9.312353910218008e-08
of O 0 1.549535255662704e-07
the O 0 5.3047653381099735e-08
genes O 0 9.317147053877761e-09
coding O 0 1.803058182758832e-07
for O 0 2.266941478978879e-08
HLA O 0 8.249395250459202e-06
to O 0 2.088858508386693e-08
those O 0 5.490039090005894e-09
coding O 0 6.174573741191125e-08
for O 0 8.156749053966905e-09
properdin O 0 3.776480070882826e-06
Factor O 0 2.3830372697375424e-07
B O 0 6.857742960164614e-07
allotypes O 0 4.468398628887371e-07
and O 0 4.077882476138939e-09
for O 0 6.972260546689313e-09
deficiency B-Disease 0 3.689040795507026e-06
of I-Disease 0 6.309893478828599e-07
the I-Disease 0 1.291834905714495e-07
second I-Disease 0 5.0339597379434053e-08
component I-Disease 0 2.096066964440979e-07
of I-Disease 0 5.189229312918542e-08
complement I-Disease 0 3.37961552077104e-07
( O 0 4.439742795625534e-08
C2 O 1 0.9566680788993835
) O 0 7.221793829614853e-09
was O 0 2.1806911831845355e-08
studied O 0 1.7265927354515043e-08
in O 0 1.1955532119856116e-09
families O 0 5.471042507920743e-10
of O 0 1.02812265367902e-08
patients O 0 1.5697194655217572e-08
with O 0 5.2333312794417e-08
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 3.84814920835197e-05

Patients O 0 4.998320036975201e-06
were O 0 6.249216966125459e-08
selected O 0 3.3951337741200405e-08
because O 0 3.820534555387667e-09
they O 0 1.0909851910767543e-09
were O 0 5.0823198982641316e-09
heterozygous O 0 4.831665378901562e-08
or O 0 1.9113242544221976e-08
homozygous O 0 1.0263738658977672e-06
for O 0 3.835267307294998e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.8885897588916123e-05

12 O 0 2.6982879717252217e-06
families O 0 2.4973484613610708e-08
with O 0 1.074288746849561e-08
15 O 0 2.3018706940547418e-07
matings O 0 3.2826417282194598e-06
informative O 0 3.886942067765631e-06
for O 0 4.1717894418979995e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 6.447440910051228e-07
found O 0 5.485519523062976e-07
. O 0 9.249403092326247e-07

Of O 0 1.276738021260826e-05
57 O 0 4.409851499076467e-06
informative O 0 3.6551523407979403e-06
meioses O 0 2.0764227883773856e-05
, O 0 5.4977437713432664e-08
two O 0 5.020686089096671e-09
crossovers O 0 4.789869834098681e-08
were O 0 4.078107629368333e-09
noted O 0 9.337749240501125e-09
between O 0 7.38657046639446e-09
the O 0 1.5685365042372723e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.6830479171735533e-08
and O 0 1.59271245081527e-08
the O 0 8.6476802607649e-08
HLA O 1 0.9513779878616333
- O 0 0.00014463865954894572
B O 0 2.383801620453596e-05
gene O 0 1.2031096119358153e-08
, O 0 1.8034024273916316e-09
with O 0 1.2292601381247437e-09
a O 0 1.1725974857768051e-08
recombinant O 0 3.0025223196616935e-08
fraction O 0 8.32540649753355e-08
of O 0 3.7773628491777345e-07
0 O 0 2.0067770947207464e-06
. O 0 1.7000971865854808e-06

035 O 0 0.062308769673109055
. O 0 0.0004615961806848645

A O 0 1.2922915630042553e-05
lod O 0 4.080315193277784e-05
score O 0 8.142682190737105e-07
of O 0 2.772963227926084e-07
13 O 0 8.408552076843989e-08
was O 0 2.029973522610362e-08
calculated O 0 9.57586632210905e-09
for O 0 4.564312483523736e-09
linkage O 0 6.663011618002201e-07
between O 0 2.853057139873272e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.3421659989253385e-07
HLA O 1 0.9998414516448975
- O 0 6.180435593705624e-05
B O 0 6.1302216636249796e-06
at O 0 2.4605727233506514e-08
a O 0 2.4400590437068104e-09
maximum O 0 5.84680304172025e-09
likelihood O 0 2.3404225224510355e-09
value O 0 2.6959172672036402e-09
of O 0 5.40030731244201e-09
the O 0 1.0348235157664476e-08
recombinant O 0 1.8307689586549714e-08
fraction O 0 4.865243496965377e-08
of O 0 1.8295163783932367e-07
0 O 0 1.5327041182899848e-06
. O 0 1.1650043916233699e-06

04 O 0 0.02409244328737259
. O 0 0.0002734060981310904

18 O 0 2.060716269625118e-06
families O 0 1.6260477408991392e-08
with O 0 1.339061483918158e-08
21 O 0 1.9325754863075417e-07
informative O 0 4.597823419771885e-07
matings O 0 3.4726326703093946e-07
for O 0 1.4464904829480929e-08
both O 0 1.712421315858137e-08
properdin O 0 3.92995571019128e-06
Factor O 0 7.859253514652664e-07
B O 0 2.706447276068502e-06
allotype O 0 1.7309339455096051e-06
and O 0 3.4230545509217336e-08
HLA O 0 0.23567694425582886
- O 0 0.00014653787366114557
B O 0 0.00035842516808770597
were O 0 1.1231707475189978e-07
found O 0 2.793352962271456e-07
. O 0 1.451503521820996e-06

Of O 0 2.302441862411797e-05
72 O 0 7.508874205086613e-06
informative O 0 3.7453837649081834e-06
meioses O 0 6.448572821682319e-05
, O 0 1.2392675330374914e-07
three O 0 3.542792015309715e-08
recombinants O 0 2.3258221517608035e-06
were O 0 2.3220643186050438e-08
found O 0 1.6271274105861266e-08
, O 0 7.130051216108768e-09
giving O 0 8.539529972040327e-09
a O 0 7.928623979580607e-09
recombinant O 0 4.565376343634853e-08
fraction O 0 1.0226195712448316e-07
of O 0 3.4015710070889327e-07
0 O 0 1.6225272929659695e-06
. O 0 1.8084309658661368e-06

042 O 0 0.026825670152902603
. O 0 0.00048613373655825853

A O 0 1.0951222066069022e-05
lod O 0 3.999010004918091e-05
score O 0 6.490663508884609e-07
of O 0 3.334296252432978e-07
16 O 0 1.3249669450488e-07
between O 0 3.0984352861196385e-08
HLA O 0 2.030768337135669e-05
- O 0 1.6360313566110563e-06
B O 0 3.841944362648064e-06
and O 0 1.1678922717806017e-08
Factor O 0 5.937984610682179e-07
B O 0 2.780292561510578e-06
allotypes O 0 2.3507730020355666e-06
was O 0 7.558539749652482e-08
calculated O 0 2.0475500406291758e-08
at O 0 1.8773576471176057e-08
a O 0 5.667337266146433e-09
maximum O 0 2.065148763108482e-08
likelihood O 0 8.439300813734008e-09
value O 0 3.938151582616456e-09
of O 0 6.0852585193060804e-09
the O 0 9.658373656407093e-09
recombinant O 0 1.4228403344418439e-08
fraction O 0 3.337489928867399e-08
of O 0 1.256115069736552e-07
0 O 0 8.557090609428997e-07
. O 0 9.121197876993392e-07

04 O 0 0.031531576067209244
. O 0 0.0004465525853447616

A O 0 8.508661267114803e-06
crossover O 0 5.644530119752744e-06
was O 0 3.0785017202106246e-07
shown O 0 1.7814208774780127e-08
to O 0 1.2160846551978466e-08
have O 0 1.8819925617918898e-09
occurred O 0 5.7513500628658676e-09
between O 0 1.2694596485118836e-09
genes O 0 8.359801739743489e-10
for O 0 9.251233112905766e-10
Factor O 0 2.1008453643389657e-08
B O 0 2.201711595262168e-07
and O 0 6.176279487846159e-09
HLA O 0 0.02054956741631031
- O 0 0.004804127849638462
D O 1 0.9984614849090576
, O 0 1.3535080611859485e-08
in O 0 2.492650086338699e-09
which O 0 5.528361324280695e-09
HLA O 0 3.998682223027572e-05
- O 0 3.359179390827194e-05
D O 1 0.6604225635528564
segregared O 0 1.1069007996411528e-05
with O 0 4.8547686759548014e-08
HLA O 0 0.00273788976483047
- O 0 4.0103873288899194e-06
A O 0 2.8275735530769452e-06
and O 0 3.387288245448872e-07
B O 0 5.499526741914451e-05
. O 0 2.9803384222759632e-06

These O 0 9.368880000693025e-07
studies O 0 1.4606111164994218e-07
suggest O 0 1.6297489580097135e-08
that O 0 1.3092545936288502e-09
the O 0 3.2532554428144067e-09
genes O 0 1.5808930831084922e-09
for O 0 1.3679400945321163e-09
Factor O 0 1.2682692158705322e-06
B O 1 0.9999984502792358
and O 0 1.8685183249544934e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 3.0225970615305187e-09
located O 0 1.179342135060324e-08
outside O 0 6.510437078333098e-09
those O 0 1.2529124404636605e-09
for O 0 3.9005496610400314e-09
HLA O 0 0.00014165279571898282
, O 0 1.1573900060568576e-08
that O 0 1.3654584130051717e-09
the O 0 6.502804517083405e-09
order O 0 6.751768921731127e-09
of O 0 3.827867089967185e-08
genese O 0 7.87204407970421e-06
is O 0 4.2504510133767326e-08
HLA O 0 5.663629053742625e-06
- O 0 7.019633017080196e-07
A O 0 5.133921376909711e-07
, O 0 5.2937858541213245e-09
- O 0 5.3228262686388916e-08
B O 0 3.027844286407344e-07
, O 0 3.6954819204737532e-09
- O 0 8.339281265534737e-08
D O 0 2.2872823137731757e-06
, O 0 9.720747762287374e-09
Factor O 0 2.521885562600801e-07
B O 0 2.053148637060076e-05
allotype O 0 0.3852175176143646
, O 0 1.0154693882213905e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 2.377402630315828e-08
that O 0 1.5239676187661644e-09
the O 0 8.840364884576957e-09
genes O 0 1.518548309320522e-08
coding O 0 1.2411735497153131e-06
for O 0 1.1796006447184482e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.038877759488969e-08
Factor O 0 6.434149213419005e-07
B O 0 9.210655775859777e-07
allotypes O 0 3.346088988109841e-07
are O 0 3.434187934026056e-10
approximately O 0 1.218687151194331e-09
3 O 0 4.802885644750177e-09
- O 0 2.133416110439157e-08
- O 0 4.4330921156188197e-08
5 O 0 2.8155131559515212e-08
centimorgans O 0 2.3249853597917536e-07
from O 0 3.975645590514887e-09
the O 0 9.868047712302541e-09
HLA O 0 2.8445019779610448e-06
- O 0 4.240571627178724e-07
A O 0 4.992917865820345e-07
and O 0 2.6429679778061654e-08
HLA O 0 0.00017590080096852034
- O 0 3.2903990359045565e-06
B O 0 4.375041953608161e-06
loci O 0 4.25717665564207e-08
, O 0 1.5444807655029535e-09
and O 0 1.0345052592342086e-09
that O 0 4.1058986766095984e-10
the O 0 3.305407059173149e-09
apparent O 0 2.812507560179256e-08
lack O 0 2.681001731730248e-08
of O 0 1.0734329691786115e-07
recombinants O 0 3.3417181839467958e-06
between O 0 9.18922893333729e-09
the O 0 2.032174073463011e-08
Factor O 0 4.171127159224852e-07
B O 0 0.0006984726060181856
gene O 0 2.7590724016590684e-07
and O 0 7.447343250532867e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.410947305657828e-07
suggests O 0 9.523336785832726e-09
that O 0 4.282239007835642e-10
these O 0 6.007366826210614e-10
two O 0 8.182455268901379e-10
genes O 0 6.073848091148193e-09
lie O 0 5.9379964056915924e-08
in O 0 4.20458468042284e-09
close O 0 7.857209993744618e-08
proximity O 0 3.782997453072312e-07
to O 0 7.456273465322738e-08
one O 0 1.328595828908874e-07
another O 0 7.322676651710935e-07
. O 0 2.5190279302478302e-06

Distribution O 0 2.2516990156873362e-06
of O 0 1.5558966879325453e-06
emerin O 0 0.00015233819431159645
and O 0 3.3432627333240816e-07
lamins O 0 2.0110102923354134e-05
in O 0 5.470505826110639e-08
the O 0 2.0643815901166818e-07
heart O 0 3.1469999157707207e-06
and O 0 6.089847204293619e-08
implications O 0 9.6568726348778e-07
for O 0 1.0995973553917793e-07
Emery B-Disease 1 0.9999370574951172
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 9.579023026162758e-05

Emerin O 1 0.9989506006240845
is O 0 1.2867976693087257e-06
a O 0 2.1115437220942113e-07
nuclear O 0 9.10775895590632e-07
membrane O 0 1.2527605974810285e-07
protein O 0 1.815454808706818e-08
which O 0 3.832124395586334e-09
is O 0 6.8186252200064246e-09
missing O 0 4.2376122166842833e-08
or O 0 1.6490636411958803e-08
defective O 0 7.327321895900241e-07
in O 0 6.43250430698572e-08
Emery B-Disease 1 0.9999771118164062
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 4.692633228842169e-05
EDMD B-Disease 1 1.0
) O 0 8.555625754524954e-06
. O 0 6.740076059941202e-06

It O 0 3.102927621512208e-07
is O 0 4.234517803070048e-08
one O 0 1.3787169628187712e-08
member O 0 1.3445357716079798e-08
of O 0 3.0269603712440585e-08
a O 0 2.3573990759473418e-08
family O 0 2.429634449185869e-08
of O 0 2.30208783591479e-07
lamina O 1 0.9999877214431763
- O 0 1.6065419004007708e-06
associated O 0 3.046467966782984e-08
proteins O 0 3.6220628718552916e-09
which O 0 2.021858014344957e-09
includes O 0 3.524042924141213e-08
LAP1 O 1 0.8939537405967712
, O 0 1.698046219189564e-07
LAP2 O 0 0.011312463320791721
and O 0 5.230467650108039e-07
lamin O 0 0.0001173519340227358
B O 0 0.0002808826102409512
receptor O 0 1.9598062408476835e-06
( O 0 3.453810109022015e-07
LBR O 1 0.9616286754608154
) O 0 1.4024728898220928e-06
. O 0 3.92624679079745e-06

A O 0 1.9134646208840422e-05
panel O 0 1.805170768420794e-06
of O 0 4.802878947884892e-07
16 O 0 3.386158198281919e-07
monoclonal O 0 6.835307999608631e-07
antibodies O 0 7.744961294520181e-08
( O 0 1.6540754543825642e-08
mAbs O 0 2.973394430227927e-06
) O 0 2.2307318658931763e-08
has O 0 1.1843509284403808e-08
been O 0 5.18942444571735e-09
mapped O 0 3.440583995484303e-08
to O 0 4.822658716818751e-09
six O 0 4.99341057391689e-09
specific O 0 3.0709341736212536e-09
sites O 0 1.642142777313893e-08
throughout O 0 8.988490840522445e-09
the O 0 4.8619039461073044e-08
emerin O 0 1.3867128245692584e-06
molecule O 0 1.680190742092691e-08
using O 0 7.801326695755506e-09
phage O 0 5.194819436837861e-07
- O 0 1.3353051997455623e-07
displayed O 0 1.4100756118295976e-07
peptide O 0 3.955829797064325e-08
libraries O 0 1.7814413055816658e-08
and O 0 7.948793623313577e-09
has O 0 4.28739843627568e-09
been O 0 2.9799052114753977e-09
used O 0 4.9691544212748795e-09
to O 0 1.1597412807873297e-08
localize O 0 9.278485777031165e-06
emerin O 0 7.990294398041442e-05
in O 0 5.380785239594843e-08
human O 0 2.144268052006737e-07
and O 0 3.0351932878147636e-07
rabbit O 0 0.09230717271566391
heart O 0 0.10103698819875717
. O 0 5.3007270253147e-06

Several O 0 8.733459253562614e-06
mAbs O 0 2.76364207820734e-05
against O 0 7.43550231163681e-07
different O 0 6.608815539266288e-08
emerin O 0 1.3606369975605048e-05
epitopes O 0 2.4758928702794947e-06
did O 0 5.929372548507672e-08
not O 0 2.0651448551234353e-08
recognize O 0 2.509407863726665e-07
intercalated O 0 8.61832177179167e-06
discs O 0 2.61637796938885e-05
in O 0 4.153414678853551e-08
the O 0 1.515779644023496e-07
heart O 0 2.144322479580296e-06
, O 0 9.694621994071895e-09
though O 0 5.832323513033089e-09
they O 0 3.1564908464787322e-09
recognized O 0 6.327043422515999e-08
cardiomyocyte O 0 4.07674815505743e-06
nuclei O 0 2.9067223294987343e-07
strongly O 0 2.4525137476416603e-08
, O 0 5.844974726443297e-09
both O 0 4.919971985373195e-09
at O 0 1.152135240545249e-07
the O 0 2.2841599900402798e-07
rim O 0 3.330944537083269e-06
and O 0 5.262238289560628e-08
in O 0 8.359777581290473e-08
intranuclear O 0 5.497952952282503e-05
spots O 0 6.3814632085268386e-06
or O 0 4.0129253875420545e-07
channels O 0 3.3292899388470687e-06
. O 0 3.762869255297119e-06

A O 0 7.942555384943262e-05
polyclonal O 0 0.00013023681822232902
rabbit O 0 1.9505596355884336e-05
antiserum O 0 2.6039346266770735e-05
against O 0 1.6235302382483496e-06
emerin O 0 0.00038198824040591717
did O 0 1.2891199219211558e-07
recognize O 0 1.0045307163863981e-07
both O 0 2.1792731175196423e-08
nuclear O 0 3.890247057825036e-07
membrane O 0 7.417874314796791e-08
and O 0 1.6493498122827077e-08
intercalated O 0 1.2554686463772669e-06
discs O 0 2.1483917862497037e-06
but O 0 9.538024592359307e-09
, O 0 5.1450546045828105e-09
after O 0 2.8731901302592178e-09
affinity O 0 1.1055041326812898e-08
purification O 0 1.2886160050129547e-07
against O 0 3.7611538772353015e-08
a O 0 3.631347667010232e-08
pure O 0 6.898081892359187e-07
- O 0 7.614036690029025e-07
emerin O 0 1.5900035577942617e-05
band O 0 4.6731869929317327e-07
on O 0 3.775882007062137e-08
a O 0 1.2166067264729463e-08
western O 0 6.46270805759741e-08
blot O 0 1.4228223335521761e-05
, O 0 2.409807642322903e-08
it O 0 5.6178843799159495e-09
stained O 0 2.3999537006602623e-06
only O 0 2.0617049401039367e-08
the O 0 1.0332047395422705e-07
nuclear O 0 2.123495960404398e-06
membrane O 0 3.139775117233512e-06
. O 0 2.964840405184077e-06

These O 0 4.1906957903847797e-07
results O 0 3.482016808220578e-08
would O 0 3.3480529459950503e-09
not O 0 9.398783973324498e-10
be O 0 7.945151758725899e-10
expected O 0 5.401193270415661e-09
if O 0 1.2522535897119269e-08
immunostaining O 0 1.949650368260336e-06
at O 0 2.523839270907047e-07
intercalated O 0 3.002029643539572e-06
discs O 0 2.978781367346528e-06
were O 0 2.2781113884207116e-08
due O 0 1.8344705310369136e-08
to O 0 5.180404993865295e-09
a O 0 4.006429854541693e-09
product O 0 1.0998864929945285e-08
of O 0 1.9419491792405097e-08
the O 0 2.942573118502878e-08
emerin O 0 3.391744030523114e-06
gene O 0 6.1754787950007994e-09
and O 0 5.197101415888028e-09
, O 0 3.6562686211993878e-09
therefore O 0 2.9518354427438e-09
, O 0 2.2692461243423168e-09
cast O 0 1.5426090627101985e-08
some O 0 3.3071732019607225e-09
doubt O 0 4.2497372731986616e-08
upon O 0 6.2814442536307524e-09
the O 0 1.132921223501171e-08
hypothesis O 0 4.637368178350698e-08
that O 0 4.680865028916514e-09
cardiac B-Disease 1 0.9999995231628418
defects I-Disease 1 0.744670033454895
in O 0 7.166580218154195e-08
EDMD B-Disease 1 1.0
are O 0 1.937206484114995e-08
caused O 0 3.6484891552390764e-08
by O 0 4.010084264649549e-09
absence O 0 1.949643291254688e-07
of O 0 7.829964943084633e-07
emerin O 0 0.001801269012503326
from O 0 1.0595414323688601e-06
intercalated O 0 0.0001054923195624724
discs O 0 0.000722811499144882
. O 0 1.0927560651907697e-05

Although O 0 3.336537020004471e-06
emerin O 0 0.00017329015827272087
was O 0 9.231214903593354e-07
abundant O 0 1.7158451726118074e-07
in O 0 1.1930185728203924e-08
the O 0 4.23024744122813e-08
membranes O 0 1.361228783025581e-07
of O 0 4.1040638620870595e-07
cardiomyocyte O 0 0.05483761429786682
nuclei O 0 6.3738576727701e-07
, O 0 9.300510583898358e-09
it O 0 4.016269095075131e-09
was O 0 4.58006397252575e-08
absent O 0 4.095555183880606e-08
from O 0 3.463164865991075e-09
many O 0 7.922125178083661e-09
non O 0 2.938003262897837e-07
- O 0 1.5714576875325292e-06
myocyte O 0 2.5177352654282004e-05
cells O 0 2.009709376693536e-08
in O 0 1.52126187202839e-08
the O 0 4.015789158984262e-07
heart O 0 3.405770257813856e-05
. O 0 4.05698756367201e-06

This O 0 1.9537790763024532e-07
distribution O 0 1.9456108191207022e-07
of O 0 3.828287447049661e-07
emerin O 0 3.07903355860617e-05
was O 0 1.154737816477791e-07
similar O 0 3.016394467536543e-09
to O 0 1.649443470697065e-09
that O 0 1.0992106114215972e-09
of O 0 6.53734204547618e-08
lamin O 0 8.773069566814229e-06
A O 0 1.1513964182086056e-06
, O 0 1.7772059379694838e-08
a O 0 1.476461175542454e-08
candidate O 0 2.9805775625391107e-08
gene O 0 1.0463709010366529e-08
for O 0 5.848888928738916e-09
an O 0 2.0980984061225172e-08
autosomal O 0 7.866399869271845e-07
form O 0 1.7737728796873853e-07
of O 0 0.0011167054763063788
EDMD B-Disease 1 1.0
. O 0 4.10830216424074e-05

In O 0 6.281117634898692e-07
contrast O 0 4.90137324504758e-07
, O 0 5.269480425340589e-07
lamin O 0 0.0011689316015690565
B1 O 1 0.9999998807907104
was O 0 1.6556874697926105e-06
absent O 0 4.3174844677196234e-07
from O 0 3.2208738787176117e-08
cardiomyocyte O 0 2.5436840587644838e-05
nuclei O 0 7.58551720991818e-07
, O 0 2.3367972445953455e-08
showing O 0 7.537721558037447e-08
that O 0 3.077913746096783e-08
lamin O 0 6.023559035384096e-05
B1 O 1 0.6714304685592651
is O 0 9.844735693320672e-09
not O 0 7.903858678659503e-10
essential O 0 7.4500432489799095e-09
for O 0 4.115121132741706e-09
localization O 0 3.3891109296746436e-07
of O 0 1.8314278804609785e-07
emerin O 0 1.096162941394141e-05
to O 0 1.2920074254907377e-07
the O 0 1.1729071047739126e-06
nuclear O 0 2.861459506675601e-05
lamina O 1 0.933743953704834
. O 0 1.8747348804026842e-05

Lamin O 1 0.9999995231628418
B1 O 1 1.0
is O 0 9.67340838542441e-07
also O 0 1.3244805074918986e-07
almost O 0 6.469898750083303e-08
completely O 0 5.091200705464871e-07
absent O 0 4.589919910813478e-07
from O 0 1.5893903082542238e-07
skeletal O 0 0.0822930783033371
muscle O 0 9.223904635291547e-05
nuclei O 0 6.859286077087745e-05
. O 0 6.04254182690056e-06

In O 0 2.9557018024206627e-06
EDMD B-Disease 1 1.0
, O 0 2.0057618144164735e-07
the O 0 2.782732622108597e-08
additional O 0 3.121789760029969e-08
absence O 0 1.076512603503943e-07
of O 0 4.797212227458658e-07
lamin O 1 0.9999668598175049
B1 O 1 1.0
from O 0 6.6464605197325e-07
heart O 1 0.9999986886978149
and O 0 1.6558168454139377e-06
skeletal O 1 1.0
muscle O 1 0.999835729598999
nuclei O 0 8.411634917138144e-05
which O 0 4.397217878704396e-08
already O 0 1.0039082098955987e-07
lack O 0 1.841384005274449e-07
emerin O 0 3.067176294280216e-05
may O 0 1.0444228593087246e-08
offer O 0 4.635658523710617e-09
an O 0 1.3930564479736063e-09
alternative O 0 1.4273007664655779e-08
explanation O 0 1.110485214894652e-08
of O 0 1.7319029765872074e-08
why O 0 1.6206231023829787e-08
these O 0 4.388225338658458e-09
tissues O 0 4.1852079135651366e-08
are O 0 1.6437400329749607e-09
particularly O 0 1.931255688703004e-08
affected O 0 6.812946651280072e-08
. O 0 7.846337268802017e-08
. O 0 1.4758383031221456e-06

Genetic O 0 6.099221081967698e-06
mapping O 0 1.4799059044889873e-06
of O 0 3.0674109439132735e-06
the O 0 3.5246123388787964e-06
copper B-Disease 0 0.000159746254212223
toxicosis I-Disease 1 0.9998401403427124
locus O 0 0.00011408419231884181
in O 0 8.364385166714783e-07
Bedlington O 0 0.00045199887244962156
terriers O 0 7.028851541690528e-05
to O 0 1.4905813827681413e-07
dog O 0 1.9004044133907882e-06
chromosome O 0 2.3465345577733387e-07
10 O 0 2.1916617853889875e-08
, O 0 6.420110221228015e-09
in O 0 5.222778654001559e-09
a O 0 2.2963336121506472e-08
region O 0 2.1455690557559137e-07
syntenic O 0 8.12207508715801e-06
to O 0 8.220695235650055e-08
human O 0 3.069448553105758e-07
chromosome O 0 1.3178535027691396e-06
region O 0 1.5310095022869064e-06
2p13 O 0 0.00011249478120589629
- O 0 4.844274735660292e-05
p16 O 0 9.742734982864931e-05
. O 0 4.95183212478878e-06

Abnormal O 1 1.0
hepatic B-Disease 1 1.0
copper I-Disease 0 0.12648791074752808
accumulation I-Disease 0 0.031256888061761856
is O 0 5.01327228619175e-08
recognized O 0 2.725216674548392e-08
as O 0 7.766377763118726e-09
an O 0 4.1400483041798e-08
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 3.614611614466412e-07
man O 0 1.6382577996409964e-06
, O 0 7.239560062544115e-08
mouse O 0 1.3181802387407515e-05
, O 0 2.9983650051690347e-07
rat O 0 0.06697650253772736
and O 0 2.1244375147944083e-06
dog O 0 0.0001844084181357175
. O 0 9.983255949919112e-06

The O 0 4.689688466896769e-06
major O 0 1.2114486708014738e-05
cause O 0 2.55461400229251e-05
of O 1 0.9693281054496765
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9997988343238831
accumulation I-Disease 0 0.002685668645426631
in O 0 3.162706008197347e-08
man O 0 8.383489102925523e-08
is O 0 1.3510396357219179e-08
a O 0 2.5441233120204743e-08
dysfunctional O 0 1.3889045931136934e-06
ATP7B O 1 1.0
gene O 0 3.8520039424838615e-07
, O 0 3.609120824421552e-08
causing O 0 9.944894827640383e-07
Wilson B-Disease 0 0.00011824235116364434
disease I-Disease 1 0.7003318071365356
( O 0 3.28964489426653e-07
WD B-Disease 1 0.9999957084655762
) O 0 1.826860739129188e-06
. O 0 3.0035159852559445e-06

Mutations O 0 3.6042890769749647e-06
in O 0 8.949866270313578e-08
the O 0 3.18958541356551e-07
ATP7B O 1 0.9999994039535522
genes O 0 1.0637131708790548e-07
have O 0 9.902362485547656e-09
also O 0 1.7388339657031793e-08
been O 0 2.9789404720759194e-08
demonstrated O 0 5.605621211657308e-08
in O 0 6.293007004387619e-08
mouse O 0 1.5617253666277975e-05
and O 0 1.6775620679254644e-06
rat O 0 0.09374268352985382
. O 0 1.4244353224057704e-05

The O 0 1.105420869862428e-05
ATP7B O 1 1.0
gene O 0 9.847526598605327e-07
has O 0 6.593958090661545e-08
been O 0 1.7967630938642287e-08
excluded O 0 3.484721133872881e-08
in O 0 1.5768575334362822e-09
the O 0 9.802820777338184e-09
much O 0 5.248285717129875e-08
rarer O 0 4.6953282435424626e-05
human O 0 2.966104375445866e-06
copper B-Disease 1 0.9989016056060791
overload I-Disease 1 0.9999988079071045
disease O 1 0.9668775200843811
non B-Disease 0 1.3439560007100226e-06
- I-Disease 0 8.907833262128406e-07
Indian I-Disease 0 1.0417195284162517e-07
childhood I-Disease 0 3.926437784684822e-06
cirrhosis I-Disease 1 0.9999982118606567
, O 0 8.077962121433302e-08
indicating O 0 3.4292961004211975e-07
genetic O 0 1.5451997796844807e-06
heterogeneity O 0 3.106663643848151e-05
. O 0 7.2540424298495054e-06

By O 0 3.8268530033747084e-07
investigating O 0 1.2448875850168406e-06
the O 0 5.412539394455962e-07
common O 0 4.3279313103994355e-05
autosomal O 1 0.9999995231628418
recessive O 1 0.9999998807907104
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 7.096467697920161e-07
CT B-Disease 1 0.9999688863754272
) O 0 5.4331337651092326e-08
in O 0 4.272811793271103e-08
Bedlington O 0 7.592829206259921e-05
terriers O 0 3.355068838573061e-05
, O 0 1.6267488689436505e-08
we O 0 2.53891085932878e-09
have O 0 4.416124688155776e-10
identified O 0 1.530638726876532e-09
a O 0 1.1371855679342957e-09
new O 0 2.773781204723491e-09
locus O 0 3.963738208767609e-07
involved O 0 1.788611569963905e-08
in O 0 3.253449420981269e-08
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.5042153791000601e-05

We O 0 2.1480843770405045e-06
examined O 0 1.4503756347039598e-06
whether O 0 6.221755910473803e-08
the O 0 1.9308475884827203e-07
WD B-Disease 1 0.9993522763252258
gene O 0 2.1075613858556608e-06
ATP7B O 1 1.0
was O 0 8.562250286558992e-07
also O 0 4.3090270906986916e-08
causative O 0 5.978795343253296e-07
for O 0 1.233196655903157e-08
CT B-Disease 0 4.009492840850726e-06
by O 0 3.843374951628675e-09
investigating O 0 4.9149942782378275e-08
the O 0 6.000364294322935e-08
chromosomal O 0 1.6427964055765187e-06
co O 0 4.7018150439726014e-07
- O 0 3.883782255797996e-07
localization O 0 1.3659940805155202e-06
of O 0 1.248792386832065e-06
ATP7B O 1 0.9999992847442627
and O 0 3.288286620772851e-07
C04107 O 0 6.873345228086691e-06
, O 0 3.290073991024656e-08
using O 0 1.4834956374443209e-08
fluorescence O 0 9.46734104445568e-08
in O 0 3.5019848354522765e-08
situ O 0 6.118855708336923e-06
hybridization O 0 1.0890065595958731e-06
( O 0 1.222142458345843e-07
FISH O 0 1.6855574358487502e-05
) O 0 5.763299668615218e-07
. O 0 2.558860387580353e-06

C04107 O 0 0.0005332148866727948
is O 0 1.44965110848716e-06
an O 0 2.671630454642582e-07
anonymous O 0 2.8956658297829563e-06
microsatellite O 0 2.397974458290264e-05
marker O 0 3.411553188925609e-05
closely O 0 1.7492378674432985e-06
linked O 0 6.626210051763337e-06
to O 0 2.743429149631993e-06
CT B-Disease 1 0.9999964237213135
. O 0 1.81537980097346e-05

However O 0 5.916757800150663e-06
, O 0 2.980443468914018e-06
BAC O 1 0.9999984502792358
clones O 0 4.842759153689258e-05
containing O 0 1.3347745152714197e-05
ATP7B O 1 0.9999959468841553
and O 0 2.923932527210127e-07
C04107 O 0 8.697154953551944e-06
mapped O 0 5.812642029923154e-07
to O 0 4.395792174705093e-08
the O 0 1.4419075000660087e-07
canine O 0 2.645640961418394e-05
chromosome O 0 9.601297961125965e-07
regions O 0 1.8871413942633808e-07
CFA22q11 O 0 0.005888717249035835
and O 0 1.5480537740586442e-07
CFA10q26 O 1 0.5501707792282104
, O 0 3.827443606496672e-08
respectively O 0 4.419499433083729e-08
, O 0 8.314326116476423e-09
demonstrating O 0 6.653767314901415e-08
that O 0 1.2942241056634884e-08
WD B-Disease 0 0.0002805424446705729
cannot O 0 1.367477011626761e-07
be O 0 2.3581186781029828e-08
homologous O 0 2.062095205701553e-07
to O 0 6.931185225766967e-07
CT B-Disease 1 0.9159814715385437
. O 0 1.3895462871005293e-05

The O 0 1.1689903658407275e-05
copper O 0 5.873301688552601e-06
transport O 0 6.787045094824862e-07
genes O 0 2.503973917100666e-07
CTR1 O 1 0.9999895095825195
and O 0 2.079239607155614e-07
CTR2 O 1 1.0
were O 0 5.875245534525675e-08
also O 0 1.9776614124111802e-08
excluded O 0 5.345065900996815e-08
as O 0 4.883528248456059e-09
candidate O 0 1.141338756838195e-08
genes O 0 8.684602370578887e-09
for O 0 7.007390667723712e-09
CT B-Disease 1 0.9872211813926697
since O 0 2.1599396049509778e-08
they O 0 7.489808773186724e-09
both O 0 1.4718275487268784e-08
mapped O 0 5.346331022337836e-07
to O 0 2.7175923378308653e-07
canine O 0 0.0015755781205371022
chromosome O 0 6.199277413543314e-05
region O 0 2.106495958287269e-05
CFA11q22 O 1 0.5740467309951782
. O 0 2.0109066099394113e-05

2 O 0 7.263111183419824e-05
- O 0 5.029836393077858e-05
22 O 0 2.6987539968104102e-05
. O 0 8.816927220323123e-06

5 O 0 0.0003151372366119176
. O 0 7.865750376367941e-05

A O 0 8.092524694802705e-06
transcribed O 0 6.443310667236801e-07
sequence O 0 4.903299100078584e-08
identified O 0 7.232076715268931e-09
from O 0 2.365261764225579e-09
the O 0 2.288690303942076e-08
C04107 O 0 4.2883843889285345e-06
- O 0 1.8782693587127142e-06
containing O 0 3.686139280034695e-06
BAC O 1 1.0
was O 0 1.8357503961397015e-07
found O 0 7.586180572616286e-09
to O 0 2.4130579756587167e-09
be O 0 2.5334543352073524e-09
homologous O 0 2.9430879955327782e-09
to O 0 3.812214544041126e-09
a O 0 1.2405476645938052e-08
gene O 0 1.874084176733959e-08
expressed O 0 9.072285145350634e-09
from O 0 1.320724862807765e-08
human O 0 6.160657051168528e-08
chromosome O 0 2.224860082833402e-07
2p13 O 0 2.658358425833285e-06
- O 0 4.80566484384326e-07
p16 O 0 6.492830380011583e-07
, O 0 1.1923496856525162e-08
a O 0 1.3043898405840082e-08
region O 0 8.221337566283182e-08
devoid O 0 7.948013944769627e-07
of O 0 9.489270524909443e-08
any O 0 6.088512094493126e-08
positional O 0 2.6119930680579273e-06
candidate O 0 9.806636853681994e-07
genes O 0 1.0270327948092017e-06
. O 0 2.5366841782670235e-06

Molecular O 0 3.3401504424546147e-06
analysis O 0 1.0538361294720744e-07
of O 0 2.8598654466804874e-07
the O 0 3.0281503882179095e-07
APC B-Disease 0 8.484797035634983e-06
gene O 0 3.4921665559295434e-08
in O 0 6.159621257495473e-09
205 O 0 6.935735541446775e-08
families O 0 1.7870966928512644e-09
: O 0 2.3212127775451563e-09
extended O 0 3.2349049661206664e-08
genotype O 0 1.3193280778978078e-07
- O 0 2.7528747637006745e-07
phenotype O 0 3.616804278294694e-08
correlations O 0 1.5282473952993314e-08
in O 0 3.326189323971107e-09
FAP B-Disease 0 1.271520432055695e-05
and O 0 6.386889239706761e-09
evidence O 0 7.848339755867073e-09
for O 0 9.964996605660303e-10
the O 0 9.113006349537045e-09
role O 0 2.7965187499034982e-08
of O 0 1.2764289181177446e-07
APC B-Disease 0 7.343163360928884e-06
amino O 0 2.0810608702959144e-07
acid O 0 7.20056050340645e-08
changes O 0 2.7550171921575384e-08
in O 0 4.5917283841845347e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999998807907104
. O 0 1.7188393030664884e-05

BACKGROUND O 0 0.0005876091308891773
/ O 0 6.04559390922077e-05
AIMS O 0 0.000102172140032053
The O 0 1.826899307388885e-07
development O 0 9.266216238756897e-08
of O 0 0.010152343660593033
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.425536179856863e-08
a O 0 1.2751923961218381e-08
variable O 0 1.0294942676125629e-08
range O 0 5.385251711231831e-08
of O 0 4.55490436479522e-08
extracolonic O 0 5.158330623089569e-06
manifestations O 0 2.3570944449602393e-06
in O 0 1.729979004494453e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.2619649169209879e-05
FAP B-Disease 1 1.0
) O 0 3.112491242518445e-08
is O 0 4.86693974011132e-09
the O 0 1.7385346495757403e-09
result O 0 1.1551708478663159e-09
of O 0 7.172143323685987e-09
the O 0 1.8244664445887793e-08
dominant O 0 2.934743861260358e-07
inheritance O 0 1.0324713457521284e-06
of O 0 5.862042598892003e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 9.606161484043696e-07
APC B-Disease 0 7.040167838567868e-05
) O 0 3.3922216857718013e-07
gene O 0 1.3552073596656555e-06
mutations O 0 1.6641439515296952e-06
. O 0 2.047755060630152e-06

In O 0 5.596880896518996e-07
this O 0 4.578754086992376e-08
study O 0 2.1897815116744823e-08
, O 0 4.589488344919346e-09
direct O 0 2.9318265593047954e-09
mutation O 0 1.8529916490095388e-09
analysis O 0 1.1484592166155494e-09
of O 0 9.797680888823379e-09
the O 0 7.689411063438456e-08
APC B-Disease 0 2.0455516278161667e-05
gene O 0 7.40934780196767e-08
was O 0 5.943174485878444e-08
performed O 0 2.83486354391016e-08
to O 0 9.534804945587894e-09
determine O 0 6.601747770673683e-08
genotype O 0 1.1387047749167323e-07
- O 0 2.8302127930146526e-07
phenotype O 0 7.354422137950678e-08
correlations O 0 3.934084702450491e-08
for O 0 4.917195539633212e-09
nine O 0 3.4479285204724874e-08
extracolonic O 0 4.450720552995335e-06
manifestations O 0 9.972189900508965e-07
and O 0 1.3300075707434189e-08
to O 0 1.3623347783209283e-08
investigate O 0 9.551718704869927e-08
the O 0 2.3508119895154778e-08
incidence O 0 3.800368801876175e-07
of O 0 1.945493863786396e-07
APC B-Disease 0 1.036368848872371e-05
mutations O 0 3.271944493121737e-08
in O 0 9.611145657117959e-09
non O 0 2.0139159460086375e-05
- O 1 0.9999996423721313
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.653591556940228e-05

METHODS O 0 2.8006028514937498e-05
The O 0 5.640946710627759e-06
APC B-Disease 0 4.5455315557774156e-05
gene O 0 6.214817176442011e-07
was O 0 3.6754011034645373e-07
analysed O 0 1.9218072111470974e-07
in O 0 1.2162981732899425e-08
190 O 0 1.6228075594426628e-07
unrelated O 0 6.245439863050706e-07
FAP B-Disease 0 0.007993565872311592
and O 0 6.366373384025792e-08
15 O 0 4.796877988155757e-07
non O 0 5.1076091040158644e-05
- O 1 0.9999997615814209
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 7.193476676548016e-07
using O 0 1.5169307232554274e-07
denaturing O 0 2.4298384232679382e-05
gradient O 0 9.715503210827592e-07
gel O 0 7.486198114747822e-07
electrophoresis O 0 2.4400284814873885e-07
, O 0 1.1723290782583717e-08
the O 0 1.582266406785493e-08
protein O 0 1.729229381908226e-08
truncation O 0 4.012083536508726e-07
test O 0 1.9886989832684776e-08
, O 0 1.9974194742644613e-08
and O 0 3.242107027290331e-08
direct O 0 2.9171977189434983e-07
sequencing O 0 3.7306645026546903e-06
. O 0 5.092786977911601e-06

RESULTS O 0 2.1818284949404188e-05
Chain O 0 2.2236349650484044e-06
terminating O 0 4.929038937007135e-07
signals O 0 7.526099921051355e-08
were O 0 6.8083716442401965e-09
only O 0 3.748747534615404e-09
identified O 0 4.4162784540446864e-09
in O 0 1.9166057629860234e-09
patients O 0 8.059935829862752e-09
belonging O 0 6.358882753687567e-09
to O 0 1.115582382027469e-08
the O 0 3.3179856018250575e-07
FAP B-Disease 1 1.0
group O 0 3.257455034599843e-07
( O 0 3.344614540878865e-08
105 O 0 8.782200211499003e-07
patients O 0 4.633239214513196e-08
) O 0 8.845968579862529e-08
. O 0 1.2345532240942703e-06

Amino O 0 7.64351170801092e-06
acid O 0 9.33811463710299e-07
changes O 0 2.3369130630612744e-08
were O 0 9.920548826869435e-09
identified O 0 5.029964444958068e-09
in O 0 1.380026537489698e-09
four O 0 4.408930998067717e-09
patients O 0 3.2733347143931724e-09
, O 0 1.301938334918873e-09
three O 0 1.317212339202456e-09
of O 0 5.0856876043781085e-08
whom O 0 3.163689399343639e-08
belonged O 0 5.424373838991414e-08
to O 0 8.705249854301655e-09
the O 0 6.908590677312532e-08
non O 0 4.315671048971126e-06
- O 0 1.0793578439916018e-05
FAP O 1 1.0
group O 0 7.956772947181889e-07
of O 1 0.5565518736839294
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.75662189576542e-05
. O 0 1.328375674347626e-06

Genotype O 0 8.688586967764422e-05
- O 0 1.198511654365575e-05
phenotype O 0 1.0949925126624294e-06
correlations O 0 3.4110860269720433e-07
identified O 0 1.9292087927169632e-08
significant O 0 2.05048120704987e-08
differences O 0 4.179002388582376e-08
in O 0 5.279990666906542e-09
the O 0 3.190795894170151e-08
nature O 0 6.336716751320637e-08
of O 0 5.2918100124088596e-08
certain O 0 3.698713513244911e-08
extracolonic O 0 1.695048740657512e-05
manifestations O 0 2.4486914753651945e-06
in O 0 5.974714412104731e-08
FAP B-Disease 1 0.9999998807907104
patients O 0 1.719212860962216e-07
belonging O 0 3.207668086702142e-08
to O 0 2.799288623123175e-08
three O 0 1.7958249998173414e-07
mutation O 0 1.2979405710211722e-06
subgroups O 0 6.895727892697323e-06
. O 0 1.2864393283962272e-06

CONCLUSIONS O 0 6.265663978410885e-05
Extended O 0 6.835941348981578e-06
genotype O 0 3.7009758671047166e-06
- O 0 2.0934428448526887e-06
phenotype O 0 4.1615913914938574e-07
correlations O 0 1.2242095692727162e-07
made O 0 1.97380618516263e-08
in O 0 2.790746522762788e-09
this O 0 1.699729468285227e-09
study O 0 5.756552123870051e-09
may O 0 1.4875126685964801e-09
have O 0 4.448223178687982e-10
the O 0 2.3067583398983516e-09
potential O 0 5.335468511447061e-09
to O 0 1.1788490184017064e-09
determine O 0 3.1270621647649932e-09
the O 0 4.459693947467258e-09
most O 0 2.9837499138096746e-09
appropriate O 0 8.407938345555976e-09
surveillance O 0 1.685826589437056e-07
and O 0 2.0528760913407496e-08
prophylactic O 0 2.7194225822313456e-06
treatment O 0 1.4558328587099822e-07
regimens O 0 7.197676410442e-08
for O 0 1.534307014772196e-09
those O 0 2.441967961175351e-09
patients O 0 1.0745300205172725e-09
with O 0 6.290420961896359e-10
mutations O 0 1.0394564320392874e-08
associated O 0 1.2608672328440207e-08
with O 0 2.8049322864376336e-08
life O 0 5.592794423137093e-07
threatening O 0 7.694568012084346e-06
conditions O 0 1.990996906897635e-06
. O 0 2.4215210032707546e-06

This O 0 5.525817527995969e-07
study O 0 1.8192997686128365e-07
also O 0 1.979510422245312e-08
provided O 0 6.805346508542698e-09
evidence O 0 5.028371941051546e-09
for O 0 5.066997932345885e-09
the O 0 4.491134930617591e-08
pathological O 0 6.324018158920808e-06
nature O 0 1.1693416013258684e-07
of O 0 4.8334907631897295e-08
amino O 0 3.5426776179292574e-08
acid O 0 2.0366362818435846e-08
changes O 0 1.7084663683775148e-09
in O 0 1.5199239644658746e-09
APC O 0 2.7436726668383926e-07
associated O 0 8.63992788424639e-09
with O 0 4.624073124404049e-09
both O 0 1.943713101582034e-08
FAP B-Disease 1 0.9999996423721313
and O 0 4.773153250425821e-07
non O 1 0.9999822378158569
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 3.0770386274525663e-06
. O 0 9.526773681045597e-08
. O 0 1.3646593970406684e-06

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.9999252557754517
cancer B-Disease 1 1.0
risk O 0 9.796328413358424e-06
of O 0 2.679563522178796e-06
the O 0 2.683391358004883e-06
APC O 0 0.0008528055623173714
I1307K O 0 0.00017817069601733238
polymorphism O 0 9.455154213355854e-06
. O 0 5.664747277478455e-06

Germ O 0 0.004296740982681513
- O 0 1.4060557987249922e-05
line O 0 3.3349431305396138e-06
and O 0 1.654233869885502e-07
somatic O 0 1.094614503927005e-06
truncating O 0 1.910865194076905e-06
mutations O 0 4.94432121911359e-08
of O 0 8.266560058700634e-08
the O 0 1.2702844287559856e-07
APC B-Disease 0 7.54886013965006e-06
gene O 0 4.36664464587011e-08
are O 0 3.252833780109654e-09
thought O 0 1.9510340010242544e-08
to O 0 1.2876252952764844e-08
initiate O 0 3.944264790334273e-06
colorectal B-Disease 1 1.0
tumor I-Disease 1 1.0
formation O 0 4.165266091149533e-06
in O 0 3.233446363992698e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0008661411120556295
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 5.026542567065917e-06
respectively O 0 3.265008217567811e-06
. O 0 3.6873348108201753e-06

Recently O 0 1.579623312863987e-05
, O 0 6.57850591778697e-07
an O 0 3.7062525848341465e-07
isoleucine O 0 0.00040380898281000555
- O 0 4.910632560495287e-05
- O 0 2.4278231649077497e-05
> O 0 4.783588792633964e-06
lysine O 0 4.399106728669722e-06
polymorphism O 0 1.7979944288981642e-07
at O 0 2.5477635290371836e-07
codon O 0 1.0837175068445504e-06
1307 O 0 5.751205662818393e-06
( O 0 3.214208987856182e-08
I1307K O 0 1.5911783748379094e-06
) O 0 1.3551638033959534e-08
of O 0 7.490569942092407e-08
the O 0 1.6738420072215376e-07
APC B-Disease 0 6.620878593821544e-06
gene O 0 5.977084782671227e-08
has O 0 9.29384302850167e-09
been O 0 3.7083114357017166e-09
identified O 0 1.638409519166828e-09
in O 0 8.430737219455864e-10
6 O 0 2.6153722743060825e-08
% O 0 1.6826495752297888e-09
- O 0 9.940247736039964e-09
7 O 0 1.6484376530456757e-08
% O 0 1.5082195492510664e-09
of O 0 6.303455979406181e-09
the O 0 1.978751740239204e-08
Ashkenazi O 0 5.554380209105148e-07
Jewish O 0 2.702277299704292e-07
population O 0 5.032778460645204e-08
. O 0 4.046382287015149e-07

To O 0 6.789557005504321e-07
assess O 0 1.426412950422673e-06
the O 0 1.9048032129376224e-07
risk O 0 1.7741517410740926e-07
of O 0 3.118058700124493e-08
this O 0 9.395202837936267e-09
common O 0 7.540727153809712e-08
APC B-Disease 0 8.321972927660681e-06
allelic O 0 7.687102333875373e-05
variant O 0 5.100706766825169e-05
in O 0 5.690508260158822e-07
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 5.762673822573561e-07
we O 0 3.025771277975764e-08
have O 0 2.7284969839058704e-09
analyzed O 0 1.6992343532251653e-08
a O 0 3.5145164556382724e-09
large O 0 2.8163080756371528e-08
cohort O 0 1.7772542548755155e-07
of O 0 1.22409161917858e-07
unselected O 0 0.00010890937119256705
Ashkenazi O 0 1.3294694554133457e-06
Jewish O 0 1.6383577872147725e-07
subjects O 0 3.079470332068013e-07
with O 0 3.166013229360942e-08
adenomatous B-Disease 1 0.9999998807907104
polyps I-Disease 0 0.0633205994963646
and O 0 6.566534693774884e-08
. O 0 3.92795129755541e-08
or O 0 0.06557794660329819
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.0734329691786115e-07
for O 0 4.104008510807944e-08
the O 0 8.51615709507314e-07
APC O 0 5.050489562563598e-05
I1307K O 0 6.79728327668272e-05
polymorphism O 0 4.550086941890186e-06
. O 0 4.072788215125911e-06

The O 0 1.1179391549376305e-05
APC O 0 4.3756896047852933e-05
I1307K O 0 3.4406184568069875e-05
allele O 0 4.573647629513289e-07
was O 0 1.6750844622492878e-07
identified O 0 1.7765620086152012e-08
in O 0 6.284655906796388e-09
48 O 0 6.533240792805373e-08
( O 0 1.772712421299616e-09
10 O 0 9.648100096626422e-09
. O 0 1.1501164465244074e-09
1 O 0 2.843218993575647e-08
% O 0 4.4720791514407665e-09
) O 0 5.4121760406644626e-09
of O 0 9.045162130405515e-08
476 O 0 4.899124633084284e-06
patients O 0 7.275411917362362e-07
. O 0 1.2415866876835935e-06

Compared O 0 4.1413952089897066e-07
with O 0 1.6741799058195284e-08
the O 0 1.9188746591680683e-08
frequency O 0 2.2269313504352795e-08
in O 0 2.3311603758457977e-09
two O 0 1.7979312483262788e-09
separate O 0 2.4695234746019423e-09
population O 0 7.817350100580711e-10
control O 0 9.489429686482254e-09
groups O 0 1.3657944775147257e-09
, O 0 3.519970315224441e-09
the O 0 5.379369483193841e-08
APC O 0 7.15131318429485e-06
I1307K O 0 8.159549906849861e-06
allele O 0 5.4873826371704126e-08
is O 0 2.511266083971009e-09
associated O 0 1.351064704557814e-09
with O 0 1.047426700928611e-09
an O 0 3.1852731563475345e-09
estimated O 0 2.0282396206994235e-08
relative O 0 2.9282343660952392e-08
risk O 0 4.793388796997533e-08
of O 0 1.1996546334103186e-07
1 O 0 3.740108468264225e-06
. O 0 3.0797925774095347e-06

5 O 0 3.150725751766004e-05
- O 0 3.485987690510228e-05
1 O 0 3.4648361179279163e-05
. O 0 1.261289889953332e-05

7 O 0 1.2574479114846326e-05
for O 0 5.107869583298452e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 1.0
( O 0 8.690188337823201e-07
both O 0 4.590033881868294e-07
P O 0 9.358501301903743e-06
= O 0 1.9527507788552612e-07
. O 0 7.871369689382846e-08
01 O 0 1.4035209460416809e-05
) O 0 5.877811872778693e-07
. O 0 4.508688107307535e-06

Furthermore O 0 6.302944257186027e-06
, O 0 1.4316746899112331e-07
compared O 0 6.823572107350628e-08
with O 0 2.8929992623716316e-08
noncarriers O 0 0.0044219898991286755
, O 0 3.8977410099505505e-07
APC O 0 5.861702811671421e-05
I1307K O 0 3.510511669446714e-05
carriers O 0 8.269761053725233e-08
had O 0 1.50356154193787e-08
increased O 0 5.405635494781791e-09
numbers O 0 9.62938528914492e-09
of O 0 1.0782264325825963e-07
adenomas B-Disease 1 1.0
and O 0 0.017069820314645767
colorectal B-Disease 1 1.0
cancers I-Disease 1 1.0
per O 0 1.145423809134627e-07
patient O 0 1.406376952672872e-07
( O 0 7.472785945594751e-09
P O 0 3.356239233198721e-07
= O 0 7.79826248020754e-09
. O 0 2.3668094151219066e-09
03 O 0 3.5121166774843005e-07
) O 0 4.967666722421882e-09
, O 0 3.848238172565743e-09
as O 0 3.884780053198256e-09
well O 0 5.3690341061951585e-09
as O 0 6.051461554079651e-09
a O 0 2.1782923909086094e-08
younger O 0 9.435217407371965e-08
age O 0 1.0012444562335077e-07
at O 0 4.888204898634285e-07
diagnosis O 0 9.270038390241098e-06
. O 0 2.6900688681052998e-06

We O 0 2.247286147394334e-06
conclude O 0 9.58778286985762e-07
that O 0 2.806077503691995e-08
the O 0 2.2920110609447875e-07
APC O 0 3.4567699913168326e-05
I1307K O 0 8.085691661108285e-05
variant O 0 1.1978765542153269e-05
leads O 0 2.943292543022835e-07
to O 0 2.7337598851318035e-08
increased O 0 7.193126521087834e-07
adenoma B-Disease 1 1.0
formation O 0 1.755047719598224e-06
and O 0 5.524780277710306e-08
directly O 0 3.604325726769275e-08
contributes O 0 3.89444103632286e-08
to O 0 5.07634245749955e-09
3 O 0 2.079187311210262e-08
% O 0 1.1326182214332903e-09
- O 0 3.079773769343319e-09
4 O 0 7.254000955470019e-09
% O 0 6.749473202560807e-10
of O 0 2.3652391156758767e-09
all O 0 3.896638567368882e-09
Ashkenazi O 0 2.464646286171046e-06
Jewish O 0 2.940050580946263e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.381698873767164e-06

The O 0 1.979799208129407e-06
estimated O 0 1.4654135327418771e-07
relative O 0 8.390671979441322e-08
risk O 0 7.985084238271156e-08
for O 0 8.815259633365713e-09
carriers O 0 2.645575669646405e-08
may O 0 8.253181249529007e-09
justify O 0 3.1565107860842545e-08
specific O 0 1.0309168629873966e-08
clinical O 0 1.5060816593859272e-08
screening O 0 1.2733670118336704e-08
for O 0 1.6004649827650042e-09
the O 0 1.0659407578827995e-08
360 O 0 1.2040673880164832e-07
, O 0 4.1008996198854675e-09
000 O 0 2.185158720635627e-08
Americans O 0 1.5603635050709386e-09
expected O 0 4.406888187702407e-09
to O 0 4.612428217143361e-09
harbor O 0 3.9753942360221117e-07
this O 0 1.7582831857154702e-09
allele O 0 1.0087024548965928e-08
, O 0 2.110370322938593e-09
and O 0 1.2999780141242923e-09
genetic O 0 5.591117346881447e-09
testing O 0 1.4673308124102391e-09
in O 0 3.410291216088268e-10
the O 0 2.5897517463846498e-09
setting O 0 2.410451038770134e-08
of O 0 1.200844579329896e-08
long O 0 1.028099116950898e-08
- O 0 7.139171742664985e-08
term O 0 2.534504339735122e-08
- O 0 4.288185806444744e-08
outcome O 0 2.1498534508168632e-08
studies O 0 3.6840597239518047e-09
may O 0 8.928136563390865e-10
impact O 0 7.216809372323496e-09
significantly O 0 1.087439471803009e-08
on O 0 1.7047617575371987e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.00017341379134450108
in O 0 1.2203415167277853e-08
this O 0 2.0735438255314875e-08
population O 0 3.5351042981801584e-08
. O 0 3.551734266693529e-07

Localization O 0 1.5466295735677704e-05
of O 0 2.2001868273946457e-06
human O 0 8.936677886595135e-07
BRCA1 O 0 8.014072250261961e-07
and O 0 1.2586446551665631e-08
its O 0 1.900509438712561e-08
loss O 0 2.4909647322601813e-07
in O 0 8.512859750453572e-09
high O 0 6.612862648580631e-07
- O 0 3.5003029097424587e-07
grade O 0 1.990336158996797e-06
, O 0 3.425575911819578e-08
non B-Disease 0 1.5408028275487595e-06
- I-Disease 0 0.0001399857719661668
inherited I-Disease 1 0.9999595880508423
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00014105973241385072

Although O 0 1.131366389017785e-06
the O 0 2.981140596602927e-07
link O 0 4.307712799800356e-07
between O 0 8.403726070582707e-08
the O 0 7.685641207899607e-07
BRCA1 O 0 0.0034697288647294044
tumour B-Disease 1 1.0
- O 0 5.690487887477502e-05
suppressor O 1 0.9860377907752991
gene O 0 2.9455389949362143e-07
and O 0 1.0642550307693455e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 6.141274155879728e-09
established O 0 2.1675403694132456e-09
, O 0 7.787377964696418e-10
the O 0 2.9482796204405304e-09
role O 0 1.370981195236709e-08
, O 0 2.2021489076706757e-09
if O 0 6.822081788371293e-10
any O 0 1.6981254180592487e-09
, O 0 3.09631276174116e-09
of O 0 3.9923957473320115e-08
BRCA1 O 0 4.63193146060803e-07
in O 0 1.575667774034173e-08
non B-Disease 0 0.00017891261086333543
- I-Disease 1 0.8985635042190552
familial I-Disease 1 0.9999988079071045
cancers I-Disease 1 1.0
is O 0 2.5926402713594143e-07
unclear O 0 6.121564979366667e-07
. O 0 1.1034965154976817e-06

BRCA1 O 0 0.0012605967931449413
mutations O 0 1.108214860323642e-06
are O 0 1.6144033665455026e-08
rare O 0 7.794205458822034e-08
in O 0 1.2128649196085917e-08
sporadic B-Disease 0 0.0011485624127089977
cancers I-Disease 1 1.0
, O 0 2.42502320446647e-08
but O 0 4.686993460012445e-09
loss O 0 2.12340154348567e-07
of O 0 9.425519351680123e-07
BRCA1 O 0 1.3246274193079444e-06
resulting O 0 2.3844412666562675e-08
from O 0 4.402645359391499e-09
reduced O 0 3.44760628934182e-08
expression O 0 1.1683334300016668e-08
or O 0 4.2519645582217436e-09
incorrect O 0 4.4221810213684876e-08
subcellular O 0 5.587979785559583e-07
localization O 0 4.198984981940157e-07
is O 0 1.6185349949182637e-08
postulated O 0 7.104139854163805e-08
to O 0 1.9994654820720825e-09
be O 0 8.966807851784608e-10
important O 0 2.8250219941128307e-09
in O 0 2.263617737696677e-09
non B-Disease 0 1.3318704077391885e-06
- I-Disease 0 0.00020042962569277734
familial I-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.7078054952435195e-05

Epigenetic O 0 0.001330724684521556
loss O 0 0.012636782601475716
, O 0 2.584883134204574e-07
however O 0 4.9761471387910206e-08
, O 0 2.7253154399886625e-08
has O 0 1.2197271637148788e-08
not O 0 2.281658639802231e-09
received O 0 1.1035322877717135e-08
general O 0 2.5365547884348416e-08
acceptance O 0 4.767593608789866e-08
due O 0 2.8423189135651228e-08
to O 0 1.68679878953526e-08
controversy O 0 4.6993042701615195e-07
regarding O 0 8.122921713038522e-08
the O 0 4.933374952997838e-08
subcellular O 0 4.012282488474739e-07
localization O 0 2.0946040990565962e-07
of O 0 1.3835409617968253e-07
BRCA1 O 0 1.9384194160920742e-07
proteins O 0 2.127758191861062e-09
, O 0 1.9254324801210032e-09
reports O 0 3.843066753717039e-09
of O 0 1.605605426391321e-08
which O 0 2.262827702992354e-09
have O 0 9.942934253714952e-10
ranged O 0 2.2183424874810953e-08
from O 0 1.3640970575323763e-09
exclusively O 0 1.0443231168721923e-08
nuclear O 0 5.2489966151370027e-08
, O 0 3.043138852021343e-09
to O 0 5.811403358535472e-09
conditionally O 0 1.1665787269521388e-06
nuclear O 0 1.8549698665992764e-07
, O 0 6.48892806154322e-09
to O 0 1.3191111314370119e-08
the O 0 1.2717049457933172e-07
ER O 1 0.9999978542327881
/ O 0 1.5848987459321506e-05
golgi O 0 1.1644150617939886e-05
, O 0 1.2643380387089564e-07
to O 0 7.383671629668243e-08
cytoplasmic O 0 2.0401450910867425e-06
invaginations O 0 1.6316034816554748e-05
into O 0 2.6066726377393934e-07
the O 0 6.180748641781975e-07
nucleus O 0 4.722054200101411e-06
. O 0 1.7276523749387707e-06

In O 0 4.936546815770271e-07
an O 0 5.4636650759221084e-08
attempt O 0 1.565904454992051e-07
to O 0 3.017345306943753e-08
resolve O 0 1.982151900392637e-07
this O 0 9.222907770833899e-09
issue O 0 1.2752633438140037e-07
, O 0 1.6278415060355655e-08
we O 0 1.2041449615196598e-08
have O 0 1.0559100260820742e-08
comprehensively O 0 2.9751188321824884e-06
characterized O 0 3.300482944723626e-07
19 O 0 5.742188591284503e-07
anti O 0 1.1708580132108182e-05
- O 0 6.948339432710782e-05
BRCA1 O 0 2.0788718757103197e-05
antibodies O 0 1.5357592246800778e-06
. O 0 2.0365371256048093e-06

These O 0 2.87949819721689e-06
reagents O 0 1.1938735042349435e-05
detect O 0 2.555509581725346e-06
a O 0 9.902385755822252e-08
220 O 0 2.818227358147851e-07
- O 0 8.934002266869356e-07
kD O 0 6.054229743313044e-05
protein O 0 7.820474223763085e-08
localized O 0 1.2312347053011763e-07
in O 0 5.256387769492221e-09
discrete O 0 1.2327632248343434e-07
nuclear O 0 2.521265116683935e-07
foci O 0 5.11054224716645e-07
in O 0 3.0840354714456453e-09
all O 0 5.196109764682433e-09
epithelial O 0 1.694070448365892e-07
cell O 0 1.1675052036252964e-07
lines O 0 5.5828934364399174e-08
, O 0 6.354033299516004e-09
including O 0 3.908630308302463e-09
those O 0 5.6573474793708556e-09
derived O 0 2.128765963504975e-08
from O 0 1.0386046511712266e-07
breast B-Disease 0 0.009078715927898884
malignancies I-Disease 0 0.009921493008732796
. O 0 7.173183803388383e-06

Immunohistochemical O 0 0.0012456427793949842
staining O 0 8.384175453102216e-05
of O 0 1.2338631677266676e-05
human O 0 4.192121650703484e-06
breast O 0 0.0017415614565834403
specimens O 0 1.4745271528227022e-06
also O 0 1.0910174097489289e-07
revealed O 0 1.0953162927762605e-06
BRCA1 O 0 5.976964530418627e-06
nuclear O 0 1.5874102246016264e-06
foci O 0 8.105153028736822e-06
in O 0 1.0305339515070955e-07
benign O 1 0.9999998807907104
breast O 1 1.0
, O 0 2.583744617368211e-06
invasive B-Disease 1 1.0
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 7.487047355425602e-07
low B-Disease 0 0.021451715379953384
- I-Disease 1 0.7084754705429077
grade I-Disease 1 0.9997393488883972
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 9.833748481469229e-05

Conversely O 0 3.841974466922693e-05
, O 0 1.3755959571426501e-06
BRCA1 O 0 3.5233115340815857e-06
expression O 0 7.434730520117228e-08
was O 0 2.9350394115112977e-08
reduced O 0 2.086326134076444e-08
or O 0 4.953550014619168e-09
undetectable O 0 1.4327578412576258e-07
in O 0 8.951803742718312e-10
the O 0 3.255639091648277e-09
majority O 0 8.047489341578284e-10
of O 0 6.851817779818248e-09
high O 0 7.309056968551886e-07
- O 0 2.469938181093312e-06
grade O 0 0.0013975604670122266
, O 0 2.149829327890984e-07
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 2.544876167576149e-07
suggesting O 0 3.851999963444541e-08
that O 0 2.663604226071925e-09
absence O 0 6.736026847420362e-08
of O 0 2.1373836034399574e-07
BRCA1 O 0 9.719386753204162e-07
may O 0 3.2459852583599513e-09
contribute O 0 3.3785172437461597e-09
to O 0 3.668829018366182e-09
the O 0 3.285019900545194e-08
pathogenesis O 0 9.013659109768923e-06
of O 0 2.0743001982737042e-07
a O 0 1.8928435707721292e-08
significant O 0 4.126236419210727e-08
percentage O 0 1.1186126869233703e-07
of O 0 1.7730168622165365e-07
sporadic B-Disease 0 0.0005707145319320261
breast I-Disease 1 1.0
cancers I-Disease 1 0.9999972581863403
. O 0 3.011096509908384e-07
. O 0 1.7506696394775645e-06

